[{"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nThe device, called the Obalon Balloon System, was approved in September by the U.S. Food and Drug Administration.\nFor the study, Pryor and her colleagues randomly assigned nearly 400 obese patients to receive a real or sham device.\nAfter six months, patients with the Obalon balloons had them removed.\n\"Such devices may be alternatives to bariatric surgery in some cases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the strongest aspects of this story is the ample use of independent sources to provide context and point out limitations of the device. However, this criterion demands that sponsors of research be identified, and this story does not tell readers that the trial was sponsored by Obalon Therapeutics.", "answer": 0}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nAs a result, the European study was terminated before completion, and the results were not previously published.\nNew ARIA-E safety analyses were reported in the JPAD publication.\nThe results published in JPAD are the first evidence from a large clinical trial to associate efficacy of an amyloid-targeted agent with APOE4 status in AD patients.\nIn these new subgroup analyses, the high dose of tramiprosate showed promising clinical effects in APOE4/4 homozygous AD patients already receiving maximal standard of care, and this dose was not associated with any events of vasogenic edema,\" said Susan Abushakra, MD, Chief Medical Officer of Alzheon and lead author on the JPAD publication.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clearly labeled as written on behalf of Alzheon, the manufacturer of the compound. The release further identifies the sources quoted as either employees of Alzheon or as investigators at one of the study\u2019s research sites.", "answer": 1}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nIt is by no means clear that doctors or patients will follow the new guidelines.\n\u201cI\u2019d rather get it checked out regularly than have to worry about that.\u201d\n\u201cOne of my cousins had cervical cancer, so that\u2019s in my head too,\u201d she said.\n\u201cFor people who\u2019ve been having the testing regularly every year, it\u2019s a big emotional change to test less frequently and there\u2019s this fear of \u2018Oh my gosh, I might be missing something,\u2019 \u201d said Ivy Guetta, 49, of Westport, Conn., who plans to continue with annual Pap tests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sourcing is excellent. Sources include:", "answer": 1}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nThis work was supported by grants from the National Institutes of Health and funding from the Taylor Family Institute for Innovative Psychiatric Research.\nThis work was funded by a grant from the National Institute of Mental Health.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "An end note points out that this study was funded by the National Institute of Mental Health.\u00a0 There was no indication of any conflicts of interest.", "answer": 1}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nHe said: \u201cBlood tests for cancer promise to be truly revolutionary.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\nWe think it could be used to make clinical decisions about whether a PARP-inhibitor is working within as little as four to eight weeks of starting therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two sources: 1) the first author, who\u2019s a researcher at the UK\u2019s Institute of Cancer Research; and 2) the Chief Executive of the very same research institution. No outside sources were mentioned, much less quoted. It was good that\u00a0funding sources were\u00a0mentioned, however.", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nAs for the next step in confirming the relationship between beetroot juice and blood pressure, she says this was a small trial.\nThe research was funded by the British Heart Foundation.\nThey found the following results:\n\nFor the trial, Prof. Amrita Ahluwalia of the vascular pharmacology department at QMUL and her colleagues recruited 64 people aged between 18 and 85 years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story offers comments from only two sources: One, a research leader at the British Heart Foundation, which funded the study, and the second, the apparent principal investigator conducting the trial.\u00a0 The story borrows liberally from a news release (more on that later) and offers no insight from individuals not connected to the project.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nThe patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not incorporate input from anyone not associated with the company or the study in question.", "answer": 0}, {"article": "For example, children with Down syndrome often have flat nasal bridges \u2014 as do typically developing African or African-American children.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nThe algorithm the NIH uses \u2014 developed by scientists at Children\u2019s National Health System in Washington, D.C., \u2014 seems to work pretty well so far: In 129 cases of Down syndrome, it accurately detected the disorder 94 percent of the time.\nHowever, the app won\u2019t give clinicians a yes or no answer to the question of, \u201cDoes my patient have a genetic disorder?\u201d\n\nThat\u2019s intentional.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s not exactly clear where the NIH work and the company\u2019s work begin and end. It talks about NIH-funded researchers gathering photos and uploading those to Face2Gene. That should be made more clear.\nAn outside expert to comment on whether this is useful would have been helpful.", "answer": 0}, {"article": "There may also be other benefits linked to omega 3 fatty acids for the fetus as well, in helping nerve development \u2014 that\u2019s why many prenatal vitamins include forms of omega 3 fats.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\n\u201cWe hope in the future to have more answers to be able to say firmly that yes, omega 3 fatty acids are the way to go [for women hoping to get pregnant,]\u201d she says.\n\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story is brief and includes no sources other than the researcher whose paper is being discussed.", "answer": 0}, {"article": "Most experts believe that the build up of beta amyloid proteins, which accumulate as plaque, is responsible for Alzheimer's.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\nPatients were able to tolerate bapineuzumab for two to four additional years without the emergence of any new safety concerns,\" said Dr. Stephen Salloway, author of one of the studies.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a quote from Dr. Ian Murray who did not appear to have a role in the studies reported on as well as comments from Dr. Salloway, lead author of the study. But we\u2019re going to rule it unsatisfactory because the story should have noted that Dr. Salloway, according to previous disclosures available online, has received research funding and has consulting relationships with numerous drug companies, including Pfizer, which makes bapineuzumab.", "answer": 0}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\nEMF Australasia awarded more than $270,000 to support Dr Furyk's research, through its Queensland Research Program, which is funded by the Queensland Government Department of Health.\nThe Foundation was established in 2007 with the support of the Queensland Government.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by Emergency Medicine Foundation Australasia, and that the quoted researcher has received \u201cmore than $270,000\u201d from that group to support his research.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two clearly independent sources are quoted, but both are market analysts who offered only global, annual sales estimates for the drugs. There seem to be no independent sources cited in regard to how promising the drugs are, what the clinical trial findings might mean, how far the drugs might be from reaching the market, etc. That\u2019s a significant oversight. Even if readers are interested in this solely as a business story, expert evaluations from independent sources on those issues would be enormously valuable. The conflicts of interest seem clear, with one exception. The story quotes Paul Aisen, director of the Alzheimer\u2019s Therapeutic Research Institute at the University of Southern California, \u201cwho presented the results\u201d on solanezumab.\u00a0Aisen is also a consultant to Eli Lilly and many other drug companies, which should have been mentioned.", "answer": 0}, {"article": "\u201cDr.\nWilson was more than patient with me as I first chose active surveillance for one year and then decided to undergo a double mastectomy when another area of DCIS was identified in November 2015.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\nThe technique has the potential to be a \u201cgame-changer,\u201d says Tzvi Small, M.D., Director of the Department of Plastic and Reconstructive Surgery at The Valley Hospital, who performed the breast reconstruction procedure on Hasbrouck Heights resident Vanessa Burt, 43.\n\u201cThis was a long journey,\u201d says Ms. Burt, a publicist for the San Francisco-based Fat Wreck Chords music company.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The Valley Breast Center is listed at the end of the release. But due to the overwhelmingly positive comments from the patient who received the procedure, it would have helped to make clear whether or not she was compensated in any form by the hospital system.", "answer": 1}, {"article": "She can read the newspaper and watch TV.\nThis is why the telescope is implanted in only one eye.\nDespite its terrific potential, the new eye telescope isn't for everyone.\nBut, like all telescopes, when vision is narrowly focused, the peripheral view gets lost.\nAnd the population who might benefit from the new device is somewhat limited.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The bottom third of the story relies heavily, perhaps too much so, on Dr. George Williams, a retinal surgeon given the vague title of \"associated with the American Academy of Ophthalmology.\" Those quibbles aside, Williams provides some great insight and counterbalancing information. It also explains that the other expert in the story, Dr. Kathryn A. Colby, was one of the principal investigators in the story.", "answer": 1}, {"article": "Rates are rising, in part because tanning became fashionable.\n\u201cThis is huge in the melanoma community,\u201d said Tim Turnham, executive director of the Melanoma Research Foundation.\nSeventy-five percent of them had already been given other cancer treatments, including Yervoy, known generically as ipilimumab.\nIt was bad enough for 8 percent of patients that they stopped taking it.\nNew data about to be released to a meeting of cancer specialists shows that 40 percent of the patients who have been taking the drug are still alive three years later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least two outside sources were quoted in addition to a study spokesperson.", "answer": 1}, {"article": "While Drs.\nThe FAME 2 trial was supported by St. Jude Medical.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\nThe present analysis was not supported by industry funding.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does well to\u00a0notify readers that the study was initially sponsored by St. Jude Medical, a global medical device company. However, it should also have noted that many of the study authors individually have financial relationships with stent makers including St. Jude Medical, Boston Scientific, and Abbott.", "answer": 0}, {"article": "\"Proteins are constantly moving and changing shape,\" said Lapidus, a professor in the Department of Physics and Astronomy.\nFox and St. Mary's Foundations, funded the study.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\nCollier and collaborator Katrina Paumier, an assistant professor of molecular medicine, began looking at previous patient data to see if individuals who were on antidepressants experienced any delay in their need to go on a standard Parkinson's therapy called levodopa.\nTo further back up his research, he enlisted the help of his colleague and co-author Lisa Lapidus, who in previous studies had already detected whether certain compounds could bind to alpha-synuclein and stop it from accumulating.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says this about the funding of the study: \u201cThe National Institutes of Health, as well as the Michael J. Fox and St. Mary\u2019s Foundations, funded the study.\u201d But the release does not identify any potential conflicts of interest. In our own reading of the material, we found that two of the study\u2019s authors \u2014 C. Justman and P. Lansbury \u2014 are on staff with a for-profit biotech company, Lysosomal Therapeutics, of Cambridge, Mass.That should have been disclosed in the release.", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nOn Monday, Horizon Pharma announced that it was acquiring River Vision, which paid for the new study.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nThe marked reduction in bulging is similar to that reported after decompression surgery, Smith and his colleagues write in the New England Journal of medicine.\n\u201cIn virtually all the responders, the changes are frequently what anyone would call dramatic,\u201d said lead study author Dr. Terry Smith of the University of Michigan Medical School in Ann Arbor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in this story was the lead investigator in the trial. No information from other unaffiliated experts was included. The story does mention that River Vision Development Corporation funded the trial, but it doesn\u2019t mention that several investigators reported receiving fees from River Vision Development Corporation separate from the study. \u00a0It does not mention grant support from the National Institutes of Health, National Eye Institute, Research to Prevent Blindness, the Bell Charitable Foundation,\u00a0among others.", "answer": 0}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nThere are varying amounts of proof supporting the effectiveness of each, and each method has its advantages and limitations, the panelists said.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nWe encourage people to choose the best option for them, in consultation with their clinician,\" former Task Force member Dr. Douglas Owens said Wednesday in a USPSTF news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from a physician who is not on the USPSTF and who expresses a different viewpoint. We won\u2019t mark down the story for not discussing conflicts of interest because the USPSTF is a voluntary, publicly-funded body and none of the members reported any conflicts in their disclosure forms.", "answer": 1}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\nIn the trials, women who took the drug had greater bone loss than did those who received placebo, and this wasn\u2019t entirely surprising.\nMood swings and night sweats were less common, and one woman in the trial died by suicide (though there\u2019s no indication that the medicine was a cause of her death).\nThat\u2019s not to mention cost: The drug\u2019s price is listed at $850 per month.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The scientist who led the two trials is clearly identified as such, but his consulting relationship with the company now marketing the drug is not mentioned, nor is the fact that that company, now positioned to benefit from selling the drug, paid for the studies.", "answer": 0}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nHe calls the study's results \"powerful.\"\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nFurthermore, the researchers actually gave the subjects the virus, assuring that everyone was exposed to the same bug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes remarks from Dr. M. Safwan Badr, who was not involved with the study. He brings some useful perspective as far as what is new about the study.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from an accompanying editorial, a member of the panel monitoring the vaccine\u2019s safety and the head of National Institute of Allergy and Infectious Disease of the National Institutes of Health augment the information presented in the article in the New England Journal of Medicine upon which the story was based.", "answer": 1}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent expert who provides valuable perspective. We are curious, though, why/how this story quotes the same U.S. expert who comments in the competing HealthDay story. ", "answer": 1}, {"article": "\"Much like you would expect if the doctor told you 'you have cancer' or 'you have diabetes,' then there are different ways you could pursue treatment,\" he said.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\n\"If you're currently opiate-dependent ... (naltrexone) takes more work,\" said Dr. Joshua Lee , the lead author of the study, who studies opioid addiction behavior and treatment at New York University.\nAddiction \"is an incredibly deadly disease,\" said Komaromy, an addiction specialist at the University of New Mexico Health Sciences Center.\nWhat is key, said Dr. Miriam Komaromy, is meeting a patient where they are and understanding what best meets their needs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the sources are clearly identified, funding information is missing in action, as are any references to possible conflicts of interest. For example, lead author Dr. Joshua Lee has accepted grant money from Alkermes, the manufacturer of Vivitrol. This should have been disclosed.", "answer": 0}, {"article": "Before treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nDr. Gerald Andriole of Washington University, who was not involved in the study, told Shots he wasn't surprised by the results.\nThat's according to a study just published in the journal CANCER.\nEven so, Andriole says, the findings may not make too much difference in the real world.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An expert in this field without ties to the study reported on was quoted in this story.", "answer": 1}, {"article": "Honey is not only cheap and readily available, it's also generally safer than cough medicine, which can have side effects or be administered in the wrong dose.\nUnder the provisions of the grant, the group was not involved in the study or the published results, Paul said.\nHoney also beat out no treatment at all.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote an independent expert in addition to the lead author of the study.", "answer": 1}, {"article": "Kite has said that at six months, 44 percent of patients were still responding, with 39 percent having no sign of cancer.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\nDozens of other companies also are working on them.\nHe said the therapy already has been life-changing for many of his patients \u2014 and for him.\n\u201cIt was the craziest feeling in the world.\u201d When she was checked a month later, she said, her cancer was gone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in this story. It would have benefited greatly from at least one outside voice commenting on the importance of the findings.", "answer": 0}, {"article": "5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\nStill, that means that 11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn't.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One indepedent source is quoted. The story was based on a news briefing at a research conference, and we understand the need to file under deadline pressure. At the same time, we think the story would have benefited from at least one discussion with an expert outside of the study or the news briefing, perhaps another expert on a panel at the same conference. The story could have noted that a patent application has been filed for the device.", "answer": 1}, {"article": "In AML, treatment involves intensive chemotherapy to try to kill the patient\u2019s leukemia cells and put the cancer into remission.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nThe results of the current trial, he said, point to the inevitable need to replace large cancer clinical trials evaluating homogeneous drug treatments with smaller trials that involve subgroups of patients, with treatments targeted to their specific mutations.\n\u201cWhat\u2019s really unique here is that all the patients in the study with TP53 mutations had a response to decitabine and achieved an initial remission,\u201d said the study\u2019s senior author, Timothy J. Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Medicine, noting that in AML, TP53 mutations have been correlated with an extremely poor prognosis.\nThe study, by a team of scientists at Washington University School of Medicine in St. Louis, is published Nov. 24 in The New England Journal of Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for this trial are clearly stated. However, the conflicts of interest disclosed in the published paper are not included in the news release. The disclosure states:\n\u201cDr. Uy reports receiving fees for serving on an advisory board and clinical-trial support from Novartis; Dr. Jacoby, receiving consulting fees and fees for end-point adjudication from Quintiles and clinical-trial support from Sunesis Pharmaceuticals; and Dr. Graubert, receiving consulting fees from Agios.\u201d\nEach of the companies mentioned market cancer drugs so its appropriate to include the researchers\u2019 financial ties with them in the release.", "answer": 0}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nThe data could represent a \u201cparadigm shift in how the disease is thought about,\u201d CEO Jeff Jonas said in a conference call.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story notes that the results were released in a news release and a company conference call, and were not peer reviewed (thus making it clear that the source is only the company and that the results have not been independently reviewed), the story should have included comments from independent experts.", "answer": 0}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the participants are part of an ongoing study of obesity interventions, but never says the study was federally funded,\u00a0or how the snacks were paid for (or donated).", "answer": 0}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\nOther centers, however, are currently in development.\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\nAs the fame of the process has started to spread, some people have been taking desperate measures to get treatment.\nThe other drawback is that the cyclotron is not cheap.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It would not have been difficult find an independent source to give perspective on the claims in this story.\nBut no independent source appeared in this story.", "answer": 0}, {"article": "Jamie Stagl worries that women with breast cancer don\u2019t get enough help coping with their diagnosis.\n(Stagl and her colleagues tracked down 100 of the original participants; another 30 had died; and 110 couldn\u2019t be found or didn\u2019t want to participate.)\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\nThe positive results surprised even Stagl.\nThe women felt better one year after the course, five years later, and \u2014 according to a new study published last month in the journal Cancer \u2014 an average of 11 years later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from at least one independent source and clearly identifies quotes from researchers associated with the recent study.", "answer": 1}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nEven More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nThe research included 11,513 children participating in a large U.K. study.\n(More on Time.com: 5 Pregnancy Taboos Explained (or Debunked))\n\nBut this does *not* mean that light drinking in pregnancy is good for your baby.\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly was built on a lot of research, but it did not bring in any outside voices.", "answer": 0}, {"article": "Currently, the most popular drugs to treat depression are called selective serotonin reuptake inhibitors, or SSRIs.\nThe GLYX-13 study is a phase 2 trial, which evaluates a drug's effectiveness while continuing to assess its safety.\nMoskal is the founder and chief scientific officer of the biotechnology firm Naurex Inc., which conducted the study.\nFindings from the team's animal research that led to the new method appeared online Dec. 3 in the journal Neuropsychopharmacology.\nA new trial that makes use of the drug in pill form is slated to get under way next year, Moskal noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Bryan Bruno is the independent expert in this story. It would have been helpful if he could have talked more about the study\u2019s limitations, but he does mention that long-term effects of the drug need to be studied before it can be used regularly in clinical practice. The article does an excellent job in bringing up a potential conflict of interest. The study\u2019s lead researcher is the founder and chief scientific officer of the biotechnology firm Naurex Inc., which \u201cdiscover and develop compounds that modulate the NMDA receptor in a new way,\u201d according to the firm\u2019s website. Naurex conducted the clinical study.", "answer": 1}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nBefore undergoing PRP treatment, I read quite a bit about it, learning that it holds promise for healing soft-tissue injuries such as tearing of the rotator cuff (the group of tendons and muscles that provide stability to the shoulder), tennis elbow, plantar fasciitis, Achilles tendinitis, patella tendinitis and hamstring tears; it may even provide relief for mild to moderate osteoarthritis.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nBased on my experience with it, I think they are right.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Along with quotes from\u00a0the author\u2019s physician (who\u00a0has already posted the story\u00a0on his website)\u00a0there are quotes from\u00a0a researcher who was involved in one small clinical trial on PRP. The inclusion of the researcher just barely squeaks by as sufficient to earn a Satisfactory rating here.\nHowever, the story would have been much stronger had the author interviewed an expert who disagrees with these two sources, which wouldn\u2019t be hard to find given the Cochrane review and other systematic reviews that cast a less rosy glow on PRP.", "answer": 1}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nOf the many embarrassing health statistics in this country, the huge number of unwanted pregnancies is perhaps the easiest to rectify.\nFurthermore, the committee stated, \u201calmost all women are appropriate candidates\u201d for the LARC methods currently available.\nThese facts prompted a committee of the American College of Obstetricians and Gynecologists this month to urge its members to introduce women of all ages to the most effective and underused methods of reversible contraception: IUDs and hormonal implants.\n\u201cWhile there is no one best contraceptive method for every woman or every couple, women should have access to all methods and should know how effective the LARCs are,\u201d Dr. Kavanaugh said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one expert, Megan Kavanaugh, who is one of the authors of one of the studies referenced in the article. Kavanaugh works for the Guttmacher Institute, and has declared no conflicts in other publications on contraception. It would have been nice to hear from someone who is totally independent of the studies and report covered in the column, but we think Dr. Kavanaugh qualifies as sufficient for a Satisfactory rating here.", "answer": 1}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nBangalore noticed that one assumption made in comparing the placebo trials -- that the patients in the group were about the same -- was incorrect.\nThe new analysis, published in Mayo Clinic Proceedings on Monday, involves a second look at 106 randomized trials with 254,301 patients that took place after 2000 and shows that during this time period patient outcomes on the two medications were remarkably similar.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The single quoted source in this story is the main author of the study and the story fails to mention that some authors have ties to major pharmaceutical firms which manufacture these kinds of drugs.\u00a0 While that linkage doesn\u2019t mean the research is definitely biased, writers should disclose that information when available.", "answer": 0}, {"article": "During an 18-month-long randomized, double-blind trial, 80 postmenopausal women with osteoporosis received daily injections of either placebo, a single unit of growth hormone or a 2.5-unit dose of growth hormone.\nThe women were between the ages of 50 and 70 when they were recruited for the decade-long study.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\nOther authors of the study include: Penelope Trimpou and Kerstin Landin-Wilhelmsen of Sahlgrenska University Hospital at the University of Gothenburg in Gothenburg, Sweden.\nThe controls were identified using the city census in Gothenburg, Sweden.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release provide no information on who funded the study. The research was funded by the University of Gothenburg as well as a variety of public grants. The independent nature of the research was worth mentioning.", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely adequate \u2013 in that the story at least cited the views of an editorial writer in addition to those of one of the study authors. ", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The format clearly excludes independent sources commenting on what the expert is saying. The interviewee himself might have quoted another source or two and strengthened his information, but overall, N/A seems reasonable.", "answer": 2}, {"article": "\u201cMy first reaction to this study, because it came as a bit of a surprise, was, \u2018Oh, are we doing our job explaining that point to patients?\u2019\u201d Dr. Gralow said.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\n\u201cFewer women are having just one breast removed.\u201d\n\nYounger women, white women and women with a previous cancer diagnosis were more likely to opt for a contralateral prophylactic mastectomy, the study found, as were women who had lobular histology, meaning the cancer started in the lobules or milk-making glands of the breast.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites Dr. Tuttle, the lead author of the study; a woman who decided to undergo a bilateral mastectomy, though she only had cancer in one breast; and Dr. Gralow, who questions the trend of prophylactic mastectomies in women who have the option to undergo lumpectomy and radiation, or lumpectomy alone (for DCIS). The story may have been more balanced by interviewing a patient who chose less treatment, along with her rationale.", "answer": 1}, {"article": "Tiotropium bromide (Spiriva)) belongs to a class of drugs called anticholinergics, which work by enlarging the airways to allow for easier breathing.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nThat's important, Peters said, because there have been some safety concerns raised about long-acting beta agonists.\nSUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\n\"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term,\" Shafazand said, but right now there is no data on long-term efficacy and safety.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites an independent source who was not, apparently, related to the study. The funding of the study was also mentioned. \nThe AP article we reviewed digs into\u00a0further conflicts of interest for the study investigators. As an aside to our review, that article also probes the\u00a0controversy over the fact that a drug company didn\u2019t donate some of the drugs used in this study.", "answer": 1}, {"article": "For more information on lung cancer, visit the U.S. National Cancer Institute.\nThe funder was involved in study design, coordination of data collection, data analysis, data interpretation, and writing of the report, the journal noted.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\nAnother expert, Dr. Norman H. Edelman, chief medical officer at the American Lung Association, and professor of preventive medicine, internal medicine, physiology & biophysics at Stony Brook University in New York, called the study \"very good bread-and-butter clinical research.\"\nThe Food and Drug Administration on Tuesday will ask a panel of outside experts to review the evidence on the Roche drug, the Associated Press said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Several sources were quoted who did not have a direct connection to the study reported on or to the company. \u00a0The story indicated clearly that the study reported on was funded by the maker of the drug studied.", "answer": 1}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nThe research, published in the British Journal of Cancer, was funded by The Freemasons of the Province of Yorkshire (North and East Ridings) and The Masonic Samaritan Fund.\n\"Out of almost a million markers studied, we were able to use our new tools to single out differences in cancer potency.\"\nThe team needed to eliminate the 'noise' of the genetic patterns that make individuals unique, to leave them with the patterns that indicate cancer.\nThey were able to do this using a computer algorithm, which left the team with 17 possible genetic markers for prostate cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "All funding sources were listed at the bottom of the release.", "answer": 1}, {"article": "Although close contact casting may be unfamiliar to some orthopedic surgeons, it can avoid surgery for older patients with ankle fractures, yet result in equivalent functional outcomes.\nFurther studies are needed to help identify which patients will not benefit from casting.\nEditor's Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\nThis technique is worth considering when treating this challenging clinical problem.\"\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding sources and conflicts are mentioned in the news release. Instead, readers are referred to the published study for details on \u201cfinancial disclosures, funding and support.\u201d However, the study is only available to JAMA subscribers.", "answer": 0}, {"article": "Learn more about ADHD from the National Institute of Mental Health.\nSome complementary medicine practices test for IgG and recommend eliminating foods high in IgG, explained Dr. Jaswinder Ghuman, who wrote an accompanying editorial in the same issue of the journal.\nGhuman said that this study doesn't answer a number of questions, such as whether or not the elimination diet reduces symptoms long-term.\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one outside expert and one expert who wrote an accompanying editorial.\u00a0Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children\u2019s Medical Center of New York in New Hyde Park, said, \u201cSince none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit. \u2026Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\u201d Jaswinder Ghuman, MD, associate professor of psychiatry and pediatrics at the University of Arizona, who wrote a commentary, says, \u201c\u201dBut, for this diet to work, you have to be very consistent with it, and you have to pay attention to nutrition. It should be done under the supervision of a primary care doctor, and if possible, a dietician.\u201d These cautious voices are very different from the more exultant opinions in the WebMD piece.", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was interviewed.\u00a0 ", "answer": 0}, {"article": "Fader no longer holds that role.\nFrom August 2011 through March 2017, Fader, Alessandro Santin, M.D., professor of gynecology and obstetrics at Yale University, and collaborators at 11 other cancer treatment centers in the U.S. randomly assigned 61 women with uterine serous carcinoma, being seen at the participating institutions, to receive either the standard chemotherapeutic regimen--a combination of the drugs carboplatin and paclitaxel--or those drugs plus trastuzumab.\nAmong all patients, the 28 controls receiving only the standard carboplatin and paclitaxel combination had an average progression-free survival time of eight months, and the 30 who received trastuzumab in addition had an average progression-free survival time of 12.6 months.\nFader and her colleagues knew that about 30 percent of all uterine serous carcinomas test positive for HER2/neu, a receptor protein that is also overexpressed in about 10 percent of all breast cancers.\nThe difference, Fader says, may be that these patients have been heavily treated in the past, are more likely to have overall poorer health and are more likely to have mutated or heterogeneous tumors, or tumors with different levels of HER2 expression.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes that the study was funded by a company that produces one brand of trastuzumab, which is good. The release also notes that one of the researchers had reported a consulting or advisory role for a pharmaceutical company. Since it mentioned that researcher\u2019s potential conflict of interest, it would be easy to assume that the other researchers (who were not mentioned) did not have potential conflicts of interest. That assumption would be incorrect. The journal article itself makes clear that several other researchers had conflicts of interest, including one researcher with ties to another pharmaceutical company (Genentech) that makes a different brand of trastuzumab.", "answer": 0}, {"article": "Because atrial fibrillation increases the risk for stroke, people with the condition are often prescribed blood thinners (also known as anticoagulants) to prevent blood clots that can cause a stroke.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\n\"In order to prove this assumption, randomized placebo-controlled trials would be needed, but such studies cannot be done because of ethical reasons,\" researchers Leif Friberg and Marten Rosenqvist, of the Karolinska Institute in Stockholm, said in a journal news release.\nAt the time they joined the study, about half of the participants were taking oral anticoagulants, such as warfarin, Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban) or Xarelto (rivaroxaban).\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We learn that the researchers came from the Karolinska Institute in Stockholm yet are not given information about any potential financial conflicts between those researchers or their institution to the makers of anticoagulants.\nAs the study itself makes clear, the researchers have financial ties to numerous drug companies that make anticoagulants including Bayer, Pfizer, and Bristol-Myers Squibb.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The two doctors quoted are both surgeons. The article would have benefited from an expert familiar with a range of treatments for breast cancer-related lymphedema; for example, a lymphedema-certified physical therapist.", "answer": 1}, {"article": "Traditional knee surgery cuts through muscles and tendons.\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\nHelp for O'Brien finally arrived in a new kind of knee surgery, developed and perfected at Chicago's Rush University Medical Center by Dr. Richard Berger.\n\"I'll be chipping and putting in three weeks \u2014 maybe four,\" joked O'Brien from the operating table.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from one patient and one surgeon were included in this piece. But there was no comment from any independent source. Since this television story ran an unusually long 5 1/2 minutes, there certainly was time to include data on the use of the device and input from other physicians. A single-source story on a topic like this is troubling. ", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nLine Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. ", "answer": 0}, {"article": "For more on chemotherapy, visit the American Cancer Society.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\nThe finding is based on a small study involving just 40 lung cancer patients.\nBut, she said, \"I would say this is certainly worthy of continuing research and exploration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Despite what we just said in the \u201cnews release\u201d criterion above, we will give the story a satisfactory score for seeking an independent perspective, but we wonder what that dietitian reacted to:\u00a0 the study itself or just a news release?\u00a0 Barely satisfactory.", "answer": 1}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nUsing sophisticated computer software, researchers were able to coordinate the actions of a commercially available continuous glucose monitoring device and insulin pump to allow automatic insulin delivery in response to real-time glucose readings.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions that one source, Aaron J. Kowalski, PhD, is affiliated with the Juvenile Diabetes Research Foundation (JDRF), and says that he \"did not take part in the study.\" However, it does not disclose\u00a0that JDRF was a sponsor of the study, which\u00a0means that\u00a0Dr. Kowalski could be more likely than a truly independent observer to look favorably on the results.\u00a0\nThe story also did not identify\u00a0the financial\u00a0ties between one of the investigators quoted in the study and a study sponsor.", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nThe research was announced Tuesday at a joint meeting of the European Cancer Organisation and the European Society for Medical Oncology in Berlin.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story included quotes from two independent experts but not much balance therein.\u00a0 One seems to inappropriately exaggerate the potential benefit of hormone therapy and the other seems to minimize the potential for harm from its use.\u00a0 The story should have also noted the sources of funding for the study. According to a news release, the study was funded by the Swedish Research Council, the Stockholm Cancer Society and Cancer Research UK. Nonetheless, the story barely meets the expectation for this criterion. ", "answer": 1}, {"article": "Bochner and his colleagues Drs.\nThe study was funded by a 2016 Dixon Translational Research Grant.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nAnne Marie Singh and Melanie Dispenza are now testing how successful the drug is at targeting allergies to food, such as tree nuts and peanuts.\nThe promising data from this pilot study could have greater implications for adults with food allergies.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study reports that this study was funded by a 2016 Dixon Translational Research Grant. However, it fails to disclose the list of industry connections, patents, stock options and other items the researchers attached to their journal letter. Two of the seven authors have ties to AbbVie, the co-producer of ibrutininib. AbbVie and Northwestern University have also announced a five-year deal to collaborate on cancer research.", "answer": 0}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nThe NCI still is compiling rates of false alarms and other risks from the study.\nNor is it clear if the study results are applicable to all smokers.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nIt is most often diagnosed at advanced stages, and the average five-year survival rate is just 15 percent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThere is no independent source quoted.\u00a0 (Please note: later versions of AP stories carried independent perspectives but we reviewed the first version we found.) ", "answer": 0}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\nThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\nShe added that the new study is \"critically important\" for the epilepsy community, which believes a CBD-based medical product would be a first-in-class therapeutic option.\nGW Pharmaceuticals, a company that is developing cannabidiol medicines, helped subsidize the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes four independent sources, a very high number for a story about a study like this. It also explains that the study was partially funded by a drug company trying to commercialize a cannabis-based drug.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes only one of the lead investigators of the study, and used the same quote found in the news release (see last criterion). Coverage elsewhere often included comments from cancer clinicians and investigators not affiliated with the study, most of whom emphasize the complexity of the risk calculations and the human factors that drive medical decision making. The journal article also included an editorial by a Johns Hopkins University scientist, which offered good information about the quality of the research and other things. It would have helped to cite it. (Full disclosure: HealthNewsReview.org reviewer Joann Rodgers consults for Hopkins.)\nAn article about a new breast cancer modeling tool that may impact future screening guidelines should definitely include quotes from breast cancer researchers and\u00a0clinicians who are not affiliated with the study.", "answer": 0}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nFor that reason, he and other experts say, most sufferers never even see an allergist.\nDr. Mitchell began to imagine a nearly needle-free office.\nDr. Mitchell, the Manhattan allergist, called that approach promising.\nThe quick turnaround allows doctors to offer a diagnosis and immediate advice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from several individuals who were not involved in the study and provided some cautionary perspective about the implications of the study. \u00a0And while this piece relied heavily on comments from Dr. Ridker, the story did mention that he was an inventor of the test for CRP was also the recipient of funding from the manufacturer of the study drug.", "answer": 1}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\nImportantly, one patient showed some improvement, though he and his colleagues noted that this outcome \"must be interpreted with caution\" since the study wasn't designed to measure effectiveness of the treatment.\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\n\"He did not want to go on the ventilator,\" she said, adding that many people prefer a \"natural death.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from two people who are not involved in the research. However, it does not mention that the study was partly funded by Neuralstem, a biopharmaceutical\u00a0company focused on stem cell technology. In addition, study authors have numerous financial ties that weren\u2019t disclosed.", "answer": 0}, {"article": "Headache, fatigue or muscle ache may occur.\nFurthermore, physicians are eligible for up to 1 hour AMA PRA category 1 CME credit for reading the article.\nThis data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\n\"We demonstrated statistically significantly better protection by Flublok based on considerably fewer people contracting the flu after vaccination with Flublok Quadrivalent.\nFurthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clearly from Protein Sciences Corporation and clearly identifies its own chief medical officer when she is quoted in the piece. The release does not explicitly state that the study was funded by Protein Sciences, but hat can be deduced from the text.\nBut omitting conflicts of interest disclosures in the release is another matter. According to the disclosure in NEJM, journal article authors \u201cDrs. Dunkle, Izikson, and Cox report being employed by and holding stock in Protein Sciences.\u201d That financial connection should have been included in the news release.", "answer": 0}, {"article": "Acupuncture has been controversial among doctors as a possible treatment for a range of conditions including chronic pain and fibromyalgia.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nPark, who was not involved in the new study, said acupuncture focuses on healing the underlying tissue injury that is causing pain, rather than treating the pain itself as medications would.\nBut patients treated with fake or \u201csham\u201d acupuncture - using retracting needles that don\u2019t stick in the skin, for example - estimated their pain at somewhere in between the other two groups, suggesting that they also got some benefit from the procedure.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story consulted one of the study authors, as well as the head of the department of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\u00a0Both of these sources are biased either by their affiliation with the study or their\u00a0general support\u00a0and belief in the effectiveness of acupuncture. \u00a0(In an admirable display of transparency, the Asian medicine expert\u00a0acknowledges that he is a \u201cbiased clinician.\u201d) The story would have been\u00a0improved with\u00a0the inclusion of comments from an expert\u00a0in pain treatment who is not invested in the study or in acupuncture as a treatment. Such an expert might well be considered biased against acupuncture, but at least readers would\u00a0be getting both sides of the argument.", "answer": 0}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\n\u201cStudies have revealed that 80 percent of Americans may be taking these powerful meds incorrectly,\u201d Dr. Aviv wrote.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nAccordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only person cited in the story is Jonathan Aviv, who wrote The Acid Watcher Diet. Input from an independent expert would have been a valuable addition.", "answer": 0}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\n\u201cMost people gain more weight than they probably should during pregnancy,\u201d Thornburg, who was not involved with the review, told Reuters Health.\nFor the new review, the researchers examined data from 65 randomized controlled trials, which are considered the \u201cgold standard\u201d of medical research.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites an independent source and makes it clear when quoting from the paper itself.", "answer": 1}, {"article": "RotaTeq contains live, but weakened, strains of rotavirus designed to build immunity without causing illness.\nThe federal Centers for Disease Control and Prevention and the manufacturer, Merck & Co. Inc. of Whitehouse Station, N.J., have promised elaborate studies to catch any safety problems.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\nBut it is also drawing new manufacturers into the vaccine market, which many drug companies had abandoned in the 1980s and 1990s, citing too little profit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The author does quote an independent source, an epidemiologist from the CDC.", "answer": 1}, {"article": "\u201cI used to be so irritable because I was so uncomfortable,\u201d Joyce said.\nAllerdent is not covered by insurance, meaning Joyce spends about $400 every three months but said the cost is worth it.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nVolunteers using the toothpaste were also required to log their usage in a journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources used in this story, just comments from one study participant and the principal investigator.\u00a0 There is no mention of conflicts although a quick web search reveals that the quoted researcher is also \u201cco-founder and chief medical officer\u201d of the company funding the research.\u00a0 It also shows that he has an \u201cequity ownership\u201d in the company, a clear vested interest and potential conflict.", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIn fact, Mummaneni says, stronger muscles might be the secret to Gokhale's success.\nLost Posture: Why Some Indigenous Cultures May Not Have Back Pain\n\nEditor's note, June 10: We have added an acknowledgement of several sources that Esther Gokhale used while developing her theories on back pain.\nShe puts Gokhale's method in the same category as Pilates and yoga for back pain.\nThis time around, Gokhale wanted to find a permanent fix for her back.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to Esther Gokhale, the story cites two physicians. The story clearly notes that one of the physicians refers patients to Gokhale.", "answer": 1}, {"article": "Previous studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nThe high-nitrate breakfast included 16 ounces of beet juice.\nThen they were sent home with lunch, dinner, and snacks that conformed to their assigned diets.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources.\u00a0 All quotes came from a university news release.", "answer": 0}, {"article": "\u201cMany have been told all their lives that if they ingest peanuts they will have a severe reaction and die,\" he said.\nIt means that \u201cthey are not going to have to worry about traces of peanut in a package that came from a plant where peanuts were used or minor contamination of food in a restaurant,\u201d said the study\u2019s lead author, Dr. Hugh Sampson, a professor of pediatrics at the Icahn School of Medicine and director of the Jaffe Food Allergy Institute at Mount Sinai.\nResearchers are trying to discover why food allergies have increased among children \u2014 the number of kids living with peanut or tree nut allergies tripled between 1997 and 2008, studies show \u2014 but there\u2019s no clear answer.\n\u201cAnd the patch may be a way of doing this that is safer.\u201d\n\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said.\nIn the second phase of a drug trial, half of participants wearing the highest dose \u201cpeanut patches\u201d for a year were able to consume the equivalent of four peanuts without reacting, researchers reported Sunday at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does offer the reaction of a credible scientist who is not affiliated with the study. But it contains no information to help the reader assess possible conflicts of interest among the study authors. A MedPageToday story about the same study notes that Dr. Sampson, the lead study author quoted in the story, disclosed a relevant relationship with DBV, the company that makes the patch. The story also offers no explanation of who funded the trial (again, DBV).", "answer": 0}, {"article": "Previously, no treatment was available for these patients.\"\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai.\nDr. Llovet was a member of the clinical trial's steering committee, and Charissa Chang, MD, Assistant Professor of Medicine and Liver Diseases at the Icahn School of Medicine, was principal investigator of the Mount Sinai testing site.\nIn this trial, regorafenib was well-tolerated with manageable adverse events, according to the paper in Lancet.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does note that Bayer funded the clinical trial. However, the release doesn\u2019t tell readers that Bayer manufactures regorafenib. We might be able to let this slide, assuming that Bayer\u2019s ties to regorafenib are inferred, but there\u2019s another problem. The journal article makes clear that a number of the researchers involved in the clinical trial have not only received grants from Bayer, but are also paid advisors and/or consultants for Bayer. That sort of potential conflict of interest is important to note.", "answer": 0}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nArtemisia annua is known to be efficacious against a range of other diseases, including other tropical maladies and certain cancers, so in our lab we are already at work investigating the effectiveness of DLA with other diseases.\"\n\"We have done a lot of work to understand the biochemistry of these compounds, which include a number of flavonoids and terpenes, so we can better understand the role they play in the pharmacological activity of the dried leaves,\" Weathers said.\n\"Successful treatment of all 18 ACT-resistant cases suggests that DLA should be rapidly incorporated into the antimalarial regimen for Africa,\" they added, \"and possibly wherever else ACT resistance has emerged.\"\nIt's a small study, but the results are powerful.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is wise to tell us that author Weathers is herself part of a project by the Polytechnic Institute to create processing techniques for the plant under study. But we are confused about patents held by Weathers and some of the other authors. Is there any profit possible for the authors, or WPI, if widespread use of the tablets was to begin?\nIf there is no conflict, the release could have said \u201cThe authors, while they hold patents related to the plant, do not have any potential profits or conflict of interest.\u201d", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from a number of individuals, all of whom have a vested interest in the RapidArc (a company spokesperson, a spokesperson for a cancer center that has acquired the technology, a professional society spokesperson, and a patient who has selected this treatment). \u00a0The story should have included comment(s) from someone who could have provided an unbiased evaluation of what, if any, added benefit this approach contributes to the arsenal of available treatment options.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article interviews only the president of the company that is developing the drug. The article includes no information from independent sources.\u00a0 ", "answer": 0}, {"article": "It's OK to ask the question,\" Hoberman said.\nBut the new studies, from the United States and Finland, come down firmly on the side of early antibiotic therapy for kids under age 2 or 3.\nMuch of the confusion, experts say, has been caused by studies that weren't careful enough about the diagnosis.\nIt's based on a slew of studies over the past couple of decades indicating that most children with ear infections get better without antibiotics.\nBut Spiro thinks \"the pendulum will swing the other way\" \u2013 that is, toward immediate antibiotic treatment \u2013 because of the new studies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a great job using independent experts who provided a reasoned, thoughtful discussion of the findings. The one omission was the failure in the blog post or the radio piece to report that two of the authors on the US study had received funding from the drug company that makes the antibiotic being studied:\u00a0GlaxoSmithKline. However, the drug is available as a generic product (especially the suspension used in kids) and the NIAID funded the study, so we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nFeb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were happy to see this story explain which drugmakers were interested in Esmya as a product line, but the story failed to make the same connection made in the AP story. The AP pointed out that the study was funded by these drug companies and that the researchers had worked as advisers for the companies. This is a big omission. The independent commentary from the researcher who wrote the accompanying editorial was welcome.", "answer": 0}, {"article": "Using CT-imaging equipment, the physician inserts a small needle-like instrument directly into the tumor to deliver the freezing power (at temperatures as low as minus 100 degrees Celsius) of liquid nitrogen to cancer cells, while sparing healthy surrounding tissue.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nFunding for their work was provided by Galil Medical, a medical device manufacturer based in Arden Hills, Minn.\n\nBecause this study was presented at a medical meeting, the conclusions should be considered preliminary until published in a peer-reviewed journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The one \u201cindependent\u201d expert quoted provided another valid perspective, although it seems that we may simply have dueling physician preferences at play here \u2013 the study authors possibly preferring cryoablation and the other expert quoted preferring stereotactic radiosurgery.\u00a0 And not enough evidence was provided to help readers/patients decipher where the weight of the evidence aligns.", "answer": 1}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\n\"And as far as I'm concerned, this is a cure.\nIt's only for moderate to severe cases, and like any surgery, there is risk of infection.\nFor Siravo, she said her memory is back to 100 percent.\nFor years, all Siravo and her husband, David, wanted was a good night's rest \u2013 and now they're finally getting it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only one expert source \u2014 and fails to tell readers that the source is a consultant for Inspire. In fairness, you won\u2019t find that information on the doctor\u2019s professional website. However, it is disclosed in a 2016 journal article by the doctor and one of his collaborators. If we could find that information (with a minimum of effort), we think its omission is a significant oversight.", "answer": 0}, {"article": "LONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\nAt the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nPublished in the journal Scientific Reports, results showed the stick test was 95 percent accurate over 991 blood samples, and the average time to produce a reading was 20.8 minutes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We did see any original quotes from an independent source, nor the study\u2019s authors.", "answer": 0}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\n\"This will reawaken both the users and the nonusers to say, wait a second, now we have data.\"\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\n\"I think it has the potential to increase business for Covidien,\" Garcia, chief of interventional cardiology and vascular interventions at St. Elizabeth's Medical Center in Boston, said Thursday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were comments from the principal investigator\u00a0 \u2013 but they only addressed business prospects \u2013 not clinical efficacy questions\u00a0 And there was a stock analyst\u2019s perspective.\nBut we expect more: independent clinical experts\u2019 perspectives on what the data on harms and benefits mean for patients \u2013 especially when the headline claims \u201ctools shown effective against PAD.\u201d", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Though the story included quotes from the author of a book on probiotics, it failed to include any insight from independent experts. \u00a0It should have included information from experts in the field without an association to a marketable product. \u00a0A link to something like NIH\u2019s site about probiotics would have lent some credibility to the information the story tried to impart.\n\u00a0http://nccam.nih.gov/health/probiotics/\nStating that the FDA is \"neutral\" obscures the fact that foods are not regulated in the same way as drugs.\u00a0 ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A few different independent experts raise concerns about the quality of the evidence supporting these products, their effectiveness, and their potential to cause harm. And the story seems to identify relevant commercial relationships that represent a conflict of interest. This was the major strength of the story; but\u00a0as noted above, we think these sources could have been put to better use.", "answer": 1}, {"article": "\"Folks can ask questions or get information about their health in a 'low-stakes,' relaxed environment,\" she said.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\n\"They understood that we were there with good intentions.\n'Medical mistrust has been an important barrier'\n\nThe study had some limitations, including that it was not blind, because both participants and researchers knew who was assigned to the pharmacist-led program and who was in the control group.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from both a barber-participant in the study and a researcher unconnected to this project.\u00a0 We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "In a paper published online Tuesday by the journal PLoS Medicine, the researchers found that those who consumed 15 grams or less of alcohol a day, which is the equivalent of one drink of any alcoholic beverage, when they were about 58 years old on average were more likely to have good overall health when they were about 70 years old.\nThat was after accounting for other factors, such as smoking.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\nThe findings fit with current federal dietary guidelines, which recommend up to one drink per day for women and just to two drinks per day for men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources cited.", "answer": 0}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\nEditorial: Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture\n\n\u201cUltimately, which therapy is selected for osteoporosis treatment may be less important than identifying and initiating an approved treatment,\u201d write Anne R. Cappola, M.D., Sc.M., of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and Associate Editor, JAMA, and Dolores M. Shoback, M.D., of the University of California, San Francisco, in an accompanying editorial.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nThe way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use.\u201d\n\n: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\n: This study was funded by Radius Health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "To its credit the release quotes two people not associated with the study from an accompanying editorial and explains that the study was funded by Radius Health. But it does not make it clear whether Radius Health is involved in making an osteoporosis drug. Instead, the release directs readers to the full study (which is behind a firewall and available only to journal subscribers) for information on financial disclosures. The disclosure shows that several of the researchers, notably\u00a0Paul Miller, MD, the corresponding author noted in the release, is a member of the scientific advisory board for Radius Health and several other pharmaceutical companies, and received research grants from Radius Health and a dozen other pharmaceutical sponsors.\u00a0We think this information was important enough to include in the release itself. ", "answer": 0}, {"article": "\"Yes, indeed.\"\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nHe said that experienced cardiac surgeons who have mastered conventional bypass surgery are the best candidates for learning to use robots because they have the skills and confidence to get themselves out of difficult situations that may arise.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article\u2019s sources\u00a0include a physician who has devoted\u00a0the last five years of his career to the robotic surgery, three satisifed patients, a marketing representative of the company that makes the device and one doctor who is skeptical about the device\u2019s utility in heart bypass surgery. Interviewing additional dispassionate sources would have strengthened the story.\u00a0\nThe article makes a brief refererence to the device maker being an \"enthusiastic backer\" of the Chicago program, but fails to indicate whether there is a financial relationship beyond that of customer and vendor. The\u00a0subject of\u00a0whether\u00a0Srivastava has\u00a0financial ties to the maker should have been explored, or, if it was, should have been addressed in the story. ", "answer": 0}, {"article": "Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nThe Russian State Research Institute of Circulation Pathology and the Siberian Division of Russian Academy of Medical Sciences funded the study.\nThe injections were made in the four major fat pads surrounding the heart.\nThe association makes no representation or guarantee as to their accuracy or reliability.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources (The Russian State Research Institute of Circulation Pathology and the Siberian Division of Russian Academy of Medical Sciences) are noted in the release.", "answer": 1}, {"article": "score of 0.9 or higher at the age of 50.\nThe long-term risk of dying from prostate cancer ranged from about 1 percent to 3 percent for these men, and the decision to screen may depend on their personal views and family histories, Dr. Vickers said.\nThe findings also suggest that at least half of men who are now screened after age 60 don\u2019t need to be, the study authors said.\n\u201cWe need to screen fewer people, screen the right people, and we don\u2019t have to treat every cancer we catch.\u201d\n\nA version of this article appeared in print on September 28, 2010, on page D1 of the New York edition of The Times.\nStill, the absolute risks for men with elevated scores were lower than might be expected.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0One clinician associated with the featured study reported on and an expert in the field without direct links with the study were quoted for this story.", "answer": 1}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nOn that score, American Heart Association spokesperson Penny Kris-Etherton, a registered dietician and professor of nutrition at Pennsylvania State University, suggested that the controversy concerning linoleic acid is not new and will continue.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from an American Heart Association expert, who provides some common-sense advice. It is worth noting, though, that the AHA spokesperson quoted in this story did not hint at the AHA \u201cconsidering re-evaluating its dietary recommendations\u201d as did the AHA spokesperson in the competing TIME story.", "answer": 1}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe study researchers, though, wondered if that conclusion was correct.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nIt took years, but the analysis showed the hypothesis was right.\nIt would, of course, be the worse possible outcome.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited several highly-credentialed prostate cancer clinician-researchers.\u00a0 However, the only one expressing a somewhat more negative tone got the least space.\u00a0 ", "answer": 1}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nBut texting, that old-school technology, may deserve some of that spotlight, too.\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\nAnd it worked to improve not just one risk factor for heart disease, but many.\nIt can't tell us whether text messaging could eventually lead to fewer subsequent heart attacks among the patients receiving those messages or whether the positive health outcomes would continue past the six-month study window.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from an outside expert who was not involved with the research. \u00a0The story clearly meets our bar here, although it would have been stronger if it had reached out to at least one more independent source \u2014 preferably one who hadn\u2019t written an editorial that ran in conjunction with the paper in JAMA. Yes, the editorial was independent and provides some insightful commentary. But it also means we already knew where this source stood on the issue. Finding another reputable expert, who hadn\u2019t already weighed in publicly on the work, would have been great.", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story referred to two separate academic papers, but does not cite any researchers, nor any interviews with experts.\u00a0The coverage would have been improved by seeking out and offering other opinions, rather than glossing over the concerns of critics with a two-sentence paraphrase of their arguments.", "answer": 0}, {"article": "In addition to a decreased mortality, men using PDE5 inhibitors or alprostadil were 40 percent less likely to be hospitalized for heart failure compared to those not taking any erectile dysfunction drugs.\nThis study received funding from the Stockholm County Council and the Swedish Heart and Lung Foundation.\nThe research is based on a Swedish national database of health records that includes all hospitals in Sweden.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\nThe researchers also were unable to account for socioeconomic status; as a next step, they are planning a larger study that will include more health records and complete information on marital status, educational level and disposable income.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding source:\u00a0the Stockholm County Council and the Swedish Heart and Lung Foundation. The published study discloses that one of the study authors received \u201cconsultancy honoraria\u201d from Actelion and Pfizer, two manufacturers of ED drugs. This should have been included in the release as well.", "answer": 0}, {"article": "Although many patients take drugs like statins and medicine to reduce their risk of stroke, surgical treatment of severe blockages in the carotid artery has been shown to be more effective than medical therapy alone in preventing ischemic strokes caused by a buildup of plaque in the arteries.\n\u201cPrior to the Crest trial, we really did not have the best evidence, but these results indicate that we have two very safe and effective methods to prevent stroke.\u201d\n\nThough there are differences in risk between the two procedures and individual variations, he said, \u201cthe results from stenting are very comparable to those for carotid surgery.\u201d\n\nBut Dr. Martin M. Brown, chief investigator for the European trial, the International Carotid Stenting Study, said that although differences in the groups studied might explain the disparate results, \u201cnobody has really shown stenting is better than surgery, so why choose a stent?\u201d\n\nDr. Brown added, \u201cEven if Crest shows little difference between the two, there are three other trials that suggest surgery is safer.\u201d\n\nStrokes are the third leading cause of death in the United States and a major cause of disability among adults.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\n\u201cWe had outstanding results, and our study, we think, is representative of these treatments in the and ,\u201d said Dr. Thomas G. Brott, director for research at the campus in , Fla., and lead author of the North American study, called Crest (for Carotid Revascularization Endarterectomy versus Stenting Trial).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It would have been nice to see some perspective from someone who was in no way affiliated with either of these studies\u2013something which the LA Times, in its defense, did provide in its coverage. Nevertheless, in the hierarchy\u00a0of sourcing priorities, we felt it was most important that the\u00a0coverage include some kind of European perspective to counterbalance the American voices advocating for stents. The New York Times managed to get a hold of the lead investigator for\u00a0the European ICSS trial. He made a\u00a0pretty good case for why one might think twice before\u00a0opting for a stent instead of open surgery.\u00a0\u00a0", "answer": 1}, {"article": "\"Now I feel relieved.\"\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\n\"It does bolster our confidence that it's effective in the real world,\" said Dr. Bruce Hirsch, an attending physician in infectious diseases at North Shore University Hospital in Manhasset, N.Y., who was not involved with the study.\nThe findings are published in the Jan. 12 issue of the Journal of the American Medical Association.\nTseng's team wanted to test the vaccine's real-world performance, so they compared 75,761 vaccinated members of the Kaiser Permanente health plan to 227,283 members who elected not to have the shot.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story includes more than one independent source. The comments from these sources add valuable perspective on this study and the larger context of shingles vaccination. The story reports that the Kaiser Permanente health plan funded the study. However, it does not tell readers that some of the researchers have received funding from vaccine companies for other studies or consulting.", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent job overall. The story had eight doctors, a nurse manager, and three patients commenting for the record. And at least some of them push back, very appropriately, against the story\u2019s general premise that the same-day procedure and anterior approach are better. The story might have clued readers in to the fact that surgeons are likely to speak highly of whatever approach it is they happen to practice. Those with faster operating times may emphasize that fact because\u00a0it\u2019s what separates them\u00a0from others with whom they are competing for business.", "answer": 1}, {"article": "Prebiotics reduce body fat in children who are overweight or obese by altering their gut microbiota, according to new research published in Gastroenterology, the official journal of the American Gastroenterological Association (AGA).\nThis work was supported by grants from the BMO Financial Group Endowed Research Fund in Healthy Living, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Canadian Institutes of Health Research (MOP115076-1).\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\nFollow us on Twitter @AmerGastroAssn, @AGA_Gastro (New!)\nThe AGA Institute administers the practice, research and educational programs of the organization.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were listed.", "answer": 1}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\nHowever, this study provides additional evidence on top of prior work from Dr. Andersen's lab and others that lithium may have therapeutic potential in PD, which is a hypothesis that should be tested in clinical trials,\" he said.\nCitation: The combination of lithium and L-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson's disease therapy.\nCorresponding author Y. Hwan Kim, a former member of the Andersen lab, is now in the Department of Biological Sciences, Delaware State University, Carol A. Lazzara, from Delaware State University also contributed to the work.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source for the research is clearly identified in the release. \u00a0However, we are not advised that the Buck Institute and the two senior authors of the paper filed a patent application for low-dose lithium in Parkinsons (US20130017274 A1).", "answer": 0}, {"article": "Then, the newly copied viruses break out of the cell, spreading to other cells nearby and repeating the process.\nOriginally published on Live Science.\nRead more at The Wall Street Journal.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the information in the story is attributed to the Wall Street Journal. Not good enough.", "answer": 0}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nThe therapy had an immediate and beneficial impact and turned Mathy Milling Downing, a skeptic about some kinds of mental health treatment, into a fan of mental health treatment done right.\nThe screening, unsurprisingly, found that Caroline's emotional problems were linked to her sister's death.\nIf Caroline were going to get the same kind of mental health care as Candace, Downing wanted no part of it.\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of mental health experts, several of whom served on major organization review panels on this topic.", "answer": 1}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nSome of the patients referred to us were found to be experiencing additional psychological difficulties, and needed further referral and management.\nIndividuals were referred to support services via the care of their GP and for suicide risk, immediate action was taken based on local service guidelines.\nPatients attending a clinic run by the King's College London Dental Institute Health Psychology Service at Guy's and St Thomas' NHS Foundation Trust were surveyed for their levels of dental anxiety, general anxiety, depression, suicidal thoughts, alcohol use and oral health-related quality of life.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not explicitly name the funding source for the research, only that the clinic where CBT was provided is run by the King\u2019s College London Dental Institute Health Psychology Service at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust.", "answer": 0}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nResearchers then analyzed health status information collected after the women turned 70.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nSept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes from the study, but includes no independent perspectives.", "answer": 0}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\nBut even a little can help, and according to Bernstein it doesn't have to be jogging for miles and miles.\nShe acknowledges it's sometimes difficult to encourage a patient with cracking head pain to get up and exercise.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s not clear whether either of the clinical sources in this story have any conflicts of interest or particular agendas. But in both cases they are commenting on areas where they couldn\u2019t be considered objective. In one case, the source discusses a study that he coauthored, and in the other case, the source discusses the treatment of one of her patients. We\u2019ll give the benefit of the doubt, because the second source speaks mainly about headaches in general rather than the patient discussed in the story. Ideally, a completely independent expert would have been tapped to question and evaluate the evidence presented.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes commentary from several experts, including those not involved with the new study. \u00a0The writer also points out that the CDC sponsored the study. ", "answer": 1}, {"article": "Currently, an early Alzheimer's diagnosis requires complex brain scans.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted someone from the company developing the test and quoted only one \"expert\" but he did not comment on the test but only on the subtlety of the disease. This is insufficient sourcing for a story that states: \"For millions who worry their forgetfulness could be the first sign of something worse, a blood test could, in the future, provide answers.\"", "answer": 0}, {"article": "Currently, lung cancer treatments rely heavily on chemotherapy, but doctors are shifting toward a more customized and precise way of treating each person\u2019s disease in order to improve their chances of survival.\nWhat\u2019s more, say the study\u2019s authors, doctors may also figure out which people are most likely to respond to the two-drug combination of nivolumab (Opdivo) and ipilimumab (Yervoy) and which are not.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\n\u201cThe magnitude of benefit was unexpected and great to see,\u201d says Dr. Leena Gandhi, associate professor of medicine at NYU Langone Medical Center and co-author of the study.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited from at least one independent expert.\nAll of the experts quoted were authors in the studies being reported. Also, all of the sourced reported conflicts of interest from either funding from a drugmaker or a pending patent that weren\u2019t mentioned in the story.", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The independent source was the NEJM editorial. We prefer to see more outside analysis of a study, but the editorial is an important source.  General conflicts of interest are identified. (Although the sources made some additional disclosures to the NEJM, none were overwhelming.)", "answer": 1}, {"article": "An enzyme is a protein that performs a chemical reaction.\nA new study, however, offers some potential for hope.\nSome experts identified limitations to the research.\nFRIDAY, Feb. 8, 2013 (HealthDay News) -- For people with celiac disease, everyday foods such as bread, pizza crust and muffins are potential enemies.\n\"People need alternatives, and this is an example of the scientific community taking novel approaches to helping people with celiac disease,\" Murray said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The expert source quoted at the end of the article provides some very important context. This is the major strength of the story. However, the story should have mentioned that Dr. Murray is on the scientific advisory board of a company testing a competing treatment for celiac disease. His comments should be viewed with that perspective.", "answer": 0}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\n\"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\nThere can be no guarantee that Entresto will be submitted or approved for any additional indications or labeling in any market, or at any particular time.\nNor can there be any guarantee that Entresto will be commercially successful in the future.\nNovartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release is coming from the manufacturer of the drug, Entresto, so the conflict of interest is clear. However, we would have liked it better if the release had identified, as the study did, that the principal author of the study receives grant support from Novartis, and several other authors are employees of Novartis.", "answer": 0}, {"article": "Cervical cancer is still the fourth most common cancer in women, with over 500,000 cases and 250,000 deaths per year worldwide.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nThis clinical trial was funded by Merck.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\nProfessor Jack Cuzick concludes: \"Following these important findings, this vaccine has been licenced in the USA and approval is currently being sought in the UK and other countries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release points out that the study was funded by the manufacturer of the vaccine and that Dr. Cuzick was a coauthor of the study.", "answer": 1}, {"article": "Biopsies may be performed via open surgery on the breast or with a less invasive core-needle biopsy in which a small sample of breast tissue from the affected area is removed through a special needle inserted through the skin.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has only one source who is a lead author of the study on which the story is based.\u00a0\u00a0 It is not made explicit in the story that she is involved in the study. \u00a0The story should include additional independent clinical sources to put the new information in perspective.\u00a0 An interview with an independent expert could help\u00a0provide \u00a0information on availability of\u00a0 various methods of CNB\u00a0and their real world accuracy (e.g. are most surgeons adequately trained to perform core needle biopsies?).", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a strong point for the story. The story cites multiple sources on both sides of the issue, and clearly notes when a given source has written about the issue and what that source\u2019s position was.", "answer": 1}, {"article": "It's very exciting.\"\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\n\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did include interview material from individuals not directly connected with the study reported on. And the story did include a comment from a stem cell researcher indicating that it is likely not a quick, straight shot from these results to use in people. The other sources interviewed provided a modicum of balance. ", "answer": 1}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\n\u2022 The average age of diagnosis is about 66 years old.\nPatients newly diagnosed with prostate cancer can contact world renowned prostate cancer surgeon and urologic oncologist, Dr. David Samadi, for a consultation or second opinion.\nWhat they found was more than minimal differences among the tumors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release isn\u2019t hiding any conflicts since it is openly sponsored and released by the prostate cancer specialist named. However, it almost appears as though the author hijacked a recent study about prostate cancer genetics in order to sell the physician\u2019s services to concerned patients. Details about the study itself are minimal.", "answer": 1}, {"article": "When a person has diabetes, their body either doesn't produce enough insulin or doesn't process blood sugar properly.\nThis research was funded, in part, thanks to grants from the Diabetes Action Research and Education Foundation and the American Diabetes Association.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nThe BYU team, comprised of graduate and undergraduate students in Tessem's lab and the labs of Ben Bikman and Jason Hansen (BYU professors of physiology and developmental biology), then dove in and dissected what was happening on the cellular level -- specifically, the beta cell level.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that, \u201cThis research was funded, in part, thanks to grants from the Diabetes Action Research and Education Foundation and the American Diabetes Association.\u201d The researchers did not list any relevant disclosures in their journal article. The release does not include funding from the \u201cVirginia Agricultural Experiment Station and the Hatch Program of the National Institute of Food and Agriculture, U.S. Department of Agriculture\u201d that is listed in the journal article.", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0One outside voice was included in the story \u2013 that of a judge in the Innovation Awards competition. The judge, a venture capital executive, is not a medical expert, and it\u2019s not made clear that he is not an investor in the company or in that technological field. Presumably the awards are not judged by people with a financial interest in the outcome, though the story does not say so. We hunted throughout the Journal\u2019s quite interesting package but could not find any \"how we did it\" story or anything about the judges. We think this weakened the story and the overall package. It would have been nice to hear from an obstetrician who would consider using such a test.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nAt study enrollment, none had signs of dementia.\nThe study was supported by the National Institute on Aging and the Judith Zwartz Foundation.\nDuring the course of the study, each person received annual, standardized testing for cognitive ability in five areas -- episodic memory, working memory, semantic memory, visuospatial ability and perceptual speed.\nTheir research findings were published in the May 4 online issue of Neurology, the medical journal of the American Academy of Neurology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The story clearly and prominently lists the sources of funding for the work, and there are no apparent conflicts of interest.", "answer": 1}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nThis study was funded by the National Institutes of Health.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nAdditional large, well-conducted studies are needed to clarify whether metformin may be used to prevent lung or other cancers, particularly in specific subpopulations, such as nonsmokers.\"\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the funding source for the research and also adequately discloses conflicts among the authors of the paper.", "answer": 1}, {"article": "\"I say, 'Go for it!'\nForeman writes a health column for The Boston Globe and other newspapers, so she's an unusually well-informed patient.\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\nJudy Foreman, another of Metson's patients, offers an example of both how surgery can help -- and why patients' expectations shouldn't be too high.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies\u00a0heavily on the perspective of Judy Foreman, the health columnist and patient, and her surgeon,\u00a0Ralph Metson, neither of whom have any conflicts of interest that we could identify. While it would have been nice to hear from an expert who wasn\u2019t involved in this particular case,\u00a0the story does enough to satisfy the criterion.\u00a0", "answer": 1}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nThat's the day scientists from the U.S. and Canada announced the discovery of the gene associated with the disease.\nBut the success of Kalydeco has been more than two decades in the making.\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter clearly did a lot of digging to craft this very well told piece, but the only two people ultimately quoted are Fred Van Goor at\u00a0Vertex Pharmaceuticals, which\u00a0developed the drug in question, Kalydeco, and\u00a0Emily Schaller, who was in a clinical trial for the drug and apparently saw a big benefit.\u00a0 No truly independent expert source was quoted.\n\u00a0", "answer": 0}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nAdditional studies are needed to confirm the finding, he said.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\n\u201cWe wouldn\u2019t recommend that every high-risk infant get an MRI until we know that the accuracy can be improved closer to the 90 percent range\u201d from the current 70 percent, Shen told TODAY.\nMore studies are needed, they said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from independent researchers, and we did not detect any potential conflicts of interest.", "answer": 1}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThis study was made available online in May 2018 ahead of peer-review and publication.\nThe authors report no other relevant potential conflict of interest.\nTwo studies will be published back-to-back in the December issue of Journal of Nuclear Medicine--one as featured article of the month--describing testing of three candidate molecules in patients with Alzheimer's disease, as well as the use of one molecule to measure the accumulation of tau proteins.\nThe study was divided into three parts.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding source for the research and addresses conflicts of interest.", "answer": 1}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\n\u201cWe now have a technology that can detect (lung cancer) early enough to make some impact,\u201d Berg said.\nThe new study provides further evidence of that.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nThere and in Canada, the lung cancer debate has centered around how often to screen smokers, and until what age screening should be done, Roberts said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good perspective added from one of the leaders of US lung screening studies.", "answer": 1}, {"article": "The outcomes are getting better and better.\"\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\n\"One of the improvements in outcome for ALL overall has been using methotrexate in a more intense fashion, by giving higher doses,\" said senior investigator William L. Carroll, MD, the Julie and Edward J. Minskoff Professor of Pediatrics, director of the Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders at NYU Langone and director emeritus of NYU Langone's Perlmutter Cancer Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the release does say that this clinical trial was run by the Children\u2019s Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest.\u00a0 Compounding that is the fact that the published study says, \u201cDisclosures provided by the authors are available with this article at www.jco.org,\u201d but that information is behind the journal\u2019s paywall for most readers, so it\u2019s unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments.", "answer": 0}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nAbout a million episodes of shingles, sometimes debilitating, occur in the U.S. annually, Tseng says.\nThe new study is published in the Journal of the American Medical Association.\nCalled Zostavax, the shingles vaccine is made by Merck.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story includes an independent source. However, the comments of the independent source don\u2019t address the specific methods or findings of this study. Instead, they begin to wander off into a discussion of the relationship between stress and shingles attacks.\nThe story does tell readers that this study was funded by the Kaiser Permanente health plan and that the lead author has received support from the vaccine\u2019s maker for other research.", "answer": 1}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strength of the story is that there are quotes from several sources. It\u2019s nice to see that in a story that offers a broad overview of a topic, valuable space is still given to conflicts; in this case, pointing out that the studies hinting at some potential health benefits were funded by industry groups and that the lead author is a paid consultant to a manufacturer.", "answer": 1}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nAnimal studies were approved by the Cedars-Sinai Medical Center Institutional Animal Care and Use Committee (IACUC) and the Division on Laboratory Animal Medicine (DLAM) at UCLA.\nHuman tissues were obtained from the USC Alzheimer's Disease Research Center (ADRC) Neuropathology Core, Los Angeles, CA (IRB protocol: HS-042071).\nClinical trials were approved by Quorum Review, Seattle, Washington, (IRB00003226) and the U.S. Department of Health and Human Services (FWA00019841).\nResearchers from NeuroVision, Cedars-Sinai, the Doheny Eye Institute, Retina Vitreous Associates Medical Group, Retinal Consultants Medical Group, Sutter Neuroscience Institute, UCLA, Geriatric Research Education and Clinical Center, Veterans Greater Los Angeles Healthcare System, and the University of Southern California contributed to the research and article.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Everyone quoted in the release is affiliated with the company that makes the diagnostic tool that is being tested, and that is made clear. The funding sources are also made very clear. And we were also happy to see this level of detail about the study:\nClinical trials were approved by Quorum Review, Seattle, Washington, (IRB00003226) and the U.S. Department of Health and Human Services (FWA00019841). Human tissues were obtained from the USC Alzheimer\u2019s Disease Research Center (ADRC) Neuropathology Core, Los Angeles, CA (IRB protocol: HS-042071).\nAnimal studies were approved by the Cedars-Sinai Medical Center Institutional Animal Care and Use Committee (IACUC) and the Division on Laboratory Animal Medicine (DLAM) at UCLA.", "answer": 1}, {"article": "In addition to retaining its first place ranking for the best hospital in the Twin Cities and second in the State of Minnesota in the U.S. News & World Report's 2016-17 best hospital rankings, Abbott Northwestern has received nursing magnet certification, a recognition earned by only five percent of hospitals nationwide.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nThey examined the outcomes of 294 patients who were treated between 2001 and 2015.\nThe Institute was founded in 1990 at Abbott Northwestern Hospital.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are listed in the release. No conflicts of interest are mentioned in the published study.  ", "answer": 1}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nBut even with those risks, it\u2019s worthwhile, Gaziano\u2019s team found.\nPatients and doctors alike complained that the new guidelines were confusing.\nIt would be, they report in the Journal of the American Medical Association.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were surprised that there were no independent sources quoted in the story. There are a lot of people talking about these studies, and the Times did a better job seeking out independent analysis.", "answer": 0}, {"article": "\u201cWe have the therapy.\nGao did not always believe the drug would ever make it out of the laboratory, because the field of gene therapy has been plagued with seemingly insurmountable obstacles, including the deaths of test subjects.\n\u201cWe are probably in the greatest innovative period of understanding human disease and how to make cures ever.\u201d\n\nThe concept of gene therapy is straightforward, beautiful even: Fix an illness caused by a faulty gene by replacing or supplementing a healthy new copy of the gene.\nGao, who was not directly involved in the clinical trial that led to Gelsinger\u2019s death, doesn\u2019t like to talk about it now, saying only that he doesn\u2019t blame Wilson.\nAAVs are not quite as efficient as adenoviruses at getting genes into human cells, but they are much safer: The human immune system barely notices the virus\u2019s outer coat or \u201cdress,\u201d as Gao calls it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer devotes a big chunk of the story to a discussion of investor excitement regarding gene therapy.\u00a0 So although we do not learn who is funding specific scientists or studies, we do learn the venture firms are providing many millions of dollars to support the development effort. \u00a0The relationship between investors and scientists included as sources in this story is not clear. The story also would have benefitted from quoting\u00a0researchers who are not part of the studies in question.", "answer": 0}, {"article": "\u201cThe person has to be wanting to quit smoking,\u201d he said.\n\u201cThey want to get this thing approved, obviously.\u201d\n\nBut, he said of the initial evidence in favor of the treatment, \u201cthis one is only a single study, which of course the people who believe in lasers will jump on ... (but) things have got to be confirmed.\nUsually three convincing studies involving large groups of human patients are needed before the FDA decides to approve a treatment.\nOne study, no matter how many patients are in it, really needs one or two confirmation studies.\u201d\n\nIf future studies do show its effectiveness, laser treatment would have a leg up over conventional methods of smoking cessation, such as medications including Chantix and Zyban, said Spielholz, who continues to work with Laser Therapeutics on getting FDA approval.\nBut the government organization had only dealt with drugs - not new technology - for smoking cessation, which has slowed down the process, Camera said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes extensive use of independent sources and the scientific literature. This story could be a lesson plan for someone wanting to teach a course in how to cover \"breakthrough\" treatments. 1. Find the studies being used to make these claims. 2. Read them. 3. Talk to the authors. 4. Talk to others who have done research in a similar vein.", "answer": 1}, {"article": "\"And in that case, I see this as just a waste of money.\"\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nInformation from this investigation will be pooled with those of another ongoing long-term study, which is tracking brain activity among an additional 100 autism patients.\n\"It adds evidence of functional impairment in brain connectivity in autism and brings us a step closer to a better understanding of this disorder.\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does, technically, bring in an outside source, but the source is not someone with expertise in diagnosing autism disorders or in radiology. The source is \"Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group Safe Minds.\" It is good that Bono \"expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\" But she may not be the best source to evaluate the results of this study.", "answer": 0}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted in the story. But some perspective from an expert likely would have helped the story by providing some much-needed context on the reasons people may stop taking a statin before surgery, and how to weigh the risks and benefits in light of this new data.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - An infusion of the anesthetic ketamine can lift mood within minutes in patients suffering from severe bipolar depression, according to a small study out this month in the Archives of General Psychiatry.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nBy developing more specifically targeted drugs, Zarate noted, it may be possible to treat patients effectively while avoiding these symptoms.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nNearly all were unemployed, Zarate and his team note, and two-thirds were on psychiatric disability.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story needed independent voices to comment on the size of the study, the study design, the potential harmful effects, etc.", "answer": 0}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nThe research was funded by Sparks UK; University of Bristol's Alumni Foundation; The Laerdal Foundation for Acute Medicine, Norway; University of Oslo, and a private donation.\nAlso, the severity of cerebral palsy is milder and seven out of ten are able to walk.\nThe research team has developed and delivered cooling treatment, known as therapeutic hypothermia, for newborns who suffer lack of oxygen during birth.\nThe study has been led by Marianne Thoresen, Professor of Neonatal Neuroscience, from the Bristol Medical School: Translational Health Sciences at the University of Bristol.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are noted and there is no apparent conflict of interest.", "answer": 1}, {"article": "Fish oil also boosts levels of glutathione, an antioxidant that protects the brain against oxidative stress.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\nBut while psychiatrists now know how to identify these individuals, he added, they don\u2019t know what to do with them.\nThese at-risk individuals may have weak or transient psychotic symptoms, and already show schizophrenia-like brain changes, Dr. G. Paul Amminger of The University of Melbourne in Australia, a researcher on the study, told Reuters Health.\nThere\u2019s considerable evidence that abnormal fatty acid metabolism may contribute to the development of schizophrenia, Amminger and his team note in the Archives of General Psychiatry.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main limitation of this story is that it did not provide insights from any independent experts.\u00a0 It only\u00a0interviewed the principal investigator who conducted the research on which the story was based.\u00a0\u00a0\u00a0Independent experts\u00a0could have highlighted the limitations of the research which would have been important to present.\u00a0 ", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story the benefit of the doubt, although the end result was imperfect.\nWe would have liked to hear an independent expert\u2019s evaluation of the InterStim device which, by word count, got most of the attention in the story.\u00a0 We only heard from a surgeon who uses it.\nBut at various times in the story 4 other sources were interviewed, although only one of them offered any critical analysis of the evidence.", "answer": 1}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\nThe tests are marketed under the name IBSchek\u2122 and are produced by Commonwealth Laboratories Inc., in Salem, Massachusetts.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We give the release credit here. It clearly notes that the lead author receives consulting fees from Commonwealth Laboratories \u2014 which is the company marketing these tests. And that\u00a0Cedars-Sinai has a license agreement with the company for patent applications covering the blood tests,", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The news story quoted two sources from academic institutions. It\u2019s difficult to know whether either individual has a potential conflict of interest.", "answer": 1}, {"article": "When a hookworm crawls into a human, it secretes chemicals that turn off the immune alarm bells and repair the tissue around it.\nShe wouldn't go so far as to call parasites good.\nIt was an intriguing result, but it's difficult to scale that kind of study.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nParasites are no joke.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited.", "answer": 0}, {"article": "Uterine fibroid embolization (UFE) is a less invasive option that involves injection of an embolic agent, typically made up of very small beads, into the uterine arteries to block the blood supply to the uterus and fibroids.\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nSince the time of writing, there were 12 additional pregnancies.\nThe researchers are continuing the treatments and compiling data.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were not mentioned. The research article states there were no conflicts of interest to disclose.", "answer": 0}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\n\"Our study demonstrated that the four pulses emitted from this device twice daily reduce the frequency of headache days by about three days per month, and 46 percent of patients had at least 50 percent or less migraine attacks per month on the treatment protocol.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\nThis data is clinically significant.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a major weakness of the news release.\nNot only is the funding for the study not mentioned (the study was supported by eNeura Inc.) but it\u2019s also not mentioned that 5 of 13 authors have financial conflicts of interest with this manufacturer of portable TMS devices.\nFurthermore, one of the lead authors is chairman of eNeura\u2019s medical advisory board.", "answer": 0}, {"article": "\u201cThe weight that it takes them one year to lose is typically back in two months,\u201d often because a body with longstanding obesity defends itself against weight loss by drastically reducing its metabolic rate, an effect not seen after bariatric surgery, which permanently changes the contours of the digestive tract.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\nMatched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources in the piece are the authors of published papers discussed in the story, though one of the sources is the author of an \u201cinvited commentary,\u201d rather than a study.\nAlso,\u00a0at least one of the sources in this story also had potential conflicts of interest that weren\u2019t disclosed:\u00a0Dr. Stacy Brethauer has worked as a speaker or consultant for several companies that provide products for bariatric surgery.", "answer": 0}, {"article": "\"If you really want this drug to have a big impact, you should use it as early as possible.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nThe report was published online Oct. 12 in the journal Neurology.\nThe decision to start Lemtrada should be made in the context of the risks, including infusion-associated reactions, infections, and autoimmune adverse events, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several potential\u00a0conflicts of interest were not disclosed. From other sources, including here, we see that lead researcher Dr. Giovannoni receives consulting fees from Bayer Schering Healthcare, Biogen Idec, Genzyme, GlaxoSmithKline, GW Pharma, Merck Serono, Novartis, Protein Discovery Laboratoires, Teva-Aventis, Vertex Pharmaceuticals, UCB Pharma, Pfizer.\nAnd as for the source from the National Multiple Sclerosis Society, the society reported receiving nearly $2.6 million from the\u00a0drug\u00a0manufacturers who funded this study (Bayer and Sanofi) in 2015.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert voices appeared in the story. ", "answer": 0}, {"article": "\"So I feel like that touches a nerve with them.\"\nOne limitation of this new study is that it relies on data from women who had to recall what they ate during high school.\n\"Unfortunately for teenagers, they're [into] instant gratification,\" and they're not necessarily focused on how their actions today will influence their future health, she says.\nShe says it can be hard to get the attention of teenagers about healthy eating.\n\"This is a really important study ... [suggesting] that the more fiber you eat during your high school years, the lower your risk is in developing breast cancer,\" says Kimberly Blackwell, a breast cancer specialist at the Duke Cancer Center.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes two researchers in regard to the study. One was the study\u2019s lead author, and the other was the author of a commentary on the study that was published in the same issue of Pediatrics. A third source is quoted in regard to what can be done to get teens to eat more fiber, but that source doesn\u2019t address the study in question. We\u2019ll give the story credit for reaching beyond the authors of the study, but we think the story would be much stronger if it had incorporated more expert analysis on the study itself.", "answer": 1}, {"article": "The F.D.A.\nThat, said Dr. Leon of Columbia, who was the trial\u2019s principal investigator, was remarkable.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nFormer skeptics like Dr. Cohn now recommend the procedure for high-risk patients.\nIt was written into the Medicare coverage decision, a first for a medical device.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article features in-depth reporting with plenty of expert testimony \u2014 a rarity in health news today and a delight to these reviewers. It might have been nice to include a source who could better explain some of the harms of TAVR.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does not include any comments from independent sources\u2013or even from one of the researchers themselves. It only refers to the original journal article. Why does this matter? It\u2019s always a good idea to consult an outside source because it\u2019s likely to yield insights and context that otherwise would be lacking. But overall, this is a case where the story\u00a0is still fairly strong, regardless of the lack of sourcing or interviews.", "answer": 0}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nThe new analysis of three separate studies included more than 4,500 people.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\n\u201cWhen the hunger comes back, the topiramate kicks in,\u201d says study author Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mention that the study author and Dr. Aronne received funding from the manufacturer of this drug. \u00a0It also included a quote from the president of the American Society of Hypertension who does not appear to have a financial tie to this product.", "answer": 1}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The first author of the study reported on and the author of the editorial about that study appear to have been interviewed for this piece.", "answer": 1}, {"article": "\"Every day.\"\nIt's called TDCS, Transcranial Direct Current Stimulation.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nA small electrical current seems to work by affecting pain centers deep within the brain, somehow muffling the perception of pain.\nThis new approach places them right on the scalp.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both sources interviewed are interested parties. At least one of them is a clinical investigator for the trial, the other his colleague at the same institution. \nThe reporter should have interviewed at least one independent expert on chronic pain for some context.\nIn addition, the only subject interviewed reports a positive outcome. \u00a0", "answer": 0}, {"article": "In the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\n\"What we tell women is that we don't know of a safe threshold for drinking alcohol during pregnancy.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nThe Kelly study appears in the Oct. 5 online issue of the Journal of Epidemiology and Community Health.\n\"But that is a world away from recommending that expectant mothers should drink,\" Kelly is quick to add.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "On this criterion, this story did better than the other one we reviewed. It includes an independent source: Dr. Eva Pressman, director of maternal/fetal medicine at the University of Rochester. She serves as the voice of moderation, and she says some things that are actually pointed out in the study itself. One thing missing from both of these stories is any mention of who funded the research, but since the funding came from a public agency, we won\u2019t penalize the story. Of course, if the funding had come from an entity connected to the alcoholic beverage industry, disclosure (and heightened skepticism) would have been imperative.", "answer": 1}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\nStill, some researchers not involved in the study said the topic required more work.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does clearly state the relevant study was funded by Pfizer \u2014 the drug company that makes Chantix. That\u2019s good. However, the story quotes only three sources. Two of them are authors of the relevant study. The third is David Abrams, who heads the Schroeder Institute for Tobacco Research and Policy Studies. A quick internet search finds that Abrams has also done smoking cessation research with funding from Pfizer. The story would have benefited from input from an expert with no ties to Pfizer\u2019s smoking cessation research.", "answer": 0}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nThe full picture of the knock-on effects of exposing your gut flora to antibiotics is still coming into focus, said Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics, and Policy and a leading voice on the dangers of mounting antibiotic resistance.\nBut he said additional studies should be conducted first to try to get a better picture of the potential consequences of using doxycycline this way, including the risk of resistance developing, the potential that it might further erode condom use, and any other unintended consequences.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nMolina insisted he would never support long-term use of antibiotics to prevent STIs, but said that the approach might be an effective short-term strategy when paired with other control approaches, like more frequent STI testing among high-risk populations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strength of the story is that it includes multiple independent sources. It reports funding from the Bill & Melinda Gates Foundation. However, the story does not report funding from a French government agency, nor does it refer to the lengthy list of industry financial ties that many of the researchers disclosed. But we will give the story a satisfactory rating because doxycycline is available as a generic drug produced by a number of companies, not just those the researchers have ties to.", "answer": 1}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThe results announced Monday at a conference in Boston left experts cautiously excited.\nMatt Sharp, 54, of suburban San Francisco, also had the treatment in September.\nThe sixth man also had modified cells, but fewer than expected.\nThe only side effect was two days of flulike symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were quoted.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources, and the fact that Novartis funded the study to support the FDA approval isn\u2019t mentioned.", "answer": 0}, {"article": "\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nThis finding came after Exubera had been pulled from the market, and the sample size wasn't large enough to draw a definitive link between the drug and the increased risk of lung cancer.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted, who pointed out that safety studies \"came out clean\" and that we don\u2019t have long-term safety data. He also confirmed the formulation\u2019s mechanism of action and associated hypoglycemia profile.\u00a0Dr. Leone-Bay\u2019s affiliation with MannKind is identified, as is Dr. Dutta\u2019s role at the Juvenile Diabetes Research Foundation. (The article should have indicated, however, whether Dr. Dutta has any financial relationships with the company that is trying to bring this product to market.)\n Nevertheless, the lack of evidence sources, balance, evaluation, and any independent analysis save for one quote precludes a Satisfactory rating on this criterion. Much more of the claims, many explicitly from the VP\u2019s mouth, needed the counterweight of independent eyes.\u00a0\nReporters have to be more cautious when using the senior executives of pharma companies for the main source of information on a new product. \u00a0These stories in particular should try to find objective, senior scientists in the field who do not work for the company to give an assessment of the new therapy.", "answer": 0}, {"article": "In the past, babies acquired Bifidobacterium from their mother during childbirth, but due to the increased use of modern medical practices such as antibiotics, C-sections and formula feeding, nine out of 10 babies born in the U.S. today no longer acquire it.\nEvivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nPoint-of-Care Diagnostic Expert Turns Focus to the Infant Gut\n\nThe development of the prototype is led by Dr. Bethany Henrick, Ph.D., Director of Immunology and Diagnostics for Evivo.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The Evivo stool test is clearly described as owned by Evolve Biosystems, Inc., and that company\u2019s associations and funding are similarly made clear.", "answer": 1}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is an example of how simply seeking independent experts\u2019 quotes isn\u2019t sufficient.\u00a0 Yes, there were four independent physicians quoted.\u00a0 But none was quoted directly addressing the evidence with any substance.\u00a0 Instead, they were quoted giving only vague reactions such as:\nThe closest thing to a helpful independent perspective was this quote: \u201cHow it works in the lab setting is very different than how it works on your skin.\u201d\nWe will give the story a BARELY satisfactory score on this one, and that\u2019s being generous.", "answer": 1}, {"article": "\"It's not something we'd recommend at this stage for the general population,\" Damian said.\nResults of the study are being presented at the annual meeting of the American Society of Clinical Oncology later this month.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\n\"If you can reduce the new skin cancer rates for these patients, it would be an enormous benefit,\" she told CBS News.\nDr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two\u00a0independent sources are quoted in this story about the study. But as with AP\u2019s coverage, the quotes offered here provide little in the way of substantive analysis.\nBut that\u2019s one of the pitfalls of reporting on abstracts that haven\u2019t even been presented to a scientific conference yet, much less published. It\u2019s almost impossible to get truly substantive analysis because the data haven\u2019t been adequately scrutinized.\nWe\u2019ll award a borderline Satisfactory, however, since their comments do relate specifically to the expected impact of the benefit reported in the study.", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nIn the new study, most of the walnut eaters snacked on the shelled whole nuts straight out of the package, Robbins says.\nAug. 15, 2012 -- If you aspire to fatherhood, it might not hurt to go a little nuts.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentions that the study was partially funded by the California Walnut Commission, and it solicits a comment from an independent fertility expert. However, the expert\u2019s comments don\u2019t really add anything in the way of critical evaluation of the research or its implications. His quote\u00a0is generally supportive of the idea that diet plays a role in fertility, but offers nothing specific about the study. He could have been tapped, for example, to evaluate the clinical importance of the results. Tough call, but since he also offers advice suggesting that we\u2019re still a ways away from concrete recommendations regarding walnuts (\u201cFor now, the idea is to eat healthy with a varied diet.\u201d), we\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "Gene therapy proposed for bleeding disorders involves introducing DNA carrying the code to produce the specific clotting factor lacking in patients.\nBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\nThe Margaritis team collaborated with University of North Carolina (UNC) scientists, led by Tim Nichols, M.D., professor of Medicine and Pathology at the UNC School of Medicine.\nBoth Nichols and Margaritis agreed: \"The table is now set to propose clinical trials that would treat people who suffer from FVII deficiency.\"\nThe CHOP team collaborated with scientists at UNC who have a long-established colony of dogs for hematology research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There were no conflicts identified. All the funding sources were listed.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert source is quoted throughout the story. This is problematic not least because representatives of both Epic Sciences and Genomic Health are quoted on the clinical utility of the test, and their claims need to be\u00a0validated or refuted by experts with no skin in the game.\u00a0It would also be important to get an independent take on the study itself, the strength of the evidence and\u00a0whether there were any limitations that should be highlighted.\nAdditionally, next to no information is given about conflicts of interest. While the lead author\u2019s affiliation is\u00a0given as Memorial Sloan-Kettering Cancer Center, the majority of co-authors of the study are employees of Epic Sciences. This surely warrants a mention so readers are not given the false impression that the company had no role in the study. Moreover, the lead author Howard Scher has received research funding, personal fees and non-financial support from all the companies behind\u00a0the prostate cancer drugs in question. Despite the fact that the blood test would theoretically identify patients who would be better off\u00a0not receiving the drugs, Scher has highly relevant conflicts of interest, thus increasing the need for independent expert sources.", "answer": 0}, {"article": "(Reuters Health) - People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.\nAbout 1,700 participants were over age 40, had no other known eye diseases and had full eye examination results from the survey.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\nIn this group, Coleman\u2019s team found that just over 5 percent, 82 people, had glaucoma.\nOverall, both medical and non-medical approaches are key to treating the disease in the future, Aref added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two opthalmologists who weren\u2019t involved in the study were interviewed, and we could detect no conflicts of interest.", "answer": 1}, {"article": "Both VEGF Trap-Eye and Lucentis block a protein called vascular endothelial growth factor that causes blood vessels to grow and leak into the eye.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nRegeneron\u2019s drug, which is called VEGF Trap-Eye, \u201cgives us the opportunity to not have to see them monthly,\u201d said Dr. Jeffrey Heier of Boston, an investigator in one of the trials and a consultant to Regeneron.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert source quoted in the story was an investigator on the study of the new drug. Although the story disclosed that he was a consultant for the drug\u2019s manufacturer, Regeneron,\u00a0it should have sought out a comment on the findings from\u00a0somebody with no stake in the research. This is especially important considering the findings were not published in a journal and presumably have not been vetted by other researchers.", "answer": 0}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\n\u201cAnd Amgen\u2019s not a company that likes to price gouge.\u201d\n\nSchmidt said Imlygic\u2019s market potential as a standalone drug is \u201cvery, very modest.\nBut for the first time, scientists are poised to bring to the US market a virus that can help thwart cancer, a development that could herald a new age of viral therapies.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\n\u201cIt\u2019s nothing short of dramatic,\u201d said Dr. Jason Chesney, an oncologist at the University of Louisville, who is involved in running a larger, follow-up study of this combination approach.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a number of experts and clearly a lot of legwork went into the reporting. But two of the sources quoted in the story consult for Amgen, the company that will sell this treatment, and they are not so identified. From the description provided in the story, some readers can probably gather that these experts are involved with the company. But it would have been better to state clearly that these are paid consultants. In addition, we wish that any of the sources quoted in the story had raised questions, pointed to limitations, or provided some critical analysis of the research. The overall tone of the piece is optimistic and positive \u2014 overly so in our view.", "answer": 0}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one was quoted, suggesting that no one was interviewed.", "answer": 0}, {"article": "Early opposition to Gardasil was based on concerns it could encourage sexual activity in the young.\n\"This is certainly a wonderful, good step in addition to our screening processes\" in helping eradicate cervical cancer, said Dr. Monica Farley, who heads the advisory panel.\nShe is a bacterial infectious disease expert at the Emory University School of Medicine.\nThursday's discussion focused on its use in preventing HPV-related disease in girls and women, including those as young as 9.\nMerck said the drug is not intended to do that.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the president of the American Cancer Society is quoted. Single-source health care stories are insufficient. See explanation at: https://www.healthnewsreview.org/rThemes.php#sss", "answer": 0}, {"article": "For those with neglect, doctors typically prescribe cognitive rehabilitation, in which therapists teach skills and help the patient become more aware of the affected side of the body.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nIt\u2019s also not clear if the treatment might help most neglect patients, or if the findings only apply to certain groups, she told Reuters Health.\nBut, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\nThe ideal option might end up being a combination treatment that involves stimulation in certain patients and other therapies that address a range of skills important for regaining function, Barrett added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an author of the new study as well as a neurologist who wasn\u2019t involved with the research.\u00a0 In fact, that independent expert was quoted before the study author was.  ", "answer": 1}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nMerck said trial results would be presented at an upcoming medical meeting.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources quoted in the story \u2013 only Merck statements about Merck\u2019s own drug.", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\n\u201cOur study showed that psilocybin facilitated experiences that drove reductions in psychological distress,\u201d says Bossis.\nThe drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nNeither patients nor researchers knew who had first received psilocybin or placebo.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a strength of the release. It not only tells readers who funded the work, but that one of the funding organizations is focused specifically on research involving psychedelic drugs \u2014 and that one of the researchers previously served on that organization\u2019s board.", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are told that \u201cthis work was supported in part by the National Institutes of Health and in part by the Paul and Irma Milstein Family Foundation and the American Skin Association.\u201d", "answer": 1}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two outside sources provided comment, and readers are told the study was funded by the National Cancer Institute, a government-funded organization.\nHowever, and unlike a STAT story on the same study, the Times didn\u2019t mention how AstraZeneca \u2014 a maker of a hormone-blocking drug for men \u2014 was a study sponsor.", "answer": 0}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nThe study, in the Annals of Internal Medicine, argues that current medical guidelines haven't adequately considered the risks from these widely used drugs.\nBut that test, which Grundy says is available for about $100, is controversial among some physicians.\nPuhan says, based on his assessment, perhaps 15 to 20 percent of older adults should be taking statins \u2013 far less than the 30 or 40 percent suggested by current medical guidelines.\nHe notes that physician guidelines don't generally compare the relative value of these drugs, which are all available as inexpensive generics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes sources that weren\u2019t involved in the study. The study\u2019s authors reported no conflicts of interest.\nThe story could have acknowledged the influence of pharmaceutical companies in creating guidelines for statin use.", "answer": 1}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\n\u201cIt\u2019s a shift from having our mental health defined by the content of our thoughts,\u201d Dr. Hayes said, \u201cto having it defined by our relationship to that content \u2014 and changing that relationship by sitting with, noticing and becoming disentangled from our definition of ourselves.\u201d\n\nFor all these hopeful signs, the science behind mindfulness is in its infancy.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe real issue, most researchers agree, is whether the science will keep pace and help people distinguish the mindful variety from the mindless.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job balancing comments from several leading proponents of mindfulness therapies with summaries of the evidence of this practice in clinical trials. The story discusses caveats that the practice may be useful as part of an integrative treatment plan; however, evidence suggests it is not a panacea for depression or anxiety, and it should be used with caution (or not at all) with some patients.\u00a0 The journalist should be commended for the range of mindfulness experts, clinicians and patients interviewed in the article. This is a well-balanced report providing the reader with good information on a trend in medicine, but appropriately tempering over-enthusiam for the practice with available evidence.\u00a0 ", "answer": 1}, {"article": "+ Loss of fat was associated with faster walking speed, while loss of muscle was associated with reduced knee strength.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\nThe research was funded by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute.\nPartial support also comes from grants by the National Institute on Aging.\nFor older adults trying to slim down, pumping iron might be the way to go.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study funders were disclosed at the bottom of the news release.", "answer": 1}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\nThe work was funded by the Wyss Institute and the Defense Advanced Research Project Agency (DARPA).\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nAs a prerequisite to their clinical study, the Wyss Institute's team had successfully tested the assay in rat and pig models of infection with pathogenic E. coli bacteria.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding sources for the research. But the release doesn\u2019t mention the financial stake the researchers have in the development and eventual marketing of the test under a start-up called Opsonix. Those ties include equity holdings and patents. According to the published study,\n\u201cD.E.I. and M.S. hold equity in Opsonix Inc., and are members of its scientific advisory board. M.C. is a consultant for Opsonix Inc. D.E.I. also holds equity in Emulate Inc., and chairs its scientific advisory board. D.E.I., M.S., M.C. and M.R. are inventors on patent applications WO2013012924, WO2011090954, WO2015009734, WO2013130875. J.T., and N.G. are inventors on patent application WO2015009734. A.W. is an inventor on patent applications WO2013012924, WO2013130875.\u201d", "answer": 0}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\nFourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\nAlley and his team presented data from KEYNOTE-028, an ongoing trial involving 13 different research sites in six different countries all looking at the effect of pembrolizumab on patients with advanced malignancies, including malignant pleural mesothelioma.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was funded by the manufacturer (Merck) and that no financial relationship exists between the lead researcher and the manufacturer.\nHowever, according to the study, four of the co-authors do have individual conflicts of interest and three of the seven authors are Merck employees, two of whom own Merck stock options. These relationships go beyond Merck\u2019s funding of the study and should have been mentioned in the news release.", "answer": 0}, {"article": "Severe temporal headaches can result from muscle spasms or enlarged blood vessels putting pressure on specific nerves located on the side of the head--specifically, the zygomaticotemporal branch of the trigeminal nerve (ZTBTN) and sometimes the auriculotemporal nerve (ATN).\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\nDr. Peled found that this short incision, placed in the temple behind the hairline, provides direct access to the ZTBTN and ATN.\nHe hopes his new technique will \"lower the bar to adoption\" of effective surgical treatment for patients with this debilitating headache condition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does a good job of disclosing the fact that Dr. Ziv M. Peled of Peled Plastic Surgery is a Member Surgeon of the American Society of Plastic Surgeons (ASPS). It isn\u2019t clear, but it seems the 19 patients mentioned in the release were Dr. Peled\u2019s private patients.\nAlthough we would have liked this to be explicitly stated, we feel this earns a Satisfactory rating.", "answer": 1}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nLink will be live at the embargo time http://jamanetwork.\nWant to embed a link to this report in your story?\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and conflicts of interest are not addressed in the news release. Is is suggested readers consult the original article (link provided) for more information.", "answer": 0}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\nThe website includes detailed assistance developed by the National Cancer Institute to support smokers trying to quit.\nFor more information on the Tips campaign, including profiles of the former smokers, other campaign resources, and links to the ads, visit www.cdc.gov/tips.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release offers very little information about the study \u2014 readers aren\u2019t told who performed the study or who paid for it. Two of the authors are CDC researchers, and the study itself was funded by the CDC. To be clear: neither of those facts is necessarily problematic; what\u2019s problematic is that the release doesn\u2019t share that information with readers.\nHowever, since the study is evaluating a CDC initiative and being published in the CDC\u2019s journal, savvy readers would most likely deduce CDC funding.", "answer": 0}, {"article": "The researchers found that 7 percent of patients on linagliptin experienced hypoglycemia, compared to 38 percent of patients treated with glimepiride.\nThe researchers noted that which drug they should be prescribed is unclear.\nThey added more research is needed to confirm their findings.\nNone of the patients had responded to metformin alone.\nThe study was published online June 27 in The Lancet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story says quite high that the study \u201cwas funded by linagliptin\u2019s maker, Boehringer Ingelheim,\u201d and it quotes one independent source. More sources would have been better.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nThe 18 different molecules are drawn from a phrasebook of chemical chatter that occurs among cells in the body.\nHe said it will take at least two years and additional studies before such a test might reach clinics around the country.\nMucke has no financial interest in the technology, although Wyss-Coray trained in his laboratory.\nBut he said that a test showing the likelihood that the disease will develop will help patients and family members prepare for what lies ahead.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from two individuals with expertise in the field but no direct connection with the publication discussed or the company which has been established to market the test.", "answer": 1}, {"article": "May 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A comment from one independent source was included in this story. \u00a0The story indicated that two of the researchers involved in the study reported on were employees of Danone Research. \u00a0Although not mentioned in the story, a third researcher who was extensively quoted in this piece is listed at her host institution, as conducting work funded by Danone and using products supplied by Danone in the work.", "answer": 1}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\nIf more funding becomes available, the researchers hope to launch a larger study, Zick said.\nThere's more on ginger at the U.S. National Library of Medicine.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted.", "answer": 1}, {"article": ", follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\nSaid Co-author Douglas P. Kiel, M.D., M.P.H., Director, Musculoskeletal Research Center at Hebrew SeniorLife's Institute for Aging Research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There are no details in the release about how the authors of this research may or may not be tied to the bone density testing industry. \u00a0But the published report makes it clear that they have ties to Hologic, which makes bone density testing machines:\nDr. Wilson is an employee of Hologic Inc. and reports personal fees, non-financial support and other from Hologic, Inc., during the conduct of the study; personal fees and other from Hologic, Inc., outside the submitted work; In addition, Dr. Wilson has multiple densitometer imaging and reporting patents which may be relevant, US and worldwide, both pending and issued owned by Hologic, Inc.\nThese are the kinds of financial ties that should always be disclosed in news releases.", "answer": 0}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\nThe fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is balanced in term of sources cited. The story identifies researchers who conducted reviews, oncologists in practice, the physician who designed guidelines for Her2/neu testing, and a representative from Genentech. Clinicians express frustration and confusion about a lack of standardization for determining who should receive Herceptin and similar treatments.", "answer": 1}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nAbbott said it does not disclose the price of its stents.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\n\"The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,\" states Evercore ISI analyst Vijay Kumar, in an investment note.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both of the sources\u2014one who conducted the research testing the stent and one who advised the FDA\u2014are clearly identified, as is Abbott Labs as the creator and presumed funder of the stent. A financial analyst is also included.\nThis is sufficient for a Satisfactory rating, though none of these sources represent the ideal of what we\u2019re looking for\u2013a medical expert who is independent of the research and the stent\u2019s FDA approval process.", "answer": 1}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nMaximum contact time was four hours of individual consultation, and neither group received any additional dietary advice or information.\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nI'd still like to lose a touch more, but I'm so delighted with the mind-set shift.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly identified. There are no apparent conflicts of interest, though the release would have been stronger if it had addressed this directly.", "answer": 1}, {"article": "The heat causes the blood vessels in the tumor to dilate, bringing more oxygen into the tumor, which makes cancer cells more vulnerable to radiation therapy.\nMPTC \u2013 which is affiliated with the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Medical Center \u2013 is the only proton treatment center in Maryland.\nMPTC offers a robust clinical trial program to all its patients to further evidence-based medicine.\nIt is also an important treatment option for children with cancer.\nAccording to Dr. Vujaskovic, the new deep-tissue thermal therapy equipment, which is made by Pyrexar, will be used to treat cancers of the abdominal and pelvic region, including cancer of the bladder, rectum, cervix, ovaries, pancreas and connective tissue, which are known as sarcomas.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies private donors and a foundation that contributed to their hyperthermia system, although they do not list other sources of funding for the proton therapy.", "answer": 1}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nBut in many cases that are nine or 10 months they otherwise would not have had.\nThis is very unusual in the world of drug development, he said.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted.", "answer": 1}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nThe National Institutes of Health, plus the Diabetes Research and Training Center and the Institute for Translational Medicine at the University of Chicago funded this study.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea.\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the sources of funding for the study, which were the National Institutes of Health and the University of Chicago\u2019s Diabetes Research and Training Center and Institute for Translational Medicine. The release also quotes two researchers and makes clear that both researchers were authors of the paper describing the work.", "answer": 1}, {"article": "Cholesterol does not leave the blood and enter the brain, instead it is made in astrocytes and plays a role in making myelin, the nerve coating, and synapses, the nerve connections.\nIn addition to senior author Dr. Rhonda Voskuhl, who directs UCLA's Multiple Sclerosis Program and holds the Jack H. Skirball Chair in Multiple Sclerosis Research, study co-first authors were Noriko Itoh, Yuichiro Itoh, and Alessia Tassoni, with other co-authors including Emily Ren, Max Kaito, Ai Ohno, Vista Farkhondeh, Hadley Johnsonbaugh, Yan Ao, Josh Burda and Michael Sofroniew, all of UCLA.\nThe work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nThe study is published in the Proceedings of the National Academy of Sciences.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release lists the funding sources. The authors declared no conflicts of interest in the published study. ", "answer": 1}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\nTotal energy intake was within the normal range.\n\"Future studies should examine which people or patients may need to limit their intake of saturated fat,\" assistant professor Simon Nitter Dankel points out, who led the study together with the director of the laboratory clinics, professor Gunnar Mellgren, at Haukeland university hospital in Bergen, Norway.\nIt may be more important for public health to encourage reductions in processed flour-based products, highly processed fats and foods with added sugar,\" he says.\n\u2022 The Study is named (FATFUNC) and was performed by researchers at the KG Jebsen center for diabetes research, Department of Clinical Science at the University of Bergen.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not list funding sources or provide any statement regarding potential conflicts for the principal investigators.", "answer": 0}, {"article": "That muddies the picture because men may see a benefit in the form of fewer heart attacks, whereas aspirin appears to lower the risk of stroke in women.\nThe new work, by Alfred Bartolucci of the University of Alabama at Birmingham and colleagues, was supported by aspirin-maker Bayer AG.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted. And the story noted that the research was funded by Bayer.", "answer": 1}, {"article": "The study comes a month after Gov.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\nIt eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes experts and advocates that represent the key perspectives in debate about CT screening for calcium deposits in coronary arteries. However, it does not include information on possible conflicts of interest.", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to \nquoting study authors, a quote from an editorial in the journal in which one of the articles was published was provided.", "answer": 1}, {"article": "medical personnel.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nThe test is so simple and inexpensive that any coach or parent potentially could administer it, the study\u2019s authors believe, and any league afford to provide it as a way to help evaluate and safeguard players.\nThe upshot, Dr. Galetta believes, is that parents and coaches \u201cshould absolutely consider\u201d familiarizing themselves with the King-Devick test and administering it to young athletes before the season starts, then having those baseline numbers and the test itself handy on the sidelines.\nThe pace-along-the-tape test was also relatively accurate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes only one source \u2014 the lead author of the study. Considering there are numerous resources now devoted to sports-related concussion research, diagnostics and treatment, and considering there is quite a bit of disagreement among experts as to what are the best methods, this story would have been a lot stronger with additional voices.", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nHe led the study and gave results Monday at a meeting of the American College of Cardiology.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nAn even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from\u00a0two of the authors of the study as well as the director of the National Heart, Lung, and Blood Institute and the president of the American College of Cardiology.\nIt might have been useful to readers to have a comment from a clinician in primary care.", "answer": 1}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe women underwent DWI followed by biopsy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No statement is made regarding the funding source for the study.", "answer": 0}, {"article": "1 Yiou et al.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\nWe anticipate that the procedure will be available to patients that meet the eligibility criteria within the next 60 days.\"\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\n\"Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release says in the second sentence that the trial was sponsored by Creative Medical Technology Holdings, the same company that is marketing the product.\u00a0It\u2019s good that this conflict of interest was disclosed.", "answer": 1}, {"article": "\"What we are developing, and a lot of other companies too, are small molecule antiviral agents that specifically target the virus.\"\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nThe research is so early that the drug hasn't been named.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "According to disclosure statements from a 2008 CME program,\u00a0Dr. Bruce Bacon, an expert source for this story, received research funding from Bristol Myers Squibb, which is developing the experimental drug being discussed. He also is a consultant to drug companies developing competing drugs for hepatitis C.\u00a0To avoid the appearance of a conflict of interest it is desirable to identify\u00a0relationships such as these clearly.\u00a0 This story fails to do so.", "answer": 0}, {"article": "Each patient completed standardized behavioral rating scales and participated in a semi-structured interview answering five open-ended questions to stimulate conversation, such as \"Do you have hope?\"\nOnly now are our algorithms capable of supporting those caregivers.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\n\"When you look around health care facilities, you see tremendous support from technology, but not so much for those who care for mental illness.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This\u00a0isn\u2019t made clear in the release, but it also isn\u2019t clear in the study itself. As one saving grace, though, the lead author \u2014 who is a professor at\u00a0Cincinnati Children\u2019s Hospital Medical Center \u2014 is clearly identified.", "answer": 0}, {"article": "Inflammation can also occur as a result of the immune system mistaking healthy cells for infected cells and attacking the body, leading to autoimmune inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nMeta-analyses of the other types of clinical trials showed similar results.\n\"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease.\nAnti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding of the review article are clearly stated in the release. However, the potential conflicts of interest among researchers involved in the studies included in the review are not mentioned. Some of the researchers received honoraria from drug companies. That should have been noted in the release.", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nHere\u2019s how he got out.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nAt 14, MS-13 was his family.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only one investigator is quoted. The story mentions an NIH meeting without any details that would allow a reader to learn more.", "answer": 0}, {"article": "Coronary angioplasty is a procedure in which arteries are opened to increase blood flow to the heart.\n\u201cWe use risk-prediction models to predict their risks ahead of time, and we plan ahead to mitigate any issues so we can facilitate a same-day discharge.\nThis is really about patient care.\nBut with advances we have in technology and equipment, those challenges are rapidly decreasing.\u201d\n\nThis work was supported by a grant from Vita Solutions, a subsidiary of The Medicines Company, for whom Amin has provided consultation; and by the National Institutes of Health (NIH), grant numbers UL1TR000448, KL2TR000450, TL1TR000449 and 1KM1CA156708-01.\n\u201cWe have unequivocal evidence and data that show better outcomes when we access the heart\u2019s coronary arteries and perform angioplasty through a blood vessel in the wrist rather than through the femoral artery in the groin,\u201d said first author Amit P. Amin, MD, an assistant professor of medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is to be commended here for how it discloses funding sources and potential conflicts of interest. It includes these disclosures in an end note which doesn\u2019t interfere with the flow of the release. This is what we\u2019d like to see in all news releases.", "answer": 1}, {"article": "47(5) pp.\nAll patients at the 15 study sites also underwent 25 minutes of lifestyle therapy administered by a blinded registered dietitian every three weeks.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\nThe Agency for Healthcare Research and Quality (AHRQ) reported significant improvements in the safety of metabolic/bariatric surgery due in large part to improved laparoscopic techniques.\nSix months after the balloons were removed, 89.5 percent of the average total weight lost during the treatment period was maintained.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to report that the manufacturer, Obalon Therapeutics, was responsible for the trial or that the \u201cStudy Chair\u201d listed on ClinicalTrials.gov is a company employee.", "answer": 0}, {"article": "The supplements taken by women in the study contained 210 mg of gamma linolenic acid, 175 mg of oleic acid, 345 mg of linoleic acid, 250 mg of other polyunsaturated acids and 20 mg of vitamin E, according to researchers.\nThe study cites research dating back to 1983 examining such a possible link.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As stated above, this story needed some independent expert comment.\u00a0 There were also no statements made about conflicts of interest. Since the market for PMS is so big, it would have been helpful to know if these scientists had any vested interest in the results.", "answer": 0}, {"article": "The American Heart Association has more on heart failure.\nTUESDAY, Nov. 16, 2010 (HealthDay News) -- By substituting a healthy gene for a defective one, scientists were able to partially restore the heart's ability to pump in 39 heart failure patients, researchers report.\nAfter that, the only option is a transplant.\nAnd research presented at meetings isn't subjected to the same level of scrutiny as studies published in peer-reviewed journals.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two independent experts and reports that the trial was funded by the company developing this gene therapy. Unfortunately, those experts\u2019 quotes didn\u2019t add much to help readers evaluate the quality and value of this trial. But it nonetheless gets a barely passing grade on this criterion. ", "answer": 1}, {"article": "Researchers found that more patients taking Prozac or Effexor had a substantial improvement in their symptoms than those taking a drug-free placebo pill, regardless of how severe those symptoms were to begin with.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nSome of the study\u2019s authors have testified for or received funding from drug companies, though the report itself was funded by national health agencies.\nStill, Gibbons said that the improvement in symptoms for the average patient wasn\u2019t insignificant.\nAbout 9,000 participants were included.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story interviewed Irving Kirsch, frequently cited/quoted on antidepressant research issues.\nIt also did a good job of noting potential conflicts of interest.", "answer": 1}, {"article": "Weight gain is a common side effect of Zyprexa.\n\"The positive result was only marginally significant, and the negative result was clear,\" said Dr. Thomas McGlashan, a professor of psychiatry at Yale and the study's lead author.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\nThose on medication gained an average of 20 pounds during the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mentions that Zyprexa is made by Eli Lilly and that the study was partly funded by this manufacturer (also funded by National Institute of Mental Health).", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites three medical sources; it reveals the financial connection between the first source and the maker of the Heartmate II device.\nPresumably the two other sources have no conflicts of interest, but it would have been useful to state that. ", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This study accurately summarized the results of the New England Journal of Medicine article on weight loss with three popular diets.\u00a0 This article provided a good balance of commentary by independent experts\u00a0representing alternative opinions and interpretation of the results.", "answer": 1}, {"article": "...\nConfirmation of these findings in ongoing clinical trials may results in improved pharmacologic treatment for moderate to severe BED,\" the study concludes.\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nThis study was supported by Shire Development, LLC, including funding to Scientific Communications & Information and Complete Healthcare Communications, Inc., for support in writing and editing the manuscript.\nThe study included 259 and 255 adults with BED in safety and intention-to-treat analyses, respectively.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "A pharmaceutical company is identified as the funder of this study in\u00a0an editor\u2019s note at the bottom of the release, and the release notes that the study authors also disclosed conflicts of interest. Also disclosed is the fact that the sponsor paid a communications company to write\u00a0and edit the manuscript.\nThat\u2019s sufficient for a Satisfactory rating, although we\u2019d add that\u00a0each of the study authors (except one, who works for another company) is heavily involved with industry above and beyond this particular study. The cumulative effects of these commercial aspects is worrisome: Where does one draw the line between experiment and \u201cexperimercial\u201d?", "answer": 1}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nA separate study in the journal documents needlessly high radiation exposures from CT scans at four San Francisco-area hospitals.\nHe says at his institution, the Massachusetts General Hospital, doctors who order a CT scan or other imaging study must list the reason.\n\"Physicians [and their patients] cannot be complacent about the hazards of radiation or we risk creating a public health time bomb,\" says Dr. Rita Redberg, editor of Archives of Internal Medicine, which is publishing the paper in this week's issue.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts, including the authors of the study, the author of the accompanying editorial and a Radiologist who was not involved with the study.", "answer": 1}, {"article": "\"Of the ones that are missed, most of them are early stage.\"\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\n\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\nThe researchers evaluated 12 years of data from 58,870 screening mammograms in 19,078 women with early-stage breast cancer and an equal number of mammograms in another 55,315 women who had never had breast cancer.\nWithin a year of the screening, 655 cancers were found in women with a breast cancer history and 342 in those without.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two independent sources are included in the article.\u00a0 Dr. William Audeh, director of the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center,\u00a0presents possible explanations for\u00a0some of the higher false positives among\u00a0women with a\u00a0personal history of breast cancer.\u00a0 Quotes from both Dr. Audeh and\u00a0Dr. Robert Smith, director of cancer screening for the American Cancer Society,\u00a0point out that screening mammography may not have been as effective among women with\u00a0a personal history of breast cancer as it was\u00a0in those without a breast\u00a0cancer\u00a0diagnosis but that most of the cancers detected were stage I or ductal carcinoma in situ, a non-invasive breast cancer. The article could have noted that study authors declared no conflicts of interest\u00a0and\u00a0\u00a0that the study was funded by a grant from the National Cancer Institute.", "answer": 1}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\n(The clip is made by Abbott, which funded the study; outside experts reviewed the trial data.)\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a mixed job.\nOn the plus side, it reported that the maker of the clip, Abbott, funded the study. It also reported that one of the physicians quoted \u201creported no relevant conflicts, but said that Columbia University gets royalties from the sale of the MitraClip.\u201d\nHowever, the story did not say whether other physicians who were quoted have conflicts of interest. At least one had a substantial conflict that we found. Gilbert Tang, MD, received $57,600 in payments from Abbott in 2017.\nMost importantly, all of the physicians quoted had some connection to the trial. The story would have benefited from at least one physician source who wasn\u2019t a cheerleader for this device.", "answer": 0}, {"article": "\"Your eyes look like they're responding beautifully!\"\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\n\"She said 'no problem,' which was probably oversimplified.\nShe told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\nThe medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0greatest threat to validity of this story is that all\u00a0experts cited have patents pending on this gene therapy, and this fact is noted in the source article in the New England Journal of Medicine. The story failed to mention this. ", "answer": 0}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nOn a beautiful September Sunday, hundreds of bicyclists pedaled the roads of eastern Dane County on The Ride to raise money for cancer research.\nThe Wisconsin Partnership Program is pleased to present its 2019-2024 Five-Year Plan, which was approved by the UW System Board of Regents in December, 2018 and goes into effect March, 2019.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release clearly states the study was initiated by Dr. Richard Bowen, an employee of the (now bankrupt) Voyager Pharmaceutical Corporation, and that the company performed the study. But it doesn\u2019t disclose that Bowen also reported owning stock in Voyager\u00a0(he\u2019s previously been described as a \u201cmajor shareholder\u201d), which holds a patent\u00a0covering the use of Lupron for the treatment of Alzheimer\u2019s. Though apparently now in bankruptcy, the company would likely still stand to benefit if this treatment approach gained new attention from researchers or was championed by new investors \u2014 and Bowen might well share in that reward. The news release wasn\u2019t transparent about this.", "answer": 0}, {"article": "Right now the American Cancer society recommends an MRI in addition to a mammogram for women who are at high risk for breast cancer.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nDoctors caught and treated Fields' cancer early.\nFortunately, her doctor had an extra tool to screen her for breast cancer - an ultrasound.\nA mammogram had missed her cancer, CBS News medical correspondent Dr. Jon LaPook reports.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only physician or expert interviewed in the story was someone who only commented on how ultrasound works \u2013 not on the findings of the study. So the merits of the study were taken at face value without any independent expert perspective.\u00a0 \n", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts involved with research, but also one more who appears independent of it, as well as a patient.\u00a0There also appear to be no notable conflicts of interest.", "answer": 1}, {"article": "\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\nDr. Robert Saper at Boston Medical Center is one of the authors.\nHe explained the results.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\n\"Perhaps most importantly reducing pain medication use.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted.", "answer": 0}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nIt is non-invasive, so doesn't require the healing time of traditional surgery.\nImportantly, the benefit of treatment was strongly driven by improvements in pain and discomfort as well as self-care.\n\"We knew radiosurgery results in pain relief, but we didn't know if the patients actually felt better,\" said Dr. Samuel Chao, corresponding author of the study.\nSome things can trigger it, like chewing or even the wind blowing, but attacks can be random.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name the funder of the study. There\u2019s also no mention of potential conflicts of interest, other than that Dr. Chao does the procedure.", "answer": 0}, {"article": "Women who undergo Caesarean sectionsmore than seven days before their due dates put their babies at higher risk of respiratory problems, longer hospital stays and other complications.\nThe Associated Press and McClatchy Newspapers contributed to this story.\nAll of the women had previously had C-sections.\n\"It's human nature.\"\nOf those, more than 13,000 had elective C-sections.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No interview material from independent experts was included in this story.", "answer": 0}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nBut, Dr. Rosenbaum said, it established a proof of principle.\nThe leptin would then serve as a sort of virtual fat.\nDr. Michael Rosenbaum, the lead investigator, said the 10-week study was too short and too small to determine whether continuous leptin treatments could allow dieters to keep off their weight permanently and effortlessly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provided a quote only from the lead investigator of the \nstudy; the story includes no input from any other independent source. ", "answer": 0}, {"article": "The machine, which is made by the Bedford company Hologic and developed partly at MGH under Rafferty\u2019s supervision, produces images that are so vivid and clear they seem to speak out loud: \u201cHey, right here!\nIn fact, technology developers had been trying in various ways for years to increase mammography\u2019s sensitivity (its ability to flag possible cases of cancer) while also increasing its specificity (its ability to filter out the false positives).\nDaniel Kopans, a world leader in breast imaging (he wrote the textbook of that name) and a radiologist at MGH, now says that the panel didn\u2019t \u201cunderstand mammography screening.\u201d Furthermore, he adds, the new guidelines had \u201cno biological or scientific reason\u201d behind them.\nThere are also costs in the sense of risks: Women who get a combo 2-D and 3-D mammogram, the protocol that confers the most dramatic jump in benefits, are exposed to twice as much X-ray radiation as the norm (albeit still an amount that\u2019s under the FDA\u2019s permitted limit).\nDebates about mammography are often so emotionally charged that this type of nuance goes missing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted in this article.\u00a0 Most of the quotes are from Dr. Rafferty, who helped to develop the 3-D equipment, and from Andy Smith, a vice-president of Hologic, the manufacturer of the equipment being profiled.\nWhile Dr. Otis Brawley of the American Cancer Society and Dr. Daniel Kopans, a radiologist at MGH, are both quoted, their quotes do not refer to 3-D imaging.\nBecause of the tendency of patients to assume that new imaging equipment is better than exisiting equipment\u00a0and that the ability to image in 3-D must be better than 2-D imaging, it is important\u00a0that an article written for the general public be balanced and based on scientific evidence.\u00a0 While certain phrases in this article appear to be an attempt at balance, there is no true balance that independent observers would provide.\u00a0 There is no scientific evidence to support the favorable quotes and positive tone of this piece.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A neruologist from the National Institute of Neurological Disorders and Stroke and an expert in cardioembolic stroke were quoted and added insights that were helpful to readers.", "answer": 1}, {"article": "A role for dietary macroalgae in the ameliorating ration of certainement Risk Factors Associated with cardiovascular disease.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nThe men's reaction was that the bread tasted acceptable as long as the seaweed content was kept under 4%.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\nIn the article Professor Mouritsen and his co-authors describe a study in which a group of overweight but otherwise healthy men were asked to taste bread with added dried seaweed from the species Ascophyllum nosodum.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The only clue as to why this news release was written comes when it says that the author of the study in question \u201chas authored several books on seaweed as food.\u201d This seems to be promotional material for his books and little more.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nBut today the company said its response fell short.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We always look for an independent perspective.\u00a0 Granted, the story was based on an FDA review.\u00a0 But we really only got a quote from a company statement.", "answer": 0}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nHe agreed to have his brain recorded during the surgery.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nThat got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\nThe intermittent system controlled overeating much better than the continuous or random protocols \u2014 and nearly as well as in a separate group of mice that got zapped manually by a researcher watching their behavior on video.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t disclose that Casey Halpern, the lead researcher, has accepted payment from the maker of the RNS System device, Neuropace.", "answer": 0}, {"article": "\u2022 Median overall survival based on beta-blocker receptor selectivity was 94.9 months for those receiving NSBBs versus 38 months for those receiving SBBs.\nOne of the researchers has acted as a paid consultant for Incyte Pharmaceuticals and received research funding from Egen Pharmaceuticals.\nThis study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson.\n\"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer.\nPortions of this study were supported by National Institutes of Health grants (CA140933, CA104825, CA109298, P50CA083639, U54CA151688, U54CA96300, U54CA96297, and CA016672), an Ovarian Cancer Research Fund program Project Development Grant, the Department of Defense (grants OC073399, W81XWJ-10-0158, and OC100237), the Betty Ann Asche Murray Distinguished Professorship, the RGK Foundation, the Gilder Foundation, the Blanton-Davis Ovarian Cancer Research Program, and a Gynecologic Cancer Foundation-St. Louis Ovarian Cancer Awareness grant.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes an exhaustive list of funding sources and notes that one of the journal article\u2019s co-authors has received funding from two pharmaceutical companies.", "answer": 1}, {"article": "Research has shown that vitamin D plays a key role in maintaining muscle integrity and strength and some studies suggest vitamin D may reduce the risk of falls.\nFunding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release cites funding sources. It makes no mention of possible conflicts of interest, but the study itself says none were found.", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nThe researchers are a now starting a small study in healthy human volunteers to look for effects on brain function.\n(Editing by Pravin Char)\nThese high and low phases are often so extreme they interfere with everyday life and work.\nChurchill worked with Sridhar Vasudevan to filter through a library of existing drugs - the U.S. National Institutes of Health Clinical Collection - that are considered safe but do not currently have a proven use.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited from some independent perspective. The two quoted sources are both researchers involved in the study.\u00a0 This was a story for which independent perspective was sorely needed.", "answer": 0}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no second source, no independent source.\u00a0 That would have helped.", "answer": 0}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nBefore the treatment, patients had tried everything without success and were considering an operation, he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a spokesman for the American Academy of Orthopedic Surgeons and it is implied but not stated that this person was not associated with the study. The spokesman provided important context.", "answer": 1}, {"article": "\u201cShe\u2019s the poster person for this test,\u201d he said.\nReading the scans is tricky because harmless nodules can be misinterpreted as suspect lesions.\nFor now, most consumers who want a scan will have to pay for it themselves, although it is expected that insurance companies eventually will approve scanning for those in high-risk groups.\nIn lower-risk groups, for instance, it\u2019s likely that thousands of people would need to be exposed to the risks of screening before a single life was saved.\nBut because the study was stopped early, a full analysis of the harms caused by screening scans is still months away.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good sourcing \u2013 including quotes from one who promotes the scans and the study findings and from two who have concerns and are skeptical or worried about the impact.", "answer": 1}, {"article": "Lung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\nwrote Dr. Mark Schoenebaum, a biotech and drug analyst ISI Group, in a note to investors.\nLisa Jarvis has more details on that at the Haystack blog.\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nIf the drug makes it to market, the foundation will receive royalties from sales.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Includes interview with CF Foundation president \u2013 not the most independent of sources since they have funded this work \u2013 but the story appropriately notes that the foundation will receive royalties from sales if the drug makes it to market.\nThe story also interviewed a biotech and drug analyst.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no additional sources of information and no attempts an independent corroboration.\u00a0 The story does not mention that AstraZeneca, makers of anastrozole, funded the research and the lead authors of the study receive speaking fees and other honoraria from AstraZeneca.", "answer": 0}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nHe was not involved with the research.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\n\"But [after several weeks of treatment], the cream made them look and feel better,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent source and identifies Dr. Draelos, the lead researcher on the study, as a consultant to Merz Pharmaceuticals, which funded the research.", "answer": 1}, {"article": "From 2001 to 2013, co-prescriptions to opioids and benzodiazepines among the studied pool of patients increased from 9 percent to 17 percent \u2014 a nearly 89 percent jump.\nAnd since the research relied on patients who were continuously insured throughout the study period, it\u2019s possible the findings don\u2019t exactly apply to people with spottier coverage.\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\nYet the study suggests the opposite has happened.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story quotes one source, an author of the study. It would have benefitted from\u00a0comments from independent physicians and public health experts on the challenges of changing prescribing patterns, as well as adequately treating pain and/or anxiety.", "answer": 0}, {"article": "Mild traumatic brain injury is a public health issue.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThe research findings published by PLOS ONE help support their objective.\nWith these findings, it appears the I-Portal goggle may be a solution.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There was no mention of funding sources and conflicts of interest in the news release. We find this highly problematic, since the principal investigator of this study is employed by Neuro-Kinetics, the manufacturer of the I-Portal google. Not only is he paid by Neuro-Kinetics, but the company is his sole affiliation (meaning he has no other hospitals or university affiliations), as listed on the PLoS One research article.\nThe news release also did not disclose the funding sources for the study \u2013 which included the National Football League (NFL), Underarmor, General Electric and the Department of Defense \u2013 through the Head Health Challenge II grant.\nFor these reasons, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nThe study was published Feb. 27 in the Archives of Internal Medicine.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interviews with other doctors not associated with the study and reported their viewpoints regarding the study findings.", "answer": 1}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nThey are looking for investors to take Islexa all the way as a fully fledged external company.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nIslexa will use CGT\u2019s labs at Guy\u2019s and facilities at Aberdeen University.\nHe will run Islexa with Michael Bennet from CGT and Anne Lewendon from Aberdeen University.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Every source in this story was also quoted in the news release.", "answer": 0}, {"article": "(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\n\u201cWith only a small amount of spinal fluid needed, CSF cytokine analysis could be used as one of the first diagnostic tests to rapidly triage serious central nervous system disorders and guide immediate intervention,\u201d said first author, Danielle Fortuna, MD, an Assistant Professor, in the Department of Pathology and Laboratory Medicine, at the Hospital of the University of Pennsylvania.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\n\u201cOnce confirmed with additional research, our test could provide a first, rapid and less invasive way to look at what\u2019s happening in the brain and guide treatment or further testing.\u201d\n\nThe results were published in the journal PLOS ONE on October 31st.\nIn the retrospective analysis, the investigators looked at samples collected from 43 patients who had received spinal taps during their hospital stays.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and potential conflicts of interest \u2014 or a lack thereof \u2014 weren\u2019t noted in the release. The published study lists \u201cnone\u201d under its author\u2019s declarations of interest. In a cursory check, we also found no evidence that the authors gained to benefit from widespread use of the Luminex FlexMAP 3D assay system, which is key to the rapid analysis of spinal tap samples.", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nThe results are remarkable.\nAn international study coordinated at KU Leuven, Belgium, has now disproven this theory.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe effect was present in everyone, regardless of the type of disease, the children's age, or the hospital in which they were staying.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no information in the release about funding or potential conflicts of interest.", "answer": 0}, {"article": "They are often obtained through diet by eating fish.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\nBabies in the DHA group had a 24 percent drop in the odds of having a combination of cold symptoms at 1 month compared to babies whose mothers were given a placebo.\nRamakrishnan said it's probably too soon to recommend routine use of DHA supplements for pregnant women, because the findings weren't \"dramatic.\"\nThe babies were assessed at 1, 3 and 6 months of age, and the mothers completed questionnaires about their babies' health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story contained a quote from a New York OB/GYN (who did not appear to have a role in the study reported on) indicating that she recommends that her patients take DHA, although her recommendation differed from that used in the study.\nAs the study was about the possible beneficial impact that prenatal supplementation has on the infant during the first months of life, it would have been more useful to include insight from indiviiduals with expertise in infant rather than maternal health.\nIt is a little troubling that the previous studies of the group of infants in the study reported on were not mentioned. \u00a0The outcomes taken together provide a better picture of the impact of supplementation with DHA.", "answer": 1}, {"article": "\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure,\u201d he says.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\nPereira wrote about blood pressure reductions in a patient getting deep brain stimulation in the January 2010 issue of the Journal of Clinical Neuroscience.\nWhile the case study is only an example of the phenomenon occurring in a single person, previous reports have observed the same kinds of reductions in blood pressure in people getting deep brain stimulation for pain, though researchers had believed that the blood pressure benefit was directly tied to the degree of pain relief the person experienced.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story features two interviews, one with an author of this case report, and another with an expert who also reported observing a blood pressure lowering-effect of DBS in a patient (though this may have been related to the patient\u2019s pain relief and not directly attributable\u00a0to the DBS device). While these individuals are clearly knowledgeable, they both are sympathetic to the idea that DBS may lower blood pressure, and neither could be called truly independent. One of these experts \u2014 Erlick Pereira \u2014\u00a0has done work sponsored by Medtronic, one of the leading DBS implant makers (as discussed here).\u00a0 In addition, according to coverage of this most recent case report in MedPageToday,\u00a0Patel and some of his coauthors disclosed financial relationships\u00a0with manufacturers of DBS devices.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story did provide some information about the controversy (\u201cWhile some experts don\u2019t think the hs-CRP test adds much to current cardiovascular risk-prediction strategies,\u2026\u201d) the majority of the comments are made by the principal investigator/inventor and an apparent advocate of the test.\u00a0 We would have liked to have seen more balance in the story.\u00a0 Fewer than 20 words to wave off skepticism, the other 838 words all devoted to those who promote the test. Why, based on what is provided in the story would any expert not believe in the test? The story doesn\u2019t give any space for that perspective.", "answer": 0}, {"article": "Vitamin C is also an antioxidant, which means it's believed to help prevent or minimize conditions that include cancer, heart disease, and inflammatory conditions such as arthritis.\nSenay explained that a research team examined 30 studies conducted over several decades, involving more than 11,000 people.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nAll compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0segment accurately\u00a0indicates the\u00a0high crediblity of the Cochrane\u00a0group, and there appear to be no underlying conflicts of interest that would call the conclusions into question. \u00a0", "answer": 1}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nGilbert cautioned that the study results are preliminary.\nThe time of survival was also up significantly from the previous average of 14 months, said Sampson, who declined to reveal the exact number until he presents the data June 2 at the American Society of Clinical Oncology meeting in Chicago.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\n\"But two years later, I'm in good shape, living a normal life and still returning cancer-free scans every month, thanks to this trial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two clinicians involved in the current study. \u00a0While it was refreshing to include the comment from the first author of the study that though enthusiastic about the results, he was \"biased\", the story would have been much better if it had included comments from experts in the field who were not involved in the study.\nInclusion of the interview comments from one of the patients who has received the experimental treatment is potentially misleading for readers because there was no framework for understanding the disease.\u00a0 While she is still alive and doing well 2 years after receiving the treatment, it is premature to conclude that this treatment is the reason for her current state of health.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story ends with a quote from an accompanying editorial by experts not affiliated with the study. Although the quote in question doesn\u2019t really add to our understanding of the results \u2014 it merely reinforces the study authors\u2019s conclusions \u2014 we\u2019ll rate this as satisfactory. We would ideally have liked for the story to have interviewed an expert, or at least called attention to comments from the editorial that provide some critical analysis of the results.", "answer": 1}, {"article": "Many more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nHowever, the findings do not apply to every stroke victim.\nThe study showed that the time window could be expanded to 16 hours.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a statement from an NIH doctor, taken from a news release.\u00a0 No independent sources were quoted.", "answer": 0}, {"article": "During the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\n\"Many patients are gratified to know what they're dealing with.\nBefore DaTscan we would watch and wait because there were no other objective tests to use.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\n\"In the past, we would have had to wait to diagnose Parkinson's or chosen different medications to test, which might have had different side effects, and this would have delayed the timely diagnosis of Parkinson's,\" Xie said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nAll of the experts quoted in the story appear to work at institutions that are promoting their ability to offer the DaTscan test. A truly independent expert source might have raised some of the important issues discussed in our review.\n", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "JACC is ranked No.\n\"Until now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life.\n\"This pioneering study represents a very important step in exploring the intersection of child development, cardiovascular health promotion and primordial prevention.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention the funding sources for the study, which was supported by government and foundation grants. Although there are no obvious conflicts of interest here, we always ask that news releases provide funding information about studies so that readers and journalists have easy access to this information.", "answer": 0}, {"article": "The findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\n\"This is a study that shows what happens if you bought the book and tried to follow\" the diets, as most dieters do.\nThe latest findings add to a growing body of evidence that the high-protein Atkins diet does not cause the harmful heart and artery effects long feared by many researchers.\nA careful read of the study shows \"no significant difference in weight loss between the Atkins and Ornish or LEARN diets after one year!\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview material with several nutrition scientists who had no connection with the study that was the subject of the story. It also contained critical comments from two individuals whose diet plans were studied.\u00a0 These comments came from respected individuals in the field and are a particularly valuable addition to the content.", "answer": 1}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nBut that's not the only reason, says Lori Mosca, a professor of medicine at Columbia University Medical Center and a spokesperson for the American Heart Association.\n\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\n\"There may be some evidence that perhaps one glass with a meal is OK,\" says Demetrius Lopes, a neurological surgeon at Rush University Medical Center, Chicago, and another spokesperson the heart association.\nHis editorial accompanies a British study that finds death rates among moderate drinkers and non-drinkers are not different enough to suggest any real health benefits for drinkers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article interviewed four solid sources at reputable academic centers \u2013 an associate professor at Harvard Medical School, a cardiologist at Cleveland Clinic, a professor of medicine at Columbia University Medical Center, and a neurological surgeon at Rush University Medical Center.", "answer": 1}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nObviously, parents could use some help in deciding whether surgery is needed.\nThey'd recommend surgery if a child has five or more throat infections a year for two years, or three or more in three years.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nThat's never without some risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one physician, and that source is a surgeon We would have liked to have seen more independent sources tapped \u2013 a pediatrician or family medicine doctor would have been helpful.", "answer": 0}, {"article": "Dr. Scott L. Spear, the chairman of the plastic surgery department at Hospital, has enlarged a patient\u2019s breasts only to have the patient undo his handiwork by losing weight.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nDr. Coleman, who was part of the task force, said, \u201cit\u2019s easy to kill fat,\u201d and worried that Johnny-come-latelies won\u2019t be meticulous.\n\u201cSuddenly everyone is claiming to have 10 years of experience,\u201d said Dr. Coleman, who is a paid adviser to Cytori.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story included more than one independent expert and it identified the professional affiliations and some of the financial arrangements between experts who were quoted and companies or practices that profit from fat grafting.", "answer": 1}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nP-Cure\u2019s first product was cleared by the FDA in 2010.\n(http://www.p-cure.com).\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It is clear that the release comes from P-Cure, the company that is producing the proton therapy being touted in the release.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Everyone quoted in the story had a conflict \u2013 a user, a consultant, a paid advser, someone who owns stock in a device maker, or a company spokesman.\u00a0 But all of those conflicts are acknowledged.\u00a0 And some of these people offer clear caveats about the approaches.", "answer": 1}, {"article": "Characterized by the World Health Organization as a \"neglected tropical disease,\" leprosy (also known as Hansen's disease) is one of the most ancient diseases known to humankind and is caused by the bacteria Mycobacterium leprae.\nA viable vaccine to prevent and/or treat leprosy is the next step in the effort to bring this disease to an end.\n\"The progress we've had to date would not have been possible without American Leprosy Missions' financial support and guidance.\"\nFounded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world.\nReed, along with scientists from a variety of scientific organizations recently published \"Innovative tools and approaches to end the transmission of Mycobacterium leprae\" in , outlining what is needed to achieve this goal.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are all clearly laid out.", "answer": 1}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nDOI: 10.1038/NCHEM.2918\n\nIt is co-authored by Dr Isolda Romero-Canel\u00f3n, Dr Carlos Sanchez-Cano, Dr Guy J. Clarkson and Dr Abraha Habtemariam.\n\"It will take time to progress from the lab to the clinic, but we are fortunate to have a talented enthusiastic, international team working with colleagues in Warwick Cancer Research Centre across the borderlines of chemistry, cell and systems biology and cancer medicine who are determined to succeed.\"\nChemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the sources of funding for the study. The release does not explicitly state that there are no conflicts of interests, but there do not appear to be competing interests here.", "answer": 1}, {"article": "...\nEven the study's lead author says the research should not be used to recommend chelation therapy, and he acknowledges that its findings could have been due to chance.\nYet some doctors say the study was far from rigorously performed, and so badly run that its marginally positive results are meaningless.\nThat could lead to a bias in favor of chelation, Atwood says.\nThat large of a dropout rate \u2014 which is normally no more than about 3% \u2014 could skew the study's findings, Kopecky says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Plenty of independent sources contribute to this piece.\u00a0If there\u2019s one thing we question,\u00a0it\u2019s\u00a0the\u00a0description of possible bias among the investigators.\u00a0The story quotes a source who says that \u201cmore than half the trial sites were led by doctors who practice chelation,\u201d\u00a0which \u201ccould lead to a bias in favor of chelation.\u201d\u00a0That may well be true, but aren\u2019t a lot of trials\u00a0led by physicians\u00a0and surgeons who use the treatment that they\u2019re supposed to be studying\u2013whether it\u2019s a drug or surgical procedure? We agree that this is a\u00a0form of bias, but it\u2019s one that\u2019s endemic to\u00a0medical research.\u00a0It feels like a double standard\u00a0to flag the study for this particular shortcoming.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAs this study was conducted on animals, results cannot yet be implied for humans.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nOne group was fed the equivalent of two servings (2 ounces) per day of walnuts for humans, while the second group received a similar control diet with no walnuts.\nCWC is an equal opportunity employer and provider.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were identified, netting this release a Satisfactory rating, but when a fundor is integrally related to the substance of the research, that mention belongs higher up in the story or release, rather than tagged onto the end, allowing readers to consider the context of the funding early in their reading of the material.", "answer": 1}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe findings are scheduled to be presented June 7 at the American Society of Clinical Oncology annual meeting, in Chicago.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\nThe observation was based on a national study launched at 118 hospitals across the United States.\n\"These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only perspective we receive in this story is that of the investigators with the study, who provide a uniformly positive take on the results. No independent\u00a0views are provided.", "answer": 0}, {"article": "In the United States study, 80% of the children on antibiotics felt better on the seventh day of treatment; 74% of the children taking a placebo also felt better on the seventh day.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\nRosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nHe, too, has been eagerly awaiting the results of these 2 studies.\nRosenfeld believes these latest studies reinforce an important message: \"It's an opportunity for a conversation with your pediatrician.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0prominence of the independent voices in this story is a real strength of the coverage. It was nice to see lengthy comments from Dr. Richard Rosenfeld, who literally wrote the book (or at least edited it) on evidence-based treatment of ear infections. There\u2019s also input from a doctor who is a stronger proponent of early antibiotic use.", "answer": 1}, {"article": "\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nNoctiva is the first FDA-approved treatment for this condition.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\nNoctiva should not be used in children.\n\u201cToday\u2019s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,\u201d said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA\u2019s Center for Drug Evaluation and Research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t mention that the efficacy trials for desmopressin to treat nocturnal poluria were sponsored by the manufacturer, Serenity Pharmaceuticals.", "answer": 0}, {"article": "Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nThe Tohoku University team wanted to find out if whole-brain rather than focused LIPUS is effective in treating mouse models of dementia, and if it was, what was happening at the molecular levels to achieve this.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\nThe first clinical trials to evaluate the effectiveness and safety of the LIPUS treatment are already underway.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "In the release, the Japan Agency for Medical Research and Development is listed as the funder. However, we note that the study\u2019s supplementary study materials say the research was supported \u201cin part\u201d by the organization, which suggests there may have been other funding sources (though the authors declared no conflict of interest).", "answer": 1}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nThere are three tests often used to look for breast cancer, Evers said.\nIn some cases, women never develop any of these symptoms, Evers noted.\nTHURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited. The article is based almost entirely on a single source in a news release\u00a0issued by Fox Chase cancer center by a mammographer.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has only one expert quoted, and that expert is an author of the study. Someone independent of the study would be in a better position to evaluate the claims objectively.", "answer": 0}, {"article": "Breast MRI is the most sensitive technique for the detection of breast cancer, with widespread application in the screening of high-risk patients and pre-surgical planning.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nTo learn more, Dr. Iacconi and colleagues reviewed records from 2,021 patients with newly diagnosed breast cancer who underwent biopsy after preoperative MRI.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not say how the study was funded. The journal article says the researchers \u201cdisclosed no relevant relationships.\u201d Still, we think it is important to clearly note funding and disclosures in all releases, even when there are no apparent conflicts of interest.", "answer": 0}, {"article": "Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\nResearchers monitored for mood and other side-effects after each treatment session.\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\n\"Elderly patients with severe depression face additional barriers when seeking treatment for the condition.\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and presence or absence of conflicts of interest are not mentioned.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple sources here with conflicts of interest, but they are all clearly identified \u2014 and the story includes at least two sources who appear to have no conflict of interest. However, it would not have been difficult to find someone with a much more skeptical take on this technology, and we wish that perspective had been included.", "answer": 1}, {"article": "of fat lost over 30 days.\n\"Because capsaicinoids (the component of hot peppers that gives them heat) are hot, it was imperative that we use an ingredient which the subjects could tolerate,\" said Vijaya Juturu, Ph.D., F.A.C.N., one of the lead researchers on the MR Study.\nA recent paper, Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device-An Open Label Placebo Controlled Acute Study, published in the journal Obesity Open Access discussed the findings of the Metabolic Rate (MR) Study, which demonstrated that an extract from red hot peppers boosted metabolic rate (Chen, et al., 2017).\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nThe MR Study was a placebo-controlled, crossover open label study with 40 healthy adults examining the effects of either 2 mg capsaicinoids from 100 mg of Capsimax or placebo on resting energy expenditure, heart rate and blood pressure.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t list any funding sources or potential conflicts of interest. The study states that researchers have no conflict of interest but then provides conflicting information suggesting that\u2019s not true. The study also notes that one of the researchers involved with the study is an employee of the supplement manufacturer and another holds a patent for the device used to measure metabolic changes and also received funding from the supplement manufacturer. Those are two clear examples of conflicts of interest that should have been mentioned in the release.", "answer": 0}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\n\"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit,\" said Dr. Michael Boyle, senior vice president for therapeutics at the foundation.\nThe most common mutation that causes cystic fibrosis is called F508del -- and it has proven tougher to tackle, Rowe said.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reported that Vertex Pharmaceuticals, Inc. is developing both experimental drugs. However, it didn\u2019t report the full extent of the conflicts of interest involved in these trials. A majority of the study authors \u2014 including one quoted in the story, Steven Rose, MD \u2014 reported receiving grants, personal fees, and other compensation from Vertex Pharmaceuticals during the trial period, according to disclosures filed with the journal. In addition, one of the authors is a Vertex employee who holds a relevant patent.\nIn addition, we think that the story would have benefited greatly from more independent sources to weigh in on the bold claims being made.", "answer": 0}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\nThe authors note some important limitations of the trial, including the lack of long-term outcomes in the nonsurgical group due to the high crossover rate.\nThirty-five subjects from the nonsurgical group opted to undergo the implant procedure, with similarly good results.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states early on that the research was funded by the company that makes the titanium implant but doesn\u2019t mention that the researchers were either employees or consultants to the company. At a minimum, the release should state what sort of financial relationship the authors had\u00a0with the company.", "answer": 0}, {"article": "Oct. 10, 2011 -- A small study shows that a new drug being tested for the treatment of Alzheimer's disease reduces the buildup of plaques in the brain associated with the fatal disease.\nThe study is published in the online edition of Archives of Neurology.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story added an important independent perspective and identified the study co-author as being a senior VP of the drug company making the drug.", "answer": 1}, {"article": "Cancer is the No.\nIt was not a slam dunk, but the test found cancer in the blood of more than half the patients who had been diagnosed with stage 1 cancer.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nThe blood test detected the majority of cancers in people with four of the biggest cancer killers: breast, colon, lung and ovarian cancer, the team at Johns Hopkins University said.\nThe agency has chastised a company called Pathway Genomics over its \"liquid biopsy\" test , saying the company had not shown the $699 test worked as advertised.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include a quote from a National Cancer Institute researcher who wasn\u2019t part of the study team, and it also acknowledges that the lead researcher has patented the technology behind the test and is the principal of a company doing genetic screening.", "answer": 1}, {"article": "The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head, and neck.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell readers who funded the research, who developed the software, or whether there are any conflicts of interest among the researchers.", "answer": 0}, {"article": "In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\nThe study was published online Oct. 1 in The Lancet.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\n\"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources in the story, as the story itself says at the bottom: \u201cSOURCES: Jack Ansell, M.D., chairman, department of medicine, Lenox Hill Hospital, New York City; Duke Medicine, news release, Oct. 1, 2012\u201d The story does point out that Ansell is \u201ca consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\u201d But it does not point out the more important fact that those companies funded the study.\nThe article was accompanied by an editorial that provided both context and balance.\u00a0 Regrettably, the story did not provide either.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter sought out opinions from two clinicians not connected to the study, a patient, the Mayo Clinic, and the National Osteoporosis Foundation. But the story was not transparent about the relationships that these sources have with commercial interests. Dr. Amy Singer has disclosed significant financial ties to Amgen, which makes an osteoporosis drug. We\u2019d also note that the National Osteoporosis Foundation receives funding from a \u201cCorporate Advisory Roundtable\u201d that includes makers of bone scanning machines and osteoporosis drugs. And the Foundation has previously been called out for its failure to educate consumers about the harms of bisphosphonate drugs when those problems were first coming to light. This context should make us wary of a push to screen more men for osteoporosis without evidence that it is beneficial. Is this drive totally about the patient or could there be a commercial motivation?", "answer": 0}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\n\"The children that received the interventions normal in their communities continued to show the reversed pattern.\"\nNormal child development depends on interactions with parents and other people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We thought the story spent too much time with the lead author of the study, but we appreciated the comments from Arthur L. Beaudet, MD, professor of molecular and human genetics, pediatrics, and molecular and cellular biology at Baylor College of Medicine, Houston. He said, \u201cTo the extent early intervention helps brain development, it is more likely to help by letting the brain compensate and get around the problems rather than reverse them. \u2026We do know if you damage the brain of a young child, like in an accident, the infant brain has a tremendous ability to recover and get around the problem.\u201d More voices like this would have helped readers understand the importance of the findings and the likelihood that they would have a broad application for children with autism.\nIt is a low bar to get one outside source but at least this was done.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included two quotes from investigators\u00a0 involved in investigation of this drug.\u00a0\u00a0", "answer": 1}, {"article": "During Pap tests, cells are swabbed or scraped from the cervix for examination under a microscope to find cancer or possible pre-cancerous changes.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nBut many women still do not get regular Pap screening, Whitlock pointed out.\nClinical trials are ongoing, Whitlock said.\nExactly what impact the new research review will have on the USPSTF recommendations is anyone's guess.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was only a single source quoted \u2013\u00a0 the lead reviewer and author, Evelyn Whitlock, a senior investigator with Kaiser Permanente in Portland, Oregon.", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\n\"So we do not need FDA clearance for the device because we are not using it to diagnose or manage disease.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Importantly, the article quotes the\u00a0CEO of the Celiac Disease Foundation as skeptical about the value of gluten sensors in general, along with purported \u201ctreatments\u201d for the disorders. And she makes clear that she \u201cwould never comment on a device that\u2019s not FDA-approved.\u201d Bravo!", "answer": 1}, {"article": "In contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\nAll had previous surgery to remove as much of the tumor as possible, and all received chemotherapy before, during or after proton therapy.\n\"While we are currently investigating quality of life differences between proton and photon treatment, I truly believe that - particularly for the youngest children - the ability to offer them proton therapy can make a big difference in their lives.\"\nStudy participants were tested for hearing, a variety of cognitive functions, levels of important hormones and height and weight at the outset of the study and at several follow-up visits for up to eight years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources and conflicts are clearly explained.", "answer": 1}, {"article": "Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\nThe new treatment came from the discovery about a decade ago that CD34+ stem cells stimulate the formation of new blood vessels, study researcher Douglas W. Losordo, MD, of Chicago's Northwestern University tells WebMD.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe stem cells have shown the ability to repair and replace them in animal models.\"\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The president of the American Heart Association was quoted liberally throughout the story. It could be argued that since the work was published in an AHA\u00a0journal, he is not the most independent observer, but we\u2019ll give the story the benefit of the doubt on this. Independent researchers working in the field of stem cell experimentation might have been better choices.", "answer": 1}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\n\u201cIt\u2019s a very, very exciting study,\u201d said Khurana, the ophthalmologist association\u2019s spokesman, who also wasn\u2019t part of the research.\nThe current research sheds light on how that long-suspected immune culprit might be working, and is \u201cthe first suggestion that there may be a treatment for geographic atrophy coming up in the future,\u201d said National Eye Institute retina specialist Dr. Wai Wong, who wasn\u2019t involved in the study.\n\u201cWe try to reinsert the braking ability,\u201d said study lead author Brian Yaspan, a Genentech senior scientist.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although there are independent sources in the story, we\u2019re not told that one of them\u2013Dr. Rahul N. Khurana\u2013has served as a consultant and speaker for Genentech, the drugmaker behind the study (as disclosed here).\nIn the story, he\u2019s quoted several times, including here:\n\u201cIt\u2019s a very, very exciting study,\u201d said Khurana, the ophthalmologist association\u2019s spokesman, who also wasn\u2019t part of the research. \u201cFrom the basic science perspective, it makes a lot of sense.\u201d", "answer": 0}, {"article": "Tuberculosis is a chronic bacterial infection that's spread through the air and usually infects the lungs, although other organs of the body can be involved.\nBut Siegel said such testing, which has been in use for more than a century, isn't always accurate.\nFurther trials of the new test are planned, the researchers said.\nThe machine costs around $30,000, but would be priced under $20,000 in poor countries, he told the AP.\nA report on the researchers' work was published in the Sept. 2 issue of the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although we wish\u00a0it featured a comment from someone willing to look a bit more critically at the findings, the story did include an interview with an expert not affiliated with the study, thus meeting\u00a0the minimum standard for the criterion.\u00a0As far as we can tell, there were no\u00a0conflicts of interest that weren\u2019t identified.", "answer": 1}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\n\u201cOne of the interesting areas that we plan to explore in partnership with large companies is actually using our platform technology to include other drugs that previously maybe haven\u2019t been suitable for topical or transdermal delivery - or drugs which may have not got through the regulatory filings because, for instance, they might have caused stomach irritation or other side effects when taken orally,\u201d said Lee.\nLee told Reuters that many commercial patches do not contain pain relief agents at all, and merely sooth the body with a warming effect.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nUniversity of Warwick research chemist Professor David Haddleton told Reuters that the polymer matrix in the patch acts as a reservoir for the drug, capable of releasing between five and ten times the amount of drugs used in gels and patches currently on the market, for periods of six hours, 12 hours, and even 24 hours.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were interviewed. The\u00a0two sources that were interviewed\u00a0for this article were\u00a0both disclosed to be affiliated with the company Medherant, producer of the TEPI patches. Since the use of transdermal patches has been around for decades, it should have been relatively easy to identify experts in the field.", "answer": 1}, {"article": "In the absence of FY26, cancer cells switch from using their defective mitochondria to using metabolic activity in their cytoplasm to generate energy.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\n), the European Research Council (Grants 247450 and 324594), and the Wellcome Trust (Grants 086357 and 102696) for support, as well as the European Union COST Action CM1105.\nFollowing the successful test results the researchers have been awarded a Wellcome Trust Pathfinder grant to begin preclinical development of organo-osmium compounds.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources were carefully noted in the release.", "answer": 1}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\nInvestigators have yet to show this.\u201d\nThey also made fewer trips to the hospital.\nEven if the findings hold up, he said, it is still unclear what accounts for them.\nNEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two skeptical independent experts made this a solid piece.", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The sponsor of the trial is given as QuantumLeap Healthcare Collaborative, a non-profit set up by Silicon Valley entrepreneurs.\nThe manufacturers of neratinib and veliparib \u2014 Puma Biotechnology and Abbvie, respectively \u2014 are listed as \u201cstrategic partners\u201d on the QuantumLeap Healthcare Collaborative website, suggesting potential financial involvement. That\u2019s a financial tie that should have been noted in the news release as well.\nBoth NEJM papers explicitly state that the pharmaceutical companies had no direct involvement in the trials except to provide the drugs.", "answer": 0}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\nSome drugs that treat the pain, including opiates, can make the constipation worse, he said.\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no mention of the fact that the study being reported on was conducted and funded by the manufacturer of the drug being tested. In addition, almost all of the\u00a0information in this story came from\u00a0the\u00a0drug manufacturer\u00a0or someone with ties to it. Examples:\nWe think this story could have benefited from an alternative perspective.", "answer": 0}, {"article": "The most common form of breast cancer uses oestrogen to grow.\nBut this is early research and greater clinical evidence is now needed to understand the potential risks and benefits of this approach.\u201d\n\nAnother charity, Breast Cancer Care, said the research was promising but needed further trials.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It states that the research was funded by Breast Cancer Now, the UK\u2019s largest breast cancer charity.\u00a0It also quotes a clinical nurse specialist from an unrelated UK charity, Breast Cancer Care. This is sufficient enough to be Satisfactory.\nHowever, It does not mention funding from the National Institute for Health Research Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, also based in the UK.The story could have quoted more outside experts in order to shed light on the challenge of hormone resistance.", "answer": 1}, {"article": "The standard drug treatment for stubborn menopause symptoms is hormone replacement therapy.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe new study, published in the journal Menopause, is based on 90 Chinese women.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The journalist interviewed an American researcher who did not agree with the study results and had conducted other studies using soy supplements and did not find any significant effects. \u00a0Also, it was stated the supplements in the study were provided by Frutarom Netherlands \u2013 a private company that sells soy supplements over the counter in the U.S.", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0There are no experts or independent sources that were quoted as part of this story.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Doctors can use a patient\u2019s abdominal CT scans to also check for signs of the bone-weakening disease osteoporosis, according to a new study.\nBoth involve radiation.\nThat may spare the patients from additional testing and additional costs.\nThe disease affects over 12 million Americans over 50.\nDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The perspectives from the editorial writer and from an independent expert were important contributions.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two researchers, each of which discusses the field at large as well as their own work. That\u2019s enough to earn a satisfactory rating here, though it would have been valuable to garner input from a mental health expert, given that the two people quoted \u2014 while actively involved in the field \u2014 specialize in issues related to emergency medicine (internal medicine) and computer science. There do not appear to be conflicts of interest, though the story doesn\u2019t explicitly state that (or where the funding came from). A look at the relevant paper shows that funding came from the Robert Wood Johnson Foundation and the John Templeton Foundation.", "answer": 1}, {"article": "They controlled for cigarette smoking, other drug use, access to health insurance and other factors.\nBechtold said the researchers wanted to \"help inform the debate about legalization of marijuana\" but that this is a very complicated issue and one, study, including his own, should not be taken in isolation and should be viewed in context of other studies on teenagers' marijuana use.\nOne major limitation of the study is that it ends when the men are in their 30s \"which may be too early for decrements in health to emerge,\" the authors acknowledge.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nHowever, the reanalysis regarding psychotic disorders contradicted the earlier conclusions -- that there indeed appeared to be a higher risk of psychotic disorders among marijuana users in the study versus non-users that approached statistical significance when using a more liberal test.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story badly needed an independent source. It would have been possible and helpful\u00a0to choose from among many researchers whose work points to potential\u00a0harm from chronic marijuana exposure. Again, letting the researcher get away with saying \u2013 unchallenged- that he wanted to \u201chelp inform the debate about legalization of marijuana\u201d in a single source story is problematic.", "answer": 0}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nThe medication is not available yet, but the U.S. Food and Drug Administration is reviewing it for possible approval, the researchers said.\nIt's promising news, Bazil added, that there were no serious side effects in this study.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nOne expert pointed out, however, that the benefit was small.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources added needed balance up against the comments of Merck\u2019s director of clinical research.", "answer": 1}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nIt was cleared by European regulators even though large so-called pivotal trials have not yet been conducted on the product.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\n\u201cThat would be one compassionate use of it, a very serious application.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. And the story never stated who paid for the study or whether the quoted researcher has any financial ties to the manufacturer.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one of the study authors and authors of an accompanying commentary in the journal, The Lancet. The reporter also sought comment from stent makers, who were mostly critical of the study \u2014 but these potential conflicts were made clear to readers.", "answer": 1}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nDr. Saman Nazarian, a cardiologist and assistant professor of medicine at Johns Hopkins Hospital, said the findings are promising and \"the new technology has enormous potential.\"\nHe also has received stock options from the company.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The independent experts who were quoted added important cautionary perspectives to the story.\nAnd the story mentioned that the study author receives grant funding from the manufacturer, works for them as a consultant, and has received stock options from the company.", "answer": 1}, {"article": "PHILADELPHIA - In a finding that suggests the potential for practice change that would reduce the use of antibiotics in dermatology, researchers in the Perelman School of Medicine at the University of Pennsylvania have found the diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women's acne.\nDavid J. Margolis, MD, PhD, a professor of Dermatology, was the study's senior author.\nIt affects 85 percent of people under the age of 18, but it also regularly impacts adults.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not provide the name of the study funders.", "answer": 0}, {"article": ".\nThe new study reports the results from two Phase III clinical trials evaluating the efficacy of mepolizumab, an antibody treatment that reduces the number of eosinophils in the blood, in moderate to severe treatment-resistant eosinophilic COPD by blocking the pro-inflammatory effects of interleukin-5.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\nIn a second, simultaneous trial, termed METREO, the team assessed the effect of a higher dose of mepolizumab in 675 patients with elevated eosinophil levels.\n\"In addition to providing a new treatment option for patients with treatment-resistant, moderate to severe COPD, the new results also are important because they identify a potential biomarker for the disease and demonstrate that eosinophilic inflammation plays a role in flare-ups in COPD,\" Sciurba said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies GlaxoSmithKline as the funder of both trials and names numerous GSK employees as authors of the study. The latter makes it possible\u00a0that\u00a0the biases could have been introduced in the writing process.", "answer": 1}, {"article": "\"I just didn't want to do that for my children.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nIn an editorial accompanying the study, Virginia Kaklamani, an oncologist at Northwestern University, says lives can be saved if women have genetic testing.\nToby was one of the women researchers from around the country tracked in the study to see how they fared after having this surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal who was not involved in this study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "But is it especially healthful?\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nThe juice is a beautiful wine-red color and tastes delicious.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While pointing out that one company that sells pomegranate products underwrites the costs of some studies done to explore the health benefits of these products, the story failed to inform the reader whether the two studies mentioned were funded by this company as well. The story also didn\u2019t tell readers where the studies were published. While it could have been informative to include material from experts in the field of anti-oxidant, free radical, or polyphenolic compounds, this article is basically an op-ed piece.", "answer": 0}, {"article": "Most drugs in development have been so called active site-directed inhibitors, which act like master keys and lock the entire enzyme, blocking both its disease-relevant functions such as collagen degradation and its other normal functions.\n\"All clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues.\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nThe findings were published today in the Journal of Bone and Mineral Research.\n\"CatK is a multifunctional enzyme with important roles in other parts of the body and we think completely blocking it is what causes unexpected side effects in other drugs,\" said Preety Panwar, a research associate in the Br\u00f6mme lab.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "On EurekAlert!, where the news release is hosted, we\u2019re told that the study was funded by Canadian Institutes of Health Research grants and a Canada Research Chair award. We encourage news releases to include funders in the body of the release, too.\nThe authors listed no conflicts of interest in the published study.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Though most of the story was about the advantages of endovascular repair of aortic aneurysms, the story did include a quote from a surgeon who does open repair indicating that he felt that open repair was a better fix.", "answer": 1}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThis technology illustrates our strengths in translating health care discoveries from the academic setting into industry, and ultimately to the patients that will benefit from them.\"\nIt's exciting to have the opportunity to test the program within a large health care system such as Mount Sinai.\"\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nMount Sinai Innovation Partners (MSIP), the commercialization-arm of the Icahn School of Medicine at Mount Sinai, has been a key partner in this development.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We were glad to see the for-profit entity, Click Therapeutics, clearly labeled as a contributor to the research and employer of at least one of the investigators.\nBut we would have liked a clearer explanation of conflicts. Do any of the study authors participate in patents related to this work? How might\u00a0researchers benefit financially? The study presentation does disclose they hold patent applications.\nExcerpt:\n\u201cMount Sinai Innovation Partners (MSIP), the commercialization-arm of the Icahn School of Medicine at Mount Sinai, has been a key partner in this development.\u201d", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited greatly by including comment(s) from someone other than a company spokesperson or someone involved in the study. This could have provided readers with some insight about what this new product might add to the field.", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two physicians, one of whom is the lead author on the articles and was funded by the manufacturer of the product. It would have been preferable to quote a spokesperson for an academic society or non-profit organization to provide some additional perspectives.", "answer": 1}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nKnowing more about the genetic mutations of a tumor enables doctors to find a potentially effective drug much more quickly and accurately.\nStill, he cautions that the targeted treatments can't be considered cures.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\nCalled a basket trial, the study is designed to include people whose tumors have the same kind of genetic fingerprint regardless of where in the body the tumors are found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both sources quoted in this story\u2013the patient and her doctor\u2013have interests that are arguably aligned. It would have been helpful to hear from a second neurooncologist who has experience with the disease, drug, and/or genetic targeting technique. However, because the neurooncologist clearly describes the limitations of highly targeted cancer-treating drugs, i.e. how they can and probably will eventually resist the drug, we\u2019ll rate this sourcing satisfactory.", "answer": 1}, {"article": "Aggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nResearchers then rated them using a well-validated scale that measures aggression and agitation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted was the lead author. He and most of the other authors are listed as consultants to the company that markets the drug and that funded the study (Avanir). Some of the authors are full-time company employees. The company even supplied a writer to \u201cprovide assistance\u201d in writing up the study. The authors clearly have deep financial conflicts here, and it\u2019s well known that sponsor-funded studies come out positive more often than those funded independently. None of this was discussed or disclosed.\nIt would also have been very easy to use the accompanying editorial to provide more balance and context to the story", "answer": 0}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nHovorka said the findings were particularly encouraging because the study included nights when the children went to bed after eating a large evening meal or having done exercise \u2014 both of which can affect blood sugar levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites one interview with a study researcher and provides no other independent perspective. It does not inform us that this source had financial ties to one of the study sponsors.", "answer": 0}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nVolition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.\nThese statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management.\nThe correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nThese statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although it is clear that this study is funded by a company hoping to market a new blood test and that most of the quotes come from company employees, the release should have explained the relationship between the company and the principal investigator. Did the company just provide funding for the study? Were there direct payments to the researchers, including consulting or lecturing fees outside of the study budget? What was the role of the company in designing the study and reporting the results?", "answer": 0}, {"article": "Most recently, the F.D.A.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\nThe total number of subjects in the trial is expected to be about 300.\nThe current study will test vaccine dosages and sequences of four or five shots; some subjects will get a placebo.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only sources affiliated with the study and Nabi Biopharmaceuticals are cited. The National Institute of Drug Abuse (NIDA) funded early phases of the study with a $4.1 million grant so the director of NIDA pharmacotherapies has an interest in the outcome of the trials. Sources not affiliated with the NicVax trials are needed for perspective on this new therapy for smoking cessation. ", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\n\u201cThis asthma data and the data we already have in atopic dermatitis really raises the possibility the scientific community has finally hit upon the key pathway across all these allergic diseases,\u201d George Yancopoulos, Regeneron\u2019s research chief, said in an interview.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\nBut she cautioned that longer trials are needed to fully assess the drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was too much reliance on sources connected to the trial. The very first quote is from the lead researcher, effusing: \u201cOverall, these are the most exciting data we\u2019ve seen in asthma in 20 years,\u201d said Dr. Sally Wenzel, lead investigator for the 104-patient study of dupilumab, an injectable treatment being developed by Regeneron Pharmaceuticals Inc and French drugmaker Sanofi. The only other person quoted is George Yancopoulos, Regeneron\u2019s research chief. At the very end, an anonymous editorial is quoted with some words of caution that most readers won\u2019t even get to.\nAt one point the story said \u201cresearchers expressed optimism.\u201d\u00a0 Which researchers?\u00a0 Those funded to do the study?", "answer": 0}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\nThey were told to lie still with their eyes closed as they wore headphones and listened to soothing music.\nFederal law prohibits the use of the magic mushroom compound for any purpose.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "A 2007 study of Chinese women in Shanghai found that middle-aged women who ate large amounts of white rice and other refined carbohydrates were also at increased risk for diabetes compared to their peers who ate less.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nThey were also asked about their medical histories.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources were quoted to give perspective about the results of the study presented. Single source medical science stories are not a good idea \u2013 not even for (especially not for?) the New York Times. ", "answer": 0}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n(Reuters) - Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two glaring problems here.\nFirst, the only quote used in this very short story is directly lifted (without attribution) from the news release. No independent sources are included.\nFurthermore, it says it comes from the lead investigator of the study (true), but fails to mention he\u2019s a paid consultant for Janssen.", "answer": 0}, {"article": "Health officials in Norway recommend that pregnant women (and women who are trying to get pregnant) take 400 micrograms of folic acid per day.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nThey also looked at questionnaires completed by their mothers to see how much folic acid they were consuming in the month before they became pregnant and during the first eight weeks of pregnancy, a critical period of embryonic brain development.\nAs a result, a cup of enriched white long-grain rice now contains 797 micrograms of folic acid, for example, and a cup of Cheerios has 493 mcg, according to this report from the Harvard Women\u2019s Health Watch.\nNor did they find any link between fish oil supplements and risk of ASDs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Unlike the Reuters Health story (which quoted two independent sources), this one does not include comments from an independent source, just a quote from a journal editorial (and that quote doesn\u2019t directly address the quality of the evidence). The competing CNN.com story (also a blog post), reviewed a day earlier, had three independent sources.", "answer": 0}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\n\"While high-risk patients may ultimately require a screening colonoscopy, many average- and low-risk patients could undergo less invasive screening procedures.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\nHe believes that the scoring system \"was only modestly able to separate people within the risk groups.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story contains two independent voices. The perspective they provide is a particular strength\u00a0of the article. We wish that more stories would reach out to experts not affiliated with the studies being reported on for context.", "answer": 1}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nIt is effective for up to five days after unprotected sex.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nTheir study was presented at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome, Italy.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted multiple independent experts.", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\n(Performance Health Brands, maker of Thera-Band, provided the FlexBars for the study but did not fund it.)\nNot all physical therapists are sold on the FlexBar.\nAnd the FlexBar makes it simple to do this kind of stretch.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes the involvement of the FlexBar manufacturer in the study that is referenced.\u00a0It also quotes an independent\u00a0physical therapist who suggests there are other ways to achieve the effect attributed to the FlexBar.", "answer": 1}, {"article": "2.\nThe group said that while some tests are backed by more evidence than others, it found no head-to-head studies suggesting any strategy \u2014 including colonoscopy \u2014 is better than another.\nBut that lack of trial data is why the Canadian Task Force on Preventive Health Care earlier this year recommended against using colonoscopy as a first-line screening method.\nIncluded on the list are two cheap, at-home poop tests intended to be done annually: the guaiac-based fecal occult blood test (gFOBT) and a more sensitive test called the fecal immunochemical test, or FIT.\nOf the two, Richard Wender, a physician and chief cancer control officer of the American Cancer Society, said the FIT is preferable, both because it\u2019s more accurate and because it requires only one poop sample and no changes in diet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three independent sources for information and the recommendations of agencies from two different governments.\u00a0 There is no suggestion that in a story offering a selection of screening techniques, with no one preferred above another, that there is any issue with conflicts of interest.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story importantly refers\u00a0to \u201congoing debates\u201d within the medical and scientific community about the wider use of the blood tests, and quotes an editorial written by an expert who did not participate in the study itself. However, while the story notes that the study was funded by Illumina, which markets the test, it did not alert readers that Dr. Bianchi, the study author who is quoted in the piece, is a paid advisor to the company. CBS, by contrast, made note of that relationship. We reluctantly grade the story Not Satisfactory based on that omission.", "answer": 0}, {"article": "In 1956, the FDA approved 17-HP for the treatment of certain cancers and other hormonal disorders, under the brand name Delalutin.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\nAnd, for unknown reasons, the U.S. rate of preterm delivery has been going up in recent years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The medical director of The March of Dimes was quoted throughout. (Although they are seen as having a very pro-progesterone slant that is not held by consumer/advocacy/health policy/maternity care groups in UK, Australia, and Canada. in those countries surveys of providers uniformly get low utilization responses with the reason stated being need for more data. Similar surveys of US providers (specialty and generalists) show the vast majority use >70% (as opposed to low double digits in more evidence-driven countries) and that mission creep has started. Indications for which it is not tested see regular use in the US.)", "answer": 1}, {"article": "Women whose cancers were detected by mammograms were more likely than the doctor- or patient-detected cancers to have lumpectomy or other breast-conserving surgery: 67 percent vs. 48 percent.\nWhen considering its recommendation, the task force took all available evidence into account, including published studies, Moyer noted.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nDr. Virginia Moyer, chair of the U.S. Preventive Services Task Force and a professor of pediatrics at Baylor College of Medicine, reviewed the study.\n\"A screening test, if it can't find something earlier than [by] clinical presentation, is a poor test,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did interview the chair of the U.S. Preventive Services Task Force (USPSTF).", "answer": 1}, {"article": "Men who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\nDuring that time, 67 men had a stroke.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\nResearchers measured the level of lycopene in their blood when the study began and followed the men for about 12 years.\nThe new study included slightly more than 1,000 men from Finland aged 46 to 65.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sourcing was strong. We hear from three different experts on stroke, who add some valuable context.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from four plastic surgeons linked to credible institutions. \nHaving said that, all of the sources are biased in favor of the procedure for reasons of economic self-interest.\u00a0\nIt\u2019s also worth noting that all four are men. \n\u00a0", "answer": 1}, {"article": "March 16, 2010 -- An experimental type of highly focused radiation therapy may control inoperable lung cancer tumors and help people with the deadly disease live longer.\nNeither option is considered ideal.\nMore than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources other than the lead author of the study. Independent experts could have provided some much-needed perspective on the importance\u00a0of the new findings. ", "answer": 0}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nThat approach saved the life of a woman who prefers to be known only by her first name, Lynn.\nOther health systems have adapted the plan, including Group Health Cooperative in Seattle and the behavioral health provider Centerstone in Tennessee.\nThe behavioral health provider in Nashville implemented the Henry Ford approach for nearly 200 patients who'd already made a suicide attempt.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t include input from experts outside of the Henry Ford Health System. The story would have been stronger if third-party experts in mental health or epidemiology had been able to provide some critical context on how effective the \u201cperfect depression care\u201d approach has been.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not tell readers anything about who paid for or managed the drug trials. It also does not report that one of the researchers quoted in the story, Dr. Bert Vogelstein, has received payments from pharmaceutical companies related to work on pembrolizumab, and that he also has a patent pending, as he stated in a New England Journal of Medicine disclosure statement.", "answer": 0}, {"article": "\u2022 In clinical trials, a plant-based vegetarian diet lowers LDL cholesterol by 12.2 mg/dL and reduces HDL cholesterol by 3.4 mg/dL, compared to control groups following an omnivorous, low-fat, calorie-restricted, or a conventional diabetes diet.\nWhat I've found is that if you want your patients to make significant health changes, you have to make them yourself.\nThe study authors--Yoko Yokoyama, Ph.D., M.P.H., Susan Levin, M.S., R.D., C.S.S.D., and Neal Barnard, M.D., F.A.C.C.--reviewed 30 observational studies and 19 clinical trials, which met their inclusion criteria.\nHe is a part-time instructor at the College of Osteopathic Medicine of the Pacific Northwest and hopes to set an example for future physicians.\nWithin a year, Dr. Ross traded a 34-year career of practicing emergency medicine for a new career path: lifestyle medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research is funded by the\u00a0Physicians Committee for Responsible Medicine. Reporters will have to dig a little deeper to learn that group supports an activist agenda on behalf of animal rights, which may have a bearing on its health and diet recommendations. But the release meets our minimum standard for a satisfactory grade.", "answer": 1}, {"article": "That compared with 42.5 percent who maintained a clinical response and a 27.4 percent remission rate in the placebo group.\n\u201cWe\u2019ll need more patients and longer-term data to really fully characterize the safety profile in Crohn\u2019s disease, but so far so good,\u201d Sandborn said.\nPatients in the study on average started at 320 or 325 on the CDAI scale, researchers said.\nAn approval for Crohn\u2019s would give the drug entry into an estimated $1.3 billion U.S. market and $2.7 billion market worldwide.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source is the primary investigator. And who funded the study? Presumably it was Johnson and Johnson.", "answer": 0}, {"article": "\u2014 Current and former smokers should avoid multivitamins with lots of beta-carotene or vitamin A; two studies have tied them to increased risk of lung cancer.\nThe National Institutes of Health paid for most of the study.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nHawk reviewed the study for the American Association for Cancer Research, which is meeting in Anaheim, Calif., where the study was to be presented on Wednesday.\nThe result is a surprise because many studies of individual vitamins have found they don't help prevent chronic diseases and some have even caused problems.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We hear from an expert who wan\u2019t involved with the study, and we receive a complete description of the study\u2019s funding\u00a0sources. The story notes that while NIH paid for most of the study, Pfizer supplied the pills.\u00a0That\u2019s a detail we didn\u2019t hear about in the competing Reuters piece.", "answer": 1}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nThe study was published Tuesday in the print edition of the journal Neurology.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did consult an independent expert. However, this expert\u2019s recommendations opened the door to a lot of questionable statements about the benefits of DHA. So this is a rare case where the story probably would have been better without this outside perspective.", "answer": 0}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\n\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nThe PCA3 test isn\u2019t a replacement for PSA testing.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nBut it improves the ability to diagnose prostate cancer, Groskopf says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story mentioned that the study was funded by the company that makes the test in question.\u00a0 The quote from the clinician from a for profit cancer treatment center barely qualified as an independent source. ", "answer": 1}, {"article": "For more on stroke, visit the National Stroke Association.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nBleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of patients, regardless of which drug they received, Campbell said.\nThe researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.\nTHURSDAY, April 26, 2018 (HealthDay News) -- After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has one independent source.\nIt also says the study didn\u2019t receive drug company funding, which is good to know.\nHowever, some of the researchers or their institutions have accepted financial support from companies that make stroke drugs and devices as well as Stryker, a company that makes vehicles designed to quickly deliver thrombotic therapies to stroke patients.", "answer": 0}, {"article": ".\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nEven the IUD can't stay in place for more than 10 years.\nThe procedure is very effective (there is less than a 1 percent chance the man's partner will get pregnant) and takes about 10 minutes to perform in the doctor's office.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote\u00a0an expert who describes the risks and benefits of the procedure fairly well. The story could have quoted another clinician\u00a0or expert to comment on the roll of Essure in clinical practice.", "answer": 1}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nFive people taking the fiber gel left the study due to problems with stomach bloating, nausea and diarrhea.\nIn terms of calories, flavor and appearance, the placebo and treatment drink were identical.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted.\u00a0 Industry funding for the study was disclosed.", "answer": 1}, {"article": "Aug. 25, 2010 -- Corneas made in the lab using genetically engineered human collagen could restore sight to millions of visually impaired people waiting for transplants from human donors, researchers say.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\nAfter several years of testing in her lab, Griffith began collaborating with Swedish eye surgeon Per Fagerholm of Linkoping University, who implanted the engineered collagen corneas into the 10 patients in Sweden.\nTo make the material, the researchers placed a human gene that regulates the natural production of collagen into specially programmed yeast cells.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses one independent voice. As with many stories of this nature, it waits until the very end to bring in the independent voice of reason. Still, because the researcher\u2019s comments in this story are so cautious, Dr. Walter Stark\u2019s comments only help to bolster the sense that more research is necessary to draw any conclusions about benefits of biosynthetic corneas.", "answer": 1}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nAfter three months the results were promising, the company said.\n\u201cThis is still investigational and requires more research.\nMedtronic shares gained 2.3 percent to close at $33.64 on Wednesday.\nThere were no adverse events reported up to three months later, but Rogers acknowledged that risks may become evident much later.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted \u2013\u00a0 the company-sponsored investigator was the only source quoted.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a physician-researcher who was not involved in the study.", "answer": 1}, {"article": "For more on dietary supplements, visit the Office of Dietary Supplements of the U.S. National Institutes of Health.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nLona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern in Dallas, cautioned that the study is short on specifics, making it difficult to draw any conclusions.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nVinson said his team was not focused on the weight-loss impact of caffeine as much as that of unprocessed, unroasted coffee's primary ingredient: chlorogenic acid.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert commented on the wisdom (or lack thereof) of basing this story on a 16-person study described only in a yet-to-be-presented meeting abstract. It also mentions that the study was funded by the supplement manufacturer.", "answer": 1}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\nThe vaccine has been tested, but never under real-world conditions in regular doctors\u2019 offices.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThere is a source who is independent of this study; however, Dr. Oxman was the lead researcher of the clinical trial that led to the approval of this vaccine. The description of him as being \u201cinvolved in a previous study of the vaccine\u201d is inadequate to describe his perspective on this vaccine. This story also fails to tell readers about study funding (from the Kaiser Permanente health plan) or support that the vaccine maker has given to some of the researchers for other research projects.\nThe comments from Dr. Oxman dealt only with benefits of vaccination. The story would have been better if there had been independent comment on the study itself, both what it adds to what we know and what potential weakness or limits there are in this sort of study. There\u2019s still a strong shared decision-making message that should be the take-home, but that didn\u2019t come across in the story \u2013 perhaps because of who was interviewed.\n", "answer": 0}, {"article": "The FASEB Journal, April 2017, vol.\n\"We are excited about this new flurry of studies, which builds on previously published research aimed to better understand the potential health benefits of red raspberries,\" said Tom Krugman, Executive Director of the National Processed Raspberry Council (NPRC).\nThe NPRC is responsible for marketing processed raspberries in the U.S. and is committed to promoting the growth of the entire industry.\nCreated in 2013, the National Processed Raspberry Council (NPRC) represents the processed raspberry industry and is supported by assessments from both domestic producers and importers.\nNPRC's mission is to conduct nutrition research and promote the health benefits of processed raspberries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release was transparent about the conflict of interest\u2014it was released by the National Processed Raspberry Council (NPRC). On its website, the NPRC says its mission is to \u201cpromote the consumption of processed raspberries based on research results.\u201d\nThe studies were all funded by the trade group, and that\u2019s noted on the EurekAlert! sidebar, where the release is hosted. \nThe news release also included a blurb at the bottom acknowledging that the NPRC \u201crepresents the processed raspberry industry.\u201d\u00a0\nMany news releases have conflicts of interest\u2014at least the NPRC was honest about it.\u00a0", "answer": 1}, {"article": "They're forgetful,\" Ashare said.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nThe research itself took a translational approach, what Ashare, a professor in Penn Medicine's psychiatry department, calls bi-directional.\nAt Penn's Center for Interdisciplinary Research on Nicotine Addiction, work on smoking cessation has been ongoing since 2001.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t explicitly state who funded the study or if there were any conflicts of interest. However, it\u2019s strongly inferred that Penn\u2019s Center for Interdisciplinary Research on Nicotine Addiction is the main sponsor. The study itself states that the research received funding from several government and non-profit research organizations and that there were no conflicts of interest. This is not a major omission but must be rated Not Satisfactory.", "answer": 0}, {"article": "The results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy.\nStill, it did not eliminate all symptoms.\nThese kids were severely allergic to cow's milk.\nBut only one-third have longterm protection.\nAnd so far there's no cure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There wasn\u2019t any independent voice in the story.", "answer": 0}, {"article": "For example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\nMarch 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited, and the\u00a0study discloses that\u00a0five of the investigators have filed a patent application \u201cpertaining to metabolite predictors of diabetes.\u201d This is crucial information for readers that was missed by the story.", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nWhile some risk factors are well-known -- including age, diabetes and poor cardiovascular health -- whether a man suffers harsh side-effects is often chalked up to random luck.\nThe debate whether to even test for it is ongoing.\nBrian Alexander (www.BrianRAlexander.com) is co-author, with Larry Young Ph.D., of \"The Chemistry Between Us: Love, Sex and the Science of Attraction,\" (www.TheChemistryBetweenUs.com), now on sale.\nDoctors usually can\u2019t predict whether a man will suffer all or none of those side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not clearly identify whether the sources are independent (one is a co-author, the other is not).", "answer": 0}, {"article": ".\nThat led to the current study, lasting four months.\nThe solution was a special device made by Kurve Technology that delivers a spray of insulin deep into the nose.\nA third also had scans to assess their brains\u2019 use of glucose.\nIn addition, she said, beta amyloid, a toxic protein that accumulates in the brain of Alzheimer\u2019s patients, seems to tie up insulin in the brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from the lead researcher on the study as well as an expert who was not affiliated with the research. The comments from the independent expert help drive home the need for caution when interpreting these results.", "answer": 1}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nThey have filed a patent and hope to move forward with clinical trials that could lead to commercialization.\nThe work was supported by a WSU fund to support entrepreneurial endeavors.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nCollaboration with Ping Wang, associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, enabled the design and implementation of the key clinical validation study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release reports that the researchers have filed a patent and hope to commercialize their product. It also states that the work was supported by a Washington State University fund to support entrepreneurial endeavors.", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to business analysts, the story quoted Lon S. Schneider, an Alzheimer\u2019s researcher at the University of Southern California\u2019s Keck School of Medicine, who \u201cwarned against reading too much\u201d into the announced results.", "answer": 1}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story misses the mark on two counts. First, it contains no independent sources. That\u2019s a particularly concerning omission since there\u2019s nothing to counter hyperbolic quotes from the study\u2019s lead researcher that the findings are \u201cexcellent news for men with early localized prostate cancer\u201d and \u201ctruly a huge leap forward.\u201d\nFurther, it says the treatment \u201cwas developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\u201d But it doesn\u2019t say that Steba, which holds the commercial license for the treatment, funded the study, a fact that was in the news release, or that all of the researchers involved in the study were compensated by Steba, which was reported in the study itself.", "answer": 0}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\nThis meant that, despite impressive results, the trial did not meet the F.D.A.\u2019s standards for approval.\nMarylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included input from several individuals expert in cardiology and the role of omega-3 fatty acids for decreasing risk of heart attack. It would have been informative for readers to have someone explain the nature of the information on heart disease and omega-3 fatty acids and why conclusive data was not available.", "answer": 1}, {"article": "But we don't know we're right yet.\"\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nBut last summer, Biogen began presenting its results with aducanumab at scientific meetings, including the Alzheimer's Association International Conference in July.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an official from Biogen (which makes the experimental drug) and the author of an accompanying editorial. But we don\u2019t hear from any truly independent sources in the story. The editorialist, Dr. Eric Reiman, is said to be the\u00a0executive director of the Banner Alzheimer\u2019s Institute in Phoenix. It doesn\u2019t explain that the Banner Institute is leading Alzheimer\u2019s Prevention Initiative, an effort to postpone and prevent the disease before it starts. The initiative partners with a number of drug companies, including Roche, Amgen, Genentech, Novartis, on its studies. These relationships merited a mention in the story.", "answer": 0}, {"article": "An intravenous method of injecting stem cells into patients who had experienced heart attacks within the previous 10 days suggested that this method works to repair -- not just manage -- heart damage, a recent study found.\nThe research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety.\nHe was not involved in the study.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nAn area of improvement would be making the stem cell treatment more efficient, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses two sources: One stem cell expert who is not involved with the research, and the lead author of the published paper.\u00a0\nWhile that\u2019s thin sourcing for a story of this length, it\u2019s sufficient to earn a satisfactory rating. ", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\nMore trials need to be done of this unique treatment, she added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this story includes quotes from experts not involved with the trial (unlike a Reuters story we also reviewed about a different trial of the same drug), it fails to tell readers that:\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 the trial was funded by Amgen\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amgen led the design and conduct of the study\n\u2013\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 key researchers receive payments from Amgen, not only for research, but also to serve on boards and conduct outreach for the company.\nAll of this conflict of interest information is clearly listed at the end of the journal article that reports the trial results. It should have been included in the story.", "answer": 0}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThey were asked to view photos both related and unrelated to smoking.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\nWomen who want to quit smoking may find it easier if they time their efforts just right.\nResearchers asked each participant to smoke one cigarette 30 to 40 minutes before undergoing an fMRI, or brain scan.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not consult with independent sources. A brief talk or email exchange with any qualified expert would\u2019ve shot down most of the inflated claims made in this story.\u00a0Any journalist who doesn\u2019t know where to turn for independent sources could access our List of Industry-Independent Experts.", "answer": 0}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All information in the story appears to come from company sources, though no one is quoted by name. [Other press coverage of the AstraZeneca statement fails to include additional comments from company spokesmen, suggesting the company did not provide more information to anyone.] \nUnnamed \"analysts\" are said to urge caution about the drug\u2019s market value until the results are published and information about side effects is known.\nBut the elephant absent from the room is the medical expert who could provide insight into Plavix\u2019s risk/benefit profile, how significant its risks are from a clinical perspective, and what value Brilinta would have if indeed it provides better outcomes and its effects are more quickly reversible. \nIt\u2019s significant to note that this medical information would be useful not just to consumers, but to Wall Street Journal readers who follow AstraZeneca\u2019s fortunes and who participate in the bloodsport of betting on drug blockbusters. \u00a0 ", "answer": 0}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nIt's actually an update of a 2008 report, with an additional three years of data on the nearly 700 men who volunteered for the trial up to 15 years ago.\nAlmost 90 percent had tumors their doctors could feel on digital rectal exams.\nSo is this a slam-dunk for radical prostatectomy?\nTwo such studies are underway.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the author of an editorial about the study reported on.", "answer": 1}, {"article": "When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release gets credit for including the funding sources of the study \u2014 Novartis Pharmaceuticals, the National Institute for Health Research in the UK, and the European Union \u2014 but it fails to point out any of the linkages among the study\u2019s authors to pharmaceutical firms. According to the published study disclosures, these relationships include speaking fees, consultancies, grants and full-time employment with Novartis and other companies. This transparency is needed for readers to ascertain bias. ", "answer": 0}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nFor the study, Reddy and colleagues reviewed the medical charts of 9,073 weight-loss surgery patients who were treated between 2002 and 2013 at NYU Langone's Weight Management Program.\n\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\n\"Psoriasis and psoriatic arthritis are chronic inflammatory conditions that can be quite uncomfortable and often painful for patients, so any treatment that might reduce symptoms may improve quality of life,\" says lead study author Soumya Reddy, MD, an assistant professor of medicine in the division of rheumatology at NYU Langone, and co-director of NYU Langone's Psoriatic Arthritis Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses that the patient histories that were reviewed came from bariatric surgery patients of NYU Langone, the institution that issued the news release. It states, \u201cFor the study, Reddy and colleagues reviewed the medical charts of 9,073 weight-loss surgery patients who were treated between 2002 and 2013 at NYU Langone\u2019s Weight Management Program.\u201d", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThe trial will be conducted in the Wisconsin Network for Health Research (WiNHR) and the Wisconsin Research and Education Network (WREN), both of which McBride directs.\nBased on these findings, Hennekens and colleagues are drafting an investigator initiated research grant proposal to the National Institutes of Health (NIH) under the direction of co-author Patrick E. McBride, M.D., M.P.H., professor of medicine and interim associate dean for faculty affairs at the University of Wisconsin School of Medicine and Public Health.\nLast month, the prestigious New England Journal of Medicine ranked the original manuscript by Hennekens and colleagues on aspirin, inflammation and cardiovascular disease, published in 1997, as their most influential original report of the last 20 years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to disclose that the trial was funded by TJA Health LLC, the maker of Plaque HD. (The journal article states that the company was not involved in the design, conduct or reporting of the trial.) And while the release devotes considerable attention to the prominent career of senior author, Charles Hennekens, MD, it does not point out that he holds patents related to CRP testing.  ", "answer": 0}, {"article": "Bernard M.Y.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\nThe study was supported by a grant from Merck (manufacturer of the simvastatin).\nThe reports are published in the Nov. 9 online edition of The Lancet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from one source beyond those involved in the study and accompanying editorial. The story also mentioned that one study was in part financed by a company that makes one of the statins. \u00a0However, there were no experts quoted providing perspective about the downside of \u00a0high-dose statins. Because this is such an important subject and because the medical community is not as unified in favor of higher dose statins as this story would suggest, we rated this category unsatisfactory.", "answer": 0}, {"article": "CDK7 is also involved in the process of transcription, a vital step in gene expression - the creation of proteins to carry out cell functions.\nIt is this molecule, in oral pill form, that was taken forward by Carrick as CT7001 and is currently in Phase I clinical trials.\nProfessor Tony Barrett, from the Department of Chemistry, said: \"This work is the result of extensive collaboration between chemists, biologists and clinicians, which has helped to bring a new treatment from discovery to clinical testing in record time, streamlining the process.\"\nICEC0942 was then licenced to Carrick Therapeutics, who developed it into a molecule named CT7001, which they have taken to early-stage clinical trials in less than two years.\nLicensing of the technology to Carrick Therapeutics was led by Cancer Research UK's Commercial Partnerships Team and Imperial Innovations, the Technology Transfer Office of Imperial, with support from Emory University.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states:\nEarly funding for the study came from the Engineering and Physical Sciences Research Council (EPSRC), and a major contribution of whole-project funding was from Cancer Research UK. Licensing of the technology to Carrick Therapeutics was led by Cancer Research UK\u2019s Commercial Partnerships Team and Imperial Innovations, the Technology Transfer Office of Imperial, with support from Emory University.\nHowever, the news release doesn\u2019t offer specifics on these financial relationships.\nA look at the manuscript describing this molecule shows the authors are inventors on a patent owned by Imperial College London and that one researcher acted as a consultant for Carrick. Do Imperial College London and Emory University stand to profit from this drug?", "answer": 0}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nBut there\u2019s still a lot to be learned, he cautioned in an interview.\nThe study\u2019s lead researcher agreed on the need for more work.\nMuscle weakness was the most common side effect in this study, van der Walt said.\n\u201cExploring new treatments is important, and it\u2019s heartening to see there\u2019s some promise here,\u201d LaRocca said of the current findings.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Actually, most of the quotes came from an independent perspective.", "answer": 1}, {"article": "\u201cIt can be the most interesting story in the world,\u201d he said.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\nBut he cautioned that in-vitro testing does not demonstrate how a final formulation works off the shelf.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nDr. Ellen Marmur, the chief of the division of dermatologic and cosmetic surgery at Mount Sinai Medical Center in Manhattan, did say Algenist could fairly claim that alguronic acid offers protection against ultraviolet damage to cells, and that she might use the product as \u201ca nice sun protection on top of S.P.F.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Again,we love that the story took this company\u2019s marketing materials and attempted to have them independently analyzed. But the story chose poorly when picking experts. After 10 paragraphs of effusive language about a new wave of ocean-derived anti-aging products, the first ostensibly critical voice in the story is given to Dr. David McDaniel, who is described as \u201ca dermatologist and the director of the Institute of Anti-Aging Research in Virginia Beach, Va.\u201d what does McDaniel say? He \u201csaid he was impressed by the in-vitro testing of alguronic acid. \u201cIn the petri dish, their data seems to show some substantial benefits to their active ingredient,\u201d he said. But he cautioned that in-vitro testing does not demonstrate how a final formulation works off the shelf.\u201d The story does not point out that the institute is a contract research organization that provides service to manufacturers including study design, laboratory testing, clinical testing and media consultations.", "answer": 0}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nThis is a randomised, controlled trial, but what we found were exploratory outcomes; in other words, it wasn't the main result that we were testing.\nProfessor Vieta was not involved in this work, it is an independent comment.\nParticipants received the study medication in addition to any stable treatments they were already receiving.\nThere are some points we need to note about this study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Study funders are noted on the sidebar of the hosting service, EurekAlert! It would be helpful to include that information in the body of the news release as well.\nCareful review of the author disclosures included in the study reveal no significant conflicts of interest.", "answer": 1}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\n\u201cPatients and their health care providers should discuss the benefits and risks of Siliq before considering treatment,\u201d said Dr. Julie Beitz, director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research, in an agency press release.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\n(Fried says he has no involvement with the drug or the drug company.)\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two sources, one an FDA official and the other a member of the medical board of the American Psoriasis Foundation. The story also points out that the APF official \u201csays he has no involvement with the drug or the drug company.\u201d However, the foundation lists Valeant, Siliq\u2019s manufacturer, as a corporate partner, and we think those sorts of details are important to disclose.\n", "answer": 0}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article includes two sources: Mark Eisner, Genentech\u2019s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization\u2019s influenza collaborating center at St. Jude Children\u2019s Research Hospital in Memphis.\nEisner\u2019s affiliation with Genentech, the drug\u2019s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what\u2013if anything\u2013is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths.", "answer": 1}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThat doesn\u2019t mean you should extend your own use of the contraceptives without talking to your doctor.\nThe study is still continuing, and it could be quite a long time before any changes to clinical recommendations are considered.\nThe implants are currently approved for three years, and the hormonal IUD used in the study is approved for five.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one is quoted by name in the story, not even from among the researchers. We would have liked an independent comment from someone who was not part of this study about its implications.", "answer": 0}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nMonday\u2019s announcement was the first about the therapy in more than two years.\nLichtinger said he was confident the data would be positive but was not expecting miracles.\n\u201cIt is important to know that we do not expect patients to get up and play basketball,\u201d he said.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the CEO of Asterias is quoted in this article. An independent source \u2013 who could have discussed the limitations and significance of the trial \u2013 would have helped balance the story, bringing a much-needed perspective to readers.", "answer": 0}, {"article": "Compliance with colonoscopy is low, since people don\u2019t want to have one, and the overall cost per detection is high because most people are healthy, and even colonoscopy misses many tumors in the upper part of the intestine.\nProponents of each test note possible weaknesses of the other.\nThere\u2019s a lot of hope for getting a stool-based test.\u201d\n\nPromising results for the blood-based tests were reported this week at a meeting in Barcelona, Spain.\nBut in the real world, the tumor DNA must be detected in stool samples, even though almost all the DNA comes from the bacteria of the gut.\nBoth tests would be less expensive than colonoscopy, and potentially more effective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story relies too heavily on researchers who are connected to the companies developing the cancer screens. Where was the truly independent perspective?", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\nIn an accompanying editorial, Dr. Joseph V. Bonventre of Harvard Medical School wrote that he had concerns about the change of therapy offered to patients in the study.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no evidence that the newspaper interviewed anyone for this story.\u00a0 The perspectives of the study\u2019s lead author and of the editorial writer both appear to be gleaned directly from the New England Journal of Medicine. \nThe story would have been improved by including comments from interviews with clinicians about what this information means to people who may need to deal with acute kidney injury in the future.\u00a0", "answer": 0}, {"article": "It\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\nThe probiotics were manufactured and provided by Nestle, which also funded the study.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\n(Study co-author Premysl Bercik, associate professor of medicine at McMaster University, says the formula used in the new research isn\u2019t commercially available, anyway.)\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is a discussion early\u00a0in the story that the research was funded by Nestle. The story\u00a0also incorporates opinions from a research scientist who was not involved with the study who provides additional\u00a0insights about the study\u2019s findings.", "answer": 1}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\n\"Patients have painful and inflamed joints.\ncan improve the efficacy of standard rheumatoid arthritis therapy and decrease cardiovascular risk,\" said Professor Babaeva.\nProfessor Babaeva's previous research showed that treatment with anticytokine drugs can decrease the activity of rheumatoid arthritis.\nWe recommend this new approach for preventing cardiovascular events in patients with moderate disease activity who are not receiving the standard biologics and who do not have severe complications.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We learn that Professor Aida Babaeva, the lead investigator, is the head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia, but not the degree to which she may have connections to companies making these drugs. Those kind of clarifications are important.", "answer": 2}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nAgain, Merck disputes the connection.\nFor instance, they started out with a history of more fractures, so the comparison isn't valid.\nThat's called the relative risk, and it seems alarming.\nThat's obviously a lot more benefit than risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "NPR provides us with three fresh sources beyond the JAMA article itself.", "answer": 1}, {"article": "Levels of the biomarker were lower in mild cases, and were much more elevated in severe case,\" said Papa.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nMoreover, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nThe biomarker this particular blood test looks for is known as glial fibrillary acidic protein (GFAP).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the journal article\u2019s lead author receives funding from NIH. The study itself was partially funded by the NIH, a subtle but potentially important distinction. \u00a0Further, the journal article notes that the lead author is a scientific consultant for Banyan Biomarkers, Inc. \u2014 a company that has intellectual property rights to GFAP testing. The journal article also states that the relevant author \u201creceives no stocks or royalties from the company and will not benefit financially from this publication\u201d \u2014 but that potential conflict of interest is still worth mentioning in the release.", "answer": 0}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\nSome experts say that estimate is overly alarming.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\n\"That's very controversial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed two sources in the story.\u00a0 One was the first author of the article being reported on.\u00a0 One appeared not to be involved in the study reported on.\u00a0 It would have been helpful to clearly identify the doctors beyond their names to explain why they were interviewed. ", "answer": 1}, {"article": "Some of the IntelliCare apps include:\n\u2022 Daily Feats: designed to motivate you to add worthwhile and rewarding activities into your day to increase your overall satisfaction in life.\nThe study was supported by grant R01 MH100482 from the National Institute of Mental Health of the National Institutes of Health.\nThe study will be published Jan. 5 in the Journal of Medical Internet Research.\nIntelliCare is a national research study.\nRebecca Rossom, a researcher with HealthPartners Institute, also was a study co-author.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was funded by the National Institute of Mental Health.", "answer": 1}, {"article": "Statins reduce cardiovascular risk and scientists believe it is because they decrease low-density lipoprotein, or LDL, the so-called bad cholesterol.\n\u201cManaged care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,\u201d they wrote in the Health Affairs blog.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nIn the studies detailed on Sunday, both drugs reduced the bad cholesterol by about 60 percent, to about 50 milligrams per deciliter from about 120 at the start of the studies.\nThe study of Amgen\u2019s evolocumab involved 4,465 patients with various degrees of risk, two-thirds of whom were randomly chosen to get the drug in addition to the medication they were already taking.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two independent doctors \u2013 Dr. Steven E. Nissen and Dr. Sanjay Kaul \u2013 both of whom pointed out the limitations in the studies. The piece also did an excellent job in disclosing potential conflicts of interest, since pharmaceutical companies often finance the development and research of their drugs. The article stated that lead study authors \u201cDr. Sabatine and Dr. Robinson have been paid consultants to the companies sponsoring the trials they led.\u201d It also made clear the fact early in the story that these studies were \u201csponsored by manufacturers.\u201d", "answer": 1}, {"article": "Millions of women stopped using the hormones after a large U.S. government study in 2002 found that postmenopausal women given HRT had higher risks of heart attack, stroke, breast cancer and blood clots than women given an inactive placebo.\nThese latest findings do not alter that advice.\nThe implications of that finding, if any, are not yet clear.\nBut they point to a need for further study into the different effects of HRT on specific organs, write the researchers, led by Dr. Katherine DeLellis Henderson of the City of Hope National Medical Center in Duarte, California.\nMost of the women were past menopause at the outset, and 61 percent were currently using HRT.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source cited was the lead author/researcher.\u00a0 We always wish stories would include an independent expert voice for additional perspective. ", "answer": 0}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe work was supported by the Department of Defense, the Meadows Foundation and the Friends of BrainHealth Distinguished New Scientist Award.\nOver an eight-week period, the strategy-based training group learned strategies to improve attention and reasoning.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are disclosed at the end of the news release.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not seek an outside perspective. The competing USA Today story quoted 3 other experts who provided valuable context.", "answer": 0}, {"article": "Among women taking tamoxifen in the study, 36 of 4,732 got uterine cancer, while for raloxifene the number was 23 of 4,712.\nGiven that there are shades of gray and room for debate about these findings, some critics questioned the way they were made public.\nThat fact was not stated in the news release, and the researchers mentioned it only briefly during the news conference, calling the results \"borderline\" significant.\nYet that distinction was not pointed out in the news release, and, Dr. Lichtenfeld noted, it was \"de-emphasized\" during the news conference.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple sources who have differing opinions of the significance of these findings.", "answer": 1}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nMerck said it recently added reports of suicide to Singulair's label, which already listed suicidal thinking and behavior as reported side effects.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nThe company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The segment draws on data from pre-approval and post-marketing trials, an interview with the family of a teenager who committed suicide after taking Singulair, and an interview with a clinical specialist in asthma and allergies.\nIt also reports its own observation that information about the side effects is buried on the drugmaker\u2019s website.\n\u00a0\n \u00a0", "answer": 1}, {"article": "\"There was no significant difference,\" Boden said.\nThe findings underscore the danger of rushing to adopt a procedure before careful studies have been conducted to fully determine its benefits, Boden and others said.\nThe findings come on the heels of questions about the safety of new stents coated with drugs to keep arteries from reclosing.\n\"The data are clear.\"\nHalf the patients received standard medical treatment involving medication and lifestyle changes such as quitting smoking, eating better and exercising.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources are quoted.\u00a0 ", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article uses as sources the study itself, the lead author, and two independent medical specialists. This is sufficient sourcing.\nIt is not known if any of the researchers had ties to interested parties such as device makers. The published abstract does not include this information. ", "answer": 1}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nDr. William Abraham, co-lead author and director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, presented findings from the study at the recent European Society of\n\nCardiology Congress in Rome.\n\"Currently, we don't have good treatments available.\n\"Not only did we see this reduction in events per hour, the patients also rated themselves better on the Epworth Sleepiness Scale (meaning they were less sleepy during the day) and on a global assessment of their overall quality of life,\" Abraham said.\nIn addition to Abraham, Ohio State's Dr. Rami Khayat and Dr. Ralph Augostini participated in this research, making Ohio State one of the high enrolling centers participating in the study worldwide.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release meets this standard with an end note stating that the study was funded by the manufacturer of the device, and that the quoted researcher is a consultant to the manufacturer.\nWe are glad to see news releases beginning to incorporate more transparency and addressing conflicts of interest.", "answer": 1}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nSamit Hirawat, head of Novartis\u2019s cancer drug development, said in an interview the side-effects profile of alpelisib held up.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes Farbrice Andre. It does not mention that Andre is the lead author of the study. It also does not mention that Andre received a grant from Novartis while the study was being conducted, which is noted in the disclosure section of the abstract.\nThe article also quotes the head of cancer drug development at Novartis.\nThere are no quotes from researchers or experts not involved with the study.", "answer": 0}, {"article": "And the news is very good.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\n\u201cFor the first time in a randomized controlled trial, we have shown that ultrasound can be precisely delivered through the intact human skull to treat a difficult neurological disease.\u201d\n\nPioneering Tremor TrialThe multi-site clinical trial included 76 participants with moderate to severe essential tremor, a condition that often robs people of their ability to write, feed themselves and carry out their normal daily activities.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release identifies the funders of the study but fails to point out that the principal investigator has a financial relationship with the manufacturer of the device used in the study.\nIn addition, the published study notes that \u201cRepresentatives of the manufacturer of the focused ultrasound system used in the study (InSightec) provided study oversight and technical support and obtained national regulatory permissions.\u201d Allowing the device manufacturers to have \u201cstudy oversight\u201d suggests a potential for bias when most studies are obligated to keep a firewall between investigators and financial sponsors.", "answer": 0}, {"article": "'In the wrong place with the wrong skin color'\n\nMelanoma cancers are dangerous, abnormal growths on the surface of the skin caused by sun damage, which can spread throughout the body if left untreated.\nHowever, she stressed the fact this new test has not undergone clinical trials.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nPatients who returned a positive result would still need a biopsy to confirm the blood test and determine how far the cancer had developed, Ziman said.\nZiman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We did not detect any conflicts of interest that should have been disclosed, though it would have been useful to explain how the study was funded (a grant from the Australian government). The story provides comments from Dr. Moffat, an unaffiliated expert who places the tests and the results in context.", "answer": 1}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nMONDAY, Nov. 14, 2011 (HealthDay News) -- Preliminary research suggests that a single injection of a man-made protein might lower levels of \"bad\" cholesterol.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nThe findings were presented Monday at the American Heart Association (AHA) annual meeting in Orlando, Fla.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story alerted readers to the fact that the study was funded and conducted by Amgen. However, at least one of the researchers who comments on the findings \u2014 Daniel Rader \u2014 consults for numerous pharmaceutical companies that produce or are developing new cholesterol-based therapies, including drugs that target the PCSK9 pathway discussed in the article.\u00a0To avoid any appearance of a conflict, the story should have disclosed these relationships.", "answer": 0}, {"article": "Botox injections are also used, often in cases where the medicine does not work.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nBoth are reasonable options.\u201d\n\u201cThis gives patients the information to make an informed decision.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent source quoted in this article. The only comment is from the lead author of the story.", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not obtain independent comment on the study findings. ", "answer": 0}, {"article": "Obese children and those with diabetes often suffer from fatty liver, a condition normally associated with alcohol abuse but increasingly common among non-drinkers who gain excessive amounts of weight.\nLustig and his colleagues think they\u2019ve produced the \u201chard and fast data that sugar is toxic irrespective of its calories and irrespective of weight.\u201d\n\nMORE: FDA Wants Nutrition Labels to Include More Detail on Added Sugars\n\nLustig\u2019s confidence comes from the unique study, described in , of 43 Hispanic or African-American children aged eight to 18 years old.\nThis study does hint however, at what might be happening.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nBut Lustig relied on the starches to prove a point in a scientific study \u2014 that the effect sugar has on the body goes beyond anything connected to its calories and to weight.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes restraining comments from two independent experts, although those comments come far down in the story and should have been placed higher. The story perhaps also could have mentioned that Dr. Lustig is author of a 2012 book called \u201cFat chance:\u00a0Beating the Odds Against Sugar, Processed Food, Obesity, and Disease,\u201d and so may have an intellectual and financial conflict of interest when it comes to sugar. \u00a0The study was funded by\u00a0the NIH and Touro University, as well as UCSF \u2014 another aspect that could have been mentioned for context.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Journalist notes that the study was \nfunded by Novartis, maker of Femara, and that many of the researchers own stock in this company or in companies for rival \ndrugs. ", "answer": 1}, {"article": "But women who consumed the most blueberries and strawberries had a 32% reduced risk of heart attack compared with the women who ate berries once a month or less.\nWhen we\u2019re making choices in our 20s, we may think that a burger and fries is great, but the message is that there are alternatives that make a difference for the rest of your life.\nIt is a powerful message that we can prevent cardiovascular disease by what we eat.\u201d Something worth remembering the next time you\u2019re in the produce aisle.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent expert, preventive cardiologist Dr. Suzanne Steinbaum, who is the same doctor quoted in the HealthDay article.\u00a0 (Hmm, why is that?) We wish that she could have talked more on the limitations of the study, although her comment on benefits later in life more of an endorsement than a critical analysis: \u201c\u2026even if you are eating these early in life, you\u2019re getting benefits that last for life.\u201d\nNonethless, because an independent expert was quoted, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe team recruited 404 people with first-episode psychosis, mostly diagnosed in their late teens or 20s.\nAbout half got the combined approach and half received treatment as usual.\nOver two years, both groups showed steady improvement.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes experts who were not authors on the study.", "answer": 1}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nFOR IMMEDIATE RELEASE\n\n\n\nNewswise \u2014 The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT to CT or MRI increases the accuracy of kidney tumor classification.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\nPathology results of surgically removed tumors showed that 8 of the 48 were benign.\nFollowing surgery, similarly \u2018blinded\u2019 pathologists analyzed the tumors without knowing the radiologists\u2019 imaging results.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release didn\u2019t mention a funder.", "answer": 0}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies sources affiliated with the two companies that make the radiation device, as well as a researcher who is funded by one of the companies. \u00a0These sources are offset by references to the JAMA Dermatology editorial and by comments from one of the editorial authors.", "answer": 1}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story features comments from independent public health and toxicology experts. It notes that some of the research supporting the benefits of kratom was commissioned by a kratom advocacy group. We think including perspective from an independent health expert would have made the story even stronger, but wasn\u2019t critical.", "answer": 1}, {"article": "Dental caries (tooth decay) is caused by bacteria on the tooth surface feeding on carbohydrates, then making acids as waste.\nDental decay was low in both groups.\nProctor & Gamble, 3M Espe and Epic provided products for study participants at reduced or no cost.\nThe authors published their initial validation of CAMBRA for ages 6 through adult in 2006, followed by several additional years of data published in 2011, 2012, 2015 and 2016.\nPlease visit http://www.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are listed, and there are no apparent conflicts.", "answer": 1}, {"article": "The women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nThe most surprising new finding relates to breast cancer.\n\u201cI hope that separation will become clearer now.\u201d\n\n \n\n\n\nThis article appeared in print on Wednesday, April 6, 2011 on page A1.\n\u201cThe big message there is that the data look much more favorable for younger women and much riskier for older women,\u201d said Dr. LaCroix.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story benefits from direct interviews with sources holding different perspectives.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nHicks and a team of researchers have been looking for an objective test that might help.\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nA better option, he says, might be blood samples, which tend to contain greater numbers of the genetic fragments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the lead researcher \u201chelped develop the test and consults for a company that hopes to market concussion tests.\u201d It also includes comments from a source who does not appear to be connected with the study, nor have any potential conflicts of interest. Though as we noted above, the way this source\u2019s comments are reported creates confusion about what the study actually looked at.", "answer": 1}, {"article": "An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nIn the new study, researchers tested corneal implants that are \"biosynthetic,\" meaning they're created with the help of living tissues.\nFor more than a century, doctors have considered transplantation of corneal tissue from deceased donors to be the best treatment, the study authors wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes one independent source who is basically a booster for the research. He also, though, raises an issue that underscores some of the information lacking in the story. The story also\u00a0could have explained what the funding sources were.", "answer": 1}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nThe lead author and researcher was Dr. Peyman Kabolizadeh, clinical director, Beaumont Proton Therapy Center in Royal Oak.\nNot only were he and Karin impressed with the advanced cancer killing capabilities of the pencil beam proton therapy, but also with the expertise of Dr. Kabolizadeh.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear the release is from a proton beam therapy provider discussing one patient\u2019s experience with undergoing the therapy. The release is clearly marked as coming from the treatment provider, so the conflict of interest is pretty straightforward. And the lack of new findings being prevented means that there is no funding source to discuss. As such, this earns a satisfactory ranking.", "answer": 1}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nAdditional information is available at http://abstract.asco.org/176/AbstView_176_165870.html.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release contains no description of funding sources or conflicts. Of the multiple authors, the link to the abstract (click the blue words \u201cabstract disclosures\u201d) identifies many connections to Merck which manufactures pembrolizumab.", "answer": 0}, {"article": "Now that Epidiolex is approved by the FDA, cannabidiol is expected to be reclassified by the Drug Enforcement Administration within 90 days.\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\n\u201cWe are just scratching the surface of what could be a range of cannabis-based medications.\u201d\n\nThe medication, which will continue to be manufactured in Britain, will be marketed by Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals.\nThe drug is the first treatment approved for Dravet syndrome.\nOthers said they are anxious to try an FDA-approved product.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is a quote from a neurologist with the American Epilepsy Society, however he consults for drug companies and the society has received substantial donations from a subsidiary of the drugmaker manufacturing this drug. This should have been flagged for readers.", "answer": 0}, {"article": "Systolic blood pressure, the top number, fell an average of nearly three points and diastolic dropped almost two points in the dark chocolate group, compared with no change in blood pressure readings in the white chocolate group.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nThe study appears in Wednesday's Journal of the American Medical Association.\nNew research from Germany adds to mounting evidence linking dark chocolate with health benefits, but it's the first to suggest that just a tiny amount may suffice.\nThe research involved just 44 people aged 56 through 73, but the results echo other small studies of cocoa-containing foods.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only \"expert\" interview in the story was with the nutrition director of the Center for Science in the Public Interest.\u00a0 But the interview bites they used from her didn\u2019t add much to the piece, so we\u2019re left yearning for some expert interpretation of the findings.\u00a0 ", "answer": 0}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\nUTMB's Cristiana Rastellini, Professor in the departments of Surgery and Microbiology & Immunology also was an author on this paper.\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\nThis research was supported by the National Institutes of Health and the Mitchell Center for Neurodegenerative Diseases.\nSince the people involved in the study mostly come from Texas, the researchers further compared their over 65 years old group with the prevalence of Alzheimer's in the general population of the state and got similar results.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are clearly identified. \u00a0The authors disclosed no conflicts of interest in the paper, a fact which the news release could also have shared with readers.", "answer": 1}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\n\u201cThe ensuing structure of those bonds during the cooling process is what makes them resistant to then being digested in the small intestine,\u201d Arciero says.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nArciero and his team monitored the women after each meal for three hours and used a device to see how many calories they burned, and what type.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There don\u2019t appear to be any conflicts of interest. However, the story does not quote any independent sources, only one of the study authors.", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert sources were physicians/researchers involved in the development of the experimental treatment or the care of patients receiving it. A perspective from someone not affiliated with this research would have helped identify the caveats and limitations that we felt were missing from this report.", "answer": 0}, {"article": "Hospitals take over with more sophisticated cooling equipment.\nBut MetroHealth and Cleveland EMS officials say they aren't convinced the therapy is proven enough to rewrite the book on cardiac arrest treatment.\nBut Dr. David Rosenbaum, director of MetroHealth's heart and vascular center, said there is not enough research data to justify a regional system.\nAsked about outcomes, he said results won't be available until the program reaches one year.\n\"I am still amazed that lots of physicians are not aware of the technology,\" Blitz said in an e-mail.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provided names and interview material from several clinicians; there was some difference in opinion about the merits for the use of this approach to treatment.\nOne problem with the reporting was that one clinician who was in favor of the use of this technology was only identified at the very end of the story as having received funding from the company that sells the device in question.\u00a0", "answer": 1}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\n\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nThe report, which was primarily funded by philanthropic groups and the British government, is published in the June 15 online edition of The Lancet.\nDr. Jerrold H. Levy, deputy chair for research at Emory University School of Medicine in Atlanta and author of an accompanying journal editorial, said that, \"these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding.\"\nLevy however, cautioned that the results of this study apply only to TXA and do not mean that people should try similar drugs hoping for similar results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the author of an accompanying editorial who was not affiliated with the study and does not appear to have conflicts regarding the research.", "answer": 1}, {"article": "The most common side effects patients undergoing viscosupplementation may endure are flare-ups - where the knee becomes hot and swollen within 24 hours after the injection - and effusions, where excessive joint fluid collects inside the knee.\n\"We have an epidemic of osteoarthritis of the knee and we have limited treatment options,\" says Dr. Richmond, who was not affiliated with the analysis but who reviewed the same data it was based on.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\nNow, a new report questions the efficacy of this treatment for osteoarthritis in the knee.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While some data (not much) is cited from the Swiss meta-analysis, no one from that research team was interviewed.\nThe only interview weight was given over to a US critic.\u00a0 Why?\u00a0 How was he chosen?\u00a0 Why was he given this platform?", "answer": 0}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nOne of medicine\u2019s greatest villains: HIV.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from multiple independent sources, which is good. The story also notes that the relevant study was funded (in part) by Bluebird Bio \u2014 a company that hopes to market the relevant gene therapy.\nHowever, the story does not note that the principal investigator for the study, David Williams, has a conflict of interest. According to an appendix of the journal article, Bluebird Bio also funds other projects by Williams. The company has also licensed one of Williams\u2019 patents. That doesn\u2019t necessarily mean that anything in the study is shady, but conflicts of interest should be acknowledged.", "answer": 1}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nPrausnitz attributed the better performance to the skin's abundance of the types of cells most adept at generating immune responses.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources are interviewed, one of whom provides valuable context regarding the difficulty of replicating mouse studies in humans.", "answer": 1}, {"article": "Hysterectomy is the surgical removal of the uterus.\nAnd to get the word out she invites doctors to come to Baptist Hospital East in Louisville and learn the procedure.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\nWarren is one of relatively few surgeons who perform hysterectomy with a minimally invasive, laparoscopic technique.\nShe thinks hundreds of thousands of them are getting the wrong operation every year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story does\u00a0quote more than one expert, it is not clear that these are actual independent experts. Dr Cahill is the Executive Director of the National Women\u2019s Health Resource Center, whose campaign \"What\u2019s going on down there?\" was supported by Ethicon, Inc, a manufacturer of surgical equipment. And it is not clear what Dr Warren\u2019s credentials are.", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nTheravalues Corp. provided the curcumin and placebos for the trial, as well as funds for laboratory testing and for Small\u2019s travel to present preliminary findings at the 2017 Alzheimer\u2019s Association International Conference.\nThe paper\u2019s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.\nThe study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer\u2019s Disease Research, the U.S. Department of Energy and the National Institutes of Health.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release lists funders and notes that \u201cTheravalues Corp. provided the curcumin and placebos for the trial, as well as funds for the laboratory testing and for [lead author] Small\u2019s travel to present preliminary findings at the 2017 Alzheimer\u2019s Association International Conference.\u201d\nWhat isn\u2019t mentioned is that UCLA owns the patent for the amyloid and tau labelling method used in the study, and that the lead author \u2014 as well as three of the co-authors \u2014 invented the method and have a financial interest in the company that sells it (TauMark, LLC). The lead author has financial relationships with a dozen biomedical companies besides Theravalues and TauMark.", "answer": 0}, {"article": "In 2015, he was ranked the No.\nFAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nHennekens notes that further research is needed, but that in the future, the use of regular claims-based surveillance for mammography as a source of data may offer some unique advantages over self-reports.\nIn 2013, he received the \"Fries Prize for Improving Health\" and in 2014, he received the Alton Ochsner Award for his pioneering work on smoking and health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of funders or potential conflicts of interest in the release.", "answer": 0}, {"article": "\u201cThe question has been, \u2018What do you do with the rest?\u2019\u201d he says.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nHe says about 75% of patients with affected skin will go into remission with these standard treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did interview a doctor outside of the current study team who cautioned about the treatment with lenalidomide may not be safe and effective for patients.", "answer": 1}, {"article": "MORE: With Early Breast Cancer Treatment, Less May be More: Studies\n\nCertain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\nAbout half of the 90,000 women who participated in the Nurses\u2019 Health Study also answered questions about their typical diet while they were teens.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\nIn the study, Farvid and her team could not find any significant relationship between fruit juice and breast cancer risk; that may be because fruit\u2019s anti-cancer effects may have to do with the fiber found in the whole fruit, which is stripped out of juice.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were included in the article, nor does it tell readers who funded the study. In this case, the work was supported by the National Institutes of Health, the Breast Cancer Research Foundation, and the Japan Pharmaceutical Manufacturers Association.", "answer": 0}, {"article": "British researchers led by David Nutt, a professor of neuropsychopharmacology at Imperial, have been exploring the potential of psilocybin to ease severe forms of depression in people who don\u2019t respond to other treatments.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nThe trial involved six men and six women, aged between 30 and 64, all diagnosed with treatment-resistant depression.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nSeven continued to show a positive response at three months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the funder was mentioned in the press release, that information was not included in the story.\u00a0There also was no outside commentary.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nOver the next 18 months or more, the tactic appeared to be safe.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nThere is no larger trial in the works yet, according to Scharre.\nBut it's far too early to know whether it has value for people with Alzheimer's, Scharre stressed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a useful comment from Keith Fargo, who directs scientific programs and outreach for the Alzheimer\u2019s Association, that it\u2019s \u201cmuch too early\u201d for for patients or caregivers to seek out this device.", "answer": 1}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Papakostas agrees the study \u201cneeds replication\u201d but said he is hopeful about the potential for future research.\n\u201cThere are many directions in research that this opens up,\u201d said Dr. George I. Papakostas, director of treatment resistant depression studies at Mass General and the study\u2019s lead author.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nDr. Papkostas, Dr. Nelson and other researchers involved in the study all disclosed several financial relationships with makers of prescription antidepressants.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was cited, the author of the editorial that accompanied the study. And all conflicts of interest were clearly pointed out. While, by the letter, it meets the standard for this criteria, we note two flaws:\n1) The piece could\u2019ve used a lot more balance to the lead investigator\u2019s hopes and excitement for his research. His quotes aren\u2019t challenged\n2) A more independent source could\u2019ve been used because Dr. Nelson and Dr. Papkostas have coauthored 3 recent studies together.", "answer": 1}, {"article": "Diet has been extensively studied as a modifiable risk factor in the development of breast cancer but epidemiologic evidence on the effect of specific dietary factors is inconsistent.\nNevertheless, these results need confirmation by long-term studies with a higher number of incident cases,\" the authors conclude.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\nThe intervention paradigm implemented in the PREDIMED trial provides a useful scenario for breast cancer prevention because it is conducted in primary health care centers and also offers beneficial effects on a wide variety of health outcomes.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures\n\nMedia Advisory: To contact study corresponding author Miguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., email Jesus Diaz at jediaz@unav.es or call +34-636-355-333.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release only offers the following statement as an endnote: \u201cAuthors made conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures.\u201d\u00a0 The paper itself points to numerous connections between the researchers and sponsors which would have an obvious vested interest in the study\u2019s outcome.\u00a0 These include grants as well as free supplies of the foods supplemented in the study.\u00a0 While this doesn\u2019t call the findings into question, disclosing this information in a release of this type provides transparency that readers appreciate and should expect.", "answer": 0}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nThe main limitation of the study is that the reports are subjective.\nThe researchers say that it is not surprising that the survey respondents noticed improvements in their respiratory health.\n\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention that one of the study authors has financial ties to e-cigarette makers and another to pharmaceutical companies making smoking cessation medications.", "answer": 0}, {"article": "In addition to the potential of rTMS in pain relief, there has been growing research into noninvasive stimulation to augment progress in physical rehabilitation soon after stroke.\nHe added that the remaining question to answer is whether the level of the patients\u2019 severe uncontrollable pain would continue to decrease if rTMS continued for several years.\nKobayashi believes neurologists would especially have an interest in this method, which is also attractive due to its low side-effect profile.\nThe study participants had all been treated medically after a blood clot or bleed in one side of the brain (unilateral ischemic or hemorrhagic stroke).\nIn this second phase, the 18 patients underwent 12 weekly rTMS sessions.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not report the funding source, which is reported in the study as coming from a Japanese government grant. That would have been helpful information to include, as it bolsters the credibility of the research.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nThe balloons have been available in Europe since 2011, where their average price is about $6,200, according to the manufacturer, ReShape Medical Inc. in California.\nRoslin also believes that, for now, patients will have to pay cash for the ReShape.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story identifies the device manufacturer, ReShape, as the financial sponsor of the clinical research on their own device. \u00a0And it includes extensive quotes with an obesity surgeon who provides expert perspective on some of the limitations of the intervention.\n\u00a0", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies the lead author of the study when quoting him and cites two additional experts who have no affiliation with the study.", "answer": 1}, {"article": "The review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included commentary from \u201cAnanda Prasad, MD, PhD, a professor of internal medicine at Wayne State University School of Medicine in Detroit, who has spent his career researching zinc\u2019s effects on the immune system.\u201d\u00a0 But, since two of his studies were included in the Cochrane report (something noted by the NY Times story), it\u2019s not truly an independent perspective. And, as noted above, his comments added to some of the confusion in the story.", "answer": 0}, {"article": "They\u2019re not producing the antimicrobials they need,\u201d he explained.\nIn lab tests and on the surface of animal skin, those substances could selectively kill Staph aureus, and even a drug-resistant strain known as MRSA, without killing neighboring bacteria like regular antibiotics do, the team reported in the journal Science Translational Medicine.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\n\u201cIt\u2019s a really important paper,\u201d said Dr. Emma Guttman-Yassky of the Icahn School of Medicine at Mount Sinai Hospital in New York, who wasn\u2019t involved with the new research.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0didn\u2019t disclose this important detail about one of the sources, which was disclosed in the news release on this study:\nTeruaki Nakatsuji and Richard L. Gallo are co-inventors of UC San Diego technology related to the bacterial antimicrobial peptides discussed, and Gallo is a cofounder, consultant, chair of the scientific advisory board and holds equity in MatriSys Bioscience, a company that is developing skin bacteriotherapy.", "answer": 0}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\nThis study was funded by the British Heart Foundation and Chief Scientists Office (Scotland).\nTrials are needed to assess the safety and effectiveness of clinical pathways that involve no further testing for such patients.\"\nThese patients are therefore potentially suitable for immediate and safe discharge from the emergency department.\nUsing this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release duly notes funders.", "answer": 1}, {"article": "That's a message Bacon hopes resonates.\nPartners in research: Funding support for this study was provided by grants from the Social Sciences and Humanities Research Council, Fonds de recherche du Quebec - Sante, the Canadian Institutes of Health Research and the Michel Auger Foundation of Hopital du Sacre-Coeur de Montreal.\nThis news release is available in French.\nWithin his sample group of 643 individuals, a whopping 245 reported doing no physical activity.\n\"Those numbers reflect the population in general,\" says Bacon, who is also director of the Centre de r\u00e9adaptation Jean-Jacques-Gauthier at Hopital du Sacr\u00e9-Coeur.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states the funding sources, which were grants from the Social Science and Humanities Research Council, Fonds de recherche du Quebec \u2013 Sante, the Canadian Institutes of Health Research and the Michel Auger Foundation of Hopital du Sacre-Coeur de Montreal. No conflicts of interests were declared, both in the original journal article and in the news release.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two sources independent of the companies\u2019 representative. There do not appear to be conflicts of interest.\u00a0The article needed more information about where the clinical trials were/are underway.", "answer": 1}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\nA neurosurgical procedure in which an implanted neurostimulator delivers electrical signals to specific areas of the brain to help regulate abnormal signals, DBS is currently only approved in the U.S. for the treatment of Parkinson's disease and essential tremor.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of the funding sources. ClinicalTrials.gov shows that the trial was sponsored by Functional Neuromodulation, Ltd. the device being studied. At least one author is associated with Functional Neuromodulation, Ltd.", "answer": 0}, {"article": "\u201cPeople were planning their lives around hemophilia, and now they are doing activities that they weren't before,\u201d George said.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nSo far, with a full year, it doesn\u2019t look like that is happening.\u201d\n\nLindsey George, the lead investigator and a hematologist at Children's Hospital of Philadelphia, said that nine of the 10 men in the trial didn't experience any bleeding episodes after the gene therapy treatment.\nStill, he noted, the study has some limitations.\nThe results, published Wednesday online in the New England Journal of Medicine, represent \u201canother example of the gene-therapy renaissance,\u201d Matthew Porteus, a pediatrician at Stanford University, wrote in an accompanying editorial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources are identified in the story, as are the funders. But missing from the text is information describing linkages between the two funders\u2014Spark Therapeutics and Pfizer\u2014and the lead researchers. It\u2019s not clear from the story that there is a financial relationship.", "answer": 0}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were quoted \u2013 only quotes from a company news release. ", "answer": 0}, {"article": "\u201cNow, it\u2019s just impatience,\u201d Kefalis said.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nIt will take years to know for sure, but so far so good.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted. While the story is focused on individuals and families living with the disease, it would not have been difficult to include a single third-party voice. No doubt many other researchers are watching the clinical trial with interest,\u00a0and they may have provided valuable\u00a0context as well as an indication of the quality of the evidence.\nThe trial is funded by GlaxoSmithKline who own the experimental therapy. Again, a quick mention would have been valuable.", "answer": 0}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nCommenting on the study, Kate Holmes of the UK\u2019s Prostate Cancer Charity, said they could prove very valuable in future.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included comments from two individuals involved with the study reported on as well as an individual with expertise in the field without links to that study.", "answer": 1}, {"article": "PAE reduced the symptoms of frequency and urgency of urination without causing side effects like incontinence, sexual dysfunction, retrograde ejaculation (ejaculation into the bladder), or bleeding.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe authors report that the dead tissue required surgical removal.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two individuals who seemingly had no connections with the research reported on were interviewed for this story. \u00a0Their comments provide good insight though it was somewhat swamped by the promotional comments about this potential treatment.", "answer": 1}, {"article": "Premature birth can lead to a long list of medical problems and puts babies at risk of dying.\nThe test may cost $150 to $250, Graves said.\nThe test wasn't as effective at 24 weeks of gestation.\n\"If you are going to be alarming a patient by saying that she may have premature delivery, you want to make sure that's truly the case.\"\nWu said the study results are promising, but more research is needed to confirm that the test is reliable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted one independent expert; it could have been improved with more comment from her or from others.", "answer": 1}, {"article": "Bipolar disorder carries one of the highest rates of suicide of any mental illness, alongside schizophrenia and alcohol and drug addiction.\nBut as with all areas of mental health there is still more research to be done.\nPeople rightly have suspicions about it.\nThere should be more sensible use of it.\u201d\n\nStephen Buckley, head of information at the charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications for people experiencing mental health problems, including bipolar disorder.\nThis may be medication, talking therapies, or a mixture of both.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the majority of the quotes come from a senior author of the research, the comments of\u00a0Stephen Buckley, head of information at the charity Mind were welcomed and provided an important second voice. \u00a0A few words from other clinicians would have been a bonus.", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nLondon, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThis study was presented at a medical conference.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nBut there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent voice or perspective in the piece. ", "answer": 0}, {"article": "It matters.\nIt turns out that the melanoma really cares if we block the gene BRAF.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\n\"It worked: 81 percent had a partial response -- which has never been seen.\nPLX4032 is the first potent inhibitor of BRAF that has made it to the clinical trial stage, Chapman said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a dermatologist\u00a0with no links to the research. Not coincidentally, she\u00a0is the only person in any\u00a0of the three stories we reviewed\u00a0about\u00a0this study to point out the lack of conclusive data on survival.\u00a0The story also notes that the trial was funded by drug maker Roche.", "answer": 1}, {"article": "In a mouse study, the team showed that the effects of corticosterone on fat cells were reduced compared with cortisol.\nUntil now, there has been little research into its activity.\nAn improved therapy to replace essential steroids in the body is a step closer thanks to new research.\nThe study, published in the journal Science Translational Medicine, was funded by Wellcome, the British Heart Foundation, the Medical Research Council and the Engineering and Physical Sciences Research Council.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The text offers information about funding sources. The reader must infer that the two sources in the release were involved in the research, but their full identifications make that relatively easy to do.\u00a0Possible conflicts of interest are nowhere to be found.", "answer": 1}, {"article": "Probiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nSo far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nSumathi Reddy has details on Lunch Break.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of expert sources are quoted. We question the value of comments from a blogger who attributes many personal\u00a0health benefits to probiotics, but we suppose those comments do help to characterize the business side of the story and explain why sales are growing.\u00a0 And despite the number of sources quoted, the story never really delivered an independent expert\u2019s evaluation of evidence.\u00a0The Children\u2019s Hospital source did not address the efficacy of probiotics, only what a microbiome is.\u00a0 Gerard Mullin from Hopkins is an author and presumably stands to gain if people want to learn more about probiotics.\u00a0 There are no sources without a conflict of interest who comment on the efficacy issue, which is what the main value of this story could be. Nonetheless, because some of the quotes at least danced around the edges, we\u2019ll rate this as borderline Satisfactory.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use any independent sources such as an outside concussion expert. There do not appear to be any conflicts of interest, but the story could have let readers know that the work was funded by the Penn Medicine Translational Neuroscience Center.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does an excellent job presenting opinions from both people involved in the companies and independent stakeholders outside of the companies.\u00a0 These independent sources\u00a0increased the impartiality of the news story.", "answer": 1}, {"article": "But the F.D.A.\nThe tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\nBut every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\nAvid suggested that after the first 35 died, there should be enough data to know if the scans gave a true picture of the pathology.\nThe Avid study was complete, and the full data will be presented at the meeting next month.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are outside sources, but they aren\u2019t used to good effect. The comment from \"Dr. Michael Weiner of the University of California, San Francisco, who is not part of the company\u2019s study and directs a federal project to study ways of diagnosing Alzheimer\u2019s\" is couched in such a way that it makes us think he could be commenting on any breakthrough that would lead to sharper detection of Alzheimer\u2019s, not necessarily this study. Did he actually review the study results? Has he seen the results of similar studies? Does this work perhaps advance his work in some way? None of that is clear. Dr. Mathis is really only used to create another eureka moment. A\u00a0good question for both Weiner and Mathis would have been, \"What is it exactly about this scan that makes you think it rises above all the other detection methods being studied? And how many years away from a clinical application are we in the best and worst case scenarios? Ten to 20 years? 20 to 30 years? Not in our lifetime?\" Nonetheless, we\u2019ll give the story the benefit of the doubt on at least approaching independent sources. ", "answer": 1}, {"article": "\u2022 Delayed surgery with long-course (25x2 Gy) radiotherapy followed by surgery after 4-8 weeks.\nEighteen Swedish hospitals took part in the study, which was financed by the Swedish Research Council and the Cancer Society in Stockholm, and through the regional ALF agreement between Stockholm County Council and Karolinska Institutet.\nResearchers from the universities in Lund, Uppsala and Link\u00f6ping also contributed to findings.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was financed by the Swedish Research Council and the Cancer Society in Stockholm, and through the regional ALF agreement between Stockholm County Council and Karolinska Institutet. According to the study, there are no conflicts of interest.", "answer": 1}, {"article": "Known generically as dupilumab, the drug can cause serious allergic reactions and eye inflammation.\nActual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not reflect discounts, rebates or patient assistance programs,\u201d it said.\nIn a nod to the sensitivity around drug prices, the company stressed that there is no single price for the drug.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\"People with moderate to severe atopic dermatitis cope with intense, sometimes unbearable symptoms that can impact them for most of their lives,\" Julie Block, president and CEO of the National Eczema Association, said in a statement provided by the company.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacks independent sources. It uses a quote from the head of the National Eczema Association without mentioning that the association lists the manufacturers of this drug as among its top funders. According to the group\u2019s web site, the companies are \u201csapphire\u201d level sponsors, which have contributed $50,000 or more.\nThe video also doesn\u2019t disclose that Dr. Paul Yamauchi of UCLA, who calls the drug a \u201cgame-changer,\u201d has been hired by the manufacturers of this drug as an investigator as well as an advisor and/or speaker, according to public disclosures.", "answer": 0}, {"article": "\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nThe study was funded by the U.S. National Institute on Drug Abuse and the U.S. National Institute on Alcohol Abuse and Alcoholism.\nThe results of the new study were released online in Alcoholism: Clinical & Experimental Research prior to publication in the May print issue.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include an independent source. There was no disclosure statement included with the preview copy of the research article, so it is not known whether any of the researchers have ties to Pfizer (the maker of Chantix) or other pharmaceutical companies in this area.", "answer": 1}, {"article": "A systematic review of C.B.T.\nMy experience is consistent with these averages.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\nDrugs, on the other hand, just treat insomniacs\u2019 symptoms without addressing the underlying cause, which is why the relief they provide may be less durable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story is a personal one, we think it could have been strengthened with the opinion of a primary care provider who commonly treats insomnia. Any story that makes health claims should have their facts/interpretation run by an expert.", "answer": 0}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nSATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\nOne expert agreed that the results were encouraging.\nThe study was scheduled for presentation Saturday at the European Society for Medical Oncology meeting in Vienna and simultaneous publication in the New England Journal of Medicine.\n\"This study addresses the problem of resistance to the mitogen-activated protein kinase [MAPK] pathway.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story informs readers that both drugs studied are being developed by GSK, which sponsored the studies. And we hear from an independent dermatologist who was not involved with the study.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two sources are quoted who have differing views on the utility of such devices. They offer some reasonable expertise and guidance to potential users.", "answer": 1}, {"article": "However, gluconate binds the zinc ion more tightly than acetate does.\nHowever, in future studies the optimal composition of zinc lozenges should be investigated.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nThe optimum frequency of their administration also warrants further investigation.\nFurthermore, one of the zinc gluconate lozenge trials was an outlier inconsistent with all the other six zinc lozenge trials.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The source of funding for the study is not identified. We\u2019ll rate this not applicable since a meta analysis of already completed trials is not particularly costly and may not have needed outside funding. The study itself noted there was no funding.\nArguably the more important issue is whether the included studies were funded by zinc manufacturers and conducted by researchers with ties to the supplement industry. While it would have been nice to see that information included, we won\u2019t dock the release for the omission.", "answer": 2}, {"article": "In the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nHowever, he said cost constraints meant it was unlikely that more than one-tenth of those patients would actually receive an artificial heart.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nGray Jr., the University of Louisville professor of surgery who implanted the first AbioCor heart in 2001, said.\nWhen all expenses are considered, including hospital and surgical expenses, it says it will cost just over $315,000, about the same as a transplant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Besides quotes from the company executive, there was only one quote from an independent expert.\u00a0 But since he was not commenting on any evidence or track record for the French\u00a0 heart \u2013 or even any comment on its concept or design \u2013 we rule this unsatisfactory.\u00a0 No independent expert was quoted on the real \"heart of the story.\" ", "answer": 0}, {"article": "The F.D.A.\napproval late next year.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nBut with less than a third of the enrollment goal of 2,500 patients completed, doctors will have a long wait for esults.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good job pointing out medical turf battle over ownership of this procedure, and \nindustry sponsorship of symposium. ", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The two doctors quoted in the story on the value of these real-time imaging surgical techniques are both leaders of high-profile programs that are dedicated to, well, advancing these real-time imaging surgical techniques. The story would have benefited from the input of an independent source.", "answer": 0}, {"article": "In Alzheimer\u2019s disease, this area of the brain is affected early on, when signs of dementia begin to appear.\nDr. Sandra Black, a brain researcher at the University of Toronto who wrote an editorial on the current study, said the findings could have implications for early stage Alzheimer\u2019s disease if tests were developed to identify this process early through imaging or genomics.\nSuzanne Haber, a neuroscientist at the University of Rochester Medical Center in New York who was not involved in the study, said she was \u201cvery excited about the finding,\u201d but she cautioned that the treatment is very invasive, very expensive and unproven in Alzheimer\u2019s patients.\nThe research was published in the New England Journal of Medicine.\n\u201cAlthough the current evidence is preliminary, is based on small samples and requires replication, the potential application of deep-brain stimulation in amnestic disorders is enticing,\u201d Black wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent source and includes a comment from an editorial that appears along with the research report in the New England Journal of Medicine. It does not refer to any conflicts of interest, but the authors reported no conflicts in the disclosure forms posted online by the journal.", "answer": 1}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\nThat might also indicate whether it could be used in tests to indicate the disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of the funders in the release.\nAccording to the published study, funding was provided by the Arthritis Research UK, the Kennedy Trust for Rheumatology Research and BT CURE. In addition, it was disclosed that \u201cdata in this manuscript are the subject of a patent filing\u201d and that the lead investigator sits on the board of and is a consultant to Nascient.", "answer": 0}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\nThe study was was paid for by Cytograft Tissue Engineering.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a journal commentator and a comment from the president of the National Kidney Foundation, who was not connected with the study. The story noted that the lead researcher is an employee of the company developing the tissue-engineered blood vessel grafts and that the company funded the study.", "answer": 1}, {"article": "In addition, BCG alters metabolism so cells consume higher levels of glucose, drawing more of it out of the blood, in a process called aerobic glycolysis.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\n\u201cThe clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system,\u201d said Dr. Mihai Netea of Radboud University Medical Center in the Netherlands, who was not involved in the study.\nThe experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The original journal article on which this story was based includes the researchers\u2019 declaration that they had no conflict of interest. The story includes two sources who were not involved in the research, although one of these sources, a researcher from Radboud University Medical Center in the Netherlands, cannot be considered fully independent, because the quote appears to have been copied from a Massachusetts General Hospital news release about the study (see news release criterion, below).\nThe story also noted that two diabetes research centers and \u201cseveral university diabetes centers all declined to speak about Faustman\u2019s results.\u201d This hints at the \u201ccontroversy\u201d noted in the headline, around the possibility of conflicts of interest that can occur when pharma-supported researchers/advocacy groups criticize this type of research. But the story didn\u2019t explore this sufficiently to prove the researcher\u2019s claim that funders aren\u2019t interested because it has low profit potential, as noted in the summary.", "answer": 1}, {"article": "Implantable defibrillators can be as small as a half dollar and are placed surgically under the skin of the upper chest.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\nKrahn said the rate of complications from surgical removal will surprise doctors, because replacing a defibrillator is considered a minor procedure.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\nThe researchers studied 2,915 patients who were tracked by 17 Canadian hospitals in 2004-05.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Article notes that the quoted expert has financial ties to device manufacturers, and that he asserts that this research was done without funding from the industry. ", "answer": 1}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nStecker says if he had it to do over again, he would have waited for more research.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nStudying how the vascular system is involved in neurologic disease is an entirely new concept, Zivadinov says.\nZamboni himself says that even if it turns out he's wrong, coming to a greater understanding of the disease would be the big reward \u2014 both for him and thousands of MS patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts who are involved in studies of vein abnormalities and potential links to MS, and their perspectives are a valuable addition to the story. However, both of these researchers (Dr. Robert Fox and Dr. Robert Zivadinov) have reported relationships with\u00a0companies that make\u00a0drugs to treat MS. To avoid the appearance of any conflict, the story should have alerted readers\u00a0to these relationships.", "answer": 0}, {"article": "Researchers noted that mental skills can sometimes compensate for physical disabilities: Knowing how to figure out directions and find a new route on a map, for example, could allow someone to retain mobility even after their night vision deteriorates to the point where driving on certain roads becomes difficult.\nThe researchers divided the volunteers into four groups, including a control group that received no training.\nThe participants in the study ranged from age 65 to their early 90s, but Marsiske said the findings apply to people in their 50s or even younger.\nA fourth group was given exercises to speed up mental processing -- being asked to identify an object flashed briefly on a computer screen while fighting off distractions.\nSally Shumaker, a professor of public health science at Wake Forest University in North Carolina who wrote an editorial accompanying the study, said it pointed the way to a future in which mental training is made widely available.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two authors of the study and the author of an editorial on the study were used as sources of information for this story.\u00a0 \n\u00a0\n", "answer": 1}, {"article": "In 2008, about 8,000 U.S. men were diagnosed with metastatic prostate cancer.\nThe new study seems to make a powerful argument in favor of PSA testing.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nHe's subtracted forever from the men whose first diagnosis was late-stage disease, even though screening could not save his life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most stories on this study relied heavily on the study\u2019s lead author, Dr. Edward Messing, a urologist, who, like most of his colleagues believes strongly in the need for more PSA screening. He\u2019s quoted here, too, of course, but the story also shares with readers important context from Dr. Barnett Kramer of the National Institutes of Health. And it includes input from a US Preventive Services Task Force member.", "answer": 1}, {"article": "For people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nHe is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nOne large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the study was funded by egg producers, but the only source quoted is the study author. This story would have benefited immensely from an independent perspective.", "answer": 0}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nThe cancer data is still preliminary, and needs to be confirmed with additional studies, but it\u2019s encouraging, says Dr. Otis Bradley, chief medical officer for the American Cancer Society, who was not involved in the study.\nPerhaps more intriguing are additional results that Ridker reported, related to cancer.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\nBut with the new results, those guidelines may change.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that its primary source, Dr. Paul Ridker, has accepted consultancy & speakers fees from Novartis, the funder of the study.", "answer": 0}, {"article": "DCIS affects one out of every five women diagnosed with breast cancer in the United States, and is often treated with surgery followed by radiation therapy and/or hormonal therapy.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\nPhysicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features, patient preference, patient age, comorbidities or consultation with other physicians.\nThe results showed that physician treatment recommendations changed for 31 percent of patients after receiving the DCIS Score result, reducing the number of patients receiving a radiotherapy recommendation by approximately one-third.\n\"The Oncotype DX DCIS Score result was validated in two studies including nearly 900 patients and is the only genomic test for patients with pre-invasive breast cancer,\" said Phil Febbo, M.D., chief medical officer, Genomic Health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The original study listed financial conflict of interests among the study authors \u2014 including the fact that several study authors are paid speakers and consultants for Genomic Health, which makes the test. One of the authors is an employee of the company. But the new release did not provide any of this context.", "answer": 0}, {"article": "For dementia, which people with Type 2 diabetes have double the risk of developing compared with non-diabetics, metformin has been found in a number of studies to cut that risk substantially.\nBut such evidence often does not pan out in human studies.\nBut the guidelines do recommend metformin first.\u201d\n\nFor patients with Type 2 whose doctor started them on a drug other than metformin, he said, \u201cI certainly would encourage people to talk with their doctor.\n\u201cThere are legitimate reasons to put patients on one drug rather than another.\nBut, Whitmer notes, \u201cI don\u2019t think the story is complete.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "By and large, this story gives the reader\u00a0reasonable\u00a0information to judge source bias. Scientists employed as sources are clearly identified as leading individual studies, although\u00a0aside from the science journalist whose anecdote begins the story, one is hard-pressed to find sources independent of studies or funders. Underlying funding is not identified for most studies, although a funder is mentioned in one case. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "\"Looking at the physiological state of the brain and evaluating the extent of tissue damage and other clinical factors seems to be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,\" says Nogueira.\nThe DAWN trial included trial locations in the United States, Spain, France, Australia and Canada.\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\nThe researchers planned to enroll a maximum of 500 patients over the course of the study period.\nThe DAWN trial results were presented at the European Stroke Organization Conference in May.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source \u2014 a device manufacturer \u2014 was disclosed.", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\n\u201cIt\u2019s like the four legs of the stool: vitamin D and calcium, exercise, medications if a person is losing bone, and the fourth leg is telling people how to prevent fractures,\u201d Zaidi said.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites the researchers\u2019 published findings, then turns in large part to an independent expert to evaluate the evidence.", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts. The story points out that one of the experts is a researcher on a Medtronic-sponsored trial of the device but does not mention any conflicts for the other experts, leaving the reader questioning the validity of some of their statements.", "answer": 1}, {"article": "Studies have shown that people with cancer are more prone to blood clots and that people with blood clots are at increased risk of cancer.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nHowever, they need to be confirmed, and the optimal dose, timing, and duration of use needs to be worked out, he says.\nThe findings were released at a news briefing held in advance of the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.\nBut if the findings are confirmed, \"patients who are taking aspirin for other reasons may see an added benefit,\" says study head Kevin Choe, MD, a radiation oncologist at the University of Texas Southwestern Medical School in Dallas.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nIt was easy to meet the basic requirement of this criterion, because the news briefing was moderated by an expert who was not involved in this study. Also, the researchers did not declare any conflicts of interest. However, it is possible that the moderator (who is also the president of the medical association sponsoring the meeting) may have had some role in selecting or shaping this study presentation and so it is hard to know for sure how independent he is.", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nExperts had different responses to the findings.\nParticipants were fed food that was prepared for them by diet experts.\nMore research is needed to show that interesting results like these are applicable in real life, she says.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from 3 outside experts who have differing takes on the research. It notes that one of the experts is the author of an Atkins diet book.", "answer": 1}, {"article": "For example, blood pressure (BP), not only tends to increase but as well become more irregular.\nFirst week control data were collected for 7 successive days.\nThe present study was aimed to investigate whether such changes can be reversed by daily melatonin ingestion.\nOver the next 2 weeks, the seniors were administered a low dose of melatonin (1.5 mg) each day by night at 10:30 p.m. On the third week data were monitored again.\nLuckily, as we show in our research, melatonin helps to ameliorate both trends.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is written as if the lead researchers wrote it themselves since the text contains no citations to sources but does offer the occasional second-person pronoun (\u201cwe\u201d). The text\u00a0contains no references to funding sources or possible conflicts of interest.", "answer": 0}, {"article": "The risk of prostate cancer is of greater concern, given that suppressing the body\u2019s natural production of testosterone can cause this cancer to regress.\nStill, this study will not answer the question of whether it is safe to use the hormone for years, even decades, which would be necessary to maintain any benefits.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\nThen again, this may be a realistic population to study, given that many candidates for hormone therapy are likely to have such health issues.\nAlthough testosterone can cause overgrowth of the prostate, studies have not shown harm to urinary function, Dr. Morgentaler said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although one source, Dr. Abraham Morgentaler, is identified as the author of a book which promotes testosterone therapy,\u00a0the story\u00a0does not disclose, as indicated\u00a0in these recent CME conference materials,\u00a0that Dr. Morgentaler also receives grant funding and is on the speaker\u2019s bureau of companies which manufacture\u00a0testosterone products. To avoid the appearance of any potential conflict, the story should have alerted readers to these relationships.", "answer": 0}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nA message left for the AAC Consulting Group, a Rockville, Md., company that filed the petition, also was not immediately returned.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nA message left for a spokesman for Ito En Inc. was not immediately returned last week.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story said that spokespersons for the world\u2019s largest green tea company and for the consulting group that filed the petition with the FDA did not respond to messages left for them. But there were no comments from individuals conducting research investigating whether green tea affects heart disease risk.", "answer": 0}, {"article": "All of the babies born by C-section were slightly more likely to use an asthma inhaler at age 5: 10.3 percent of planned C-section babies and 10.19 percent of unscheduled C-section babies wound up using an inhaler, compared with 9.6 percent of vaginally born babies.\nEven attempted labor may provide some exposure to bacteria, she said.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\n\u201cIt\u2019s an education process that says, \u2018Calm down, you\u2019re going to be seeing this antigen again, you don\u2019t have to be so aggressive,\u2019\u201d Dr. Neu said.\nThe Scottish study took advantage of the small country\u2019s rich trove of linked birth and medical databases to track the long-term health of 321,287 babies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent experts were quoted.", "answer": 1}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\n\u201cThis is a common condition that has serious psychological effects on relationships,\u201d said Patrick, who wasn\u2019t involved in the study.\nIn addition, the authors write, the studies are so different, it\u2019s tough to draw conclusions about the different options.\nBias was unclear in most of the studies, and only five used stopwatches to measure IELT, which is the \u201cgold standard\u201d for premature ejaculation studies, Patrick said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The researchers interviewed don\u2019t appear to have any conflicts of interest, and several independent sources were included.", "answer": 1}, {"article": "The average age of the participants was 11.\nMONDAY, Dec. 7, 2015 (HealthDay News) -- Evidence is mounting that a marijuana-derived oil might benefit some children with epilepsy whose seizures aren't controlled by approved medications, two new studies show.\nBut experts say these positive findings may have been influenced by a \"placebo effect.\"\n\"We know that our placebo rates can be as high as 30 percent, and sometimes higher,\" said Dr. Amy Brooks-Kayal, American Epilepsy Society president, who wasn't involved in the studies.\nOne child remained seizure-free, but 12 of the initial participants dropped out of the study because the cannabidiol didn't seem to do them any good.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story does make clear the distinction between researchers involved in the studies discussed and those not involved, there is no mention of funding. Who funded the study is a very important question. It would also be important to know if any of the researchers involved/quoted were consultants/paid by this company. A news release issued in advance of the American Epilepsy Society meeting, where these studies were scheduled to be presented, notes that the medicine used (called Epidiolex) and was supplied by manufacturer GW Pharmaceutical. That information didn\u2019t make it into the story.", "answer": 0}, {"article": "Moffitt is the No.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nThe study was published in the December 13th online issue of Clinical Cancer Research and was supported by funds received from R01-CA096997, P30-CA016520, Pennies-in-Action\u00ae, and the Henle Foundation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study states the funding sources of the study. According to the paper, the researchers reported no conflicts of interest.", "answer": 1}, {"article": "Until recently, studies of osteoporosis drugs just measured changes in bone density, assumed to equate with lower fracture risk.\nThe effectiveness of denosumab and existing drugs appears to plateau after two or three years, she added.\nStill, he called the drug a \"tour de force of modern molecular medicine\" because it is potent and was designed by making antibodies cloned over and over from cells in the lab to block one pathway involved in the how the body naturally breaks down bone cells.\nThe two studies were released Tuesday by the New England Journal of Medicine.\nThe biotech company designed the studies, handled data collection and analysis, and helped write the journal reports.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were interviewed for this story.\u00a0 The writer also points out that both trials were paid for by Amgen, the manufacturer of denosumab, and nearly all the researchers were employed by the company or received consulting or advisory fees from them.\u00a0 ", "answer": 1}, {"article": "\u201cI want to be a normal housewife \u2026 a normal grandma.\u201d\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\nSucceeding in getting drugs across the barrier is \u201ca huge achievement\u201d said Dr. Nathan McDannold, a radiologist at Boston\u2019s Brigham and Women\u2019s Hospital, who has been working to open the barrier with ultrasound since he first accomplished the feat 15 years ago in animals.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several experts who, according to the story, were outside of the group that did the research were quoted. However, two of these sources are\u00a0involved with the funding organization \u2014 the Focused Ultrasound Foundation. These individuals are listed as experts on the foundation website.\nAlthough the funding source is a foundation, it receives support from numerous industry sources (as well as individuals and other sources). In addition, at least one of these experts (Ghanouni) leads other foundation-support research efforts. It\u2019s possible that experts associated with this foundation may have an incentive to cast this foundation-supported research in a positive light. The story could have alerted readers to these links or, even better, tapped into a wider network of independent experts to provide a more critical evaluation of the research.", "answer": 0}, {"article": "The effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nBut I still believe that something will be found at some point which could be useful.\nThere is extensive research in this field and I hope that it eventually will come up with a result.\n\u201cWhat we are hoping for with this device is to find a treatment for movement disorders where Levodopa, Parkinson\u2019s disease where Levodopa is not enough.\n\u201cI have become hardened in the sense that I do not have too great expectations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides useful comments from the primary study investigator, but that\u2019s not quite enough to earn a satisfactory rating here. At the least, we\u2019d expect\u00a0a comment from a clinician who cares for Parkinson\u2019s patients to provide some independent insight on this treatment.", "answer": 0}, {"article": "Graphic artist Colleen Kelly decided in 2000 that she had nothing to lose by enrolling in an experimental study of VNS.\nGrassley questioned whether Medicare and Medicaid should pay for the device, which costs $15,000 and must be replaced every five years or so when the battery runs low.\nAbout 35,000 epilepsy patients have received the implant.\nCyberonics officials testified that 30,000 people commit suicide annually, most of whom were diagnosed with severe depression.\nMore than 3,700 psychiatrists, including doctors affiliated with Suburban, Georgetown, Sheppard Pratt and Howard University hospitals, have been trained in the use of VNS, the first device ever approved to treat depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Patients, providers, FDA spokesperson, device manufacturer, skeptics and supporters are interviewed or cited.", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does quote representatives from the device manufacturers, as well as a university professor conducting the lab tests, it also quotes an environmental scientist from the National Institutes of Health and an infectious disease specialist from an unaffiliated medical center.", "answer": 1}, {"article": "\u201cYou have to be pretty bad to do poorly on this exam,\u201d she said.\nBut the alternative involves referring patients for a battery of neuropsychiatric tests that can take hours to complete and cost $1,000 or more.\nAlgase, who said she has no financial ties to the company, agreed to use the Cognivue in her practice about three years ago after meeting Duffy at a conference.\nA patient can perform the inexpensive and simple test while a time-strapped primary-care physician tends to other patients.\n\u201cI think it\u2019s a really potentially valuable tool,\u201d said Leslie Algase, an internist who tends about 2,000 patients in Rochester, at least 30 percent of whom are older than 65.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a difficult call. The story includes extensive comments from a company source and two clinicians who are early adopters of the device. The comments of the two users especially are quite helpful and demonstrate thorough reporting. With that being said, we hesitate to call any of these sources truly independent. Although the story qualifies that one of the physician users has no ties to the company, the fact that she\u2019s been using the system for several years, presumably with the equipment and support being supplied by the company at no cost, suggests a close relationship between the source and the manufacturer. The intent of this criterion is encourage a truly outside perspective. We think that comments from other sources not as close to the work and who could speak to other diagnostic approaches would have been helpful. The Not Satisfactory rating is not meant to suggest a lack of thoroughness on the part of the story or that the sources provided were not appropriate. It reflects our desire and hope that stories will always also include the perspective of at least one impartial expert.", "answer": 0}, {"article": "Obesity is associated with heart disease, stroke, diabetes and some cancers, and researchers estimate that it is the second-leading cause of preventable death, after tobacco use.\nDr. Sharaiha did not have any disclosures for DDW research.\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nThe meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes a reference stating that the researcher actually making the presentation does not have any conflicts of interest to report. However, there is no information on conflicts of interest regarding the other researchers, nor does the release tell readers who funded the research.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nThe new research, which appears in today's issue of the New England Journal of Medicine, seems destined to heat up that argument.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\n\"I think it provides valuable information on many things.\nWhat it will take to prove that CAT scans are either useful or a waste of time and money is a matter of great controversy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple independent sources, providing much needed balance in the story.", "answer": 1}, {"article": "Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes at the end a listing of funding sources for this research and there is no information to suggest any conflict of interest.\u00a0 The original research paper specifically states there are no conflicts.", "answer": 1}, {"article": "In recent years, emergency service dispatchers have been coaching callers in hands-only CPR rather than telling them how to alternate breaths and compressions.\nBut less than a third of victims get this essential help.\nGoodall, a 49-year-old construction contractor, said he had been healthy and fit before the collapse, and there'd been no hint that he had clogged heart arteries.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\nThe CPR guidelines had been inching toward compression-only.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The medical correspondent cites no sources aside from the AHA recommendations. At least one independent expert should have been consulted. ", "answer": 0}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nNone of the other study authors reported any conflict of interest or financial disclosure relevant to the topic of this study.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\n\"By putting pressure on specific muscles in the feet, we are able to create a response in the brain that relaxes the muscles activated during RLS,\" said Phyllis Kuhn, MS, PhD, and the study's lead researcher.\nThese results show promise in otherwise healthy individuals for a nonpharmaceutical option that appears to have rather minor, temporary adverse effects for some users,\" said Rob Danoff, DO, an osteopathic family physician and program at Aria Health Care in Philadelphia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We will give the release credit for clearly noting that one of the authors works with the Lake Erie Research Institute, which developed the foot wrap, and that she is receiving compensation for her research work. The release also points out that further disclosure details are listed in the journal article. However, the release could have also specifically mentioned that the additional disclosure information includes the fact that the institute receives royalties from the company that bought the rights to the foot wrap.", "answer": 1}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Great sourcing \u2013 with 3 independent voices besides the study authors.", "answer": 1}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\nRunning may also slow the process that leads to osteoarthritis\n\nWe all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health.\nWhen the same fluids were extracted before and after a non-running condition, the inflammation markers stayed at similar levels.\nBYU professors Sarah Ridge and Ty Hopkins were also coauthors on the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no funding source listed, but there is also no funding source listed in the paper.\u00a0 The authors do declare in the paper that there is no conflict of interest and what any conflict would be, considering that the \u201ctreatment\u201d discussed is running, is a puzzle.\nOur standard here is to require some discussion of funding sources. Even if no funding was provided, the release should say so.", "answer": 0}, {"article": "\u201cIt wasn\u2019t effective.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\nWhile Botox is commonly used for cosmetic purposes, doctors say the reasoning behind the treatment for depression may not be what you expect.\nAs for Cooke, she said she noticed a change in her depression almost immediately.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites no experts other than Dr. Finzi, author of a published study about the effects of Botox as a treatment for depression. This omission is made worse when you learn that Finzi\u2019s\u00a02014 study was funded by the Chevy Chase Cosmetic Center, where Finzi is medical director and president, that he has received a US patent for the treatment of depression with botox and was a paid consultant for Allergan in the past.\u00a0In other words, the sole interviewee for this story holds\u00a0an approved patent for the treatment in question,\u00a0stands to gain financially if the treatment receives FDA approval, and has been a paid consultant for the company manufacturing the drug.\u00a0Not telling readers\u00a0about these major conflicts of interest\u00a0is irresponsible.", "answer": 0}, {"article": "All rights reserved.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\nAmong the thirteen IBS options that Dr. Enck and the authors reviewed, only peppermint oil had the lowest NNT (number needed to treat) of 2-3 patients needed for one patient to benefit from the therapy.\nThe publication has published a comprehensive review article exploring Irritable Bowel Syndrome (IBS).\nBOCA RATON, Fla., Sept. 27, 2016 /PRNewswire/ -- IM HealthScience\u00ae (IMH) today announced that the growing medical consensus on the utility of peppermint oil in Irritable Bowel Syndrome (IBS) has been highlighted once again by comments in a recent prestigious publication, Nature Reviews: Disease Primers, an international peer-reviewed scientific journal.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to reveal that the trial of IBgard it highlights was funded by the manufacturer, IM HealthScience, and authored by two employees and a consultant. The release does not reveal that the expert it quotes, Brooks Cash, M.D., is the company consultant.", "answer": 0}, {"article": "\"If you think about it, the worst thing that you want is an immune system that's out of control,\" Loke says.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nIt could be that the whipworm larvae weren't prepared correctly.\nBut this can help with something else.\nCoronado Biosciences put together about six large studies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses several sources with various points of view, and we couldn\u2019t find any outright conflicts of interest.", "answer": 1}, {"article": "Among these adults, about 9 percent have resistant hypertension, which means that even taking three or more medications to control their blood pressure, it remains higher than 140/90 mmHg.\nThe procedure is safe as well as effective, the study authors said.\nThe study was funded by medical device maker Medtronic.\nAll the patients suffered from drug-resistant hypertension.\nThe treatment was effective for at least six months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Medtronic funding\u00a0 was disclosed.\nThere was an independent expert who provided some needed balance \u2013 although that expert was not quoted about any real critical analysis of the evidence.\nNonetheless, enough to get a satisfactory score.", "answer": 1}, {"article": "Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\nTo determine whether a woman's endometrium (uterine lining) is healthy and can sustain the embryo, the research team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the study, which is necessary to meet our standard. It does note that the \u201cresearch team used the endometrial function test (EFT\u00ae), which was created by study co-author Harvey J. Kliman, M.D., director of the Reproductive and Placental Research Unit in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.\u201d However, the release doesn\u2019t acknowledge an important conflict of interest that is addressed in the study manuscript itself: \u201cH.J.K. is the inventor of a patent related to the monitoring of endometrial glandular development.\u201d", "answer": 0}, {"article": "Dry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\nEpub March 3, 2017. doi:10.2519/jospt.2017.6994\n\nThe study was approved through the Baylor Scott & White Health Institutional Review Board.\nCo-authors on the paper are Bryce C. Allen, MD, and Yolanda Munoz Maldonado, PhD, also with Baylor Scott & White Health.\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t mention any conflicts of interest, and none were reported in the study. The release also echoes the study\u2019s statement that funding came from Baylor Scott & White Health, which is a Dallas-based healthcare system.", "answer": 1}, {"article": "Stem cells are immature cells that differentiate into adult cells such as intestinal cells.\nThe team, led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology, published their findings in a recent issue of the journal Cell.\n'However, our work is the first to identify AIM2's role in controlling proliferation of intestinal stem cells.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nThe paper's other authors are Qifan Zhu, Liqin Zhu, Zhiping Liu, Rajendra Karki, Ankit Malik, Deepika Sharma, Liyuan Li, R.K. Subbarao Malireddi, Prajwal Gurung, Geoffrey Neale, Scott Olsen, Robert Carter, Daniel McGoldrick, Gang Wu, David Finkelstein, Peter Vogel and Richard Gilbertson, all of St. Jude.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the primary funding sources as the National Institutes of Health and ALSAC (though readers have to do their own searches to learn that ALSAC stands for the\u00a0 American Lebanese Syrian Associated Charities). However, the release fails to mention that Genentech supplied the Aim2-deficient mice. And neither the release nor the original article in Cell tell readers whether or not there are any financial or other ties between the researchers and Genentech\u2026 or whether any of the researchers hold any patent or royalty rights that are relevant to this work.\nWe\u2019ll give the benefit of the doubt since we did not see any evidence of conflicts of interest, although we would encourage all news releases to make a clear statement regarding the presence or absence of such conflicts. Readers should not be left in the dark to guess about potential conflicts.", "answer": 1}, {"article": "She said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\n\"This reduced functional connectivity in the brain helps us understand impairments associated with autism,\" she added.\nThis was especially true in the left hemisphere regions of the brain responsible for language.\nLanguage, for example, requires coordination across the auditory, visual, and motor brain regions, as well as the participation of the prefrontal cortex, she said.\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019re giving this one a pass here, but we thought that more time could have been spent with the only other independent expert quoted in the story, who was given one sentence to offer perspective.", "answer": 1}, {"article": ".\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nBGU researchers surveyed 2,736 patients 65 years and older who received medical cannabis through \"Tikun Olam,\" the largest Israeli medical cannabis supplier.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the news release mentions that the subjects surveyed \u201creceived medical cannabis through \u2018Tikun Olam,\u2019 the largest Israeli medical cannabis supplier,\u201d it does not point out the following:\nThis is definitely something readers should know in a news release that implies efficacy in treating nearly a dozen different conditions in the first two paragraphs. It\u2019s quite clear that people over 65 represent a growing target market for medical cannabis.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This one barely squeaks by. There is one independent comment on the trials from\u00a0David Felson at the Boston University School of Medicine, who said that the lack of a control group \u201craises questions of whether it is cupping that is really working or if it has a placebo effect.\u201d But more detailed comment on each of the cited studies\u2019 shortcomings and limitations would have been hugely helpful in producing a more balanced view on the benefits of cupping.", "answer": 1}, {"article": "To date, cognitive psychologists and neuroscientists have largely rejected evidence that computer-based cognitive-training software or \u201cbrain games\u201d have any effect on cognitive function.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\nThe institute is part of the National Institutes of Health, which funded the study.\nThe program is now incorporated in Posit Science\u2019s BrainHQ.com brain training program.\nThe letter was in response to heavy marketing by companies touting the benefits of their programs based on scant scientific data.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article introduces past and current investigators of the study, and their relationship to the company Posit Science:\n\u201cThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science. Edwards also was a paid consultant for the company for part of 2008.\u201d", "answer": 1}, {"article": "Although surgeons can also take X-rays during the posterior procedure, it is much more difficult, and they wait until patients are in the recovery room, where, Bollinger says, \u201cthere\u2019s not much that can be done.\u201d He explains that while the body \u201ctolerates an imperfect alignment pretty well, if a new hip gets dislocated, it\u2019s often because it\u2019s not in perfectly.\u201d\n\nRobert Saunders, a nurse at Alta Bates Summit Medical Center in Berkeley, Calif., sees about 200 hip replacement patients a year.\nThe case of Daniel Ellsberg \u2014 who in 1971 released the Pentagon Papers, a secret study about U.S. involvement in Vietnam \u2014 is instructive.\nMany patients aren\u2019t aware of the option.\nBesides his study, there have only been a few others.\nAnd this creates economic issues.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a wide variety of sources. We wish that more of the \u201cold guard\u201d were represented, but we give it a pass here.", "answer": 1}, {"article": "But on Oct. 23, the F.D.A.\nJohn Doerr, the company\u2019s technology guru, was in Washington this week making the case for greater availability of peramivir, according to a person who met with him there.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\nRight now, Dr. Lurie said, peramivir is the only drug that can be used intravenously so the government had to pay a high price.\nMr. Stonehouse defended the price of the drug, saying it would save the health system money by getting patients out of intensive care earlier.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story did not point out that one of the supporters of faster and broader access to peramivir, Dr. Richard Whitley, has long been a booster of the drug, which is being commercially developed by a spin-off of the University of Alabama department he works in. \nSee Whitley comments in a 2005 article promoting the potential of peramivir: \nhttp://main.uab.edu/show.asp?durki=87834\nHere we also point out that the story profiled only one patient and includes a quote from the patient\u2019s father crediting peramivir with saving his daughter\u2019s life. The story does not give any examples of similar patients who either survived after getting approved drugs or who received peramivir and yet did not survive. Despite the clear caveats in the story, the reliance on only a single anecdote may give readers a skewed sense of the benefits of the unapproved drug. ", "answer": 0}, {"article": "Researchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\nThe study appears online in the Journal of Clinical Investigation.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent clinician, who offers useful context. We are not aware of any conflicts that should have been identified.", "answer": 1}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\n\"This area of research is not well-developed.\nIf it also improves cognitive performance -- like we've seen here -- even better.\nBut they've never all been connected before.\n\"It really has to be a concerted effort, especially in a culture where fish is not as commonly served or smelled.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We learn the connections between the funders of the research and the investigators and there is no sense that a conflict of interest exists here.", "answer": 1}, {"article": "Thanks to members Drs.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nThere is a general consensus that the initial management of knee OA treatment should include weight loss and strengthening exercises.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The information is being provided by the American Society for Sports Medicine, a multidisciplinary group of clinicians who specialize in sports medicine. There is a potential for an inherent bias. In case that needs spelling out the potential bias is that the association may be seeking new patients beyond its athlete patient base, and expanding into the aging population of \u201cbaby boomers\u201d who have the greatest incidence of knee osteoarthritis.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nDr. Lauren Streicher, medical director of the Center for Sexual Medicine at Northwestern Memorial Hospital in Chicago, said the results cited in the Dutch study are averages, and while Addyi doesn't work for everyone, many of her patients have benefited from it.\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nShe said she and her colleagues included the results of the unpublished studies because sometimes negative studies of a drug don't get published.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It was unfortunate not to have included the many and direct ties between those attacking the review (such as the International Society for the Study of Women\u2019s Sexual Health, which is supported by pharmaceutical manufacturers) and one of their board members, Dr. Lauren Streicher, who has declared ties to\u00a0Noven Pharmaceuticals, Inc and Shionogi & Co., Ltd. We know that patient testimony at the flibanserin hearings at the FDA was supported by Sprout, the maker of flibanserin, which gave financial support to those attending the hearings. But it is unclear if the patient mentioned in this story received such support.", "answer": 0}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nSuch results could not have been achieved with any single therapy alone.\nThe authors proposed that this end point may serve as a first step toward establishing a curative paradigm.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nMany in the field agree, but note that the longevity of effect is essential to prove the point of curability.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the work or whether there were any conflicts of interest.", "answer": 0}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nDr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore, said the study is well done and looks promising, but needs to be replicated.\nWe know early intervention is extremely important.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\nEEGs are also relatively inexpensive, painless and safe, Bosl said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story spent the most time quoting the lead author,\u00a0William Bosl from Children\u2019s Hospital Boston. It also quoted Dr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore. We wish the story had made better use of Ewen and allowed him to help readers make sense of the study. His comments come too late to dampen the boosterism of Bosl hoping for every child to be hooked up to an EEG at nine months of age. Nonetheless, in citing an independent source, the story barely meets the criterion.", "answer": 1}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nScheduled biopsies were performed two and four years after they entered the trial.\nBut none had evidence of cancer when biopsies were performed within six months of entering the trial.\n\"But we don't have studies saying that they decrease the risk of death from prostate cancer.\"\nThe men were assigned to receive either placebo treatments or daily 0.5-milligram doses of Avodart for four years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent sources, including an expert from the American Cancer Society.", "answer": 1}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any experts who could have provided some valuable perspective on the importance of the new findings. This is particularly important for industry sponsored trials.\u00a0 ", "answer": 0}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nDr. Henschke\u2019s research has been controversial because of its statistical methods and its financing, which included money from a tobacco company.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThere is an independent source and the story reports that the trial was government-financed. \nHowever, the story does not tell readers that the independent source, Dr. Claudia Henschke, has been a loud critic of this trial. Dr. Henschke has been criticized both for making claims about benefits of CT screening that went beyond the available evidence, for having ties to a leading manufacturer of CT scanners, and for taking funding from a tobacco company. She should have been identified as someone who has frequently clashed with those who have supported this trial.\n", "answer": 1}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThis will be Hitachi\u2019s fifth PBT system in North America.\nTOKYO--(BUSINESS WIRE)--Hitachi, Ltd. (TSE:6501, \u201cHitachi\u201d) today announced that Johns Hopkins Medicine has selected Hitachi to provide its proton beam therapy (PBT) system at Sibley Memorial Hospital located in Washington, D.C.\nIn fiscal year 2015 (ending March 2016), one of Hitachi's new PBT site is planning to start treatment of patients.\nThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the release comes from Hitachi, the PBT system manufacturer and marketer.", "answer": 1}, {"article": "NEW YORK -- Three years ago, Tomas Sandoval was looking forward to the birth of his second child when he was diagnosed with a rare form of a blood cancer called lymphoma.\nSide effects included flu-like symptoms and confusion, and there were three treatment-related deaths.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nThe FDA will review these results and could make a decision on approval by the end of the year.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is not satisfactory\u00a0on all counts. It does not report that the treatment maker, Kite Pharma, paid for the trial, with additional funding from the Leukemia & Lymphoma Society (which lists Kite Pharma as a Patron level sponsor). The story also does not report that the researcher quoted in the story has disclosed in previous publications about this trial that he has served as an advisory board attendee for Kite Pharma. There are no independent sources noted in this story.", "answer": 0}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\nIncontinence may sound funny, but it\u2019s no joke, the researchers said.\nAmundsen said it\u2019s not clear why but her team is studyingthis to find out.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\nThe women in the study had to suffer at least six episodes of incontinence over three days.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We didn\u2019t see\u00a0any backstopping of this study by an outside source. Although nonprofit websites are quoted, that material is used for purposes of background \u2014 not to assess the study\u2019s claims. Another significant oversight here is no mention of co-authors\u2019 financial relationships with the products used in both arms of the trial.\u00a0(We give props to a Duke University press release about the study for pointing this out.)\nA quick Google search of the lead author\u2019s name and the term Medtronic reveals that she has been a consultant for the neurostimulator devicemaker, as well as for Allergan, Botox\u2019s manufacturer.", "answer": 0}, {"article": "Separate strands of material become stronger when they link up.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\nWriting in the journal Nature Materials, the team said they searched databases for materials that were already on the market and recognized as safe that could take a whole new approach to skin care.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\n\u201cSuch a result has been previously achieved only by a lower lid blepharoplasty, an invasive surgical procedure,\u201d they wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include at least one independent source, although that perspective is buried at the bottom of the story, long after the many potential benefits of the technology have been extensively touted. As as to potential conflicts of interest,\u00a0the story didn\u2019t point out the researchers have equity interest\u00a0in the companies, instead it said they had \u201cclose ties,\u201d which warrants a Not Satisfactory rating.", "answer": 0}, {"article": "In a study published in the Sept. 28 issue of the journal Menopause, scientists reported that about half the women in the study reduced the frequency of hot flashes, while half did not.\nHis spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\nDisclosure: Coeytaux has a financial interest in an organization involved in recruiting study subjects and administering acupuncture treatments at one of the two study sites.\n\u201cWomen will know pretty quickly if acupuncture will work for them.\nCo-authors include: Beverly Levine, Ph.D., Scott Isom, M.S., and Timothy Morgan, Ph.D., of Wake Forest Baptist; and Remy R. Coeytaux, M.D., Ph.D., of Duke University School of Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does a nice job here, mentioning how the study was funded and clearly outlining the potential conflicts of interests. One of the co-authors is the primary shareholder of Chapel Hill Doctors which was subcontracted by Wake Forest School of Medicine to recruit volunteers for the trial.", "answer": 1}, {"article": "Cancer cells and normal tissue scatter light differently because they have different microstructural and molecular features, Boppart said, so OCT gives physicians a way to quantitatively measure the cellular feature of a tumor.\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\nThe National Institutes of Health supported this work.\nThe diagnosis is made based on subjective interpretation and often other pathologists are consulted.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release discloses financial and commercialization interests of the principal investigator.", "answer": 1}, {"article": "\"Patients don't get a lifetime certificate saying you're cured,\" Calkins said.\nCatheter ablation is covered by most insurance, including Medicare, the researchers said.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAccording to Dr. Hugh Calkins, \"Atrial fibrillation ablation is a well-established procedure that has imperfect results.\"\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two cardiologists unconnected to the study, but fails to disclose possible conflicts of interest among the researchers. For example, the lead researcher has accepted money from Biosense Webster, a company that makes medical products for atrial fibrillation treatments.", "answer": 0}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\nDrew Pardoll, director of Hopkins\u2019 Bloomberg-Kimmel Institute for Cancer Immunotherapy, said that it is too early to know whether the findings will translate into longer survival.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nThe studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the \u201cSuper Bowl of lung cancer immunotherapy.\u201d\n\nThe reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has one independent source:\n\u201cScientists who weren\u2019t involved in the study agreed that it was highly significant. H. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u2018It is literally practice-changing \u2014 immediately.\u2019\nHowever, it doesn\u2019t say that the studies were sponsored by the drugmakers and many study leaders as well as another oncologist who\u2019s quoted, Roy Herbst, MD, has received consulting fees for companies that make immunotherapy drugs.", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWorking with colleagues at the Mayo Clinic in Rochester, Minnesota and the MD Anderson Cancer Center in Dallas, Texas, Michael Chuong, MD, an assistant professor of radiation oncology at the school, compared two kinds of X-ray radiation with proton therapy, an innovative, precise approach that targets tumors while minimizing harm to surrounding tissues.\nThe researchers looked at nearly 600 patients and found that proton therapy resulted in a significantly lower number of side effects, including nausea, blood abnormalities and loss of appetite.\nThe results were presented on May 22 at the annual conference of the Particle Therapy Cooperative Group, held in San Diego.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The University of Maryland release does note that UMD is poised to open its own proton therapy later this year, and that the 110,000 square-foot center cost $200 million to build. The release also lists Mayo Clinic and the MD Anderson Cancer Center as partners in the research being reported. But the release doesn\u2019t note that both Mayo and MD Anderson have also built large, expensive proton therapy centers. In other words, all three institutions have invested heavily in proton therapy and have a strong financial incentive to promote its benefits. There is no information in the release on how the study was funded.", "answer": 0}, {"article": "\u2022 Using other options to collect urine, such as bedpans.\nAs for improving infection control in intensive care units, Huang said, \"further analysis may help us understand why this intervention didn't work.\"\nDr. Susan Huang, a professor of infectious disease at the University of California, Irvine, wrote an editorial accompanying the study.\nAn intervention that focuses on changing the culture in hospitals to make them more responsive to the problem of infection control -- one that involves \"rallying around a focused problem and ensuring team-based solutions -- is integral to improving infection control in hospitals,\" she said.\nShe said, \"While we've known the correct care processes for managing urinary catheters, we haven't been able to reliably reduce catheter-related infections.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer included comments from Dr. Huang, an editorial writer in NEJM, which suffices as an independent source.\nBut, we\u2019re not told that Dr. Saint \u2014 the lead author \u2014 is a paid advisory board member for the health services companies Doximity and Jvion.\u00a0This was probably worth mentioning, since Jvion sells a data product to hospitals \u201cthat looks at the patient population and predicts the risk of an illness or condition before symptoms occur\u201d so that \u201cproviders are better able to stop hospital acquired conditions, prevent patient suffering and deterioration, target population health activities, and save resources.\u201d", "answer": 0}, {"article": "Epilepsy is a neurological disorder in which the brain's normal electrical activity is temporarily disrupted, leading to a seizure.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nBut experts said the results are promising, and should prompt further studies.\nThe study was funded by NeuroVista, the Seattle-based company developing the technology.\nTwo patients ultimately had the implants removed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert source contributed important cautious perspectives.\u00a0 The fact that the study was funded by the device manufacturer and that several of the authoring researchers work for the company was disclosed.", "answer": 1}, {"article": "They had been treated with an average of seven different therapies, including Herceptin, Tykerb, and Xeloda, and each had failed.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nIn another 12%, tumors stopped growing for at least six months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article includes dramatic quotes from the investigator, that the results were \"unheard of\" and \"as good as we\u2019ve ever seen\" in this population. While a source presumably unrelated to the study was used and confirmed that the results were \"exceptional,\" Edith Perez has received grant funding from Genentech, a sponsor of the Krop study. (Dr. Perez is also the lead author on a Genentech-supported study of trastuzumab presented at the same conference.) Acknowledging this connection, or citing another or an additional specialist without ties to the sponsor, would have added more balance, or at least the appearance of balance, to the claims of efficacy and tolerability, including the interpretation of the death that occurred during the study.", "answer": 0}, {"article": "People with schizophrenia experience a range of symptoms, which may include delusions, muddled thoughts and hallucinations.\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\n\"This is the first controlled trial to precisely determine an anatomically defined brain area where high frequency magnetic pulses can improve the hearing of voices\", said lead researcher, Professor Sonia Dollfus (University of Caen, CHU, France).\nNOTE: The full title of this release is \"Scientists discover brain area which can be targeted for treatment in patients with schizophrenia who 'hear voices'\" It has been shortened in some versions to comply with Eurekalert title limits.\nThis means two things; firstly it seems that we now can say with some certainty that we have found a specific anatomical area of the brain associated with auditory verbal hallucinations in schizophrenia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study funders (French Health Ministry (PHRC) and Basse Normandie Regional Council) are listed on a sidebar of the EurekAlert! site, where the release is hosted. We encourage news release writers to include funders in the text as well. The release doesn\u2019t address whether the researchers had any conflicts of interest. To be clear, we are not claiming that such conflicts of interest exist (it\u2019s impossible to tell, since the release doesn\u2019t tell us the names of all the researchers involved). But a release should make clear whether any such conflicts exist. If there are no conflicts, say so.", "answer": 1}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nFor more information about the NIDDK and its programs, see www.niddk.nih.gov.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.To schedule an interview, please contact Krysten Carrera, 301-496-3583, NIDDKMEDIA@niddk.nih.gov.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The principal investigator in this research is an employee of a federal agency. There does not appear to be any conflict of interest and funding sources are named.", "answer": 1}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nAngle founder and chief executive Andrew Newland said the study had demonstrated the ability to correctly detect cancer, and importantly correctly detect the absence of cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u2019s sole source is clearly identified as the chief executive of the company that appears to have funded the work.\u00a0 But the presence of only that source is a problem, as the text offers no independent viewpoints.", "answer": 0}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert who wasn\u2019t involved in the current study. However, since the source is involved in the development of a competing \u201celectronic nose\u201d technology, we don\u2019t think he qualifies as a truly independent voice.\u00a0Someone with expertise evaluating cancer screening evidence could have probably provided more useful context for readers.", "answer": 0}, {"article": "After the cap is placed on the patient's head, it is attached to a vacuum pump that sucks the air out of the cap, jamming the tiny grounds together to form a rigid layer that conforms closely to the shape of the patient's head.\nOn the strength of these results, Vanderbilt University has applied for a patent on the design and the technology is available for licensing.\nStudy coauthors also include graduate student Neal Dillon and former postdoctoral fellows Jessica Burgner, professor engineering at Leibniz University in Hanover, Germany, Ray Lathrop, senior consultant engineer at Eli Lilly and Company, and Raul Wirz, medical imaging processing research scientist/engineer at Vanderbilt University Medical Center,\n\nThe research was supported by National Institutes of Health grant R01 EB017467 and National Science Foundation Graduate Research Fellowship grant 144519.\nThey found that the cap reduced targeting errors by 83 percent.\nThe new design allowed them to attach several dozen markers directly to the surface of the cap, which the researchers believe will also contribute to improving the guidance system's accuracy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release says the research was supported by grants from the National Institutes of Health and the National Science Foundation. It states that one of the researchers now works for Eli Lilly and Company, and that the university is seeking a commercial partner to bring the device to market.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes outside experts and notes that the principal investigator is an unpaid consultant to the company that makes the test. We\u2019re also told that the study was funded by the maker of the genetic test.", "answer": 1}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\n\"This information will guide clinicians in terms of expected quality of life outcomes with sleep apnea treatment.\"\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\nThe AASM encourages patients to talk to their doctor about sleep problems and visit http://www.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did include a section at the bottom describing the funding sources for the study. However, it neglected to note that the first author has ties to two industry companies (Phillips Respironics and ResMed), both of which make money on the sale and upkeep of CPAP machines and supplies. This is an important financial conflict of interest to include.  ", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nBut not everyone finds that Provent alleviates their apnea.\nIt is also more expensive, and it doesn\u2019t work for every patient.\nBut it was only a year and a half ago that he finally went to a sleep clinic, prodded by his wife, who worried about his heavy snoring.\nMs. Nemoga, who lives in Baldwin Harbor, N.Y., has moderate apnea that caused her to snore and gasp in her sleep.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes from a range of sources, and we give it high marks for that. We are a little troubled that one of the most outspoken boosters of this product is Dr. Joseph Golish, who works for another medical device company, CleveMed. He was also quoted raving about Provent in The Plain Dealer. A mention of his device company work would have been good context.", "answer": 1}, {"article": "Those patients survived one-third longer than patients with low levels of vitamin D -- an average 32.6 months, compared with 24.5 months, the researchers found.\nThe report, scheduled for presentation this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more weight to suspicions that vitamin D might be a valuable cancer-fighting supplement.\nIt did not prove cause and effect.\nBut vitamin D also influences cellular function in ways that could be beneficial in treating cancer, Ng said.\nMONDAY, Jan. 12, 2015 (HealthDay News) -- Higher vitamin D levels in patients with advanced colon cancer appear to improve response to chemotherapy and targeted anti-cancer drugs, researchers say.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an outside expert offering an important piece of context and caution about the findings. And it includes a statement from a second outside source with expertise in oncology who underscores the important finding about progression-free survival. Yes!", "answer": 1}, {"article": ".\nThis research was funded by the Commonwealth Foundation, Agency for Healthcare Research and Quality grant R01 HS018657, and National Institute of Mental Health grant R21 MH100721.\n\"Our results should encourage clinicians to seriously consider resuming anticoagulation among patients who survived a major bleeding event, particularly if the source of bleeding was identified and addressed,\" said senior author Samir Saba, M.D., associate professor of medicine and associate chief of cardiology at UPMC Heart and Vascular Institute.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\n\"They should also take into account that the benefit-to-risk ratio of post-hemorrhage use of anticoagulation is not the same for all medications.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states the study\u2019s funding sources: the Commonwealth Foundation, the Agency for Healthcare Research and Quality, the National Institute of Mental Health, and La Caixa foundation. However, it does not state that one of the authors, Samir Saba, M.D., received research support from Boston Scientific, Medtronic, and St. Jude Medical, all of which make mechanical heart valves that require the use of anticoagulants to lower the post-operative risk of complications from blood clots. Since the potential conflict here is not direct, we will give the benefit of the doubt and award a Satisfactory rating.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\n\"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines,\" Patz said.\nHe added that improving the accuracy of LDCT screening for lung cancer would also significantly reduce the number of annual screens.\n\"This has significant public policy implications,\" said Edward F. Patz, Jr., M.D., the James and Alice Chen Professor of Radiology at Duke and lead author of a study published online March 21, 2016 in The Lancet Oncology journal.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding or conflicts of interest were mentioned in the news release. While changes in lung cancer screening schedules could have benefits for a wide range of people, we\u2019d still like the release to address the issue of sponsorship. We\u2019re not implying there was a conflict (we don\u2019t know if there were outside funders), but if a manufacturer did sponsor such a study it could pose a potential for conflict of interest that readers should be made aware of.", "answer": 0}, {"article": "The average age of children in the study was 7.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\nCurrent Biology strives to foster communication across fields of biology, both by publishing important findings of general interest and through highly accessible front matter for non-specialists.\nTo receive media alerts for Current Biology or other Cell Press journals, contact press@cell.com.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell readers who funded the research. The release also doesn\u2019t mention the fact that, as the paper itself states, \u201cThe results of this manuscript are under consideration of patent at the Weizmann Institute Office of Technology Transfer.\u201d That\u2019s worth mentioning, particularly since the release quotes the study\u2019s corresponding author, who is on faculty at the Weizmann Institute of Science. This isn\u2019t an unusual state of affairs for potentially useful research being done at large institutions, but we feel it is something that a release should share with readers.", "answer": 0}, {"article": "Infections are also a problem when doctors put tubes into the body.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\nAlthough his team did not evaluate enough patients to study the problem directly, \u201cWe feel this technology is capable of preventing those types of infections as well,\u201d Verbrugh said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source\u00a0cited\u00a0outside of study authors is Dr. Richard Wenzel\u2019s quote from his NEJM editorial regarding his opinion on the primary uses of the new technique. We might have graded this satisfactory \u2013 although barely \u2013 were it not for the following omission.\u00a0 \nConflicts of interest were not identified. As reported in the NEJM article, the study was supported by grants from GSK and Molnlycke, the drug companies that make the treatments used in the study,\u00a0Bactroban and\u00a0Hibiscrub.", "answer": 0}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does note that Pfizer funded the research, but you\u2019ll only see that listed on a sidebar of the EurekAlert!-hosted version of the news release. The disclosure isn\u2019t included in the release text, meaning it probably won\u2019t be noted in subsequent reprints of the release or many articles launched by the news release.\nPerhaps more importantly, the release \u2014 unlike the study itself \u2014 doesn\u2019t disclose that the lead author received a research grant from Pfizer, which makes a lidocaine-containing line of products called Lignocaine. This is an important consideration not only in terms of sponsorship transparency; it also raises the question of whether Lignocaine results can be generalized to other lidocaine products.", "answer": 0}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nAn extension and expansion of that trial with long term follow-up, the current results are based on data from 282 human study participants - 52 with type 1 diabetes who participated in the BCG clinical trials and 230 who contributed blood samples for mechanistic studies.\nNetea was not involved in the current study.\nThat trial is fully enrolled, and there are seven additional BCG clinical trial groups currently recruiting or enrolling at MGH, with a pediatric trial in the planning stages.\nThe lead author of the npj Vaccines paper is Willem M. K\u00fchtreiber, PhD, MGH Immunobiology Laboratories.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "According to the news release the study \u201cis entirely funded by private philanthropy from individuals and family foundations.\u201d\nNo conflicts of interest are reported in the published study.", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nThese are not all of the potential side effects of phentermine.\nThese are not all of the potential side effects of phentermine.\nAs with all KVK Tech products, Lomaira will be exclusively manufactured and packaged in the United States, in the strictest accordance with FDA, DEA, and DEP guidelines.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of who funded the studies that the FDA would have required for them to approve this use of the drug, nor is there any mention of potential conflicts of interest on the part of any investigators. The study referenced at the end of the release, however, did identify funders and addressed potential conflicts.", "answer": 0}, {"article": "CNN Films Presents:\" Glen Campbell ...\nMuch more research is needed\n\nThe study was not big enough to answer some important questions, such as whether patients taking resveratrol actually had lower levels of amyloid-beta plaques in their brain, and most importantly, whether they experienced less decline in their mental faculties.\nThe only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\n\"The study is encouraging enough that we should certainly go ahead and do a [larger] clinical trial because we showed that it is safe and does have significant effects on Alzheimer's biomarkers,\" said Dr. R. Scott Turner, professor of neurology at Georgetown University Medical Center and lead investigator of the study, which was published on Friday in the journal Neurology.\nIn addition, resveratrol on its own might not end up working as well as a combination of resveratrol and other polyphenol compounds found in red wine, grape juice and grape seed extract, which could help people at risk of Alzheimer's and those who already have mild symptoms, Pasinetti said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from two outside sources who provided important insight into the work. The story is much stronger thanks to the input of these two sources, who addressed the novelty of the work, the need for additional research, and how resveratrol could potentially become part of a multifaceted treatment regimen. The story doesn\u2019t mention who funded the research (NIH), which would have been good. And while the story doesn\u2019t mention that several study authors had ties to pharmaceutical companies, it\u2019s not clear that those companies have any ties to the research.\nSo the overall rating here is Satisfactory, although we did notice the spokesperson from the Alzheimer\u2019s Association mentioned that the currently available cholinseterase inhibitors slow progression of disease, which they do not \u2014 they treat symptoms in a minority of patients for a short period of time. He also opined that eventually the likelihood is that treatment will take a combination of several drugs (and lifestyle measures). Both lines are consistent with the huge amount of pharma money pumped in to the Alzheimer\u2019s Association.\nSimilarly, the other source apparently holds a patent on the use of a grape seed extract to treat Alzheimer\u2019s and Parkinsons \u2014 an interest that could impact his views on this similar approach.", "answer": 1}, {"article": "The print edition is scheduled to be published in August.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the release came from the Alzheimer\u2019s Research & Prevention Foundation, and that the study author is also the Foundation\u2019s president and medical director, Dharma Singh Khalsa, MD. The release states that the\u00a0Foundation supports holistic and lifestyle approaches to dementia prevention, which distinguishes it from the vast majority of prevention/treatment efforts that are based on drugs.", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nThe Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We will give this story a passing grade here because it does include a quote from a physician skeptical of elderberry extract. However, there is no mention of whether the trials of elderberry extract have been done by independent researchers or just manufacturers or others with a financial interest in the results. At least one study we\u2019re aware of cites Razei Bar, a manufacturer of elderberry extract, as its sole sponsor.", "answer": 1}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\nIf nothing else, it might allow people who would be reluctant to take medication more treatments to choose from.\nThe therapy was also able to increase brain activity in the insula, a part of the brain that helps monitor how the body feels psychologically.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only two researchers \u2014 and both were authors of the paper being discussed.", "answer": 0}, {"article": "Studies of large databases such as Medicare records or registries that enroll pregnant women already taking particular drugs are the chief ways to discover and measure possible risks to the fetus from prescription drugs.\nIt paid for the ACE-inhibitor study with help from the Agency for Healthcare Research and Quality.\nIt's considered unethical to include pregnant women in studies of new drugs unless the medication is intended to treat pregnancy-related conditions.\nIncreasingly, the FDA is seeking such data.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources of information appear to be the journal article, an author of the study and spokespersons from the FDA and its Center for Drug Evaluation and Research. ", "answer": 1}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nAnd for 15 of the women, transplantation had taken place more than five years earlier, the researchers said.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\nAnd no cancer developed in the transplanted tissue, Jensen said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two of the authors of the original study, Jensen and Andersen, as well as a third researcher, Hershlag, who appears to be independent of that group. The inclusion of multiple sources is a strong point in the coverage.", "answer": 1}, {"article": "Many Type 2 diabetics become resistant to insulin and have to inject additional amounts.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nFor now, the new approach has been demonstrated only in mice, according to the research, published Monday in the journal Nature Medicine.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nBut Ronald Evans, director of the institute's Gene Expression Laboratory and lead author of the new study, said in an interview that if it shows the same promise in primate studies, clinical trials on humans could begin in a couple of years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story fails readers by withholding the fact that the leading researchers are co-inventors of the molecule. The journal notes that they \u201cmay be entitled to royalties.\u201d This financial interest should have been reported in the story.\nWhat\u2019s more, the story does not include any independent experts who could put the study results into context.", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\nBut he also acknowledged the results so far were a surprise.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included comments from two of the study\u2019s authors but failed to get any independent perspective. ", "answer": 0}, {"article": "\u201cThe most important thing is, it sets up a secondary immune response and really destroys the distant tumor cells.\u201d\n\nThe very first patient was Stephanie Hopper, who was diagnosed with a glioblastoma when she was just 20.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\n\u201cThe average survival rate for all malignant brain tumor patients is only 34.7 percent,\u201d the group says.\nIt\u2019s not clear why just one in five patients benefits, said Dr. Annick Desjardins, who worked on the study team.\nTwo patients died during the trial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has no independent sources, and does not mention that seven study authors have a financial tie with a firm that holds the patent.", "answer": 0}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nPrologo consults for Galil Medical, which funded the study.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notifies us that the study was funded by Galil Medical, and that one of the sources consults for them. It also obtains a comment from an independent expert, who\u00a0adds some important context regarding the uncertain long-term safety of the procedure.", "answer": 1}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nIt is also inexpensive and easy to use.\nResearchers say that until now, the function of POPG has been unclear.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nThere is no vaccine or easy, effective treatment for RSV.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is interviewed in the story. ", "answer": 0}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nThe findings impress Columbia University researcher Gregg W. Stone, MD.\nStone has in the past received honoraria from the makers of both Plavix and Brilinta and serves on the advisory boards of Boston Scientific and Abbott Vascular.\nAnd in the new study, patients had less bleeding after stent installation.\nBoth drugs increase the risk of dangerous bleeding.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story quotes one independent source and identifies potential conflicts of interest. It would have been better if the \"independent\" commenter didn\u2019t have industry ties. ", "answer": 1}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nFor one thing, he says, dry needling as performed by a physical therapist is not rooted in ancient Chinese medicine \u2014 there\u2019s no talk about redirecting the body\u2019s energy flow by placing needles at certain points in the body.\nMark Crislip, an infectious-disease doctor in Portland, Ore., who recently wrote about dry needling for Science-Based Medicine \u2014 a website critical of alternative medicine \u2014 says the version practiced by physical therapists doesn\u2019t \u201ccome with the mystical baggage that accompanies acupuncture.\u201d But he says it may well be a \u201ctheatrical placebo.\u201d\n\nWhat do published studies say?\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story should be commended for its extensive sourcing. There are many sources packed into this piece and likely more sources who were interviewed and not quoted given the amount of reporting that clearly went into it.\nAt the same time, most of the sources have a potential conflict of interest\u00a0in some way:\nAll of these potential conflicts\u00a0are called out in the piece, which is commendable.\nThe one person who brings a fairly down-the-middle view is Matt Briggs, a physical therapist who is studying the technique to see whether it works. But our question about him is whether he also is a practitioner of the technique.", "answer": 1}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nWhen treatment was stopped, the benefits gradually tapered off, Baker said.\nhe said.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert\u2019s input was important at the end of the story.", "answer": 1}, {"article": ".\nThis study was funded, in part, by The Ben & Catherine Ivy Foundation.\nSince then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.\n\"New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome,\" said Dr. Harshil Dhruv, a TGen Research Assistant Professor and lead author of the study.\n\"Clinical trials revealed that PPF can cross the blood-brain barrier, and has minimal side effects,\" Dr. Tran said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by the Ben & Catherine IVY Foundation and NIH grants.", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThe other 10 received a fake treatment.\nEveryone took tests that measured their abilities after the study and then again two weeks later.\nThis is often not enough to make a meaningful improvement.\nAnd according to the new study, it helps.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had excellent sourcing and included comments from four different experts.", "answer": 1}, {"article": "Today, the United States is the third largest pear-producing country in the world, and Oregon and Washington comprise the nation's largest pear growing region with 1,600 growers producing 84% of all fresh pears grown in the United States.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\nIf that isn't reason enough to fill your shopping basket, there's another reason to add this fruit to your grocery list.\n\"We believe fiber intake may have driven the lower body weights that were seen in this study because there was no difference in energy intake or level of physical activity found between the fresh pear consumers and non-consumers.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is transparent in acknowledging that the Pear Bureau is the source of its pear promotion and the \u201ccommissioning\u201d of studies, in this case at the Louisiana State University Agricultural Center.", "answer": 1}, {"article": "Their systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.\nHis interest in L-Nutra has been disclosed and managed per USC's conflicts of interest policies to assure objectivity and a lack of bias in the conduct and reporting of his research.\nUSC also has an ownership interest in L-Nutra, and the potential to receive royalty payments from L-Nutra.\nUSC's financial interest in the company has been disclosed and managed under USC's institutional conflict of interest policies.\nStudy co-authors from USC Davis were Min Wei and Sebastian Brandhorst (lead co-authors) and Mahshid Shelehchi, Hamed Mirzaei, Chia Wei Cheng, Julia Budniak, Esra Guen, Stefano Di Biase, Pinchas Cohen and Todd Morgan.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We applaud the release for including detailed information on the financial conflicts of the lead author and the University of California at Davis. Here is how the release disclosed the financial conflicts:\n\u201cLongo is the founder of L-Nutra, whose food products were used in the study. His interest in L-Nutra has been disclosed and managed per USC\u2019s conflicts of interest policies to assure objectivity and a lack of bias in the conduct and reporting of his research.\nUSC also has an ownership interest in L-Nutra, and the potential to receive royalty payments from L-Nutra. USC\u2019s financial interest in the company has been disclosed and managed under USC\u2019s institutional conflict of interest policies.\u201d", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\n\u201cBased on current evidence, bisphosphonates should not be used for prevention of colorectal cancer,\u201d Jacobs said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories only quoted one outside source:\u00a0Eric Jacobs of the American Cancer Society. But the Reuters Health story made better use of his comments and did not allow the lead author to go unchallenged with some of his more sweeping comments.", "answer": 1}, {"article": "Interventional radiologists perform GAE for knee pain by inserting catheters through a pinhole-sized incision, blocking the very small arteries or capillaries within the lining of the knee, reducing the inflammation caused by osteoarthritis.\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\nTogether the scales represent an 80 percent improvement in function compared with pre-procedure conditions.\nThe treatment was successfully completed in all 13 patients, with no adverse events.\nThe study has completed enrollment of 20 patients and final results are expected in summer 2018.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note how the study was funded.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nWood says he\u2019s most excited about research into using psychedelics to treat addiction, and he published a review on September 8 in the Canadian Medical Association Journal covering recent work in this field.\nTwelve out of 15 patients in this small study had given up smoking six months after a psilocybin-assisted therapy session.\nBut not so with psychedelics, which represent \u201ca total paradigm shift in the way that mental illness is treated,\u201d he adds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert quoted is the author of the Canadian Medical Association Journal review article that seems to be the news hook for the story. It would have been interesting to hear a second opinion.\nEditor\u2019s note: This review originally stated that that there was no independent source quoted, which is incorrect. The story quotes Dr.\u00a0Charles Grob who was not involved with the review article that\u2019s the launching point for the story. The rating has been changed to Satisfactory.\u00a0\nThere is also no information about the potential conflicts around such research, and even though such conflicts may be unlikely given the source of drugs studied, a sentence to confirm the independence of the research would have raised the credibility of the article.", "answer": 1}, {"article": "\u201cMany babies with Down syndrome appear normal on an ultrasound,\u201d she says.\n\u201cPatients are very concerned about loss rates with aminocentesis and CVS and want reassurance about their pregnancies, so we are always looking for a better test,\u201d says Jennifer Wu, an obstetrician/gynecologist Lenox Hill Hospital in New York City.\nThe new test looks \u201cvery promising,\u201d says Cathy Sullivan, a genetic counselor at the University of Texas Health Sciences Center in Houston.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides a wealth of outside experts who provide great commentary and context about the study\u2019s findings. We wish more stories about screenings had quotes like these:\u00a0\u201cIn a year or two, this test may be available, but it won\u2019t replace existing technologies, it will nudge its way into our armamentarium of available methodologies,\u201d says Mark I. Evans, MD,\u00a0\u00a0director of Comprehensive Genetics in New York City, and an obstetrician/gynecologist at Mount Sinai School of Medicine, also in New York City.\u00a0\u201cThe bad news is that prenatal diagnosis is not just about Down syndrome\u2026Down syndrome represents about 50% of what we find, and this new test can help with that, but it may also give women a false sense of reassurance.\u201d", "answer": 1}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nAbout 15 percent of dialysis patients have HCV, the researchers said.\nSharif acknowledged, however, that using HCV-infected kidneys would represent \"a significant shift in our attitude to risk, procurement of organs and counseling potential recipients appropriately about the risks -- albeit minimal.\"\nSharif said the excellent short-term outcomes and 100 percent cure rate of HCV in organ recipients should prompt transplant centers to rethink use of HCV-infected kidneys.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted one source not involved in the study, Adnan Sharif, MD, a consultant transplant nephrologist at Queen Elizabeth Hospital and University of Birmingham in the United Kingdom, who wrote an editorial that accompanied the study.\nMore importantly, the story didn\u2019t inform readers that the study was funded by Merck, maker of the HCV drug combination elbasvir/grazoprevir, which is marketed under the name Zepatier. (Merck stands to profit from HCV-infected kidney donations becoming more common.)\nIt also didn\u2019t mention that six of the study\u2019s physician authors reported relationships with drug companies that make HCV treatments and/or transplant anti-rejection drugs. That included lead researcher Peter Reese, M.D., who is quoted extensively in the story. Reese reported grants from four companies including Merck and another HCV treatment maker, Bristol-Meyers Squibb.", "answer": 0}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is little more than a re-worked news release. It alludes to the announcement made by Bayer Healthcare. None of the other statements of fact are attributed.\nThis story would have benefited from feedback from an independent expert, who could have explained the harms associated with the device and helped readers understand whether or not a new test might help improve outcomes for patients electing to undergo the Essure procedure.\nReporters needing to find independent voices for their stories are invited to refer to an extensive list of experts maintained by HealthNewsReview.org. All of these experts are free of industry ties \u00a0and sensitive to reporter deadlines.", "answer": 0}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nThe research team is now looking to fund a full clinical trial.\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe research team used a gas chromatography sensor system called Odoreader that was developed by a team led by Professor Probert and Professor Norman Ratcliffe at UWE Bristol.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are stated and the origins of the equipment being used and tested is also made clear in the release.", "answer": 1}, {"article": "Suboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nIt's an orange pill that's dissolved under the tongue.\nBrian felt helpless.\nHe felt out of control.\nexplained Dr. Marc Gourevitch.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are several important shortcomings here:", "answer": 0}, {"article": "Their average age was 69.\n\"If this gets approved, and there is no reason to think it won't, this will be the second drug available for the treatment of high-risk osteoporosis,\" said lead researcher Dr. Paul Miller of the Colorado Center for Bone Research.\nThe editorial was co-written by Dr. Anne Cappola of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, associate editor of JAMA, and Dr. Dolores Shoback of the University of California, San Francisco.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nAmong the nearly 2,000 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo, the researchers found.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Caroline Messer of the Center for Pituitary and Neuroendocrine Disorders at Lenox Hill Hospital was interviewed as an independent source. She correctly pointed out that a head-to-head trial directly comparing Forteo and abaloparatide is needed in the next step of research.\nThe story also discloses that the research study was\u00a0funded by the maker of abaloparatide, Radius Health.\nHowever, the story doesn\u2019t\u00a0point out that the study author (whom they quote extensively) also serves on a Radius Health Advisory Board.", "answer": 0}, {"article": "Combining ursolic acid with either curcumin or resveratrol prevents cancer cells from gobbling something that they need to grow, glutamine.\nFunders of this research include that National Institutes of Health and the University of Texas System.\nPublished online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\nAdditional authors include Xiyuan Lu, Bo Wang, Enrique Sentandreu, Meghan Collins, all of UT Austin; and Mikhail Kolonin of The Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that funders include that National Institutes of Health and the University of Texas System, and there were no conflicts of interest that we could find.", "answer": 1}, {"article": "(Health.com) -- People who consume lots of foods rich in vitamin B12 -- such as fish and fortified cereals -- may be at lower risk of developing Alzheimer's disease than people who take in less of the vitamin, a small study conducted in Finland suggests.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\nMaria Carillo, Ph.D., the senior director of medical and scientific relations at the Alzheimer's Association, a nonprofit research and advocacy group, urges caution in interpreting the new findings, especially given that so few study participants developed the disease.\nAnd he worries that the results may spur doctors to recommend B12 injections to their patients -- a preventive treatment that he says is unfounded and already overused.\n\"The role of supplementation remains unclear.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\n\u201cIt seems really practical,\u201d said Stanford University chemical engineering professor Zhenan Bao, who also researches novel biomedical materials but wasn\u2019t involved with the sweat patch.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes\u00a0an independent source, a researcher who also works in developing biomedical materials. However, there are no medical experts who could comment on how well this technology might work in clinical or athletic settings.\nAnd, the story does not mention that three of the authors are inventors on a patent application that covers \u201cdevices and related methods for epidermal characterization of biofluids.\u201d Nor does it state that two authors are officers and co-founders of MC10, a company that develops wearable, stretchable electronics. Three other researchers are affiliated with cosmetics firm L\u2019Oreal, which began marketing a stretchable patch for UV monitoring this year. L\u2019Oreal was also among the funders of this study.", "answer": 0}, {"article": "A healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\nThis amount is in line with current Canadian health guidelines.\nBut the body scans used to assess bone density also allowed the team to measure the children's muscle and fat mass.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Even though the researchers did not disclose any conflicts in their journal article and the study was funded by a government agency, the release should have identified the funding source.", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from several sources, and tells readers precisely what sort of financial ties each source has to relevant drug companies. Kudos.", "answer": 1}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\nWhen they do, the screening and treatments are not as good, Chen said, so blindness may be more likely.\nThe antioxidants in human milk may help, Chen said.\nNo information was given about how long the breast-feeding continued.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Thumbs up here for interviewing an independent source, Dr. Adolfo Llanos. Although, we question the choice to end the article with the following\u00a0quote from Dr. Llanos\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\nThat\u2019s slightly puzzling, since the stated conclusion in the original study\u00a0is much more tentative\nBased on current limited evidence, in very preterm newborns, human milk feeding\u00a0potentially plays a protective role in preventing any-stage ROP and severe ROP.\nThe story would have probably done better to omit this source\u2019s simplistic conclusion.", "answer": 1}, {"article": "Alzheimer's disease is the most common cause of dementia, and two out of three Alzheimer's cases are women.\nThe largest study comprised approximately 230,000 Finnish women and the follow-up time in different studies was up to 20 years.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\nThe research data was from the MEDALZ (Medication use and Alzheimer's disease), OSTPRE (Kuopio Osteoporosis Risk Factor and Prevention Study) and CAIDE (Cardiovascular Risk Factors, Aging and Dementia) studies.\n\"In the light of these findings, hormonal replacement therapy may have a beneficial effect on cognition if started early, around the time of menopause.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention any of the funding sources for the studies. It would be preferable if all funding sources were cited, but we don\u2019t penalize releases or stories unless they fail to report industry funding and commercial ties. These reports were funded by government and academic research institutions, and foundations.", "answer": 2}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nBut the scientific evidence has been slim.\nDo melatonin supplements really help people sleep?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources of information appear to be related to the single study mentioned and the lead author of the paper on that study. ", "answer": 0}, {"article": "But the F.D.A.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nThe other, polidocanol, had not been legal, although some doctors used it, importing it from abroad or obtaining it from pharmacies that make drug compounds.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story gets high marks for tapping a number of expert sources, it should have done more to identify potential conflicts of interest. One expert who supports laser surgery is appropriately identified as the developer of a laser technique, but Dr. Robert Weiss, another\u00a0expert quoted in the story,\u00a0is\u00a0identified only as the director of\u00a0the Maryland Laser, Skin and Vein Institute. If fails to mention that he is also a consultant to Medicis Pharmaceuticals, which manufactures Asclera,\u00a0a\u00a0drug recently approved by the FDA which is discussed in the story.\u00a0To avoid the appearance of any bias, the story should have disclosed this relationship. It also should have tried to get a comment from someone who doesn\u2019t benefit financially from these procedures.\u00a0", "answer": 0}, {"article": "MRI has long been known as an effective breast cancer screening modality that offers better sensitivity than mammography and ultrasound.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\n\"The interval cancer rate in our study was zero percent.\nNot a single cancer was undetected that became palpable,\" she said.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name the sponsors.", "answer": 0}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nAnother possible limitation was the loss of patients during the follow-up, which could have affected the results, the researchers noted.\nThe average age of the men and women studied was about 52, and three-quarters were men.\nMaciejewski acknowledged that the study has limitations.\nThe new study is notable because of the decade-long follow-up, said Maciejewski, who is also a research career scientist at Durham Veterans Affairs Medical Center.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources are clearly identified, along with information about their links to the study itself (one scientist was the study\u2019s lead researcher, and the other quoted in the story was independent).", "answer": 1}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\n\u201cFor some women, hormone therapy is the best option, for some soy is best, and for some, it\u2019s just watchful waiting until the hot flashes subside,\u201d Bachmann said.\nIt\u2019s thought to have similar effects to estrogen on the brain, bones, and blood vessels, Bolanos-Diaz told Reuters Health by email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One apparently independent expert was quoted in the story.", "answer": 1}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nOur ultimate goal was to enhance the body\u2019s ability to repair itself,\u201d said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.\nThe National Center for Advancing Translational Sciences is a distinctly different entity in the research ecosystem.\n\u201cThe ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,\u201d said Ursula Utz, Ph.D., program director at the NINDS.\nWe asked if we could find a faster and less invasive approach by using drugs to activate native nervous system stem cells and direct them to form new myelin.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are told up front that the study was funded by a division within the National Institutes of Health, and there is no\u00a0apparent conflict of interest according to the paper.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nBut until the vaccine is linked to an actual survival benefit or improvement in tumor status, Diamond said, no one can say if it helps the patients in a meaningful way.\nHow to explain the 27 percent who responded without the vaccine?\nThe science is early, Hale stressed, and it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\nThat study will be done, Hale said, and they plan to follow the women for three years and look at survival differences.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article contained quotes from a different researcher who was very cautious about drawing conclusions from the current study\u2019s findings.\nWe do wonder,\u00a0 though, what it means when the story says that the independent expert \u201creviewed the findings.\u201d\u00a0 What did he review?\u00a0 Since the researcher\u2019s findings hadn\u2019t even been presented yet when the story was written, did the independent observer review the short abstract that appeared in the conference program?\u00a0 Did he have access to a more complete data set or a more complete description of the work?", "answer": 1}, {"article": "A group of 1,537 women were randomly assigned to a daily diet that included five vegetable servings, three fruit servings, 16 ounces of vegetable juice and 30 grams of fiber.\n\"It sends us back to the drawing board,\" said Susan Gapstur of Northwestern University's Feinberg School of Medicine, who co-wrote an accompanying editorial.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nThe study appears in today's Journal of the American Medical Association.\nThat led some experts to suggest that weight loss and exercise should be the next frontier for cancer prevention research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the author of an editorial on the newly published data.\u00a0 Her comment needs further explanation, so more information from her or from other researchers or clinicians not affliated with the study would have been useful, especially regarding a discussion of other benefits associated with a high-fiber low-fat diet focusd largely on plant-based foods. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to the first author of the study, quotes from several clinicians who were not involved with the present hypothesis paper but who had expertise about folate, were\u00a0included in this story.", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does use some independent sources, but it does not identify conflicts of interest. Again, this is a big missed opportunity because the authors of this paper have potential conflicts. They have worked with many drug and device makers, including Siemens, one of the big MRI\u00a0makers, as well as: Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Sanofi, Solvay Pharmaceuticals, GlaxoSmithKline, Wyeth, Genentech, LifeCycle Pharma A/S, ReNeuron, Novovision, NeuroLogica Corporation, Avanir Pharmaceuticals, Micromedex, AstraZeneca, Bayer Schering Pharma, Takeda Pharmaceutical Company Limited, Embrella Cardiovascular, Millennium Pharmaceuticals, Novo Nordisk, Otsuka Pharmaceutical Co., Pfizer, Mitsubishi Tanabe Pharma Corporation, PDL BioPharma, Inc., Terumo Neurovascular Monitoring, Guidant, Cordis, Bard Peripheral Vascular, Inc., Abbott, Boston Scientific, Olea Medical, Lantheus Medical Imaging, and, believe it or not, even more.\u00a0Two hold patents on MR devices. Might they stand to beneft?", "answer": 0}, {"article": "Traumatic injuries to the head, often from car accidents, tend to sever brain cell connections and leave many neurons intact.\nDoctors from the University of Cambridge and the University of Li\u00e8ge in Belgium collaborated on the research.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nThis means by definition that the young woman has transitioned from an unresponsive, vegetative state to a sometimes responsive condition known as a minimally conscious state, Dr. Laureys said in an interview.\n\u201cIf you put her scans together with the other 12 volunteers tested, you cannot tell which is the patient\u2019s,\u201d Dr. Owen said in an interview.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple, independent sources who were not directly involved in the research study and who provided valuable perspectives.", "answer": 1}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nWhile he calls finding more DCIS with computer-aided detection also ''likely a good thing,\" he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\nThe additional tests that turn out to be unnecessary, because no cancer is found, are not desirable, he said.\nSome of the very early cancers diagnosed in older women, he noted, may not have caused them a problem during their lifetime.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments by Dr. Daniel Kopans, who was not connected with the study. \u00a0Because Dr. Kopans\u2019 comments are extensive & mainly support the use of CAD, observations by a second independent source with a different opinion would have provided needed balance for the reader. \u00a0Comments by lead study author Dr. Fenton, point out some problems with CAD but analysis by another independent source would be helpful for readers.\nKopans clearly offers a counterpoint to Fenton, but some of Kopans\u2019 statements, such as the following, should not have gone unchallenged and it would have been easy to find other experts who believe this is not the case:\n\u201cWhile he calls finding more DCIS with computer-aided detection also \u201dlikely a good thing,\u201d he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime. Although the treatment of DCIS is debated among experts, Kopans said, \u201cIn my mind, it is always worth it to find additional cancers.\u201d", "answer": 0}, {"article": "\u2022 Khin NA, et.al.\nThis press release contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits of esketamine.\nWhat makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant.\nHowever, the study narrowly missed statistical significance for its primary efficacy endpoint.\nThe reader is cautioned not to rely on these forward-looking statements.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the work was funded by Janssen Pharmaceutical Companies, and the affiliation of the experts quoted in the piece is similarly clear.", "answer": 1}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nJan. 6, 2010 -- A new imaging technique that measures the random motion of water within the brain may prove useful for detecting early signs of Alzheimer's disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story did include a quote from a neurologist who did not appear to be directly connected with the study. \u00a0That said, his comments were general in nature and were not explicitly about the research reported on.", "answer": 1}, {"article": "Those who consumed above the median amount of caffeine for this group (with an average intake of 261 mg per day) were diagnosed at a lower rate than those who fell below the median (with an average intake of 64 mg per day).\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nThe researchers adjusted for risk factors such as hormone therapy, age, race, education, body mass index, sleep quality, depression, hypertension, prior cardiovascular disease, diabetes, smoking, and alcohol consumption.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health.", "answer": 1}, {"article": "For at least 2,000 years Chinese healers have used acupuncture to treat pain and other ailments.\n\u201cI believe that\u2019s part of the reason why they get better.\u201d\n\nA version of this article appeared in print on August 24, 2010, on page D5 of the New York edition of The Times.\nAnd critics contend that the study was poorly designed.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nBut in this study, the patients in the \u201creal\u201d acupuncture group all received needles inserted in the same way.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes many sources \u2013 most of them involved in the research in question.\u00a0 One interviewee appeared to be independent of any of the studies being discussed. ", "answer": 1}, {"article": "Blood tests for iron deficiency without anemia have been developed but they are more costly and difficult to obtain in the doctor's office compared to hemoglobin testing for anemia.\n\"I think we need to establish the optimal timing for an objective assessment of adolescent iron deficiency and anemia.\"\nThe research was recently published in the journal PLOS ONE.\nThis research received $62,500 of federal funding from The Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (grant number K12HD055882), which funded 100 percent of the project.\nMurray-Kolb and Paul also worked on the study in The Journal of Pediatrics, along with Eric W. Schaefer, a biostatistician in the Department of Public Health Sciences.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the source of grant funding for both journal articles referenced. We wish it had also said \u201cthere are no conflicts of interest.\u201d", "answer": 1}, {"article": "March 15, 2010 -- A common pain reliever may help people with type 2 diabetes control their blood sugar levels.\nBut the results do merit further research.\nNo single dose of salsalate seemed safer or more effective than another.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\nOther markers of glycemic control and heart disease risk also improved in the three salsalate groups compared with the placebo group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were used. \nThe investigators didn\u2019t disclose\u00a0any substantial conflicts of interest related to the study.", "answer": 0}, {"article": "\u201cDoes everybody need to practice at least 20 minutes a day three times a week?\nBut she cautioned that her study looked specifically at deep stretching that is far more involved than the brief, light stretches most people do before or after a workout.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\nA number of earlier studies suggested that regular yoga classes might benefit back pain sufferers, though most were limited by small sample sizes, short study periods and other flaws.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The New York Times article did not offer commentary from an independent source. The evidence on chronic back pain is complex and challenging, as is the evidence on yoga and stretching. So the article would have benefited from additional expert input. The authors of the clinical trial did not disclose any conflicts-of-interest, so there was no need to report on this criterion in the article.\n", "answer": 0}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nSo far, the medical community lacks results from any definitive clinical trial that might provide clear guidance.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nThe new VA study is likely to draw attention because of its large size and relatively long follow-up period.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the study itself offers\u00a0full disclosure regarding funding and conflicts of interest (the investigators assert no such conflicts), none of this finds its way into the news release.", "answer": 0}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nUnless you have specific symptoms that a low-FODMAP diet alleviates, Gibson says, \u201cenjoy your FODMAPs!\u201d\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\nBut there\u2019s a problem with a low-FODMAP diet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is Dr. GIbson, one of the creators of the low-FODMAP diet and an author of a book entitled, The Complete Low FODMAP Diet: A revolutionary Plan for Managing IBS and Other Digestive Disorders.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses multiple sources and in one case points out that the source was not part of the study.\u00a0 In another case, the story points out that a source \u201chas been a paid consultant for the makers of Oncotype DX and Decipher, but has no financial interest in the companies.\u201d\u00a0 One quoted source, however, is part of a company \u201cwhose aims include curbing overtreatment,\u201d which using these tests apparently might prevent.", "answer": 1}, {"article": "Ketamine infusion therapy, the controversial treatment for depression, has been resisted by many physicians due to concerns about short-lived benefits, risks of addiction, and the lack of large scale studies.\nIts findings stand in direct contrast to warnings from the American Psychiatric Association (APA).\nWhile controversial in academic settings, Dr. Henderson said his direct experience supports a different strategy for multiple-infusion treatment regimens and his clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\nAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nDr. Henderson's findings challenge the oft-held beliefs that ketamine must be given frequently to have any benefit and that ketamine has no long-lasting benefit.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that Henderson is co-founder of a center that uses the treatment but the release does not point out for readers the potential conflict of interest. The study even states \u201cnone\u201d in regard to conflict-of-interest which seems implausible.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites several sources and provides their affiliations.", "answer": 1}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nThere are already plenty of reasons to exercise, and now better quality sperm is one more worth noting.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nAnother group did high intensity exercise on the treadmill but in short interval bouts.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does provide a quote from an expert unaffiliated with the research team, and we found no conflicts of interest that should have been noted.", "answer": 1}, {"article": "OsteoRx\u2122 is a new joint health system comprised of an OTC topical analgesic combined with a natural antioxidant to support overall joint health.\nThe clinical studies support powerful marketing claims.\n\"We demonstrated superior treatment outcomes with our acne product in a head-to-head clinical trial against the market-leader, and now we've done the same with OsteoRx\u2122.\nEach HSRx OTC drug product is proven in independently conducted clinical studies to provide superior treatment outcomes.\n\"All HSRx OTC drug products are designed to become category leaders,\" noted Frank Parise, the company's Chief Financial Officer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We aren\u2019t told who sponsored the referenced clinical trial, just that it was performed by an \u201cindependent clinical research organization.\u201d\u00a0 The release should have provided information about where the trial was conducted, by whom, and whether there was any conflict if the study was funded by the manufacturer of the product.", "answer": 0}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\nThe research followed 21 severely obese teenagers between 14 and 18 years who had Laparoscopic Adjustable Gastric Banding (lap band surgery) in the South Australian Health Service.\n\u201cOur findings support lap band surgery as a safe and effective option for management of adolescents with severe obesity \u2013 provided it is performed by an experienced surgeon and managed afterwards in a paediatric multidisciplinary environment with regular follow-up until adulthood.\u201d\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are not mentioned in the release although that information is provided in the text of the journal article. The study coauthors all claim no conflicts of interest, but that information is not provided either.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\n\u201cBehaviourally mice aged faster when these cells were removed during early ageing,\u201d Cai told the Guardian.\nThe latest investigation from the US team pinpoints which cells are important and how they might work.\n\u201cOf course humans are more complex,\u201d said Dongsheng Cai, who led the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote one source unaffiliated with the research and we didn\u2019t detect any conflicts of interest. (The paper itself notes that the authors of the study have no conflicts of interests.)", "answer": 1}, {"article": "A new study shows men who ate the most foods rich in a group of antioxidants known as flavonoids were 35% less likely to develop Parkinson\u2019s disease than those who ate the least.\nThis was an observational study and therefore can\u2019t establish cause and effect.\nNor is it clear why the results differed for men and women.\nThis study will be presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only quote comes from the researcher from a news release.\u00a0 No independent perspective appears in the story.", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\nKetamine \"helped me get my life back,\" says James, who asked that we not use his last name to protect his career.\nAnd almost from the time it reached the market it has also been used as a mind-bending party drug.\nHe says his response was dramatic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only two experts quoted in the story are research collaborators who have long advocated for expanded use of ketamine treatment. One of them, Demitri Papolos, has applied for a patent on a ketamine delivery device. The story should have reported this potential financial interest.", "answer": 0}, {"article": "Get the facts.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nThe Gardasil vaccine, on the other hand, caused some people to faint after getting it, and others got mild skin infections\u2014both of which occur somewhat rarely with other vaccines too, as you might expect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent voice included, nor does the story alert readers to the fact that Merck funded the study. Drug company funding is obligatory for post-marketing surveillance data of this type. So while it\u2019s worth mentioning, such funding is arguably not as important as when a company funds a study with glowing findings on a new unapproved device or drug.", "answer": 0}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nAfter two years, 46 percent receiving standard treatment alone were free of tumor recurrence versus 66 percent of those like Brian who also received the antibody.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nIn results released Thursday, immunotherapy improved the outcomes of patients with advanced neuroblastoma.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The experience of one patient, and the thoughts of his parents and his doctor (who was also a co-author of the abstract) were included in the story. \u00a0There was no interview with independent experts in childhood cancers or neuroblastoma specifically. This would have help provide context for viewers about the likely impact of this treatment. \u00a0", "answer": 0}, {"article": "The incidence of shingles increases as we get older, because the body's natural immunity declines.\nThe full paper is published online by the Journal of Infectious Diseases as Editor's choice: https:/\n\nThe Shingrix vaccine is developed by GlaxoSmithKline.\nLead researcher Professor Tony Cunningham from the Westmead Institute for Medical Research said the study shows that the vaccine stimulates production of a specific immune memory cell (CD4 T cells), generating a strong and sustained protection against the virus.\nParticipants in the trial received two doses of the vaccine, with the doses given two months apart.\nThis is 12 times higher than other less effective shingles vaccines.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study was funded by the manufacturer of Shingrix, GlaxoSmithKline, and many of the authors are listed in the study as being GSK employees or having other financial interests in shingles vaccines. None of that is mentioned.", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nOther Johns Hopkins scientists who contributed to the research include Carol Ann Huff, Janice Davis, M. Victor Lemas, Susan Fiorino, Jeffrey Bitzan, Anna Ferguson, Amy Emerling, Leo Luznik, William Matsui, Jonathan Powell, Ephraim Fuchs, Gary L. Rosner, C. Epstein, Lakshmi Rudraraju, Richard F. Ambinder, Richard J. Jones and Drew Pardoll.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nNone of the participants had serious side effects from the MILs therapy.\nThe average follow-up time is currently more than six years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for this research are listed in an end note in the release.\u00a0 No conflict of interest information is provided in the release, although the research paper discloses no conflicts.", "answer": 1}, {"article": "Special software monitors the electrical activity in your brain.\nAnd one chapter of the book is devoted to neurofeedback.\nEllison has written a book about living with ADHD called Buzz: A Year of Paying Attention.\nNeurofeedback is better for people with ADHD, she says, because it provides constant feedback during a session, which is usually done in a therapist's office.\nSo the approach remains promising but unproved, says David Rabiner, a researcher at Duke University who writes a newsletter about treatments for ADHD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to extensive comments from the journalist book author who discusses her experience with neurofeedback, the story quotes a Duke University researcher who is an expert on ADHD and offers some counterbalancing perspective.", "answer": 1}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nIn the study, published in the New England Journal of Medicine on Wednesday, 76 patients were treated with focused ultrasound, and their tremor was evaluated after the first, third, sixth, and 12th month.\nNeurologist Dr. Bryan Ho, who is not involved in the trial, noted that tremor suppression remained sustained throughout the 12 months.\nResearchers found that the severity of essential tremor reduced significantly over that time in the patients who underwent the treatment versus those who had a sham procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only fulfills part of our criteria. It does use one independent source, a physician who was not involved in the study. It also accurately reports the trial\u2019s funding sources: InSightec, which developed the device; along with Focused Ultrasound Foundation, which is funded by device makers and philanthropic organizations; and the Binational Industrial Research and Development Foundation, an Israel-U.S. government partnership that receives corporate support.\nHowever, the story falls short because it does not report the fact that nine of the study authors reported conflicts of interest, with most receiving financial compensation of some sort from device makers in the field. Lead researcher G. Rees Cosgrove, M.D. who is quoted in the story, reported receiving consulting fees from InSightec.", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotes or other indications that independent sources were consulted.\u00a0An outside perspective, particularly from someone who could point out that the benefits were very modest clinically, would have been valuable.", "answer": 0}, {"article": "To assess the effectiveness of phone counseling for easing these symptoms, Letourneau and colleagues identified 64 mothers with symptoms of major depression within 24 months after delivery and offered them up to 12 weekly peer support calls.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\nOver the second half of the study, 34 mothers had at least one phone conversation with a peer counsellor.\nOn average, they spoke about three times.\nThe new moms found that the conversations helped relieve symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two outside sources and notes explicitly that they were not involved in the current study. Gratifying!", "answer": 1}, {"article": "\"I can do what everybody does.\"\nIn a sense it's a field of science that works backward: Stimulation is applied to the brain, some people get better, and doctors try to figure out why.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nWolter, who lives in Oconomowoc, fit that profile well.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed one patient with a self-reported positive outcome, and four medical specialists. \nThe reporter\u2013eventually, in the last phrase of the story\u2013mentions that the research was paid for partly by the maker of the deep-brain stimulation device.\u00a0 \nOn balance, the sourcing of this story is acceptable.\u00a0 ", "answer": 1}, {"article": "Side effects from antidepressants can include constipation, diarrhea and dizziness.\n\"Major depressive disorder is a disabling and prevalent form of depression, experienced by more than 16 percent of U.S. adults during their lifetime,\" said Arlene Bierman, M.D., Director, Center for Evidence and Practice Improvement, at the Agency for Healthcare Research and Quality, which funded the study.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nThe research from the RTI International-University of Chapel Hill Evidence-based Practice Center was published today in the British Medical Journal.\nA journal article describing all the review findings will be published in the Annals of Internal Medicine in January.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the Agency for Healthcare Research and Quality (AHRQ) funded the study. AHRQ is a government agency that studies and promotes improved quality in health care.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only quote is from the senior author of the research study (Cancer Research 2007; 66(14):6882-6888).\u00a0 The story could have provided views of surgeons or other researchers who work with current technologies.\u00a0 How does the National Cancer Institute or a cancer research organization assess this research? ", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not do a good job finding unbiased sources to speak to the difference between IVF and IVM treatments\u2013only one person is cited. An additional\u00a0 researcher or fertility expert could provide a balanced review of the evidence (both benefits and harms) of these and additional fertility treatments, which might also be appropriate for women who cannot take hormones typical of IVF regimens.\u00a0 The story does interview women who serve mainly to promote Dr. Batzofin\u2019s clinic. ", "answer": 0}, {"article": "Larsson isn't sure why.\nThe new Swedish study echoes previous research in men and women.\nThe research is published in the Journal of the American College of Cardiology.\n\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nIt also adds new information.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study includes comments from an expert source not affiliated with the study, who provides valuable context on the\u00a0increased desirability of dark chocolate over milk chocolate.", "answer": 1}, {"article": "This can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\nThe patients who are at high risk are candidates for surgery, he said.\nThe report was published in the Aug. 17 online edition of Neurology.\nFor the study, a research team led by Topakian followed 435 people with asymptomatic carotid stenosis for two years.\nIn addition, over the two years of the study, 10 people had TIAs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two individuals who were not involved in the study reported on were included in this story.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\n\u201cThis is probably the first example of a migraine preventing drug that was rationally designed, rather than serendipitously found,\u201d he added.\nAmgen and Novartis, the codevelopers of erenumab, funded the trial, while Amgen also supplied the drug and conducted the data analyses.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\nA new migraine drug that can halve the length of attacks has been hailed as \u201cthe start of real change\u201d in how the condition is treated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Many news stories fail this test, but this one shines: Not only does the article cite an expert who wasn\u2019t involved in the study, but it also discloses that the drugmakers of erenumab \u2014 Amgen and Novartis \u2014 funded the study, supplied the drug, and did the data analyses. (One thing the story missed, though: The first draft of the study was put together by a company-funded writer.)", "answer": 1}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\n\"Modafinil was found to have an effect on impulsivity in healthy individuals and so would be able to have an even bigger effect on food addicts, who are lacking in certain types of dopamine,\" said Professor Vlaev.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes no mention of who funded this study, nor does it mention any potential or possible conflicts of interest on the part of the researchers.", "answer": 0}, {"article": "Friday 5 p.m.\nAfter the advisory committee's decision in July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA complaining that \"the (FDA advisory) committee's concerns appear to have been based on cost-effectiveness,\" and adding that a reversal on accelerated approval would amount to \"cost-rationing.\"\nReflecting splits in the medical community, the European Medicines Agency said Thursday that Avastin would remain an approved therapy for breast cancer in European Union countries, although only in one particular combination: with the drug paclitaxel.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\nHowever, patients currently taking Avastin as part of their chemotherapy regimen will not immediately be affected, and \"doctors should use their medical judgment on whether to continue\" its use, said Dr. Janet Woodcock of the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was some room for improvement here. Two independent sources were used: an interview with a cancer doctor and a statement on the ACS website. \u00a0The story neglected to point out that the former, Joseph Sparano, has served as a consultant and speaker\u00a0on Avastin\u00a0for Genentech, as WebMD acknowledged when they interviewed him for their story.\nSee \u201cQuantifying Benefits\u201d for our request for more information about Dr. Sparano\u2019s quote regarding 1-year survival.\nOn a side note, it may have balanced Dr. Sparano\u2019s quote had the story included a little more of the ACS statement that spoke directly to the FDA decision, such as their conclusion that until we have a better way to determine\u00a0who will derive the most benefit from Avastin, \u201cgiving all women with metastatic breast cancer [bevacizumab] may harm more women than it helps.\u201d", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Swedish teenagers who consumed more folic acid got better school grades, a small study published in the journal Pediatrics has found.\nThe researchers looked at 386 15-year-olds who were finishing up ninth grade.\n\u201cThere is very little deficiency of folic acid in North America,\u201d Deborah O\u2019Connor, a nutrition researcher who was not involved in the study, told Reuters Health.\nThe differences remained even after the researchers accounted for gender, smoking, the mothers\u2019 education and which schools the kids went to.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from independent sources who helped provide context and perspective on the study and its results.", "answer": 1}, {"article": "More than half of people who took Xyrem reported at least a 30% improvement in pain, says Kim Dupree Jones, PhD, of Oregon Health & Science University in Portland.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nThe new study was presented at the annual meeting of the American Pain Society.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A source was interviewed, and conflicts of interest are identified, including the drug company that funded the study. Although we are told the source was not involved in the study per se, the story suggests that he is a consultant for the drug company.\u00a0 IF this is in fact the case, there is a question about the independence of the source.\u00a0 Furthermore, no source provides analysis of the research itself. The consultant is quoted downplaying the abuse observed for Xyrem in narcolepsy and the potential role of a new product in the management of this disease. We don\u2019t necessarily dispute his underlying points, and there\u2019s evidence in the literature supporting his characterization of the abuse. But these points would mean a lot more coming from someone who is an independent source.\nThe drug is sometimes used off-label for fibro, as we can deduce from the\u00a0patient anecdote talking about her success with the drug. We\u2019re also not sure this selective anecdote was appropriate to include:\u00a0without any other quotes or independent analysis to balance it, it paints an overly heroic picture of the drug. \u00a0As a bit of background, note that Jazz has gotten into trouble in the past in this arena: its subsidiary\u00a0plead guilty\u00a0to a federal\u00a0indictment\u00a0of promoting Xyrem for off-label uses, including fibromyalgia.\nPerhaps a more minor issue, we\u2019re not sure that the article ever says explicitly that Jones was the investigator on this study. \u00a0It will be obvious to some readers, while others may feel she is an expert commenting on the research.", "answer": 0}, {"article": "Jet lag occurs when sleeping and waking patterns are not synchronized to circadian rhythms.\nThere's still more testing to be done before the technique is available to the public.\nParticipants were able to sleep through the flashes of light without waking.\nThe treatment \"exploits biology in the eye\" to speed up the brain's adjustment to time changes, he said.\nThis time around, researchers tried to further optimize the process.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside expert was asked to comment and cast a critical eye on the quality of the evidence and the soundness of the study.", "answer": 0}, {"article": "6 Kowdley KV, et al.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nNo children discontinued the study due to side effects or had a severe or life-threatening adverse event related to the study drug.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release says research funding came from the manufacturer, Gilead Sciences, and the National Institutes of Health, and the study authors own stock in Merck. Kudos for transparency.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story did include the thoughts of two analysts, this story would have been more useful to readers if it had included comments from a clinician or scientist not involved in the study who could have commented on why the benefits of this drug differ from those of others currently used for treating this condition.", "answer": 0}, {"article": "Dr Quentin Anstee, Clinical Senior Lecturer at Newcastle University, Consultant Hepatologist within the Newcastle Hospitals and joint senior author explained what it could mean for patients: \"This scientific breakthrough has great promise because the majority of patients show no symptoms.\nThis research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre.\nTimothy Hardy, Mujdat Zeybel, Christopher P. Day, Christian Dipper, Steven Masson, Stuart McPherson, Elsbeth Henderson, Dina Tiniakos, Steve White, Jeremy French, Derek A. Mann, Quentin M. Anstee and Jelena Mann.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nDr Timothy Hardy is a hepatology registrar within Newcastle Hospitals and a Medical Research Council-funded clinical research training fellow at the University.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly identified, as are researchers who are quoted and their affiliations related to the work. There do not appear to be any relevant conflicts of interest.", "answer": 1}, {"article": ".\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\nIt is important to realize, she adds, that \u201cas the risk increases, the benefits tend to be greater.\nKala Visvanathan, the lead author of the ASCO recommendations and a faculty member at the Johns Hopkins School of Medicine, said the cutoffs provide only a rough estimate of risk.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes good use of actual interviews with more than one source. The perspective these experts provide is crucial.\nSince the story emphasizes patient decision-making surrounding preventative drug treatment, it would have been useful to include the voices of some actual patients who did and did not opt for drug treatment.", "answer": 1}, {"article": "Oral and injectable medications are also prescribed.\nResearchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThe results showed clinically and statistically significant risk reductions with all definitions.\nThe study was carried out in collaboration with Biogen and academic collaborators from NYU School of Medicine's Division of Biostatics, University of Alabama at Birmingham School of Medicine, and Rocky Mountain Multiple Sclerosis Clinic in Utah.\nIn addition to Dr. Zhovtis-Ryerson, Ilya Kister, MD, associate professor of neurology, Judith D. Goldberg, professor of population health and environmental medicine, and Xiaochun Li, PhD, research scientist of biostatistics, were co-authors at NYU Langone Health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the news release does mention that natalizumab is manufactured by Biogen \u2014 and that Biogen \u201cprovided the researchers access to their data and statistical support\u201d \u2014 it does not mention that the lead author\u00a0receives research support from Biogen, as well as personal compensation from Biogen for speaker and advisory board activities.\nIt\u2019s also not mentioned that half of the 14 coauthors listed for this study\u00a0are employees of \u2014 and own stock and/or stock options \u2014 in Biogen.", "answer": 0}, {"article": "Drs.\nUnsurprisingly, that difference wasn't seen in people who smoked tobacco.\nGrant R01 MH083671 from the National Institute of Mental Health funded this research.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\nSo for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "That\u2019s pretty well covered, with lots of information about Group Health and the grantors.", "answer": 1}, {"article": "\"I've been treating cocaine-addicted patients for something like 25 years, more, and I've never heard of anybody throwing away cocaine,\" says Dr. Charles Dackis of the University of Pennsylvania, who led a pilot study that suggested modafinil more than doubled addicts' chances of going cocaine-free for at least three weeks.\nBut for Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse, the narcolepsy medicine tops the list of promising potential therapies.\nWASHINGTON -- The hottest topic in cocaine addiction is another drug _ a medicine already sold to wake up narcoleptics.\nScientists are cautious: In a hunt spanning two decades, no one has found a medication to help treat cocaine addiction, and there's no guarantee that modafinil will pan out.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t mention any potential conflict of interest of the sources cited. Dr. Dackis is a hired speaker for Cephalon, maker of modafinil, though this is not mentioned in the news story. The disclosure is readily available in the source journal article. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cited one of the study\u2019s authors, but no independent source who might have expressed greater uncertainty about the significance of the study findings.", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nSonia Skarlatos, Ph.D and deputy director of the Division of Cardiovascular Sciences at the NIH\u2019s National Heart, Lung, and Blood Institute says this early research is very exciting and a move in the right direction.\nThis could change in the future if larger clinical trials and longer patient outcomes confirm the results of this early research published Monday in the journal The Lancet.\nFurther research will hopefully also help answer those questions, she says.\nThe study authors say based on these results, further research is warranted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have sought a little wider circle of independent experts. But we thought the reporter elicited good comments from Sonia Skarlatos, Ph.D and deputy director of the Division of Cardiovascular Sciences at the NIH\u2019s National Heart, Lung, and Blood Institute, which funded the study. We have to give an \u201cunsatisfactory\u201d here, though, because the story failed to mention the financial interest that the lead researcher has in the stem cell therapy. The press release for the study mentions this, as does a competing WebMD story.\n\u00a0", "answer": 0}, {"article": "Floaters become more prevalent with age and although most patients grow accustomed to them, many find them bothersome, and they can worsen visual quality.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nA limitation of the study was its small sample size and short follow-up period.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name any funders. ClinicalTrials.gov states that Ophthalmic Consultants of Boston sponsored the study. The journal article notes that neither coauthor had conflicts of interest.", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nResults are in the current online issue of Human Reproduction.\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nThe researchers also note that the overall generalizability of this work is limited because the study population may not be representative of the general population with regard to fecundability, and exercise habits may differ in women with prior miscarriage compared to those without.\nHowever, he adds, \"We were happy to be able to conduct research considering women having the most difficulty getting and staying pregnant, and to provide messages about common lifestyle factors they may be able to address.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study funders are listed on a sidebar on the EurekAlert! site, where the release is hosted. We encourage news releases to include funders and any conflicts of interest in the body of the release so that the information is carried over by news organizations or blogs running the release verbatim.\nThe published paper lists no conflicts of interest among the authors.", "answer": 1}, {"article": "According to the U.S. Centers for Disease Control and Prevention, high blood pressure affects 30 percent of American adults.\nMONDAY, Jan. 24, 2011 (HealthDay News) -- Doctors administering deep brain stimulation to control a patient's severe pain report that they discovered the treatment consistently lowered the man's hard-to-control high blood pressure.\n\"I think it's really interesting physiology,\" added Penn, noting that the results would need to be repeated multiple times before a therapy based on it could be developed.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story seeks out independent perspectives, it should have alerted readers to the fact that several authors\u00a0have received speaking honoraria and other financial support from companies that make DBS devices. According to coverage of the study at MedPageToday, these disclosures were included in the published article.\nWhile we can\u2019t award a satisfactory,\u00a0this story did a better\u00a0job than WebMD of talking with people who provided a less optimistic take on the implants. For example, the first independent quote in the WebMD story says, \u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain\u2026.\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure.\u201d That is much more supportive of the technology than the first quote in the HealthDay story, which says, \u201cIt\u2019s a really interesting paper. \u2026 I thought it was compelling, though single cases are always questionable\u201d to generalize.", "answer": 0}, {"article": "In a third type of weight-loss procedure, known as sleeve gastrectomy, surgeons remove part of the stomach.\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\nMore people in the bypass group had complications right after the surgery.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nAnd certain procedures may still be preferable for certain patient populations, added Roslin, such as bands for patients with lower BMI who don't have so many metabolic challenges.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert source and weaves his comments into the coverage nicely. Remarks from a second source would have been even better.", "answer": 1}, {"article": "Overall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\nBringing this program into the mainstream presents some challenges, however.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\nThe new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only person quoted in the story is the lead author of the study. It is always important to hear from at least one independent expert in order to put new\u00a0results the views of researchers into context. Without hearing from a dispassionate third party,\u00a0it is hard to know how important this new research actually is.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included at least one independent source, and we didn\u2019t detect any conflicts of interest that should have been disclosed. The story was heavy on positive patient anecdotes, which may not be reflective of the typical patient experience.", "answer": 1}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nThe SBRT study for prostate cancer was supported by a grant from the U.S. Department of Defense.\nUTSW is currently the only accredited site in Texas at which this spacer gel can be used.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\nAdditional UTSW researchers involved in the study include Dr. Yair Lotan, Professor of Urology and holder of the Helen J. and Robert S. Strauss Professorship in Urology, and Dr. Xian-Jin Xie, Professor of Clinical Science.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release provides the funding source (the U.S. Department of Defense) although it does not explicitly comment on the absence of conflict.", "answer": 1}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\nThe cause of PCOS is unknown and there is currently no cure for the condition.\nHaving tools that make diagnoses more accurate can reduce unnecessary treatment for otherwise healthy teenagers at a critical stage in their lives.\n\"Whether it's through counselling or medication, girls can manage their symptoms and decrease the risk of further complications such as fertility problems, hirsutism (excessive hair growth) and type-2 diabetes\".\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and conflicts of interest are not mentioned at all. Even when it\u2019s difficult to determine what any conflict of interest might be, it\u2019s important to note where funding for health studies came from.", "answer": 0}, {"article": "Watching her patients undergo bone marrow transplant ?\nGiving these cells when disease is in remission after transplant \"might actually be helping patients who have a high risk of relapsing to not relapse down the line,\" said Dr. Aude Chapuis, cancer physician and immunotherapy researcher at Fred Hutch, one of the study's leaders.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nShe co-leads this research with Greenberg and Dr. Dan Egan of Fred Hutch, the trial's principal investigator and the care provider for trial participants.\nChapuis's role in this trial is on the laboratory side of the research, ensuring the quality of the genetically engineered cell products and monitoring the activity of the cells after infusion.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release reports that funding came from the National Institutes of Health and from Juno Therapeutics. It says that one of the researchers is \u201ca scientific co-founder\u201d of Juno Therapeutics. So we will give the release a passing grade on this criterion. However, readers have to have sharp eyes to intuit that this disclosure means that the researcher owns part of the company and so stands to profit from any treatments that result from this work.", "answer": 1}, {"article": "The watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\n\"Rather, its technology has the potential to help Parkinson\u2019s patients manage symptoms that impede regular functions.\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Readers sorely need the voice of a scientific and medical expert or two, especially one who\u2019s well-versed in treatment methods for Parkinson\u2019s, to assess the concept of this watch and any related research that speaks to its novelty (or lack thereof).", "answer": 0}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nAnd right now, there is a way to go before most doctors will have those systems in place.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nOnly about 10 percent had a \u201cfully functional\u201d system that included extensive information on patients\u2019 medical history.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The comments from the author of the editorial that accompanied the journal article were helpful.", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nBut it will be some years before that approach is proven -- or not.\nBut specialists don't think that anymore.\nDuggal is not impressed with reported success rates.\n\"So I think people should take that message and go with it.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story finds experts on both sides of this issue and gives them each a reasonable amount of air time.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThere are no previously approved therapies for TRAPS or HIDS/MKD.\nApprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data.\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of funding or conflict of interest, but these don\u2019t (or shouldn\u2019t) apply to regulatory approvals. It\u2019s presumed that the studies will have been conducted by the company seeking approval.", "answer": 2}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were two apparently independent sources quoted.", "answer": 1}, {"article": "In addition, availability of a blood test for mTBI/concussion will likely reduce the CT scans performed on patients with concussion each year, potentially saving our health care system the cost of often unnecessary neuroimaging tests.\u201d\n\nAccording to the U.S. Centers for Disease Control and Prevention, in 2013 there were approximately 2.8 million TBI-related emergency department visits, hospitalizations and deaths in the U.S. Of these cases, TBI contributed to the deaths of nearly 50,000 people.\nTest results can be available within 3 to 4 hours.\n\u201cHelping to deliver innovative testing technologies that minimize health impacts to patients while still providing accurate and reliable results to inform appropriate evaluation and treatment is an FDA priority.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name study funders. ", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a good job talking with experts who recommend a cautious approach to the new therapies. There is no cheerleading in this piece.", "answer": 1}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\nWEDNESDAY, July 6, 2011 (HealthDay News) -- For the millions of Americans with chronic low back pain, a silver bullet to alleviate the condition has yet to be identified, a new study suggests.\n\"In short, no single therapy is better than another, although some individuals are likely to have more success with one therapy than another,\" said study author Sidney Rubinstein, a research fellow at VU University Medical Center in Amsterdam.\n\"With low back pain, there are many reasons people don't get better,\" added Perle, also a professor of clinical sciences in the College of Chiropractic at the University of Bridgeport in Connecticut.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did include expert commentary by a spokesman for the American Chiropractic Association. He offered reasonable and interesting comments.\nHowever, one could argue that a spokesman for a professional organization that is heavily involved in the provision of spinal manipulation is not a truly independent and impartial source. That spokesman might be viewed as having a conflict-of-interest in offering commentary on this topic. So it would have been useful for the article to include the views of another expert commentator as well.", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story does include a couple of independent sources, it could have done a better job identifying the connections between other sources and industry. The story does not tell readers that Dr. Judith Tsui is an advisor to the company developing the app she is studying. Another quoted source, Alain Litwin, appears to have received consulting fees from several pharmaceutical companies. The story does identify one proponent of smartphone apps, Dr. Richard Garfein, as a co-developer of an app.", "answer": 0}, {"article": "\"By using our novel nanochip technology, injured or compromised organs can be replaced.\nTNT doesn't require any laboratory-based procedures and may be implemented at the point of care.\nResearchers plan to start clinical trials next year to test this technology in humans, Sen said.\nThe procedure is also non-invasive.\nThe cargo is delivered by zapping the device with a small electrical charge that's barely felt by the patient.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the funders. The published research letter states researchers have no financial conflicts of interest.", "answer": 1}, {"article": "PITTSBURGH, June 2, 2016 - Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\nThe study received scientific advisement from UPMC and assistance with statistical analysis from epidemiologists at the University of Pittsburgh Graduate School of Public Health.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\nThis research was primarily funded by the Turkish Federation of Societies for Breast Diseases.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions who did the study and how it was funded.", "answer": 1}, {"article": "Grip strength was assessed using a handgrip dynamometer.\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThese associations persisted even after taking into account differences in other factors that can affect mortality or heart disease such as age, education level, employment status, physical activity level, and tobacco and alcohol use.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This rating is for a sin of omission. It does not appear that any conflicts were hidden, but all news releases should routinely report a summary of funding sources and disclosures.\nThe journal article reports funding sources for the study and lead authors. There are no competing interests reported. The maker of the dynamometer used does not appear to have played any role in the study. But even in cases like this, where it does not appear that there any funding or other conflicts of interest, news releases should routinely include some reference to funding and disclosures by researchers.", "answer": 0}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\nBerryhill explained how the implants function and their possible risks.\nNaberhaus also suffered from extreme hearing loss, a result of long-term exposure to loud noises.\nHe was nervous about this because, being left-handed, he favors his left ear and was worried that he wouldn't be able to do one of his favorite pastimes: talking on the telephone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites several sources: a patient; the patient\u2019s mother, teacher, and physician; and a commercial website. The story should have included a trusted independent source with expertise on the subject who had no personal or economic interest in this patient or his treatment. ", "answer": 0}, {"article": "Protons enter the body with a low radiation dose and stop at the tumor, matching its shape and volume or depth.\nThe study's primary endpoint was OS.\nThe study opened at MD Anderson in 2006; in this research, Chang and his colleague report on the study's five-year results.\nChang noted his study is not without limitations.\nVivek Verma, M.D., now at the University of Nebraska Medical Center, also contributed to the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of funding or conflicts of interest in this release.", "answer": 0}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nHe was cautious about possible wider applications, but said that if it was developed further, the device may someday be used to help people with severe cases of age-related macular degeneration, the leading cause of blindness in older people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote one presumed independent source, Robert Maclaren, a professor of Ophthalmology at Britain\u2019s Oxford University. In the above mentioned Medical Technology Alert, the manufacturer announced that Dr. Maclaren will be the lead investigator on a clinical study expected to enroll\u00a0six subjects to advance this same retinal implant technology. As a result, Dr. Maclaren can hardly be described as an independent expert. Overall, we felt that the story was missing a strong, independent analysis. Had the reporter talked with more researchers in the field or more clinicians, perhaps the story would have had a more thoughtful tone.", "answer": 0}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more about vaccines.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nT-cells are located in lymph nodes and blood, as well as in peripheral tissues such as skin and lung.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources \u2013 only quotes from a lead investigator in a news release. ", "answer": 0}, {"article": "\"The human body, even bone, can be stretched,\" he said.\nTHURSDAY, April 21, 2011 (HealthDay News) -- For men who believe size matters -- and that their penises don't measure up -- success can be found in certain non-surgical penile lengthening treatments, a new study analysis by Italian researchers contends.\nDr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said functional issues resulting from conditions such as birth defects or prostate cancer surgery may warrant penile surgery, but such cases are unusual.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\nStudy co-author Dr. Paolo Gontero said urologists are constantly approached by men concerned about their penis size, despite the fact that the majority are average, with a flaccid length of 1 to 4 inches.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses independent sources, and we applaud that. We wish that the second independent source quoted had not been a penile enhancement practitioner.\u00a0The story did not, however, note that the co-author of the study has conducted research for a European company that produces a penile traction device and is a member of the company\u2019s medical advisers (http://www.andromedical.com/medical-committee/committee-members/). This was not included in the conflict of\u00a0interest statement that\u00a0was published with the study,\u00a0but this is a reminder that reporters should perform basic\u00a0background checks when covering research and quoting experts.", "answer": 1}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nNow, there's new information showing how important folic acid is.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nBut a few small lessons now can turn out to be valuable later in life.\nYou can't see or smell it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no comments from experts in B vitamins or prenatal development.\u00a0 We really don't what sources were used.\u00a0 ", "answer": 0}, {"article": "Too much coffee may make it harder to conceive and can increase the risk of miscarriage.\nWe receive many comments on this blog each day; not all are posted.\nHowever, coffee alone may not be the answer according to some experts.\nOur hope is that much will be learned from the sharing of useful information and personal experiences based on the medical and health topics of the blog.\nThey looked at nine existing studies and analyzed how much coffee was consumed by more than 5,000 cancer patients and about 9,000 healthy people.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the researchers and two independent sources were interviewed \u2013 something WebMD didn\u2019t do. ", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\nIn addition, a pooled analysis of data from the ZOE-70 and ZOE-50 trials showed that the candidate vaccine effectively reduced the risk of subsequent chronic neuropathic pain, also known as postherpetic neuralgia (PHN)1 which is the most common, and often severe, complication of shingles3,4.\nBased on these and the previously reported ZOE-50 data2, GSK expects to start submitting regulatory applications for the candidate vaccine for the prevention of shingles in people 50 years and above later this year.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release was issued by GSK so it\u2019s assumed that GSK provided the funding for the study.\nThe release makes no mention of numerous potential conflicts of interest between the many researchers involved in the study and GSK. These include holding GSK stock, employment with GSK, serving on a GSK board, grant support, lecture fees, consulting fees, travel fees, honoraria, and royalties from a zoster vaccine patent. ", "answer": 0}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nThe study included only males between the ages of 7 and 28 because they were part of a bigger research project at the University of Utah, which is following males with autism for a longer period.\nBut she cautions that using this method as a true diagnostic tool to detect autism in a child is \"a long way off.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a far better job than the Reuters story in making use of independent sources. Both Carissa\u00a0Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine,\u00a0Zachary Warren, who is the director of the Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders (TRIAD), offered cautious views of the study.  ", "answer": 1}, {"article": ".\nStill, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\nFor the study, researchers at the Larner College of Medicine at the University of Vermont analyzed data on more than 16,000 Americans using the National Health and Nutritional Examination Survey (NHANES).\nThe authors say capsaicin also possesses antimicrobial properties that \u201cmay indirectly affect the host by altering the gut microbiota.\u201d\n\nThe research corroborates a 2015 study conducted in China and published in the BMJ that found regular consumption of spicy food is associated with a lower risk of death.\nThe research is observational, so no cause and effect relationship can be established.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites phrases\u00a0from the paper itself, but otherwise the study authors are not quoted. The only true quote is pulled from a 2015 CBS News story about another study in which eating spicy food is linked to lower risk of death; the quote comes from that study\u2019s author. No other\u00a0sources were quoted, which could have given the story much needed context.", "answer": 0}, {"article": "\"I would have bandages on me all the time.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\nIntense discomfort that interferes with activity is a common problem after bariatric surgery, says plastic surgeon Sarah Holland, an instructor at Columbia University Medical Center in New York -- and it can be almost constant.\nHe blamed the rise in do-over surgeries on increased demand for body contouring procedures and surgeons who \"lack adequate experience.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although several plastic surgeons appear to have been quoted for this story, the perspective from a bariatric surgeon or a weight loss surgery program would have been more balanced rather than speculation about what patients are or are not told about excess skin.", "answer": 0}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe microparticles are inserted using a catheter run through a pinhole-sized incision, in a procedure that lasts between 45 and 90 minutes, Bagla said.\nResearchers are already kicking off a second, larger trial to better understand how the procedure works and which patients it might benefit, Bagla said.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story stated that Boston Scientific, maker of the microparticles, funded the study.\nIt also had one independent source, Suresh Vedantham, MD, a professor of radiology and surgery at the Mallinckrodt Institute of Radiology at Washington University in St. Louis. We did not detect any conflicts of interest.", "answer": 1}, {"article": "The F.D.A.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nRobyn Karnauskas, a biotechnology analyst at Deutsche Bank, said in a note to clients Wednesday that the assessment of moderate evidence in support of Provenge boded well for reimbursement.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\nMedicare advisers will meet next Wednesday to discuss the drug, which was developed by Dendreon, a Seattle-based biotechnology company.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nAlthough the story uses excerpts of written statements from a financial analyst and the president of a cancer advocacy group, it does not include an independent source who addresses the scientific issues raised by the analysis of Provenge done for Medicare. The story does not tell readers that the cancer advocacy group it cites receives support from and promotes its services to health care corporations, including pharmaceutical companies.\n", "answer": 0}, {"article": "LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\n\u201cOne of the big questions is ... will those persistent T-cells continue to work and prevent that tumor from coming back,\u201d said Urba, who was not involved in the study.\nThe treatment appears safe, but researchers said more study was needed.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both stories cited just one outside source. The Reuters story, though, did a superior job here by quoting someone who had some words of caution. Dr. Walter Urba of the Providence Cancer Center in Portland warned that \u201cthe long-term viability of the treatment is still unknown.\u201d", "answer": 1}, {"article": "Men and women are equally affected, and age does not appear to affect prognosis.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\n\u201cObviously, a randomized trial cannot address that question.\nThe paper was published last week in The Cochrane Library, a journal devoted to systematic reviews of health care interventions.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job of putting the results of this study in perspective by interviewing experts in the field of addiction treatment and research. ", "answer": 1}, {"article": "In the first study, published Monday in the journal Cancer Epidemiology, Biomarkers and Prevention, scientists found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing prostate cancer, compared with other men.\n\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nThat\u2019s what the findings of two new studies published this week suggest.\nThe patients\u2019 average age at diagnosis was 65.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert source was cited to comment on either finding.", "answer": 0}, {"article": "Veterans who received this pain-focused care while also being treated for addiction found that the intensity of their pain decreased, their ability to function increased, and their alcohol use went down, compared to veterans who received a less-focused approach.\nThe larger ongoing study, based in an abstinence-based treatment facility in Michigan and funded by the National Institute on Drug Abuse, has largely avoided that issue by decreasing the delay between study recruitment and the start of the treatment groups, Ilgen says.\nAnd while existing prescription guidelines do not explicitly prohibit the use of opioid painkillers in people with pain who have substance use disorders, these guidelines recommend only using opioids sparingly and under close supervision, he says.\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly identified. And while the release does not address conflicts of interest, there do not appear to be any conflicts of interest to address.", "answer": 1}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n\u201cDon\u2019t get me wrong \u2014 I really want it to work,\u201d said Dr. Senna, who also teaches at Harvard Medical School.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a dermatologist and researcher from Massachusetts General Hospital, who says she\u2019s unable to recommend the product to patients because of a lack of data. Given the extensive commitment involved, including nightly applications of six hours, input from a patient who didn\u2019t achieve hair growth from this product would have been a great addition to this story.", "answer": 1}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\n\u201cHe\u2019s very philosophic about it, but he\u2019s a scientist, and his motivation is to help the science,\u201d Dr. Tuddenham said.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an editorial writer calling the trial \u201ca landmark study.\u201d\u00a0 But that editorial writer had much more to say in that editorial \u2013 including raising specific concerns on potential harms.\nThe one independent expert quoted only called it a \u201cterrific advance\u201d but wasn\u2019t quoted giving a specific analysis of the research \u2013 what it means or what it may not mean.\nA second external voice was included \u2013 but that was a researcher who, although a competitor, was nonetheless listed as a co-author of the paper because her lab helped monitor the patients.", "answer": 1}, {"article": "Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Alternative and Complementary Therapies, Medical Acupuncture, and Journal of Medicinal Food.\nThe article is available free on the JACM website until July 19, 2017.\nComplete tables of content and a sample issue may be viewed on the JACM website.\nA complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the work. In this case, the work was funded by Autism Speaks. Many people have strong feelings about Autism Speaks, one way or the other, making the funding organization particularly worth mentioning here. It also doesn\u2019t mention any conflicts of interest but there don\u2019t appear to be any.", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\n\u201cIt should not be permitted by the F.D.A.\u201d\n\nTechnically, it is not.\nIt also warned that women who are pregnant or trying to conceive should avoid melatonin \u201cbased on possible hormonal effects.\u201d (Drank\u2019s bottle now say it is a dietary supplement.)\n\u201cFor me, it\u2019s not to chill.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent experts \u2013 independent of the product manufacturers \u2013 were quoted.", "answer": 1}, {"article": "The test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\nResearchers hope the test will become part of a \u201cuniversal screening\u201d tool that doctors can use to detect cancer in patients.\nProf Nicholas Turner from the Institute of Cancer Research in London described the findings as really exciting and as a possible universal screening tool.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t disclose that the researchers had significant conflicts of interest. (See disclosures.)", "answer": 0}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nIn fact, there's enough research that the Cochrane Collaboration was able to put together a review of the evidence.\nAnd while he claims that Livia is more effective at treating period pain than the cheaper, already available TENS units (he said \"its frequency and wave shape are unique and optimized especially for relieving menstrual pain\"), without publicly available studies comparing the two, all we have to go on is his word.\nAs far as gadgetry for women's health goes, this one is novel.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The comments from an\u00a0independent expert\u00a0help ground the claims made by the company CEO.\u00a0The outside source is the key to balance in this article.", "answer": 1}, {"article": "Andrew Keaveney, now 73, shattered his ankle in a fall from a truck while hanging flags as an American Legion volunteer.\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\n\u201cBut I can\u2019t tell you how many patients come in, and I mention this option they don\u2019t even know exists.\u201d (Dr. Radnay, who says he has performed more than 100 ankle replacements using an Inbone device from Wright Medical Group of Arlington, Tenn., is now a paid consultant to the company, helping to gather data on long-term success rates.)\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nThough the four devices in common use have technical differences in design and in how they are implanted, doctors say the choice of device matters far less than the experience of the surgeon.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly indicates that all of the experts interviewed had ties to manufacturers of the joint implants.\u00a0 While this may be expected due to the relatively small number of surgeons who perform this procedure, this is a clear example of conflict of interest.\u00a0 The story should have included comment from an independent unconflicted surgeon or referring physician (non-surgeon) with no stake in this.\u00a0 Disclosure is one thing; providing balance is quite another. ", "answer": 0}, {"article": "Parkinson's disease is a neurological disorder that can cause tremors, stiffness, slowness of movement, trouble balancing, problems walking and difficulty coordinating movement.\n\"A lot of time, people come in and say they or a family member has a tremor, and they believe it's Parkinson's disease,\" said Wright, who also was not involved in the study.\nSpecialists and sub-specialists are available only in big cities, Wright said, and access to a simple blood test would enable a correct diagnosis in a primary care office.\nNon-specialists \"do not really know exactly what questions to ask the patient and the special signs to look for,\" Hansson wrote in an email.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included two independent sources not connected with the research.\nHowever, several of the authors in the study had connections to companies that work on this kind of test, and that wasn\u2019t disclosed in the story.", "answer": 0}, {"article": "Cocoa flavanols refers to the group of bioactives found naturally in fresh cocoa beans.\nThis second study just published in the AJCN looked to address this question.\nNote to Editors: This research trial was carried out with a special cocoa flavanol test product, designed to deliver a standardized amount of flavanols within a nutritionally suitable drink.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nThis test product is currently not commercially available.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release was issued by Mars Inc., and it says high up, \u201cThis study, conducted by researchers from Italy\u2019s University of L\u2019Aquila and Mars, Incorporated\u201d. While the release references Mars throughout, and we don\u2019t think any reporter would be confused about who was behind the study, the release could have stated directly that Mars funded the study.", "answer": 1}, {"article": "[3] Yokell et al.\nWe believe patients and caregivers are the experts on how their medical condition impacts their lives, and are an integral part of our product development process.\nOur mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions.\n[9] Most life-threatening OIRD emergencies occur in the home and are witnessed by family and friends who may be in the best position to intervene quickly.\n[6],[7],[8] Seconds count when a life-threatening OIRD event occurs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "If a news release is going to quote the president and CEO of the company that makes the drug, readers can assume he has a financial interest in his statements.\nBut they are left to wonder about the quotes from health professionals. It might have been a good idea to point out whether they, too, have a financial stake in their statements. If they do not, letting the reader know that might have made their statements appear more persuasive.\nBut since we don\u2019t have specific evidence of a conflict of interest among any of the quoted sources, we\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\nWhat often makes the difference in whether or not a diet is successful, she said, is whether or not there's a counseling and support component to the plan.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nMONDAY, Jan. 25, 2010 (HealthDay News) -- A low-carbohydrate diet helps people shed as many pounds as a low-fat diet plus the weight-loss drug orlistat does, and the low-carb plan may be better at helping lower blood pressure, researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not mention that two of the researchers on the study have received funding from the Robert C. Atkins Foundation, which promotes research on low-carb diets and is associated\u00a0with the Atkins diet books and products. The story\u00a0did include comments from an independent dietitian,\u00a0which is a strength, but this isn\u2019t\u00a0enough to overcome the omission.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not contain any independent sources. Also, it quotes Dr. Susan M. Domchek at the University of Pennsylvania\u2019s Abramson Cancer Center without stating her institution\u2019s role in the clinical trial.", "answer": 0}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nResearch reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) award CE12-11-4667.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\n\u201cPatients who were treated with surgery or radiation had side effects, while those who were managed with active surveillance, for the most part, did quite well,\u201d Barocas said.\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the grant sources for the research. It would have been better if the release had also stated (as the study did) that there were no conflicts of interest among the authors.", "answer": 1}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nThe drug could be a good option for some people, but it's most likely not a silver bullet, said Dr. Melina Jampolis, CNNHealth's physician nutrition expert, who is not connected with the study.\nAmong the 2,487 study participants, nine became pregnant, and none of their children were born with cleft palates, the report said.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to \u201cDr. Melina Jampolis,\u00a0 CNNHealth\u2019s physician nutrition expert, who is not connected with the study.\u201d\u00a0 We wish the story had given us some background on her expertise.\nIt also stated that \u201cThe study was funded by the pharmaceutical company Vivus.\u201d", "answer": 1}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\nIn fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\nCritics claim Weinstein's studies are flawed because some patients, like Susan, decided to have surgery, even though she had been in the group that wasn't going to be operated on.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the study's lead author. The story should have quoted other clinicians/researchers who could have provided other perspectives.", "answer": 0}, {"article": "Some research has suggested a link between lower levels of insulin in cerebrospinal fluid and the formation of plaques often found in the brain tissue of people with Alzheimer\u2019s.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nFIND THIS STUDY February issue of the Journal of Alzheimer\u2019s Disease (www.j-alz.com).\n3 (in press)\u201d and search for \u201cinsulin.\u201d\n\nLEARN MORE ABOUT dementia at ninds.nih.gov/disorders and www.familydoctor.org.\nAnyone considering changing or beginning treatment of any kind should consult with a physician.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We give the story credit for recommending that readers go to two independent sources for more information about dementia:\u00a0ninds.nih.gov/disorders\u00a0and\u00a0www.familydoctor.org. However, we think that all health stories could use some perspective \u2014 in the text of the actual story \u2014 from an independent expert. We realize that a 300-word column like this may never meet our standard here. But we\u2019ll continue hold out for that ideal.", "answer": 0}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes representatives from the drug company. The story should have quoted other, independent researchers or clinicians who could have provided additional perspectives.", "answer": 0}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\nFirst responders asked Reisch to smile and immediately recognized his drooping mouth as a sign of a stroke.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources were included, but the story missed an important detail about conflicts of interest: The study was funded by Medtronic, the maker of the device used in the study. \u00a0This detail was easy to find in the published paper about the study, which also provided a list of all the conflicts of interest declared by all the authors.", "answer": 0}, {"article": "About 8% and 18% of Serada users reported daytime sleepiness and dizziness, respectively, compared to about 3% and 8% of women who took a placebo.\n\u201cEstrogen and estrogen-progestin drugs are about 95% effective for treating hot flashes,\u201d he tells WebMD.\nUtian is now an independent consultant and was a co-author of one of the studies.\n\u201cThese side effects, when they did occur, tended to occur early in treatment and disappear within a few weeks,\u201d Sweeney says.\nThe study was presented in Chicago at the annual meeting of the North American Menopause Society (NAMS).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article is up-front about where this information is coming from and the potential conflicts the sources may have. Still, the story relies heavily on comments from company representatives or researchers involved with the study. The only comment from a truly independent observer doesn\u2019t address the research itself and is about the general need for non-hormonal treatments for hot flashes.\u00a0A close one, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\n\u201cNo one medication works for all patients suffering from chronic gastrointestinal disorders,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nParticipants were randomly assigned to receive a placebo or Trulance, once daily.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release notes that Synergy Pharmaceuticals Inc. makes the new drug, it does not say where the clinical trial results were published or what groups supported or carried out the research.", "answer": 0}, {"article": "For example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\n\"Quitting smoking is one of the simplest ways to improve global public health, but as the dismal efficacy of current therapies demonstrates, it is also one of the hardest.\nOur goal is to solve this crisis of public health with an innovative, integrated smoking cessation solution, and the data we presented demonstrates that we are on the right path.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the news release is fairly clear that Chronos Therapeutics is the main funder of the clinical trial, it fails to mention that the company had received a study grant from the National Institutes of Health. That\u2019s noted on the study abstract. Further, the release quotes only company executives \u2014 the CEO and a member of the board of directors. While we don\u2019t expect a news release to consult an independent source as we would a news story, we\u2019d like to point out that typically, a scientist involved with the research lends more credibility when reporting results.", "answer": 0}, {"article": "Pain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\nThe study was conducted by researchers from London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario; Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta; and Children's Hospital of Wisconsin, Milwaukee, Wisconsin.\n\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "On EurekAlert!, where the release is hosted, it\u2019s noted that the research was funded by Western University. We encourage news releases to include funders in the body of the release as well. The original study reports no conflict of interest.", "answer": 1}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nThe great lengths to which the researchers of the Circulation study went to make their trial scientifically rigorous, however, should reinforce the results in the eyes of some skeptics.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nStudies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nMost doctors say meditation can't hurt you, but now there's reassuring evidence that it may help you as well when it comes to warding off disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only interview source for this story one of the study authors, Dr. Robert Schneider.\u00a0Considering that Dr. Schneider works at an institution\u00a0founded by the creator of transcendental meditation (Maharishi College of Perfect Health), his objectivity on this issue is certainly open to question.\u00a0The story could have addressed any\u00a0concerns about\u00a0objectivity by balancing Dr. Schneider\u2019s\u00a0comments with those\u00a0from an independent cardiology expert.", "answer": 0}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\nA pilot study was funded by Diabetes Research and Wellness Foundation and the extended study was financially supported by the Diabetes Research Fund in Gateshead.\nShe believes this new research is a major development in understanding the best ways to further improve treatment in Type 1 diabetes.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions that the study was funded by the Diabetes Research and Wellness Foundation and the Diabetes Research Fund in Gateshead. Neither the news release or published study address potential conflicts of interest. The funding foundation lists only its board of directors and no background information on the group is readily available.", "answer": 1}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nThe addition of apples to the diet probably kept the women feeling fuller because of the fiber content in the apples, she explained.\nTUESDAY, April 12, 2011 (HealthDay News) -- Eating apples every day may be good for your cardiovascular health, new research suggests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story credit for seeking the input from an independent clinical nutritionist, although she apparently only had a news release and/or an abstract to comment on \u2013 which is incomplete basis for comment much less a story.", "answer": 1}, {"article": ".\nEditor's Note: The study authors' and editorial commentary authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests are available in the study and the commentary, which are embargoed until 12:01 a.m. EST on Thursday, Feb. 4.\n\"Overall, considering the accumulating evidence of fetal benefit and safety, influenza vaccination of pregnant and postpartum women should be a public health priority in accordance with national recommendations,\" the commentary authors wrote.\n\"All pregnant women should receive annual influenza vaccination to prevent influenza and associated complications for themselves and their infants,\" the study authors wrote.\n\"Treating pregnant women who have influenza with antiviral drugs can have substantial benefit in terms of reducing length of stay in the hospital,\" said Sandra S. Chaves, MD, MSc, of the Centers for Disease Control and Prevention (CDC) and senior author of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t articulate funding sources or conflicts of interest. We have to assume the study was sponsored by the CDC because the lead author quoted works there. We are sometimes surprised when a news release fails to mention that there were no conflicts of interest. This is important information, and can only improve one\u2019s perception of the research. Why not mention it? When we looked at the published study we read that the study authors have no conflicts to declare.", "answer": 0}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nManson and her colleagues are launching such a trial.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\nThe evidence is strongest for colorectal cancer, she says.\nNeither study subjects nor investigators will know until the end which regimen they are on.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Several respected experts in the field of vitamin D research and the epidemiology of disease were quoted for this story.", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nFor some it's a moderate situation, but for others it's a really significant problem.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n\"And I've actually had patients who have had acupuncture with good success, so I'm not surprised by the finding,\" she added.\nThe finding continued to hold up for a half-year after the acupuncture sessions ended.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite one independent source, and there don\u2019t appear to be any conflicts of interest.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nHalf of them received traditional acupuncture treatment.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one was quoted.\u00a0 No independent expert evaluation.", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nThere are important limitations to the study, Adesman said.\nHirsch noted the study is preliminary and, as such, has some limitations.\nFurther work is needed to refine the test, Hirsch added.\nThis test costs no more than a standard MRI, which runs around $1,500, Hirsch noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "HealthDay continues its laudable tradition of listing the story\u2019s sources at the end of the piece.. We thought the quotes from independent experts were great and provided some strong context.", "answer": 1}, {"article": "Patients had nine weekly treatments, each session lasting 20 minutes.\n\"Although it was allowed for the participants to continue with the pharmacological [drug] treatment they were taking beforehand, when the study was finished, the patients who received individualized acupuncture were taking less medication than the group on sham acupuncture,\" Vas said.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nOne year after treatment, acupuncture patients had an average 20 percent drop in their pain score, compared with a little more than 6 percent among those who had simulated therapy, the researchers found.\nStill, Shrikhande said, \"the findings in this study help demonstrate that acupuncture is a safe and effective treatment for chronic pain patients.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes\u00a0experts other than those conducting the research, as well as providing additional information from other sources. One of the quoted experts appears not to be an acupuncturist, which is good.\nThe story does not mention any potential conflicts of interest but the research paper itself states there were no conflicts. Readers might have benefited, however, from knowing the funding source for this research, which was The Spanish Ministry of Health and Consumer Affairs and the Andalusian Public Health System, two public agencies.", "answer": 1}, {"article": "Consumers have been advised to swap saturated (animal) fats \u2014 found in foods like whole milk, cheese, butter, and fatty cuts of beef and pork \u2014 for unsaturated vegetables oils.\nA new study suggests the answer may be no.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nHow does this translate to what we eat every day?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There don\u2019t appear to be any conflicts of interest, and the story includes an independent source.", "answer": 1}, {"article": "The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more on rheumatoid arthritis.\n\"This actually isn't a new concept.\n\"We would also remind patients to observe recommended government limits for alcohol consumption,\" he added.\n\"There are limitations to any research which asks patients to report their exposure to something (such as alcohol) over a period of time,\" Maxwell added.\nBecause the researchers assessed drinking frequency, rather than the amount of alcohol consumed, it is not clear how much alcohol might be helpful, they said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One apparently independent expert was quoted. \u00a0 We weren\u2019t told why he was quoted or whether he was involved in the research. But he\u2019s not listed as an author of the study, so we\u2019ll give the story the benefit of the doubt \u2013 by a hair.\u00a0 ", "answer": 1}, {"article": "The results have not previously been published or presented.\nThis presentation outlines the results from two recently completed phase III trials (TESEC-05 and -06).\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nIn the second double-blinded trial, researchers were primarily concerned with testing how accurate C-Tb was in HIV-positive patients and in young children--populations in which the accuracy of the TST and the IGRA is known to be compromised.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Unfortunately, the release offers no information on either funding sources for these trials or on any possible conflicts of interest that might affect the researchers.", "answer": 0}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nHer report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nThe study showed there was no need for the procedure.\nAn expert not involved in the research, Dr. Steven E. Nissen, chairman of cardiovascular medicine at the Cleveland Clinic and president of the American College of Cardiology, said the study was independent and well conducted.\nIf anything, those who had angioplasty seemed to fare a bit worse than those who did not, but the differences were not statistically significant and might have been because of chance, Dr. Hochman said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The first author of the study discussed, the director of the NIH institute funding the study, and an expert in the field not associated with the study all appeared to be sources of information for this story.", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nThe Menlo Park, California-based company\u2019s shares were up 3 percent at $33.00 in extended trading on Wednesday.\nDermira said it had expected to apply for marketing approval for the drug in the second half of 2017, subject to completion of the drug\u2019s long-term safety trial.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nBased on the most recent estimates, about 7.8 million Americans have some form of excessive sweating including palms, feet, underarms or head, and about half of this population suffer from the underarm form, said Dermira spokeswoman Erica Jefferson, in an interview ahead of the data readout.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A spokesperson from the company is quoted. However,\u00a0no independent sources are used.", "answer": 0}, {"article": "No randomized, controlled study has assessed the risks for serious events like heart attacks, kidney failure and gastrointestinal bleeding, but other types of studies have found no association between topical Nsaids and these serious risk factors.\n\u201cFuture research needs to be done using patients with co-morbidities to know that these agents are safe in the highest-risk population,\u201d said the author of the analysis, Dr. Una Makris, an associate research scientist at the Yale School of Medicine.\nAnd some, including Vioxx and Bextra, were taken off the market after they were linked to heart attacks and strokes.\n\u201cI think many people are not aware of topical Nsaids, or there is a perception that they don\u2019t work well, or people confuse topical Nsaids with other topical drugs, like the topical salicylates or capsaicin,\u201d Dr. Chou said.\nThe topical painkillers are not for everyone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes quotes from several experts and points out that two of them have accepted consulting fees or research support from pharmaceutical companies.", "answer": 1}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\nAnd for this, patients should do their part.\nBoth groups could do things to improve the detection rate, they said.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes two independent sources to great effect. Without their commentary, readers might be inclined to doubt the results of their colonscopies or seek repeated screenings beyond the recommended schedule. In a short amount of space, this story was able to bring in some valuable perspective on an important study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although several sources are quoted, all of them have some connection to organ swapping and all of them praise it. It\u2019s not clear if the reporter sought any independent opinion from physicians not directly tied to organ-swapping transplant efforts. The story does not obtain any perspective from someone who may think organ swapping may violate current laws, which is the reason stated for needing clarifying legislature. ", "answer": 0}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nThe study was funded by the National Institutes for Health.\nResearchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not cite any independent sources, nor does it note that two of the study co-authors have ties to pharmaceutical companies \u2014 including a company that focuses on an oral testosterone replacement therapy.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A daily dose of electricity delivered to a specific part of the brain can lift depression, new research confirms, even for people who\u2019ve already tried multiple antidepressants to no avail.\nThe biggest issue with studies so far, he explained, has been that it\u2019s tough to fake the sound and sensation of the real device in order to run a gold standard clinical trial in which some people get the treatment, and others get a sham treatment, no one knowing which.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nIn a second phase of the study, all patients were given the real TMS treatment.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the story relied on a single source who was also lead investigator on the study being covered.\u00a0 It failed to note that this source has received research grants from, and is an advisor to,\u00a0several different companies involved in the manufacture of TMS-related technology. To avoid the appearance of any conflict of interest, the article should have disclosed these ties.", "answer": 0}, {"article": "Attention, memory, and language improved.\nThe researchers stress that research in this area is important due to the expected extensive population aging over the next 20-30 years.\n\"I would therefore recommend people to try to adhere or switch to a MedDiet, even at an older age,\" Hardman added.\n\"The most surprising result was that the positive effects were found in countries around the whole world.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the published study indicates that none of the principal investigators received funding to conduct this study, presumably minimizing conflicts of interest, the news release doesn\u2019t address these issues. That\u2019s unfortunate, since the investigators\u2019 independence would be\u00a0a strength of the study.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from only two physicians, the lead researcher and the author of a related editorial.\u00a0\nThat is not sufficient for a story of this importance and length.\u00a0 \nAt minimum, an experienced OB with no connection to the study should have been consulted.\u00a0 ", "answer": 0}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story does not include comments from any independent sources. The lack of perspective deprives readers of the context needed to appreciate what this study says\u2026 and does not say. Since the researchers are employees of federal agencies, not associated with the supplement or food industries, and they reported no financial disclosure, it is of less concern that the story does not address potential conflicts of interest.", "answer": 0}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several sources interviewed for the story. However, the one independent source\u2019s insight was greatly overwhelmed by the personal anecdotes without critical evaluation of their statements. Nonetheless, because there was independent perspective, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story gets valuable input from a clinical neuropsychologist from the Mayo Clinic who was not involved in the research. It also notes the role of the California Walnut Commission in funding some of Dr. Ros\u2019 previous work. We\u2019ll call that good enough for a Satisfactory rating, but we\u2019d note that the donation of nuts and olive oil by commercial concerns in this study is more than a trivial contribution. The acknowledgment of that donation is buried in the original paper under \u201cAdditional Contributions,\u201d below mention of the statistics analyst. We think that contribution deserved a more prominent acknowledgment than either the original study or this story gave to it.", "answer": 1}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0had several independent sources but it didn\u2019t disclose at least one important relationship.\nIt said \u201cDr. Sam Gandy\u2026is not affiliated with Neurotrope.\u201d However, he has worked as a consultant for them, as the \u201cindustry relationships\u201d section of his bio explains.\nUpdate 5/4/2017: STAT has issued a correction at the bottom of their story: \u201cThis story has been corrected to say that Dr. Sam Gandy consults for Neurotrope.\u201d", "answer": 0}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\n\"The uniqueness of this study is that each of the 33 participants consumed both diets,\" said Kirwan.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\nThis research shows that eating whole grains reduces the risk of heart disease,\" said John Kirwan, Ph.D., principal investigator and director of the Metabolic Translational Research Center, which is part of Cleveland Clinic's Endocrinology & Metabolism Institute.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funders of this research as both the National Institutes of Health and the\u00a0Nestl\u00e9 Corporation and points out that\u00a0Solon and Cereal Partners Worldwide provided \u201cthe study meals and foods.\u201d However, it does not mention, as the published study does, that three of the authors work for Nestl\u00e9.", "answer": 0}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nWe've agreed to use only his middle name; disclosing his trouble with alcohol publicly, he says, would jeopardize his business.\nBut they are substantially underused, according to the review.\nHe worked from home, so he was able to mask the problem for a while.\nHe has not stopped drinking completely, but says he has cut way back.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a number of independent sources, and we could detect no potential conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nA larger study of vaginal microbial transfer is underway at N.Y.U., Dr. Dominguez-Bello said.\nAnal samples from the swabbed group, oddly, contained the highest abundance of bacteria usually found in the mouth.\nThe small proof-of-principle study suggests a new way to inoculate babies, said Dr. Maria Gloria Dominguez-Bello, an associate professor of medicine at New York University and lead author of the report, published on Monday in Nature Medicine.\nThe results show the complexity of labor, said Dr. Alexander Khoruts, a microbial expert and associate professor of medicine at the University of Minnesota.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes several outside sources with the comments of Drs. Gilbert and\u00a0Khoruts.", "answer": 1}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nAnd so far, patients on the experimental treatments report limited side effects that consist mostly of pain at the injection site.\nHe has good reason to be: Each of the therapies decreases migraine frequency by at least one to two days per month.\nAt that price, Mauskop and other neurologists expect insurance companies to require patients to have tried just about everything else first.\nRight now, the longest patients have been on one of these new therapies is one to two years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two physicians who don\u2019t appear to have interests in promoting these treatments are quoted.", "answer": 1}, {"article": "The caveat is that VX-770 is designed to counter one specific genetic mutation that accounts for about 4 percent of cases of cystic fibrosis.\nmay have a profound effect on the disease.\u2019\u2019\nMany do not live past age 40.\nShe said other results of the trial were encouraging.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "\"I could ride a bike!\nAt a week old, doctors amputated his dead forearm and hand.\nHe expects to get fitted with his new arm later this month.\nComprehensive statistics aren't available for the number of children with amputations, such as Wyatt.\nEach electronic limb takes about 30 to 50 hours to make and assemble.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources. Everyone quoted is involved in some way with the printing of 3-D prosthetics.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding sources are mentioned in the news release regarding the DigniCap clinical study. We find this problematic, since the makers of DigniCap collaborated with Target Health, a clinical research organization (CRO), to conduct the clinical trial and prepare the FDA application.\nAccording to its website, Target Health is\u00a0a privately held, New York City-based full-service contract research organization (CRO) committed to serving the pharmaceutical community with knowledge regarding regulatory affairs, clinical research, biostatistics, data management and Internet-based clinical trials.\nAs a result, we rate this Not Satisfactory.", "answer": 0}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nTwo experts agreed that early intervention is key.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\n\"Research has shown that subtle markers of autism are identifiable in the first year of life,\" explained Dr. Ron Marino, associate chair of pediatrics at Winthrop-University Hospital in Mineola, N.Y. \"Video feedback seems like a natural and potentially very potent extension of intervention when it can be most effective,\" he added.\nHe was cautiously optimistic about the promise of the video feedback approach.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We commend the story for including interviews with the lead author of the study as well as two experts who appeared to be unaffiliated with the research. However, only a sentence would have been needed to alert readers to the fact that the funders of the research included autism advocacy groups.", "answer": 0}, {"article": "In 1917, two German inventors first used pressurized pure oxygen to treat decompression sickness, which occurs when undersea divers return to the surface too quickly.\nEfrati agreed that hyperbaric treatment requires more research.\nBut we are seeing the results with our patients.\nSince then, he said, he has treated about a half-dozen brain-injury patients, with mostly positive results.\nTwo years ago, he became chief medical officer for Hyperheal Hyperbarics, a company with three clinics in the Baltimore area.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It should have been made more clear that the research supporting positive outcomes \u2014 as well as the two glowing anecdotes \u2014 came from physicians who run hyperbaric therapy clinics.\nHaving said that, we appreciated the inclusion of Dr. Cifu\u2019s skepticism, as well as the cautionary last paragraph regarding anecdotes, and that more research is clearly needed in this area.", "answer": 0}, {"article": "It describes circulating tumor cells as cancer cells that have detached from a tumor and are found at very low levels in the bloodstream.\n\"We have developed and continue to develop a broad range of technologies that are evolving what we know about cancer and cancer care.\"\n\"It is appropriate to view announcements such as the one today with enthusiasm, but recognize that we must temper that excitement with the realization that there is still much research to be done to determine the true impact of this test on the treatment of patients with cancer.\"\nIt has the potential to turn cancer into a chronic disease, because we can monitor patients individually and respond with treatment to the genetic makeup of their cancer.\"\nThe American Cancer Society said the new research is exciting, but it's important to remember it's just another step in the scientific process.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Too much of the story comes from conflicted sources.\u00a0 There is input from Dr. Len Lichtenfeld of the American Cancer Society at the very end.\u00a0 But the story fails to mention that the American Cancer Society has supported research in this area.\u00a0 And the story didn\u2019t even include the much stronger types of comments Lichtenfeld made on his own blog, such as:\u00a0\n\u201c\u2026this is an announcement of a research deal.\u00a0 Nothing more, nothing less.\u00a0 It is not a new breakthrough. It is not something that has been proven effective in improving cancer detection and treatment.\u00a0 Not that it is anything less than stunning to develop and demonstrate that this technology works \u2013 but as with all research it is a giant step to go successfully from the laboratory phase of development to the clinical phase of making a real difference in patients\u2019 lives. So that in essence is what the fuss is all about: the researchers have signed a contract with a company to further develop this research and determine whether in fact it can be applied successfully to large numbers of patients in a more efficient and less expensive manner.\u201d  ", "answer": 0}, {"article": "\u201cOnce again pregnant women are being told it\u2019s O.K.\n\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\nBoth reports have come under criticism from environmental groups and from the Consumers Union.\nThe two studies, which conflict in important aspects, seem unlikely to provide much clarity.\nDr. Mozaffarian agreed that, because the evidence is based on observational studies and clinical trial data, it is not definitive, but he added, \u201cIt\u2019s the best evidence we have.\u201d As for the study\u2019s finding that total mortality could be cut by 17 percent, he said, \u201cWhile one can argue over the precise size of benefits, even if the benefit is only one-half or one-quarter as large, it still greatly outweighs the risk.\u201d\n\nThe report from the Institute of Medicine tells the government that much more research is needed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites an array of scientific experts, regulatory authorities, industry sources, and representatives of various advocacy groups. It also provides sufficient information to determine their potential conflicts of interest.", "answer": 1}, {"article": "Over the last decade, the makers of medical devices have developed techniques that have widened diabetes management options beyond pricking the finger several times a day to test blood glucose levels.\nDr. Renard, whose commentary accompanied the study in The Lancet, has been a consultant and speaker for several makers of diabetic products, he said.\nDr. Hovorka, a principal research associate in pediatrics at Cambridge, said he had been a consultant or speaker for several makers of diabetes products.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes\u00a0from interviews with one of the study investigators and another researcher, and identifies both as having ties to diabetes products manufacturers. It also quotes an analyst at an investment firm. It would have been better had they\u00a0included one more source who didn\u2019t have commercial ties to specific products.\u00a0 ", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nBut let\u2019s say you take heart in the first of these studies and now believe that avoiding gluten will make some people feel better even though they don\u2019t have an allergy or celiac disease.\nFor those of you keeping track at home, that means that while 30 percent of Americans are trying to cut gluten from their diet, probably at most only 1 percent of Americans may have NCGS.\nIf you think avoiding gluten will make you feel better, there is a reasonable chance that it will \u2014 even if gluten is irrelevant.\nRegardless of the reason, we are left with little convincing evidence that gluten avoidance matters.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story offers an excellent overview of the literature on NCGS and gluten-free diets, but includes no input from sources other than the author \u2014 an economist who has done extensive work on the economics of health-related issues. We think the story stands up pretty well without that independent perspective, but it certainly couldn\u2019t hurt, and would likely have helped, to hear from experts in related health fields, such as a nutritionist or gastroenterologist.", "answer": 0}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are quoted. An expert would likely have emphasized the limitations of a study like this.", "answer": 0}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\n\u201cThat said, there is not enough evidence to date to fully suggest the use of bright light therapy to avoid collision,\u201d Griffin added by email.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\n\u201cThere is evidence that the use of bright light at the office (or even at home directly prior to beginning the work shift) may be beneficial in preventing sleep deprivation-related motor vehicle collisions,\u201d said Russell Griffin, a researcher at the University of Alabama at Birmingham who wasn\u2019t involved in the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strong point of this story is how sources in the story are clearly identified as aligned with or independent of the study, and there were several of them. \u00a0We could find no potential conflicts of interest with the researcher who was interviewed.", "answer": 1}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cFrom my interactions with colleagues from across the globe, I do not believe that what we have observed is Australian-specific,\u201d she told Reuters Health by email.\nThe findings may be applicable to other countries, too, according to senior author Dr. Susan R. Davis from Monash University in Melbourne.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from an independent expert, but it doesn\u2019t note that the lead study author is a paid consultant to a company that makes an estrogen therapy. (See the disclosure in this recent Medscape article she co-authored.)", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\nHere, the researchers, from Kashan University of Medical Sciences, Kashan, and Islamic Azad University, Tehran, Iran, present results from a randomized, double-blind, controlled clinical trial on a total of 52 women and men with Alzheimer's between 60 and 95 years of age.\nThe study is published in the open-access journal Frontiers in Aging Neuroscience.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was supported by a grant from the Deputy of Research of Kashan University of Medical Sciences, and that the probiotic supplements were produced and provided by Tak Gen Zist Pharmaceutical Company in Tehran, Iran. The authors declared no commercial or financial relationships that could be construed as a potential conflict of interest.", "answer": 1}, {"article": "The risk of having a baby with Down\u2019s \u2014 which occurs when a child has three copies of chromosome 21 instead of the normal two \u2014 increases sharply as women get older.\nThe risk for a 40-year-old mother is 16 times that for one who is 25.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\nPatsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent perspective, which was sorely needed \u2013 especially regarding predictions of availability and impact on the field.", "answer": 0}, {"article": "A CT chest scan, for example, exposes a patient to more than 150 times more radiation than a standard chest X-ray.\nThere are many reasons for the increase, including improvements in the technology that have speeded the procedure, a growing list of uses and a proliferation of the machines.\nYou can't get that kind of information any other way.\n\"That's the real issue people are worried about.\"\nBut nothing comes free of risks.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple, independent experts who can provide differing perspectives.", "answer": 1}, {"article": "Only 1.8 percent of men with PSA scores below 1.0 were diagnosed with prostate cancer, with only 0.04 percent dying of the disease.\nOne caution, though, is that the study only looked at three surgeons performing RALP.\n\"This gives us some confidence that annual PSA screening is going to soon become a thing of the past,\" said Dr. Nicholas J. Vogelzang, chair of the Developmental Therapeutics Committee of US Oncology, who moderated the teleconference.\nBut the maker of Avodart (dutasteride), GlaxoSmithKline, is unlikely to apply for new approval to market the drug for what is essentially prevention, meaning it would be used off-label in this context, he added.\nEighty percent of men in the group had PSA levels below that threshold.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There do not appear to have been any independent sources used to verify the veracity of the information presented at the meeting or to provide context for the details reported.", "answer": 0}, {"article": "A patient undergoes an electroencephalogram while doing a cognitive task, and the EEG records how the brain responds.\nThe study was funded in part by Quadrant Biosciences, a biotech company that hopes to bring a saliva test for concussion to market in the next 12 to 24 months, Hicks said.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two independent sources: the JAMA Pediatrics editorial and a neurologist, Dr. Jeffrey Kutcher, who directs The Sports Neurology Clinic at The CORE Institute in Michigan. In addition, the story explains that Quadrant Biosciences, which is hoping to market a saliva test for concussions, provided part of the funding for the original study. It also notes that Kutcher is consulting for a company working on an alternative approach to testing for concussion severity using electroencephalograms (EEG).", "answer": 1}, {"article": "Because about half of deaths in people with diabetes are caused by heart disease, reducing heart risk is considered essential to their care.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\n(Reuters) - Novo Nordisk\u2019s (NOVOb.CO) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study, but the result disappointed investors who had hoped for more.\nThe findings, which involved following 9,340 patients for a median 3.8 years, were also published online in the New England Journal of Medicine.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No third-party scientist is quoted, although the views of one industry analyst are paraphrased. It\u2019s not clear, however, if this analyst was actually interviewed for the story, and his comments pertain only to the market\u2019s expectations for the drug. We didn\u2019t think this was substantive enough to rate as Satisfactory.\nThe story does mention that Novo Nordisk funded the study and the focus is squarely on the pharmaceutical industry, making the company\u2019s role clear to the reader.", "answer": 0}, {"article": "Dry eye syndrome is a multifactorial disease of the tear film and ocular surface that produces symptoms of ocular discomfort, eyesight disorders, and tear film instability with potential damage to the ocular surface.\nIn this context, Sylentis has participated at this event presenting the pre-clinical and clinical results of various compounds that are being developed for the treatment of ocular disorders.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nThe purpose if this meeting is to share the latest breakthroughs in research in the area of ophthalmology, to contribute to the progress in basic science and also in cutting-edge clinical research.\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "PharmaMar, the parent company of he drugmaker, is listed as the study funder on the EurkekAlert! website which hosts the news release. We encourage news releases to include sponsors and conflict of interest information in the body of the news release so that information follows when the release is picked up verbatim by news aggregators.", "answer": 1}, {"article": "\u201cIt\u2019s like a weather man using a computer model to see what the weather is rather than looking outside the window,\u201d Lee said in a telephone interview.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\n\u201cIt is not a small difference,\u201d said Dr. Mark Helvie of the University of Michigan Health System, who worked on the study published in the February issue of the American Journal of Roentgenology.\nThose guidelines recommended against routine mammograms for women in their 40s and said women in their 50s should get mammograms every other year instead of every year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only independent source quoted in the article is the chair of the Breast Imaging Commission of the American College of Radiology.\u00a0 This source would be biased toward recommending more frequent screening.\nThe article should also have included reactions from members of the USPSTF or from groups that supported the recommendations of the Task Force.\nThe article does not mention that one author of the analysis is a consultant to GE\u00a0Healthcare, a major manufacturer of mammography equipment.\u00a0 The other author of the analysis has received grant support from GE\u00a0Healthcare.", "answer": 0}, {"article": "Grocers shelves add new coconut-water products regularly.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\nThat\u2019s one of the attractions, said Tom Rich, who is in charge of grocery operations for Whole Foods Rocky Mountain region.\n\u201cIt\u2019s a good time to own a coconut farm, that\u2019s for sure,\u201d said Daniel Fabricant, vice president for government and scientific affairs at the Natural Products Association, a trade association in Washington.\nCoconut water \u201cis very healthy, and that\u2019s our aim,\u201d said Kevin Conrad, a sales executive with GoFast, a Denver energy drink that now includes a version containing coconut-water concentrate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a lot of people. Unfortunately, most of them are connected to the sales or marketing of coconut products in some way.\u00a0Daniel Fabricant, vice president for government and scientific affairs at the Natural Products Association, a trade association in Washington says coconut products have everything a healthy consumer would want. \u201cIt\u2019s a holistic approach.\u201d\u00a0\u201cIt\u2019s an effective drink for rehydration that doesn\u2019t bring in the added sugars and the additives,\u201d says Dani Little, dietitian for a Whole Foods Market in Boulder. Also quoted are:\u00a0John Craven, the founder of Bevnet.com, a trade publication for the beverage industry.\u00a0Arthur Gallego, a spokesman for the New York-based Vita Coco;\u00a0Laura Sauls, a spokeswoman for Hermosa Beach, Calif.-based Zico and\u00a0Kevin Conrad, a sales executive with GoFast, a Denver energy drink that now includes a version containing coconut-water concentrate.That leaves just\u00a0Jessica Crandall, a Denver dietitian who is president of the Colorado Dietetic Association. The closest we get to any medical sources is Crandall saying that she \u201cwas meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d Note the use of the word \u201cclients.\u201d Everyone is being sold coconut oil or not sold something in this story. The last word goes to a Whole Foods executive. \u201cIt\u2019s healthy \u2014 and simple, too. That\u2019s one of the attractions, said Tom Rich, who is in charge of grocery operations for Whole Foods Rocky Mountain region.\u00a0\u201cIt\u2019s something you don\u2019t have to figure out,\u201d he said. \u201cPeople know what it is and where it grows. It\u2019s simple all the way around.\u201d \u201c", "answer": 0}, {"article": "\"We've got a lot of repeat customers, unfortunately,\" Shah said.\nShe and others say they know of no other physician in the Washington area who favors the radial approach.\n\"I think there is a reluctance among physicians who are used to doing procedures a certain way\" to change, said Mazhari, who learned to do the procedure last year and uses it about 80 percent of the time.\n\"There's a lot of buzz about this right now,\" he said of radial procedures, which account for about 150 of the 8,000 cardiac catheterizations done at his hospital annually.\nSome senior interventional cardiologists say they worry that the method may be hyped.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview material from clinicians who utilize this technique only rarely as well as those who rely on it extensively. \u00a0In addition, there were several patient quotes that presented the view from the other side of the table.", "answer": 1}, {"article": "Men with prostate cancer face a confusing maze of options today, including not only surgery but hormone therapy, different kinds of radiation therapy and even simply foregoing medical treatment while monitoring the cancer closely (\"watchful waiting,\" also known as \"active surveillance\").\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nThe data presented in the May 5 issue of the New England Journal of Medicine is a 15-year follow-up of a study for which three-years of follow-up had previously been reported.\n\"Currently, the potential benefit and side effects of treatment needs to be addressed on an individual basis in relation to the risk stratification of disease, patient desires, health status and risk tolerance,\" Danziger added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two clinicians who were not involved in the study provided quotes which were used in the story.", "answer": 1}, {"article": "The greatest risk was found for drugs that target gonadotropin-releasing hormone: 159.4 cases of diabetes per 1,000 person-years, compared with 87.5 for men who did not have androgen deprivation therapy, as well as a 35 percent increased risk for sudden cardiac death, a comparable increase in heart attack risk and a 22 percent increased risk for stroke.\nAlbertsen wrote an accompanying editorial in the journal.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nThe study she led looked at its effects on about 37,000 men treated for prostate cancer at Veterans Affairs hospitals.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Comments from two clinicians who were not directly associated with the study reported on were included in this story.", "answer": 1}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nIn their study, the investigators analyzed data from all 40,075 Norwegian women who had received a diagnosis of breast cancer from 1986 to 2005, a time when treatment was changing markedly.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes comments from several independent sources offering a variety of perspectives. It does not mention that the study was funded by the Cancer Registry of Norway and the Research Council of Norway.", "answer": 1}, {"article": "An ultrasound instrument with a vibrating needle is used to break up the cataracts, and a vacuum sucks them out.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\nHe reviewed the findings for WebMD.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story appropriately discloses that\u00a0an author of one of the studies \u2014 Mark\u00a0Packer, MD \u2014\u00a0consults for a manufacturer that makes lasers, it did not mention that the lead author of the second study\u00a0\u2014 William Culbertson, MD \u2014 also has relationships\u00a0with laser\u00a0manufacturers, as disclosed in this recent Medscape CME article\u00a0(login required). \u00a0In addition \u2014 and more troubling \u2014 it did not disclose the fact that an\u00a0\u00a0American Academy of Ophthalmology spokesman quoted in the story \u2014 James Salz, MD \u2014 has received clinical research grants from another laser manufacturer (as disclosed in a different Medscape CME article\u00a0\u00a0\u2014 login required). Since readers may justifiably assume that Salz\u00a0is presenting disinterested views on behalf of the association, the failure to discuss his industry ties is a significant shortcoming of the piece.", "answer": 0}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nSinclair says he was aware of research into red wine and certain health benefits.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\nIt's normally inactive, but when it is active, Sinclair believes it triggers a survival mechanism that extends life.\nTo maintain their sterile environment, the 60 Minutes team had to suit up to visit them with Ricki Colman, the \"project leader.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes individuals or researchers who are heavily invested in the claims made, both financially and with their personal involvement. The story does a disservice by not quoting other experts who could have provided some badly needed perspective.", "answer": 0}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nDr. Faber noted that Ms. Slimak's clean room work -- like much of the research on toxicity in autism -- \"hasn't been written for the main [scientific] literature\" but instead has been written mostly for the Internet.\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main source of information for this article was the project\u2019s lead pediatrician.\u00a0 No other experts or expert opinions were included to provide balance to the story or to minimize potential bias.\u00a0 This\u00a0omission is particularly egregious in an article about a disorder that can be so heartbreakingly severe and recalcitrant, and about untested theory.\u00a0 The devotion of millions of dollars to a \"fringe\" therapy may mean these dollars are diverted away from compassionate, scientifically based care.\u00a0 ", "answer": 0}, {"article": "In a hip replacement, an artificial joint comprising a ball and socket is implanted to replace the natural ball and socket in the pelvis, enabling movement that is typical of the hip joint.\nUsing the risk assessment tool, the researchers identified 192 of 1,009 patients as high risk for a dislocation after surgery.\nThis research presented at the conference has not yet been published in a peer-reviewed journal and is currently in submission.\nFuture studies aim to examine how the algorithm affects long-term outcomes and clinical benefits in patients at high risk for dislocation.\nFor the study, researchers reviewed data on 1,082 total hip replacements performed using computer navigation between January 2014 and December 2015, during which period no dual-mobility implants were used.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t discuss funding for the study or possible conflicts of interest among the study authors. A quick search of the federal Open Payments database shows that the lead author, Dr. Jonathan Vigdorchik, receives payments from a number of device companies, including those that make dual mobility hip implants.", "answer": 0}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nDublin City University's Anne Matthews, the review's lead researcher, says it was disappointing not to find more studies that were consistent in testing the same approaches.\nBut Matthews says reviewers found few high-quality studies about any treatment.\n\"The onus is back to researchers to carry out studies that would stand up\" to rigorous review and that would build on what's already been tested.\nAlso, inconsistencies in methodology from study to study made it difficult to pool the results and draw firm conclusions.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted in the article was an author of the study being covered. As we discussed in our review of the competing LA Times piece, one could argue that this criterion should be ruled not applicable in this case since the Cochrane group authors are, by definition, an independent group of evaluators.\u00a0Since\u00a0other experts do sometimes dispute the way in which Cochrane authors analyze the evidence,\u00a0however,\u00a0we feel it would have added value\u00a0to include the voice of another expert who wasn\u2019t affiliated with the study.", "answer": 0}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\nBut a few experts say you might want to ask your server to hold the statin at this point.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The use of independent voices here is key, and the reporting team did a lot of reading to give readers a fuller picture of the debate about statins. If people could hear more doctors saying that a particular drug is \"not a magic bullet\" in news stories, we probably would pay far less for the drugs that do work well.", "answer": 1}, {"article": "Public health officials also waged awareness campaigns about prevention, reminding people to practice safe sex with condoms and get tested, and that early HIV treatment can save lives.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\n\u201cIt\u2019s a step forward toward getting another candidate into trial that could have some promise.\u201d It\u2019s too soon to say if and when the mosaic vaccine might work to prevent the virus from spreading in humans, he added.\nThe mosaic vaccine was the best tolerated and also capable of generating anti-HIV immune responses in all the people who received the shots.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barouch, the lead investigator, is only identified with the vaccine center but his previous disclosures show he has licensed patents to Crucell Holland, a subsidiary of Johnson & Johnson, which is funding the current research. The extent of his financial involvement with them should\u2019ve been made more clear.", "answer": 0}, {"article": "Why?\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\nBut, the guidelines say, the tests are to be used only for research, and not for diagnosing Alzheimer's in the general public.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nAlthough the overall tone of this story is cautious and balanced, only one expert is quoted. Readers don\u2019t get any sense of how widely accepted the panels conclusions are or what dissenting opinions other experts might hold.\nMore importantly, this story does not tell readers about the links between panel members and companies that are developing tests or treatments for Alzheimer\u2019s disease. The journal article announcing the new guidelines includes this note about the expert quoted in this story: \u201cDavid Knopman serves on a Data Safety Monitoring Board for Lilly Pharmaceuticals, is an investigator for clinical trials sponsored by Elan Pharmaceuticals, Forest Pharmaceuticals, and Baxter Healthcare, is deputy editor of Neurology, and receives compensation for editorial activities\u201d. ", "answer": 0}, {"article": "Some insurance plans cover EMDR.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\n\u201cEMDR processing is untangling the knot.\u201d\n\nOnce the memories are processed, therapists say, they are less vivid \u2014 less like the film reel Henn would see in her mind.\nShe asked a close friend to write a speech from Nate\u2019s point of view, as if he were speaking at the celebration.\nThis distraction had a positive effect on her, she said, allowing her to dive deeply into the therapy without freezing in the face of fear.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is at least one independent source not connected with the patient\u2019s story. We would have liked to have seen input from a psychiatrist, as well (not just psychologists).", "answer": 1}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nIt took a decade, but eventually Allison's big idea was ready for testing in people.\nAnd at Belvin's follow-up appointment a year later, Wolchok delivered news that was hard for her to take in: \"Sharon, you no longer have cancer.\"\nThat was in 2005; today, Sharon Belvin is still cancer-free.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a former director of the National Cancer Institute, which is good. And the story clearly outlines Allison\u2019s search for pharmaceutical industry partners to develop ipilimumab into a drug that can be used in clinical practice.", "answer": 1}, {"article": "\"Is that what you have?\"\nThere was Tony Sideman, who underwent surgery in April 2007 and has lost 140 pounds; there was Janet Rovak, who lost 90 pounds in the eight months since her surgery; and there was Travis Goodbou, who lost 260 pounds in the seven months since he underwent the operation.\nAsked how many people gain the weight back, Dr. Hutcher tells Stahl, \"You know I think when you're dealing with an incurable disease that kills many people, if you have an 85 to 90 percent success rate, that's pretty darn good.\"\n\"Most people with severe obesity who undergo gastric bypass do not become fully normal, in terms of body weight.\nDr. Hutcher says the operation itself can take type 2 diabetes - which has ballooned in this country - and throw it into complete remission.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The segment draws on the experience of eight patients, all of whom have had positive results. \nIt also quotes at length a surgeon who is an enthusiastic advocate of the surgery, a surgeon participating in Brazilian clinical trials on the procedure\u2019s effect on diabetes and a physician who had the surgery himself with positive results.\nA doctor who expresses mild skepticism about the total weight that follows surgery is quoted. \u00a0\nThe segment quotes an American Cancer Society epidemiologist, who describes the links between obesity and several cancers.\nAbsent are skeptics who could raise questions about such issues as the long-term effectiveness of the surgery\u2019s ability to \"cure\" diabetes, the nutritional challenges of a post-surgical diet, and the wider range of outcomes observed for different forms of the surgery.\u00a0\nAbsent also are patients who had outcomes different from those repeated so frequently here: Those who developed illness due to nutritional deficiences, those who regained the lost weight, and those whose diabetes was not \"instantly cured.\"\u00a0 \u00a0", "answer": 0}, {"article": "Sure enough, in the week when they ate eggs, volunteers had lower acylated ghrelin and higher PYY3-36 compared with the week when they ate cereal.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nThis message was brought to you by the American Egg Board.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes clear that the study\u2019s funding source was the American Egg Board, but doesn\u2019t seek out a comment from an expert who might be able to put the findings in perspective or show us how the funding conflict may have led to a warped result.", "answer": 0}, {"article": "The study published Tuesday found that patients who had received the bioengineered proteins during spinal fusions for lower or middle back pain did not have increased complications when compared with those who did not get the product.\nBoth companies deny the accusations.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nThe research team based its report on records collected through a database known as the Nationwide Inpatient Sample, which gathers information from 20 percent of the nation\u2019s hospitals.\nThe products\u2019 use in cervical fusion procedures is a small component of their total sales, which reached an estimated $760.3 million in 2008, with Medtronic\u2019s share the larger one, according to Millennium Research Group, a consulting firm in Toronto.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThe story includes comments from two independent experts, as well as a study author and a spokeswoman for a manufacturer. ", "answer": 1}, {"article": "In spinal cord stimulation, a wire runs along the spinal cord sending pulses along the entire spine, but the pulses don't target the specific pain source.\nIt shows long-term data that patients experienced significant pain relief and functional improvements, she said.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\nOne pain specialist not involved with the study saw the benefits of this procedure.\nAmong the participants, 17 had the device for over a year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The authors of this study reported no conflicts of interest in the abstract. However, the story didn\u2019t mention that a doctor who\u2019s quoted, Kiran Patel, MD, received nearly $12,000 in 2017 from Abbott Laboratories, which makes a DRG device. Kiran is also listed as a \u201cDRG specialist\u201d on Abbott\u2019s web site.\nFurther, the story didn\u2019t say who funded this study.", "answer": 0}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\n\u201cSubstantial savings could be seen if open surgery is done in a laparoscopic fashion.\u201d\n\nBut he acknowledged that the study has major limitations.\nThe new study, in the Annals of Surgery, doesn\u2019t settle that question.\nWith his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\nAnd second, it\u2019s not a randomized controlled trial, which means the patients being compared could be different in important ways, explaining at least part of the outcomes of the two types of surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no independent perspective offered.\u00a0 So, even though the lead researcher offered his own caveats about the limitations of the research, we always wish for an independent expert\u2019s voice to be heard in such stories.", "answer": 0}, {"article": "Idarucizumab (Praxbind) is an antibody that chemically binds and neutralizes the blood-thinning effects of dabigatran.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe association makes no representation or warranty as to their accuracy or reliability.\nThis reassurance could lead to more strokes prevented by increasing the use of an effective blood thinner.\"\nVideo clips with researchers/authors of the studies will be added to the release link as available.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does tell readers that the study was funded by Boehringer Ingelheim, which markets both Praxbind and Pradaxa. However, it tells readers that study author disclosures (i.e., conflicts of interest) \u201care on the abstract.\u201d Given that there is no link to the abstract, and we couldn\u2019t find it when we looked (and we did look), that\u2019s not very useful. We did look up Richard Bernstein, who is the lead study author, and his faculty page lists Boehringer Ingelheim under \u201cIndustry Relationships.\u201d Readers shouldn\u2019t have to hunt down an abstract (or look an author up online) to learn that.", "answer": 0}, {"article": "Paul Little is a primary care researcher at the University of Southampton in Britain.\nThose who had six Alexander lessons showed some improvement.\nHe cautions though that it may be something else entirely that accounts for the apparent success of the Alexander Technique.\nHe led a study of some 460 patients who were given Alexander lessons, massage, or the usual care of pain killers and exercise.\nLittle's research was published in the British Medical Journal in 2008.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did not include commentary from an independent expert source\u2014to its detriment. Independent commentary might have allowed readers to come to a much better understanding of the potential benefits of the Alexander Technique, and the level of evidence supporting it. The journalist did not provide any information on potential conflicts-of-interest.\n\n \n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The news story cites two noted authorities on spine care, the lead author of the study on degenerative spondylolisthesis and the physician who wrote the accompanying editorial in the New England Journal of Medicine. ", "answer": 1}, {"article": "Some patients experience grueling withdrawal if taken off opioids, while for others the symptoms are much less severe.\n\u201cOne day in June, in my inbox were 42 deaths.\u201d\n\nThe findings show the balancing act of opioid policy: Even if doctors need to pull back opioids, they must be careful to ensure patients suffering from debilitating pain and other problems can still meet their other care needs.\nThough the researchers found a lot of studies to pool from, they generally graded these studies as \u201cvery low\u201d in quality and methodology.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\nMost of the studies analyzed were of poor quality \u2014 meaning there\u2019s a serious need for better research in this area.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A refreshing number of outside experts are quoted or cited in this story, and their remarks weren\u2019t the typical \u201cthe study was intriguing\u201d variety. Their quotes added some helpful context, such as how long it can take doctors to wean people off opioids (\u201cmonths or even years\u201d) and how everyone responds differently to tapering \u2014 and how some do poorly with it.", "answer": 1}, {"article": "SOURCE: bit.ly/qhsaZ0 Journal of the American College of Cardiology, October 10, 2011.\nWhether that theoretical benefit translates into real-life benefits remains to be proven by rigorous studies, however.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nAmong those with the highest weekly chocolate intake \u2014 more than 45 grams \u2014 there were 2.5 strokes per 1,000 women per year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was the only major shortcoming \u2014 no independent perspective. An expert in epidemiology might have\u00a0pointed out,\u00a0for example,\u00a0that the data on chocolate consumption were collected from\u00a0subject self-reports, and therefore should be viewed cautiously.", "answer": 0}, {"article": "However, about half of patients who undergo hormone therapy suffer from hot flashes similar to those that women experience during menopause.\nTheir reported level of hot flashes dropped markedly.\nThey received acupuncture twice a week for 30 minutes over four weeks.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\n\"The symptoms don't (normally) get better by that much that quickly.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert was interviewed.", "answer": 1}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\nThe research was also supported by the Van Andel Research Institute SU2C/AACR Epigenetics Dream Team.\nThe clinical trial included 22 patients with metastatic colorectal cancer who had been treated previously with irinotecan and whose disease was progressing.\nIt is manufactured by Astex Pharmaceuticals, a supporter of the Johns Hopkins-led study.\nThe drug combination is being tested in an ongoing phase II clinical trial (NCT01896856) in a larger group of metastatic colorectal cancer patients at multiple institutions to determine the effectiveness of the dual therapy compared with chemotherapy regimens that do not include guadecitabine, says Azad.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that the study was supported by Astex Pharmaceuticals, which manufactures guadecitabine.", "answer": 1}, {"article": "At age 6, children whose mothers took fish oil supplements while pregnant had a 395 grams higher total mass, 281 grams higher lean mass and 10 grams higher bone mineral content than children whose mothers who took olive oil during pregnancy, the findings showed.\nBut Rabin, who was not involved in the study, did add a few caveats about the findings.\nThe report by Bisgaard and colleagues was published online Sept. 4 in the BMJ.\nWEDNESDAY, Sept. 5, 2018 (HealthDay News) -- Taking fish oil supplements during pregnancy might translate into healthier growth in children during their first six years of life, a new study suggests.\n\"This study highlights the fact that in utero exposure can have a profound effect on the fetus that lasts through childhood,\" said Dr. Jennifer Wu, an obstetrician-gynecologist from Lenox Hill Hospital in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from independent sources unaffiliated with the research. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nThe transdisciplinary team, including William Ray, Department of Biochemistry; Andrea Dietrich, of the Charles E. Via Jr. Department of Civil and Environmental Engineering in the College of Engineering; and Glenn Lesser, from Wake Forest Baptist Medical Center, previously identified the role of lactoferrin, a specific milk protein, in diminishing the metallic flavor stimulated by chemotherapy medications.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are excluded.\nCareful review of the author disclosures included in the study reveal no significant conflicts of interest.", "answer": 0}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nTo do this, all of the study volunteers were given all three tests.\nNone of the study volunteers had a history of smoking.\n\"This is potentially a great tool.\nBoth Appleyard and Leath noted that cost might initially limit the use of an electronic nose.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two independent sources and identifies their affiliations.", "answer": 1}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\nFurther tests are required before this latest method can be used within a clinical setting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does point out that the researchers work for \u201cGoogle\u2019s parent company Alphabet\u201d and for the company Verily, which used to be Google Life Sciences, so the conflict of interest is obvious.\u00a0 But it fails to identify any of the researchers, even though it includes two quotes from a nameless source.\u00a0 No independent sources are quoted.", "answer": 0}, {"article": "Almost never?\nBut a closer look at the data suggests that this is probably just a statistical artifact: This intense running group contains only 36 people and two deaths, versus hundreds of people in the more casual running groups.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nThe ideal measure would combine the length of time spent exercising with the amount of energy expended \u2014 basically, we want to figure out a way to credit people who walk at half the speed for twice as long the same amount as those who walk faster for less time.\nBut since the people in the studies are of different ages, researchers can\u2019t just look to see whether they have, say, a 2 percentage point lower risk of death in a given year, since that lower risk would mean a lot more for someone who is 30 than for someone who is 90.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In a sense, this story is a data-driven op-ed piece \u2014 there are no quotes from any outside sources. The story does link to all of the relevant source material, which is great, but the story could have been stronger if it had gotten input from, well, anyone in the medical community with relevant expertise that could have helped readers synthesize all of the study data the story cites. For example, it\u2019s possible that a clinical professional would have pointed out the potential harms of running and helped readers sort through the tradeoffs involved \u2014 making the overall coverage more useful.", "answer": 0}, {"article": "\"It's very exciting,\" Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nA government committee of health experts yesterday opened the door to selling Orlistat, a prescription weight-loss drug in a reduced dosage directly to consumers.\nThus, the gastrointestinal problems.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Provides quotes from drug maker, researchers, and public watchdog organization", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the piece, which straddles the line between commentary and news. We found it in the health section where it wasn\u2019t labeled as opinion and the headline reads like a straight news story. But some first-person passages make one wonder if it\u2019s more of an opinion piece.\nRegardless, we would have liked to have seen at least some references to work outside of this one study, since the claim being made is\u00a0significant, while the evidence being given for the claim\u00a0is less so. We want to know: What kind of evidence is required before pediatricians can feel confident saying \u201ctreating ADHD will not only\u00a0take care of\u00a0immediate behaviors, it will create safer behavior as your child grows?\u201d", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nThis study suggests that it is,\" said Hooton, clinical director of the division of infectious diseases at the University of Miami School of Medicine.\nDr. Hunter Wessells, who wasn't involved in the study, called the additional fluid intake \"substantial,\" leading to a corresponding increase in urine output.\nDr. Susan Bleasdale, medical director of infection control at the University of Illinois at Chicago, said the study \"may be a game changer\" for antibiotic \"stewardship\" programs aimed at reducing inappropriate antibiotic use.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source. However, it unfortunately left out that Danone, which sells several brands of bottled water, was heavily involved in the study. This is disclosed in the study abstract.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No one truly independent of the Medtronic-Lilly partnership was quoted.\u00a0 We would have liked to have seen independent expert perspective on the approach.", "answer": 0}, {"article": "Chemotherapy before surgery might provide a false assurance that there's no more residual cancer, whereas microscopic tumour may remain after the surgery, leading to cancer recurrence and possibly, death.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\n\u2022 The surgery should be aggressive in an attempt to remove all visible signs of the tumour, and to avoid leaving any residual disease.\n\"For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced-stage ovarian cancer, but there are many survivors as well,\" said Dr. Narod, senior scientist at Women's College Research Institute.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention funding sources and conflicts of interest, but there do not appear to be any conflicts of interest since the release is highlighting an opinion piece that analyzes previous research studies. Because the research isn\u2019t advocating use of a specific drug or technology and because the published review states the author has no competing interests, we\u2019ll give them the benefit of the doubt.", "answer": 1}, {"article": "While some cases of anosmia may be treated by caring for an underlying cause (often nasal obstruction, in which odors can\u2019t reach the nerves of the olfactory system due to swelling, polyps or sinus disease), other cases involving damage to the sensory nerves of the nose (i.e.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\n\u201cOur work shows that smell restoration technology is an idea worth studying further,\u201d said corresponding author Eric Holbrook, MD, Chief of Rhinology at Mass.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention any sources of funding or potential conflicts of interest. To be clear, even if the work was internally funded and there are no conflicts of interest, that is worth noting. The release acknowledges previous work of \u201cresearch colleagues\u201d at the Virginia Commonwealth University but should have gone further in explaining that the researchers hold a patent for an olfactory implant system and have formed a company to develop the technology.", "answer": 0}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nThe longer people took the drugs, and the higher the dose, the greater the anticancer benefit.\n\u201cAlso, this potential cancer-protective effect should be taken into account when discussing benefits and harms of NSAID use.\u201d\n\nAlice Park is a writer at TIME.\nYou can also continue the discussion on TIME\u2019s Facebook page and on Twitter at @TIME.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted. An independent voice could have helped address some of the unanswered questions.", "answer": 0}, {"article": "Most advanced drugs, like bapineuzumab, have focused on removing clumps of amyloid plaques, which are thought to stop brain cells from functioning properly.\n\u201cIt demonstrated that the drug has an effect on the pathological hallmark of Alzheimer\u2019s disease,\u201d lead researcher Juha Rinne from Finland\u2019s University of Turku told Reuters.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nInvestor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses.\nRinne\u2019s imaging study was funded by Elan and Wyeth, which is now part of Pfizer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included a quote attributed to Sam Gandy at New York\u2019s Mount Sinai School of Medicine without explaining what expertise he might bring. \u00a0Nonetheless, he was enthusiastic about the potential benefit from the measurement technique the study used. \u00a0And though the story was focused on an Alzheimer\u2019s treatment, he mentioned that it\u2019s too early to say anything about effectiveness to treating Alzheimer\u2019s disease.\u00a0 \nThe story did report that the study was funded by the manufacturer of the drug being studied.", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nJeffrey Rimer, associate professor of chemical engineering at the University of Houston, was lead author of the study, published Aug. 8 in the online edition of Nature.\nIn addition to Rimer and Asplin, authors on the paper include Giannis Mpourmpakis and his graduate student, Michael G. Taylor, of the University of Pittsburgh; Ignacio Granja of Litholink Corporation, and Jihae Chung, a UH graduate student working in Rimer's lab.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nThe findings are the result of a combination of experimental studies, computational studies and human studies, Rimer said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to disclose that the study\u2019s lead author has patented the use of a molecule for kidney stone treatment, nor does it identify the study\u2019s funding source. The study was funded by grants from federal, foundation and university sources according to the acknowledgements section of the journal article. In addition, the patent disclosure was included in supplementary material posted on the Nature website.", "answer": 0}, {"article": "That\u2019s because when you up one circuit in the brain, you\u2019re probably impairing another system.\u201d\n\nEarly studies attributed a lot of short-term benefits to nootropics \u2014 so much so that in 1983, Russian scientists turned to phenylpiracetam to boost the physical and mental performance of cosmonauts during space flight.\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\n\u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game.\nFounded by two Stanford University computer graduates, the company has initiated an international fasting group on Facebook; at last count, there were 3,500 members.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacks comment from an independent expert who\u2019s not involved with selling, prescribing or taking nootropics or some other cognition-boosting product.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes input from researchers, editorial writer, and from drug maker. However, it is not clear if the story included any input from any independent source not directly tied to the study. ", "answer": 1}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\nThe study was published Dec. 21 in the New England Journal of Medicine.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\n\"Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,\" Dr. Alejandro Hoberman said in a university news release.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The disclosure form from the New England Journal article tells us that \u201cDrs. Hoberman and Martin report receiving consulting fees from Genocea Biosciences; and Dr. Hoberman, receiving grant support from Ricoh Innovations and holding pending patents related to the development of a reduced clavulanate concentration version of amoxicillin\u2013clavulanate potassium (U.S. patent application serial number, 14/371,731) and the development of a method and apparatus for aiding in the diagnosis of otitis media by classifying tympanic-membrane images (U.S. patent application serial number, 14/418,509). No other potential conflict of interest relevant to this article was reported.\u201d\nThis potential conflict of interest information was not in the\u00a0HealthDay story.", "answer": 0}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\n\u201cIt is very important to keep in mind that multivitamin users tend be \u2018healthier\u2019 in general.\nSimilar studies have been done in men, with some confirming the current findings and others contradicting them, Rautiainen said.\nShe concluded: \u201cThe question of whether multivitamins are good for you still remains!\u201d\nWhile conventional wisdom holds that taking vitamins could help prevent heart disease, the researchers add, there\u2019s actually little evidence to back up this claim.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources appear to have been used to put the current study results in context. \u00a0Comments from experts in the field could have shed valuable light on this topic.", "answer": 0}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nRestoring Copeland's sense of touch was a painstaking process, but the Pittsburgh team knew it was possible.\nThe scientists published details of their work online Thursday in the journal Science Translational Medicine.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nIt was several weeks before the team was able to send the first tiny pulse of electricity to Copeland's brain.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not quote anyone outside the Pittsburgh team that collaborated on this project.", "answer": 0}, {"article": "While prenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders such as Down syndrome, new research shows certain types of tests may also reveal markers of cancer in mothers.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nMore testing showed she had anal cancer.\nThe findings are published in the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story noted that the study was funded by the manufacturer of the test and that the study author quoted has a relationship with the company. That\u2019s useful context, but we require an independent voice to meet our standard on this criterion. No one was quoted except one of the study\u2019s authors.", "answer": 0}, {"article": "For further information, please contact:\n\"When the benefits of phospholipids on PMS and PMDD came to light through Lipogen's research, we immediately explored its potential,\" says David Rutenberg, CEO for Lipogen.\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\n\"Based on these strong results, we improved the formulation and applied for a patent in the US market,\" explains Rutenberg.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear from the release that Lipogen, the company that issued the release, also funded the study. According to the release:\n\u201cWhen the benefits of phospholipids on PMS and PMDD came to light through Lipogen\u2019s research, we immediately explored its potential,\u201d says David Rutenberg, CEO for Lipogen.", "answer": 1}, {"article": "At the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nSome had been diagnosed with Alzheimer\u2019s and some with MCI, while others did not have any neurological conditions.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t offer independent sources and only paraphrases information from the graduate student/principal investigator.", "answer": 0}, {"article": "\u201cBut it does give us hope.\u201d\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\n\u201cAnd, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable.\nChildren without autism were used as a control for the study, the news release reported.\n\u201cTransplants are working for people with other gastrointestinal problems,\u201d lead study author Ann Gregory, a microbiology graduate student at The Ohio state University, said in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is no independent source quoted in the story.\nUpon further investigation of the original journal publication on the study, we found a statement about several of the authors holding patents related to fecal transplantation. These seven authors have \u201cpending/approved patents related to the use of FMT and or probiotics\u201d for a variety of conditions, including autism. Five authors have received research funding from Crestovo and several are advisors for Crestovo. None of these were quoted in the story. Crestovo is a for-profit biotech company.\nThe story and the news release should both have made note of these conflicts.", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources, either independent or connected to the scientific paper. We realize that space and length limitations may make it difficult to include such sources in a brief story such as this one. Nevertheless, we wanted to hear more context for this study. Ginger has already been studied for relationships to cardiovascular disease and cancer. A comment from someone in nutritional biochemistry, or an allergist, might have helped readers take better stock of the findings.", "answer": 0}, {"article": "Symptoms of lung cancer include persistent, intense coughing, shortness of breath, pain in the chest, shoulder or back and changes in the color and/or volume of phlegm or mucus, hoarseness and coughing up blood.\nThat means the machine is staffed at times when it is not able to be fully used for other diagnostic procedures, time that provides a natural window for lung screening using just the CT imaging capability in under five minutes from arrival to exit, Thomson said.\nIn the last decade, CT technology has gotten increasingly adept at picking up early, small nodules, Thomson said.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the story doesn\u2019t explicitly state where the funding for the initiative came from, it\u2019s also not clear whether there was any external source of funding. Based on the description, the study comes across as a clinician-driven initiative designed to make use of down time on diagnostic equipment. There does not appear to be a conflict of interest.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the study was funded by Kite and it quotes two outside sources. First, Dr. Roy Herbst of the Yale Cancer Center, who has not disclosed any relationship with Kite Pharma. Also quoted is Dr. Steven A. Rosenberg of the National Cancer Institute\u00a0\u201cwho had no role in Kite\u2019s study\u201d but who has had T-Cell immunotherapy research funded by Kite Pharma within the past year (a fact not disclosed in the piece).\nThe story makes a good faith effort to provide independent, objective perspectives on the research. However, to make a point of saying Dr. Rosenberg had no role in \u201cthis\u201d study but not mention he has been funded by Kite Pharma in the past for similar research is enough of a red flag to warrant an unsatisfactory mark for potential conflict of interest.", "answer": 0}, {"article": "Researchers said no Aimovig patients stopped treatment due to side effects, while around 1 percent of placebo patients discontinued because of side effects.\nHe said previous studies excluded patients who had tried more than two other treatments.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\n\u201cThis is a trial in really difficult to treat patients,\u201d professor Uwe Reuter, trial investigator and managing medical director at Charit\u00e9 Universit\u00e4tsmedizin in Berlin, told Reuters in a telephone interview.\nAimovig has the \u201cpotential to help fill treatment gaps in more difficult patient populations whose migraine has not been adequately managed with current therapies,\u201d Sean Harper, executive vice president of research and development at Amgen, said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources in the story are the trial\u2019s lead investigator and an Amgen official. Many aspects of this coverage could have been improved with an independent voice.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story wins points for reaching out to multiple independent experts, including a Nobel Prize winner who helped discover how telomeres protect chromosomes.", "answer": 1}, {"article": "Autologous CD34?\nAppeared or available on-line: May 4, 2016\n\nThis study, scheduled to be published later this year in a special cardiovascular issue of Cell Transplantation, is currently freely available on-line as an unedited early e-pub at: http://www.\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\nThe Co-Editors-in-Chief for CELL TRANSPLANTATION are at the Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA and the Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention funding sources or address potential conflicts of interest. For example, as the relevant journal article notes: \u201cBaxter Healthcare sponsored the study and was responsible for the conduct of the investigation.\u201d At least two study co-authors were former Baxter employees. Another author is listed in the paper as being an employee of Caladrius Biosciences, but a cursory search finds that he was previously a vice president at Baxter. Yet another author has received an honoraria from Baxter, and another has received research funding from Baxter. The paper was not as transparent about these conflicts of interest as it should have been, and the release fails to address them at all. In addition, the release appears to have been issued by the \u201cCell Transplantation Center of Excellence for Aging and Brain Repair.\u201d\u00a0 Given that the researcher cited in the release is based at the Cedars-Sinai Heart Institute, one could assume that the center is located there. But that would be wrong. There is no center by that name. Instead it appears to be a hybrid of the journal name and the name of the center where it is housed. This is confusing (at best) and misleading (at worst), since the center had nothing to do with the research. Frankly, this is very confusing for readers.", "answer": 0}, {"article": "In a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\n\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut that is not what we found.\u201d\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Durado Brooks provides some great context at the end, and it would have been nice if this were higher up.", "answer": 1}, {"article": "However, these results are not proof that bitter melon extract prevents or cures breast cancer.\nEating bitter melon could also have a beneficial effect, Ray said.\nIf so, human trials might follow.\n\"It will probably delay or perhaps have some prevention.\"\n\"It has ingredients which are good for the health.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted.", "answer": 1}, {"article": "Beta-blockers are usually taken to treat high blood pressure, heart arrhythmias and other cardiovascular conditions, though metoprolol (Lopressor or Toprol), propranolol (Inderal) and timolol (Blocadren) can also help with migraines.\nFive of the six co-authors of the new guidelines, including Silberstein, disclosed that they receive research funding, speaking fees and other payments from drug companies.\nIn addition, an herbal remedy derived from a family of plants called Petasites or butterbur was found to be effective, according to the review.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\n\u201cPeople need to keep in mind that all drugs, includingover-the-counter drugsand complementary treatments, can have side effects or interact with other medications, which should be monitored,\u201d Silberstein said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story noted that 5 of the 6 guideline authors disclosed relationships with drug companies. However, the only source quoted in the article is one of the guideline authors \u2014 no independent perspective was included.", "answer": 0}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\n\"While we can operate on ears later in the patient's life, waiting not only increases the surgery's difficulty and expense, but may expose the child to teasing, bullying, and loss of self-esteem,\" comments Editor-in-Chief Rod J. Rohrich, MD, in a featured video on the Plastic and Reconstructive Surgery website.\nArticle: \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System\" (doi: 10.1097/PRS.0000000000003150)\n\nFor more than 70 years, Plastic and Reconstructive Surgery\u00ae (http://www. )\nClick here to read \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release refers to study co-author H. Steve Byrd four times, but never mentions that he has a financial interest in EarWell systems. In fact, as the journal article states: \u201cDr. Byrd has a royalty agreement with Becon Medical [which markets EarWell] for his work designing the EarWell device.\u201d And Byrd isn\u2019t the only one. Another of the co-authors is also listed in the journal article as having an investment in Becon Medical. This sort of conflict-of-interest information needs to be disclosed in a news release.", "answer": 0}, {"article": "Many researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nJewel Samadder of the University of Michigan at Ann Arbor, who led the study.\nWASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only quotes came from the lead researcher, pulled from a university news release. No independent expert was quoted.\u00a0 \n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three different sources fill out this compact story\u2014a spokesperson for the medical society representing the nation\u2019s orthopaedists, a spokesperson for knee implant manufacturer Zimmer, and chief of the knee service at one of the busiest joint replacement centers in the world (who has consulted for one of Zimmer\u2019s chief competitor, the story notes)\u2014a balanced group whose potential conflicts readers can judge for themselves.", "answer": 1}, {"article": "Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nTHURSDAY, June 8, 2017 (HealthDay News) -- Scary pit vipers may need an image upgrade: Their venom might end up helping human heart patients, research suggests.\n\"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation,\" Marzo added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was at least one independent source. But the story didn\u2019t disclose that the researcher interviewed in the story has a patent application for the compound, and other financial interests that are related.", "answer": 0}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nIt could take two to three years to come to market in the United States, the company said.\nMichael Sand, director of clinical research at Boehringer, said the company intends to pursue regulatory approval based on the late-stage study findings.\n\"To the extent that the drug may act as an incentive to bring the subject up, that will be a good opportunity,\u2019\u2019 he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The information in this story comes primarily from expert interview and quotes from a representative of the drug manufacturer. But there was no comment on whether any of the expert interviewees had financial ties to the drug maker.\u00a0 ", "answer": 0}, {"article": "Elastography measures the compressibility and mechanical properties of a lesion.\nDr. Eliot L. Siegel, vice chairman of the radiology department at the University of Maryland School of Medicine in Baltimore and the study's lead author, said in the news release that \"dermatologists tend to biopsy any lesions that seem visually suspicious for disease.\"\nTUESDAY, Dec. 1, 2009 (HealthDay News) -- When used with ultrasound, elastography helps distinguish between cancerous and benign breast lesions, which reduces unnecessary biopsies, U.S. researchers have found.\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America.\nIn another study scheduled to be presented at the meeting, researchers found that high-frequency ultrasound with elastography can help distinguish between cancerous and benign skin lesions, which could improve the efficiency of skin cancer diagnosis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only experts who were involved in the study. Even worse, the two experts who are quoted are also quoted in the press release. The story should have also pointed out that the senior author is listed as an investigator for the company that produces the device used for the study.\u00a0 This is a major flaw of the story. Persepctives from independent sources could have tremendously improved the quality of the story.", "answer": 0}, {"article": "That is very powerful.\"\n\"This study suggests an intriguing link between patients taking L-DOPA and a lower incidence and delayed onset of AMD,\" said Paul A. Sieving, M.D., Ph.D., director of the National Eye Institute.\n\"Results suggest a new path forward in our fight against AMD that may even include a strategy to prevent those at risk of the disease from ever developing it,\" said Brian McKay, Ph.D., associate professor, Department of Ophthalmology and Vision Science, University of Arizona.\nThis research, titled \"Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration,\" was supported by National Center for Advancing Translational Sciences, National Human Genome Research Institute, Research to Prevent Blindness, Bright Focus Foundation, The Edward N. & Della L. Thome Memorial Foundation, Wisconsin Genomics Initiative, National Eye Institute, Marshfield Clinic and University of Arizona.\n\"Research points to this as a pathway to regulate and prevent this most common cause of blindness in adults,\" said Murray Brilliant, Ph.D., director, Marshfield Clinic Research Foundation Center for Human Genetics, Marshfield, Wisconsin.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funding sources of this research but does not alert readers to the conflict of interest disclosure found in the published results. While the lead author has not yet received income from the drug application, he is the patent holder. \u201cDr. McKay is an inventor on an approved patent for the use of L-DOPA to treat or delay AMD,\u201d according to the published paper. Just because he hasn\u2019t received royalties yet doesn\u2019t mean he or his institution will never accept royalties if and when L-DOPA is approved for treating AMD. The release should have called attention to this.\u00a0 ", "answer": 0}, {"article": "For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is where the story excels in one way and fails in another. It excels by taking pains to point out the conflicts of interest of everyone it quotes. It nearly gives the lead author, Mark Pimentel,\u201d a pass by calling him \u201cdirector of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars\u201d in the second paragraph and waiting until paragraph 14 to tell readers, \u201cThe studies were funded by Salix Pharmaceuticals Inc., which makes rifaximin. Pimentel serves as a consultant to Salix and serves on its scientific advisory board. He discovered the use of the antibiotic for IBS. Cedars-Sinai holds the patent and has licensed the rights to Salix.\u201d It goes on to quote Jan Tack and says, \u201cTack has served as a scientific adviser to companies evaluating IBS drugs.\u201d Its last source is\u00a0Christine Frissora, of whom the story says, \u201cFrissora reports research funding from Tioga Pharmaceuticals for a study of an IBS drug and serving on the speakers bureaus for Prometheus Therapeutics and Diagnostics, Salix Pharmaceuticals, and Takeda Pharmaceuticals North America.\u201d See a pattern here? Where are the independent voices in the story?\nSo, for example, when Dr. Frissora says the findings \u201cwill probably encourage other doctors to try it, especially primary care doctors who may not [yet] know about this data\u201d \u2013 why don\u2019t we hear from an evidence-based primary care doc about whether he/she will change practice based on this info?", "answer": 0}, {"article": "Those on beta blockers had a substantial reduction in the formation of distant cancers, or metastases, and of local recurrence.\nOther experts called the results interesting, but preliminary.\nPowe is due to present the findings Friday at the annual European Breast Cancer Conference in Barcelona, Spain.\nPowe said he plans to do another study to validate the results.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A medical oncologist and the deputy chief medical officer for the American Cancer Society provided independent commentary for this story.\u00a0 ", "answer": 1}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\n\"Furthermore, it was also better tolerated.\nThe faculty of almost 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments.\nThe institution's faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985.\nThe Nature research was supported by grants from the National Institutes of Health including the SPORE; Peloton Therapeutics, Inc.; and the Cancer Prevention and Research Institute of Texas; the National Center for Advancing Translational Sciences (Center for Translational Medicine); National Natural Science Foundation of China; and philanthropy, including the Tom Green Memorial fund.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release was particularly fulsome in explaining the multiple, overlapping conflicts of the researchers, the sponsoring pharmaceutical company and the academic institution that has a financial stake in this discovery. Well done.", "answer": 1}, {"article": "Keytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\nIt was one of these independent committees that recommended stopping the trial based on what they saw but that doesn't necessarily mean they shared the details with the company or anyone else.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\nSo it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple independent sources quoted in the story.\nHowever, all of the quotes in this story sound like this:\u00a0\u201cI suspect the findings were significant enough that this will be a practice-changing finding.\u201d If there were numbers being released to back up a claim like that, we would be more comfortable with these kinds of quotes. Without more evidence, though, it gives readers the impression that the drug will have a massive impact.", "answer": 1}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nA recent study published in adds to the growing evidence that fiber might be a critical gut-nourishing nutrient.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes one source who was not affiliated with the relevant study, but makes clear that the source is a vocal proponent of the idea that a high-fiber diet is important for maintaining a \u201chealthy\u201d gut microbiome and that the microbiome can have a significant impact on health.", "answer": 1}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nThe study appears online in the Archives of Internal Medicine.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story does not directly quote the study\u2019s authors, it does include three independent experts \u2013 two medical doctors and one licensed acupuncturist. However, the article could have benefited if an independent expert specifically addressed any limitations of the study or of acupuncture.", "answer": 1}, {"article": "Developed by plastic surgeons who noticed that some migraine patients had fewer headaches after cosmetic forehead-lift, migraine surgery procedures address trigger sites linked to certain headache patterns.\nThe study included 90 patients who underwent migraine surgery, performed by Dr. Austen, between 2013 and 2015.\nThe final analysis included 74 patients who completed both questionnaires at one-year follow-up after migraine surgery.\nOne year after migraine surgery, the patients had a very large percent improvement in average PSEQ score: on average, 112 percent higher than baseline.\nBefore migraine surgery, the patients had \"extremely poor\" PSEQ scores, indicating a high level of disability.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention the funding sources, and that earns a Not Satisfactory rating here. The study does disclose that none of the researchers have conflicts of interest.", "answer": 0}, {"article": "Obesity is a risk factor for T2D, and both obesity and T2D increase CVD risk.\nThe study was funded by the National Pecan Shellers Association.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release made it clear that the study was funded by the National Pecan Shellers Association. The published study also noted that the researchers had no conflicts of interest.", "answer": 1}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\n\u201cWe believe this vaccine candidate will prove safe for human trials,\u201d said Janda in a statement.\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nThe researchers did not observe any harmful side effects from the intervention.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The comments of an independent knowledgable\u00a0source provide balance to the story. However, the story did not disclose that the researcher, Kim D. Janda, has filed a\u00a0 patent application on this technology. See \u201cHeroin Haptens, Immunoconjugates and Related Uses.\u201d", "answer": 0}, {"article": "To recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Pratic\u00f2 and colleagues used specially engineered tau transgenic mice, which develop tau pathology - characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability - as they age.\nEach TUHS member organization is owned and operated pursuant to its governing documents.\nThe research was funded in part by grants from The Wanda Simone Endowment for Neuroscience and the Scott Richards North Star Charitable Foundation.\nTheir superior performance suggested a successful reversal of memory deficiency.\nEach year, the School of Medicine educates approximately 840 medical students and 140 graduate students.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are named.", "answer": 1}, {"article": "For example, uncontrolled high blood pressure, or high cholesterol, obesity, age and diabetes can all increase heart disease risk.\nThese new recommendations aren't final, and are open to public comment.\nNissen worries that many people are mistaking their actual heart disease risk.\nPeople should talk with their health care provider to find out if they have health problems that would justify taking aspirin, according to Dr. Douglas Owens, a professor of medicine at Stanford University and a member of the task force.\nPeople who don't really need to should not be taking aspirin every day, says Nissen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t delve into potential conflicts of interest, but it does point out that the task force is an independent panel, and interviewed Dr. Nissen who is not part of the panel.", "answer": 1}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\nOther LA BioMed researchers who participated in the study were: Suguru Matsumoto, Rine Nakanishi, Dong Li, Anas Alani, Panteha Rezaeian, Jeby Abraham, Michael A. Fahmy, Christopher Dailing, Ferdinand Flores and Sajad Hamal.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While this release does mention that the study was funded by a company that produces the garlic supplement and that the study\u2019s main author received payments from that company, it doesn\u2019t go nearly far enough with disclosures. The paper, published as a paid supplement to the Journal of Nutrition, needed to be labeled as such. Paid supplement articles differ from routine, peer-reviewed\u00a0 papers published in the journal. The work was presented at a symposium sponsored primarily by commercial interests from the nutrition industry and the main author served as the paid chair of that meeting. All of this is information that readers should have to properly evaluate the value of the information.", "answer": 0}, {"article": "So this is like a teaser.\"\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nThere are studies based on symptomatic things such as pain, and I think there's pretty good evidence that it does have benefit in that respect.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story deserves praise for seeking out comments from two experts who provide valuable perspective on the results. Unfortunately, though, the story didn\u2019t point out that the researchers in this study have filed\u00a0a patent application\u00a0for vision-related acupuncture points.\u00a0This constitutes a significant potential financial conflict that should have been disclosed to readers. ", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\n\"It sounds sort of creepy and weird when you think about it, but for the most part, it is safer in general than taking a medicine.\n\"Generally speaking, just because a device, procedure or medication has been approved or is deemed to be safe by some entities does not mean that it is automatically covered,\" BlueCross BlueShield spokeswoman Kelly Allen said.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\n\"We had several patients who were headed toward the hospital, who had this treatment and were able to avoid that,\" said Dr. Scott West, a psychiatrist who pioneered the treatment in Nashville 2 and one-half years ago.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Besides the glowing comments by a psychiatrist who uses the device and the originator, we do have a comment from a spokesperson from an insurance company who does not as yet provide coverage. Given the controversy in this 15 year old technology, we would have liked to have seen comments from an expert in the field.", "answer": 0}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nStill, the PSA test remains \"a blunt instrument,\" when it comes to determining the aggressiveness of a particular tumor, Neal said.\n\"Our study has a longer follow-up than previous studies, but shows that in those men invited [to the study], the risk of dying is only half of that in the control group.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\nAmbivalence over the test hasn't been confined to the United States.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from several experts.\u00a0 But we\u2019re going to rule the story\u2019s performance on this criterion as unsatisfactory for reasons of balance.\u00a0 It\u2019s possible to have several sources and still have an editorial imbalance in the story.\u00a0 ", "answer": 0}, {"article": "Along with obesity, high levels of blood fats can lead to heart disease and other health problems, including diabetes.\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nIndeed, of all the children in the study whose LDL levels were above 160, one-third were in the group who would not have been screened.\nRather than calling for all youngsters to have their cholesterol tested, which would entail considerable expense on the national level, Dr. Ralph Sacco, president of the American Heart Association (AHA), suggests looking more critically at current screening guidelines.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe journal Pediatrics stated that the study authors did not have any relevant financial interests. The story does include comments from an independent expert; however, the independent expert addresses only questions about the efficiency of screening, not the health benefits or harms of identifying children with elevated cholesterol.", "answer": 1}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\nFor the study, researchers at McLean and a team led by Dr. Janet Lainhart the University of Utah used an MRI that was tuned to pick up microscopic features of the brain\u2019s wiring \u2014 a technique known as diffusion tensor imaging.\nThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story has no independent sources, and, worse yet, it gives readers the mistaken impression that the lead author of the study is an independent voice. After the lead and setup, the story says. \u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts. Doesn\u2019t that sound like someone outside the study explaining why the findings are important? Unless readers latched on to a passing reference to \u201cresearchers at McLean\u201d they might read the entire story thinking Lange was unaffiliated. As CNN points out in its story, Lange actually helped create the MRI being used and would likely stand to benefit financially from its commercial rollout.", "answer": 0}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study aren\u2019t named in the release. In addition to Australian government and foundation grants, the project was supported by a private individual, and the lead investigator\u2019s research work is currently supported by Servier Australia and Pfizer (manufacturer of Pitocin), according to the published study.", "answer": 0}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nGiven those findings, along with the results from this trial, a rapid change in clinical practice is expected, noted Dr. Jotte.\nThis study received funding from F. Hoffmann-La Roche Ltd.\n\nView the disclosures for the 2018 ASCO Annual Meeting News Planning Team.\nAbout the Study\n\n The IMpower131 trial enrolled 1,021 patients with stage IV squamous NSCLC.\nASCO Perspective\n\n\u201cThis is one more example of how immunotherapy is making steady gains against a number of cancers.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the trial received funding from F. Hoffmann-La Roche. We will give the package of release and abstract a satisfactory rating because the abstract includes a long list of ties between the researchers and industry. The disclosure statement is almost as long as the description of the trial and its results.", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nMedications can help, although many people complain of side effects, Kohler said.\nBuysee said there shouldn't be any safety issues.\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\nThe cap is not yet available to consumers, although the lead researcher, Dr. Eric Nofzinger, has plans to bring it to market, Buysse said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent sleep researcher was quoted.", "answer": 1}, {"article": "But he cautions against overdoing it.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\nShe says some patients get caught in a \"push and crash\" cycle.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted two people, but we like that it at least attempted to bring in a different view on how to treat chronic fatigue. In talking with Lucinda Bateman at Fatigue Consultation Clinic in Salt Lake City, the story brought out some of the limitations of the study.", "answer": 1}, {"article": "October 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nFurther surgery was required in six shoulders; in two cases, the RTSA procedure was considered a failure.\nAll had \"massive, irreparable\" tears of the rotator cuff muscles, causing shoulder \"pseudoparalysis,\"with little no ability to lift the arm.\nBut there are concerns about how well the results of RTSA will hold up over time in this group of patients.\nThe new study focused on long-term outcomes of RTSA in patients under age 60.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release never mentions funding for this study, nor does it mention that the corresponding author has been paid by two joint replacement manufacturers, information that was readily available in the scientific paper.", "answer": 0}, {"article": ".\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\nBesides being tiny, Guiles said they offer the advantage of flexibility.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nThis technique, which Lee helped develop and has been using for about a year, represents a big advance over conventional kidney-cancer surgery, which can require a foot-long incision and, sometimes, removal of a rib so the doctor can reach the malignancy, according to experts.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes no sources other than the surgeon who developed the technique. The story would have been much improved by including some perspectives from surgeons who do not have something to gain by what is said about the technology.", "answer": 0}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\n\u201cOne is called \u2018best possible self,\u2019\u201d Eric Kim, who also co-led the study, told CBS News.\nWhile the study is observational and cannot prove a cause-and-effect relationship between optimism and a longer life, the researchers have some theories for what might be behind the connection.\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two of the study\u2019s authors are interviewed. Chatting with an outside source would definitely have strengthened this story, and may have exposed the reverse causation issue we\u00a0previously\u00a0brought.", "answer": 0}, {"article": "Post-operative cognitive dysfunction (POCD), a condition mostly observed in older patients following surgery under general anesthesia, is characterized by impaired memory and concentration.\nIf so, the use of an anti-inflammatory drug may have a protective effect,\" said Maria Jos\u00e9 Carvalho Carmona, a professor of anesthesiology at the University of S\u00e3o Paulo's Medical School (FM-USP) and principal investigator for the study.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\nThe researchers evaluated 140 patients aged between 60 and 87 who underwent surgery under propofol-induced general anesthesia at the Central Institute of Hospital das Cl\u00ednicas, FM-USP's teaching hospital, in most cases for removal of gallstones.\nBefore that, older patients were rarely subjected to major surgery, and significant research in this field has only been conducted for approximately 15-20 years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not explicitly note who funded the study. However, the study does not appear to have received any external funding. According to the ClinicalTrials.gov page for the study, the work was sponsored primarily by the University of S\u00e3o Paulo and Duke University (where the authors work), with additional support from the Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo (or S\u00e3o Paulo Research Foundation), which is public. It\u2019s not unusual for universities to avoid mentioning funding for projects that they funded themselves. But it would have been a stronger release if it didn\u2019t leave readers wondering who paid for the work.", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted one source \u2013 the study\u2019s lead investigator.\u00a0 The story should have included some input from observers not directly involved the study about their interpretation of the results. ", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Job well done in quoting sources outside of the City of Hope investigators and putting the findings into cautious perspective throughout the article. If the story was to be done at all (a debatable decision), this article makes the best of the context problem.", "answer": 1}, {"article": "It is much rarer in people who take a lower-dose bisphosphonate (such as Actonel, Boniva or Fosamax) for osteoporosis.\nBut, she pointed out, Forteo is not yet approved for this indication, so \"we can't recommend it next week.\"\nIt's also possible that the corticosteroid therapy she was taking could have contributed to the woman's bone loss, the authors stated.\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites the editorial and one source who seems independent. It fails to mention that Forteo\u2019s dad, Eli Lilly, provided financing for this study, and one author disclosed an additional financial relationship with Lilly.\n More of the perspective from the editorial would\u2019ve been a great asset to this article, as it provided a realistic appraisal of the study\u2019s results.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nThis work was supported in part by NIH grants EB00489.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nMore information is available at the NIBIB website: http://www.nibib.nih.gov.\nIt could also become useful as a non-invasive way to assess breast cancer treatment progress.\u201d\n\nThe team plans to complete safety testing of the imaging agent during the next three years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The article noted that the research was partially funded through an NIH grant. There are no conflicts of interest.", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a number of outside experts, including Riad Salem, chief of interventional oncology at Chicago\u2019s Northwestern Memorial Hospital;\u00a0Ken Thomson, a radiologist in Australia who studied the devices; and\u00a0\u00a0Tim Clark, director of interventional radiology at Penn Presbyterian Medical Center in Philadelphia. Importantly, the story also makes\u00a0the distinction\u00a0between the\u00a0claims the company\u00a0is making\u00a0and the claims being made by the clinics and\u00a0hospitals who have bought\u00a0the machines\u00a0(and are trying to recoup their investments.) It quotes the CEO of the machine\u00a0manufacturer saying,\u00a0\"We are not part of the whole PR machine. It\u2019s not something we are happy about.\"", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three researchers with interest in vitamin D were cited as was one researcher who was involved in one of the articles discussed in the story.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story employs several independent sources. A minor point, but it would have been helpful to hear from a source from one of the countries where using nitrous oxide during labor is far more commonplace, and for an ACOG spokesperson to comment on the lack of guidance on using it during labor.\nAlthough not strictly conflict of interest issues, the article rightly points out two advocacy considerations. First, that many midwives are advocating for nitrous as a low-tech option at a time when labor and delivery are becoming increasingly medicalized. Second, that some hospitals are approaching nitrous as a marketing tool; presumably to position themselves as low-tech-friendly.", "answer": 1}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nSupplements are an additional tool to be used when needed.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nAnyone over 50 will need an additional 200 milligrams.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are quoted.", "answer": 0}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nNPA is the leading trade association for the U.S. pasta industry.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nCertain grain foods, like pasta, are a great complement to a healthy well-balanced meal and provide plenty of opportunities for improving the diet,\" explains registered dietitian Diane Welland, Nutrition Communications Manager for the National Pasta Association.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states that an industry financed association paid for the research. Readers should be able to take the hint (without being told explicitly) that the association has a financial interest in selling more pasta.", "answer": 1}, {"article": "The United Kingdom\u2019s National Health Service offers free HIV testing.\nA sizable fraction of the undiagnosed may be people who have been tested, just not recently enough.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nThis wasn\u2019t because they had never been screened; 81 percent of the undiagnosed men had been tested for HIV previously.\nBioSure\u2019s test goes beyond any of the at-home tests available on the U.S. market, which are either not as fast or not as accurate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources identified in this story. That would be ok for an op-ed, which is how this story reads. But the byline is from a news writer, so our standard of at least one independent source applies here. Again, the independent studies reported on did not actually look at self-testing at home.", "answer": 0}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nWith statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nIf the results are confirmed, \u201cThis is game changing science,\u201d said Dr. Richard A. Stein, a spokesman for the American Heart Association who's not related to the study author or involved in the research.\nAdditional results for PCSK9 inhibitor drugs are expected to be presented at the annual American College of Cardiology meeting which begins Saturday in Chicago, he said.\nStein called the trial results \u201ca very important breakthrough,\" while being careful to note that they represent early science which should be confirmed through larger and longer studies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mixed bag.\nThe story did quote the editorial writers and did seek comment from an American Heart Association spokesman.\nBut the story did not report, as MedPage Today did, that: \u201cMany of the co-authors were employees of Regeneron, one of whom jointly wrote the paper with Stein.\u201d\nWe\u2019ll give the story the benefit of the doubt.\n\u00a0", "answer": 1}, {"article": "Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\nThe ONCOblot\u00ae test is based on more than 20 years of basic research.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\nMorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was done by MorNuCo, the company that developed the ONCOblot test.\nAnother useful flag apparent to close readers is that the only person quoted in the release is not a researcher, but the company\u2019s vice president of business development.", "answer": 1}, {"article": "That accounts for a small percentage of people.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nThe test detects only three out of more than 1,000 known BRCA mutations.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides useful information from an FDA news release and clearly notes that the relevant testing is a test being marketed by a specific company. That said, the story lacks\u00a0 actual interviews with third-party expert sources not connected with the FDA or the gene testing company.", "answer": 0}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story brings in some strong independent voices who help make sense of this complicated study: James Fang, a cardiologist at University Hospitals Case Medical Center in Cleveland, who wrote an editorial accompanying the study, Raymond Gibbons, a cardiologist at the Mayo Clinic, and Clyde Yancy, chief of cardiology at Northwestern University\u2019s Feinberg School of Medicine. Rarely do you see a story that spends as much time with independent experts as it does with the authors of the study.", "answer": 1}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\nMight non-opioid painkillers work just as well as these addictive drugs?\nData on pain came from the participants' ratings; no information on side effects was collected.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources cited in the story, nor does the story address potential conflicts of interest. We get that this story is part of a series that aims to present brief \u201csnapshots\u201d of recent research findings that are interesting or important \u2014 little news nuggets you can read in the amount of time it takes you to wait for the elevator.\nBut we think getting outside input is sort of a threshold issue for journalism, and perhaps especially so for health care journalism. It could simply be a sentence from an independent source noting whether this is valuable information for clinical decision-making in emergency rooms. Are opioids regularly prescribed to patients with these types of injuries?\nLikewise, there don\u2019t appear to be any conflicts of interest related to the paper. A few words to that effect would have been very welcome.", "answer": 0}, {"article": "\"We were looking for areas of the brain that are more responsive during listening to bedtime stories than when they're not hearing that,\" Eyler said.\nBut another expert pointed out that the study is still extremely preliminary.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\nRight now, experts have little to go by in detecting autism other than carefully monitoring the regular developmental milestones in children, Young said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The idependent sources were well chosen and well quoted. The researchers themselves are given the proper context, for the most part, too. The story does not identify conflicts of interest. One could see if one of the researchers had an interest in an fMRI machine manufacturer, but everyone involved and not involved seems to agree that we are a long way from a marketable product.", "answer": 1}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\nThe exact cause of this discrepancy isn't known.\nBut the FDA might have more questions related to the study before making a final ruling.\n\"If they had a problem with folic acid, it would be too late at that point to prevent the birth defect.\"\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes independent sources.", "answer": 1}, {"article": "Active older people resemble much younger people physiologically, according to a new study of the effects of exercise on aging.\nThis conundrum is particularly true in terms of inactivity.\nOf course, this study is based on a single snapshot of an unusual group of older adults, Dr. Harridge said.\n\u201cIf you gave this dataset to a clinician and asked him to predict the age\u201d of one of the cyclists based on his or her test results, Dr. Harridge said, \u201cit would be impossible.\u201d On paper, they all look young.\nAs it turned out, the cyclists did not show their age.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We are given no comments by a non-involved source on the value or limitations of this small study. What\u2019s more, the story does not include any independent experts who could put the study results into context. Even a sentence or two of caution could have gone a long way here.", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is neither an independent source nor any discussion of potential conflicts of interest.\n", "answer": 0}, {"article": "Please see paper for the complete list.\nOther collaborators on the study include Edwin C. Amos, Jonathan Canick, Mary Ackerley, Cyrus Raji, Milan Fiala, and Jamila Ahdidan.\nTHE BREDESEN PROTOCOL, Dr. Bredesen\u2019s book describing for a lay audience the interventions described in this paper, will be released by Penguin Random House in May 2017.\nAnother patient, a 49-year old woman who noted progressive difficulty with word finding and facial recognition went on the protocol after undergoing quantitative neuropsychological testing at a major university.\nAn MRI showed hippocampal volume at only the 17th percentile for his age.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that the National Institutes of Health (NIH) provided some funding, but it does not list all of the study\u2019s funding sources. Those include the Accelerate Fund, an early-stage investment fund based in Canada. The researcher also apparently stands to benefit from sales of a book set to be released in May 2017 through a mainstream book publisher.", "answer": 0}, {"article": "\u201cOur next step will be to more precisely determine the underlying chemistry of how and why particular foods can yield dramatically different results for different people.\nMeanwhile, we strongly recommend that IBS patients work with their physician and a registered dietitian to navigate the Low-FODMAP diet to take control of their IBS symptoms.\u201d\n\nEswaran received funding to conduct the research from the University of Michigan Nutritional and Obesity Center and Prometheus Diagnostics.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nMany practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says the research was funded by the University of Michigan Nutritional and Obesity Center and Prometheus Laboratories Inc. It might have disclosed that Prometheus Laboratories is owned by the global food and beverage giant Nestl\u00e9, and that it sells diagnostic tests for IBS.", "answer": 1}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\nKathiresan and co-author Dr. Amit Khera, a Mass General cardiologist, are co-inventors on a patent application for the system.\nInstead, Kathiresan can calculate risk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote one source unaffiliated with the research effort and also points out that two of the researchers \u201care co-inventors on a patent application for the system,\u201d so their potential for conflicts is clear to the reader.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from experts who were not involved in this trial and it identified others as being researchers for this trial or working for Amarin. However, when the first quote calls this drug \u201cabsolutely the most significant study in the field of cardiovascular risk reduction since the statins were introduced\u201d, it is not enough to identify the source as \u201ca Vascepa study investigator\u201d when that researcher, Matthew Budoff, received over $120,000 in 2017 from Amarin, including payments of more than $4000 per appearance for speaking and teaching engagements on behalf of the company.\n[Note: The text has been corrected to indicate that the\u00a0quoted source\u2019s name is Matthew Budoff, not Martin Budoff as it initially appeared.]", "answer": 0}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nThe Genefolio test confirmed gene variants within Ellis\u2019 DNA that made her more susceptible to certain side effects with newer classes of medications, so Stanley prescribed an older class of antidepressant and experimented with a lower dose.\nFinally, her psychiatrist, suspicious that her body might process medication differently than most, recommended a genetic test to see why Ellis wasn\u2019t responding to the prescriptions.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only three sources in the story are two employees of different branches of the Avera medical organization, which developed the specific genetic test (Genefolio) discussed in the article, and a depression patient whose doctors used that test to help identify why the patient was responding so poorly to previously described drugs.", "answer": 0}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\nIn addition, Penn says, the mother's hands were not strapped down and the intravenous line was put in her nondominant hand so she could hold the baby.\nPenn and the staff at Anne Arundel Medical Center quickly realized the procedure would require some changes, including adding a nurse and bringing the neonatal team into the operating room.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It seems that all the experts interviewed in the story have ties to the mothers who are advocates for this approach or to the concept of the family-centered cesarean. One of the people interviewed was Dr. William Camann, a pioneer of the procedure in the US. It would have been interesting to hear from a doctor who opts for a traditional C-section instead of a family-centered one, or one who routinely performs C-sections. That would have been a good opportunity to put an independent perspective into the piece and also to expand on the question, \u201cWhy aren\u2019t family-centered cesareans more popular in the US if mothers are so happy with them?\u201d", "answer": 0}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\nThis project was funded in part by Shire Pharmaceuticals, the National Institute of Mental Health, the National Institute on Aging, and the National Institute on Drug Abuse.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\nIn addition to Epperson, other Penn co-authors are Sheila Shanmugan, Deborah R. Kim, Sarah Mathews, Kathryn A. Czarkowski, Jeanette Bradley, Dina H. Appleby, Claudia Iannelli, and Mary D. Sammel.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the release does identify the four funding entities underwriting the research, it fails to point out what the research paper actually does: That two authors receive grant support from Shire, the drug\u2019s manufacturer, and that that the lead author has stock holdings with five different pharmaceutical firms (although not with the manufacturer of the drug used in the study). Readers need this information to be able to interpret the evidence.", "answer": 0}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nGetting an intrauterine system generally just requires one office visit, Espey said.\nThere was no difference in the rates of surgery or sexual activity between the two groups.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\nInsertion of the device may be mildly uncomfortable for some women, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is another doctor who does not appear to be affiliated with the study quoted in the story.", "answer": 1}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nThe therapy passed a first test Monday evening as doctors adjusted the electrical impulse level to Bardwell's satisfaction.\nBecause new drugs can only be tested on top of existing therapy, introducing potentially better drugs is difficult.\nHollis Bardwell, 61, sounded excited about the possibility Monday evening, five hours after surgeons finished putting the pacemaker-like device in the side of his lower back and threading an attached 35-inch wire up his spine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes interviews with one of the study researchers and a patient, but it should have tapped someone with no links to the research for an independent take.\u00a0We\u2019ll flag this one as unsatisfactory. \u00a0\u00a0", "answer": 0}, {"article": "The researchers found a 63 percent response rate in women who received the depression-specific acupuncture, while the response rate was 44.3 percent in the control acupuncture and massage groups.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nBut, she added, because this is the first study of its kind, and the acupuncture protocol used was specifically designed for this study, \"you always need replication of the findings.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one independent expert who provides valuable commentary on the importance of the new findings. ", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on flu.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nLamps with this type of UV light currently cost less than $1,000, Brenner said, but that price would likely fall if the lamps were mass-produced.\n\"Far-UVC light has a very limited range and cannot penetrate through the outer dead-cell layer of human skin or the tear layer in the eye, so it's not a human health hazard,\" said Brenner, who directs Columbia's Center for Radiological Research.\nIt could offer a new, inexpensive way to eliminate airborne flu viruses in indoor public spaces such as hospitals, doctors' offices, schools, airports and aircraft, said the team from Columbia University Medical Center in New York City.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The lead researcher, as well as two physicians not affiliated with the study, are quoted. But, the story did not reveal the researcher\u2019s conflict of interest,\u00a0which the TIME Health story did disclose:\n\u201cBrenner says his team is working with a company to develop a commercially available version of the lamp..\u201d", "answer": 0}, {"article": "To study the matter, researchers at the Technical University of Munich approached healthy male runners, most in their early 40s, who were training for the Munich Marathon, and asked if they would \u2014 in the name of science \u2014 be willing to drink a considerable amount of beer.\nBut you may not want to start a raucous celebration just yet.\nFor that, at least, the beer can be full-potency.\nThe men drinking the nonalcoholic beer reported far fewer illnesses than the runners swallowing the placebo beverage.\nThe beer was effective only if it was nonalcoholic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the lead author extensively.\u00a0 Unfortunately, no other independent perspectives are provided. No potential conflicts of interest are noted.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nIt\u2019s hard to tell whether an independent source is included. There is no doubt that the story fails to inform readers about the financial ties between most of the quoted experts and the company that funded their research and is now marketing the bronchial thermoplasty device. The conflict of interest statement included with the journal article on the key trial is more than a thousand words long, detailing payments from companies, including Asthmatix, the maker of this device (now part of Boston Scientific), to the lead researchers.\nThe story does disclose that the company provided the contact information for all of the patients quoted in the story. It does not say whether any of the control group participants who got the sham treatment were contacted.", "answer": 0}, {"article": "Ishdori A, Capps O, Murano PS.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nThe forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato--a nutritious vegetable--in promoting health for all age groups.\n\"It's important that consumption of all vegetables, particularly those that are good sources of potassium and dietary fiber, be encouraged in children,\" says Theresa A. Nicklas, DrPH, USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, and one of the supplement's authors.\nThe journal supplement features seven papers authored by leading nutrition scientists that explore the state of the science pertaining to vegetable consumption in children.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes:\nThe supplement is the outcome of a November 2014 USDA/ARS Children\u2019s Nutrition Research Center at Baylor College of Medicine roundtable on vegetable consumption in children. The forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato\u2013a nutritious vegetable\u2013in promoting health for all age groups.\nThat\u2019s good information as far as it goes, but the release does not acknowledge that the authors of the main study that is the basis for the release are both paid by the Alliance (one is an employee, the other a consultant), which is a membership group for potato growers.", "answer": 0}, {"article": "Structured clinical interviews, such as the Hamilton Depression Rating Scale and the Hamilton Anxiety Rating Scale, and patient questionnaires, like the Beck Depression Inventory and the State-Trait Anxiety Inventory, assessed depression and anxiety.\nBoth studies are published in the Journal of Psychopharmacology on Dec. 1.\nThe access code is 48330192.\nAdditional authors included Matthew Johnson, Michael Carducci, Annie Umbricht, William Richards, Brian Richards, Mary Cosimano and Margaret Klinedinst, all of The Johns Hopkins University.\nTo participate, U.S.-based media may call 855-698-2663; international media should dial 011-646-754-2524.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly lists the sources of funding for the research. That\u2019s enough to earn it a satisfactory rating.", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only delivers information from an FDA documented posted online and from a drug company spokesperson. So, in fact, we don\u2019t hear from a truly independent voice and not from any expert in clinical care either.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This study was partially funded by Eli Lilly and AstraZenaca, makers of Evista and tamoxifen, though this is not mentioned. There is also no mention of whether the breast cancer expert cited from the American Cancer Society has financial ties with these drug companies. ", "answer": 0}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nIf we haven\u2019t yet processed the prior set of information, we can\u2019t understand it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In-depth reporting was clearly undertaken (and independent research is cited) in the process of putting together this piece. Also,\u00a0the column discloses conflicts of interest within the industry, which is important.\nHowever, the story didn\u2019t include direct quotes from independent sources. The author states that he consulted with experts in this field as part of his research, and that\u2019s another check in the \u201cplus\u201d column. But on the downside, readers don\u2019t know who those sources are or what expertise they bring to bear. From a reader standpoint, this would be useful information to include and it\u2019s important information to look for. Considering all aspects of the issue, we\u2019ll rate this a borderline satisfactory.", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nThere was not enough evidence before to extend that recommendation to full-term babies, but Rabe thinks this study should tip the balance in favor of delay.\nKjersti Aagaard, vice chair of obstetrics and gynecology at Baylor College of Medicine and Texas Children's Hospital, is more skeptical.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nThen, moments after birth, that cord is severed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted a separate source not involved in the study with a different point of view. And\u00a0while we applaud the story\u2019s inclusion of that voice, we think the air time could have been used more fruitfully. Asking the reader to talk to a doctor/make an individual choice [Dr. Ishani speaking here as someone such people are sent to], without more explanation as to why they would choose one route or another, misses an opportunity to deliver succinct, useful information about the downsides of delayed clamping.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources\u2013the one person quoted\u00a0is study coauthor, Dr. Robert Lustig, who has a potential conflict of interest. Lustig wrote a book that\u2019s extremely critical of sugar, and has spoken of fructose as \u201cpoison.\u201d", "answer": 0}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included information from an unaffiliated expert, and it alerts readers that pharmaceutical companies developed the two vaccines. That\u2019s good reporting and useful context. However, the story also says that the latest study was conducted by the \u201cU.S. and Liberian governments and elsewhere,\u201d while neglecting to mention that \u201celsewhere\u201d includes GlaxoSmithKline and Merck (which employs several of the researchers). The story also doesn\u2019t mention that several of the researchers have other economic ties to the companies. This one\u2019s a close call, but there\u2019s not quite enough information to clear our bar.", "answer": 0}, {"article": "Follow us on Facebook and Twitter.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nBecause the study was observational, it couldn't establish a cause-and-effect relationship between breastfeeding and lower stroke risk, meaning that it is possible some other characteristic that distinguishes between women who breastfeed and those who don't is the factor changing the stroke risk.\nThe Association makes no representation or guarantee as to their accuracy or reliability.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly discloses the source of research funding. The release also notes that \u201cauthor disclosures [regarding potential conflicts of interest] are on the manuscript.\u201d It would have been much better to simply disclose the conflicts on the release itself by saying: \u201cThe authors report no potential conflicts of interest.\u201d", "answer": 1}, {"article": "A rare and aggressive form of skin cancer, MCC, is 35 times less common than melanoma, but on average, it is about three times more likely to be deadly.\nNewswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nDr. Paul Nghiem, affiliate investigator of the Clinical Research Division at Fred Hutch, and the George F. Odland Endowed Chair in Dermatology at the University of Washington School of Medicine, is a senior investigator on the clinical trial that led to the FDA approval and the senior author on the Lancet Oncology article that preceded the approval.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nTom Judd, who lives near Portland, Oregon, knows what it is like to be diagnosed with a deadly cancer for which there is no approved drug.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release appropriately explains that the clinical trial in question was for a drug made by Merck and that the lead scientist in the clinical trial receives ongoing funding from other companies. (We should note, too, that one of the reviewers on this news release, Bill Heisel, works at the University of Washington where some of the researchers on the clinical trial work as faculty.)", "answer": 1}, {"article": "Women are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\n\"We're talking about small numbers, really tiny numbers\" of study participants, Modesitt said, noting one limitation of the study.\nModesitt, of the UVA's Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, was most surprised by the dramatic changes seen in the patients' metabolic profiles derived from the gut microbiome, the population of microorganisms living inside us.\n\"So I could never say that effect is definitive, but it is suggestive, given that we know already the incredibly strong link between endometrial cancer and obesity.\"\nThe findings have been published as a lead article in the scientific journal Gynecologic Oncology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The authors declared no conflicts of interest in the paper. But one of the study authors was an employee from the company that provided the technology for some of the analyses in the study. This probably was worth a mention.", "answer": 0}, {"article": "Androgens, including testosterone, are thought to contribute to the growth and development of prostate cancer.\nThe study represents an important, if incremental, step for clinicians, noted Dr. William See, chair of the urology department at the Medical College of Wisconsin, who wasn\u2019t involved in the study.\nBecause prostate cancer can progress relatively slowly, the study \u2014 which ran from 1998 to 2003 \u2014 needed an extended follow-up period to be sure of the effects, Shipley said.\nThe men in the trial received the ADT drugs for two years.\nMore research will be needed to confirm which men benefit most from taking the drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was included. And this STAT story noted an important detail that the NYTimes missed: how AstraZeneca \u2014 a maker of a hormone-blocking drug for men \u2014 was a study sponsor.", "answer": 1}, {"article": "\"She had a persistent boil on her buttocks,\" he explained.\nMolan suggests there may be another reason the United States has been slower than some other countries to adopt medicinal honey: the scientific establishment's resistance to traditional remedies.\nFor biochemist Peter Molan, honey's ancient power to heal is not a matter of faith.\nAs with other natural health-care products, many of the claims for manuka's efficacy are sweeping and scantily supported.\n(And there's wide agreement among medical professionals that people should not test the treatment themselves by slathering their cuts and burns with honey from the pantry shelf.)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story quotes multiple researchers, they were all involved in honey research in one way or another. The story should have quoted other, independent researchers/experts (perhaps with infectious disease expertise) who were not related to the research.", "answer": 0}, {"article": "I will say it\u2019s an effective method of controlling pain.\u201d\n\nDr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy.\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\n\u201cI was like, \u2018Well, O.K., I\u2019ll get to meet some people, it will get me out of the house.\u2019 I didn\u2019t believe any of it.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\nThe fibromyalgia study involved the yang style of tai chi, taught by a Boston tai chi master, Ramel Rones.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Most of the quotes in the story are from people not affiliated with the study.", "answer": 1}, {"article": "The I.V.\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\nA longitudinal study would be needed to back those claims with evidence, she added.\nSchwartz, though, said the supplements are completely safe.\nThe research on injectable vitamins of any kind is thin and the results unimpressive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story chose sources who were outside the retail industry selling supplements, and we didn\u2019t detect any potential conflicts of interest.", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sourcing of this story was good. We hear from\u00a0academics, government researchers, and industry executives. Their voices provide balance and give texture to the coverage.\u00a0It should be noted, however, that most of these experts have a vested interest in the field or the success of a particular treatment, whether because of industry ties or because they are leading experiments on\u00a0a particular approach. Even the government experts might be biased by their provision of significant financial support for research in this area. It would have been nice to hear\u00a0a comment about the vaccines from someone\u00a0who is certifiably free of all potential conflicts.\u00a0\u00a0But we can\u2019t justify docking points\u00a0since there is no voice that is overly enthusiastic about the concept.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this story does identify which of the quoted experts stand to make money from products or classes, it should have let readers hear from more than just the boosters of breathing exercises. A quick look at the medical literature produces a long list of reviews that note the poor quality and inconsistent results of research on this topic. The story could have included comments from researchers on the gap between the rosy claims of promoters and what the available evidence actually shows.", "answer": 0}, {"article": "About two-thirds of breast cancers are hormone sensitive.\nApproval as an initial treatment likely would boost that sharply.\nTykerb had sales of $189 million last year.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source interviewed in the story is an employee of the drugmaker.\u00a0 Where was any perspective from an independent clinician? ", "answer": 0}, {"article": "\u201cThe key question is, will the consumer view as credible that ingesting a pill will prevent (sun) damage?\u201d\n\nIn another experiment, Laboratoires Inneov scientists gave the tanning pill to 80 women and asked them to sunbathe as they normally would over the summer, applying sunscreen at their discretion.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\n\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story identified conflicts of interest that even a publishing journal did not \u2013 and it showed how this happened.\u00a0 And it quoted several skeptical expert sources. ", "answer": 1}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nA week later, under no medication, participants returned to repeat the experiment.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\nThe work was supported by the Swiss National Science Foundation, University of Zurich and Wellcome.\nThe screen would flash either blue or red, and one of the colours was associated with a 50% chance of receiving a painful electric shock.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the funding sources and the study stated that there were no conflicts of interest.", "answer": 1}, {"article": "Abaloparatide-SC also reduced new vertebral fractures by 86%, nonvertebral fractures by 43%, clinical fractures by 43%, and major osteoporotic fractures by 70% compared with placebo after 18 months of treatment.\nTo learn more about the Society and the field of endocrinology, visit our site at http://www.\nFollow us on Twitter at @TheEndoSociety and @EndoMedia.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\nThe Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release prominently and early notes that the research is \u201cindustry sponsored,\u201d and names the company (Radius Health, Inc.). It also notes that the investigator quoted in the release is a consultant to the company. Kudos!", "answer": 1}, {"article": "Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\nIn this small trial of 79 Iranian women aged 45 to 60 years, soft capsules containing 100 mg of fennel were administered twice daily for eight weeks.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t tell us who funded the study. According to the Iranian Registry of Clinical Trials, the study was funded by Tehran University.", "answer": 0}, {"article": "Among other changes, they found that levels of human growth hormone, or HGH, surged after fasting \u2014 increasing 20 times in men and 13 times in women.\nHe said the group was planning additional research into the potential health effects of regular fasting.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nRegular fasting may be good for your heart.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert was quoted, something sorely lacking in the story.", "answer": 0}, {"article": "She exercised.\n\u201cIf this study is confirmed, this will make a difference because it\u2019s one of the cancers we don\u2019t have any reliable screening test for,\u201d he added.\nIt now needs to be taken over by some diagnostic corporation before it can launch into something for widespread use.\u201d\n\nWhat needs to be determined is \u201cwhat the sensitivity and specificity would be in a screening population of 100,000 people,\u201d said Dr. Brian Wolpin, of the Dana Farber Cancer Institute.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nBut, he said, \u201cthis is just a speculation based on the current strength of the study.\u201d\n\nHad such a test been available, it might have save the life of Dr. Teresa Flippo-Morton, a prominent breast surgeon from Charlotte, N.C.\n\n\u201cShe was an expert in oncology,\u201d said Dr. Derek Raghavan, a colleague and president of the Levine Cancer Institute where Flippo-Morton worked.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We give the story a pass here because there are multiple voices in the piece. But it should be noted that there was only one dissenting opinion, at the very end, from Dr. Brian Wolpin, of the Dana Farber Cancer Institute. He brought up the point that should have been in the second paragraph of the story: \u201cIn this study the patients were known to have cancer or not to have cancer. In this kind of sample sensitivity and specificity tend to look good.\u201d", "answer": 1}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\n\nEditor's note: The data in these releases may differ from those in the published abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\n\"Pulsed radiofrequency creates a nerve modulation, significantly reducing inflammation and its associated symptoms,\" said study senior author Alessandro Napoli, M.D., Ph.D., professor of interventional radiology at Sapienza University of Rome in Italy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Study funding is not included.\nA review of the meeting abstract reveals no conflicts of interest disclosed by the seven authors.", "answer": 0}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\n\"One repair isn't appropriate for all circumstances.\"\n\"You'll patch it to prevent it from continuing to protrude.\"\nIt was developed in the 1990s, Brunt said.\n\"There's less pain and a bit of a faster recovery from the laparoscopic procedure.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source provided useful context about the important continuing role of the traditional \u201copen\u201d procedure.", "answer": 1}, {"article": "\u201cModels are models,\u201d Lin said.\nTwo prominent experts in cancer prevention and statistics agreed, but said they did not want to be publicly identified as criticizing the new analysis because some of its authors are colleagues of theirs.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nDr. Kenneth Lin of Georgetown University Medical Center, a former staffer at the USPSTF, said crediting PSA tests with reducing prostate cancer mortality by around 30 percent was probably an overstatement, especially since mathematical models are only models.\nA mortality reduction of 30 percent would lower the death rate to 1.75 percent, said epidemiologist Ruth Etzioni of Fred Hutchinson Cancer Research Center, the study\u2019s senior author.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A wide range of outside voices give this article depth and heft. The inclusion of voices of researchers who chose to remain anonymous reminds us of the very controversial and potentially career-altering aspects of this research.\nHowever, as with the Los Angeles Times story, this story didn\u2019t note the financial disclosures of the study authors, including the senior author, Ruth Etzioni, who disclosed she owns equity in a company developing medical imaging technology that it says could be applied in prostate cancer patients. Dr. Etzioni stated that she does not consider the equity ownership to be a conflict of interest, but considering that an increase in PSA screening would boost demand for more precise and less invasive follow-up testing, it appears that her company would benefit.\nThe study was funded by the National Cancer Institute. While that source does not raise any red flags, and the study stated that the funder had no role in the study, news stories are more informative when they note study funding.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Four different physicians are quoted in the story. However, according to Dollars for Docs, three of these physicians have recent financial ties to companies actively involved in stem cell product development. This was not disclosed.", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good sourcing.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nIn their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\nThe commentary was coauthored by Dianna Gaballa, a fourth-year medical student; Joanna Drowos, D.O., M.P.H., an associate professor of integrated medical science and associate chair of the Department of Integrated Medical Science; and Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean, all in FAU's Charles E. Schmidt College of Medicine.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nThe researchers caution that the reliable detection of small to moderate risks and benefits of drug therapies requires cogent data from large-scale randomized trials designed a priori to test the hypothesis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes an entire paragraph about the commentary\u2019s senior author, but it fails to note that the author serves \u201cin an advisory role\u2026to Pfizer and their legal counsel\u201d \u2014 as noted in the commentary itself. Pfizer is the company that markets Chantix. Note: this does not mean that the author is doing anything untoward, but it does raise the potential for a conflict of interest, and a release needs to make that clear.", "answer": 0}, {"article": "The effect, however, typically lasts only about seven months before the cancer starts to grow again, though some patients benefit for more than two years.\nThe results of both trials were published online by The New England Journal of Medicine in addition to being presented here.\nDoctors are eager to try the two drugs together.\nIn the latest trial, a big one was liver damage.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources cited.", "answer": 1}, {"article": "Co-authors with Sharma, who presented the data at ASCO, are Petri Bono, Helsinki University Hospital, Helsinki, Finland; Joseph Kim, Yale Cancer Center; Pavlina Spiliopoulou, Beatson, West of Scotland Cancer Centre, Glasgow; Emiliano Calvo, Centro Integral Oncol\u00f3gico Clara Campal, Madrid,Spain; Rathi Pillai, Emory Winship Cancer Institute, Atlanta; Patrick Ott, Dana Farber Cancer Institute, Boston; Filippo DeBraud, Istituto Nazionale dei Tumori, Milan, Italy; Michael Morse, Duke University Medical Center, Durham, N.C.; Dung Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Dirk Jaeger, Heidelberg University Hospital, Heidelberg, Germany; Emily Chan, Vanderbilt University, Nashville, Tenn.; Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, of Bristol-Myers Squibb, and Jonathan Rosenberg of Memorial Sloan Kettering Cancer Center.\nBoth nivolumab, known as Opdivo, and ipilimumab, known as Yervoy, were developed and marketed by Bristol-Myers Squibb, which funded the clinical trial.\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\nTwo patients discontinued therapy because of adverse events related to the drug.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the clinical trial was funded by Bristol-Myers Squibb, which developed and markets both nivolumab and ipilimumab. However, the release doesn\u2019t note that the lead author has served as a consultant to the Bristol-Myers Squibb Immuno-Oncology Network, among several others.", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes it clear that one of the sources is chief corporate officer of Veru Healthcare, which distributes the female condom known as FC2.\u00a0 ", "answer": 1}, {"article": "U.S. guidelines recommend Americans consume less than 2.3 g of salt daily, or 1.5 g for certain people who are more at risk for high blood pressure or heart disease.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\nFor this review, Taylor\u2019s team found seven studies that together included 6,489 participants.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nBut even so, the scientists think they would need to have data from at least 18,000 people before they could expect to identify any clear health benefits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from several independent sources were included as part of this story.", "answer": 1}, {"article": "But even without prostate treatment, 21 of the 27 men showed decreased levels of PSA.\nBissada is now conducting follow-up research to support the first study's findings.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nCase Western Reserve dental researchers Nishant Joshi, Catherine Demko and Robert Skillicorn; and University Hospitals Case Medical Center researchers Donald Bodner, Lee Ponsky, Sanjay Gupta and Gregory T. MacLennan contributed to the study.\nHe hopes to make periodontal treatment a standard part of treating prostate disease, much like cardiac patients are often encouraged to visit their dentist before undergoing heart procedures and a dental checkup is advised for women who are pregnant or considering pregnancy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t discuss funding, but the paper says that the study was sponsored by the authors\u2019 departments at the university. There\u2019s really no harm in leaving this information out, so we\u2019ll rule this Satisfactory.", "answer": 1}, {"article": "This was not statistically different.\nThe U-M study involved patients undergoing knee replacement surgery at any of the 29 Michigan hospitals in the surgical quality group.\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The disclosure statements included with the journal article reporting on this study note that Blue Cross and Blue Shield of Michigan support the quality improvement group that did this study and pay some of the salaries of key researchers. Even though the disclosure statements say Blue Cross and Blue Shield did not specifically fund the work on this study, the release should have noted the funding relationship.", "answer": 0}, {"article": "\"In these types of studies you think of things like this,\" Haber said, \"but how real it is, is something we're going to have to see.\nThe study is published Feb. 9 in the New England Journal of Medicine.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an independent source. Although it does not mention whether the researchers have any conflicts of interest, the authors reported no conflicts in the disclosure forms posted online by the New England Journal of Medicine.", "answer": 1}, {"article": ".\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nThis data highlighted compelling early results using the company's MRIdian system for the treatment of inoperable, locally advanced pancreatic cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This research was sponsored by ViewRay, the company that developed the MRIdian system, and the release does a good job calling attention to this. However, according to the published study, at least one of the co-authors received honoraria from ViewRay Medical Systems. Since this was not included in the release we\u2019re rating this criteria Not Satisfactory.", "answer": 0}, {"article": "\u201cBut it is definitely a breakthrough.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n\u201cOn average, the participants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources quoted were authors of the study who had relationships with the company that makes the treatment. Independent sources could have provided more context, including a more balanced view of how this treatment might affect the care of people with peanut allergies.", "answer": 0}, {"article": "Pneumonitis was more frequent among patients who were not actively using ace-inhibitors (Odds Ratio (OR) = 3.49, p = 0.02) and less frequent in smaller tumors (OR = 0.03, p < 0.01).\nAbstract and Presentation Details\n\u2022 Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer in Patients 80 Years and Older: A Multi-Center Analysis\n\u2022 News Briefing: Friday, March 17, 1:00 \u2013 1:45 p.m. Pacific time, Foothill F, http://bit.do/thoracic2\n\u2022 Poster Session, Thursday, March 16, and Friday, March 17, Yerba Buena Salons 7 and 8\n\u2022 This news release contains additional and/or updated information from the study author(s).\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nTo schedule an interview with Dr. Cassidy or an outside expert, contact the ASTRO media relations team at press@astro.org or 703-286-1600.\nThe symposium will be held March 16-18, 2017, at the San Francisco Marriott Marquis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not report anything about the funding of the study or any disclosures by the researchers. There is a note about how to seek information about the author disclosures, but this information should be contained in the release itself.", "answer": 0}, {"article": "Bone-marrow transplants, which infuse healthy blood cells taken from a donor, are used when chemotherapy and radiation fail to stop cancerous blood cells from taking over and ultimately destroying a person\u2019s immune system.\nIn the past, a patient\u2019s body would reject as a foreign intruder anything but a perfect or near-perfect match, a usually fatal development.\nEvery biological child is a half-match for a parent, and vice versa.\nThe advance should be particularly valuable for minorities and people of mixed-race background, whose chances of finding a matched donor were slim to none.\nUmbilical-cord stem cells, however, are sort of a blank slate because they haven\u2019t been exposed to much life \u2014 such as bacteria and viruses \u2014 and thus are more easily accepted even if they aren\u2019t a perfect match.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Every source in the piece is either directly involved in the types of treatments being discussed or is a patient who has undergone treatment.", "answer": 0}, {"article": "It dilates blood vessels, giving it the potential to ease an abrupt cold water-induced constriction of blood vessels in the arms and legs that can lead to blood pooling in the heart and lungs.\n\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\nWhen the SIPE participants were given sildenafil and then performed the same underwater exercise, the pressures were no longer as elevated.\nNone of the participants in either group had heart abnormalities, but the SIPE-susceptible athletes had higher pulmonary arterial pressure and pulmonary artery wedge pressure during the underwater exercise, confirming that SIPE is a form of pulmonary edema caused by high pressure in the blood vessels within the lungs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders are mentioned, although the release makes no effort to clarify possible conflicts of interest. The study on which this news release\u00a0is based states\u00a0that the principle investigators have no conflicts of interest.", "answer": 1}, {"article": "\"For many women with symptoms and especially with concerns about hormone replacement therapy, trying soy for six to 12 weeks to see if it relieves their symptoms could be a first line of treatment,\" says Melissa Melby, PhD, a professor of medical anthropology at the University of Delaware.\nThe study had no industry funding.\nTwo co-authors, not including Melby, have ties to the soy industry.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Perhaps the only saving grace of the story:\u00a0 One clearly skeptical independent expert and one other who noted limitations.", "answer": 1}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nAmong the study participants was Liz Stegall, who enrolled at the request of the family of Linda Nelson Taylor, a friend who died of ovarian cancer that wasn't diagnosed until it was advanced.\nOne expert said the study is an important step but definitely needs follow-up work.\nLu said the study isn't large enough to justify recommending yet.\n\u201cIt's a well-done study about which its authors are appropriately careful in their conclusions,\u201d said Dr. Len Lichtenfeld, deputy medical director at the American Cancer Society.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert from the American Cancer Society who provides much-needed perspective.", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not cast a very wide net for sourcing, relying entirely on the contents of the New England Journal of Medicine paper and an accompanying editorial. But we give the story points for at least presenting a diversity of views. For one, both the Times story and a competing Reuters story referred to the editorial, but only the Times story used the editorial to note the study\u2019s limitations and failure to prove the drug\u2019s efficacy.\n\u201cIn the commentary, Dr. Michael E. Wechsler of National Jewish Health in Denver, said that in actual medical practice, patients would not be taken off their existing medications. The real need, he wrote, is for drugs to help control asthma when used in addition to the existing medications, and the study had not demonstrated that dupilumab could fulfill that role.\u201d\nThe Times also did something that Reuters did not do. It pointed out that the lead author on the story \u2013 quoted liberally by Reuters by not quoted here \u2013 \u201chas been a consultant to Regeneron.\u201d", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Lower blinds and turn off lights so your room is as dark as possible.\nHe applied for funding of the research a few years ago, to no avail.\nI suspect it's part of the picture, along with lack of exercise and dietary indiscretion.\"\n\"It's a shame,\" he says.\nLettuce, too, has a \"long history of helping people get to sleep,\" Aziz says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The author cites three independent sources and identifies each of their affiliations.\u00a0", "answer": 1}, {"article": "Because obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\nThe study was published online Feb. 26 in the New England Journal of Medicine.\n\"I don't think the evidence from this study is enough to say now that you should absolutely get this surgery so you have a better pregnancy outcome.\"\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the independent source who wrote the editorial that came with the research article. This is a strong point of the story\u2019s coverage.", "answer": 1}, {"article": "The researchers argue that while nicotine replacement appears to help people quit, it is not enough to prevent relapse in the longer run.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nThey interviewed the participants three times, about once every two years during the 2000s, asking the smokers and quitters about their use of gum, patches and other such products, their periods of not and their relapses.\n\u201cWe were hoping for a very different story,\u201d said Dr. Gregory N. Connolly, director of Harvard\u2019s Center for Global Tobacco Control and a co-author of the study.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is the only one of the three stories we reviewed that did not quote someone directly connected to GlaxoSmithKline, the maker of some of the best selling tobacco replacement products. Several independent sources were quoted.", "answer": 1}, {"article": "Heart attacks can occur when plaque blocks blood flow to the heart.\nMONDAY, Jan. 14, 2013 (HealthDay News) -- Eating three or more servings of blueberries and strawberries each week may help reduce a woman's risk of heart attack, a large new study suggests.\nThe study can't say specifically what about the berries seemed to result in a lower risk of heart attack among these women, or that there was a direct cause-and-effect link between eating the berries and lowered heart attack risk.\n\"Berries were the most commonly consumed sources of these substances in the U.S. diet, and they are one of the best sources of these powerful bioactive compounds,\" said study lead author Aedin Cassidy.\n\"Berries can also help people lose weight and maintain that loss because they feel fuller faster.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts, preventive cardiologist Dr. Suzanne Steinbaum and nutritionist Dana Greene. We wish that the experts were quoted on a more analytical view of the study, instead of talking so much about berry diets. Greene is even quoted as saying, \u201c[Berries] are so good for you,\u201d and \u201cThere is no downside\u201d to eating berries. Again, too much of anything could become more of a harm than a benefit, as mentioned above. It\u2019s interesting that Steinbaum was also interviewed in the competing TIME story.\u00a0 Why?", "answer": 1}, {"article": "U.S. regulators in October approved Keytruda on an accelerated basis for patients with advanced non-small cell lung cancer whose tumors produce PD-L1.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nKeytruda thereby met its main goal of the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does note that the Keytruda trial information came from Merck, which produces Keytruda. However, the story does not appear to include any input from independent sources.", "answer": 0}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nDr. Gunter is supported by the National Institutes of\n\nHealth: NIH T32 HL110853.\nSupport for this study came from the Agency for Healthcare Research and Quality: AHRQ R21 HS023395.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that support came from the Agency for Healthcare Research and Quality and that lead author Rebecca L. Gunter, MD, is supported by the National Institutes of Health.", "answer": 1}, {"article": "\u201cOur lab is on an island in the South.\nI know that it\u2019s not realistic to say \u2018no sun.\u2019 \u201d\n\nShe is, however, quite knowledgeable about how to be safe when you\u2019re in the sun.\nA REFRESHING outdoor shower, an icy cocktail and a comfortable spot to watch the sunset: One could argue that the most relaxing parts of a sunny summer day don\u2019t happen until it\u2019s over.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nThe devotion to hats and rash guards, the careful selection of sunscreen and thorough application and reapplication every 90 minutes is at best tedious, and when children are involved, the process can be truly demoralizing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dermatologist Rand\u2019s one-line caution \u2014 \u201cthere\u2019s nothing you can do to reverse sun exposure\u201d \u2014 is welcome, but does not suffice to balance the overwhelming weight of the rest of the story promoting\u00a0the products.", "answer": 0}, {"article": "Heterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nAt the same time he says, there was no evidence of safety concerns.\nClear evidence Baeten said, that PrEP substantially reduces infection risk.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nHe is the iPrEx protocol chair.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least one independent source is quoted, and there don\u2019t appear to be any conflicts of interest that should have been pointed out to readers.", "answer": 1}, {"article": "Nonetheless, the doctors were pleased when M.R.I.\n\u201cThis will substantially alter the way that chemotherapy is given in the future,\u201d said Dr. John Boockvar, the brain surgeon who devised the trial.\nBy mid-November, the researchers had treated five patients, including Mr. Sugrue; they first infused mannitol, waited five minutes and then sprayed in the Avastin.\nTheir study involves a technique first developed about 30 years ago, which uses mannitol to open the blood-brain barrier temporarily to get chemotherapy into the brain.\nMrs. Sugrue said the doctor urged her and her husband to resist doing an Internet search for glioblastoma because they would just read that it was a death sentence.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter draws on three principal sources: two physicians involved with the research and an independent expert on glioblastoma from NIH. ", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe label warns that evidence is limited.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\n\u201cThe guidelines for how to approach allergens in children are changing, the science is changing, and it\u2019s important for parents to know.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the physician-developer of the product, government officials and physician-patient advocates. While we would have liked an expert source with no direct ties to industry or advocacy, we\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nThe study is preliminary and doesn't prove cause and effect.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Independent sources were used to write this story; there was, however, \u00a0no information about sources of funding for this research.", "answer": 1}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\nScientists from the University of Nottingham and Harvard University's Wyss Institute hope so.\nThe stem cell procedure is in the earliest stages of development, said Celiz.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nCould root canal procedures go by the wayside in the not-too-distant future?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacks viewpoints from independent experts, such as someone from the American Association of Endodontists.", "answer": 0}, {"article": "More than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23 to 26 percent of the population.\nNone of the patients in the HF10 therapy group experienced paresthesia.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\nIn the study, researchers examined 171 patients with chronic back or leg pain who were implanted at 10 comprehensive pain treatment centers.\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell readers that the study was funded by the Nevro Corporation, which makes the device that was studied, nor that the study authors had ties to the company and other medical device makers.", "answer": 0}, {"article": "Patients with heart disease or who are using antidepressants known as selective serotonin reuptake inhibitors should also be careful when taking sumatriptans, said Waltman, who added that she thought the patches \"are wonderful.\"\nAnother expert described the problem this way.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nAccording to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine.\nNuPathe Inc., which makes Zecuity, hopes to have the patch on the market later this year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Based on a brief Web search, the two expert sources quoted in the story don\u2019t seem to have any\u00a0conflicts of interest related to this issue.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\nThe comprehensive meta-analysis and assessment of human clinical trials, published in the official journal of the American Urological Association, The Journal of Urology\u00ae, assures practitioners and their patients that cranberry products are a low cost, low risk and effective way to help prevent recurrent UTIs.1\n\nTo answer the question, \"Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections?\"\nLuis A, Domingues F and Pereira, L. Can cranberries contribute to reduce the incidence of urinary tract infections?\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is satisfactory, yet the release could have been more transparent about the organization that issued the release. The study itself was supported by a Portuguese university and a Portuguese bank, which is noted in the release. However, the release lists a PR firm as the contact but includes a quote from the director of the Cranberry Institute and a summary of the Institute as background, without ever mentioning the group\u2019s relationship to the study.\u00a0 After looking at the Cranberry Institute\u2019s website it\u2019s clear that the trade group has worked with the PR firm previously on news releases. Why not explain the Cranberry Institute\u2019s interest in the research?", "answer": 1}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nThis study evaluated 186 patients, comparing 94 Medicaid patients at an addiction treatment facility with confirmed cases of opioid abuse, and 92 healthy patients with no history of opioid use.\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No information is provided about who provided the funding for the study. The news release quotes three of the study\u2019s authors, including Dr. Ashley Brenton, who is identified as the \u201cAssociate Director of R&D for Proove.\u201d The two other authors quoted do not appear to work for Proove. The journal article on which the new release is based also omitted\u00a0 information about the funding source for the study.", "answer": 0}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nThis article is featured in Newsweek's Special Edition: Nature's Remedies\u2014Heal Your Body.\nThis article was excerpted from Newsweek's Special Edition: Nature's Remedies\u2014Heal Your Body.\nThe most common, not surprisingly, are headaches.\nEven those who are approved to undergo the treatment face another barrier as TMS is not widely covered by health insurance.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The one scientist quoted in this story holds patents on several brain stimulation methods and apparatuses, a potential conflict of interest that receives no attention in the story.", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We spent some time on the fence here, but we were ultimately willing to give the story the benefit of the doubt. The blog calls out a link to a much more complete Wall Street Journal story about the study, and it says, \u201cRead the WSJ story to get perspective from Medtronic and Boston Scientific.\u201d But it spends too much time quoting the lead author and does not quote anyone else. It does, however, provide information that was missing in the LA Times and other coverage. \u201cAuthors of the study reported receiving funding from Medtronic and other device- and drug makers.\u201d We thought that context, along with the link and a quote from statement from the Heart Rhythm Society were enough to pass this criteria. As with the LA Times story, though, we don\u2019t understand why the editorial accompanying the journal article wasn\u2019t cited.", "answer": 1}, {"article": "Older mothers are more likely to give birth to Down syndrome babies.\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\n\"This is due to an extra chromosome 21, and that leads to physical and mental impairment.\"\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included the perspective of one independent expert.", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\nBut conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The lead author of the story is the only source cited, and we\u2019re not told if he has any conflicts of interest. The HealthDay story we reviewed rated better on this criteria.", "answer": 0}, {"article": "The result: at week 24, all of the patients receiving either dose of ocrelizumab fared better in terms of lesion count than either the placebo or standard treatment groups.\nTo test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nAnd I see no major advantage of this drug versus that older drug.\nThe new therapy's potential is only in the early stages of exploration, cautions an international study team comprised of researchers from the United States, Canada, Switzerland and the Netherlands, in the report published in the Nov. 1 online edition of The Lancet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Mayo expert\u2019s input was the one saving grace of the story.\nThe story also disclosed that two drug companies funded the study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any independent researchers or clinicians who could comment on the impact of this new development on the management of osteoporosis.", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\nThe patient, who had both HIV infection and leukemia, received the bone marrow transplant in 2007 from a donor who had a genetic mutation known to give patients a natural immunity to the virus.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\n\u201cFrom these results, it is reasonable to conclude that cure of HIV infection has been achieved in this patient,\u201d they wrote.\nSchneider\u2019s team found no evidence of HIV anywhere.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u2019s main expert source was\u00a0Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS. His comments offered context and appropriate cautions. While the story does not discuss potential conflicts of interest, the researchers declared in their journal article that they had no competing financial interests and the work was supported by non-commercial institutions. ", "answer": 1}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nDr. Laetsch will be the national leader for that clinical trial in children.\nThe research appears in The Lancet Oncology.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release lists the funders of the trial and notes that the lead investigator is a paid consultant for Loxo Oncology.", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\n\"Hopefully, there will be less anxiety about getting a recall.\"\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nThe study wasn't really designed to answer the question of which screening regimen is best, study researcher Rebecca Hubbard, PhD, says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were quoted.", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nFirst Take: The new research, published in Circulation on Monday and funded by the National Institutes of Health, mined three large, ongoing epidemiological studies (74,890 women in the Nurses\u2019 Health Study, 93,054 women in the Nurses\u2019 Health Study 2, and 40,557 men in the Health Professionals Follow-up Study), following them for at least 20 years.\nChan School of Public Health, did something clever: they ran the analysis on nonsmokers only.\nOverall, the conclusions have been pro-coffee.\nBut given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The STAT story included not just any \u00a0\u201coutside\u201d expert comment, but chose \u00a0a co-author of a seminal 2013 study, whose professional credibility added to the story\u2019s. And unlike the CNN story, it offered details of the ongoing epidemiological studies from which the new data were drawn.", "answer": 1}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe study was inspired by a finding in an early trial of Gelesis100, a novel hydrogel which demonstrated pronounced weight loss in people with prediabetes.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\nPresented at the American Diabetes Association's 77th Scientific Sessions on June 11, 2017, the additional research includes an examination of patients in the Prevencion Dieta Mediterranea (PREDIMED Study), a Randomized Trial of a Low-CHO Diet for Obesity (CHO Study), and The Healthy Weight for Living Study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not state the funder of the research. A deeper dive into the full-text publication of the research revealed that the study was funded by Gelesis Inc.,\u00a0a biotechnology company working to develop therapies to induce weight loss and improve glycemic control in overweight and obese patients.", "answer": 0}, {"article": "Nearly 20 percent of women in the United States who are eligible for cervical cancer screening report they haven't been tested for cervical cancer within the recommended time interval, national surveys have shown.\nSome travel expenses for Des Marais were paid by Hologic, and others have consulted for the company.\n\"We are already working on the next step, which is a clinical trial in which women who aren't up-to-date on screening get either a referral to a free clinic appointment to receive a screening, or receive a self-collection kit in the mail, followed by referral to a free clinic appointment.\nIndividual researchers were supported by the China Scholarship Council.\nNeither Hologic nor Rovers had input into the research design, analysis or interpretation of results.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes information about not only sources of funding, but also sources of research equipment \u2014 which is really good to see. The release also includes clear information regarding potential conflicts of interest.", "answer": 1}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIt enhances laboratory capacity around the globe through training and resources.\nNext, the team will work with clinicians to develop safety tests of the ZIKV-LAV in glioblastoma patients.\nIt provides a network for scientists in academia, industry and clinical settings.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source for the study is not mentioned.", "answer": 0}, {"article": "Vertigo -- episodes of dizziness that can last for minutes or days -- may be triggered by a number of health issues, ranging from an inner ear disorder to tumors.\nThe others' outcomes were not revealed.\nIn some cases, the cause is unclear.\nOf these, one-third saw their symptoms reduced or they recovered completely.\nSome had attacks rarely, maybe once a year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides only one source \u2014 a member of the research team \u2014 and no independent sources.\u00a0 It doesn\u2019t disclose who funded the study, either.", "answer": 0}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nIt was funded by an \"educational grant\" from Glaxo SmithKline, which makes Paxil.\nAfter six weeks on Paxil, his fear level dropped to a 4 -- an improvement that led him to continue the medication after the trial.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The source of information for this study appears to be a journal article.\u00a0 No one is quoted. There is no evidence of any input sought from any source independent of the study. \u00a0 ", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story makes it clear that several companies are working to develop medicines that can act as immune modulators, and at least one of the doctors appears to be independent of the research.\nIt does not, however, make an effort to link its sources to any of those companies. In at least one case, a dermatology professor on the front lines of eczema treatment research offers information\u00a0in her employer bio\u00a0indicating that she is a consultant for one of the companies featured in this story.", "answer": 0}, {"article": "The United States Preventive Service Task Force (USPSTF) currently recommends that physicians screen patients for dysglycemia (prediabetes or type 2 diabetes) when they are 40 to 70 years old and are overweight or obese.\nO'Brien will be presenting his findings today at the Society for General Internal Medicine conference in Denver, Colorado.\nDr. Ronald Ackermann is the study's senior author.\nThe study was published today, Friday, April 13, in the Journal of General Internal Medicine.\nThe other co-authors were from the CDC.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are satisfactorily explained and detailed.", "answer": 1}, {"article": "They didn\u2019t advise against using the devices.\n\u201cIt is a constant struggle for a patient who is an adolescent to stay in control of any therapy,\u201d said Steve Sabicer, a spokesman for Minneapolis-based Medtronic Inc., which makes the top-selling insulin pump.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The original AP story included the perspective of an independent expert, the American Diabetes Association\u2019s president for medicine and science.\u00a0 It also included input from the editor of a patient newsletter.\u00a0 But the Pioneer Press deleted these perspectives.\u00a0 Instead, the St. Paul story included a quote from the manufacturer of the top-selling insulin pump. Why?\u00a0 Because it\u2019s a local Twin Cities company?\u00a0 ", "answer": 0}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThis study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\nThe findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release discloses that the study was funded by the Yale Cancer Center\u2019s Arthur R. Sekerak Cancer Research Fund.", "answer": 1}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nCurrently, there is no definitive test for MS.\nThe research was funded by an Incubator grant from MS Research Australia.\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\nThe research was made possible through the generosity of patients at the Brain & Mind Centre's multidisciplinary Multiple Sclerosis Clinic, a collaborative service offered by Royal Prince Alfred Hospital, and the University of Sydney.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is identified. Since the goal is to devise a commercial diagnostic test, we would also encourage releases to point out any potential conflicts of interest. In this case, there doesn\u2019t appear to be any.", "answer": 1}, {"article": "\"We can't say this research is definitive,\" Dr. Senay said.\n\"The next step would obviously be to do an intervention trial where one group eats the diet, the other eats a traditional American diet and then look at the outcome.\nFor more further information, you can see the studies here and here.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has a medical editor reporting on the latest study of the Mediterranean diet. It is difficult to tell what sources of information were used. Citing other medical experts would have been very helpful to put the results of this study in perspective and give the public advice on how to adopt aspects of this diet in place of a high-fat, highly processed foods typical of the American diet. ", "answer": 0}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nThe study was to be presented Tuesday at the Alzheimer's Association meeting in Chicago.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\nPatients underwent significant overall improvement in their other behavioral symptoms, and had small benefits in their brain function and nutrition during the study.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A lead researcher and a source from the Alzheimer\u2019s Association were quoted. Since this research was presented at the Alzheimer\u2019s Association meeting, this does not meet the bar for an independent source.", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story uses independent sources, it fails to note that Merck, the maker of boceprevir, sponsored the two clinical trials published in the New England Journal of Medicine. It also fails to mention that many of the study authors have received funding from Merck.\u00a0\n ", "answer": 1}, {"article": "This can result in a significant decrease in sperm count--leading to infertility--because the body needs its own testosterone to produce sperm.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nFull citation: \"Oral Enclomiphene Citrate Raises Testosterone and Preserves Sperm Counts in Obese Hypogonadal Men, Unlike Topical Testosterone: Restoration Instead of Replacement.\"\nThrough the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising.\nOver five months, patients had 10 clinic visits with one overnight stay.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Two of the three researchers, co-authors of the journal manuscript,\u00a0are consultants to Repros Therapeutics. This is disclosed in the journal manuscript but not mentioned in the news release. \u00a0Enclomiphene is in their product pipeline.", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert, the father of a young girl being vaccinated. The story should have quoted additional experts or clinicians who could provide some additional perspective.", "answer": 0}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nDr. Stevenson likened such information to the game of \u201cJeopardy!\u201d \u2014 doctors are given answers in search of a question.\nDr. Richard Page, president of the Heart Rhythm Society, said doctors wonder if they can be held liable if they do not look at all the data.\nThe company has no editorial control over the papers the scientists write, Dr. Saxon said.\nThose with the nontransmitting device were seen in their doctor\u2019s offices every few months, the standard of care.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0Clinicians who were involved with the makers of the devices discussed were quoted in this piece.", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nGonzalez said the new trial addressed a serious medical need.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\nBesides Gonzalez, the trial involved other investigators from the stroke centers of Cedars-Sinai and UCLA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains that the study was funded by grants from the National Institutes of Neurological Disorders and Stroke of the National Institutes of Health.", "answer": 1}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is associated with some serious side effects.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nThe crystals cause swelling, redness, pain, and stiffness in the joints.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Inadequate. We weren\u2019t told who funded the research.\u00a0 And why do we have to hear claims of novelty only from a company president, lifted from a news release?\u00a0 That\u2019s inadequate sourcing. ", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\nBack then, she couldn't even wipe the tears from her eyes \u2014 and there were plenty of tears shed.\nImagine being an active and athletic woman, playing in a softball league and riding horses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two physicians from the clinic that provides the treatment. The story should have quoted other, independent physicians or researchers who could have provided some much needed perspective.", "answer": 0}, {"article": "Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals.\nSo our goal is to make warfarin safer.\nNo patient died during the trial.\nBut we continue to prescribe it because it is highly effective, reversible and inexpensive.\nThe adverse events were bleeding, formation of blood clots in the veins and warfarin overdoses.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Nicely done and quite complete.", "answer": 1}, {"article": "The subjects were followed for 10 years.\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nDr. Krumholz and Dr. Khurram Nasir, a preventive cardiologist at Baptist Health South Florida, who conceived the new study, reasoned that research on heart scans had not been designed to help doctors make treatment decisions they face today.\nFirst, he asks patients for whom statins are recommended according to the current guidelines if they would want to avoid taking the drugs if they turn out to have a calcium score of zero and an actual risk of less than 5 percent.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a split decision that we ultimately ruled Not Satisfactory. There are multiple independent sources in the story, so it clearly addresses that element of the criterion. However, the story does not report the financial relationships some of the study authors have with manufacturers of scanners and other medical devices. One of our reviewers argued that these scanning machines are essentially generic and that therefore a conflict of interest disclosure is not relevant in this case. Two others voted that the potential conflict, minimal though it might be, was still directly relevant to the story and merited a brief mention. This is an instance where a binary Satisfactory/Not Satisfactory rating does not capture the nuance involved in our decision-making, which is why we always encourage readers to pay more attention to the comments than the ratings.", "answer": 0}, {"article": "Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\n\"In this first prospective phase II trial for refractory metastatic SCCA, our exploratory analysis of pre- and on-treatment tissues samples revealed potential correlations between immunologic biomarkers and clinical outcomes to nivolumab,\" said Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology and national study principal investigator.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nFinal clinical results for the study will be reported at the American Society of Clinical Oncology's 2016 annual meeting in Chicago by Eng on behalf of the National Cancer Institute's Experimental Therapeutics Clinical Trials Network (ETCTN) and its collaborators.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release could have been transparent about financial backing. Funding sources are listed, but there is no mention of whether individual researchers have potential conflicts of interest. In our review of MD Anderson\u2019s kidney cancer news release last fall, we noted that one of the researchers involved in that study is a paid consultant to the maker of nivolumab, Bristol-Myers Squibb. That researcher, Padmanee Sharma, M.D., is also part of the anal cancer study team. Neither news release noted her financial tie, and the reader is left to wonder whether any of the researchers have vested interests in the study outcome.", "answer": 0}, {"article": "After adjusting for factors that might play a role in dying, such as age, gender, ethnicity and common causes of death, the researchers found those taking statins lived longer than those who were not taking them.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n\"We need to further investigate the reasons for patients with high cholesterol having improved mortality in four of the most common cancers,\" said senior researcher Dr. Rahul Potluri, a clinical lecturer at Aston University School of Medicine in Birmingham.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not identify whether there are any conflicts for the study authors, but they do not appear to have any when we researched them ourselves. We are glad the story included a quote from an independent source\u00a0at\u00a0the American Cancer Society.", "answer": 1}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nTo overcome the challenges of conventional combination therapy, the NUS team of engineers developed the CURATE.AI platform, which uses the patient's own clinical data - such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood - to calibrate his or her unique response to treatment.\nMultiple clinical trials using CURATE.AI-guided combination therapy for oncology and additional applications such as post-transplant immunosuppression are underway.\nThis new study demonstrates that CURATE.AI can optimise multi-drug regimens.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It is not made clear who funded the relevant study, who funded the creation of CURATE.AI, or whether CURATE.AI has been patented or is under consideration for being marketed as a for-profit medical tool.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nWickii Vigneswaran, MD, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology.\nImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\n\u201cThe net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma,\u201d Dr. Vigneswaran concluded.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any funding sources for the study but we\u2019ll rate this \u201cNot Applicable\u201d since the surgeries described were performed in one surgeon\u2019s practice. There are also no new drugs or devices in play and the procedures are not new or novel.", "answer": 2}, {"article": "\"We're kind of on the edge of this becoming more accepted.\"\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nResearchers then tracked the participants for roughly 15 years, taking special note of the 936 patients who died.\nIn this new study, doctors referred 9,715 healthy patients in the Nashville area between 1996 and 1999 to a cardiology outreach screening program provided by the military's Tricare Healthcare System.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story goes a long way toward satisfying this criterion by including comments from an expert who was not connected to the research. But it fails to tell readers that some of the researchers receive funding from General Electric Healthcare, which sells scanners used for CAC tests, or from pharmaceutical companies who stand to garner more patients if CAC testing is expanded.", "answer": 0}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nDr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.\nWEDNESDAY, March 2, 2011 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article includes quotes from an independent expert, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City and from a related editorial also published in The Lancet.\nThe story\u00a0points out that the study was funded by the company that markets eribulin but it should have further noted that several of the authors of the study received grants or consultancy fees from Eisai.\u00a0 In addition, five of the study authors are employees of Eisai.\nWe\u2019ll rule this one barely satisfactory.", "answer": 1}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\n\u2022 Lesser-known signs of breast cancer women should watch out for\n\nDr. Deanna Attai, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles, said that while it's an observational study, not a clinical intervention, its larger point about diet and health is important.\n\"The sexy headline is eat this and you'll have a lower risk of breast cancer, but I'd shift the focus to, eat more fiber because it's better for you and you'll be a healthier person and you're less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\" said Attai.\nIn an accompanying editorial, Duke University Medical Center's Dr. Kimberly Blackwell said there's longstanding evidence that dietary fiber may cut down on circulating estrogen levels through changes in the gut microbiome.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from multiple independent sources who provide valuable perspective on the research. We particularly liked this line from Dr. Deanna Attai.\u00a0(Full disclosure: Dr. Attai is also a reviewer for HealthNewsReview.org.)\n\u201cThe sexy headline is eat this and you\u2019ll have a lower risk of breast cancer, but I\u2019d shift the focus to, eat more fiber because it\u2019s better for you and you\u2019ll be a healthier person and you\u2019re less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\u201d\nAnd while the story does not address conflicts of interest, there do not appear to be any conflicts of interest to report.", "answer": 1}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nFounder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\nWALNUT CREEK, Calif., Jan. 15, 2016 /PRNewswire/ -- Child screams from the pain of earache; exhausted parent ventures to drugstore in wee hours to find\u2026nothing.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No confusion here. The release is clearly a promotional vehicle for ClearPop which is noted in the dateline and throughout the copy. It also provides links back to the ClearPop website and states that the creator of Clearpop also started and leads the company.", "answer": 1}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\n\"They will be more interesting if we ever get this kind of data in a screening population.\"\nDr. Durado Brooks, director of colorectal cancer at the American Cancer Society, agreed.\n\"Hopefully, this is a good start for a more reliable test.\"\nAhlquist noted that the test still needs to be refined.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least the input of the director of colorectal cancer for the American Cancer Society was important.", "answer": 1}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nGeneral support for Marb\u00e1n's laboratory is provided by the National Institutes of Health.\nCapricor has licensed additional intellectual property from Cedars-Sinai and the University of Rome.\nCedars-Sinai and Marb\u00e1n have financial interests in Capricor.\nThe team is studying the use of stem cells to treat patients with Duchenne muscular dystrophy as well as patients with heart failure with preserved ejection fraction, a condition that affects more than 50 percent of all heart failure patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that \u201cgeneral support\u201d for Marban\u2019s lab is provided by the National Institutes of Health, and that Cedars-Sinai along with its heart institute chief Eduardo Marban, a co-author of the study, have financial interests in Capricor, which own the process to grow cardiac-derived stem cells.", "answer": 1}, {"article": "It attacks and breaks down a naturally-occurring protein in the body which normally prevents cancer cells from spreading.\nHe said this was \u201ca difficult but not impossible task\u201d and one that would be made easier by the better understanding of the biological processes gained in this early research.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nHe said his team is now working with other scientists to try to design a drug which could interrupt the gene\u2019s activity.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses no independent sources. It quotes just two people: Surinder Soond and Andrew Chantry, the two authors of the paper published in Oncogene. (You need a subscription to view it.)\u00a0 The claims made in this story needed independent analysis.", "answer": 0}, {"article": "Researchers also found suggestive associations with lower reporting of other symptoms, including joint problems, hair thinning/loss and memory less in women who consumed more soy foods, but these associations did not reach statistical significance.\n\"These symptoms can adversely impact survivors' quality of life and can lead them to stopping ongoing treatments, she says.\nThe authors report having no personal financial interests related to the study.\nThe study was funded by a Lance Armstrong Foundation Young Investigator Award and the National Cancer Institute (CA139408).\nConnect with Georgetown Lombardi on Facebook) and Twitter (@LombardiCancer).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There was disclosure of the funding sources, and the release tells us that the study authors had no financial conflicts of interest. Good job.", "answer": 1}, {"article": "\"All drugs of abuse operate using some shared pathways.\nThe studies, published Monday in the journal JAMA Internal Medicine , compared opioid prescription patterns in states that have enacted medical cannabis laws with those that have not.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\n\"This study adds one more brick in the wall in the argument that cannabis clearly has medical applications,\" said David Bradford , professor of public administration and policy at the University of Georgia and a lead author of the Medicare study.\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted the lead authors of each of the studies. It also quoted the independent co-author of the invited commentary. Another source was Melissa Moore, New York deputy state director for the Drug Policy Alliance. The article did not mention that the Drug Policy Alliance advocates for legalizing and regulating marijuana. There is one brief paragraph in the article that described \u201csome skeptics\u201d who \u201cargue that medical marijuana could actually worsen the opioid epidemic\u201d but no one is quoted.", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\nReplacing anticonvulsants is not merely an end in itself.\nAt William\u2019s worst point, a night in July 2010, he had a seizure every time he fell asleep, suffering 23 grand mals between midnight and 6 a.m.\n\nDr. Devinsky had prescribed weekly doses of prednisone, a steroid, and in desperation Ms. Moller decided to administer a mega dose.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We applaud the reporter for talking to so many people for this piece. It must be noted, though, that most of the sources quoted in the story have a stake in the outcome of research on anti-inflammatories for drugs. The first is William Moller\u2019s mother, Elisa, who has elected to give her sun mega-doses of steroids, unproven to show long-term efficacy without significant side effects. The second is William Moller\u2019s doctor, Orrin Devinsky, director of the Comprehensive Epilepsy Center at the New York University Langone Medical Center. He, too, must be hoping that his treatment protocol for William and other patient\u2019s is justified. Then there are Eleonora Aronica, a neuropathologist at the University of Amsterdam, and Annamaria Vezzani, a neuroscientist at the Mario Negri Institute for Pharmacological Research in Milan, both of whom have made inflammation\u2019s relationship to epilepsy the central focus of their research. Dr. Jacqueline French, a neurologist at the N.Y.U. Comprehensive Epilepsy Center, is leading a drug trial for treating epileptics with anti-inflammatories. Only one expert appears to be speaking from a place of academic objectivity: Dr. Tallie Z. Baram, an epilepsy expert at the University of California, Irvine, who says, \u201cLike any new field, there\u2019s a lot of enthusiasm and almost a bit of religion involved.\u201d Indeed. And the religion in this story wins out, with it ending on Elisa Moller being paraphrased saying, \u201canti-inflammatories were a miracle intervention for her son.\u201d", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nBut none are as accurate as a standard blood-sugar test.\nand made by DexCom, is said by some researchers to be a bit more accurate, as is a third device, from Abbot, which has not yet been approved.\nI also had three sensor catheters slip out and require early replacement, which would be especially annoying to anyone paying the $35 that each sensor costs; I wasn\u2019t, because MiniMed had supplied everything free for testing, but everybody else will, since the sensors are not yet covered by insurance.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources of information were obtained. In fact, the only information is related anecdotally by only one man, which could be biasing. ", "answer": 0}, {"article": "A study published in this month's issue of the Archives of Neurology found that the diet might protect against blood-vessel damage in the brain, reducing the risks of stroke and memory loss.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent perspective provided and \u2013 if the journalist isn\u2019t going to do a critical analysis of the evidence \u2013 then an independent perspective is sorely needed in such stories.", "answer": 0}, {"article": "Advising patient with chronic sinus congestion to use nasal irrigation - a popular nonpharmacologic treatment - improved their symptoms, but steam inhalation did not, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal).\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\n\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release does not make any comment on the study funders. According to the UK clinical trial registry, the study was sponsored by the University of Southampton (UK).", "answer": 0}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\n\"As a whole, the study is negative,\" study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nSince the current study was presented at a meeting, its findings should be considered preliminary until published in a peer-reviewed journal.\nColeman disclosed receiving speaker fees from Novartis; the researchers also received academic grant funding from the drug maker.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quoted an independent source. It also addressed conflicts-of-interest among the researchers.", "answer": 1}, {"article": "Secondary cancer, known as metastasis, is the most common cause of death in breast cancer patients as there are few effective treatments once it has taken root.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release didn\u2019t note any funding sources. The published study stated that the study was funded by Novartis, which makes the bisphosphonate drug Zometa, and by Inbiomotion which developed the MAFTest that tests for amplification of the MAF gene. (The release does mention that the test was developed by Inbiomotion.)\nClearly, both companies would benefit from positive study results and positive news coverage and thus must be mentioned in the news release as funders of the study in the interest of transparency.", "answer": 0}, {"article": "Despite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\nThis higher incidence of tumor recurrence can contribute to a poorer prognosis,\" said Nikita Wright, first author of the study and a senior Ph.D. student in Dr. Ritu Aneja's laboratory in Georgia State's Biology Department.\nThe study was funded by the National Cancer Institute of the National Institutes of Health.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly states the funder: \u201cThe study was funded by the National Cancer Institute of the National Institutes of Health.\u201d\nAs far as conflicts of interest, one of the authors, Padmashree C. G. Rida, disclosed receiving a salary from Novazoi Theranostics, which is described in one business directory as a \u201cDiagnostic Substances business / industry within the Chemicals and Allied Products sector.\u201d It doesn\u2019t appear that the tie represents a potential conflict relative to this study, but we think it\u2019s always prudent to disclose such commercial affiliations in news releases.", "answer": 1}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nThe two tests together appeared to generate both sensitive and specific results.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\n\u201cWhat we\u2019ve found is that your risk of having an aggressive cancer if you\u2019re in the high group is about 40%, and if you\u2019re in the low group, the risk of having an aggressive cancer is only about 7%,\u201d Tomlins says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentioned that the study reported on was funded by the company making the test; and it also mentioned that several of the authors of the study had financial interests in the company.\nThe story included quotes from a study author, as well as Dr. Jones from the Cleveland Clinic, though there was no mention of whether Dr. Jones had any financial interest in the test reported on.", "answer": 1}, {"article": ".\n\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\nIn fact, in a previous study published last fall, Papa and her team at Orlando Health tested both.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release mentions that a lead researcher is \u201cNIH funded\u201d but does not specify funders for this study nor does it include a statement about potential conflicts of conflicts. (Just to clarify \u2014 we\u2019re always pleased to see a statement even if no conflicts are known to exist.) The journal article itself has a disclosure footnote that states Papa is an unpaid consultant to Banyan Biomarkers, Inc., while Welch and Lewis disclosed receiving contract research funding from Banyan. Banyan is a for-profit biotech company in Florida seeking to commercialize a biomarker for head injury. We think this connection between the research and the biotech should have been mentioned in the release.", "answer": 0}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\n\"Products that block PD-1/PD-L1 interactions are part of an evolving story about the relationship between the body's immune system and its interaction with cancer cells.\"\nThese are distinct programs intended to facilitate and expedite the development and review of certain new drugs in light of their potential to benefit patients with serious or life-threatening conditions.\nThe agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This release describes the approval of a new drug by a regulatory agency, but we\u2019d still like to know who sponsored the study that\u2019s the basis for the approval. It\u2019s not enough to state who markets the drug.", "answer": 0}, {"article": "Dark chocolate generally has a higher percentage of cocoa content than milk chocolate.\nFeb. 7, 2011 -- Giving your sweetie chocolate for Valentine's Day may show you care for their health as well as their heart.\n\"When looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\"\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\n\"These substances help keep the arteries healthy and are protective against cardiovascular disease,\" says preventive cardiologist Suzanne Steinbaum, MD, of Lenox Hill Hospital in New York City, in an email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story discloses that the research was conducted by Hershey scientists, and it solicits comments on the findings from an expert who was not affiliated with the study. Although this is\u00a0enough for a satisfactory, we wish the story would have\u00a0sought out someone with a more skeptical take\u00a0on the results.\u00a0This\u00a0expert\u2019s comments \u2014\u00a0\u00a0\u201cWhen looking for a sweet snack, a square of dark chocolate might, in fact, be your healthiest choice!\u201d\u00a0\u2014 don\u2019t do much to help readers put the findings in the appropriate context.", "answer": 1}, {"article": "Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.\nThe Atlas study was paid for by various organizations including the United States Army, the British government and AstraZeneca, which makes the brand-name version of tamoxifen.\n\u201cThey don\u2019t feel well on them, but it\u2019s their safety net,\u201d said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug.\nThe results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent use of sources.\u00a0 A variety of researchers, clinicians, and a patient were represented.\nThe story clearly stated that AstraZeneca, which makes a form of tamoxifen, helped finance the study.", "answer": 1}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nThe consistency of the fcMRI scans makes them a promising diagnostic tool.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study are listed on a sidebar of the news release hosting site, EurekAlert!", "answer": 1}, {"article": "\u201cShe would wake up in the middle of the night with night terrors at a very young age, she stopped napping around 15 months \u2026 any type of change in our schedule could set off an epic tantrum.\u201d\n\nOakes didn\u2019t know it then, but her daughter Mallory was one of more than 10 percent of American children living with attention deficit hyperactivity disorder (ADHD)\n\n\u201cShe was diagnosed in first grade after there were some difficulties in the classroom,\u201d Amy said.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cWhat thinking really is is really coordinating different networks in the brain so that we can bring all of those networks together at one time,\u201d Melillo told FoxNews.com.\n\u201cAnd if [kids] have poor coordination in their body, they often have poor coordination in their brain -- poor coordination between their networks -- so they can't bring all these networks together to learn in the most optimal way.\u201d\n\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources independent of the franchise that sells the \u201ctraining\u201d to families. The fact that the story ends with a link to the commercial Brain Balance Centers website reinforces the notion that this is more promotion than journalism.", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\nInterest in Circassia had been sky-high \u2014 the small biotech\u2019s market value had shot up to $1 billion earlier this year on speculation that its drug would prove effective.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\nThe potential market is huge: It\u2019s estimated that 50 million Americans have allergies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article casts a pretty wide net of sources, including interviews with allergy researchers at Stanford and at Mass General Hospital in Boston, as well as investigators with drug companies.", "answer": 1}, {"article": "But there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\nAnd that could help with stigmatization of the elderly and disabled.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\nIn Canada, that\u2019s roughly 3.6 million people.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names several sources of funding.", "answer": 1}, {"article": "By Amy Norton NEW YORK (Reuters Health) - People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping.\nBoth LaRocca and Corey-Bloom said there were limitations to the current study.\nBut it\u2019s not clear if that would have any long-term consequences, Corey-Bloom said.\nBut another limitation, she pointed out, is that the study looked at the effects, and side effects, of marijuana over only a few days.\nBut the big caveat, researchers say, is that it\u2019s not clear that the downsides of pot smoking are worth it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent perspective was used in the story, and it contributed a great deal to the context and balance.", "answer": 1}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\nOur Knowledge Center article on the health benefits of avocado reveals some of the other ways the food may be good for us, as well as the potential risks of avocado consumption.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from the principal author that help place the study in context, and it notes that the story was funded by Haas Avocado Board. However, the researcher\u2019s quotes are taken directly from a press release, whereas the other outlets that covered this story all spoke directly with the study author. Additional useful information could have (and, we think, should have) been gleaned by speaking with someone who was not affiliated with the study. That\u2019s why we\u2019re rating this unsatisfactory.", "answer": 0}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nThis research was posted online in the nature.com journal Scientific Reports on October 19th, 2016.\nThe researchers developed a belt-type medical device that uses a special type of rubber to transmit MES and HS at the same time.\nThis determined the most effective treatment frequency.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that the study was funded by the Japan Agency for Medical Research and Development, Grants-in-Aid for Scientific Research. The journal article in Scientific Reports also acknowledges the belt device was provided by the Tsuchiya Rubber Co., Ltd. (Kumamoto, Japan).", "answer": 1}, {"article": "However, the researchers found that the resolve to quit seemed to disappear postpartum as many of these women started smoking again.\nDr. Abroms has stock in Wellpass Inc. (formerly Voxiva, Inc.) and has licensed Text2quit and Quit4baby to Wellpass.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n*The headline of this release was edited for clarity to match the content in the body of the release.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release offers information about both funding and conflicts of interest. It notes that the lead author, \u201cDr. Abroms has stock in Wellpass Inc. (formerly Voxiva, Inc.) and has licensed Text2quit and Quit4baby to Wellpass.\u201d This is a real strength of the release.", "answer": 1}, {"article": "Researchers found that people with the highest blood levels of these essential fatty acidsfound in fish such as salmon and tunawere more likely to perform well on tests of mental functioning and to experience less age-related brain shrinkage.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nWhether the association would apply to other ethnic and racial groups needs to be explored, the authors said.\nTan added, however, that it remains possible that factors they did not control for, such as fruit and vegetable consumption, are really responsible for the brain benefits.\nThis might include reducing blood pressure and inflammation, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert, and there were no conflicts that should have been identified.", "answer": 1}, {"article": "According to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nThere may even be a reason to start for people in their late 30s and up, he says.\nCoffee was the main, or only source, of caffeine among people in the study.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nThe findings will appear in the Journal of Alzheimer's Disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert injects some important cautionary notes, We wish this perspective had been featured more prominently, and that more experts had been consulted.", "answer": 1}, {"article": "The incidence of serious adverse events was lowest among patients sedated with ketamine-alone and highest among patients sedated with combination drugs ketamine plus propofol or fentanyl.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n\"We've been able to identify sedation medications and practices associated with the best clinical outcomes, which is practice-changing.\"\n\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes that the study was funded by a federal Canadian program.", "answer": 1}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\nThe Hass Avocado Board helped pay for the research, which was also funded by the U.S. government.\n\u201cAnd certainly there's an emerging research base showing that some of these bioactive components may affect another lipoprotein particle favorably, like high-density lipoprotein.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any independent sources. But it somewhat makes up for this omission through an extensive interview with one of the study researchers, who provides excellent context. The story also clearly states that the study received funding from an avocado industry organization.", "answer": 0}, {"article": "They found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\nExperts agreed that the findings held promise, but much more research will be needed.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nBut that convenience also brings its own problems, Wright added.\nSUNDAY, July 19, 2015 (HealthDay News) -- It's still very early, but scientists say a test based on a patient's saliva might someday help detect Alzheimer's disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Nice job here. Two of the three sources quoted in the story are apparently unaffiliated with the institution conducting the research, suggesting independent voices. A comparison with a Time story about the same study makes this story seem exceptionally well-sourced.", "answer": 1}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nLower consumption levels were not associated with the risk.\nHowever, research into the topic remains scarce.\nApproximately 2,000 men participated in the study.\nThe findings were published in the British Journal of Nutrition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding for the study is not mentioned.\nReview of the authors does not reveal any major conflicts of interest.", "answer": 0}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\nIt might be that Canadian doctors were not sufficiently skilled.\nAnd they should do a high volume of screening.\nThat leaves several other possibilities.\nThey should take at least eight minutes to withdraw an endoscope from the colon.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Nov. 14, 2011 -- The first use of heart stem cells in humans looks like a major breakthrough for people suffering heart failure after heart attacks.\nHare was not involved in the study.\nIt is stories like that that makes these results really encouraging.\"\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story presented one independent perspective and a quote from an editorial that accompanied the study.  ", "answer": 1}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nSeveral of the authors have received speaking fees or consulting payments from Novartis, AstraZeneca (which makes letrozole), and Pfizer (maker of the aromatase inhibitor exemestane).\nThe study, which was also published Sunday in the New England Journal of Medicine, was partially funded by Novartis, which sells letrozole \u2014 the aromatase inhibitor used in the trial \u2014 as the branded drug Femara.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Kudos here, too. Dr. Richard Schilsky was interviewed as an independent source. Conflicts of interest were also disclosed: The study was funded by\u00a0Novartis which sells letrozole, and several of the study authors are connected to pharmaceutical companies.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story includes a quote from a single university-based vaccine expert, but it does not state whether he has any potential conflicts of interest. The story fails to note that two researchers received consulting fees from one or more pharmaceutical companies\u2013including MedImmune, which manufactures the FluMist inhaled vaccine in partnership with the researchers\u2019 employer, the University of Michigan. ", "answer": 0}, {"article": "And is the outcome the same for everyone?\u201d\n\nPuigserver, who runs a cancer biology lab at Dana-Farber Cancer Institute, noted that addressing health and aging through metabolism involves a complex web of pathways and mechanisms.\n\u201cBut we will be data-driven and will communicate the complexities of science in simple ways.\u201d\nAnd what exactly is being repaired in the body?\n\u201cWe need more information on how this works precisely in people before we can advise them to take anything,\u201d he said.\n\u201cWhat does it mean, to improve metabolic health?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes a reputable source who provides an appropriately skeptical view \u2014 one of the strongest aspects of this piece", "answer": 1}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nThere are some limitations to mention about the new meta-analysis.\nThere are some understandable reasons why.\nMore work needs to be done to confirm these findings.\nBut it\u2019s not a foregone conclusion that later start times will ensure teens sleep more.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No sources appear to have been interviewed for this story, though it contains a lot of citations to studies and quotes used in past stories.", "answer": 0}, {"article": "The W.H.I.\noptions and select the best treatment for women 45 and older with menopausal symptoms, the North American Menopause Society has developed a mobile app, MenoPro, for iPhone/iPad and Android devices.\nIn a Danish randomized controlled trial of 1,006 women entering menopause, among those given hormones for 10 years, \u201cthere was a reduction in cardiovascular disease and breast cancer \u2014 a clear benefit with nominal risk,\u201d Dr. Hodis said.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\n\u201cThe cardiovascular protection found in observational studies involved women who were younger and within a few years of menopause when they started taking H.R.T.,\u201d he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Danish trial referenced in the study was partially funded by drug companies and the authors disclose a long list of drug company affiliations not mentioned in the story. In addition, the first author of the 2013 study showing harm from avoiding hormone therapy has served as a consultant Noven Therapeutics, which makes hormone therapies.\nThe two experts quoted in the story are JoAnn Manson and Howard Hodis. Manson is one of the authors of the editorial about the mobile phone app, and the paper says she has no conflicts. Hodis is a member of the board of the North American Menopause Society. The NAMS receives support from a long list of pharmaceutical companies. Links to some of them here.", "answer": 0}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nAlso, there was limited research on long-term results.\nHowever, this strong benefit only applies to the first couple of years following surgery, Chinnadurai said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a quote from a clinician not affiliated with the study, which adds some useful context. It does not mention any possible conflict of interest but none are expected from a large Agency for Healthcare Research and Quality (AHRQ)-commissioned evidence review, which this was.", "answer": 1}, {"article": "On the other hand, longer treatment was tied to a 24-percent decrease in hip fractures, which along with wrist and spine fractures affect about half of all people with osteoporosis.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nBut that\u2019s a very rare problem, experts say, which only affects about one in 100,000 people on bisphosphonates.\nPark-Wyllie and colleagues tapped into data on more than 205,000 Ontario women at least 68 years old who had taken the bone drugs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Reuters gives us two voices in this piece, including a study author and a treating physician. We are not told anything about whether the treating physician has any ties to the industry, but we couldn\u2019t find any in a brief online search.", "answer": 1}, {"article": "But many others are tough calls.\n\"A biopsy takes a few minutes in my hands, so if there's an issue with any lesion we will always biopsy, whether we have a MelaFind picture or not,\" said Dr. Leonard Goldberg, a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\n\"The device is only good for certain lesions, and that's why you have to be a dermatologist to be able to classify and categorize those lesions appropriately,\" said Christy Foreman, director of FDA's Office of Device Evaluation.\nThe company plans to bring them next year to just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\nAbout 8 percent of growths scanned in the company study came back as \"unevaluable.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use a truly independent source because everyone appears to have some sort of conflict, but this is also one of the stories strengths. Rarely have we seen conflicts presented with this kind of detail. For example, the story says describes Dr. Leonard Goldberg as \u201ca dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\u201d", "answer": 1}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nThe test is awaiting approval by the U.S. Food and Drug Administration and already is approved for use in Europe, Catalona said.\nThe Hopkins group is trying to identify other biomarkers that would improve the program's predictive value, he said.\nIt is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The experts quoted in the story appear to have an association with Beckman Coulter, Inc, the company planning to market the test reported on.\u00a0 This was not made clear in the story. ", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nAcupuncture skeptic Dr. Stephen Barrett said the study results are dubious.\nThe new analysis was published online Monday in Archives of Internal Medicine.\nThe federal government's National Center for Complementary and Alternative Medicine paid for most of the study, along with a small grant from the Samueli Institute, a non-profit group that supports research on alternative healing.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an acupuncture \u201cskeptic\u201d and the author of an accompanying editorial. It mentions that the study was mainly funded by the federal government, with some additional funding from a non-profit with an interest in alternative medicine.", "answer": 1}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\nThis may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.\nO'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not include information about Dr. O\u2019Shaugnessy\u2019s funding from the drug company for consulting & travel.\u00a0 Observations from other researchers about the study would have provided needed perspective about the results.", "answer": 0}, {"article": "Using electromagnetic radiation, infrared lamps warm your body directly.\nBeever makes it clear all of these reports were based on small groups and require further study.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\nBeever says infrared heat may damage sperm as do other forms of heat, but at this point there\u2019s no data on those risks.)\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both of the sources have direct ties to the research mentioned. \u00a0One of the sources, Dr. Beever, appears in advertisements/advertorials for the Sunlighten brand\u00a0of infrared saunas. The story would have been strengthened by including an expert independent of the research.", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert. The story should have quoted other experts who could have provided more balance.\u00a0 It could have turned to a spinal trauma expert from one of the many institutions that do not offer this form of treatment. ", "answer": 0}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nUntil then, Ms. Pisano said, many insurers are denying coverage on the grounds the procedure is experimental.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\nBut the procedure is expensive, costing around $20,000, and insurers have been reluctant to cover it.\nDr. McEvoy argued that it made economic sense, and earlier this year Health Partners agreed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from several independent sources and from an insurance industry spokesperson, thereby satisfying our criteria. As noted above, however, we don\u2019t think it would have been difficult to find a clinical expert with a more skeptical view of the evidence supporting bronchial thermoplasty.", "answer": 1}, {"article": "\"A five-millimeter distance will make you either overexposed or underexposed,\u201d he explained.\nWithout the software, doctors must plan where to place the tiny pellets and then recreate the position of the prostate.\nI think most patients want to get their treatment done as quickly as possible.\u201d\n\nAlgan said he doesn't extol one technique over the others; all are acceptable depending on the patient.\nThe computer calculates radiation exposure to nearby nerves and tissue, which is important because overexposure can cause erectile dysfunction and other problems.\nBecause the prostate is small and tiny shifts in position can make accurately targeting tumors difficult, OU Physicians has software and a real-time machine that allow doctors to place the seeds exactly where they are needed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The portion of the article on breast cancer includes an interview with one patient who was treated with apparent success, a physician employed by the cancer treatment chain that treated her, and a radiologist from a local university. \nThe reporter should have spoken to one or two nationally recognized experts on radiation therapy and brachytheraphy specifically in order to put the generally positive information in the story in context. The American Society of Breast Surgeons has written guidelines about the appropriate use of brachytherapy. One of its authors would have made an excellent source.\u00a0\nThe section on prostate cancer treatement includes only one source\u2013a urologist who performs the procedure and uses the new software he is enthusiastic about. As with the rest of the story, the article here uses comments about popularity but none about effectiveness or risk. \u00a0", "answer": 0}, {"article": "Ketamine was developed as an anesthetic and received FDA approval for this use in 1970.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nIt found that current antidepressants really aren't much better than a placebo.\nOne is that its ability to keep depression at bay can fade pretty quickly.\nEncouraged by research showing that ketamine can relieve even the worst depression in a matter of hours, these doctors are giving the drug to some of their toughest patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies almost entirely on a single passionate advocate and a single compelling patient. The story would have been strengthened and balanced by an interview with someone with a contrary opinion. We\u2019ll give the story a pass for featuring a skeptical blog quote from the director of the National Institute of Mental Health. But the story could have done more to highlight experts who are critical of the use of ketamine and feature patients who didn\u2019t respond to the drug.", "answer": 1}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nThis press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates.\nIRVINE, Calif., Aug. 2, 2018 /PRNewswire/ -- MDxHealth SA (OTC: MDXHF.BR) today announces that a new study validates the cost-effectiveness of the SelectMDx\u00ae for Prostate Cancer test, a non-invasive, urine-based (liquid biopsy) test that helps identify patients at increased risk of aggressive prostate cancer.\nThe full paper is accessible via the online edition of The Journal of Urology.\nThe SelectMDx test can help predict the likelihood that clinically significant prostate cancer will be found by a biopsy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Neither element shows up in the text.\u00a0 Since the news release comes from the company MDxHealth, which is marketing the test, one might assume that the company paid for the study.\u00a0 But the text of the research report suggests otherwise, indicating funding from the American Cancer Society and a foundation focused on urological research. That would have been a useful addition to the release.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Aside from the Navy official, the story lacks input from independent mental health experts and patient advocacy groups. However, his inclusion in the story is sufficient to rate Satisfactory.\nWe do want to point out that the California-based advocacy group that\u2019s mentioned as wanting to seek funding for studies (the Multidisciplinary Association for Psychedelic Studies) states on its website that it has created a subsidiary that may generate profits in the sale of legal MDMA (\u201cecstasy\u201d or \u201cmolly\u201d) if and when it gains FDA approval. So beyond\u00a0selling newspapers, there may be other financial incentives for the promotion of hallucinogens-as-therapy.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\nThe DRCR.net had complete control over the design of the study, data ownership and content of presentations and publications related to this study.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\nWith the rate of diabetes increasing dramatically worldwide, many individuals will be at risk for vision loss from diabetic eye complications and DME is a major global health concern,\u201d says Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee, and an Investigator in the Section on Vascular Biology, an ophthalmologist in Beetham Eye Institute at Joslin and an Assistant Professor at Harvard Medical School.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources and the donation of drugs from the pharmaceutical companies are clearly stated. The Joslin researchers quoted in the article don\u2019t appear to have any direct conflicts of interest with companies involved in the research.", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is not clear that any of the experts who commented in this study were independent, disinterested sources. All appeared to have some kind of relationship with the developer of Botox. How hard can it be to find a headache specialist who is not on the company payroll?\nThe article did not adequately describe the relationships of the quoted experts with the company that manufacturers and markets Botox. For instance, the article noted that one of the quoted experts is the principal investigator of one of the Botox trials. However, the journalist didn\u2019t reveal that this expert has also been a consultant to the drug company.", "answer": 0}, {"article": "However, common side effects included headache, dizziness and nausea.\nHowever, one expert was not sold on this new drug.\nThe report is published in the July 15 issue of the New England Journal of Medicine, and was sponsored by Arena Pharmaceuticals, of San Diego, Calif., which used its own doctors as part of the study group.\nWEDNESDAY, July 14, 2010 (HealthDay News) -- A weight-loss pill called lorcaserin not only helps people drop pounds but does so with few side effects, new industry-funded research reports.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Of the three, this story makes the best use of outside sources and does the best job of identifying conflicts of interest. It should have taken the extra step of noting Arne Astrup\u2019s conflicts of interest, given that he is the chief \"independent\" booster of the drug. But in the first two paragraphs it says \"industry-funded research,\" \"work was sponsored by the drug manufacturer\" and \"was sponsored by Arena Pharmaceuticals.\"", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\n\"Our research could help develop policies that make the service more accessible to low-income women,\" added senior author Nazeem Muhajarine, a professor in community health and epidemiology at the University of Saskatchewan and McRae's supervisor while she conducted the research.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\n\"Our findings show that women who are more vulnerable benefit from the care of a midwife, likely because they receive more time, counselling and education on how to care for themselves,\" said the study's lead author Daphne McRae, a post-doctoral research fellow at the UBC school of population and public health who conducted the study while she was a PhD student at the University of Saskatchewan.\nThe study was co-authored by Patricia Janssen, Saraswathi Vedam, Maureen Mayhew at the University of British Columbia, and Deborah Mpofu and Ulrich Teucher at the University of Saskatchewan.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not state how the study was funded, which was through scholarships. It also did not mention that the lead author disclosed in the published study that as of May, she had been providing consulting services to the Midwives Association of BC.", "answer": 0}, {"article": "Source: Brightling C, et al.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nThe pill may be a \u201cgame changer for future treatment of asthma,\u201d said Professor Chris Brightling, a National Institute for Health Research (NIHR) Senior Research Fellow at the University of Leicester, in a press release.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u2019s no comment from an independent source, leaving unchallenged a researcher\u2019s assertion that fevipiprant may be a \u201cgame changer for the future treatment of asthma.\u201d\u00a0 The story could have let readers know that funding came from Novartis, as well as a European Union grant program, and the Leicester (U.K.) National Institute for Health Research Respiratory Biomedical Research unit. Several researchers involved in the trial reported receiving financial compensation from Novartis and other drug companies.", "answer": 0}, {"article": "The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\nThe complete response rate was 22 percent.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story says\u00a0that both drugs are made by Bristol-Myers Squibb, it fails to note that the study itself was supported by Bristol-Myers Squibb. That\u2019s a significant oversight. Also, while the story quotes two people, one of them is\u00a0a co-author on the study and the other is the Bristol-Myers Squibb employee who was responsible for developing the relevant drugs. An independent perspective would have been very welcome.", "answer": 0}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\n\u201cIf you take the core patients who are at highest risk, it makes you appreciate how important this drug class is,\u201d said Dr. Amit Khera, Director of the Preventive Cardiology Program and Associate Professor of Internal Medicine at UT Southwestern.\nThis news release is available on our home page atwww.utsouthwestern.edu/home/news/index.html\n\nTo automatically receive news releases from UT Southwestern via email, subscribe at www.utsouthwestern.edu/receivenews\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t talk about funding for this individual patient, which is fine. But it does talk about a number of researchers who were involved in developing evolocumab and alirocumab. Were those researchers supported by the relevant drug companies? Does the medical school itself have partnerships with these companies? It\u2019s not clear. If those potential conflicts do not exist, it would have been good to make that clear \u2014 particularly in a case like this, where the rationale for the news release is not clear to readers.", "answer": 0}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\n\"This study is the first to compare the cancer-fighting potency of plant- versus marine-derived omega-3s on breast tumour development,\" said the professor in the Department of Human Health and Nutritional Sciences.\nPublished in the Journal of Nutritional Biochemistry, the study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2.\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and conflicts of interest aren\u2019t mentioned. According to the study, which is behind a paywall, funding came from the Public Health Agency of Canada, the Canadian Institutes of Health Research-Institute of Cancer Research, the Canada Foundation for Innovation, and the Ontario Research Fund, Ontario Graduate Scholarship. Canada is a world leader in both seafood and flax seed exports. The authors reported no competing interests.", "answer": 0}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe National Cancer Institute, the Swedish Cancer Society and several foundations paid for the work, and one researcher holds patents for two PSA-related tests.\nThe results are \"provocative,\" but this type of study can't prove that screening prevents deaths, said Dr. Matthew R. Smith of the Massachusetts General Hospital Cancer Center.\nThe new study \"is not going to end the controversy, but it suggests a very interesting middle ground,\" Lichter said.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0made good use of experts who put the studies\u2019 findings into context. The story also noted the funding behind the studies and one potential conflict of interest, saying, \u201cThe National Cancer Institute, the Swedish Cancer Society and several foundations paid for the work, and one researcher holds patents for two PSA-related tests.\u201d", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As already noted, the quote from the California geriatric neurologist was crucial.\u00a0 But other independent experts were quoted as well.\u00a0 Excellent sourcing.", "answer": 1}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\n\u201cThe identification of biomarkers that predict treatment response is crucial in reducing the social and economic burden of depression and improving quality of life for patients,\u201d said Prof Carmine Pariante from KCL\u2019s institute of psychiatry, psychology and neuroscience.\nThe experts involved believe the breakthrough could lead to depressed patients receiving personalised treatments that are more likely to relieve their symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two independent sources, but does not mention study funding or conflicts of interest. The research was funded by the government-run Medical Research Council and the National Institute for Health Research Maudsley Biomedical Research Centre, according to the King\u2019s College London news release.\nOne researcher, Carmine Pariante, M.D., received funding directly or indirectly from pharmaceutical firms Johnson & Johnson, Lundbeck, GSK, and Pfizer as well as the UK-based Wellcome Trust, according to the study.\nJ&J has a vested interest in developing drugs that might be used after this blood test is given, so this was\u00a0important\u00a0to disclose.", "answer": 0}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nFor information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nThe SBI includes leading international breast imaging specialists nationwide among its membership.\nThe SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The Society of Breast Imaging and the American College of Radiology are clearly indicated.", "answer": 1}, {"article": "This new approach is much simpler and it works.\"\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nThe study was funded by the National Health and Medical Research Council of Australia as part of the Global Alliance for Chronic Disease.\nThe researchers tested an entirely new way of treating hypertension by giving patients three drugs, each at half dose, in a single pill for early treatment of high blood pressure.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although this is mentioned \u2026\nThe study was funded by the National Health and Medical Research Council of Australia\n\u2026 what\u2019s not mentioned is that the two lead authors quoted in the news release both receive a salary from George Health Enterprises (GHE is the product commercialization arm of The George Institute for Global Health). According to disclosures cited in the published study:\nGeorge Health Enterprises has received investment funds to develop fixed-dose combination products containing aspirin, statin, and blood pressure-lowering drugs and has submitted a patent for the treatment of hypertension", "answer": 0}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nAll patients felt self-conscious wearing the device, Ritholz noted.\nPeople who used the device more than six days per week saw improvement, regardless of age, he added.\nSUNDAY, June 27, 2010 (HealthDay News) -- New research suggests that artificial pancreas technology can help diabetics gain greater blood sugar control overnight, even when they have eaten a big meal or had wine for dinner.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No sources appear to have been quoted besides those on the teleconference. We don\u2019t know the basis for the call, but it sounds like a press briefing.\nConflicts are mentioned for the people directly involved in the research. But readers can\u2019t know or judge for themselves whether others who were quoted in the story were truly independent sources \u2013 with no funding connection to this research.", "answer": 0}, {"article": "And sometimes we have to make decisions about using drugs that are probably a little less effective but at the same time we have to take into account the financial standpoint,\" said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.\nRead the full guideline at the American Society of Clinical Oncology.\nThe new guidelines replace previous guidelines issued in 2002, and subsequent updates in 2003 and 2004.\nAromatase inhibitors are not effective in this age group, the experts note.\nCrystal Denlinger, assistant professor of medical oncology at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\nThe study is published in the March issue of Obstetrics & Gynecology.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\n\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nNo independent experts were interviewed for this story.\u00a0\u00a0 \n", "answer": 0}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder \u2014 the Boerger Research Fund for Alzheimer\u2019s Disease and Neurocognitive Disorders from the Foundation of the American Society of Neuroradiology \u2014 is noted on the sidebar of the release hosting site, EurekAlert! We encourage news release writers to include funders in the body of the news release text as well.\nWe didn\u2019t observe any conflicts of interest among the researchers.", "answer": 1}, {"article": "Autopsies show that most men will develop prostate cancer in their lifetimes but often die of something else.\nWong acknowledged that the study's design had limitations, making it important that the findings be confirmed by additional research.\nBut she said she and her colleagues analyzed the data carefully to account for factors that could have influenced the findings, such as the subjects' ages and whether they had other health problems.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\n\"This gives support to the idea that active treatment can be beneficial.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article provides multiple sources of information, some of whom appear to be independent of the current study.\u00a0 The sources also provide a range of opinions about what the latest study means, which adds balance.\u00a0 ", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story contained information and quotes from the editorial accompanying the published research study, it did not appear to tap into the knowledge base of others in the field to assess the importance of the study results.\nThe story did note that those working on the study had ties to the manufactorer of the drug reported on.", "answer": 1}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nThe study is scientifically sound in many ways, Kruper said.\nHwang believes the study does arm women with valuable information.\n\"They looked at socioeconomic status, and they kept it early stage.\"\n\"This refutes that.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did include the perspectives of two independent sources.", "answer": 1}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly identifies one source as the leader of the study and includes a second source who appears to be independent of the research.\u00a0 Funding sources are missing from the story, but the study\u2019s declarations of funding do not seem eyebrow-raising.", "answer": 1}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nWe need some oversight body to say whether something is effective.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\nBut here's the catch: Avastin costs more than $8,000 a month.\nVisco says the new studies on Avastin, AVADO and RIBBON-1, should settle the issue.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes interviews with individuals who are for and against revoking Avastin\u2019s approval, providing some counterbalance; however, the focus on the personal success story of one patient tips this balance.\u00a0 Because of the strong comments by people like Fran Visco and some of the physicians quoted, we\u2019ll give this story a satisfactory score on this criterion. \nHowever, if you\u2019re going to play the personal anecdote game, we think you have an obligation to balance the glowing positive story with the more representative story of people who didn\u2019t benefit. The plural of anecdote is not data. \nAlso, from a balance perspective, why wasn\u2019t the statement of Senator David Vitter \u2013 who has politicized breast cancer a number of times without showing a concern for evidence \u2013 balanced by a statement from a politician who is more evidence-based?\u00a0 Again, if you\u2019re going to play the politics game, how about leveling the playing field a bit? ", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\nIn a fresh look at the medical evidence for the blood test, she and her colleagues analyzed 57 earlier studies that included more than 6,500 pregnancies.\nBianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses independent sources, and notes that the lead author of the JAMA\u00a0study, Diana Bianchi, is an investor in a related cell-free fetal DNA test for Down syndrome.", "answer": 1}, {"article": "Can a cup of blueberries keep the doctor away?\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe study, in The Journal of the Academy of Nutrition and Dietetics, found that those who ate the blueberry preparation saw an average 5.1 percent decrease in systolic blood pressure (the top number) and a 6.3 percent decrease in diastolic pressure.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not utilize any independent sources or expert analysis, something that might have clued readers into the study\u2019s limitations. In addition, there was no direct mention or description of any potential conflict of interest in the story. The study was partly funded by the\u00a0US Highbush Blueberry Council, and it stands to reason that they are very interested in increased blueberry sales as a result of greater health benefits.", "answer": 0}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\n\"We are excited that the benefits observed in the early pilot and preclinical research extended to this larger trial,\" says Luke G. Huber, ND, MBA, vice president of product innovation and scientific development at Life Extension.\n\u2022 Senthilingam M. Cable News Network (CNN) U. S. Edition [online].\nFORT LAUDERDALE, Fla., July 26, 2016 /PRNewswire/ -- New research published in Lancet Neurology and reported by CNN has found using a green tea extract (decaffeinated) in combination with cognitive training improves some measures of cognition and behavior in subjects with Down syndrome.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes it clear that the study was supported by Life Extension and discloses Life Extension\u2019s involvement in an earlier pilot study. The two sources quoted in the news release have ties to Life Extension \u2013 a fact the news release also makes clear in their titles.\nWe applaud the news release for disclosing this information, which is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nThat confirmed what researchers had believed for several years.\nBut a separate finding about the effect of the drug on death risk was a surprise.\nUsing the two drugs together as a one-two punch may be even more powerful.\nIf this had not happened, \"the benefit of aromatase inhibitors over tamoxifen would probably have been somewhat greater,\" they surmised.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a two-source story, with quotes from two professors who had ties to the studies. The report desperately needed an independent expert, who could talk about some of the missing details \u2013 like the design and limitations of the studies, the quality of evidence and harms of the interventions.", "answer": 0}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cIt\u2019s a little baffling that you\u2019re keeping patients alive, but not having any effect on those secondary endpoints,\u201d said Needham & Co analyst Chad Messer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The doctor quoted in the story was identified as the lead investigator for the study. However, the story didn\u2019t include his potential conflict of interest\u2013that he received funding\u00a0from the drug company\u2013which was stated and easy to find in the study. For this reason, we\u2019re rating this Not Satisfactory.\nWe were please to see the story included an additional outside source, even if it was a financial analyst. A second, independent medical source would have made the story stronger.", "answer": 0}, {"article": "AMHERST, Mass.\nThe study was supported by a grant from NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development.\nParticipants in the study contributed more than 1 million person-years of follow-up, during which 2,041 women experienced early menopause.\nNearly 90 percent have continued to participate in followup.\nOthers on the study team were from Brigham and Women's Hospital and Harvard Medical School.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was supported by a grant from NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development. The researchers reported no conflicts.", "answer": 1}, {"article": "Identifying patterns that help couples maintain their bond could make it easier for caregiving spouses to find meaning and improve satisfaction with their marriage.\nFuture research might focus on interventions that could help diffuse these frustrations, the paper noted.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only a single source, the lead investigator, and offers no additional independent sources.\u00a0 It fails to mention funding for the study, nor does it offer any information that would allow readers to gauge potential conflicts.", "answer": 0}, {"article": "Healthy dietary patterns were generally higher in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and they were lower in red meat, salt, and refined sugars.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nTo investigate, a tem led by Giovanni Strippoli, MD, PhD (University of Bari, in Italy and Diaverum, in Sweden), and Jaimon Kelly (Bond University, in Australia) analyzed the medical literature, finding 7 relevant studies that included a total of 15,285 participants.\n\u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d\n\nDisclosures: The authors reported no financial disclosures.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says that the authors had no financial conflicts of interest.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article enlists a variety of sources to balance its commentary on the drugs implicated in the new research, and includes sufficient information for readers to assess the sources\u2019 potential conflicts of interest. ", "answer": 1}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nFunding for this research was provided, in part, by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health, the Department of Defense, Prostate Cancer Research Program, the American Cancer Society and the UC San Diego Clinician Scientist Program.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n\u201cProstate cancer can often be an indolent disease, where a patient may only require surveillance rather than aggressive surgery,\u201d noted co-author Christopher J. Kane, MD, professor of urology at UC San Diego.\n\u201cThis new approach is a more reliable imaging technique for localizing tumors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources are fully listed. There is no indication of a conflict of interest.", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does not provide commentary from any independent sources. In this case, a single comment from a biostatistical consultant would have provided helpful perspective.\u00a0 ", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\nEven with one implant, Merlo called the results \"surreal.\"\nShe used the television's closed-captioning feature.\nFor patients with profound hearing loss, a cochlear implant is a better option, he said.\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article appropriately points out that the surgeon was trained by the device\u2019s manufacturer, Envoy Medical Corp. An independent source would have greatly helped to put the implant\u2019s effectiveness into perspective.", "answer": 0}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\nThe study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.\n\"Transplants are getting better but we need better therapy, there's no question.\"\n\"But they're not an easy group of patients to transplant.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interviews with two independent experts who weren\u2019t involved with the study.", "answer": 1}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nBut questions remain, experts say.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nA larger trial involving 60 people is being planned.\nThere were no signs of ill effects on any subjects, Vinson reported Tuesday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts added important perspectives to the story.", "answer": 1}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\n\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nThat warning was especially strong for those with a family history of allergies.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only one scientist, and that is his written comment from an editorial accompanying the study, not an interview.\nThis source, Dr. Matthew Greenhawt, has a potential conflict of interest that wasn\u2019t disclosed: He\u2019s a member of the scientific advisory council for the National Peanut Board, among other affiliations clearly stated in the study\u2019s editorial.", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nBut while bright-light treatment is helpful, he said, it is not sufficient for him.\nWhy, then, do so few doctors prescribe bright-light therapy?\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses independent sources, but strangely does not quote anyone who participated in the single research study cited from 2006.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quoted one scientist in a story that was ostensibly all about the science. Instead, it spent more time with nicotine gum users and a blogger. We thought that had more space been devoted to independent experts, the evidence would have been more clearly sorted out. We did appreciate, though, that the story took pains to point out the extent of drug industry funded research in this area. It says, for example, \u201cHowever, the study reported no difference in the quit rates of the two groups when they were checked at the one-year mark, revealing the fact that many people began smoking again. The senior author of the study, funded by federal grants, has served as a consultant for GlaxoSmithKline.\u201d", "answer": 1}, {"article": ".\nThey each slept alone, and the bedroom layout with furniture arrangement was kept consistent.\nOn another night, the windows and door to the room were kept closed.\nThe study participants were asked not to drink alcoholic beverages or caffeinated drinks, which could influence sleep.\nOpen windows and doors helped reduce carbon dioxide levels and improve ventilation and air flow, which was related to better sleep quality for the healthy young adults in the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A sleep researcher who wasn\u2019t involved in the study was interviewed, and we could detect no conflicts of interest.", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThis is great news for anyone who feels too busy on weekdays to work out but enjoys outdoor activity on the weekend.\nHowever, there are also some limitations to this study, the researchers say.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\nRelated: Post-workout cold immersion likely won\u2019t help you heal\n\nThere are risks that come with a weekend warrior exercise schedule, especially for people who aren\u2019t used to being active.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does provide some precautionary words from an independent expert in the field related to the risks associated with strenuous exercise. We would have liked to have seen an expert in the field provide comments on the study, the inherent limitations and on the conclusions drawn.", "answer": 1}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\n\"They are not regularly performed by cardiologists or radiologists or neurologists.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts, one of whom chaired the committee that wrote the guidelines (Powers) and the other (Kandazari) who was apparently independent of the guideline-writing process. The solicitation of an outside expert opinion is commendable, but the story should have notified readers that Dr. Kandazari is a paid consultant for companies, such as Medtronic and Boston Scientific, that make the devices that are used in these procedures. See this Wall Street Journal report and the disclosures on this online CME program.", "answer": 0}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nFunding of this work was supported by the Nemours Foundation along with the regional economic development initiative of the Florida High Tech Corridor.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses the study\u2019s funding sources, which include the Nemours Foundation and the regional economic development initiative of the Florida High Tech Corridor.\nWe were not able to find any potential conflicts of interests.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "Kilmer McCully of the V.A.\nBut Steven E. Nissen, president of the American College of Cardiology, said the findings should end debate about the theory, which had already lost credibility among many scientists.\nThe studies, released early by the New England Journal of Medicine to coincide with their presentation at an American College of Cardiology meeting in Atlanta, confirm the results of another large study that was published in 2004 in the Journal of the American Medical Association.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nVitamins should not be expected to perform like drugs -- their greatest promise is in prevention,\" said Annette Dickinson in a written statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to the discussion of the studies, a quote was pulled from an editorial in the journal that published the studies. ", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\n\"Future studies should explore what the underlying mechanisms are that explain this specific relationship between vitamin D and visceral adipose tissue.\"\nIt's encouraging that a simple intervention could have these effects and this certainly merits further investigation to consider its potential impacts on vitamin D supplementation for children with obesity.\"\nThe team measured participants' vitamin D levels, body fat percentage, as well as their markers of liver and heart function at the start of the study, and again 12 months later.\nThe researchers randomly assigned 117 children with supplements containing 50,000 IU vitamin D for six weeks, while the others acted as the control group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appears to be at least one expert, Mary Fewtrell (of the Royal College of Paediatrics and Child Health), who comments on the study yet is not involved in the research.", "answer": 1}, {"article": "Compared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often.\nUp until June 1, LabCorp of America had a product on the market.\nTwo Massachusetts-based companies have a license to develop a practical screening test based on Markowitz's work.\nBut all of this hasn't been enough to convince a lot of people make those appointments.\nCBS Evening News anchor Katie Couric, whose husband died of the disease, co-founded the group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source cited in the news story is the researcher whose team developed the stool DNA test. There are no independent sources.", "answer": 0}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nResearchers will continue to follow the participants in the study and check in on them every year and a half, Scarmeas said.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\nThe study looked at 712 people over the age of 65 living in New York.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story has a quote from a clinician who does not appear to be associated with the research to be presented that was reported on.", "answer": 1}, {"article": "When all seizures were taken into account, children who did not have surgery were four times more likely to have a seizure during that year than youngsters in the surgery group, the researchers calculated.\nHe was not involved in the research.\nBut Dr. Schomer said the children were only followed for one year, and \u201cthat may be too soon to see a noticeable change\u201d in the intelligence quotient.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\n\u201cThe results are impressive,\u201d he told Reuters Health by phone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does quote a Boston specialist who was not a part of the study, which was conducted in India.", "answer": 1}, {"article": "Cryotherapy, or freezing the affected skin area, is also used but can sometimes leave a scar.\nHalf got the new gel and the other half received an inactive placebo.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nThe new study was funded by Picato manufacturer LEO Pharma.\nThe new study included 547 people with actinic keratoses on their face or scalp and 458 people with these lesions on their mid-section or arms and legs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story explained that \u201cThe new study was funded by Picato manufacturer LEO Pharma.\u201d\nBut it didn\u2019t offer any independent perspective.\nAnd it didn\u2019t report that several authors disclosed a variety of ties to the drug maker, including consultant fees, serving on advisory board, fees for being on a speakers bureau \u2013 and that two of the authors are employees of the drug company.", "answer": 0}, {"article": "Some years ago, Italy instituted a countrywide rule requiring competitive athletes to undergo an electrocardiogram, a test that records the electrical activity of the heart.\nResearchers hope to screen a total of 640 before they're done.\nToday, the Cincinnati mother of two is thankful she didn't.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nThat led to unnecessary physical restrictions of athletes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No experts other than the researchers doing this study are quoted.", "answer": 0}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nLed by Dr. Linda Papa, director of clinical research and an emergency physician at Orlando Regional Medical Center, the research team focused on two blood proteins that have already been linked to brain injury.\nThey collected blood from 584 people coming to the Orlando Regional Medical Center, which is a Level 1 Trauma Center, for trauma-related injuries.\nPapa and her team expanded on that work by studying how levels of these two proteins, or biomarkers, change immediately after head trauma.\nEven at that point, the study shows, GFAP levels might be higher than normal and therefore might indicate TBI and need for further tests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included no independent sources, and failed to mention a potential conflict of interest with the only source quoted in the story. As stated in the JAMA Neurology\u00a0study, lead researcher\u00a0Dr. Linda Papa was listed as one of several researchers who have consulted or received contract research funding from Banyan Biomarkers, Inc. Banyan is a for-profit biotech company in Florida seeking to commercialize a biomarker for head injury.", "answer": 0}, {"article": "An underlying cause of obesity may be an impaired gut microbiota composition, an imbalance in the complex mix of beneficial and harmful microorganisms that inhabit the digestive tract.\nThe control group, however, had no clinically relevant alterations in their microbiota composition, Luzi said.\nThe research team also measured blood levels of glucose (sugar), insulin, pituitary gland hormones and neurotransmitters such as norepinephrine.\nResults of the technique, called deep transcranial magnetic stimulation (dTMS), will be presented Sunday at ENDO 2017, the Endocrine Society's 99th annual meeting in Orlando, Fla.\n\"Despite numerous preventive and therapeutic interventions, none has stopped obesity from reaching epidemic proportions.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No funding sources or conflicts of interest are described in the news release.", "answer": 0}, {"article": "Due to diffuse symptoms, pancreatic cancer is usually diagnosed very late in the disease progression.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\nThe next step has already been initiated, which is a large US prospective study for high risk individuals.\nThe study used samples from patients in both Denmark and the US, at different stages of the disease.\nThe results have been published in the Journal of Clinical Oncology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It should have been shared with readers that nearly half the study authors have financial ties to Immunovia AB, the biotech company developing this IMMray\u2122 blood test for detecting pancreatic cancer.\nThe lead author quoted in the news release is a co-founder of the company and the chairman of its board of directors.", "answer": 0}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nThe study was presented at the Genitourinary Cancers Symposium.\n\"The results were similar regardless of whether the men took one capsule or three,\" Carducci tells WebMD.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The input from the Sloan-Kettering expert saved the story.\nAnd the story did disclose that the lead author \u201cis an unpaid consultant to POM Wonderful, which makes both the pomegranate capsules and the juice used in the earlier study.\u201d", "answer": 1}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\n\u201cIt gives us some hope that if there is no way to extend sleep during the week, people should try very hard to protect their sleep when they do get an opportunity to sleep in and sleep as much as possible to pay back the sleep debt,\u201d said lead study author Josaine Broussard of the University of Colorado Boulder.\nThe study doesn\u2019t prove sleeping late every weekend can counter the ill effects of insufficient rest every other night of the week, Broussard cautioned.\nAfter the four nights of sleep deprivation, the volunteers\u2019 insulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did a good job, as noted earlier, of highlighting the limitations of the study, and quotes an outside researcher saying as much. Kudos!", "answer": 1}, {"article": "\"Nothing happens,\" he told Stahl.\n60 Minutes decided to keep track of Kanzius and his invention, so we followed him for over a year, as he pushed to speed up the research on his machine and fought to slow down his own cancer, which was killing him.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\nWhen 60 Minutes correspondent Lesley Stahl first met Kanzius, he told us he didn't have a background in science or medicine; he didn't even have a college degree.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThat journalists with the resources and airtime available to \u201c60 Minutes\u201d failed to present any independent experts or even to let viewers know about the patent and other financial interests of the people interviewed is just mind-boggling. Given the fact that there are literally thousands of scientific articles on related topics, it is mystifying that Stahl failed to present an iota of context or perspective from anyone without a personal stake in the device. (The comments of the pathologist in the piece don\u2019t count, since he had no way of knowing whether the blood cell counts he looked at displayed the effects of Kanzius\u2019s device or merely the expected results of chemotherapy.)\n It is impossible to watch this story without reaching the conclusion that Stahl and the producers made a conscious decision to exclude any independent experts.", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nOther estimates are far higher.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were pleased to see discussion from many experts, however, the story left out two important potential conflicts of interest. The story states that:\nDr. William E. Boden, a cardiologist and professor of medicine at Boston University School of Medicine, called the results \u201cunbelievable.\u201d\nReaders should have been informed that Boden has received fees from Abbott, a major stent device maker.\nAlso, the story states that:\nDr. David Maron, a cardiologist at Stanford University, praised the new study as \u201cvery well conducted\u201d but said that it left some questions unanswered. The participants had a profound blockage but only in one artery, he noted, and they were assessed after just six weeks.\u00a0\nThe story didn\u2019t disclose that Dr. Maron is an \u201cemployee of and stockholder in Cardiovascular Services of America, which provides outpatient cardiac catheterization and computed tomography angiography services,\u201d which was disclosed here.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story. The only sources are the initial clinical trial patient, the doctor who is conducting the clinical trial and the founding CEO of Aura Biosciences, the drug\u2019s developer.", "answer": 0}, {"article": "The daily regimen, once learned, took 12 minutes to complete.\nA pharmaceutical company is unlikely to fund a study that doesn\u2019t involve a drug, and in any event, the research requires a large group of volunteers tracked over a very long time.\nOn the other hand, yoga\u2019s \u201cside effects,\u201d Dr. Fishman and colleagues wrote recently, \u201cinclude better posture, improved balance, enhanced coordination, greater range of motion, higher strength, reduced levels of anxiety and better gait.\u201d\n\nWeight-bearing activity is often recommended to patients with bone loss, and Dr. Fishman argues that certain yoga positions fit the bill.\nEven if bone density did not increase, improvements in posture and balance that can accrue from the practice of yoga can be protective, Dr. Fishman said.\nKnowing that more than 700,000 spinal fractures and more than 300,000 hip fractures occur annually in the United States, Dr. Fishman hoped that similar findings from a much larger study might convince doctors that this low-cost and less dangerous alternative to bone-loss drugs is worth pursuing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Fishman invested a \u2018significant chunk\u2019 of his own money into the research and we appreciate that the story put that financial interest out in the open. Apart from the selling of the DVDs used, it hard to imagine how there could be a significant financial gain from the study. However, given that investment, it wold have been valuable to have comments from others in the field speaking to the study results and the basic premise entailed. This kind of research might be more influenced by more subtle\u00a0intellectual conflicts of interest, where the researchers are intellectually identified with an idea (yoga=good) and would have difficulty accepting alternative hypotheses. The lack of a control group becomes somewhat problematic as it is possible that a similar group of non-yoga performing people would also see increases in their bone density.", "answer": 1}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nThe findings were published online today in Pediatrics.\nAll the infants were diagnosed with colic, born full-term at a healthy gestational weight, had no history of gastrointestinal disorders, were breastfed, not formula fed, and did not receive any other probiotic supplements during the week prior to the study.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A real shortcoming. No independent perspective\u00a0was provided nor were the\u00a0researchers themselves interviewed for the story. In addition, the story failed to point out that the study was funded by probiotic manufacturer BioGaia. \u00a0\u00a0", "answer": 0}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nIcon was developed in Germany and has been available in the U.S. for just over a year.\nBecause it's so new, it's still unclear how the Icon resin filling holds up over time.\nThat cringe-worthy sound may be on the way out.\nHopefully it works.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nAlthough this story includes comments from an independent source and it identifies the lead researcher as being on of the product\u2019s developers\u2026 it fails to point out that the dentist featured in the story also has received financial support from product\u2019s manufacturer.\nReference: http://www.compendiumlive.com/print.php?id=3103", "answer": 0}, {"article": "However, nearly 46 percent of low-risk women aged 50 to 59 were screened, as were 59 percent of low-risk women aged 60 to 64.\nThe study was published online May 19 in the Journal of General Internal Medicine.\nReminder notes to doctors and patients might help, one expert said.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story offers no independent voices to put the findings in context. It makes no mention of funding, though there appear to be no conflicts of interest.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites one source\u2014the chief of the knee service at a major New York hospital that performed 2500 knee replacements in 2006. It offers no independent sources who might have balanced his enthusiasm with information on harms, costs, and other treatment options.", "answer": 0}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "A major weakness of this news release is failing to mention that four out of six of the authors are \u201cnamed inventors on a patent\u201d related to this screening test.\nAlso, the funding for this study is not included.", "answer": 0}, {"article": "Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nAccording to the FDA approval letter, the company has until December to submit the full trial data to the agency.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nAll five drugs are part of a new class of treatments designed to unleash the body\u2019s immune system to fight cancer by interfering with proteins known as PD-1 or PD-L1 that help malignant cells evade immune attack.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has no sources. It needed\u00a0an independent voice to provide comment on what it means to see survival increase by only a handful of months, particularly for such an expensive treatment. Is the trade-off worth it? Will doctors readily prescribe this treatment?", "answer": 0}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nAnd all of the people in this study are white, so that's a limitation.\nThe results were published Tuesday in JAMA, the journal of the American Medical Association.\nMore than 100,000 people were involved.\nBut there's not much data to back the notion that a bit more pudge is protective.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no apparent conflicts of interest. However, only one researcher was quoted, but nobody else independent of the work.", "answer": 0}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\nThis method is expensive, invasive and has some risk of complications,\" study author Dr. Sheraz Markar said in an ECC news release.\nStudy results presented at meetings are generally considered preliminary until they've been published in a peer-reviewed journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not appear to include input from independent sources.", "answer": 0}, {"article": "About 2.2 million Americans currently live with an irregular heartbeat condition, known as atrial fibrillation.\nAll had already undergone at least one failed drug regimen.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nTHURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u2019s actually no interview \u2013 only a rehash of what was published in a journal, restated from a news release.\u00a0 No independent source cited. ", "answer": 0}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\n\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nTwo HPV vaccines are now approved by the FDA: Cervarix and Gardasil.\nThe vaccine is recommended for optional use in boys and men.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources included one of the study researchers and additional perspective from the author of an editorial in the New England Journal of Medicine. It did not point out that Merck, the manufacturer of Gardasil, contributed to the money for this study.\u00a0 We\u2019ll call it barely satisfactory.", "answer": 1}, {"article": "About 800,000 people in the United States suffer from a stroke each year.\n\u201cWhat surprised us most was the remarkable recovery some patients had,\u201d Dr. Gary Steinberg, professor and chair of neurosurgery at Stanford, told Medical Daily, \u201cWhile we had hoped for that, we didn\u2019t really expect it.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\nAlthough more than 75 percent of patients reported suffering headaches afterward, the researchers said it was probably due to the surgical procedure rather than the stem cells themselves.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, this article appears to have been drawn substantially if not exclusively from the news release, although the writer appears to have interviewed the principal investigator; but it\u00a0offers not a single source outside of the investigators who presumably approved the news release issued by Stanford.\nThere is disclosure about industry funding in the news release, but none at all in the article. The article would have gone a long way to put credibility and context into a genuinely promising experimental therapy if it had sought comment from an independent stem cell therapy researcher.", "answer": 0}, {"article": ".\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\nDr. Ross, who is also an Associate Professor of Pediatrics at Case Western Reserve University School of Medicine, was joined by UH Rainbow colleagues and study co-authors James Chmiel, MD, MPH, Professor of Pediatrics, and Ross Myers, MD, Assistant Professor of Pediatrics.\nAsthmaNet studies are currently being conducted in 14 states.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "University Hospitals Case Medical Center discloses in its first paragraph the fact that the National Institutes of Health and the National Heart, Lung and Blood Institute\u2019s Asthma Network (AsthmaNet) funded the study.\nHowever, according to the published study, several of the researchers have ties to Pfizer, the maker of Children\u2019s Advil, and to McNeil Consumer Healthcare and Johnson & Johnson, makers of Tylenol. These are important ties to mention in a news release.", "answer": 0}, {"article": "According to a new study, a medication, ancetrapib, appears to simultaneously raise the level of HDL \u2013 sometimes called \u201cgood\u201d cholesterol- and to lower the level of LDL, or \u201cbad\u201d cholesterol.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nDr. PK Shah, cardiologist at the Cedars-Sinai Heart Institute, said that he\u2019s encouraged by DEFINE but that some of the details give him pause.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThis is a strong point of the story. It offers readers comments from several independent experts who highlight some of the key questions that still need to be investigated. (However, the story leaves all the caveats out of the lead paragraphs, so readers have to dig down to find the vital context.) It also points out that the trial was sponsored by the company developing this drug.\nThe story should have pointed out that the lead researcher has financial ties to this drug company and others, including board membership and grants.", "answer": 1}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\nThe cancer institute is using the Oncotype DX test, which includes genes associated with response to chemotherapy, among them genes involved with a cell's response to estrogen.\nIt took two years before the National Cancer Institute and its researchers could even agree on a design for the large new American study that will test the idea that many women might safely forgo chemotherapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Many sources of information are cited and these are from trusted organizations of cancer research and information (e.g. National Cancer Institute, American Cancer Society). Dr. Berry, the lead author of the main study discussed, receives funding from several pharmaceutical companies, including Eli Lilly, Novartis and Bristol-Myers, however, the study was not funded by these companies. ", "answer": 1}, {"article": "More than one million athletes experience a concussion each year in the United States.\nThe study was supported by the National Institutes of Health and the National Science Foundation.\nHowever, what these detected blood flow changes mean to a patient's clinical care is still unclear.\"\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nTesting of the TCD technique at the sideline at the time of injury will be an important next step to determine its ultimate utility,\" said Randolph S. Marshall, MD, MS, with Columbia Presbyterian Medical Center in New York and a member of the American Academy of Neurology's Science Committee.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the news release makes clear that the National Institutes of Health and the National Science Foundation funded the study, it does not illuminate the potential conflict of interest of the lead investigator. The lead investigator is identified in the release as the co-founder of Neural Analytics which developed the technology, and a journalist or other reader must then infer that the company may well be a beneficiary of the adoption of this technology. At minimum, some acknowledgement of the financial prospects for the company would be appropriate.", "answer": 0}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A quote from an independent source was included in the story commenting on the study and reflections about the benefits of a \u2018Mediterranean diet\u2019.", "answer": 1}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\nThe results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the 'omega-3 Index'-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues.\n\"This science has demonstrated the importance of food nutrients to promote good health and prevent ill health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release never specifically says who funded the research, although most readers would assume it was Devenish, the manufacturer of the chicken feed being touted and the company that issued the release. The release does disclose that \u201cThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\u201d \nThe release should have noted whether there were any financial ties between the researchers and Devenish. Without a published study this is hard for us to verify.", "answer": 1}, {"article": "For example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nLilly has filed for approval of the drug by the U.S. Food and Drug Administration.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nStanford\u2019s Department of Medicine also supported the work.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the manufacturer paid for the trial and the key spokesperson, the principle investigator served as a consultant to Eli Lilly.", "answer": 1}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThe reduction in risk was even greater for early deliveries.\nThe findings were also published simultaneously in a special online issue of the New England Journal of Medicine.\nThis is important because it will reduce the need for preterm delivery, which is risky for the baby.\"\nThey continued taking the pills until they were 36 weeks' pregnant, or sooner if they delivered the baby early.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and we could find no conflicts of interest.", "answer": 1}, {"article": "The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences.\nThe study was supported by the National Institutes of Health (grants F32 GM114948 and CA041101).\nBut Boger calls this the \u201ceasy part\u201d of the project, compared with the challenge of designing the molecule in the first place.\nEven if the process isn\u2019t streamlined, Boger believes the new vancomycin\u2019s lifesaving powers make its production valuable.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly identified, and there does not appear to be a conflict of interest for the researchers. The release would have been stronger if it had clearly stated that there was no conflict of interest.", "answer": 1}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\n\"If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change,\" says study author Margaret L. Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, in a news release.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nBut Sheiner was extremely committed to trying it.\nThis was exactly the case for Sheiner.\nSheiner is a software designer and programmer.\nNoninvasive measures are always the first lines of defense, she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes the perspective of one independent expert.", "answer": 1}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have benefitted substantially from independent commentary by a researcher or healthcare provider not associated with the study. There were no stated conflicts-of-interest in the study. So none needed to be identified in the article.\n\n\n\n\n\n\n", "answer": 0}, {"article": "Tendon stem/progenitor cells regulate inflammation in tendon healing via JNK and STAT3 signaling.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\nSubmit to The FASEB Journal by visiting http://fasebj.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The quoted expert source in the release is identified clearly as a co-investigator of the study, but we can find no information in the release about funding sources or possible conflicts of interest.", "answer": 0}, {"article": "Overall, nearly 83 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with about 81 percent in the combined group, and 78 percent who took painkillers alone.\nBut two days later, most patients were satisfied.\nMore than 80 percent still had a pain rating of at least 4, the findings showed.\nMONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story offers quoted statements only from the lead investigator for the trial. No independent sources or quoted, nor are we told who funded the study.", "answer": 0}, {"article": "Patients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nThese findings suggest the pills may help protect against death in patients with pneumonia.\nLONDON (Reuters) - Taking cholesterol-lowering statin drugs such as Pfizer\u2019s Lipitor and AstraZeneca\u2019s Crestor could help prevent people dying from pneumonia, according to a study by British scientists released on Tuesday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only perspective provided comes from the study\u2019s lead researcher, via a press release.", "answer": 0}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include one statement by a physician not part of the research team. But it doesn\u2019t point out that all of the researchers are either the employees of the pharmaceutical firm, Teva Pharmaceuticals, which makes the new drug, or they are consultants to dozens of other pharmaceutical firms. These ties should have been disclosed.", "answer": 0}, {"article": "Anti-gravity treadmills get patients running again after knee surgery\n\nPatients recovering from knee operations are being helped back to sport and exercise through expert rehabilitation at the University of Kent.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nNews releases can also be found at http://www.\nThe cartilage covering the bone surface is not able to heal itself when it is damaged and this is why surgical procedures are available to repair the damaged area.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say if the author received funding to complete the case study. It also doesn\u2019t give readers any information about potential conflicts of interest, or the absence of any, between the study authors and anti-gravity treadmill manufacturers.", "answer": 0}, {"article": "Regular aspirin use may lower the risk of Alzheimer\u2019s.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nBut what about Alzheimer\u2019s?\nBut more recent, randomized studies have called those findings into question.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story did not appear to contain material obtained from individuals with expertise in this area.\u00a0 No one was quoted.", "answer": 0}, {"article": "Through a blood vessel in the groin, doctors snake a tube to a blocked heart artery.\nTo the surprise of the researchers, both groups fared about the same: approximately 19 percent had a heart attack or died within seven years, adds LaPook.\nThe new study shifts the argument from which type of stent to use to whether to do the procedure at all.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\n\"We deliberately chose to enroll a sicker, more symptomatic group\" to give angioplasty a good chance to prove itself, Boden said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one cardiologist not associated with the study and gives no rationale for why he was chosen. (Is it because he's in New York and readily available?) The story could have quoted other clinicians or experts who could have provided some valuable perspective on the impact of this new development on the management of heart disease.", "answer": 0}, {"article": "Lupus is an autoimmune disease, in which the defense system against pathogens attacks the body\u2019s own tissues.\nIn 2000, the company\u2019s share price soared to over $100 on anticipation that understanding the human DNA blueprint \u2014 the human genome \u2014 would lead to a cornucopia of drugs.\nBut Human Genome Sciences, in consultation with the Food and Drug Administration, restricted the Phase 3 trials to a subset of patients who seemed to respond better to the drug in the earlier trial.\n\u201cThe question was, \u2018Can you prove in a very large trial what we\u2019ve proven here?\u2019 \u201d\n\nThe 865 patients in the trial, who were mainly in Asia, South America and Eastern Europe, received either Benlysta or a placebo in addition to the drugs they were already taking.\nBecause the disease\u2019s symptoms wax and wane on their own and vary considerably from one patient to another, it has been hard to demonstrate the efficacy of drugs in clinical trials.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a company spokesperson, a clinician who is a consultant for the company, and a clinician with expertise in lupus who does not appear to have overt ties with the company. \u00a0The story would have been more informative to readers had several clinicians with expertise in treating people with lupus been interviewed as part of this story. \u00a0The comments of those involved with drug development or promotion have limited credibility.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story should have mentioned that Dr. Kuehl appears on the Cherry Marketing Institute\u2019s \u201cpower team.\u201d\nAnd there was no independent perspective quoted.\u00a0 Only one author saying his work \u201ccould someday provide an alternative treatment\u201d and another author saying \u201cthere are some interesting and potentially exciting results on the horizon. Stay tuned.\u201d", "answer": 0}, {"article": "Bitter taste receptors as targets for tocolytics in preterm labor therapy.\nDetails: Kaizhi Zheng, Ping Lu, Ellen Delpapa, Karl Bellve, Ruitang Deng, Jennifer C. Condon, Kevin Fogarty, Lawrence M. Lifshitz, Tiffany A. Moore Simas, Fangxiong Shi, and Ronghua Zhuge.\nSubmit to The FASEB Journal by visiting http://fasebj.\nThe FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB).\n\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not list the funding sources, although the paper does list them. There is no mention of conflict of interest in either the published study or the news release.", "answer": 0}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nThe drug is called Gammagard.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story explained that the study was funded by the drug company that makes the drug being studied.\u00a0 And it did seek opinions from two independent experts. ", "answer": 1}, {"article": "JACC is ranked No.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\n1 among cardiovascular journals worldwide for its scientific impact.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Neither the funding source nor any conflicts of interest are disclosed.", "answer": 0}, {"article": "\u201cI\u2019d be very rich.\u201d\nBut work was slowed by lack of money, and by 2004, BioSpecifics was about out of cash.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nThe ointment, sold by licensees under the name Santyl, was a modest success, but the company never truly prospered.\nWith its belated success, BioSpecifics has sold off its ointment business.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most of the sources in this story are affiliated in some way with organizations that will profit from the sale of Xiaflex. These conflicts are disclosed, however, and the story does offer some clinical perspective from a hand specialist who does not appear to be connected to\u00a0Xiaflex. \u00a0", "answer": 1}, {"article": "In the current review, researchers found several trials that compared different doses of radiation and different types of radiation therapy, including external beam radiation therapy, in which a radiation is delivered through a beam through the skin, or brachytherapy, in which radioactive isotopes are delivered via injection into the prostate.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nBrooks said more comparative effectiveness research, which compares different kinds of treatments, is needed.\nThe study is published in the June 6 issue of the Annals of Internal Medicine.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to Dr. Durado Brooks of the American Cancer Society for an independent perspective.", "answer": 1}, {"article": "Currently many women with a gene mutation choose surgical removal of their breast tissue and ovaries to reduce their chance of developing breast and ovarian cancer.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nTo progress this work, denosumab would need to be formally tested in clinical trials in this setting as it is not approved for breast cancer prevention,\" Professor Lindeman said.\nProfessor Visvader said the discovery had its basis in more than a decade of investigations of breast stem cell function.\nThe research, which also involved researchers at the Australian familial cancer consortium kConFab and US biotechnology company Amgen was published today in Nature Medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes Amgen in the sections of the release that list all of the organizations that were involved with conducting the research and which supported the work financially. However, the release does not tell readers that Amgen is the company that currently markets denosumab (under the trade names XGEVA and Prolia).", "answer": 0}, {"article": "The world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an unattributed quote lifted from the Roche news release, and a quote from a financial analyst, who discusses the drug\u2019s shifting market share\u2013not the science. This was not sufficient sourcing.", "answer": 0}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nHowever, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nGiven the current understanding and strength of evidence supporting the importance of nutritional supplementation during pregnancy, \u201cit is impossible to imagine that these results, on their own, should change current practice,\u201d they write.\n\u201cTogether, the three analyses appear to point toward a potential inverse association between multivitamin use with ASD with intellectual disability,\u201d say the authors.\nThe researchers stress that their findings cannot establish cause and effect, but say they raise questions about a possible association that warrant further investigation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes no mention of either funding sources or potential conflicts of interest involving the study authors. This information is plainly provided in the journal article\u2019s footnotes which\u00a0 lists the government funding sources and notes that \u201cResearchers were independent from funders.\u201d", "answer": 0}, {"article": "Of those 40 women, 26 had mutations carrying low to moderate risk of breast or ovarian cancer, eight had mutations associated with Lynch syndrome, which increases colon and ovarian cancer risk, and three had high-risk breast cancer genes.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\n\u201cMany cancer genetics experts have again urged caution, characterizing the use of multigene testing in the clinical setting as premature,\u201d Dr. Elizabeth M. Swisher of the University of Washington Medical Center in Seattle writes in a commentary accompanying the new paper.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article mentions that several of the study\u2019s authors have links to the industry and to companies that produce the genetic test panels. The story also quotes from an editorial written by an expert who wasn\u2019t involved with the study. Conducting an interview with an outside expert might have unearthed additional useful context, but the story is pretty solid here as it stands.", "answer": 1}, {"article": "\"We know that art therapy can work, music therapy can work.\nResearchers loaded a menu of 70 apps onto the tablets for the study.\nThese significant improvements are a clear testament of the tablet's potential as a clinical tool.\"\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\nVahia cited several examples of the tablet's potential to improve a patient's condition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention who funded the study.", "answer": 0}, {"article": "\u201cPills and rings should be sitting next to each other as options.\u201d\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nThese age differences are probably due in part to how the women used the drug, the researchers say.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t mention the makers of the device or any potential conflicts of interest. However, one of the authors of the study presented in abstract form (the \u201cSPIRE\u201d study) is affiliated with the International Partnership for Microbicides, Silver Spring, MD, which is involved with product development, partnerships with pharmaceutical companies, and marketing of this and related devices. The device is licensed from Janssen Sciences, a large pharmaceutical company. The International Partnership for Microbes describes itself this way: \u201cAs a nonprofit product developer, IPM partners with a variety of organizations to facilitate strategic planning from the earliest stages of product design to ensure future access to products.\u201d\nThere are two people quoted in the story, the lead author of the study and the head of AVAC, a global HIV-prevention advocacy group. (AVAC issued a news release on the two studies.) While the story includes insightful comments from these two sources, both have some investment (even if only on an intellectual level) in the project. The story would have been been stronger if it had included an expert with no relationship at all to the device studies, ideally someone active in providing health care in sub-Saharan Africa, who might have provided insights into adherence, product acceptance or any practical obstacles (such as costs) in the way.", "answer": 0}, {"article": "On average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nStephen Allen, a pediatrician at Swansea University in the United Kingdom who lead the review, tells Shots that probiotics were effective in almost all the studies, which had more than 8,000 participants total, his team evaluated.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited in this story \u2013 only the lead author of the study.", "answer": 0}, {"article": "Although total sleep deprivation or partial sleep deprivation can produce clinical improvement in depression symptoms within 24 hours, antidepressants are the most common treatment for depression.\nThis research was funded by National Institutes of Health grants (R01 HL102119, P30 NS045839, R01MH107571, R01MH098260, P41 EB015893, R01 MH080729), National Aeronautics and Space Administration grants (NNX15AK76A, NBPF02701, NNX08AY09G, NBPF03401, NBPF02501, NNX14AM81G, NX16AI53G), National Heart, Lung, and Brain Institute (U01 HL125388), National Institute on Drug Abuse (1 R21 DA040902-01A1), the Office of Naval Research (N00014-11-1-0361), the National Aeronautics and Space Administration (NNX14AN49G), National Space Biomedical Research Institute through NASA (NCC 9-58), and grant support from Merck and Philips Healthcare/Respironics.\n\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\n\"These studies in our analysis show that sleep deprivation is effective for many populations,\" said lead author Elaine Boland, PhD, a clinical associate and research psychologist at the Cpl.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release listed the federal grants and two medical device companies that provided funding for the study. One of the device companies manufactures devices for sleeping and respiratory care. There does not appear to be any direct conflict, but we would have liked a statement saying that.", "answer": 1}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nAnd on Monday, the American Academy of Neurology released a new study showing that an agent called florbetaben also allowed detection of amyloid plaques when used with a PET scan.\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nMany patients experiencing cognitive lapses may also be reassured if the test fails to reveal amyloid plaques, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert source, Dr. Michael Weiner, who was involved in the development of Amyvid, but it does not mention that he has disclosed relationships with a number of pharmaceutical companies, including Eli Lilly, Amyvid\u2019s manufacturer. In addition, the story mentions that Weiner is the leading researcher on the Alzheimer\u2019s Disease Neuroimaging Initiative, but does not disclose that this consortium is partially funded by industry.\nSince the drug had previously been rejected by the FDA\u2019s scientific advisory committee,\u00a0 a dissenting voice would not have been hard to find.", "answer": 0}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nThis work was supported by the National Institutes of Health (1R01CA195500, 1R01CA193380).\n\"Nearly everyone said they preferred it to a traditional speculum and more than 80 percent of the women who tried the device were able to get a good image.\nAsiedu is also working to automate the screening process.\nRamanujam believes she can replace at least two of these requirements.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release acknowledges in a footnote that the research was\u00a0funded by the National Institutes of Health. That\u2019s enough to meet our standard, but putting this information in the body of the release would make it more likely to be picked up by syndicators and others who might redistribute this content.", "answer": 1}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nSaposnik said more studies will help clarify the association between chocolate and stroke risk.\nStill, two of the three studies analyzed in the review provide yet another suggestion that health benefits lurk in chocolate, dark chocolate in particular, said review co-author Dr. Gustavo Saposnik.\nChocolate is a major source of saturated fat, which raises bad cholesterol and boosts heart disease risk, said Clark, an assistant clinical professor at the University of California at San Francisco.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0A dietitian and a nutrition researcher \u2013 both apparently unaffiliated with the research \u2013 were quoted. ", "answer": 1}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\n\"The findings are most important for populations at high risk for cardiovascular disease, such as Type 2 diabetics, who have normal levels of LDL cholesterol, but elevated levels of non-HDL or apo B,\" said Dr. Vladimir Vuksan, research scientist and associate director of the Risk Factor Modification Centre of St. Michael's.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\n\"Health Canada, the FDA and several health authorities worldwide have already approved health claims that barley lowers LDL cholesterol, but this is the first review showing the effects on other harmful lipids.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of funders and financial ties to industry which should always be disclosed as a potential conflict of interest. Several of the researchers involved have financial ties to both trade groups and corporations, according to the published report. For example, one of the authors holds Canadian and U.S. patents on a medical use of viscous fiber for certain health conditions.", "answer": 0}, {"article": "They may work quite well for a period of time but a person's lenses will continue to change with age and, ultimately, the patient may need cataract surgery.\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\n\u201cThere\u2019s a healing process after the inlay is put in that requires eye drops be put in on a daily basis for around three months,\" says Hamilton.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It was not clear from the story whether either one of the experts quoted \u2013 Ralph Chu or D. Rex Hamilton \u2013 had any conflicts. In fact, Chu is one of the researchers\u00a0in a clinical study of the Raindrop implant, according to a peer-reviewed journal article we found.", "answer": 0}, {"article": "After treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nNewswise \u2014 COLORADO SPRINGS, CO \u2013 Shoulder instability is most common in the young, athletic population, bringing a focus to how these injuries are best treated.\n\u201cDeciding between a non-operative program or going forward with surgery can be a challenging decision for medical professionals treating shoulder injuries in young athletes,\u201d noted the study\u2019s lead author Tyler J. Marshall, MD, from Alabama Ortho Spine and Sports in Birmingham, AL.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It would have been helpful had the news release noted that\u00a0Alabama Orthopedic Spine & Sports Medicine Associates carried out the surgeries.", "answer": 0}, {"article": "\u201cEveryone was hoping vitamin D would be kind of a panacea,\u201d Dr. Black said.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\nBut, the committee concluded, a level of 20 to 30 nanograms is all that is needed for bone health, and nearly everyone is in that range.\nBone health, though, is only one of the benefits that have been attributed to vitamin D, and there is not enough good evidence to support most other claims, the committee said.\nIt was asked to examine the available data \u2014 nearly 1,000 publications \u2014 to determine how much vitamin D and calcium people were getting, how much was needed for optimal health and how much was too much.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The diversity of independent voices included in this story is a real strength. Although it solicits the obligatory comment from a supplement industry spokesman, it didn\u2019t go out of its way to find any of the more widely known vitamin D experts,\u00a0some\u00a0of whom have been issuing recommendations that are untenable based on current evidence. The enthusiasm of some of these researchers\u00a0might be\u00a0explained by\u00a0their significant career and financial\u00a0interests in promoting vitamin D.", "answer": 1}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nPeople who were taking medication for OCD continued to do so for the trial.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\nThe Food and Drug Administration made the announcement on Friday, expanding the use of a technology that has been around for decades.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article is weakened by the absence of expert comment and attribution of claims made by the company and the FDA. Nor does the reader learn anything about whether those who conducted the clinical trial have or had any ties to Brainsway or other conflicts of interest.", "answer": 0}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\nResearchers agree there is a strong genetic component.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the sources for this story was not involved in the research and has no obvious conflicts of interest.", "answer": 1}, {"article": "Frailty predicts postoperative mortality and illness more than age alone, thus presenting opportunities to identify the highest-risk surgical patients and provide tailored clinical care to improve their outcomes.\nThe absolute reduction in 180-day mortality among frail patients was more than 19 percent, with improvement remaining robust even after controlling for age, frailty, and predicted mortality.\u201d\n\n: This investigation was supported by a grant from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development.\nThis study included 9,153 patients (average age, 60 years) from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 30, 2016\n\nAlso available at the For the Media website, the commentary \u201cA Call for Frailty Screening in the Preoperative Setting,\u201d by Anne M. Suskind, M.D., M.S., and Emily Finlayson, M.D., M.S., of the University of California, San Francisco.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We learn that the study \u201cwas supported by a grant from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nThe research was supported in part by funds from the National Mango Board and USDA.\nLonger-term studies involving other population groups are warranted.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes that the research was partially funded by the National Mango Board. We were unable to access the published study to check whether any conflicts of interest were disclosed.", "answer": 1}, {"article": "About 35% of U.S. adults take calcium supplements, alone or in multivitamins, according to a recent report in the medical journal JAMA.\nThe larger review did not include all potentially relevant studies, says Erin Michos, an associate professor of medicine and epidemiology who led the Johns Hopkins study.\n\u201cIf you look at the overall totality of the evidence, there\u2019s a lack of association between supplement use and heart attack and other cardiovascular events,\u201d says Manson, who co-wrote an editorial accompanying the review.\nAnd its findings were quickly refuted by a larger review of 31 previous studies, including some with more rigorous designs.\nBut the study, published in the Journal of the American Heart Association, was not designed in a way that could prove the supplements caused the artery changes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a strong point. The story not only incorporates input from multiple sources, but clearly identifies any affiliation that could be perceived as influencing their perspective (e.g., noting that one source wrote an editorial that was published in conjunction with the JAHA paper). In addition, the story clearly notes that the meta-analysis was done with support from a pharmaceutical company that manufactures calcium supplements.", "answer": 1}, {"article": "Without intervention, 80 to 90 percent of infants who are born to mothers infected with hepatitis B develop a chronic infection.\nThis research was supported by Gilead Sciences.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study.", "answer": 0}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nIt aims to screen 1,700 men for five years, but results from the first 300 men were published in the British Journal of Urology International.\nEeles said the findings added to the increasing evidence that BRCA gene variation carriers develop more aggressive disease and supported the idea that men with genetic risks should be routinely screened for prostate cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A major problem with this story is that it only quoted one expert who is one of the researchers on this study, and all comments from him appear to be from the press release. The story could have been greatly improved by quoting another expert who could have provided some valuable perspective on the importance of these results.", "answer": 0}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nAnd, one of the study authors, Eric Rimm of the Harvard School of Public Health, has been sponsored by the Distilled Spirits Council of the United States to speak at academic conferences.\n\"It's the difference between a B and an A\" on a test, says Wraga.\nCAUTIONS: The study looks only at spatial reasoning.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert, the lead author on the study. The story should have quoted multiple experts who could provide more perspective.", "answer": 0}, {"article": "Male condoms and oral pills dominate the $5.5 billion contraceptive market in the United States.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\nOppenheimer analyst Leland Gershell said he expects Amphora, the company\u2019s lead product, to bring in sales of up to $415 million by 2032.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "With a new birth control product, we\u2019d like to see comments from independent physicians or researchers that are experts in the field\u2013and we think this is something investors would value seeing, too. However, this story quotes the CEO of the product\u2019s maker, as well as two business analysts.", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had several independent sources and we detected no conflicts of interest.", "answer": 1}, {"article": "Dr. Kenneth Liao used the da Vinci surgical robot Thursday to restore lost blood flow to the heart of 58-year-old John Carter Holmes.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes two physicians, both of whom use the machine\u2013and work at hospitals that have invested in the machines. \nThe reporter should have talked to at least one surgeon who has declined to use the device, and one independent researcher with no conflict of interest who could summarize the findings of safety and efficacy.\nFinally, there is some federal data about negative outcomes with the device\u2013including at least one unnecessary death early in the device\u2019s development\u2013that should have been drawn on.\u00a0", "answer": 0}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\nPatients were randomly assigned to 12 acupuncture sessions or 20 one-to-one Alexander Technique lessons plus usual care, or usual care only.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not disclose funding sources for the study. In addition, the study was more transparent than the release in disclosing\u00a0potential\u00a0conflicts of interest. Two of the authors of the original study, Drs. Woodman and Ballard, are both on the Society of Teachers of the Alexander Technique and contributed toward obtaining funding for the study. Coincidentally, all practitioners recruited in the study for the Alexander Technique came from the same society. The fact that the study authors and practitioners were all closely allied with the Alexander Technique was worth disclosing to readers, especially journalists, who were relying on the release.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nThe therapy was nine sessions on average plus exercises to do at home, which experts say is key to success.\nYet they ended up the same as those who got surgery right away, as well as the rest of the physical therapy group who stuck with it and averted an operation.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two study leaders, an editorial author, and two patients.", "answer": 1}, {"article": "Like mifepristone, ella is a type of drug known as a selective progesterone receptor modulator (SPRM) that interferes with the hormone progesterone, which is critical for pregnancy.\nWith Plan B sold over the counter, most women have to pay for the drug themselves \u2014 roughly $50 \u2014 rather than have their health insurance cover it, Allina said.\n\u201cData on pregnancy outcomes after EC (emergency contraceptive) failure with ulipristal were too limited to draw any definitive conclusions regarding the effect of ulipristal on an established pregnancy or fetal development,\u201d they wrote.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\nIt was not clear what effect the drug had, if any, when a woman still became pregnant despite taking it, they added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes no independent sources outside of the FDA or the pharmaceutical company. Quoting independent sources to provide some perspective on what this might mean to women, would have greatly improved this story.", "answer": 0}, {"article": "In undeveloped countries, 75,000 women die from pre-eclampsia each year.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nWriting in the journal Hypertension, the researchers said they did a simple study, testing the blood of 60 women who developed pre-eclampsia later in pregnancy and 60 women who did not.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\n\u201cA high caliber predictive test would allow women who are identified at high-risk for pre-eclampsia to seek obstetric care by specialists and to be monitored more vigilantly,\u201d Eleni Tsigas, executive director of the Pre-eclampsia Foundation, said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did include a comment from Eleni Tsigas, executive director of the Preeclampsia Foundation. A better source would have been another researcher, perhaps one of the many cited in the article. The article did not mention whether any of the researchers had conflicts of interest regarding the development of the diagnostic test. The study itself says the authors had no disclosures and reports the study to be entirely government funded. Given that at least one outside source was contacted and that there were no obvious conflicts to disclose, we give this one a pass.\n\u00a0\n", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nThe picture of selenium\u2019s health benefits \u2014 or possible health risks \u2014 has been anything but clear.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\nThe finding \u201cis not generalizable to other patients,\u201d he said.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert source for this story was a co-author on the study being discussed. Although his comments are appropriately cautious, they are not sufficient to satisfy this criterion.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent use of independent sources, including the \u201cnot the breakthrough we were anticipating\u201d quote from one of them in the story\u2019s second sentence.", "answer": 1}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nIn an upcoming study, Furman and others will soon investigate the immune systems of 1,000 people; he hopes to use that information to develop a reference range of immune-system components to tell people whether their levels are normal, or if they\u2019re at higher risk for developing chronic conditions driven by inflammation.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n\u201cClearly in aging something is breaking down, and we become less effective at managing this inflammation,\u201d says Mark Davis, director of the Stanford institute.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only researchers associated with the study and does not tell readers who funded the work. In this case, all of the funding appears to come from well-regarded research institutions, such as NIH and the Howard Hughes Medical Institute. Input from third-party experts may have helped better place the findings in context.", "answer": 0}, {"article": "\u201cNo,\u201d Dr.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nThe type of sugar you eat may affect your cravings for high-calorie foods, researchers report.\nWhen choosing between tasty high-calorie food or a delayed monetary reward, fructose drinkers were more likely than glucose drinkers to choose the food.\nThe study, published in the journal PNAS, found that compared with glucose, consuming fructose produced greater responses to food cues in the orbital frontal cortex of the brain, a region that plays an important role in reward processing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only one source, and clearly notes that the source is an author of the relevant study. However, the story lacked an independent expert to put the work in context.\u00a0This story badly needed that context to give us a sense of how important this work might be, and what similar work may have been done in this area. For example, maybe the cues for people to eat junk/high-calorie foods are so strongly triggered by other behavioral patterns that making substitutions of sugars in processed foods won\u2019t matter anyway.", "answer": 0}, {"article": "Oxytocin,which is produced in abundance when a mother is breast-feeding her baby, is known as the \"bonding\" hormone.\nThere were, however, wide variations in individual responses, the team noted.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nThe new study, led by Angela Sirigu at the Center for Cognitive Neuroscience in Lyon, France, was published in this week's issue of Proceedings of the National Academy of Sciences.\nAlthough there are many kinks to be worked out, experts feel the strategy holds promise to treat one of the core symptoms of autism spectrum disorder.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites several independent sources and provides several quotes for balance. The study authors themselves identified no conflicts of interest.", "answer": 1}, {"article": "Achillion\u2019s ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Even though this is a business story focused on the market prospects for the drug, the actual efficacy of the drug is key. To that end, an independent expert in hepatitis would have been a welcome addition.", "answer": 0}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nThe Weinblatt study and an editorial by NIH researchers Juan Rivera, PhD, and Robert A. Colbert, MD, PhD, appear in the Sept. 30 issue of the New England Journal of Medicine.\nRigel funded the study, and three of the study's six authors are Rigel employees.\nWeinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\nFor now, R788 looks very promising, the researchers report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in this story and, indeed, no named sources quoted.\u00a0High in the story, it says\u00a0\"Now Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial,\" giving the imprimature of independent, academic reserach. But the\u00a0story includes this helpful paragraph at the end. \"Rigel funded the study, and three of the study\u2019s six authors are Rigel employees. Weinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\"", "answer": 0}, {"article": "The full article, \"OFF!\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\nClip-on Repellent Device With Metofluthrin Tested on Aedes aegypti (Diptera: Culicidae) for Mortality at Different Time Intervals and Distances,\" is available at http://dx.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We wish the release was more clear about sponsorship. The release doesn\u2019t explicitly say who funded the study but the implication is that it was sponsored by the Anastasia Mosquito Control District in Florida. An acknowledgement in the study states that readers shouldn\u2019t view the study as a product endorsement. \u201cThis is a research report only and mention of specific names of commercial products does not imply endorsement by the Anastasia Mosquito Control District.\u201d", "answer": 0}, {"article": "Researchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Italian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nThe study is in the Clinical Journal of the American Society of Nephrology.\nRecipients were at most seven years older or younger than the donors.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nOld age is not necessarily a barrier to kidney donation.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The post included no independent sources.", "answer": 0}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses the study\u2019s funding sources, which include the Boston University School of Medicine and a Boston University Ignition Award.\nThe original journal article states the study authors have no competing interests.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "\u2022 Ovarian cysts may occur but usually disappear.\n1Kyleena Prescribing Information, September 2016.\nKyleena is a trademark of Bayer.\nThe clinical trial had no upper or lower weight or BMI limit.\nKyleena is available by prescription only.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clearly marked as being from the manufacturer of Kyleena.", "answer": 1}, {"article": "\u201cThe field is moving fast.\nIn checking their findings against data gathered in a separate study, the researchers found that among 57 patients with mild cognitive impairment who went on to develop Alzheimer\u2019s within five years, 100 percent had the characteristic protein levels five years before.\nDr. John Morris, a professor of neurology at Washington University, said the new study \u201cestablishes that there is a signature of Alzheimer\u2019s and that it means something.\nThe new study included more than 300 patients in their 70s, 114 with normal memories, 200 with memory problems and 102 with Alzheimer\u2019s disease.\nHe suggested that, because most family doctors and internists are not experienced with the test, there could be special spinal tap centers where they could send patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story includes comments from independent sources, but it fails to note the industry connections of key researchers and the industry funding of the study.\n Several of the researchers who were responsible for the conduct of the study and the interpretation of the results are or were employees of a company (Innogenetics) that produces key components of the spinal fluid test and thus would benefit from clinical use of such a test. Also, funding for the study came from an institute (the Alzheimer\u2019s Disease Neuroimaging Institute) that is a partnership between public and private entities and that has received more than $20 million from pharmaceutical companies involved in developing potential tests and treatments for Alzheimer\u2019s Disease, as well as from the Alzheimer\u2019s Association and some other groups.", "answer": 0}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nIt cuts the death rate in these women by about 15%, says Otis Brawley, MD, chief medical officer for the ACS.\nThe U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did include helpful quotes from Dr. Otis Brawley of the American Cancer Society.\nHowever, for a story that mentions the US Preventive Services Task Force (USPSTF) three times, it failed to include any response from anyone on the USPSTF!", "answer": 0}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nThe study began in the 1980s, and along the way has recorded valuable data from participants, including diabetes test data.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nIn the new study, researchers led by Hopkins epidemiologist Elizabeth Selvin looked at data on more than 13,000 people in a long-running U.S. heart disease study.\nThis could change care, \"potentially allowing a major simplification of current clinical practice guidelines,\" Selvin said in a university news release.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tapped independent diabetes experts.\nWhile the study was funded by government grants, one of the authors disclosed grants and personal fees from industry, unrelated to the study.", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does make clear that the information about the ongoing study came from a company that makes one of the relevant drugs. That\u2019s good. However, the story does not incorporate input from any independent sources.", "answer": 0}, {"article": "Women with breast arterial calcification were more likely to be older, have high blood pressure and chronic kidney disease, and less likely smokers.\nThe study was funded, in part, by the Flight Attendants Medical Research Institute.\n\"This information is available on every mammogram, with no additional cost or radiation exposure, and our research suggests breast arterial calcification is as good as the standard risk factor-based estimate for predicting risk,\" Hecht said.\nEligible media should contact Shealy Molpus, smolpus@acc.org, to receive access to the briefing.\nBased on our data, if a mammogram shows breast arterial calcifications it can be a red flag--an 'aha' moment--that there is a strong possibility she also has plaque in her coronary arteries,\" said Harvey Hecht, M.D., professor at the Icahn School of Medicine and director of cardiovascular imaging at Mount Sinai St. Luke's hospital, and lead author of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the Flight Attendants Medical Research Foundation was a partial funder. We aren\u2019t told who else sponsored the research or if there were any potential conflicts of interest.", "answer": 1}, {"article": "In fact, although diet and exercise are the usual prescription for dropping pounds, high stress and too little sleep (or too much of it) can hinder weight loss even when people are on a diet, the researchers report.\nThose in the second phase of the trial continued their diet and exercise program.\nThey monitored the eating habits of the participants as they spent six days sleeping four hours a night and then six days sleeping nine hours a night (or the reverse).\nAnd the extra calories mostly came from saturated fat, which can spell trouble for waistlines.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included expert quotes and also some insight from the results of a recently presented study.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted for context and synthesis of the literature.", "answer": 1}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nThe randomized controlled trial included 74 people, mainly in their late 70\u2019s, with mild cognitive impairment (MCI).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We can\u2019t give this a satisfactory score because, unlike the MSNBC story, this one does not include any information from clinical experts not involved in the study.\nIt does, however, note that some of the authors on the study have received drug company funding and funding from tobacco makers. It also noted that the nicotine patches themselves were provided by Pfizer.", "answer": 0}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nShe owns her eggs, no question.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\nIf you decide to try egg freezing, don\u2019t wait too long.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several good independent sources cited. ", "answer": 1}, {"article": "The researchers hypothesize that the antidepressant effects of diclofenac and minocycline may be due, at least in part, to their abilities to reduce inflammation.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\nThe FAERS database contains more than 8 million patient records.\nAbagyan says it's still possible, though unlikely, the effect could be due to a still unidentified confounding factor.\nThe team is now working to separate Botox's beauty effects (which could indirectly make a person feel better emotionally) and its antidepressant effects.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the funder, not in the release text itself but on the EurekaAlert! website which hosts the news release.", "answer": 1}, {"article": "A team led by Dr. Philip Dennis of the National Cancer Institute, part of the National Institutes of Health, studied metformin in mice exposed to a potent, cancer-causing agent in tobacco called nicotine-derived nitrosamine ketone or NNK.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThey treated the mice with metformin either orally or with an injection.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A hesitant satisfactory on this one only because it quoted a comment from an expert \"who wrote a review on metformin research in the same journal.\" There was no evidence of any interview having been conducted, though. ", "answer": 1}, {"article": "But it also lowered women's risk of dying from breast cancer by 11% and men's risk of dying from prostate cancer by 23%.\nThe study was well conducted and was able to control for a number of important confounders.\n(CNN) An aspirin a day may keep the doctor away.\nEven the ancient Egyptians used the natural form of it for pain relief centuries ago.\n\"It is good to remember, though, if a person wants to take a low-dose aspirin, especially if a person has had cancer, they will want to have an initial conversation with their doctor first.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in this story.", "answer": 0}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nAll had high blood pressure.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nThe finding stems from a study of 700 people, who averaged 56 years old.\nShe's a researcher with the George Institute for Global Health at the University of New South Wales in Sydney, Australia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story.", "answer": 0}, {"article": "In previous adolescent and adult clinical studies, SHP465 demonstrated a statistically significant difference versus placebo at 16 hours post dosing, with onset of action starting 4 hours post dosing, as measured by the Permanent Product Measure of Performance (PERMP).\n\"These results represent an important step toward a new treatment option for patients with ADHD.\nShire looks forward to including these data as part of the FDA resubmission and is eager to continue advancing this clinical program.\"\nStatements included herein that are not historical facts, including without limitation statements concerning our announced business combination with Baxalta and the timing and financial and strategic benefits thereof, our 20x20 ambition that targets $20 billion in combined product sales by 2020, as well as other targets for future financial results, capital structure, performance and sustainability of the combined company, the combined company's future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements.\nOur strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear that the drug sponsor issued the news release and sponsored the study. We\u2019re provided a quote from the study\u2019s principal investigator (PI), Matthew Brams, an assistant professor at Baylor College of Medicine, but we\u2019re not told what financial arrangements the PI had with Shire. According to ProPublica\u2019s \u201cDollars for Docs\u201d database, Brams (one of ProPublica\u2019s designated top earners of speaking and consulting fees from drug companies) has received payments for serving as a consultant for Shire. That\u2019s a disclosure we\u2019d like to see in the news release.", "answer": 0}, {"article": "The F.D.A.\nBut such talks, while encouraging, are still in the early stages, a Novartis spokesman said.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\nBlacks and those with a previous history of the condition were at increased risk, it said.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two people are quoted in the story. One is an analyst at an investment firm, with no clear ties to Novartis, who was quoted in regard to the drug\u2019s potential to generate revenue for Novartis. The other is the head of Novartis\u2019s pharmaceutical division. An outside perspective on the potential health impact of the drug would have been very welcome.", "answer": 0}, {"article": "Cardiac fibrosis itself is caused by a variety of factors including high blood pressure, overwork of cardiac muscle and long-term consumption of a diet that is high in both saturated fat and sugar--all cause increased stress to heart cells.\nThis research was supported by the Canadian Institutes of Health Research.\n\"This would be a significant advance in the fight against heart disease.\"\nImproving their quality of life will do wonders for these individuals.\"\nOnce that occurs, the team hopes to work with cardiologists to quickly move the research into clinical trials, involving chemotherapy and heart transplant patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly notes the funding source, the Canadian Institute for Health Research.", "answer": 1}, {"article": "People taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nThe volunteers took pills once a day for six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nFasting blood samples were taken at the start of the trial and then at intervals of one, three, and six weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only two authors of the study were quoted \u2013 no independent expert source was cited. ", "answer": 0}, {"article": "Reduction in high blood pressure has added health benefits because it can potentially reduce the likelihood of heart attacks, strokes, chronic heart failure and kidney disease.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nThe study is very useful in telling and confirming that we should talk to the patients, no matter how we do it,\u201d said Bernard Wong, a cardiologist based in Hong Kong.\n\u201cSecondly, we only look at the trade-off between efficacy and safety, but your study is looking more at efficacy and effectiveness and practicality, issues that are also very important.\n\u201cThe electronic counseling (e-Counseling) intervention had an effect similar to that of adding an additional blood-pressure-lowering medication,\u201d said Robert P. Nolan, the lead author of the study, a senior scientist at the Peter Munk Cardiac Center at the University Health Network and an associate professor at the University of Toronto.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from two experts who spoke at the conference session where this research was presented. They do not appear to have any conflicts of interest. However, it\u2019s unclear if the reporter interviewed the sources directly, or used statements they made to the entire audience at the session. The former is more suitable for obtaining comments that pertain to a lay audience like the Post\u2019s.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nWare agreed that more research is needed.\n\u201cA lot of the treatments that are used for neuropathic pain ...might also be associated with disruptions in sleep,\u201d Dr. Andrea Hohmann, who studies marijuana and pain at the University of Georgia and was not involved with the current study, told Reuters Health.\nBut there are still questions about marijuana\u2019s long-term safety as a pain reliever, he said.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two outside experts, one of whom is completely independent from the study and the journal, Dr Andrea Hohmann. Beyond that, we would bet that the reporter spent more time interviewing Dr. Mark Ware, the lead researcher, or at least asked tougher questions. Because Ware is more measured in this story than in the WebMD story. He even goes so far as to say, \"What about long-term safety issues?\" he asked. \"These need to be considered before the drug becomes prescribable.\" As with the WebMD story, it would have been nice to see who funded the research. Unlike the WebMD story, this one did not point out the conflicts of interest of Dr. Henry McQuay.", "answer": 1}, {"article": "Scientists use statistical methods to try to tease apart the impact of diet as part of people's overall lifestyle.\n\"Relying on evidence from observational studies...carries the potential limitation of confounding bias,\" states an editorial that was published alongside the study.\nThe editorial raises the possibility that the effect of confounding factors such as socioeconomic status and physical activity could be substantial.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nThe Tufts researchers used studies that had controlled for these lifestyle factors, but it's not a perfect science.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes from an accompanying editorial, which leads to some useful discussion of the limitations of observational research.", "answer": 1}, {"article": "About 1% of children and young people are affected by autistic spectrum disorder, which ranges from mild to severe.\nOther experts applauded the work.\nThe children in the intervention group, though, got better.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Outside sources were included in evaluating the impact of the study, including one from an autism\u00a0advocacy group. But none of the experts noted limitations or cautions about over-interpreting the data in the long-term follow up. Almost every source was cheerleading.", "answer": 1}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes Dr. Elizabeth Rogers, a pediatrics professor who wasn\u2019t involved in the study. Her comments help balance the story, bringing the research into perspective, and also help shed light on how other doctors might react to the study\u2019s findings.\nThe article also points out that the research was supported and funded by the National Institutes of Health.", "answer": 1}, {"article": "More than 5 million Americans have Alzheimer\u2019s, and this number is expected to grow as the population ages.\nThe study is a very long way from showing that.\nResearchers trying to answer the question say they found the treatments are at least safe.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nBut it does show it\u2019s worth going forward with more tests, said Dr. Sharon Sha, who ran the test program at Stanford.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019ll give the story a Satisfactory here since it does quote one source unaffiliated with the research and points out that earlier work led to the formation of a private company which intends to market a product derived from the research. However, the story would have been stronger if it had commentary from an independent expert with a more skeptical perspective.", "answer": 1}, {"article": "\"That makes for a powerful marketing advantage,\" Sullivan said.\nTUCSON, Ariz., Nov. 18, 2015 /PRNewswire/ -- In a clinical trial conducted for HSRx Group, an Arizona-based biopharmaceutical company, the OTC acne treatment product HSRx 2121 significantly outperformed a market-leading product in reducing acne count, redness and severity.\n\"For consumers desiring immediate results, HSRx 2121 is the clear choice,\" said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Group.\n\"Our acne treatment product has enormous commercial potential, evidenced by the significant licensee interest it has attracted.\n\"Acne is a universal plague,\" said Frank Parise, HSRx Group Chief Financial Officer, citing a recent NASA warning that even the International Space Station harbors germs that can cause the disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We\u2019ll give the benefit of the doubt here. The release states that the trial was conducted by their pharma company HSRx Group and speaks openly about marketing. In fact, most of the release talks about what a great business opportunity it is and the potential for profit (vs. how it might impact the millions of sufferers): \u201cThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\u201dThat makes for a powerful marketing advantage,\u201d Sullivan said.\u201d And: \u201cOur acne treatment product has enormous commercial potential, evidenced by the significant licensee interest it has attracted. As with each of our\u00a0next generation\u00a0OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\u201d Parise said.\u201d\nIf you go to the website of the research organization you will find their acne study summaries (which interestingly DO mention the types of acne formulations used). Makes one wonder even more why the news release neglected to mention this.", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThe palliative team was composed of one board certified PC physician, one nurse practitioner, one social worker, a chaplain, and one to two trainees.\nFor more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.\n\u201cOur results highlight the need to adopt this practice at acute care hospitals across the nation,\u201d said Dr. Smith.\nConsultation with the palliative care team included establishment of goals of care, advance care plans using standardized communication protocols, transition planning and symptom assessment and treatment using the Edmonton Symptom Assessment Scale (ESAS).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is not identified.", "answer": 0}, {"article": "\"Many labs are looking at this.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nAug. 3, 2011 -- A new blood test for Alzheimer's disease is 96% accurate at identifying the disease and can perhaps detect it even before symptoms such as memory loss appear, says the test's developer.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nHe is also founder of Durin Technologies Inc., the company that is developing the test.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes a spokesperson from the Alzheimer\u2019s Association. It does not appear that this group was involved with this study. We would have preferred hearing from an independent scientist rather than someone from an advocacy group. Nonetheless the Association spokesman adds some important perspectives. The story does point out near the top that the lead researcher is the founder of the company developing the test.", "answer": 1}, {"article": "Acupuncturists used five different points in the head, face, hand, and leg.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nWhile some previous research has found acupuncture for lazy eye effective, the researchers couldn't find a study that directly compared acupuncture with conventional treatments such as patching.\nAmbylopia was evaluated as resolved in nearly 17% of patched eyes but nearly 42% of the acupuncture group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story brought perspective from two independent experts who helped put the results in the appropriate context.\u00a0Unfortunately, it\u00a0didn\u2019t point out that some of the study investigators may have a financial incentive to promote acupuncture because they are trying to patent needle placement sites related to vision. The competing coverage also\u00a0failed to\u00a0identify this conflict.", "answer": 0}, {"article": "The Chinese developed tai chi thousands of years ago, but it has recently piqued the interest of Western medicine as an alternative mind-body therapy to treat disease.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent perspectives provided in the story. At the very least, the story could have incorporated some\u00a0comments from an editorial that accompanied the study\u00a0(subscription required), which raised questions about the size and statistical power of the study as well as other\u00a0issues.", "answer": 0}, {"article": "Olive oil users may, for example, have higher incomes, eat better overall or exercise more often than people who never use the oil.\n\u201cWe need to remember that this is an observational study,\u201d said Dr. Nikolaos Scarmeas, a neurologist at Columbia University Medical Center in New York who wrote an editorial published with the study.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nThe researchers on the new study, led by C\u00e9cilia Samieri of the French national research institute INSERM, tried to account for those differences.\nSuch clinical trials are considered the \u201cgold standard\u201d of medical evidence.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included strong input from a researcher who wrote in an editorial on the study.", "answer": 1}, {"article": "In recent years, surgical techniques, anesthesia and other medical care advanced, and death rates fell.\nThis improved dramatically as the study went on, from 85 percent in the early years to 98 percent by its end.\nThe studies were reported at an American Heart Association conference this week in New Orleans.\nEven more impressive: 65 percent survived without any long-term complications \u2014 a \u201cvery, very remarkable\u201d result, Kurlansky said.\nOverall, 90 percent survived their surgery to leave the hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from individuals involved in the study reported on. \u00a0It failed to provide insight from experts who could comment objectively about the results of the study.", "answer": 0}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\n(Such a delay is atypical, Ms. Riley said, adding, \u201cmost 510Ks are cleared within six months.\u201d)\n\nLast month, Dr. Robert B. Seltzer, a dermatologist in Pasadena, Calif., ran an advertisement in The Los Angeles Times for an informational seminar that called Zerona \u201cthe holy grail.\u201d In a phone interview, however, he said, \u201cI\u2019m not 100 percent convinced\u201d and planned to return his Zerona if he didn\u2019t continue seeing results in his patients.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\nGordie Nye, the chief executive, sent an e-mail message declining to be interviewed for this article.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed ten sources\u2013two patients [one with good results, one with poor], one federal spokesperson, and seven doctors. Six of those doctors are not objective due to financial interest in the devices\u2019 efficacy. But one is fully independent. \nWith a story like this, which features new technologies, it\u2019s hard to find sources who know the devices well enough to understand them but have no interest in them. The reporter did a good job with sourcing under these circumstances.\u00a0 ", "answer": 1}, {"article": "\"The band has a spotty history,\" Deveney said.\nMeanwhile, in a critique published alongside Himpens work, Dr. Clifford W. Deveney, a professor of surgery in the department of surgery at Oregon Health and Science University in Portland, concluded that the current study does \"not shed a favorable light on the use of LAGB\".\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\nThe procedure \"appears to result in relatively poor long-term outcomes,\" the researchers concluded.\nBut he added that \"it is still defendable for surgeons to continue doing this.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u00a0quoted an author of the study, the author of a critique on that study, and a surgeon who did not appear to have ties with the study. But the story missed a key fact that WebMD found in the study and reported, which is the conflicts of interest for the study\u2019s lead author, who, as WebMD pointed out, \u201creports consultant work for Ethicon Endosurgery, which makes another gastric band, Realize, and for Covidien, a health care products company.\u201d Not pointing out that the author has worked for a competing gastric band maker is a significant drawback to the story.", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\nThe research was funded in part by Cystic Fibrosis Canada.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is clearly marked and there does not appear to be a conflict of interest. However, it\u2019s not clear whether the \u201cspecialized technique developed at McMaster\u201d is being patented for use in the marketplace, or if it is being made freely available to other researchers. Either way, that would be a valuable point to make in the release.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story utilized product claims from advertisements and comments from an individual with relevant expertise in the field.", "answer": 1}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\n\"It's again the diet per se, not any one individual component of the diet.\"\nMost of the studies allowed the researchers to rule out other factors, such as family history.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included one independent expert\u2019s perspective.", "answer": 1}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nNatural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is such a brief summation of various studies that we don\u2019t feel this category applies. No one was quoted or cited.", "answer": 2}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThey are currently conducting experiments to better understand which ingredients in the bar are most important in the complex mixture for the observed effects.\nThe CHORI-team thinks the broad scale improvements observed with the CHORI-bar may be the result of \"oiling\" multiple joints by the complex nutrient mixture.\nIts composition is therefore complex, and required a number of years and a series of clinical trials to develop.\nResults presented in this publication are compiled from 3 two-month clinical trials that also included a significant number of overweight/obese individuals.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "One can find no information about either funding or potential conflicts of interest.\u00a0A brief look at the manuscript reveals that the investigators were funded by the CHORI itself, a charitable foundation, and the lab company Quest Diagnostics. A number of industry sponsors provided the materials for the bars, including Dow Chemical.The study authors reportedly have a patent on the CHORI bar concept.", "answer": 0}, {"article": "But numerous physicians, researchers and therapists insist there's no proof mercury causes autism, that Lupron removes mercury or that autistic kids have excessive testosterone.\nGeier could not be reached for comment despite several attempts by phone.\nHe told one parent he did not plan to comment for this story.\nLupron therapy grew from the mercury camp.\nTeresa Badillo was at the meeting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent expert sources were quoted. ", "answer": 1}, {"article": "An ultrasound has a 48% accuracy rate at predicting a due date that's within two weeks of a baby's actual birth, while the blood test was 45% accurate.\nBut the findings are promising, particularly because premature delivery is such a serious problem.\nThe test, if it does turn out to work in clinical trials, would be cheaper than ultrasound, said Quake.\nThere's a lot more work to be done before these tests becomes available, including clinical trials.\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We don\u2019t get a crucial outside perspective on the study; the only source named in the story is one of the lead authors. On the plus side, the story is very thorough given its short length, and it offers a blunt if not skeptical summary on the research. It also helps that we\u2019re told the study was funded by the March of Dimes and \u201cother nonprofit sources,\u201d and that the authors have applied to patent the blood test, implying they stand to profit from its approval and widespread use.", "answer": 0}, {"article": "It defines low birthweight as being when a baby is born weighing less than 5 pounds, 8 ounces.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nBut overall, the findings support the benefits of kangaroo mother care, the team concluded.\nKangaroo mother care was first described in Colombia, and the team of experts there who first showed it was safe did a 20-year follow-up to see how the babies fared as they grew up.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story lacked comment from independent sources. While there are some statements about KMC attributed to the World Health Organization, those statements don\u2019t address the findings of this study. An independent source likely could have provided some context and important reassurances to parents who had premature babies but either weren\u2019t offered kangaroo care or weren\u2019t able to because of birth complications, which is a growing problem in the U.S.", "answer": 0}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\n\"We are feeling more and more confident that we are on the cusp of a treatment revolution,\" said Roger Perlmutter, president of Merck Research Laboratories, which has its own, similar drug called Keytruda.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story quotes three different experts who comment on this area of cancer research, we would be hard-pressed to call any of them independent or unconflicted. The main source \u2014 Pasi Janne \u2014 is the director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, which recently entered into a\u00a0partnership with Bristol Myers Squibb to explore cancer immunotherapy. The other two sources are with competing drug companies who are developing their own cancer immunotherapies. Had any of these sources been able to give some type of evaluation of the study that\u2019s supposedly being reported on, we might have rated this satisfactory. A surefire way to earn a satisfactory would have been to quote an independent expert oncologist with no horse in this race.", "answer": 0}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\n\u201cThe question for me would be if there is a difference between patients who were treated with [both] immunotherapy [in the form of low doses of peanuts] and probiotics, and those who were treated with just immunotherapy.\u201d\n\nThat may have to wait for another study.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\nThe results are encouraging, allowing the children who were treated to eat peanuts without fear of an allergic reaction.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include input from one independent source, and that source highlights some significant questions regarding the study. For example, as the source notes, it\u2019s not clear what role (if any) the probiotics played in the study outcomes. In other words, it\u2019s not clear if the combination therapy achieved better results than would have been achieved using only immunotherapy without the probiotics.\nBut while the story did touch base with an independent source, it did not clearly address conflicts of interest. Here\u2019s a line from the Aug. 16 news release issued by the Murdoch Childrens Research Institute (MCRI), where the relevant clinical trials were conducted: \u201cThis follow up study was initially funded by MCRI and the Australian Food Allergy Foundation. It then received a $15 million funding commitment in 2016 from capital investment firm, OneVentures. A biotech company Prota Therapeutics, was jointly set up by the MCRI and OneVentures to develop [a combined probiotics and oral immunotherapy treatment] towards an FDA approved product with a plan to make the vital treatment available globally to people with peanut allergy.\u201d That\u2019s the sort of thing readers should know.", "answer": 0}, {"article": "There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase.\nImportantly the circulating tumor DNA results were highly concordant with the tumor sequencing results, and they were much easier to determine.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\nTo identify the patients in this study who carried the new HER2 mutation, the researchers required tissue from the tumor, a biopsy, from which they could extract and sequence the genetic material to determine the presence of the HER2 mutation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release didn\u2019t name funders or discuss any potential conflicts of interest, instead referring readers to the full study, for which a journal subscription is required. The published study on which the release is based does list the full funding sources and the study authors\u2019 conflicts of interest. Puma Biotechnology Inc, the maker of neratinib, was one of the study funders. This should have been disclosed in the release. All three corresponding authors of the study have multiple financial ties with Puma Biotechnology and other pharmas. This, too, should have been noted in the release.", "answer": 0}, {"article": "This will help for that,\u201d Destounis said.\nDr. Stamatia Destounis, a radiologist at Elizabeth Wende Breast Care in Rochester, New York, who was not involved in the study, said radiologists have been quoting results of the Swedish study for years and the new findings show breast cancer screening is \u201ceven more of a benefit than we understood.\u201d\n\nShe said sweeping changes in the U.S. screening guidelines two years ago that scaled back recommendations on breast cancer screening caused a lot of confusion among doctors and patients about the benefits of mammograms.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\nNow, 29 years after the study began, the researchers found that the number of women saved from breast cancer goes up with each year of screening.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included a quote from a radiologist not involved in the study, but one could argue that a radiologist has a vested interest in mammography screening. (And why/how was that radiologist chosen?) Additional perspectives would have been welcomed. For instance, why was no one from the U.S. Preventive Services Task Force asked to comment? That is difficult to understand.\u00a0 And while the study authors had no potential conflicts of interests to disclose, it\u2019s well known that some of the study authors are long-time proponents of mammography screening and this is worth mentioning.\n", "answer": 0}, {"article": "The General Director of the Danish section of MSF Jesper H. Brix notes:\n\n\"Acute malnutrition is still a major global health problem.\nThe study was primarily funded by Danida, MSF-Denmark and MSF-Norway, and USAID via the World Food Programme.\nThe research was conducted in a malnutrition project run by the medical humanitarian organisation The Alliance for International Medical Action (ALIMA) and its Burkinabe partners Keoogo and SOS M\u00e9decins.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nChristian Fabiansen, MD PhD and a team from the Department of Nutrition, Sports and Exercise at the University of Copenhagen conducted the study in collaboration with a PhD-student from the Institut de Recherche en Sciences de la Sant\u00e9 in rural Northern Burkina Faso, where there was a high prevalence of acute malnutrition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The major funding sources for the study are listed, but financial relationships between two of the authors and Nutriset, a producer of LNS products, were not included in the release. According to the published study they are Nutriset patent holders.", "answer": 0}, {"article": "Those with the BRCA1 mutation also have a 36 to 63 percent higher risk of ovarian cancer and those with the BRCA2 mutation have a 10 to 27 percent higher risk of ovarian cancer.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n\u201cIt\u2019s not cookie-cutter medicine,\u201d Pruthi, who was not involved in the study, said in a telephone interview.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal and one other expert who was not involved in the study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nEllis is one of the majority of children for whom the treatment works.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nThere are more than a few caveats when it comes to the treatment regimen.\nOverall, participants experienced fewer side effects during the study than the researchers had anticipated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes several expert sources, including a doctor who was not involved in the study and who does not appear to be funded by potential treatment-makers.", "answer": 1}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThey also plan to look at how the video game can be integrated into a rehabilitation program together with other rehabilitative techniques.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\n\"This increased connectivity reflects the fact that video gaming experience changed the mode of operation of certain brain structures,\" Dr. De Giglio said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t share any information on how the research was funded, while in fairness, neither does the original research paper. Neither does it discuss any potential conflict of interest, although the research paper suggests there is none. Given the mention of the use of a commercial game, information about funding and conflict of interest is relevant.", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two outside sources were consulted, and there didn\u2019t appear to be any unidentified conflicts of interest.", "answer": 1}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nThe study appears in Scientific Reports.\nThe researchers analyzed records from the NICHD Fetal Growth Study, a large observational study that recruited more than 2,000 low-risk pregnant women from 12 U.S. clinical sites between 2009 and 2013.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although not explicit, it seems clear the research was funded by NIH.", "answer": 1}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nUnder previous therapies, none had shown progress.\nThey implanted electrodes into the area and connected them to a pulse generator under the skin.\n(Editing by Andrew Roche)\n\u201cThe fact that the procedure was associated ... with improvements in affective and obsessional symptoms is of key importance,\u201d they said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two independent experts.", "answer": 1}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\n\u201cIt\u2019s quite probably real,\u201d said Helen Petousis-Harris, lead author of the New Zealand article and head of immunization research and vaccinology at the University of Auckland.\nThe study, published Monday in the Lancet, was funded by GSK and Auckland Uniservices, the commercialization arm of the University of Auckland.\n\u201cWhile it is still very early days, these findings represent a positive step in the search for a vaccine against this common and distressing disease that is increasingly resistant to antibiotic treatment,\u201d said Robin Gaitens, a spokeswoman for GSK, which owns the product that contains this meningitis component.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the study was funded by GSK and Auckland Uniservices, the commercialization arm of the University of Auckland. It does not mention that one of the researchers in the study has been a paid consultant for GSK and other drugmakers.\nThe story appears to use one independent source, Dr. Jean Longtin, head of Quebec\u2019s public health laboratory. It also quotes from an accompanying editorial by Kate Seib, of Australia\u2019s Institute for Glycomics, who declared no conflicts.", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe story cites three patients, three orthopaedic surgeons, and one spokesperson for a company that manufactures the implants and tools used in the new procedure.\u00a0 ", "answer": 1}, {"article": "Most clinics just draw the cells from bone marrow or fat and inject them back into the patient without checking for stem cells, hoping that patients get better,\u201d he says.\nFunding for this study was from Mayo Clinic\u2019s Center for Regenerative Medicine.\nThe study was conducted in Mayo\u2019s Human Cell Therapy Lab.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nStudy investigators include Mayo Clinic in Florida senior author Mary L. O\u2019Connor, M.D., Shari E. Kazmerchak, Michael G. Heckman, and Abba C. Zubair, M.D., Ph.D. Dr. O\u2019Connor is now at Yale University.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release duly notes that funding was by the Mayo Clinic in Florida\u2019s Center for Regenerative Medicine.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent sourcing.", "answer": 1}, {"article": "While effective in lowering the risk for gout attacks in the long-term, uric acid-lowering treatment can initially boost the risk for flare-ups as it breaks up and releases the uric acid crystal deposits at the source.\nThe other half received sugar pills.\nGout, a debilitating and painful form of inflammatory arthritis, now affects upwards of 8.3 million Americans, according to the release.\nAll were placed on a chronic uric-acid lowering regimen of the standard drug allopurinol.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert is quoted.", "answer": 1}, {"article": "The armpits, palms, and soles are often affected.\nThe study was small and the findings are preliminary.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A weak satisfactory grade on this.\nTwo dermatologists were quoted besides the researcher:\u00a0 one really didn\u2019t add much.\u00a0 The other has a connection to a competing technology for hyperhidrosis.\nAnd the story did note that the researcher received a grant from the company making the technology.", "answer": 1}, {"article": "Varenicline contains no nicotine.\nIn some of the test groups, overall success rates were fairly low, Lerman noted, but the study was conducted during the Great Recession, a time when financial stress may have depressed the chances of succeeding for everyone, regardless of which approach was used.\nResearchers did not test nicotine gum because it delivers a less consistent flow of nicotine to the user, she said.\nAnd given how difficult it is to kick the habit, smokers need all the help they can get to succeed the first time they try, Lerman said.\nThis may seem like common sense, but no one had ever tested it before, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We appreciate that this story took the time to interview one of the study authors, who provided useful context. However, one other perspective, at least, would have been great and might have yielded many of the details we wish this story had included. In addition, the story could have mentioned that the medication used in the study was provided by Pfizer \u2014 a detail noted in this press release.", "answer": 0}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nThe study appeared online May 13 in The Annals of Rheumatic Diseases.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\nBut they found that the number of children born to a mother did not affect the results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThis story cites a single source, the lead researcher of the study summarized in the news brief. No independent source is cited.\n", "answer": 0}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nThe red berries of a weed found in the southern United States contain an compound that can disarm a deadly superbug, according to research published Friday.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had no independent sources, and it didn\u2019t disclose that the researcher interviewed in the story has a provisional patent on the application of these extracts.", "answer": 0}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nBut now the study that led to FDA approval is finally out in this week's New England Journal of Medicine.\nDeep in the data is further mystery.\nAnd it's clear that experts are still scratching their heads about just how Provenge works.\nSo it's not surprising there's a lot to be learned, and that it's pretty pricey.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Solid quotes from the written editorial accompanying the study in the New England Journal of Medicine and even an appropriately cautious quote from the lead author of the study. ", "answer": 1}, {"article": "According to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\nThe task force looked at the most up-to-date research on both the benefits and harms of taking aspirin for the primary prevention of both heart disease and colorectal cancer to arrive at their recommendations.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\n\"The task force recommends that all patients talk to their doctor to evaluate their risk for cardiovascular disease and bleeding before making a decision about aspirin use, but this is particularly important for people in their 60s,\" Bibbins-Domingo said.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a close call, and just barely squeaked by as Satisfactory. The story included quotes from two interviewees, the chair of the task force and from another physician. However, that quote is lifted from a CBS TV interview from last year, and not regarding this latest report.", "answer": 1}, {"article": "I weigh 160 pounds, and when I do this I put about half my weight into it,\" he said.\nThe new guidelines, published in the journal Circulation, recognize that recent research has shown no real advantage to conventional mouth-to-mouth CPR in outside-the-hospital cardiac arrest cases.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nDr. Chris Barton, acting chief of the Emergency Department at San Francisco General Hospital, supports the new guidelines.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article cites three sources, two of them associated with the American Heart Association (which developed the new guidelines) and one an apparently independent expert who supports the guidelines. ", "answer": 1}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\nIt does not have the side effects or dose limitations of commonly prescribed treatments or the need for invasive implantation procedures, which can be inconvenient, costly and high-risk.\"\nThe Food and Drug Administration approved a device on Tuesday meant to treat cluster headaches \u2014 a rare form of headache that affects mostly men.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t quote any independent\u00a0sources \u2013 not even from\u00a0the editorial in the journal that offered a critique\u00a0about the study\u2019s limitations and conclusions.", "answer": 0}, {"article": "For example, some early cancers may not secrete DNA fragments into the bloodstream and require other types of detection.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\nAnother concern is that the tests may pick up on markers that are never destined to be cancer, something already known to occur in blood tests for prostate cancer, Kopetz said.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nDoctors, however, need an indication of how many patients will get a false positive result, something that can only be determined in a very large clinical trial, said Vogelstein.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted more independent sources than the competing Bloomberg story, and it also did a good job of identifying where people had conflicts. For example, the last expert quoted says that the test should undergo a large clinical trial, a point of agreement among multiple experts quoted in the press. But then the story says that this expert, \u201cis advising two companies developing liquid biopsy tests for cancer screening: Sysmex and Personal Genome Diagnostics.\u201d", "answer": 1}, {"article": "He drank to forget.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n\u201cI could see all these things from combat I was afraid to look at before, and I had a totally new perspective.\nI realized I had viewed myself as a monster, and I was able to start to have some compassion for myself.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The unique funding for this project, as well as \u201cwho cashes in if MDMA becomes legal\u201d is thoroughly covered and a very nice addition to the article.\nThe lead authors appear to have no financial conflicts of interest, and multiple sources were tapped.", "answer": 1}, {"article": "Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\n\"In lesions with less than 50 percent narrowing, one in five lesions still produce an ischemia,\" said study coauthor Philipp A. Kaufmann, M.D., professor and chair of nuclear medicine, and director of cardiac imaging at University Hospital Zurich in Switzerland.\n\"In a previous multicenter trial, with hybrid imaging we were able to see that about one in five patients should be revascularized in another coronary artery than originally planned.\nDr. Kaufmann said that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularization procedure such as bypass or angioplasty.\nThe present study now documents the prognostic importance of the comprehensive assessment provided by hybrid imaging.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study\u2019s first author disclosed that he is on the speaker\u2019s bureau for GE Healthcare, which manufactures the nuclear imaging machines discussed in the news release. Although the author claims that this relationship is not relevant to the current study, we don\u2019t see how that can be accurate. If the author has a financial relationship with a company that stands to benefit from the approach advocated in the study, that certainly seems relevant to disclose and the news release should have done so.", "answer": 0}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\nAnd in an accompanying comment article, Justin Stebbing, a professor in the department of surgery and cancer at Imperial College in London, said that \"despite increasing evidence supporting the use of [circulating tumor cells] as biomarkers, how this information can be integrated into present practice is uncertain.\"\nCirculating tumor cells were detectable in about one-quarter of the participants, the investigators found.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nThe more tumor cells a woman had in her bloodstream, the higher the likelihood of relapsing or dying, according to the report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two experts not connected with the study are quoted.\u00a0 Both provide valuable perspective on the clinical\u00a0usefulness of the blood test to current patients.", "answer": 1}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nThe funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s mentioned that The Cherry Marketing Institute \u201cprovided financial support for the study.\u201d\nIt\u2019s not clear if any of the researchers involved have financial ties to the institute.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nRebecca Branstetter, psychologist who blogs at Notes from the School Psychologist, says this dyslexia brain scan could provide useful information, but it doesn't highlight environmental factors -- such as the quality of instruction in the child's classroom -- that could contribute to reading problems.\nAnother important limitation in the study is that some children in the study did receive tutoring or reading interventions, to which they were not randomly assigned.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story does include independent experts. Although it does not discuss conflicts of interest, the authors of the main study declared no conflicts and reported that their study was supported by a number of grants from public agencies and foundations, though the baseline assessment of the participants was supported by a company that markets treatment interventions for people with dyslexia. One troubling point: the story describes one person who claims to have been helped by \u201ctraining at a learning development center.\u201d If this individual was associated with the company that helped sponsor this research, the story should have disclosed that connection.", "answer": 1}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nAt the moment, the UK average is 15g.\"\nThe research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\nTo get the same increase from fibre alone, we would need to eat around 60g a day.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release discloses funding sources.", "answer": 1}, {"article": "Unlike CT scans or MRIs, PET scans can show a tumor's internal activity, not just its size.\nGraham said there are maybe a dozen published human studies so far, most involving too few patients to draw a firm conclusion.\nAnd the drug company research would produce data to help persuade federal regulators to approve FLT PET for use in tracking therapy.\nBut the FLT PET scans offered an answer as soon as a day after treatment started.\nResearch into FLT PET is still in the early stages.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources include: \nNo independent sources are consulted to provide context or less enthusiastic viewpoints.\nThe story did not report whether any of the sources has a financial conflict of interest. \u00a0 ", "answer": 0}, {"article": "Previous studies have also suggested that beetroot\u2019s blood-pressure-lowering effects may not be as strong in women.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\nBut when researchers limited their analysis to men only, they found a significant reduction of about 4.7 points among those who drank the beetroot juice.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an expert not affiliated with the study, but this researcher is a well known advocate for increased nitrate consumption from foods. (See this article he wrote on the topic.)\u00a0\u00a0We suggest that\u00a0if only one source was going to be quoted, there were probably better choices for a truly\u00a0objective comment about the results.\nThat issue aside, we must\u00a0flag the story for not mentioning that the research was commercially funded by the\u00a0Sunraysia Natural Beverage Company, which sells beetroot juice.", "answer": 0}, {"article": "People with higher levels of vitamin D in their blood have been shown again and again to have a lower risk of developing diabetes in the future.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nIn fact, the physician has wagered a few good bottles of champagne that none of three large randomized trials now underway will find proof of positive effects.\nUnfortunately, the lessons of history have shown repeatedly that many of these supplements that appeared to be very promising did not pan out in more rigorous testing.\u201d\n\nManson should know.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The experts cited are leaders in the field. (Well done on the part of the story to entice these folks to comment.) There do not appear to be any major conflicts among the sources quoted.", "answer": 1}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Excellent use of independent expert perspectives. A true strength of the piece.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Screening smokers and former smokers for lung tumors using three-dimensional X-rays reduced their risk of dying from lung cancer by 20 percent, researchers said on Thursday.\nThe researchers said their findings could save thousands of lives.\nHer ideas were controversial to start with and widely disregarded when other researchers found her work had been paid for by a tobacco company.\n\u201cNothing has ever shown a 20 percent decrease in mortality in this disease ever before.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The study raises many questions that will likely be debated for years by the experts. The failure to provide a single independent voice to the discussion is curious to say the least.", "answer": 0}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nMost of the participants were white.\nAll were taking the medication at least three times a week.\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t note who funded the research, nor does it incorporate input from independent sources.", "answer": 0}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nBut there is not yet strong evidence that these women benefit, Alfirevic said.\nIn general, he and his colleagues found, the trials included in the review, which were mainly done in the 1990s, had their shortcomings.\nSome had flaws in their design, while in other cases the researchers failed to provide details on key elements of the study design.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n\n \nThere is no information in the story that appears to come from an independent source. Comments from experts in the field would have helped put the authors\u2019 comments into perspective. \n", "answer": 0}, {"article": "Prozac was developed by Eli Lilly and is now available in a cheaper generic form as fluoxetine.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\n\u201cDepression after stroke is a common enough complication to have raised the question of treating with antidepressants early after stroke,\u201d he said in an emailed comment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The journal\u2019s editorial and one outside source, Roger Bonomo, were cited. The article would have benefited from independent quotes that counterbalanced the forward-looking statements about this preliminary study, as opposed to only using quotes that reinforced the authors\u2019 conclusions.\nDr. Chollet\u2019s conflict of interest was identified. We see no other relevant conflicts in the research that warranted disclosure in this story.", "answer": 1}, {"article": "Anderson Cancer Center.\nIf it can be shown that screening improved outcomes, it could one day be used to screen the general population.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only expert quoted in the story is a coauthor of the study. We think it\u2019s always prudent to consult an independent third party to vet claims. In addition, while the story includes some background on the prevalence and outcomes of pancreatic cancer, these reviewers were disappointed to see that these statistics were not sourced. There are a couple reasons why attributing sources of claims and statistics is important. Obviously, readers may want to do additional reading and providing a source points them in the right direction. Another reason it\u2019s important to provide attribution is that statistics have been known to vary among advocacy groups, medical associations, companies, foundations and government institutions. It\u2019s not unheard of for groups pushing for more awareness and funding to select a higher number \u2013 among those available \u2013 to further their cause.", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two surgeons who were not authors on the review in the Annals.", "answer": 1}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nFor instance, \"When you put a little bit of garlic extract on cancer cells, they die.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one physician, who is also a patient. The story could have been greatly improved by quoting an expert or researcher in this field who is not so emotionally involved. ", "answer": 0}, {"article": "The difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S., researchers estimate.\nFederal grants helped pay for the work.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nKellum had no role in the two studies, which were discussed Tuesday at a critical care conference in San Antonio and published by the New England Journal of Medicine.\n\u201cWe\u2019ve been sounding the alarm for 20 years\u201d about possible harms from saline, said Dr. John Kellum, a critical care specialist at the University of Pittsburgh.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two sources: One not involved with the study, and one who\u2019s a study leader.\nIt\u2019s mentioned \u201cfederal grants helped pay for the work,\u201d which is sufficient.", "answer": 1}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\nWe call them \"highly motivated patients,\" said lead author Monica Pammer, PA-C, a physician assistant in Electrophysiology at the Hospital of the University of Pennsylvania.\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\nOf these patients, 84 had been ablated, sixteen were being treated with drug therapy, and three had implanted devices that served as a quality control check.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It seems that the funding sources are very transparent as is the involvement of the researchers.", "answer": 1}, {"article": "\"Because of this, we can take advantage of the 'side effect' and decrease involuntary sweating associated with hot flashes, and decrease the hot flashes as well,\" he explained.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\nThe research was scheduled to be presented Friday at the San Antonio Breast Cancer Symposium in Texas.\nThe patient said she was willing to stop her hormone therapy and risk the return of breast cancer rather than live with her current symptoms, she said.\n\"Oxybutynin is an option that can control these symptoms and improve quality of life,\" said lead researcher Dr. Roberto Leon-Ferre, an assistant professor of oncology at the Mayo Clinic in Rochester, Minn.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes Dr. Alice Police, regional director of breast surgery at the Northwell Health Cancer Institute in Sleepy Hollow, NY, who was not affiliated with the study. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nThe study was published in SLEEP, the official journal of the Sleep Research Society.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\nAdditional training in the therapy for behavioral health providers in all branches of the military is needed, he said.\nKristi Pruiksma, a STRONG STAR collaborating investigator and clinical psychologist, served as a clinician on Taylor's study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the funding source. The researchers reported no conflicts of interest.", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nThe authors discuss their findings in the Aug. 16 issue of the Annals of Internal Medicine.\nThe 2009 H1N1 (\"swine flu\") pandemic sparked influenza cases around the globe, resulting in nearly 18,000 deaths, the authors said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides commentary from one of the study authors and a representative of the dietary supplement industry. Neither of these sources could be called truly independent.\u00a0\u00a0A primary care physician or public health person could have provided\u00a0perspective about who is a candidate for treatment with antiviral drugs.", "answer": 0}, {"article": "After four weeks, when there tends to be some improvement in the placebo patients, 80 mg patients slept 7.7 percent more, while those who got the 40 mg dose slept 7.9 percent more.\nThe findings were presented at Associated Professional Sleep Societies meeting in San Antonio, Texas.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nHe said the 80 mg dose was likely more than most people need.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources, and they are sorely needed.", "answer": 0}, {"article": "This test will most definitely save lives.\"\nWomen with a strong family history can get tested for two genes that sharply increase their predisposition, but they account for only 1 to 3 percent of all breast cancers.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test\u2013unlike Decode\u2019s chief executive, who is also interviewed, mainly promoting his company\u2019s product.\u00a0 Researchers help educate the reader about a new test may have many more cons than pros.\u00a0 The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts.", "answer": 1}, {"article": "For more information on atrial fibrillation, visit the U.S. National Heart, Lung, and Blood Institute.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\n\"Warfarin is labor-intensive to manage,\" said study researcher Dr. Jack Ansell, chairman of the department of medicine at Lenox Hill Hospital in New York City.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\n\"Sometimes it impairs the patient's quality of life and the outcomes are very dependent on how well the drug dosing is managed,\" he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted a study researcher, a company spokesperson, and a cardiologist who did not appear to have ties to the study reported on.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources here. Claus G. Roehrborn, who is referred to as a co-author on studies of enlarged prostate treatments, is a paid consultant to the study\u2019s funder, NxThera (see\u00a0this 2015 paper), but the story didn\u2019t disclose that. As noted above, input from an independent source would have made this story much stronger.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story appears to have relied largely on statements from a representative of the drug manufacturer. An additional expert is cited, but it\u2019s not noted whether this person has any affiliation with the drug maker. ", "answer": 0}, {"article": "By Christmas morning, the pain had subsided.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t solicit a comment from any independent expert about the findings. This is a considerable deficit. With a\u00a0complicated issue such as this,\u00a0expert feedback is critical to highlighting the nuances in\u00a0these studies and how they might impact\u00a0decision-making. That the story takes on an authoritative tone when disseminating incomplete information\u00a0exacerbates the failure in this area.", "answer": 0}, {"article": "Insulin may have a relationship with cancer.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\nThe reduction is real and ranges from 30 to 70 percent.\"\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nAnd, pointed out Dr. Lucas Wong, associate professor of internal medicine at Texas A&M Health Science Center College of Medicine and co-director of the Gastrointestinal Cancer Program at Scott & White in Temple, Texas, while the new research is \"interesting and thought-provoking, what's proven in humans is totally another level.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources interviewed \u2013 including one who appears to be independent of this research. ", "answer": 1}, {"article": "The American College of Obstetrics and Gynecologists (ACOG) recommended the change after concluding that more frequent testing did not catch significantly more cancers and often resulted in girls and young women experiencing unnecessary stress, anxiety and sometimes harmful treatments because of suspicious growths that would not cause problems.\n\"More testing is not always more intelligent testing.\"\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sourcing is excellent. Sources include: ", "answer": 1}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\n\"But it's also possible [some of them] never truly had a food allergy.\"\nHe says many of the patients in the study may have outgrown their allergy, just like Jula did.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites one expert not involved in the research, and we could find no potential conflicts of interest that should have been disclosed. The independent source provided a quote that we wished had been explored more in-depth: \u201cBut it\u2019s also possible [some of them] never truly had a food allergy.\u201d This is an important point\u2013how much did the study help actually overturn incorrect diagnoses?", "answer": 1}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nAlong with her husband and co-founder Dr Raoul Scherwitzl, Berglund created the algorithm used in the app for personal use, before deciding it was something she should share with the rest of the world.\nThe app was approved as a class IIb medical device by T\u00fcv S\u00fcd, a notified body in Sweden where it is based.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nFor starters, it can only protect against pregnancy, not STIs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to talking to the founder of the company that produces\u00a0the app, the story includes two independent experts who comment on the app and on aspects of sexual biology.", "answer": 1}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\n\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\n\"There has been debate for many years over the safety and efficacy of ACE inhibitors compared to ARBs, with many of them using an 'ACE inhibitor-first' approach, with ARBs regarded as less effective,\" study author Dr. Sripal Bangalore said in a medical center news release.\n\"We believe that our study ends the debate and gives physicians the option to prescribe either drug for their patients,\" added Bangalore, an associate professor in the division of cardiology, in the department of medicine at NYU Langone.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story quotes only the primary author as a source, failing to offer additional perspectives.\u00a0 It also fails to mention that some of the authors have ties to major pharmaceutical firms which, while not directly impacting the quality of the research, is information that readers should be aware of in cases of stories about medications made by such companies.", "answer": 0}, {"article": "Hot flashes are a sudden rush of heat, followed by facial flushing and sweating, often followed by chills and clamminess.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nThe progression is familiar to most women of a certain age.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The WebMD quotes a researcher tied to the study and the\u00a0Executive Director of the\u00a0North American Menopause Society (NAMS). The study was published in Menopause, which is the journal of NAMS. A comment from an independent source would have been welcome, especially if he/she discussed the study\u2019s limitations and significance. Furthermore, any potential conflicts of interest are not mentioned.", "answer": 0}, {"article": "HIV, which stands for human immunodeficiency virus, infects and can destroy or change the functions of immune cells that defend the body.\n\u201cWe\u2019ll continue investigating these cells and how they interact and cause inflammation specifically in the brain,\u201d Rizzo said.\n\u201cThe patients who didn\u2019t smoke marijuana had a very high level of inflammatory cells compared to those who did use,\u201d Kaminski said.\nHis lab was the first to identify the proteins that can bind marijuana compounds on the surface of immune cells.\n\u201cIt\u2019s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,\u201d said Norbert Kaminski, lead author of the study, now published in the journal AIDS.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources of the study are not mentioned.", "answer": 0}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nDr. Nagele's research has been supported by grants from the Michael J.\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\nRobert Nagele, PhD, presented his team's most recent findings October 18 at OMED 15 in Orlando.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Two funding sources for the research are disclosed.", "answer": 1}, {"article": "For more information on ginkgo biloba, go to the U.S. National Center for Complementary and Alternative Medicine.\nStill, Schneider won't object if someone wants to try it.\nNo measurable effect from ginkgo is seen on cognition, Schneider said.\nEarlier results from the same study found that ginkgo did not prevent or slow the development of Alzheimer's or other dementias, DeKosky said.\n\"Further, the subjects in the study were not monitored for certain cognitive parameters until several years after the trial began, creating difficulty in determining accurately whether they experienced a decline in cognition or not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Yes, the story sought out different perspectives.\u00a0 But oddly, despite the mounting negative evidence, it afforded more space (265 words) to those defending ginkgo biloba than it did to those discussing the evidence raising huge questions about its value (249 words).\u00a0 He said/she said science journalism doesn\u2019t serve anyone well. ", "answer": 0}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Another cautious \u201cSatisfactory.\u201d One source is clearly identified as someone independent of one of the studies cited.\u00a0 Two others experts are not so identified but are not listed as coauthors on any of the studies.\u00a0 Funding for those studies is not mentioned.\nIt\u2019s worth noting here that two of the sources seem to be heads of institutes that are involved in the development of technological/Internet-based treatment approaches; both could benefit financially from being able to treat many more\u00a0patients online.\n\u00a0", "answer": 1}, {"article": "For more information, visitwww.asmbs.org.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\n\u201cOur findings demonstrate that Elipseprovides individuals and their caregivers with a safe, effective, andnon-invasive weight loss intervention that does not require surgery,endoscopy, or anesthesia.\u201d\n\nResearcherspresented interim results for the first 34 patients of a multi-centerstudy that showed individuals lost an average of 22 pounds after fourmonths or 37 percent of their excess weight.\n\u201c Newtreatment options are being studied and approved for the treatment ofobesity, which is good news for our patients and the healthcareprofessionals involved in their treatment,\u201d said Dr. Nguyen, whowas not involved in the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the manufacturer is \u201cstudying what it says is the first procedureless gastric balloon.'\u201d It isn\u2019t exactly clear what role the the manufacturer had in the study but the release does disclose that one of the quoted study co-authors \u201cholds an equity position in Allurion Technologies,\u201d the manufacturers of the device. This means he has an ownership interest in the company and will profit if the device is approved and adopted.", "answer": 1}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\nOther experts are intrigued by the findings, but note that the research is still in very early stages.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\nIt also didn't result in the blood pressure increases that helped doom torcetrapib.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although this story includes a strong lineup of independent sources that put the results in context for readers, it fails to report either that the trial was sponsored by the drug company developing anacetrapib or that the researcher quoted in the story has financial ties to that and other drug companies.", "answer": 0}, {"article": "\"Why does it work for some people and not others?\"\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\nNo one is quite sure why placebos work for some people and not for others, said Deng.\nTUESDAY, Aug. 25, 2015 (HealthDay News) -- Needles beat pills for treating hot flashes in breast cancer survivors, according to a new trial that compared acupuncture, \"sham\" acupuncture, the medication gabapentin and a placebo pill.\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The fact that two of the study authors consult for Pfizer, which makes gabapentin, merited a brief disclosure/acknowledgment in the story, and the lack of such disclosure is the basis for our Not Satisfactory rating here. We did enjoy the observations of outside expert Dr. Gary Deng, who was consulted about the effects of placebo and had some interesting comments to share with readers. We wish the story had also included a direct expert comment regarding the quality of the study and the patient-care implications of the findings.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nThe technique is \"a minimally invasive treatment option,\" said the study's lead author Dr. Kenneth Mandato, a vascular and interventional radiologist at Albany Medical Center in Albany, N.Y.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article provided an independent source not connected to the research. Dr. Richard Lipton, director of the Montefiore Headache Center in New York City, was quoted saying the findings were \u201cpromising\u201d and \u201cvery dramatic.\u201d He does mention that the results need to be replicated in a larger, longer study. This would have been a good opportunity for the story to address some of the drug\u2019s harms, the lack of a control group in the study, as well as other migraine treatments.", "answer": 1}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included comments from several individuals without direct ties to the study reported on but with active research programs examining the potential of benefit from omega-3 fatty acids.", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nSwan said that she and her colleagues published similar findings last month.\nOne expert who's done her own research in this area applauded the study.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted \u2013 although one is identified as doing research in this field so her laudatory comments about the importance of this work might be understandable.", "answer": 1}, {"article": "Instead of shrinking as expected, as part of the normal aging process, the memory center in the brains of seniors maintained their size and, in men, grew modestly after two years in a program that engaged them in meaningful and social activities, new Johns Hopkins Bloomberg School of Public Health-led research suggests.\nThey are helping their brains.\nThey work with young people.\nThey work in teams.\nExperience Corps is a national program, however it can be costly and isn't available everywhere.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly lists the funding sources.", "answer": 1}, {"article": "Prostate cancer is the most common cancer among men.\nThe study was published Tuesday in the journal The Lancet Oncology.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\nThe procedure was carried out under general anesthesia and most of the patients had hospital stays of less than 24 hours after the treatment.\n\u201cWhen you look at the current standard of care, there\u2019s a 1-in-3, or 1-in-2 chance of having the perfect outcome.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were quoted \u2013 only the lead researcher.", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nProject coordinator Professor Tobias Hartmann, Saarland University Germany, explained that this is the most likely reason the primary endpoint was not met.\nThe drink contains \"Fortasyn Connect\", a specific combination of fatty acids, vitamins and other nutrients.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nThe project's predecessor, LipiDiet, was incorporated within the 5th EU research programme in 2002.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release focuses on the involvement of the European Commission, but it omits the involvement of Dannon, the massive food company, which holds the patent on the nutritional drink being studied.", "answer": 0}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nHowever, the new study followed participants for a longer period than most previous studies on antioxidants and dementia.\nIt is unlikely that people could get too much vitamin E from food.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the story is generally well balanced, it could have benefited from the inclusion of an independent\u00a0comment on the findings. Valuable context about prior studies and the serious limitations of the current study would have been\u00a0helpful.", "answer": 0}, {"article": "What does that mean for men today?\nBut Carter contends the findings suggest that men should consider getting a baseline PSA test around age 40, instead of the more usual 50, to use as a comparison for future changes.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\nThe study is far from proof that making health decisions based on so-called PSA velocity can really save lives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the lead author, who has very encouraging things to say about using PSA velocity to screen men for prostate cancer.\u00a0 The author even goes so far as to encourage men have a baseline PSA test at age 40, which is not currently part of any guidelines.\u00a0 The article also obtains independent input from a physician who cautions readers about the value of PSA velocity, providing balance to the lead author's comments.\u00a0 The line \"The study is far from proof that making health decisions based on the so-called PSA velocity can really save lives\" also helps provide balance to\u00a0the lead author's\u00a0enthusiasm.", "answer": 1}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cOur finding was unexpected, but extremely important because this is the only heart treatment that is clearly better in women than men,\u201d Dr. Arthur Moss of the University of Rochester Medical Center, whose study appears in the Journal of the American College of Cardiology, said in a statement.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\nThe device also included a defibrillator used to shock dangerous heart beats back into normal rhythm.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited or quoted. \u00a0The story did mention that the study reported on was funded by the manufacturer of the device discussed.", "answer": 0}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe study makes that last point very clear.\nThat doesn't tell the whole story.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nThat'll help avoid creating viruses resistant to the drug when patients miss doses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on the CDC\u2019s evaluation and warnings about proper use of the drug.\nWe would have liked to have seen a clinician-researcher\u2019s perspective \u2013 someone not affiliated with the CDC analysis.", "answer": 0}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nIt encompasses eight earlier studies that compared cancer deaths among more than 25,000 people randomly assigned to get aspirin (of different doses) or placebo.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nFor cancer prevention experts, the British study is provocative and significant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story makes pretty good use of outside sources. It points out that \u201cthe U.S. Preventive Services Task Force\u2019s currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\u201d At the same time,\u00a0the statement that the effects on cancer are larger than for heart disease is misleading for middle-aged and older adults who are not at high risk for cancer. Heart disease is 10 times more likely in these populations, so even with a lower relative risk reduction, more heart attcaks are going to be prevented than cancers. The story would have been better if it had told readers that although this study received no outside funding, some of the authors have had consulting relationships with pharmaceutical companies. ", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts are quoted.\u00a0 The story appears to rely heavily on Pfizer input:\u00a0", "answer": 0}, {"article": "\u201cHasta la vista.\u201d\nThe new study only included national data through 2005, the most recent year they were available, but, said Dr. Durado Brooks, director of prostate and colorectal cancers for the American Cancer Society, \u201cthere is no reason to believe it has changed significantly since 2005.\u201d Doctors said there are several reasons screening seems to continue indefinitely as men age.\n\u201cThey often don\u2019t appreciate the downside of screening,\u201d Dr. Brooks said, \u201cand they don\u2019t appreciate the delay in benefit.\u201d In addition, Dr. Brooks said, primary care doctors often \u201coverestimate the likelihood that early detection of prostate cancer will lead to survival benefits.\u201d\n\nAdded to that, Dr. Brooks said, is the length of time it takes to discuss the pros and cons of screening with patients.\n\u201cIt is harder to get rid of an aberrant behavior than to adopt a new one.\u201d\n\nDr. Andriole said the very concept of not screening is difficult.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Numerous independent sources without ties to the study reported on were quoted as part of this story.\nOne thing that does concern us is the way the piece ended.\u00a0 The story profiled two men \u2013 and both choose to be screened.One recently found a small cancer, and is thinking of \u201chaving the whole thing taken out.\u201d\u00a0 Why was there no balancing profile of a man who chooses not to be screened?", "answer": 1}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding is not mentioned.\nA version of the study published in April 2018 noted that the lead author had no conflicts of interest to disclose.", "answer": 0}, {"article": ", or find Mount Sinai on Facebook, Twitter and YouTube.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nInvestigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nTo watch study author discuss this research, click this link: https:/\n\nPneumonia is the leading cause of death in children worldwide, according to the World Health Organization (WHO).\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was conducted at the Icahn School of Medicine at Mount Sinai but doesn\u2019t disclose sponsors or potential conflicts of interest. According to the journal article, one of the researchers has a consulting relationship with an ultrasound company. This should have been included in the release.", "answer": 0}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\nDr. Grant also praised the strong support and efforts of Trillium Gift of Life, which co-ordinates organ and tissue donation across Ontario, in helping to ensure that the transplant team could begin their clinical trials with this new technique.\nThe technique, unique solution, and device are part of a Phase I clinical trial at Toronto General Hospital (TG), University Health Network (UHN), assessing the safety of the device, with subsequent phases examining its efficacy.\nGenerous philanthropic support, made through Toronto General & Western Hospital Foundation, has played and continues to play an integral role in the development of ex vivo technology and its impact on patients\u2019 lives.\nResearch for the ex vivo kidney perfusion project was supported by the Canadian National Transplant Research Program (CNTRP), a national research network designed to increase organ and tissue donation in Canada and enhance the survival and quality of life of Canadians who receive transplants.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s not disclosed that Dr. Markus Selzner has an existing relationship with Veritas Therapeutics (an offshoot of the\u00a0University Health Network Toronto Transplant Institute) and is one of the inventors of an assigned patent.", "answer": 0}, {"article": "Medicare typically follows USPSTF guidelines in determining coverage and the Affordable Care Act specifies that USPSTF recommendations rated at the strongest levels must be used as a floor for coverage for private insurers.\n\u201cPeople in this group should make an individual decision with their doctor about whether to start taking statins,\u201d the task force advised.\nThis post has been updated.\nIndividual doctors are free to take the advice or leave it, and in recent months there has been a lot of debate about what the scientific evidence really shows regarding the therapy.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes independent sources and we didn\u2019t see any apparent conflicts of interest.", "answer": 1}, {"article": "With brachytherapy, also known as internal radiation therapy (RT), implants are surgically inserted in or near cancerous tissue to deliver a curative radiation dose directly to the tumor while limiting exposure for surrounding healthy tissue.\nAt an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable.\nOne thing that this study has made clear, however, is that the extremely low toxicity and complication rates leave room to escalate the single fraction dose in subsequent trials,\u201d said Dr. Krauss.\n\u201cIt is becoming apparent that patients may be treated definitively for their prostate cancer in as little as a single day with a minimally invasive outpatient procedure,\u201d said lead study author Daniel J. Krauss, MD, a radiation oncologist at Oakland University\u2019s William Beaumont School of Medicine in Royal Oak, Michigan.\nFor the study abstract, visit http://www.redjournal.org/article/S0360-3016(16)33096-6/abstract.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t tell us who sponsored the study. The published report indicated there were no conflicts of interest.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a quote from the first author of the study was included. No \nindependent second source. ", "answer": 0}, {"article": "\u2022 Cardiovascular disease affects one in six Australians or 4.2 million people.\n3303.0, September.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\n\u201cThese needs are unmet in the traditional MedDiet, which makes it difficult for people to adopt in the long term.\n\u201cThis study delivers healthier options for Australians by tailoring the nutrients in the MedDiet to meet the needs of a non-Mediterranean population.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release didn\u2019t include funding information. It should have noted that the research received funding from Dairy Australia, an industry trade group, as well as government and foundation grants.", "answer": 0}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nThe precision of the process is crucial to limiting side effects, the researchers said.\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\nThis discovery won the Nobel Prize in 2006.\nThe experiment proceeded just as planned, as biopsies later showed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted. ", "answer": 1}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes one outside expert and one expert who wrote an accompanying editorial.\u00a0Eugene Arnold, MD,\u00a0\u00a0professor emeritus of psychiatry at Ohio State University\u2019s Nisonger Center, Columbus, says\u00a0\u201cThere is a risk of malnutrition if you don\u2019t pay attention to the balance of nutrients.\u201d But he also gives the impression that the diet is worth trying, even based on the limited evidence of efficacy. \u201cIf there is no improvement in two to five weeks, forget it,\u201d\u00a0he says.\u00a0Jaswinder Ghuman, MD, associate professor of psychiatry and pediatrics at the University of Arizona, who wrote a commentary, says, \u201cIt is very difficult to carry out,\u201d and added,\u00a0these are interesting findings and it does present an alternative treatment option for the children.\u201d Taken together, these comments tend to underscore the idea that people should try this diet, a very different take away from the HealthDay story, which said high up \u201cthe evidence isn\u2019t yet conclusive.\u201d", "answer": 1}, {"article": "Old friendships fell apart.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Given that this is primarily an interview with a book author, we\u2019ll rate this N/A. However, a source who is independent of the book author (the only other person quoted is one of the research doctors), could have provided important perspectives\u00a0on the treatment being discussed anecdotally.", "answer": 2}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\nThis was seen even among patients who did not have the EGFR genetic mutation that Tarceva targets, they reported in Lancet Oncology.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent sources were entirely absent. An independent voice might have added the missing caveats to the preliminary nature of the iloprost data, the fact that the results had already been presented last year, etc. \nFor the coverage of the\u00a0erlotinib study,\u00a0independent appraisal might have added some objective context beyond taking the investigators\u2019 claim that their study shows that more clinicians should follow their strategy. The independent source could have been the Lancet Oncology\u00a0editorial\u00a0that accompanied the erlotinib study, which discussed some potential limitations in this approach in clinical practice, e.g., regarding EGFR mutations and a history of chemotherapy treatment. Finally, an unaffiliated voice may have pointed out the history and context:\u00a0in April, the FDA used the results of the erlotinib study to approve Tarceva for the use in maintenance therapy, and not without\u00a0some controversy. It was against the recommendation of the FDA\u2019s advisory panel, who voted 12-1 vote against approval. (See this article for more details.) The story makes the publication of this study in the journal sound like a bombshell in a vacuum.\nNo conflicts of interest were identified. The erlotinib study was funded by a drug company.", "answer": 0}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nAdditional funding for the study was provided by NIH\u2019s National Center for Advancing Translational Sciences.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nResearchers evaluated 6,121 extremely premature infants who had been born between 22 and 27 weeks of pregnancy at sites in NICHD\u2019s Neonatal Research Network.\nAmong the three groups, researchers found significant differences in rates of death, complications such as bleeding in the brain (severe intracranial hemorrhage), intestinal problems (necrotizing enterocolitis), lung disease (bronchopulmonary dysplasia) and brain and nervous system impairment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies the funding source in its headline and first sentence \u2013 the National Institutes of Health. It later adds that NIH\u2019s National Center for Advancing Translational Sciences also provided funding for the study.\nThere was no mention of conflicts of interest, since there were none reported in the original journal article.", "answer": 1}, {"article": "\"Some will benefit in a very large way.\n...\nHow many lives?\nThis means some women will undergo needless surgery, radiation, or chemotherapy.\nSo should U.S. women continue to get routine mammograms?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nThe results were \u201cstriking,\u201d said study coauthor Dr. Dan Barouch, a professor of medicine at Beth Israel Deaconess Medical Center and Harvard Medical School.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\n\u201cThat increases the chance that we will have at least one, if not more than one, that works in the end.\u201d\n\u201cIt\u2019s always good to have multiple different vaccine candidates in both clinical and pre-clinical testing,\u201d Barouch said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes only sources directly involved with the research.", "answer": 0}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have done a better job with sources. In the original AP story there were two sources quoted, one of whom works for the CDC which issued the recommendations, and the other is independent.\u00a0 But the NY Daily News cut out the independent source interview. The story might have included a pulmonologist not on the recommending panel, or at a primary care physician, to give perspective on the current evidence and clinical implications of vaccinating 31 million adult smokers while providing smoking cessation counseling. ", "answer": 0}, {"article": "NSAIDs also include prescription medicines called COX-2 enzyme inhibitors, such as Celebrex (celecoxib).\nMeanwhile, Dr. William Ting, a private practice dermatologist in San Ramon, Calif., praised the study despite agreeing that many factors are at play when it comes to skin cancer formation.\nAlso, the potential cancer-protective effect should be taken into account when discussing benefits and harms of NSAID use,\" she noted.\nIn turn, prescription histories were gathered for both the cancer patient group and almost 179,000 healthy Danes.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert was quoted, although unfortunately his comments tend to reinforce the story\u2019s exuberance rather than restrain it. Why this private practice dermatologist was chosen as the one independent expert is unknown.\u00a0 Does he have a research background?\u00a0 The quote doesn\u2019t offer any evaluation of the evidence.", "answer": 1}, {"article": "For decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids).\nThe study is actually a reanalysis of data that had not been included in the original publication of results from the Sydney Diet Heart Study, a trial that was conducted from 1966 to 1973.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nThe latest results, however, raise questions about that advice.\n\u201cI wouldn\u2019t necessarily say that the [current advice] is necessarily completely wrong,\u201d he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a comment from an American Heart Association spokesperson, who interestingly suggests that the new research may play a role in a re-analysis of the organization\u2019s diet guidelines. That\u2019s different than the stance taken by\u00a0the spokesperson contacted by HealthDay, who hinted that the results wouldn\u2019t have much effect on current recommendations.", "answer": 1}, {"article": "\u201cAll it does is allow us to choose the best embryos to transfer so that we can get the patients pregnant faster,\u201d he said.\nFor 6.7 million American women of child-bearing age, getting pregnant is not an easy task.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nExperts say the couples are not the only people who benefit from these tests.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are two sources cited here, both of whom appear to offer these fertility services in clinics where they work. The story is upfront about that. And while this type of screening is fairly controversial, that is largely due to debates over the morality of terminating an embryo. And that debate is not the focus of the story, at least not directly.", "answer": 1}, {"article": "Henderson E J et al.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\n\"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance.\nThis is a real breakthrough in reducing the risk of falls for people with Parkinson's.\"\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the study was funded by the Parkinson\u2019s UK organization. When we looked at the published study we noted that the second author describes a conflict of interest with a company that manufactures fall risk assessment tools: \u201cSRL declares that the FallScreen fall risk assessment tool is commercially available through Neuroscience Research Australia (NeuRA); any profits from sales of the assessment are shared equally between the inventor (SRL), the falls and balance research group at NeuRA, and the NeuRA central fund. All other authors declare no competing interests.\u201d\u00a0 In addition, the charity\u2019s website states that about 0.5% of its income comes from pharmaceutical companies but that \u201cOur industry supporters don\u2019t have any input into the content of\u00a0our information.\u201d While not critical, because these connections may not have any relationship to the pharmacological intervention, it would have been nice to have that spelled out.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert is cited and makes clear that effectiveness, while important,\u00a0is only one factor in a woman\u2019s decision about a contraceptive method.\nThe potential for conflict of interest is adequately addressed, noting that one of the researchers is involved in training doctors on how to use one of the implantable methods.", "answer": 1}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any sources. The story should have provided some perspective from experts who have no stake in the claims being made.", "answer": 0}, {"article": "A drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source was quoted. But it would have been better if he\u2019d been quoted on the quality of the evidence.", "answer": 1}, {"article": "Lung cancer is the No.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n\u201cHowever, unique to this study, we have been able to report less advanced cancer in those who do develop cancer, a decreased frequency of squamous cell and small cell carcinomas, and improved survival, when controlled for stage, in people taking metformin and/or TZDs.\u201d\n\nThe team reviewed the medical records of 157 lung cancer survivors with diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Is it an independent source if the quote is copied from the press release? Perhaps that\u2019s a philosophical question. We gave it a pass on this one because we\u2019ve already dinged the story for relying too much on a news release in the criterion above.\nWe\u2019re given affiliations of the lead investigator and ACCP president. But it\u2019s unclear from the abstract whether A)\u00a0conflicts of interest were never disclosed by the researchers or B) that Dr. Mazzone disclosed that he had none. We\u2019re not told about the other authors\u2019 disclosures. From here we see no relevant problems, but it\u2019s another consequence of unpublished research: once it\u2019s peer-reviewed and published, we\u2019ll get clear, direct, and complete information about author conflicts of interest and study funding.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nThe new results were similar to those previously published on the more intense cognitive behavioral therapy.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\nOn average, for every 2.4 participants treated, one responded favorably and one overcame insomnia, report the researchers in the Archives of Internal Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes comments from the author of a commentary article that appeared in the Archives of Internal Medicine along with the research article. In the disclosure section of their article, some of the researchers reported ties to pharmaceutical companies, but since this trial tested a non-drug approach and was funded by public agency and academic grants, it seems reasonable to consider the industry links as not being relevant to this study.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does a very good job of noting the conflicts of interest of those quoted.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Most doctors opt for screening women for cervical cancer more often than guidelines suggest, according to a new study.\n\u201cNo test is perfect,\u201d said Philip Castle, an HPV expert at the American Society for Clinical Pathology in Chicago.\n\u201cA woman should know what test is being used,\u201d said Dr. Mona Saraiya, a co-author on the new study.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\nThey asked doctors and staff what tests they used for cervical cancer screening and presented them with three patient scenarios.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert from the American Society for Clinical Pathology was interviewed \u2013 someone not involved in the study.", "answer": 1}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only one source, a physician at the National Cancer Institute, is quoted. In a story of this potential magnitude, other sources and perspectives are needed. It doesn\u2019t add that much time to a story, even in broadcast. ", "answer": 0}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nStill, Thun said the results would favor broadening the aspirin guidelines to include cancer prevention based on an individual risk-benefit assessment.\n\u201cNews about the cancer potential of aspirin use has been really encouraging lately,\u201d said Dr. Michael Thun of the American Cancer Society, who worked on the study.\nRay called for trials that specifically check people for new cancers at given intervals to weed out the selection bias marring the previous research.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The input from independent expert Dr. Kausik Ray was important.\u00a0 And it pointed out the recommendation of the US Preventive Services Task Force discouraging the use of aspirin \u201cto stave off colorectal cancer in people at average risk for the disease.\u201d", "answer": 1}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe study was supported in part by a grant from the National Institutes of Health.\nThe study was published on August 5th in the Journal of the American Academy of Dermatology.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nThe research team retrospectively analyzed more than 100 cases of atypical moles.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the study was \u201csupported\u201d in part by the National Institutes of Health. However, neither the news release nor the study explains where other funding was obtained. The news release does not say whether any of the researchers had conflicts of interest, although no conflicts of interest were declared in the study.", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nHerv\u00e9 Hoppenot, the president of Novartis Oncology, called the research \u201cfantastic\u201d and said it had the potential \u2014 if the early results held up \u2014 to revolutionize the treatment of leukemia and related blood cancers.\nDr. John Wagner, the director of pediatric blood and marrow transplantation at the , called the Pennsylvania results \u201cphenomenal\u201d and said they were \u201cwhat we\u2019ve all been working and hoping for but not seeing to this extent.\u201d\n\nA major drug company, , is betting on the Pennsylvania team and has committed $20 million to building a research center on the university\u2019s campus to bring the treatment to market.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nDr. June said that producing engineered T-cells costs about $20,000 per patient \u2014 far less than the cost of a bone-marrow transplant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent experts are quoted in the story, although their input is used primarily to reinforce the \u201cbreakthrough\u201d nature of the findings. The story could have gotten a lot more mileage from these sources had it probed more\u00a0for limitations, caveats, and concerns about the research and its application to larger numbers of patients.\u00a0 The story also noted Novartis\u2019 investment in the work, something not mentioned in the competing Philadelphia Inquirer story.", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nThe findings are published in TheJournal of the American Medical Association.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent expert who seems generally supportive of antidepressant therapy for hot flashes. While we don\u2019t think it would have been difficult to find someone\u00a0with a more skeptical take\u00a0on the results, which would have added value for readers,\u00a0the story\u00a0did enough to satisfy this aspect\u00a0of the criterion.\n(UPDATED COMMENT INSERTED ON 2/24/11:\u00a0 We originally but erroneously wrote that this story failed to disclose potential conflicts of interest. But it actually did, when it stated:\u00a0\u201cThe study was funded by the National Institute on Aging and other sources. Freeman reports having received research support from Forest Laboratories Inc., and other pharmaceutical companies that make antidepressants. For this study, Forest, which makes escitalopram, provided the drug and placebo pills but no funding.\u201d)", "answer": 1}, {"article": "Leukemia is the most common childhood cancer and accounts for about 30 percent of all childhood cancers.\nEfrat L. Amitay, Ph.D., M.P.H., and Lital Keinan-Boker, M.D., Ph.D., M.P.H., of the University of Haifa, Israel, reviewed the evidence in 18 studies on the association between breastfeeding and childhood leukemia.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Neither the news release nor the study cited any outside sponsors. The study was completed by epidemiologists at the School of Public Health in Haifa, Israel, and the Ministry of Health in Ramat Gan, Israel.", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\n\"This is the largest clinical study done in the world on conventional electrodes and will have major implications for doctors and their patients who need their long-term hearing restored,\" said the study's lead investigator, George Wanna, MD, Site Chair, Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel; Chief, Division of Otology-Neurotology and Director of the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\nDr. Wanna and a team of researchers from Vanderbilt University examined roughly 230 patients with every type of cochlear implant, including three FDA-approved implants that use different types of electrodes to stimulate the auditory nerve.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We know that the lead researcher is with the\u00a0Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel, as well as the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System and that he had a team of researchers from Vanderbilt University.\nThe release doesn\u2019t tell us if any any of the researchers or their institutions have any conflicts of interest in either the surgical technique or the type of cochlear implants studied in this trial.\nAccording to the published study, four of the authors, including the first author and the senior author, have financial conflicts of interest in the form of consulting arrangements with cochlear device companies.", "answer": 0}, {"article": "\"You don't get back the time you lost at work or the time you lost with your children.\"\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\nColeman, of Alexandria, Va., also urges fellow sufferers to keep working with their doctors: His own migraines took 40 years to control.\nSilberstein adds that some patients have not been properly diagnosed or made aware of their options.\nThey were presented at an academy meeting and published in the journal Neurology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent expert source and had some valuable input from a patient advocate group. It also included the perspective of a patient \u2014 a rarity in health stories \u2014 who said she didn\u2019t get much benefit from her medication and experienced signficant adverse effects.\nUnfortunately, however, the story failed to mention the extensive commercial conflicts of the panel that wrote the guidelines, including the author quoted in the story, Dr. Stephen Silberstein. Here is what he disclosed to readers in the guidelines text:\u00a0 \u201cDr. Silberstein is on the advisory panel of and receives honoraria from AGA, Allergan, Amgen, Capnia, Coherex, Colucid, Cydex, GlaxoSmith-Kline, Lilly, MAP, Medtronic, Merck, Minster, Neuralieve, NINDS, NuPathe, Pfizer, St. Jude Medical, and Valeant. He is on the speakers\u2019 bureau of and receives honoraria from Endo Pharmaceuticals, GlaxoSmithKline, and Merck. He serves as a consultant for and receives honoraria from Amgen and Novartis. His employer receives research support from AGA, Allergan, Boston Scientific, Capnia, Coherex, Endo Pharmaceuticals, GlaxoSmithKline, Lilly, MAP, Medtronic, Merck, NINDS, NuPathe, St.Jude Medical, and Valeant Pharmaceuticals.\u201d\n\u00a0", "answer": 0}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included interview comments from a company spokesperson and one of the authors of the study, both of whom were clearly identified. \u00a0The story also included this important detail about the quoted author, which was missed by the HealthDay story we reviewed. \u201cHimpens reports consultant work for Ethicon Endosurgery, which makes another gastric band, Realize, and for Covidien, a health care products company.\u201d In addition, the story had comments from two surgeons who do not appear to have direct ties with either the manufacturer of the product or the study reported on. We were a little concerned about some of the phrasing in the story. It says, \u201cBut some, including the manufacturer of the Lap-Band \u2014 used in a technique called laparoscopic adjustable gastric banding \u2014 take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.The critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\u201d This leads readers to believe that there are mulitple critics out there pointing out flaws in the study. The story itself, though, only quotes one actual critic: the company spokewoman. The criticisms may be valid, but readers deserved a strong independent analysis of the study\u2019s limitations.", "answer": 1}, {"article": "\"Doctors will say, 'There are side effects, but they are manageable,'\" Turnham says.\nDoctors will present 288 melanoma studies, compared to only 62 a decade ago.\nPatients with a limited time to live may not be so positive, Turnham says.\nAll improve survival by a few months.\nDoctors now dare to hope that giving these new drugs in sequence, or in combination, will help people with melanoma live for years while feeling relatively good.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Adequate sourcing, including important contributions in quotes from the executive director of the Melanoma Research Foundation.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nYet there was only a slight drop in deaths from the condition over the same period, suggesting many of the clots were too small to cause harm.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\nBut with increasingly sophisticated tools, doctors may be spotting clots that would never have been fatal in the first place.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted. It would have been interesting to solicit opinions from radiologists, for example, that might have placed some of this in a different light.", "answer": 0}, {"article": ".\nThe study was funded by European pharmaceuticals company NeuroSearch A/S.\nThe study included 437 Huntington's disease patients from eight European countries.\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Alessandro Di Rocco from NYU Langone Medical Center is used as an independent source. The story also adds that the study was funded by European pharmaceuticals company NeuroSearch A/S.", "answer": 1}, {"article": "In 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\nStill, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nWhile the episodes usually aren\u2019t serious, the resulting visits to the doctor alone cost the U.S. an annual $7.7 billion, according to the new report.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Our posted criterion doesn\u2019t allow us to give a satisfactory grade to a story that relies on just one source, even a source as smart as Dr. Meenu Singh, the author of this study.", "answer": 0}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nIt began in September 2016 when Berg was rushed to the hospital after experiencing a major heart attack in her car.\nAfter a series of tests, the doctors made a shocking discovery.\nBut the heart attack wasn't the only danger.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One of the sources, Gustavo Oderich, MD,\u00a0has reported being a consultant\u00a0for Cook Medical and W.\u00a0L. Gore, both makers of endovascular grafts. The story did not disclose this.", "answer": 0}, {"article": "While many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\n\"At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care,\" added Alan Lotvin, MD, Executive Vice President, CVS Specialty.\nCVS Health Research Institute findings support a continuous quality improvement environment, which encourages product innovation and development to benefit CVS Health patients, clients and their members.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\nFind more information about how CVS Health is shaping the future of health at .\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clear that the study was done by the CVS Health Research Institute. Since this is a news release from a profit-making company that operates directly to sell services under study, we hope the readers quickly understand there is an inherent conflict. This is the equivalent of a Coca Cola study about the benefits of drinking their product.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nMany of them took part in the clinical trial, and all have gotten extensive training by Grupp and others.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\n\u201cThis is truly pushing the envelope and at the cutting edge of science.\u201d\n\nThe biggest concerns, however, center on safety.\nYet along with the enthusiasm come pressing questions about safety, cost and the complexity of the procedure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources in the story are patients, parents of patients, are associated with the pharmaceutical industry, or were involved with the relevant research being discussed. That said, the sources \u2014 and their conflicts of interest \u2014 were all clearly identified. Still, the story would have benefited from some independent, expert input.", "answer": 0}, {"article": ".\nA free abstract of this article will be available via the Cancer News Room upon online publication.\nPublished early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.\nFor more information or to obtain a PDF of any study, please contact:\n\nDawn Peters (US) +1 781-388-8408 \n\nsciencenewsroom@wiley.com \n\nFollow us on Twitter @WileyNews\n\nFull Citation: \"Dietary Isoflavone Intake and All-Cause Mortality in Breast Cancer Survivors: the Breast Cancer Family Registry.\"\nCANCER; Published Online: March 6, 2017 (DOI: 10.1002/cncr.30615).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study was funded by the National Cancer Institute; noting that would have strengthened the release.\nSophisticated health news consumers appreciate knowing whether a study was government funded or funded by a special interest such as the soybean industry. Readers should also be told that this research is part of a larger study that has been ongoing since 1995.", "answer": 0}, {"article": "She turned to RESTASIS\u00ae because she didn\u2019t want to keep worrying about constantly using eye drops.\nTomei, a self-proclaimed animal lover, expressed that the effort is close to her heart.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\nAfter toting around eye drops, Tomei said she has found a solution with Allergan\u2019s prescription drug RESTASIS\u00ae, which works by increasing the eyes\u2019 natural ability to produce tears.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Presumably the celebrity in question, Marisa Tomei, is working for the company, but even that detail was not presented.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nDr. Bernard Fuh, director and owner of Advanced Spinal Health in Tulsa, said spinal disc decompression therapy has repaired ruptured discs, eliminated back pain and caused some patients at his center to \u201cgrow\u201d a few inches.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one physician, the owner of a center that provides spinal decompression. This is a major flaw in the story. The story should have quoted other clinicians or researchers to provide some context for the claims being made.", "answer": 0}, {"article": "Previous studies have found that magnesium is inversely associated with the risk of diabetes, which is a risk factor of pancreatic cancer.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\nOf those followed, 151 participants developed pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\nUsing information from the VITamins and Lifestyle study, Dibaba and the other co-authors analyzed an enormous trove of data on over 66,000 men and women, ages 50 to 76, looking at the direct association between magnesium and pancreatic cancer and whether age, gender, body mass index, non-steroidal anti-inflammatory drugs use and magnesium supplementation play a role.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study aren\u2019t named in the release. According to the published findings, the research was supported by grants from the National Cancer Institute and the National Institute of Health Office of Dietary Supplements.", "answer": 0}, {"article": "Lung cancer is the deadliest and most common of all cancer types.\nI am therefore very encouraged with the results of this study, showing that EpiCheck has the ability to identify both non-small-cell and small-cell lung cancer at early stages, with a high level of sensitivity and specificity.\n\"Furthermore, these results were validated prospectively in an independent cohort.\nLung EpiCheck was validated on this independent test set comprising 181 lung cancer cases and 141 current or former smoker controls.\nAt the moment, low-dose computerized tomography (LDCT) screening which has been shown to reduce mortality from lung cancer in the very large NLST study is only reimbursed in the US for high-risk individuals.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s clear from the release that the research was\u00a0supported by the company that makes the proposed lung cancer screening tool.\u00a0 Neither the release or abstract provide information on whether or not there are financial conflicts of interest between the investigators and the company that makes the test.", "answer": 2}, {"article": "GAITHERSBURG, Md.\nAs the International AIDS Conference convenes next week, there are more than 20 drugs available to suppress the virus and at least 82 additional HIV therapies in development.\nThat hints at the opportunity to use bevirimat in potent combination with existing drugs, said Dr. Daniel R. Kuritzkes, director of AIDS research at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.\nExperimental AIDS therapies in clinical trial or awaiting FDA approval hint at more life-saving benefits, like the once-a-day AIDS pill that the agency hailed last month as the ``holy grail\" of drug development because it simplifies drug delivery in developing nations.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Researchers and physicians who work with HIV/AIDS therapies are cited to provide perspective on this potential new drug treatment. Sources who are paid consultants for Panacos Pharmaceuticals are appropriately noted. Some appropriate attempt at balance is provided by the concluding quote from Dr. Anthony Fauci of the National Institutes of Health. ", "answer": 1}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\nTheir finding is published in the Journal of Neuroscience.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\nNewswise \u2014 Stony Brook, NY \u2013 Embargoed for August 4 @ 5:00 PM EST, 2015 \u2013 Sleeping in the lateral, or side position, as compared to sleeping on one\u2019s back or stomach, may more effectively remove brain waste and prove to be an important practice to help reduce the chances of developing Alzheimer\u2019s, Parkinson\u2019s and other neurological diseases, according to researchers at Stony Brook University.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not tell us who funded the study. According to the study, the work was supported by \u201cFBRI\u201d (not clear what that stands for), the National Institutes of Health,\u00a0and the Department of Anesthesiology at Stony Brook Medicine.", "answer": 0}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\nWhether you call it water running, aqua jogging or hydrotherapy, you can\u2019t beat a workout in water for an array of health benefits, many experts say.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\n\u201cAt waist height, it\u2019s at about 50 percent of body weight.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes four experts, making this a strong point. It would have been helpful for one of these experts to point out that there is very little evidence supporting water-based PT compared to standard PT.", "answer": 1}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\nThe technology is two decades old, but Mass.\nIt's the most expensive device in medicine today.\nAt double the cost of standard treatments, many experts say it's being used without proof it's more effective.\nAnd with no side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "HPV is the leading cause of cervical cancer in women, but also has been linked to penile cancer and other malignancies in men.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\nAmong participants who completed the three-vaccine series, Gardasil afforded 90 percent protection against HPV.\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory. The story notes that the research was partially funded by Merck, the manufacturer of the vaccine. It quotes only one expert not affiliated with the study, and would have been stronger if that single expert was not from the American Social Health Association, which lists advocacy for these vaccines as one of its stated positions.", "answer": 1}, {"article": "\"People say, 'What's the harm in screening?'\nThe task force and other groups concluded previously that it was unclear whether the benefits of the prostate-specific antigen, or PSA, test outweigh the risks.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\nBut the panel concluded that the evidence remains inconclusive for those men as well.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from a number of individuals with relevant expertise. \u00a0The story did not do an adequate job of indicating whether those quoted served on the recommendation task force other than for Ned Calonge, who was mentioned as chair of the US Preventive Services Task Force.", "answer": 1}, {"article": "The disease, transmitted through infected blood, can lead to liver cancer, scarring of the liver, known as cirrhosis, and death.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story leans heavily on the comments of Dr. Eugene Schiff, who is identified only as the director of the University of Miami\u2019s Center for Liver Diseases. However, as a recent disclosure statement from\u00a0a continuing medical education program in which he participated shows, Dr. Schiff is\u00a0a consultant to Bristol Myers Squibb, which is developing BMS-790052, as well\u00a0as Vertex and Schering Plough, which are developing the other two\u00a0experimental drugs mentioned\u00a0in the article.\u00a0We\u00a0feel these relationships should have been disclosed to readers.\u00a0", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites statistics showing increased use among males, but cites no source. \nThe reporter interviewed one enthusiastic practitioner who services Hollywood stars, an enthusiastic paid celebrity spokesman, one enthusiastic patient and his even more enthusiastic wife. \nNo dissenting voice, even a comic one, is included.\u00a0 ", "answer": 0}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\n\u201cIt also made me afraid to do things.\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\n\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\nOne doctor said screening isn\u2019t enough; patients need close monitoring to make sure they get help.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts.", "answer": 1}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nUntil this study, doctors have been \"guessing\" which form of those two diagnostic tests is best, Douglas said.\nThe 10,000-plus patients, who visited 193 health centers in the U.S. and Canada, had no prior diagnosis of coronary artery disease.\nAnd while there's often no wrong choice between CTAs and stress tests, the new findings underscore a vital nuance, she added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Neither the story nor the original press release indicates the presence of conflicts of interest. \u00a0That may be reasonable, as the research was funded by the National Heart, Lung, and Blood Institute of NIH. \u00a0The one outside scientist quoted in the story is clearly described as independent of the study.", "answer": 1}, {"article": "The active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\nAnd, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes some independent sources.\u00a0 We just wish the story had made better use of these sources. Why not ask them to help quantify the benefits and harms?\u00a0 Why not have them discuss some of the alternatives to sticking a patch on the affected area?  ", "answer": 1}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\nIt was funded by the Brazilian Ministry of Health and other sources.\nOne of the subjects was insulin-free for one year but then relapsed after a respiratory viral infection, said lead author Dr. Julio Voltarelli, associate professor at Ribeirao Preto Medical School at the University of Sao Paulo in Brazil.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes a source associated with the research and also quotes a source not associated with the research.\u00a0 ", "answer": 1}, {"article": "Multiple myeloma is the second most common type of blood cancer in the U.S., impacting more than 25,000 people each year and disproportionatly affecting African-American men.\nThe MASTER trial is supported by Amgen and Janseen, both with drug and finaincial support.\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\nIn addition to UAB\u2019s study leadership, Vanderbilt University Medical Center, Duke University, Medical College of Wisconsin, University of Wisconsin, and Oregon Health and Science University are recruiting for the trial as well.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release reports that this trial is supported by Amgen and Janssen, makers of two of the drugs it uses. (Executives at Janssen may not be happy that the release misspelled the company\u2019s name as \u201cJanseen\u201d.) The disclosure would have been more complete if it had noted that the lead investigator, Luciano Costa, MD, PhD, has also received speaking fees and other personal payments from Amgen and Celgene (which sells another one of the drugs being tested).", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nThe study's findings have been met with cautious optimism by dementia organizations.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\n\"What we do know is that the blood supply in the brain is incredibly important, and that maintaining a healthy heart and blood pressure is associated with a lower risk of developing dementia,\" said Carol Routledge, Director of Research at Alzheimer's Research UK, who was not involved in the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not address conflicts of interest. The study abstract notes that several researchers have ties to The Brain Protection Company. It is not clear to what extent that company may potentially benefit from the findings, if at all. The company does have patents related to dementia treatment (such as this one).", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes information from an author of the study cited, as well as from a researcher not involved in the study, but who specializes in bipolar treatment. The story mentions that the study was sponsored by the National Institute of Mental Health, and the authors disclose the potential conflicts.\u00a0\u00a0", "answer": 1}, {"article": "After looking for other possibilities, those who took statins regularly had a 41 percent lower risk of developing rheumatoid arthritis compared with people who were not taking statins regularly.\nThis work received no outside or corporate finding, the researchers noted.\nFor the study, Chodick's team collected data on 1.8 million patients who got their health care through the Maccabi Healthcare Services, an HMO in Israel.\nThe report was published online Sept. 7 in PLoS Medicine.\nThe only way to prove the connection is with a clinical trial, Myerburg said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story includes both an independent source and the information that the researchers did not receive any outside funding for their work.", "answer": 1}, {"article": "These study participants had a 37 percent reduction in a pro-inflammatory cytokine called interleukin-6, or IL-6, as compared to those in the placebo group, who saw a 17.2 percent reduction in IL-6.\nPrivate contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs.\nDuggan encourages women to speak to their health care providers about measuring their levels of vitamin D to determine the most appropriate dosage.\nFor more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nThe Breast Cancer Research Foundation, Susan G. Komen for the Cure, National Institutes of Health, Seattle Cancer Consortium Breast Cancer Specialized Program in Research Excellence, Fred Hutchinson/University of Washington Cancer Consortium and Safeway Foundation funded the research.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are well documented.", "answer": 1}, {"article": "\"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments.\nThese data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the \"pivotal\" trial that will determine approval.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\nBorges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions Array BioPharma, which originally developed tucatinib, but it does not state specifically that Array provided the funding for this study, nor does it explain that three of the authors of the original paper are Array employees. It does note that its only source, Dr. Virginia Borges, director of the Breast Cancer Research Program and Young Women\u2019s Breast Cancer Translational Program at the University of Colorado Cancer Center, \u201chas been a major driver of the drug\u2019s development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\u201d", "answer": 0}, {"article": "Glenn Jaffe, M.D., a professor in the Department of Ophthalmology at Duke University School of Medicine, said adalimumab works to treat uveitis by targeting a protein that is thought to promote inflammation.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nDr. Jaffe served as a consultant for AbbVie, and other study authors also report financial relationships with the company.\nFurther author disclosures are available in the study\u2019s manuscript.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release dedicates a whole paragraph to summarizing potential conflicts of interest, which is welcome and we hope to see this kind of transparency showing up in more releases in the future. It further directs readers to the published study\u2019s supplementary documents for more extensive disclosure information.\nIn the PDF of supplementary materials we learned that only two out of the 17 authors had no conflicts of interest to declare. ", "answer": 1}, {"article": "Most men with prostate cancer do not experience symptoms.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nIf it is found to be effective, it could be an important tool for physicians.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have benefited from more sources who weren\u2019t connected to the research (both of the advocate sources were from organizations that helped fund the study). Also, most of the information wasn\u2019t cribbed from other news outlets (in this case, the Guardian and BBC News).", "answer": 0}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\nThe margarines used in the study were developed for the researchers by food and consumer goods giant Unilever.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from one of the authors of the study and a clinician who was not connected with the study.", "answer": 1}, {"article": "Major tobacco players such as Altria Group and British American Tobacco are grappling with sales declines in the U.S. market and hoping to recoup revenue through novel tobacco and nicotine products such as e-cigarettes.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nGottlieb said the FDA was also seeking public opinion on whether a product standard should be implemented all at once or gradually.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story contained information from two FDA officials, one quote from an antismoking group (the identical quote was found in several different news stories), and a comment from a cigarette maker. We only wished that there was an outside source commenting on the quality of the projected benefits or of the possible harms of this plan.", "answer": 1}, {"article": "Compared to placebo, the medication stimulated growth hormone secretion and was associated with an increase in lean muscle mass, improved balance as demonstrated by heel-to-toe walking, and a better ability to climb stairs.\nThe government has approved use of growth hormone for a limited array of conditions in adults and children, Dr. Merriam said.\nOther researchers involved in the study were affiliated with Duke University, Stanford University, the University of Arkansas, Johns Hopkins University, the Veterans Affairs health care system, and Pfizer, which supported the project.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nDr. Merriam said Merck and other companies also are investigating similar treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources of information appear to be researchers who presented their work at a scientific meeting. (There can be problems with such reporting. See \u201cMedia reporting on research presented at scientific meetings: more caution needed,\u201d at: http://www.mja.com.au/public/issues/184_11_050606/wol10024_fm.html) The story does mention that the study was sponsored by Pfizer, maker of the growth hormone drug capromorelin. ", "answer": 0}, {"article": "These medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\nThe increased risks, while double in relative terms, are small.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a good job citing a range of clinicians, patients and pharmaceutical spokespeople.\u00a0 Regarding the latter, the story notes that findings from pharma-sponsored research were either more positive, or similar to that of the FDA\u2019s review. The interviews in this story provide context for the new information; however, Dr. Nierenberg makes a blanket statement about the risks not outweighing the benefits. For some of these drugs, the benefit in bipolar disorder has not been shown.We are not told if Dr. Nierenberg or Dr. Harden receive pharmaceutical funding. ", "answer": 1}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe studies for these drugs, which are not yet on the market, were funded by the drug manufacturers.\nThese dangers are nothing new \u2014 the MS drug Tysabri was pulled from the market after some patients came down with rare brain infections.\nThose painful welts are something he would happily do without \u2014 and the new pills could be the answer.\nThe main benefit of the pills will be that they are easier to take.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used one independent expert source in addition to interviewing one of the study authors. ", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\nDr. Klein has no personal financial interest in the company.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The IsoPSA test was developed by Cleveland Diagnostics, which also funded, designed and conducted the study. The principal investigator is a co-founder and chief medical officer of Cleveland Diagnostics and has investment interest in the company.\nSince the news release disclosed these facts, we give it a Satisfactory rating here.", "answer": 1}, {"article": "\u201cWhat we\u2019ve been able to show in our advanced cancer studies of men with prostate cancer and women with breast cancer, is when they have tumor in their bone that Prolia is more effective than the best available therapy at delaying significant fractures or other skeletal-related events,\u201d Perlmutter said.\nAmgen shares rose to $52.92 in extended trading from their Nasdaq close at $50.76.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nInvestors greeted the good news by sending Amgen shares more than 4 percent higher in after-hours trading.\nProlia, or denosumab, was compared with Novartis\u2019 Zometa in late stage clinical trials of advanced cancer patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe study quotes the author of an editorial that also appears in the issue of the Archives of Neurology that carries the study article. The story notes that the study author who is quoted developed the experimental test and works for a biotech company. It also points out that the study was funded by a partnership that includes private interests.", "answer": 1}, {"article": "The Lancet.\nThe call will also be archived on Vanda's website for a period of 30 days.\nThe conference call will be broadcast simultaneously on Vanda's website.\nVarious statements in this release and to be made on the conference call are \"forward-looking statements\" under the securities laws.\nThe Vanda management team will host a conference call and live webcast today, March 5, 2018, at 8:30 AM ET to discuss these updates.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Information and references for further information about financial support are contained at the end of the release and it\u2019s clear that Vanda sponsored the trial.", "answer": 1}, {"article": "Tobacco use accounts for some 85 percent of lung cancer cases in the U.S., and one estimate puts a smoker\u2019s lifetime absolute risk of developing lung cancer between 12 percent and 17 percent.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nThe high so-called \u201cfalse positive\u201d rate is an issue, said Dr. James Hanley of McGill University, who also reviewed the findings for Reuters Health, but many mammograms also find lesions that turn out to be benign.\nOverall, research is suggesting that CT scans of people at risk of lung cancer might make a dent in cancer mortality, and it\u2019s possible that more frequent screening might make an even bigger dent, Hanley noted.\nAnd for lung cancer, doctors know there is a high false-positive rate and have a set protocol to follow in order to determine which lesions are dangerous, added Johnson.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story quotes two independent experts who provide valuable perspectives on this study. We wish more stories provided similar attention to independent experts. It also notes that Dr. Henschke has been criticized in the past for accepting funding from tobacco companies and that this study was supported in part by manufacturers of CT scanners.", "answer": 1}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nThe electroacupuncture was given in addition to medication that the patients were already taking and meant to augment their treatment, Zhang told a news conference.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent expert perspective was included.", "answer": 0}, {"article": "The U.S. National Library of Medicine has more on heart disease.\nTUESDAY, April 13, 2010 (HealthDay News) -- Researchers report they've used magnets to guide stem cells to damaged areas of animal hearts.\n\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\nThe study was published online April 8 in the journal Circulation Research.\nMarban and his wife, Linda, are founders of a company that has filed patents for the techniques.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The source is a medical center news release. And the quotes, from that news release, are from a researcher who is \"founder of a company that has filed patents for the techniques,\" according to the story.\u00a0 So, while, that conflict was disclosed, there is no independent perspective in the story. That\u2019s unsatisfactory in our view.\u00a0 \n\u00a0", "answer": 0}, {"article": "No serious adverse events were reported.\nFevipiprant, which is being developed by Novartis, reduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients, researchers said on Saturday.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t contain comments from outside experts who could put some perspective on the trial results and explain what this might mean for patients.\nThe story could have let readers know that funding came from Novartis, as well as a European Union grant program, and the Leicester (U.K.) National Institute for Health Research Respiratory Biomedical Research unit. Several researchers involved in the trial reported receiving financial compensation from Novartis and other drug companies.", "answer": 0}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\n\"The evidence suggests that there is some epigenetic connection,\" said Crowgey.\nThe work represents a collaboration among researchers at Nemours, the University of Delaware (UD) and Genome Profiling LLC (GenPro for short).\n\"We're still in the early phases, but the results are extremely promising and we're excited about the sensitivity of the test that we are seeing in our retrospective analysis,\" said Crowgey.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release names the various funding sources for this work and is clear in pointing out the commercial role, and potential economic benefit,\u00a0to some of the authors.", "answer": 1}, {"article": "Rayman and her associates concluded that selenium supplementation does not appear to have a negative impact on blood cholesterol levels overall, and may in fact be \"modestly beneficial.\"\nShe added that the team's observations were based exclusively on an analysis of British residents, and that the findings may not necessarily apply in North America.\nThere's more on selenium at the U.S. National Institutes of Health.\nBlood tests determined blood selenium, good cholesterol and bad cholesterol levels at the start of the study.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent expert source was quoted and there were no obvious conflicts of interest that weren\u2019t disclosed.", "answer": 1}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThe results were published in January in Nature Medicine.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The major funding sources for the study are listed at the end of the release. The online version of the published study notes that Tibor Keler, one of the study authors, is employed by Celldex Therapeutics which manufactures 10-1074. This should have been noted in the release.", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\nThe researchers looked at dietary intake of five major flavonoid sources: tea, berries, apples, orange juice and red wine.\nBut, berries are protective in both men and women,\" said the study's lead author, Dr. Xiang Gao, a research scientist at the Harvard School of Public Health and an associate epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted an independent expert, who cautioned that people who already have Parkinson\u2019s disease won\u2019t benefit from eating berries or other flavonoid-rich foods.", "answer": 1}, {"article": "At 12 months in patients receiving torcetrapib, there was a 72 percent increased in good cholesterol and a 24.9 percent decrease in bad cholesterol.\nA long-awaited postmortem released this morning of Pfizer's (NYSE: PFE) failed heart drug held out hope for the discovery of a safe version of the revolutionary heart pill.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote any independent experts or researchers, a major flaw of this story. It\u2019s not clear that anyone was actually interviewed, since only a study and an editorial were cited.\u00a0 Perhaps an independent expert could have put into perspective for the reader the fact that this story focuses on a small, theoretical part of the overall story at the expense of the facts.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted many experts.\u00a0 Most, however, were used to at least hint at the idea that Reiki has some benefit. We do appreciate some of the candor, though. \u201cBarrie Cassileth, chief of the Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, calls the energy theory \u2018absurd\u2019 but says light-touch therapy can have a \u2018great relaxing effect\u2019 on cancer patients \u2018who are constantly poked, prodded and given needles.'\u201d", "answer": 1}, {"article": "It needs to be tested in large trials,\" he said.\nHowever, preliminary results from small trials of mechanical clot removal have not been promising, Jolly noted.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\nJolly said there are mechanical methods of removing clots, which were not tested in this study.\nA number of studies have suggested a benefit from manually removing clots during an angioplasty, but this trial found no clinical benefits for doing so, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The information was released simultaneously in the New England Journal of Medicine and presented at a conference. The story references data from the study and quotes an expert who was not affiliated with the study. While the story meets our standard, we wish that the independent expert had been pressed for a more meaningful evaluation, as discussed above.", "answer": 1}, {"article": "Over 3 percent of patients treated by cryoablation experienced a serious condition \u2014 a narrowing of the pulmonary vein in 7 out of 228 patients, one of whom required another procedure to widen the vein.\nCryoablation is an alternative that is growing in popularity.\nOver the past decade, more patients have been referred for ablation procedures when drugs proved ineffective.\nOnly Johnson & Johnson (JNJ.N) has an ablation device approved by U.S. health regulators specifically to treat atrial fibrillation.\nMedtronic shares were up 3.7 percent to $45.55 in late-morning trading on the New York Stock Exchange.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0There were no independent sources interviewed to discuss the potential of this device to affect outcomes and patient care. \u00a0This is a problem.", "answer": 0}, {"article": "Kouzarides\u2019s team found that in the disease, the MLL-fusion proteins are targeted to leukemia-causing genes by proteins from the BET family, which recognize certain chemical \u201ctags\u201d on chromatin, the scaffold on which DNA is arranged.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n\u201cThis ... is an exciting new avenue for drug discovery which we hope will be useful for other types of cancer in addition to MLL-leukaemias,\u201d said Tony Kouzarides of the Wellcome Trust/CRUK Gurdon Institute at Cambridge University, who co-led the study.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted in the story.", "answer": 0}, {"article": "Instead of simply providing patients and their doctors with the results of an X-ray or an M.R.I.\nAnd the answer, Dr. Modic reported, is that it did not.\nscan, he said, radiologists should put the findings in context.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nDr. Modic gave the results to only half of the patients and their doctors \u2014 the others had no idea what the M.R.I.\u2019s revealed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple experts. The story quotes Dr Jarvik but does not describe his speciality or institutional affiliation. [Note: the NYT later added this]", "answer": 1}, {"article": "One screening test, the colonoscopy, in which a flexible, lighted tube with a video camera is inserted to examine the colon, requires dietary restriction and preparation of the colon.\nAhlquist called the 85% figure ''very high\" and adds: \"It would be very hard to find a noninvasive approach that could get that range.\"\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\n''One in every 17 of us will have colon cancer in our lifetime,\" says David Ahlquist, MD, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn., who presented his findings on the new colon cancer screening test.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mixed bag:\u00a0 The story did include comments from two independent experts, which was good.\nBut the story never fully explained the lead researcher\u2019s true ties to the company making the test.\u00a0 There was only this vague and unhelpful line:\u00a0 \u201cAhlquist and Mayo Clinic are working in collaboration with Exact Sciences Corp. of Madison, Wis., to develop the test.\u201d\nNonethless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "The median age was 75 years (range 41to 94).\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\nDisclosure: This research was partially supported by Elekta through a research grant with all institutions being members of the Elekta Lung Research Group.\nElekta (EKTA-B.ST) today announced new data demonstrating stereotactic body radiation therapy (SBRT) is a safe treatment option for early-stage lung cancer patients aged 80 or older.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes it clear that the findings were produced with funding from Elekta. However, it does not make it clear that Elekta is a large medical technology company that manufactures SBRT and other equipment used in radiation oncology.", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\nThe National Pain Foundation has more about cluster headache.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were cited in the story. ", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nA swollen lymph node on the neck was the only symptom Karen Anderson noticed.\nTwo years ago, she gained access to an experimental immune-enhancing treatment in clinical trials at Providence Cancer Center in Portland.\nThey felt hot to me.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Story quoted one independent source in addition to one of the study co-authors. ", "answer": 1}, {"article": "DOI: 10.1016/j.ophtha.2016.04.026.\nThe authors receive financial support from ForSight VISION5, manufacturer of the bimatoprost ring.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the authors of the study receive financial support from ForSight VISION5, which makes the ring.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article appropriately obtains various expert opinions about the claims of superiority of this surgical approach. Some experts appropriately point out that there is no evidence that this is superior to other approaches. ", "answer": 1}, {"article": "In the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\nBut, they were proven to be wrong and these life-saving drugs are now standard therapy for heart failure treatment.\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention either how the study was funded or whether there were conflicts of interest for the authors. The study was funded by the National Heart, Lung, and Blood Institute, and there don\u2019t appear to be any conflicts of interest \u2014 but it\u2019s important to tell readers that.", "answer": 0}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAnd the result is a life saved.\nIt doesn't cost much.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nThe results were just published online by the medical journal The Lancet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s difficult to find room for an independent perspective in a 245-word brief, and this story didn\u2019t find the room. ", "answer": 0}, {"article": "Please see full Important Safety Information for additional information.\nDUBLIN, Dec. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting\u00ae treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\nCoolSculpting is available through a network of CoolSculpting Centers worldwide.\nWith this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.\nMillions of CoolSculpting treatments have been performed in more than 80 countries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The 2015 clinical study we found online states that Zeltiq Aesthetics, then manufacturers of the CoolSculpting System, sponsored the research. All three authors of the study were on the medical advisory boards for\u00a0Zeltiq and received research support and grants from the company. One of the investigators also owned Zeltiq stock.\nJust for clarification, Dublin-based Allergan acquired Zeltiq Aesthetics in April this year.\nSince none of this is explicitly disclosed, we rate this one Not Satisfactory.", "answer": 0}, {"article": "STAR was a retrospective analysis of IRE performed on 200 consecutive patients diagnosed with locally advanced (Stage III) pancreatic cancer (LAPC) at six centers in the U.S.\n\"This new analysis of IRE could help change the standard of care for Stage III pancreatic cancer patients whose only treatment options until now were chemotherapy or a combination of chemo-radiation therapy, which will only stabilize the disease and not destroy the tumor.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nFor more information, visit our web site, http://www.uoflphysicians.com/surgical-oncology or call (502) 583-8303.\nIRE was successfully administered to all patients.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We aren\u2019t told what the funding sources are, nor whether there\u2019s any conflict of interest. This information is also missing from the abstract itself. But by digging just a little bit, we learned that the lead author of the study and the primary source for this release (Dr. Martin) is a paid consultant to Angiodynamics\u00a0(scroll to the bottom for disclosure info),\u00a0which makes the NanoKnife system. This is critical information to disclose with these results.", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One quote from the head of the National Eye Institute.\u00a0 But he didn\u2019t really evaluate evidence \u2013 only talked about hope. \nMeantime, no mention that Genentech funded\u00a0 the trial (a strength of the NYT story was its discussion of the \"pay for play\" aspect of the research) \u2013 and no mention that Dr. Bressler disclosed financial ties to Genentech.\u00a0 From the Times: \nSome doctors criticized the organizers of the trial for testing Lucentis rather than another Genentech drug, Avastin, which works in the same way as Lucentis.\nAlthough it is a cancer drug, Avastin is often used off-label for eye diseases because it is far cheaper than Lucentis, costing only $20 to $100 a dose, compared with $2,000 for Lucentis.\nAvastin is undercutting sales of Lucentis, which totaled $1.1 billion in the United States last year.\nOrganizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing \u2014 but only if Lucentis were used.\n\u201cObviously you can\u2019t underplay $9 million,\u201d said Dr. Ferris of the eye institute, which is part of the part of the National Institutes of Health. But he said there were other factors as well, like a belief that Lucentis might have been the better drug.\nDr. Philip J. Rosenfeld, a professor of ophthalmology at the University of Miami, said the decision was \u201cclearly a case of pay to play\u201d since Genentech\u2019s money dictated the choice of drugs.", "answer": 0}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\n\u201cIf you transplant leg hair on the head, it\u2019s not going to start acting like head hair.\n\u201cThe back of the head is where you find the thickest hair on the head.\n\u201cThey\u2019ve been told to forget about it by many other clinics.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is not a single independent voice in this piece. Instead, it ends with a sales pitch from the surgeon marketing this technique. In a story about a review of a cosmetic procedure in just two patients, a story should never include a phrase like this: \u201cIt\u2019s life-altering for them when they realize that this is possible.\u201d Yet, this is the message that readers are given as a take home.\n\u00a0", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. David Frid, a cardiologist from the Cleveland Clinic, reminds us that the studies need to be reproduced in other populations, and that statins have been show to reduce heart attacks (not just cholesterol).", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a single source \u2013 the FDA \u2013 is quoted.", "answer": 0}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story does report that the researcher quoted is the president of the company hoping to market this pill, and that the company funded the study. The story also quotes an independent source. But as noted above, the overall presentation is out of balance, because the boosterism of the company president is given top billing, while the skeptical comments of the independent source are almost entirely relegated to an addendum at the bottom of the story.", "answer": 1}, {"article": "First awarded the status in 2006, it was re-awarded in 2011.\nIt also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.\n\"Even though the number of men surviving prostate cancer is increasing, it's still the second most common cause of cancer death in UK men.\nStudy co-leader Dr Emma Hall, Deputy Director of the Cancer Research UK-funded Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, which co-ordinated the study, said:\n\n\"This phase II clinical trial combined a highly targeted cancer drug with cutting-edge genomic sequencing.\nWe showed that a subset of men whose tumours had mutations in their DNA repair machinery responded particularly well to treatment with olaparib.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We recognize that it can be challenging to sort out and explain complex partnerships in a brief news release but it is better to point out that potential conflicts exist.\nAlthough the release mentions a pharmaceutical backer of the study (AstraZeneca) and lists other funders, we rated this Not Satisfactory because the vast majority of investigators had multiple, complex ties to pharmaceutical makers including\u00a0some who have patents and other commercial interests in the success of these treatments. These are mostly highly financially conflicted researchers whose\u00a0conflicts are never mentioned in the news release, even though we know that such financial entanglement will mean that any news release will put the best possible face on the outcome of their research.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nThere's a catch: it's expensive \u2014 about $2,000 per injection \u2014 although Medicare and most insurance companies cover most of it.\nPeople with macular generation have to look at the world through a magnifying glass,reports.\nThree months ago, he noticed his vision was distorted.\nIt's not a cure, but it's a blessing for Rochelle Faller.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert. The story should have quoted other researchers or clinicians who could provide more context.", "answer": 0}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\nSanten and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\nThe Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t state any funding sources. Several of the review authors have received industry funding and any relevant industry funding should be noted in the release.", "answer": 0}, {"article": "That was not statistically significant.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\nThe Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute.\nMerck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company\u2019s share price.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were several problems here. First, the story offered no independent expert perspective on the findings \u2014 only one of the study authors is quoted. And, as explained above, it is a little unclear where all the information in the story had its origin, and that connects to conflicts of interest. The story says, incorrectly it seems, that \u201cthe Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute.\u201d But it also talks about Merck making announcements about the study\u2019s findings before they were published. The study itself says at the end, \u201cSupported by Merck Sharp & Dohme, a subsidiary of Merck.\u201d And the study authors reported on their disclosure forms conflicts of interest with Merck and other diabetes drug makers. While the study authors may describe their work as an \u201cindependent collaboration,\u201d we expect stories to dig deeper and explain what exactly that means.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nNotable requirements of the Siliq REMS Program include the following:\n\u2022 Prescribers must be certified with the program and counsel patients about this risk.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not disclose funding sources for the clinical trials. A 2016 FDA briefing document online (page 6, second paragraph) implies that the drug company funded the clinical trials to support its application for FDA approval.\nSince none of this is mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "It can also cause digestive problems.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\n\u201cThis is the first time that we have a therapy that is directed at the cause of cystic fibrosis,\u201d says Dr. Michael Konstan, the chair of the Department of Pediatrics at Rainbow Babies and Children\u2019s Hospital in Cleveland and one of the authors of the study.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story fails to include an independent source and fails to report financial disclosures. What\u2019s worse is that most readers probably believe there is an independent source quoted. While the average reader is likely to assume that the CEO of the Cystic Fibrosis Foundation is speaking independently, the actual fact is that the foundation is a major funder of the drug\u2019s development and may stand to profit from sales of the drug. Readers should have been told of the tight financial relationship between the CF Foundation and Vertex Pharmaceuticals.\nThe story should have also noted that the researcher quoted in the story works as a consultant to Vertex, and that employees of the company were involved in designing and conducting the trial as well as writing the final report. These disclosures were openly declared in the journal article and accompanying documents and should have been included in the story.", "answer": 0}, {"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\n\u201cThis is an important finding,\u201d said co-lead researcher Prof David Murray.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\nResearchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) publishing in the BMJ Open journal found that the less invasive procedure was being used less than it could be.\nIn addition, more partial knee replacements will be done and more patients will benefit from this procedure.\u201d\n\nEd Burn, first author of the paper, said they needed to get surgeons on board.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not appear to incorporate input from any independent sources. All the quotes were taken from the news release, without attribution.", "answer": 0}, {"article": "During gastric bypass, the upper portion of the stomach is stapled off to create a smaller pouch that restricts the amount of food a person can eat at one time.\nThat, he added, makes the risks of duodenal switch seem even less worthwhile.\nAlong with the risks of surgery, he said, there is still uncertainty about whether it actually lengthens people\u2019s lives.\nBut he also questioned the value of weight-loss surgery, in general, for severely obese people who do not have medical conditions that stand to improve or resolve after surgery.\n\u201cAnd a closer follow-up after surgery is required after such procedures.\u201d\n\nBut an expert not involved in the study went further.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to quoting the lead author of the Annals article, we liked the balance provided by Edward Livingston in his comments about both the duodenal switch procedure and his comments about the value of surgery in general over medical management.", "answer": 1}, {"article": "Many Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote some outside experts and includes this important comment: \u201c\u201cMany people may wonder if they should start taking daily aspirin, but it would be premature to recommend people starting taking aspirin specifically to prevent cancer,\u201d said Eric J. Jacobs, an epidemiologist with the American Cancer Society.\u201d We think that, on balance, comments like that were overshadowed by the comments from the study\u2019s author. \u201c\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford. \u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\u201d Nevertheless, it meets the basic requirement on this criterion. However, it should have noted that while there was no outside funding for this study, some of the authors have ahd consulting relationships with pharmaceutical companies.", "answer": 1}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\nThe company plans to develop the discovery into an over-the-counter (OTC) product to combat cachexia.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention in the release of who funded this research, nor is there a journal paper which we could find that might offer that information.\u00a0 The release does say that the \u201cdiscovery\u201d has been licensed to a pharmaceutical firm that plans on developing an over-the-counter drug, and quotes a company official praising the work.\u00a0 There is no information that suggests the researchers are free from any potential conflicts of interest, with that company or other firms.\nA search of the Google Patents database shows that the lead investigator and the University of Iowa Research Foundation have applied for a patent for the compound.", "answer": 0}, {"article": "\"You're killing the bad cells and regenerating with cells that are more functional.\"\n\"The results of the study are encouraging and warrant more research in this area,\" says Toribio-Mateas.\nFasting has been performed by communities and cultures for millennia and Longo's team are curious about the advantages.\nThe food items used, however, were specific to the trial and if translated to the public would involve designing meals made up of the right combination of nutrients.\n(CNN) How much -- or how little -- you eat could influence how long you live.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Whoo boy. We\u2019re giving this a satisfactory rating since the story does let us know there is a potential conflict of interest\u2013one of the researchers plans to sell nutrition products promoting this type of dieting. However, we wish this fact would have raised more red flags for CNN, and led to a more critical analysis of the piece.\nA second source quoted in the story \u2014 nutritionist\u00a0Miguel Toribio-Mateas \u2014 espouses some unorthodox views on his website, including that one can\u00a0\u00a0\u201cgrow younger from inside by providing the necessary building blocks that enable cellular processes to keep us looking and feeling our best as we age.\u201d\nWhile we question the source\u2019s expertise, we think the story meets the standard for a Satisfactory rating. But readers should be wary of the guidance being provided, which doesn\u2019t seem to be based on particularly strong evidence.", "answer": 1}, {"article": "\"If the question were just, 'Does egg freezing and thawing work to achieve a pregnancy?'\nIt's not clear when \u2014 or if \u2014 a big-scale study might happen.\nAll told, costs can easily exceed $40,000, money Montoro doesn't have.\nThe Challenge Of Setting An Age Limit\n\nIt's quite a concept: Put your eggs in deep freeze and disconnect from that nagging biological clock.\nStill, Widra would like a larger-scale, longer-term track record.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did a good job with asking a variety of potential patients for their opinions. It did not do quite so well in providing a diversity of medical experts.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nThe study, published in the American Journal of Clinical Nutrition, was led by CHORI Senior Scientist Janet King, PhD.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "None of the authors reported conflicts of interest related to the study. The research was supported by a grant from HarvestPlus, a research program advocating for biofortification to breed higher levels of micronutrients \u2014 like iron, zinc and vitamin A \u2014 directly into staple food crops. Additional funding came from the NIH Office of Dietary Supplements.\nThe news release does not disclose these funding sources, which is why we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Paul J.D.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\nThe sonoillumination research was funded in part by a 2015 Fast Track grant from the University of Missouri System.\nThe team is in the planning stages of developing a start-up company to commercialize the technique.\nEditor\u2019s Note: For more information on the patent application for sonoillumination, please see: https://www.google.com/patents/US20150351841\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We applaud the inclusion of a link to a patent application, which both highlights a potential benefit to the researchers and provides a great deal more detail about the device itself. The application states that the patent has been assigned to the University of Missouri, but it is reasonable to assume that commercialization of this device would benefit the careers of the researchers. The release says the research was funded by a University of Missouri program called FastTrack, which is intended to support the development and commercialization of technologies.", "answer": 1}, {"article": "Studies conducted by the CDC through its Adult and Youth National Tobacco Surveys found increased experimentation by youth trying out e-cigarettes but not conventional cigarettes.\n\"Patches and gums are a very small market,\" says Etter about the quitting devices which first came onto the market 40 years ago.\nBut as it seems e-cigarettes are here to stay, most calls are for informed regulation rather than prohibition.\n(CNN) It's a portable piece of technology providing seemingly bottomless access to a drug craved by more than 1 billion people worldwide -- nicotine.\n\"They are a gateway out of smoking,\" says Etter.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story showed good initiative in chasing down and quoting a variety of experts.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nThe first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008.\nHowever, despite the complex and critical nature of these procedures, our series demonstrates favorable outcomes and reproducibility by surgeons with adequate robotic experience.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t tell us who funded the study or if there were any potential conflicts of interest.\nThe lead author, Ronney Abaza, MD, Robotic Surgery Director at Ohio Health Dublin Methodist Hospital, has conducted training programs on behalf of the manufacturer of the robotic device.", "answer": 0}, {"article": "The Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNobody looks forward to having a cavity drilled and filled by a dentist.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a real strong point. The story draws on input from a variety of experts, and clearly marks their relevant affiliations. What\u2019s missing, though, is commentary from an expert on the research behind the method.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included primary quotes from clinicians, industry spokespersons, and individuals who had undergone gastric banding.", "answer": 1}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nThe researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nBut another experiment got the researchers more excited.\n\u201cThe patients walk in the door and they have something wrong with them \u2014 we don\u2019t know what.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "       \n \nNo independent experts were interviewed for this story. Furthermore, the story failed to mention that Dr. Spira, one of the study\u2019s authors, is the founder of Allegro Diagnostics and currently sits on the Board of Directors and serves as a consultant. The story only says he is \"working with\" the company. What does that mean? \n ", "answer": 0}, {"article": "One patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\nThis study was supported by intramural funds from the National Cancer Institute.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\n\"Based on the current safety and clinical benefit data, the dose of the vaccine was increased to 40 million dendritic cells per injection and the trial opened to patients who have previously been treated with a HER2-targeted therapeutic, including patients with breast cancer,\" said Berzofsky.\nAmong the 11 patients who received either 10 million or 20 million dendritic cells per injection, six had clinical benefit.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by the National Cancer Institute at NIH.\u00a0The study abstract states the lead scientist declared no conflicts of interest.", "answer": 1}, {"article": "\"It took quite a bit of time to get approval,\" Mithoefer says.\nConducting a study with an illegal drug is a complex process.\nMithoefer and his team are now gearing up for a similar study involving combat veterans, which is scheduled to begin later this year.\nTwo months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "MAPS is a drug legalization organization. In its stated mission, it says, \"We believe that psychedelics and marijuana, when used in proper settings, can be beneficial for such uses as psychotherapeutic treatment, physiological research and treatment, treatment of addiction, pain relief, spiritual exploration, creativity research, shamanic healing, psychic research, brain physiology research and related scientific inquiries\u2026.We also provide psychedelic emergency services at festivals where psychedelics are likely to be used in an effort to model harm reduction techniques in a post\u2013prohibition world.\" There aren\u2019t many purely scientific\u00a0research organizations that sell posters of\u00a0celestial beings\u00a0shooting light rays from their eyes. This is noted nowhere in the story and is important information for the reader to have in deciding how to evaluate the findings. There are no independent sources in this story, and they are sorely needed.", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did state doctor affiliations to the company making the device and also quoted some people not affiliated with the company.", "answer": 1}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n(And) because the game is interesting, even those patients with a general lack of motivation are spurred on to continue the training.\u201d\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the article. And, while there don\u2019t appear to be any conflicts of interest, it would likely have been worth noting that the \u201cbrain game\u201d research was funded by Janssen/Johnson & Johnson \u2014 a large pharmaceutical company.", "answer": 0}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nThis study shows that treatment delays of even one month can greatly increase the incidence of cognitive [mental] decline,\" Lee said.\nAlthough the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A second source appears to be independent of the study, although readers are not given enough information to determine that. It\u2019s not clear who funded the study, and we think that should have been included.", "answer": 0}, {"article": "Leading A.D.H.D.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\nDr. Swanson, a co-author of a landmark federally funded study, the Multimodal Treatment of Attention Deficit Hyperactivity Disorder, said that follow-up research found overall improvement but no greater long-term benefits after three years for children who were treated with medication compared to those who weren\u2019t.\nIn arguing for \u201cnormalization,\u201d Dr. Wilens cited a major review in the Journal of Clinical Psychiatry in late 2013, which looked at 29 brain-scan studies.\nto take medication when they don\u2019t want to, adding that \u201cmost kids don\u2019t want to.\u201d\n\nDr. Jensen, who now heads the REACH Institute, a national nonprofit organization concerned with children\u2019s mental health, once surveyed 100 parents of sons and daughters in their 20s who had been diagnosed with A.D.H.D., asking what made the most difference.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The best feature of this story is the presentation of experts with different perspectives who outline the reasons for their views. It also notes concerns about financial ties between some experts and the pharmaceutical industry.\nWhile we\u2019ll award a satisfactory rating, we wish the story had put more emphasis on some of these researchers\u2019 checkered history with respect to conflict disclosure. Notably, the lead author of the study cited as evidence for a normalizing effect on brains reportedly failed to disclose payments totaling more than $1.6 million dollars from drug companies. And the source citing that study,\u00a0Dr. Timothy E. Wilens, failed to disclose similar payments.", "answer": 1}, {"article": "Testing cholesterol in toddlers and babies?\nThe study was led by Dr. David Wald at Queen Mary University of London.\nThe work was funded by the Medical Research Council, the British government\u2019s health research agency.\n\u201cWe really need to pay attention to this,\u201d said Dr. Elaine Urbina, director of preventive cardiology at Cincinnati Children\u2019s Hospital Medical Center and a member of the US.\nHe and another author founded a company that makes a combination pill to prevent heart disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included independent sources. Also, the story discloses this: \u201cThe study was led by Dr. David Wald at Queen Mary University of London. He and another author founded a company that makes a combination pill to prevent heart disease. The work was funded by the Medical Research Council, the British government\u2019s health research agency.\u201d", "answer": 1}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nThe researchers argue that the findings, drawn from data on four years of claims made in seven states, support coverage of bariatric surgery by insurers because of the savings and improvements in patients' health.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nAlso, at two years after surgery, data were available for less than half the patients.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not include comments from independent sources. The researchers did not make any financial disclosures. The study was funded by a public agency, the U.S. Agency for Healthcare Research and Quality. It used data that was originally gathered for an obesity care project funded by a surgery device company and an insurance company.", "answer": 0}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nAnd even the company\u2019s founder and CEO acknowledges the test can\u2019t provide clear and definitive answers on which treatments women should try next if they\u2019re struggling with infertility.\nThe Fertilome test, which must be ordered by a doctor, analyzes a woman\u2019s DNA for 49 genetic variants that have been linked to various conditions that can sometimes cause fertility problems.\nBeim, the Celmatix CEO, said the test is already bringing \u201ctremendous\u201d value, in part by providing guidance that can act as a \u201ctiebreaker\u201d to help patients and their doctor decide which treatment to prioritize.\nAfter questions from STAT, the company added a disclaimer acknowledging that testimonials are not quite as they were promoted from the start: the names, images, and details of patients\u2019 stories have been changed to safeguard their privacy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The company\u2019s CEO is clearly identified. Physicians who serve as sources and who have used the test are distinguished from those who have not.", "answer": 1}, {"article": "Delaying the clamping of the cord allows more blood to transfer from the placenta to the infant, sometimes increasing the infant's blood volume by up to a third.\nBut Rabe said these infants may actually benefit most from the practice.\nRabe's editorial accompanied the study published Tuesday in the journal JAMA Pediatrics.\nThe other half were clamped less than 10 seconds after birth.\nIt is unclear whether the practice could harm infants' health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story made very good use of independent sources beyond the study authors.", "answer": 1}, {"article": "Because even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nSymptoms range from mild stomach or skin reactions to a constriction of the airways.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is Dr. Wesley Burks of Duke University Medical Center, one of the researchers who presented work at the meeting.\nThe reporter fails to disclose that Burks has financial relationships with a number of drug, food and device companies with an interest in allergies. \nThe reporter should have interviewed at least one additional source with deep knowledge of peanut allergies and no connection to the research.\u00a0 ", "answer": 0}, {"article": "Common symptoms of PPD \u2013 a mood disorder in women that can be triggered by fluctuations in reproductive hormones \u2013 include low mood, feeling overwhelmed, anxious and ruminating thoughts, potential withdrawal from the baby and her family, and suicidal thoughts in the most severe cases.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\nA New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that Sage Therapeutics funded the research.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials. A New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation. The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018.\nWhat the release doesn\u2019t tell us is that both quoted researchers disclosed financial ties with Sage Therapeutics.\u00a0 This information was included in the studies published in the Lancet.\nSM-B reports personal fees from MedScape and grants from Sage Therapeutics, awarded to the University of North Carolina \u2026 DRR reports personal fees and has stock options in Sage Therapeutics\u2026.", "answer": 0}, {"article": "\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from an dietitian\u00a0who spoke about the potential detrimental effects of poor nutrition on cognitive development. It would have been helpful to hear\u00a0from an expert on neurodevelopment, who could have commented on the size of the effects observed and their\u00a0relevance to real world\u00a0performance.\u00a0\u00a0A comment from a pediatrician about counseling families on healthy diets also would have been\u00a0helpful.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nTo the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\nExamples of forward-looking statements contained in this press release include, among others, statements regarding the safety, potential efficacy, therapeutic potential, and commercial potential of VYXEOS\u2122 (also known as CPX-351), our expectations regarding the timing of our regulatory filings, our expectations regarding our research and development programs and advancing our CombiPlex platform and the potential to establish research and development collaborations applying our proprietary technologies with other biotechnology/pharmaceutical companies.\nSuch risks and uncertainties include, among others, the uncertainties inherent in the conduct of clinical studies, whether clinical study results obtained to date will be predictive of future results, whether the final results of our clinical studies will be supportive of regulatory approval to market VYXEOS and other matters that could affect the commercial potential of our drug candidates.\n\"The successful outcome of this Phase 3 trial represents an important advance for AML patients, their families and clinicians,\" said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We aren\u2019t told anything about the relationship between the study\u2019s principal investigator, Dr. Jeffrey E. Lancet, and Dr.\u00a0Gail Roboz and Celator, the\u00a0company whose drug they are discussing. If there is or isn\u2019t a financial conflict of interest, that needed to be spelled out in the news release. We do know that Scott Jackson, chief executive officer of Celator Pharmaceuticals, has obvious financial ties to the company whose drug he is praising.", "answer": 0}, {"article": ".\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\nThe Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention in the release about the funding for the research or any information about potential conflicts of interest among the researchers. The published research paper, however, readily discloses that the study was supported by a pharmaceutical manufacturer and that the lead researcher is a paid consultant to that company. Numerous other potential conflicts among the research team are also outlined in the paper. All of these financial ties should have been mentioned in the release. ", "answer": 0}, {"article": "The second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nThey have gained nearly 8 percent since December 18.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source appears to be the drug company CEO.", "answer": 0}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides many clinical perspectives\u00a0on the CAD technology.\u00a0 The reporter interviews not only the study author and the author of an accompanying NEJM editorial, but also clinicians and radiologists who talk about use of CAD in practice. Interviews with clinicians who provide their rationale for not using the CAD technology provide excellent balance to the story. ", "answer": 1}, {"article": "An estimated 25 million to 45 million Americans suffer from irritable bowel syndrome, or IBS, a gastrointestinal condition that can cause miserable symptoms.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\nIrina Obenauer was diagnosed with IBS years ago after suffering from diarrhea and bloating, but it took doctors a long time to rule out other possible diagnoses first.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The quoted CBS news correspondent casts a sufficiently critical view of the test, yet it is hard to say if he is conflicted or not, seeing as he works for the same news outlet the news story has appeared in. \u00a0It would have been relatively easy to discuss the tests with an outside expert unconnected to the test manufacturer or the\u00a0news network.\nIn addition, Dr. Pimental is quoted in the story as \u201cthe developer of the tests.\u201d Most people will probably understand that he has a financial interest, but this could have been made more clear by saying so \u2014 disclosing that he\u2019s a paid consultant of the companies developing the tests commercially.", "answer": 0}, {"article": "In addition, we saw that several smaller brain areas actually started to grow in response to training,\" says Ulrik Dalgas.\nA bigger and more in-depth on-going study will help to clarify this, and may also lead to improved treatment options, says Ulrik Dalgas.\nThis is the main finding of a study conducted by a research partnership between Aarhus University, Aarhus University Hospital, the University of Southern Denmark and the University Medical Center Hamburg-Eppendorf, that has just been published in Multiple Sclerosis Journal.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release names the study\u2019s funders in a sidebar on the EurekAlert! website as the Augustinus Foundation, Hestehandler Ole Jacobsens Mindelegat and Biogen Idec. We encourage news release writers to include funders in the text of the release as well.", "answer": 1}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\nShe is a principal investigator on the study, which will appear in the June issue of The Lancet Neurology.\nBreaking the diet with so much as a few cookies can cause seizures to flare up.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Apparently a not-yet-published journal article was one source. \u00a0\u00a0 Another was an interview with the principal investigator of the study reported on. \u00a0In addition, there was an interview with a clinician with expertise in the area but who was not directly associated with the story reported on.", "answer": 1}, {"article": "\"We are not going to reverse any of the chronic diseases in this country by changing the composition of the diet,\" Dr. Howard said.\nOthers cautioned against being too certain that a particular diet would markedly improve health, and said that whether someone developed a chronic disease might not be entirely under their control -- genetics also plays a role.\nBut the Mediterranean diet has not been subjected to a study of this scope, researchers said.\nBut Dr. Freedman, the Berkeley statistician, said the overall lesson was clear.\nAlthough all the study participants were women, the colon cancer and heart disease results should also apply to men, said Dr. Jacques Rossouw, the project officer for the Women's Health Initiative.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Scientists with a variety of different perspectives and interests are quoted. It is unfortunate that the quotes used focused more on personal beliefs than on evaluation of the evidence. ", "answer": 1}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\nThe report describes the use of the test to analyze samples from six patients.\n\"This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are noted in the sidebar where this release is hosted on EurekAlert! but not in the release itself. We encourage news release writers to include funders in the body of the release. There is no mention of conflicts of interest in the release, nor in the study itself.", "answer": 1}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release goes into significant detail about the funders and their mission. Funders include the National Institutes of Health, the National Multiple Sclerosis Society, and a private foundation. The drugs and placebo used in the study were provided by Synthetic Biologics, the manufacturer. The release also notes, somewhat vaguely, that Synthetic Biologics has licensed some rights from UCLA. ", "answer": 1}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\nJustin B. Dimick and David C. Miller, both of the University of Michigan, wrote in an editorial.\nPatients should try to stay in the immediate vicinity of their surgical hospital for at least a week, Brooke said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a quote from the editorial that accompanied the study. But this quote is not very informative.\n\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical.\u201d\nThe point of this criterion is to encourage critical evaluation of the research, so we\u2019re hesitant to give credit for a quote that\u2019s mostly superfluous. The editorialists did comment on some of the important limitations raised in the quality of evidence domain above, but the story didn\u2019t use any of that text.", "answer": 0}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nThe study published online May 16 in Circulation: Arrhythmia and Electrophysiology.\n\"Based on that, the study may provide more certainty in terms of cost-effectiveness.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not say who paid for the work or whether any of those involved in the studies cited had conflicts of interest.", "answer": 0}, {"article": "It also said Repatha\u2019s effect on mental function was similar to placebo, likely alleviating concerns that it might impair cognition in some patients.\nRepatha and a rival drug from Regeneron Corp and Sanofi have had endured anemic sales as a result.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source mentioned in the story is an official from Amgen, the drugmaker.\u00a0 Therefore, there is an assumed conflict of interest since the company is touting the success of their product, even without any substantive data to back that up.\u00a0 No independent source is included in the story.", "answer": 0}, {"article": "Using the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nLONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": " ", "answer": 0}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nResults on these groups are not yet ready \u2014 the study is continuing.\nIt\u2019s not pretty.\u2019\u2019\n\nThe test costs $4,175, which Medicare and many insurers cover.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Associated Press interviews five experts for the article \u2013 one is the study\u2019s lead author and the rest are independent sources. This is a strong point in the story.\nBut while the story also mentions the funding source (National Cancer Institute), there was a relevant conflict of interest that was overlooked here. Dr. Joseph Sparano, the study\u2019s lead author, reported a patent \u201crelated to tests to predict responsiveness of cancer patients to chemotherapy treatment options\u201d in his NEJM disclosure forms (p.79-80). Since we feel this is significant enough conflict of interest that should have been touched upon in the story, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\n\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\nThe study is published in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included a second source, but he can\u2019t be viewed as an independent source since he, too, has been involved in research of the drug and has been a paid consultant and investigator for Abbott. \nThe story also did not disclose what is clearly disclosed in the journal article \u2013 that the principal investigator:\n\u00a0\nIt also didn\u2019t disclose what the journal article disclosed, that Abbott personnel helped write the manuscript and helped with the statistical analyses.\n\u00a0\n The Statement of Principles of the Association of Health Care Journalists includes these clauses:\u00a0 ", "answer": 0}, {"article": "A moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\nAll said they had taken MDMA for recreational purposes at least twice in their lives.\n\"Now, there's a long way to go between that and proving effectiveness.\nBut if used in the right setting wisely, many things can also be helpful.\nYet the closeness it sparks might not be result in deep and lasting connections.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no truly independent source quoted.\u00a0 The only quote coming from anyone outside the current research team came from a researcher who also reported on MDMA research months ago.\nWhat about the observation of someone who does not have a dog in the hunt?", "answer": 0}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nAbout MM36\n\nMedimetriks has sole, exclusive US rights to MM36.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\nThe Company is dedicated to addressing unmet physician and patient needs with unique therapies that advance patient care.\nThe JAAD article discussing the Phase 2 results can be found by visiting www.jaad.org.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t include any information about how the study was funded. The study itself discloses that several authors are paid consultants for the companies making the drug.", "answer": 0}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nThe team is careful to note that no definite links can be established at this point, however.\nThe team is therefore keen to research this topic further, to see if the discovery relating to Parkinson's disease could have implications for other neurodegenerative disorders as well.\nHowever, the scientific research regarding this topic has drawn mixed conclusions.\nLevels of parvalbumin are much higher in fish after they have had a lot of sun, so it could be worthwhile increasing consumption during autumn,\" says Nathalie Scheers, Assistant Professor in the Department of Biology and Biological Engineering, and researcher on the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for the study and any potential conflicts among the researchers are not mentioned in the release. The published article acknowledges funding from the Knut and Alice Wallenberg Foundation, the Swedish Research Council, the Olle Engqvist Foundation and the Chalmers Foundation.", "answer": 0}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\nThe findings have been published in Scientific Reports.\nThe study by Professor Bartlett, Dr Belmer, Dr Patkar and Dr Vanessa Lanoue (Queensland Brain Institute) can be accessed here.\n\"This drug is relatively new and available only in China and Japan.\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes no mention of the funding sources of this research, nor does it provide any information on potential conflicts of interest.", "answer": 0}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\n\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\nWe need to better understand the biology behind the treatment and follow patients for long-term side effects,\" Robert E. Ratner, MD, chief scientific and medical officer of the American Diabetes Association, tells WebMD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The chief scientific and medical officer of the American Diabetes Association was quoted with independent perspective.", "answer": 1}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\nThe study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a previous story from an independent expert, who spoke on the general topic of fasting diets. More comments from independent sources about this particular study would have strengthened the story.\nThe story should have noted that two of the authors have recently written books about fasting and weight loss.", "answer": 0}, {"article": "As the researchers had hypothesized, the participants' Fitbits captured a portion of this fertile window by showing that their resting heart rates rose one or two days before ovulation, as well as during ovulation itself.\nAn expert told BuzzFeed News at the time that her heart rate increase may have been an indirect result of elevated body temperature, another symptom of pregnancy.\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nH\u00f6gqvist Tabor said she soon realized what the finding meant, and broke the news to the marketing director: She was pregnant.\nUpon a Redditor\u2019s suggestion, she took a test that confirmed she was in fact pregnant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources in the story. Only two sources are quoted, and each of them works for a tech company whose products address fertility issues.", "answer": 0}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nBut the weekend warriors also saw substantial health benefits if they met the physical activity target too.\n\u201cThe novel finding is that it appears the duration, and possibly the intensity, of leisure time physical activity is more important than the frequency,\u201d Ekelund said.\nNearly 9,000 of the study participants died in the period.\n\u201cWe find a clear benefit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources don\u2019t appear to have any conflicts of interest, and there was one additional source included beyond the lead researcher.", "answer": 1}, {"article": "In practice, Performance with Purpose means providing a wide range of foods and beverages, from treats to healthy eats; finding innovative ways to minimize our impact on the environment and reduce our operating costs; providing a safe and inclusive workplace for our employees globally; and respecting, supporting and investing in the local communities where we operate.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n\"The satiety benefits of instant oatmeal alone were important findings,\" remarked lead author Candida Rebello, MS, RD, of Pennington Biomedical Research Center at Louisiana State University.\n\"When we took it a step further and evaluated the intake four hours post-breakfast, we found that after consuming instant oatmeal, the participants chose to eat significantly less at lunch compared to those who ate the oat-based, cold cereal.\"\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for the study are not made clear in the release, nor does the release tell us that the study researchers included PepsiCo employees. The journal article discloses all of this information so it would have been easy enough to find and include.", "answer": 0}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nThe contributors are affiliated with one or more of the following institutions: Baylor College of Medicine, Peptides International, Inc. and Icahn School of Medicine at Mount Sinai.\n\"In previous work, we identified a potassium channel on FLS of patients with rheumatoid arthritis and found that the channel was very important for the development of the disease,\" Beeton said.\nThis work was supported by the Arthritis Foundation grant 6483 and the National Institutes of Health grants GM088129, AI050831, AR069960, HL007676, CA125123 and HG006348.\n\"Cells called fibroblast-like synoviocytes (FLS) play a major role in the disease.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release reports that the study was supported by Peptide International, makers of the peptide iberiotoxin, the Arthritis Foundation and the National Institutes of Health. We didn\u2019t find any undisclosed conflicts of interest.", "answer": 1}, {"article": "In the UK around 536,000 people suffer fragility fractures each year, including 79,000 hip fractures.\nHalf of the women were screened to compare screening with routine care.\nThe team used a University of Sheffield developed tool called FRAX, which predicts the probability of a hip fracture or a major osteoporotic fracture (a hip, spine, upper arm or lower arm fracture), to identify older women at high risk.\nMortality at one-year post-fracture is approximately 20 per cent.\"\n\"We welcome this community based screening programme and any other research that reduces the likelihood of fractures.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The source of funding and universities involved in the study are clearly stated.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an exemplary\u00a0job of citing credible, outside sources about the study. We did not detect any conflicts of interest that were overlooked.", "answer": 1}, {"article": "Their median age was 63.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\nA large, randomized, prospective study currently being conducted by the Eastern Clinical Oncology Group should produce the most reliable data on the subject to date, he said.\nTwo small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nHere's how he survived]\n\nPrevious research has reached the same conclusion, but a significant problem with this study and others like it is that they rely on retrospective data, looking back over any number of years, said Michael S. Sabel, the chief of surgical oncology at the University of Michigan, who was not involved in the newly published study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Washington Post report interviews two independent sources \u2013 the chief surgical oncologist at the University of Michigan and the medical director of a breast cancer center \u2013 and their comments bring a much needed critical perspective to the piece.\nNo conflicts of interests are reported, both in the original research article and in the Washington Post story.", "answer": 1}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nByron Caughey, Ph.D., a senior investigator in NIAID\u2019s Laboratory of Persistent Viral Diseases, is available to comment on this study.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that the research was supported by the NIH but doesn\u2019t mention other significant funders such as the Parkinson\u2019s and Movement Disorder Foundation and the Shiley-Marcos Alzheimer\u2019s Disease Research Center at the University of California San Diego.\nIt also doesn\u2019t note (as the published article does) that four study authors have applied for a US provisional patent application on the technology. ", "answer": 0}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While this\u00a0article accurately states that its sources were two articles published in the New England Journal of Medicine,\u00a0funding sources were not reported in this article.\u00a0\u00a0The journal did report that funding for the research was primarily in the form of national, federal and foundation grants.\u00a0 One co-author on the British study and four authors of the U.S. study reported financial and/or consulting relationships with pharmacuetical companies.\u00a0 In addition, no opinion from an expert not involved in the trial was provided.", "answer": 0}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nThe abstract was one of thousands of studies released on Thursday ahead of presentation at the American Society of Clinical Oncology (ASCO) next month in Chicago.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nData from a second arm of the study is still being evaluated.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nNot only were there no independent sources, the reporter did not include comments from any experts at all. The story appears to be based entirely on reading presentation abstracts.\nEven though disclosures about study funding and other potential conflicts of interest are posted on the same web site as the meeting abstracts, this story failed to report that both trials and the study authors received funding from Bristol-Myers Squibb, the company developing the drug, and that one of the trials was also supported by a second company, Medarex. The abstracts themselves also mention that some of the researchers are employees of Bristol-Myers Squibb or Medarex. Readers deserve to be told about these financial relationships.\n", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\n\u201cWe must bear in mind that this is a pilot study with a small sample,\u201d Anna Fenton, co-editor of Climacteric, said in commentary on the work.\nBut they stressed that the trial was small, so far larger studies are needed to confirm the results.\nBut sales of HRT drugs have fallen sharply since a large study in 2002 found higher rates of ovarian cancer, breast cancer and strokes in women who took the pills, and the search has since been on for alternatives.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does not quote any outside sources, which we know can be driven by deadline demands. The bigger problem with the story, and it\u2019s a problem shared by many stories about hormone treatments, is that it does not acknowledge the authors\u2019 conflicts of interest. Dr. Andrea Genazzini, for example, has worked with pharmaceutical companies on multiple articles that were ghostwritten by the companies\u2019 marketing firms. You can find this by looking in the Drug Industry Document Archive. We know that it\u2019s tough to cover all the bases when juggling multiple stories in a day, but we hope that more reporters will take the time to at least do a name check on researchers involved in studies of hormone therapy, antidepressants and other drugs that have been the subject of lawsuits and federal investigations. There is a wealth of information in the archive, and readers deserve to know more about it.\n\u00a0", "answer": 0}, {"article": "But for relapsed ovarian cancer, surgery is usually not an option.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\nBut she stopped short of saying it should be eliminated, saying that in any event, patients would not accept that.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several experts who are not involved in the story, providing valuable perspective on the results.", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three sources: \nGiven the fact that [as the story discloses] the study was paid for by the test maker, the lack of independent sources is glaring. \nThe story would have been much stronger if it had comments from a disinterested oncologist who could speak to the test\u2019s practical value in a clinical setting. ", "answer": 0}, {"article": "BLOOMINGTON, Ind.\nAs one of the largest analyses on the risks and benefits of ADHD medication, the study drew on anonymous health care data from 146 million people with employer-based health insurance in the United States from 2005 to 2014.\nSpecifically, the researchers mined the data to identify people with ADHD whose records showed periods of ADHD medication use and periods without ADHD medication use -- as well as one or more visits to the emergency room due to drug or alcohol use.\n\"This study contributes to growing evidence that ADHD medication is linked to lower risk for many types of harmful behavior, including substance abuse,\" said Patrick D. Quinn, a postdoctoral researcher in the IU Bloomington College of Arts and Sciences' Department of Psychological and Brain Sciences, who led the study.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release noted the funders but did not mention any of the authors\u2019 conflicts of interest. One of the authors has served as a speaker for\u00a0Eli Lilly and Shire, and was awarded a research grant from Shire. Shire produces ADHD medications, including\u00a0Vyvanse and Adderall. Eli Lilly also produces an ADHD medication, Strattera. This is a big conflict of interest that should have been noted in the release, particularly since both Adderall and Strattera were mentioned by brand name in the release.", "answer": 0}, {"article": "Modern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\n\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\n\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No conflicts of interests were reported in the original journal article. The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.\nThe CBS report only quoted comments from the study\u2019s lead researcher and then excerpts from the accompanying JAMA Pediatrics editorial. Technically, these editorial comments are sufficient to clear our bar, but we\u2019d note that the thrust of the quote is mainly to confirm what the researchers are reporting. We would have liked to have seen a quote from someone willing to provide a more critical perspective on the study, such as the significance of its limitations and their impact on the research.\nWhile we give the benefit of the doubt here as we always do, the story didn\u2019t really fulfill the spirit of this criterion.", "answer": 1}, {"article": "For the control group, 56 percent displayed a significant increase in cognitive capacity, while 44 percent had no change.\nFull text of the article is available from the APA Public Affairs Office and at\n\nThe American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nArticle: \"Sending Your Grandparents to University Increases Cognitive Reserve: The Tasmanian Healthy Brain Project;\" Megan E. Lenehan, PhD, University of Tasmania-Launceston; Mathew James Summers, PhD, University of the Sunshine Coast; Nichole L. Saunders, PhD, Jeffery J. Summers, PhD, David D. Ward, PhD, and James C. Vickers, PhD, University of Tasmania-Hobart; and Karen Ritchie, PhD; Neuropsychology, published online Nov. 16, 2015.\nPrior research has shown that college study earlier in life may increase cognitive capacity, and it appears the same may be true for older adults, Lenehan said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources weren\u2019t noted, nor conflicts (which could have been covered if just noted that it was a largely government-funded study). The published article\u00a0is also silent on the matter. Given the subject, it is difficult to identify any meaningful potentials for a conflict of interest. But we think all news releases should discuss funding as a matter of course. That\u2019s our line in the sand.", "answer": 0}, {"article": "Other research has consistently supported the benefits of NSAIDs in preventing colorectal cancer, and provided some evidence they may work for breast, esophagus, and stomach cancers, as well.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nUnfortunately, the technique \u2014 comparing people with melanoma to those without - is fraught with potential problems, said Asgari.\n\u201cI think it\u2019s just too early\u201d to say NSAIDs offer any protection, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story turned to Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored a 2008 study.\u00a0 Oddly, no author/researcher on the new study was quoted.", "answer": 1}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nThat\u2019s particularly important in Asia, where those cancers are common.\nAnd they can pick from a number of tests that have all been found to cut the risk of dying from colon cancer.\nAnd it\u2019s much cheaper: iFOBT is more expensive than the older stool tests, but it is still roughly $30.\nImmunochemical FOBT is now largely replacing the older test.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We wish the story had included an interview with a US screening expert or a member of the US Preventive Services Task Force.", "answer": 0}, {"article": "Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nA limitation of the study was the modest number of participants.\n\"Results lend support to current national initiatives from the National Academies, White House, and bipartisan legislation requesting that the U.S. Food and Drug Administration create a new regulatory classification for hearing devices meeting appropriate specifications to be available over the counter,\" the authors write.\nFor more details and to read the full study, please visit the For The Media website.\nTo place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release asks the reader to see the study for \u201cauthor contributions and affiliations, financial disclosures, funding and support,\u201d which is better than nothing, yet doesn\u2019t make it easy for readers to draw conclusions about any potential bias.", "answer": 0}, {"article": "None did.\nDr. P. Murali Doraiswamy, a biological psychiatrist at Duke who had helped recruit patients for the study, called the results among \u201c the most highly anticipated data from the entire meeting.\u201d\n\nTo compare the scans with autopsy results, the company scanned the brains of 35 people in hospices who were expected to die within six months.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nDr. Reisa A. Sperling, an Alzheimer\u2019s expert at Brigham and Women\u2019s Hospital in Boston and co-chairwoman of the session where the results were presented, said, \u201cPersonally, I found the data quite convincing.\u201d\n\nDr. Sperling, an investigator on a different AVID study but who is not paid by the company, said the challenge now will be to see whether the scans can accurately predict whether people are developing Alzheimer\u2019s before they have symptoms.\nIn addition, the company scanned the brains of 76 younger people who would not be expected to have plaque in their brains.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story quotes three clinicians, all of whom had ties to the company involved with promoting the test reported on or the study of that test. \u00a0So while conflicts of interest were identified, there did not appear to be any independent sources interviewed on the topic. The story mentioned that \u2018experts who attended said the data persuaded them that the method works\u2019 but were they all in some way connected with the company? ", "answer": 0}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nExperts said the findings, published online Feb. 16 in the journal JAMA Internal Medicine, are encouraging.\nThe caveat, according to Spira, is that this study tested that specific program.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nThere is no guarantee that the course at your local senior center or a book would have the same chances of working.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It\u2019s clear that the reporter spent some time reviewing existing research on sleep disorders among older adults and in talking to the two main sources: the author of the study and an independent expert who wrote a commentary about the study. The story would have been even stronger had made the expert\u2019s\u00a0independence abundantly clear.", "answer": 1}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nThey see the potential of these games to not only make money \u2014 but to save money, too.\nBut this kind of goal requires a totally different business model; before they can deliver their game to players, they first have to go through the Food and Drug Administration \u2014 the FDA.\nSo some scientists believe that by playing this game \u2014 Project Evo \u2014 you can improve a range of cognitive skills and, by extension, relieve a range of symptoms associated with cognitive disorders.\nHere, Ehlers touches on a broader controversy around games like Project Evo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a key strength of the story. Several different experts and viewpoints are presented, so that readers are shown a range of opinions and perspectives. The affiliations of key sources are identified, so that readers can see how their interests might influence their outlook.", "answer": 1}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Everyone quoted in the article is an advocate of efforts to teach, learn and use CPR in bystander situations. Those perspectives are fine, but the story should have at least quoted or cited some source about the risks, downsides, and low survival rate of those who undergo CPR. The conflicts of interest are apparent: those quoted are all survivors, survivor advocates, or CPR trainers.", "answer": 0}, {"article": "Researchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nIt was funded by the government of France.\nThe treatments lasted for six months.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nThe study is published in this week\u2019s issue of the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited.", "answer": 0}, {"article": "SIR's members work in a variety of settings and at different professional levels--from medical students and residents to university faculty and private practice physicians.\nAmgen, the pharmaceutical company that makes T-VEC, was a sponsor of the trial.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\nResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identified Amgen, the pharmaceutical company that makes T-VEC, as a sponsor of the trial.", "answer": 1}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nThe study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\n368 infants from the Basel-Bern Infant Lung Development birth cohort in Switzerland were included in the study.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release provides no information as to the funders of this research, nor does it provide any information on possible conflicts of interest involving the researchers, only one of which is mentioned in the release.\u00a0 Additionally, neither the abstract nor the full research paper was available when the news release was published, so other information describing the research was unavailable.", "answer": 0}, {"article": "For more on heart failure, visit the American Heart Association.\n\"Right now we have many therapies that we use for heart failure, and these patients [in the study] were on all of those therapies and still had significant heart dysfunction,\" said lead researcher Dr. Daniel Lenihan.\nDespite the encouraging results of this first trial, a lot more testing will be needed before cimaglermin can be considered a standard treatment for heart failure, Bishopric said.\nThe study was funded by Acorda Therapeutics, the maker of cimaglermin, and the report was published online Dec. 26 in the journal JACC: Basic to Translational Science.\nFor the study, Lenihan and his colleagues randomly assigned 40 patients to get an infusion of cimaglermin or a placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does get credit for quoting a researcher not affiliated with this project, but it neglects to mention some obvious potential conflicts of interest among the members of the research team. According to the research paper, eight of the 13 researchers have some linkage to pharmaceutical firms and seven of them have a connection to the sponsor of the study, Acorda Therapeutics, Inc., either as consultants, employees, or stockholders, and two of them have had research funded by the company.", "answer": 0}, {"article": "Her back hurts, and surgeons have replaced her left knee once and her right hip twice.\nPotential patients must be evaluated for other causes of pain, Collins noted, because problems with thumbs or other hand parts can make the wrist hurt.\nOccasionally, other conditions must be addressed in addition to joint damage.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story relies on one patient and one \u201cexpert,\u201d a surgeon who performs wrist replacements. It provides no information on potential conflicts of interest and no conflicting points of view. Input from experts outside of this institution would provide balance and potentially clarify the risks and benefits of this procedure.", "answer": 0}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nDepending on how the first procedure goes, the hospital will enroll more people into its trial.\nSince the procedure is experimental, there may be some unknown risks as well.\nThe hospital recently received the green light from federal authorities to start the first ever human trial of DBS for stroke, and plans to announce Tuesday that it will perform the procedure as soon as an initial patient is identified.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes a single source\u2013the head of the clinical trial who will also be the person leading the DBS surgery. There is no discussion\u00a0about potential conflicts of interest.", "answer": 0}, {"article": "Sitting has been identified as a risk factor for early mortality, independent of the presence of a disease, such as cancer or diabetes.\nHaley Scott and Danel Voorhees are co-authors on the paper.\nActive Ideas LLC, which offers the HOVR device used in study, funded the research.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes in the last sentence that the research was funded by the company that makes the HOVR device used in the intervention.", "answer": 1}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nDr. Jenkins, who is not affiliated with the company, has continued to monitor Mason.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nMason believes the stem cells accelerated his recovery.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does tell viewers that the physician who performed the procedure \u201cis not affiliated with the company\u201d sponsoring the trial. However, it should have included an independent expert and named\u00a0the trial sponsor.", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cIn fact, the first patient in the trial was actually riding a bike within a week of his treatment.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder(s) of the study aren\u2019t mentioned. We don\u2019t know how heavily the lead researcher, his research center or partners, or even the patient could be conflicted with the company developing the technology. That information would have been very helpful.", "answer": 0}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from two individuals who are not directly involved in the specific study to examine whether salsalate improves outcomes for individuals with type 2 diabetes. \u00a0In addition to comments from Dr. Shoelson who is a proponent of expanding the application of salsalate, the story had comments from a researcher with an opposing viewpoint as well a spokesperson from the governmental agency funding the project.", "answer": 1}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\n\"Prescribing exercise may be just as important as prescribing medications \u2014 perhaps even more important in some cases,\" the editorial said.\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\nPhysicians can also help.\nNot so.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an independent source, and doesn\u2019t appear to have missed any conflicts of interest.", "answer": 1}, {"article": "Earlier studies have suggested that omega-3 fatty acids can alleviate clinical depression and other psychiatric disorders, although there have been mixed results.\nAmminger and colleagues warn against over-interpretation of their findings.\nThe study appears in the February issue of Archives of General Psychiatry.\nThey do, however, strongly urge further research.\nIt's also not clear how fish oil might prevent psychiatric disorders.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not include commentary from any independent sources. \u00a0Furthermore, the quote provided by the study authors was pulled directly from the discussion section of the article. ", "answer": 0}, {"article": "This is when estrogen plummets, and estrogen helps protect bone health.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\n\u201cWhat is right in 2010,\u2019\u2019 she said, \u201cmight not be right in 2011 in a rapidly evolving medical science.\u2019\u2019\n\nDr. Felicia Cosman, clinical director of the National Osteoporosis Foundation and a professor at Columbia University, said the swirl of new information makes it critical for patients to review with their physicians their treatment decisions.\n\u201cI believe all women should have a bone screening test approximately at the time of menopause,\u2019\u2019 said Cosman, emphasizing that \u201cthis is my personal opinion as a specialist who treats women,\u2019\u2019 and not representative of her position with the National Osteoporosis Foundation.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included commentary from several independent experts who provided useful insights. The article did not discuss potential conflicts of interest among these experts. However, the journalist\u2019s hard work in soliciting a diversity of comments outweighs the lack of discussion of financial conflicts.\u00a0\n\u00a0\n ", "answer": 1}, {"article": "\"Cancer patients tend to develop clots in their legs and lungs more frequently and also patients who develop clots in their legs and lungs tend to develop cancer more frequently,\" Choe noted.\nAnd, at least according to this retrospective review of medical records, this did indeed appear to be the case.\nExperts note that studies presented at scientific meetings do not face the same peer-review scrutiny as those published in reputable journals.\nRetrospective studies -- where researchers look back over previously collected data, looking for associations -- are not as reliable as prospective trials, however.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story does not quote any independent sources. ", "answer": 0}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nThe study tested 193 members of five different choirs.\nIn 2016, the RCM was ranked by The Guardian as the leading Higher Education Institution in the UK for studying music.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\nDiane Raybould, 64, took part in the study and has been singing with the Bridgend Sing with Us choir since 2010.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the non-profit Tenovus conducted the research, in collaboration with The Centre for Performance Science, which is a new partnership of the Royal College of Music and Imperial College London.", "answer": 1}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nBut, replacing insulin isn't easy.\nSeveral weeks later, the participants came back for another meal and switched overnight regimens.\nAlthough an accompanying journal editorial noted that the artificial pancreas is still \"in its infancy,\" some experts were cheered by the findings.\nThe second arm of the trial simulated a meal out.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources quoted in this story.", "answer": 0}, {"article": "Previous recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nThis study was funded by the Canadian Institutes for Health Research.\nThe researchers randomly assigned 1,186 children in 52 Hutterite colonies in Alberta and Saskatchewan, Canada to receive either the nasal spray vaccine or the flu shot and also followed 3,425 community members who did not receive a flu vaccine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify the chief funder of the study, the Canadian Institutes for Health Research, although it offers no information on possible conflicts of interest among any of the researchers. The abstract\u00a0of the study does state that two of the researchers do have links to pharmaceutical firms, but not in relation this study.", "answer": 1}, {"article": "However, yoga has been predominantly evaluated for breast cancer, and research on its role in alleviating prostate cancer patients' side effects has been lacking, largely due to the perception that men would not be willing to participate in this form of holistic exercise.\nThis trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\n\"This study represents one of many research projects we are conducting in an effort to pinpoint the best, most effective practices to help patients with these needs.\"\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nThese latter aspects may in turn improve erectile dysfunction and urinary incontinence, said Vapiwala.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes no mention of funding or possible conflicts of interest. It does say that the oral abstract was presented at the\u00a0Society of Integrative Oncology\u2019s 12th International Conference.", "answer": 0}, {"article": "Current ACS prostate screening cancer guidelines recommend that men make an informed decision with their doctor about whether to be tested for prostate cancer.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\n\"The velocity didn't add anything more to detecting aggressive prostate cancers.\"\n\"PSA velocity measurement is not useful,\" Brawley said.\nAs part of the trial, all of the men agreed to have a biopsy at the end of the trial, needed or not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent sources were quoted.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included a comment from the first author of the study from which the results were derived. There was no obvious attempt to get independent insight about the study results. A quote from a nutritional epidemioloigst not associated with the study would have given some perspective on the observations reported on in the story.", "answer": 0}, {"article": "More than 24 million people in the United States have diabetes, which is a main cause of kidney failure, heart disease, stroke, limb amputations and new-onset blindness.\nStudy participants, who still undergo physical screening twice a year, show benefits, even for those with a weight loss of only 5 pounds.\nThe study also concluded that participants who underwent positive lifestyle changes delayed type 2 diabetes by about four years, compared with the control group.\nElizabeth M. Venditti, assistant professor of psychiatry at University of Pittsburgh Medical Center's Western Psychiatric Institute and Clinic and director of the Lifestyle Resource Corps for DPPOS, said the study proves people can prevent or delay the onset of diabetes.\nThat was 10 years ago, when he joined the Diabetes Prevention Program Outcomes Study with the University of Pittsburgh Graduate School of Public Health, one of 27 institutions participating in the research.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter spoke only with two study participants\u2013an area man who was a subject and a researcher who headed local efforts.\nThe local researcher does offer properly moderated comments, casting the study as suggestive of benefits under certain conditions.\u00a0 \nThis is a good start for sourcing but insufficient. At minimum the reporter should have spoken with one disinterested diabetes or obesity clinician or epidemiologist who could help put the findings in context.", "answer": 0}, {"article": "The combination of ibuprofen and acetaminophen may represent an effective non-opioid alternative.\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\nWhy The Research Is Interesting: The United States is facing an opioid epidemic with almost 500,000 individuals dying from opioid overdoses since 2000.\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\n: Link will be live at the embargo time http://jamanetwork.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release says only that information about financial disclosures and funding are available in the JAMA article itself \u2014 which isn\u2019t very helpful. For the record, the study was funded (at least in part) by the National Institute on Aging, and there don\u2019t appear to be any conflicts of interest \u2014 but the news release could have said as much.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from a number of physicians involved in the treatment of liver disease and liver transplantation as well as quotes from two mothers of patients and one patient himself.\nThe story would have benefited from having a clinician who would have summarized the big picture for readers.\u00a0", "answer": 1}, {"article": "It\u2019s very apparent that he\u2019s dying.\u2019\u201d\n\nLandon began to refuse chemotherapy and turn into a \u201clittle psychopath,\u201d says Riddle.\nWhile cannabis is legal in many U.S. states, the drug is still classified by the Drug Enforcement Administration as a Schedule 1 narcotic (along with heroin and cocaine), which make it very difficult for scientists to conduct clinical trials on people.\nHowever, that may change as other nations, such as Israel, take the lead and fund marijuana research.\nAt the time, Colorado was one of only about a dozen states in the U.S. that had legalized medical cannabis.\nBut there\u2019s also an emerging body of research that suggests marijuana might be effective as a treatment for cancer on its own, or in conjunction with standard therapies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are quotes from multiple experts. Those who are proponents of cannabis oil treatment are identified as working for marijuana businesses.", "answer": 1}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nBut help could soon be at hand in the form of a nasal spray, new research suggests.\nThat uninterrupted sleep period extended to more than four hours, Kaminetsky said.\nThere's more on nocturia at the National Association for Continence.\nIn the United States there's no approved drug to treat the problem, the study authors said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An outside source was used in this story. We\u2019re also told that the was paid for by the drug company.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job providing multiple balanced perspectives on current trends in laser eye surgery. The story includes perspectives from ophthalmologist researchers, laser eye surgeons and patients who have had the procedures. ", "answer": 1}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nBut only 29 women fell into the \"never had a mammogram\" group.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nThe second group also included women who had never had a mammogram.\nThe women were separated into two groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the study author and an outside source.", "answer": 1}, {"article": "\"Everyone heals differently.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nMONDAY, Jan. 2, 2012 (HealthDay News) -- Spinal manipulation and home exercise are more effective at relieving neck pain in the long term than medications, according to new research.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain.\nResults of the study are published in the Jan. 3 issue of the Annals of Internal Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes quotes from multiple independent sources. It reports that funding for this trial was provided by \u201cU.S. National Center for Complementary and Alternative Medicine.\u201d It might have been helpful to point out that the center is part of the National Institutes of Health, so that it would be clear to readers that it is a public institution. Although the story does not report on any potential conflicts of interest on the part of the researchers, the article authors did not disclose any conflicts in their journal article.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No mention of sources' potential conflict of interest or sources of funding for this procedure. The cost may be free to the patients currently undergoing the transplantation, but someone is paying for the research and surgeons' efforts. ", "answer": 0}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nIn the first seven months on market, about four in five cardiologists and two in five primary care doctors had prescribed it to more than 250,000 people, Wa\u2019el Hashad, Boehringer\u2019s vice president for cardiovascular marketing, said in an interview last week.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentioned that the study reported on had been funded by the drug maker. \u00a0It included comments from a clinician who had no ties to the study reported on.", "answer": 1}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\n(Note: the site receives funding from Nestle Health Science, which is marketing low-FODMAP products).\nSince then, several studies have strengthened the case for the diet, says guideline co-author Brian Lacy, a professor of medicine and chief of gastroenterology at Dartmouth-Hitchcock Medical Center, Lebanon, N.H.\nBut few dietitians are trained in the diet, and insurers typically do not cover the visits, Lacy notes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "William Chey, a professor of gastroenterology,\u00a0is listed as a consultant to Nestle on one of the studies.\u00a0Nestle Health Science markets low-FODMAP products. Also, another source, dietitian Kate Scarlata, has a forthcoming book on FODMAP. We think both of these details should have been in the story.\nWe were\u00a0glad to see that the story does note that the University of Michigan\u2019s website for low-FODMAP diet resources, which is referenced in the article, receives funding from Nestle Health Science.", "answer": 0}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotations in the story, only reporting on what appeared in the journal Menopause.\u00a0 There are no comments from independent sources and also no mention of conflicts of interest.", "answer": 0}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nAll had low levels of physical functioning at the start and reported fewer than 20 minutes per week of regular physical activity in the month prior to starting the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is clear that the research was supported by the National Institutes of Health.\nWhile some of the researchers disclosed pharma funding in the published study, that funding wasn\u2019t relevant to this research and we agree with the decision not to include it in the release.", "answer": 1}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nThe National Heart, Lung and Blood Institute, which funded the study with new \"stimulus\" money from the American Recovery and Reinvestment Act, is more bullish on the implications.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nWell, the study's lead author tells Shots that it might be enough to \"tip the balance a little bit, but not overwhelmingly so.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Dr. Laura Mauri, who wrote\u00a0an accompanying editorial, has a few words of caution about patients switching from stents to open-heart surgery. And the story nicely points out that \u201cMauri is an interventional cardiologist \u2013 i.e., a specialist who does coronary stenting \u2013 at Brigham and Women\u2019s Hospital in Boston.\u201d That doesn\u2019t mean that Mauri would recommend stents against the evidence, but it helps readers understand her perspective.", "answer": 1}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nThe study was funded by Pfizer Inc and the National Institutes of Health (5P30 CA16520-25).\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\n\"This drug has minor effects on normal cells other than neutrophils (white blood cells),\" said the study's senior author, Peter J. O'Dwyer, MD, a professor of Hematology/Oncology at Penn and director of the Developmental Therapeutics Program at the ACC.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that Pfizer and the National Institutes of Health funded the review.", "answer": 1}, {"article": "\"It's still new and it's quite different than previous genetic testing that's been available,\" says Norton.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\nThis can reveal if there's an increased risk of certain disorders, but it's not very accurate and produces a lot of false alarms.\nFor example, here's one thing that might turn out to be a little more complicated than would-be parents might expect.\nBut she had recently moved to Alabama, and the clinic she went to there wasn't as familiar with it \u2014 although when she talked to her doctor, she learned the clinic had just had a visit from a company's sales representative.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story sought out several expert sources for their opinions about the testing, and it appropriately noted that one of these sources (Dr. Lee Shulman) is a consultant to firms selling the new screening tests. However, it failed to note that another of these expert sources (Dr. Diana Bianchi) was also a paid consultant to a testing company. In addition, it didn\u2019t caution readers that the study the story links to was paid for by a testing company.", "answer": 0}, {"article": "\"The ability to provide this kind of therapy to Americans can be life changing,\" said Dr. Comella.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\nResults are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.\nThe healed tear could not be penetrated by the probe.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While it isn\u2019t explicitly stated, readers probably assume that this research was funded by US Stem Cell, Inc. The lead investigator is identified as the company\u2019s chief science officer, so her potential conflict is clear.\u00a0 There is no additional information offered on the remaining two investigators.", "answer": 2}, {"article": "Several companies do not sell tests in China or India, where boys are prized over girls and fetuses found to be female have been aborted.\nThe study \u201chas wide-reaching implications,\u201d said Dr. Louise Wilkins-Haug, director for maternal-fetal medicine and reproductive genetics at Brigham and Women\u2019s Hospital in Boston, who was not involved in the research.\nRebecca Griffin, a founder of the biggest seller, Intelligender, said two independent studies found it 90 percent accurate at 10 weeks.\nLawyers for Acu-Gen could not be reached for comment.\nIt also helped her plan, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted four sources, in addition to the study\u2019s lead author.", "answer": 1}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nThe drug was also granted a priority review.\nNo drug in this class is approved to treat patients with dementia-related psychosis.\nNuplazid was granted for the treatment of hallucinations and delusions associated with Parkinson\u2019s disease.\nThe effectiveness of Nuplazid was shown in a six-week clinical trial of 199 participants.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release\u00a0tells us Nuplazid is marketed and funded by Acadia Pharmaceuticals.", "answer": 1}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\nThis cancer trap can be used for early diagnosis and treatment of metastasized cancer.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cWe are putting biological agents in a cancer trap to attract and kill cancer cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While the release does mention the institution\u2019s overall level of funding for cancer research, it does not say where any of that funding came from \u2014 much less who funded the \u201ccancer trap\u201d research. Federal agencies? The private sector? Nonprofit organizations?", "answer": 0}, {"article": "Scientists hypothesize that the electrical currents may disrupt bacteria in two ways: by interrupting the production of chemical messages that instruct bacteria to develop biofilms and by weakening the molecular structure of existing biofilms, potentially making them more susceptible to antibiotics or the body\u2019s natural immune response.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nMade of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury.\nThe content of this release is solely the responsibility of the CCTS and does not necessarily represent the official views of the NIH.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release identifies the funder of this work as the National Institute of Health, and notes that \u201cthe team already has interest from several industry partners.\u201d", "answer": 1}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\n\"Some patients have now been treated for up to a year, and the effect is as good as it was at the beginning,\" Dandona said at a news conference webcast from Boston.\n\"Over a protracted period of time, as their diabetes continues to be well controlled, there is delightful improvement in patients' well-being.\"\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\n\"It is a dramatic change.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notifies readers that this study was conducted without drug company support, but that a corporate-funded trial is in the works. The story could also have notified readers that the lead researcher, Dr. Dandona, disclosed numerous relationships with pharmaceutical companies in the abstract for this study \u2014 although none with Victoza manufacturer Novo Nordisk.\nThe story fell short of the bar when it failed to obtain feedback from an expert who wasn\u2019t involved with the research. Context is everything, and even hearing from a practicing diabetes expert would have been helpful.", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nA separate clinical trial, now getting underway, will examine whether anti-VEGF injections given at an earlier stage of diabetic eye disease can help prevent people from developing both DME and the sight-threatening PDR stage of the disease at all, Dr. Aiello said.\nFunded by the National Eye Institute (NEI) and conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), the trial compared Lucentis injections with a type of laser therapy called panretinal photocoagulation, which has remained the gold standard for PDR since the mid-1970s.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\n\u201cLucentis should be considered a viable treatment option for people with PDR, especially for individuals needing anti-VEGF for DME,\u201d said Jeffrey G. Gross, M.D., of the Carolina Retina Center in Columbia, South Carolina, who chaired the clinical study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does tell readers that the study was funded by the National Eye Institute. However, it does not make clear that Lloyd Paul Aiello \u2014 who is quoted in the release \u2014 was also a co-author of the journal article. The release also fails to mention that several co-authors receive research funding or consulting fees from Genentech, which developed ranibizumab and markets it in the U.S., and Novartis, which markets the drug outside the U.S.", "answer": 0}, {"article": "To learn more about breast cancer, including HER2-positive cancers, visit the American Cancer Society.\nThose given Tykerb alone had a 25 percent response.\nThe study was published online Jan. 17 in The Lancet.\nGlaxoSmithKline, the maker of Tykerb, helped fund the study.\nThe study was funded by drug makers GlaxoSmithKline, Roche and Sanofi-Aventis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source quoted.\u00a0 Drug company funding of the study was noted.\n\u00a0", "answer": 1}, {"article": "\"We're trying to make it simpler, but we don't want to lose the efficacy,\" he said.\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\nBredesen said that to simplify the program, they are connecting patients with health coaches.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nOne expert, Dr. Dale Bredesen, a professor at the Buck Institute for Research on Aging and a professor at the Easton Laboratories for Neurodegenerative Disease Research at UCLA, thinks he might have found a way to reverse memory loss, a hallmark of the disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include an independent source, Florida Atlantic University professor James E. Galvin, M.D., M.P.H., who\u2019s quoting saying that personalized approaches are promising, but more study is needed. \u201cNot all things from the (MEND) approach have a lot of scientific support behind them,\u201d he says in the story.\nBut, the story does not describe funding sources, which include the National Institutes of Health (NIH) and the Accelerate Fund, an early-stage investment fund based in Canada. As we reported in our earlier news release review, lead researcher Bredesen also apparently stands to benefit from sales of a book set to be released in May 2017 through a mainstream book publisher.", "answer": 0}, {"article": "It's best to move cautiously, agreed Dr. Robert M. Califf, vice chancellor for clinical research at Duke University.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nAnd though statins are widely used and most often successful, an alternative to them would be welcome, Ladenson said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nAt best, results would not be available for \"at least two to three years,\" Angelin said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Important caveats were included in the independent expert\u2019s views at the end of the story. ", "answer": 1}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\n\u201cReplacing the aortic valve improves functional capacity,\u201d Kapadia, who wasn\u2019t involved in the study, said by email.\n\u201cThese symptoms lead to reduced functional capacity (inability to perform physical exertion) and also impact a patient\u2019s overall sense of wellbeing and quality of life,\u201d Cohen, who wasn\u2019t involved in the study, said by email.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts who weren\u2019t involved in the analysis, which is good. However, both have received payments from companies that make heart valves, according to CMS\u2019 Open Payments search tool. Those connections were not disclosed in the story.", "answer": 0}, {"article": "Some see Qnexa as a test of the FDA trying to recalibrate how it weighs risks and benefits for weight-loss drugs.\nShe had tried everything.\nShe quickly noticed a big difference.\n\"The sheer magnitude of the problem really requires us to address it more aggressively and thoughtfully than we have.\"\nThe company is submitting new data it says show that the risk is lower than had been feared.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were cited.", "answer": 1}, {"article": "Atopic dermatitis is the most common of the many types of eczema; onset typically begins in childhood and can last through adulthood.\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\n\u201cFDA\u2019s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nScratching leads to swelling, cracking, \u201cweeping\u201d clear fluid, and finally, coarsening and thickening of the skin.\nThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention of who funded the research leading to the FDA approval, although many readers will assume it was supported by the manufacturer Regeneron.", "answer": 0}, {"article": ".\nThe research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD (using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development).\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nResearchers stopped enrolling new participants in the study in 2011 due to the rate of adverse events, particularly depression and other mood disorders, reported by the participants.\nSerious adverse events that were assessed as probably or possibly related to the study included one case of depression, one intentional overdose of acetaminophen, and a man who experienced an abnormally fast and irregular heartbeat after he stopped receiving the injections.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD, using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development. It also states that the hormones were provided by drugmaker Schering, which has since merged with Bayer.", "answer": 1}, {"article": "Eat as you dare.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nAccording to Stewart, the meaning behind the numbers is clear.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story would have been stronger if it had included analysis from at least one independent source who had no connection to this study. Especially considering that many of the study\u2019s authors, including the source who was indirectly quoted in the story, received support from a variety of pharmaceutical companies, including GlaxoSmithKline, which is mentioned in this story.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The companies responsible for developing and marketing these two tests are front and center in this story, with scientists affiliated with the companies clearly identified. At least two sources in the story\u2014one of them a scientist affiliated with the National Comprehensive Cancer Network\u2014appear to be independent of the companies.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no independent medical expert interviewed for the story.\u00a0 The story also quoted the same patient we saw profiled in other stories.\u00a0 Did the drug company provide access to her for all who quoted her?", "answer": 0}, {"article": "Patients who had lumpectomy plus radiation had more local recurrences than the mastectomy patients but had fewer deaths.\nWho and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nStudy Limitations: Some data were missing; investigators didn't have information on tamoxifen use; treatments in the study population weren't randomly assigned; and the possibility remains that the decision to undergo radiotherapy was associated with other favorable prognostic factors.\nAuthors: Steven A. Narod, M.D., of Women's College Research Institute, in Ontario, Canada, and co-authors\n\nResults: A small improvement in breast cancer survival was associated with radiation plus lumpectomy for DCIS.\nTo Learn More: The full study is available on the For The Media website.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The style of this news release was to punt the question of funders and \u201cconflicts\u201d into a web link where the reader has to chase it down. It would better serve readers to have funders and any conflicts of interest spelled out in the release.\nHere is what the release states:\nEditor\u2019s Note:\u00a0The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nThe study notes that researchers received funding from Canadian government agencies.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two clinicians, both of whom are authors on the current study. The story should have quoted other clinicians who are not affiliated with the study who could have provided some perspective.", "answer": 0}, {"article": "When the heart beats, it generates a waveform, and with a healthy heart and vasculature there are fewer and smaller waves.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\n\"It significantly and rapidly reduced stiffness,\" Raed says.\nTwo thousand IUs decreased stiffness by 2 percent in that timeframe.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention any particular funding source.", "answer": 0}, {"article": "Another difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nI should tell you that the new vaccine is not exactly a walk in the park.\nWhat makes Shingrix so much better is the inclusion of a substance called an adjuvant that boosts the body\u2019s immune response to the vaccine.\nBut for about 15 percent of people, shingles does not end there.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Study funding is not mentioned. Perhaps more importantly, the story takes an advocacy position in favor of vaccination\u2013and presents the reporter\u2019s opinion as medical advice.", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes important backstopping from an independent source. We did not detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nWhile the company has done studies of women taking the drug up to a year, some experts believe the long-term health profile of a drug needs to be evaluated up to seven years, Dr. Jacoby says.\nThe company expects a decision by May.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\nDr. Al-Hendy says the changes to the endometrium don\u2019t raise the risk of endometrial cancer, which some have raised as a concern.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes one outside expert whose comments focused on the use of an injectable alternative to the oral drug, and the downsides of this alternative. But it also has a comment from Allergan\u2019s researcher noting that longer-time follow up is needed for UA. These source\u2019s commercial relationships are appropriately disclosed.\n[Editor\u2019s note: Following publication of this review, we learned that Allergan provides financial support to the White Dress Project. The story would have done well to acknowledge this relationship.]", "answer": 1}, {"article": "A portable device common in optometrists' offices may hold the key to faster diagnosis of schizophrenia, predicting relapse and symptom severity and assessing treatment effectiveness, a Rutgers University study finds.\nIn the just-published study, the researchers evaluated 50 participants: 25 with schizophrenia and 25 with no diagnosed psychiatric disorder.\nAlthough we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\nThe participants were tested in normal light and after sitting in the dark for 10 minutes to assess activity in different types of retinal cells.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release did not mention who funded this study, and it which wasn\u2019t mentioned in the study itself, as far as we could tell. The release also didn\u2019t mention that one of the authors is employed by LKC Technologies, which makes these devices.", "answer": 0}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\nSome other experts in the field saw great promise in the research.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We were pleased to see multiple independent sources interviewed for this story. Seeking out multiple viewpoints can often surface new details about the illness or field of study, and place it in the context of wider research efforts and the typical patient experience.", "answer": 1}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nAdd to that the aggressive public awareness campaign for colonoscopy screening led by celebrities like Katie Couric, who allowed TV cameras in as she got her first test, and it\u2019s clear why more people are familiar with the scope than with its virtual cousin.\nGiven the fact that more hospitals are offering virtual colonoscopy, it\u2019s worth discussing with your doctor.\nIn the end, it\u2019s a matter of personal preference \u2014 it\u2019s less important how you get screened, just that you do get screened.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes only one expert in the story \u2013 a director of a CT center.\nWhile the story discusses what unnamed skeptics say, we should have heard from some directly to balance the story.", "answer": 0}, {"article": "This direct antiviral approach has been used with great success in treating H.I.V.\nThat is seen as essentially a cure.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nBut analysts expect the drug to cost tens of thousands of dollars for a course of treatment.\nIt is not quite clear how those drugs work.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We would have liked to have seen independent voices inject more context into the story, but the reporter did at a minimum take these results to another legitimate researcher. The reporter also went to a patient advocacy group that, unfortunately, just spat out the standard \"we welcome any cure\" spiel.", "answer": 1}, {"article": "Reavill says he may be proudest of his intention to hire disabled veterans in southern Illinois, a hard-hit region economically.\nHe recently procured a bank loan agreement and is hoping the award recognition and hospitals' willingness to try the catheter will attract a venture capitalist.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nIt remains to be seen whether that saved time will result in saved lives.\nReavill likes to say it's \"stupidly simple\" because the individual parts have been around for decades, but no one had thought of this particular configuration before.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story at least turns to two physicians who are considering use of the catheter at their hospitals.", "answer": 1}, {"article": "It is for use only in those aged 12 or more, the F.D.A.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from two sources at the FDA, but the information appears to stem from an FDA statement. Information from pharmaceutical companies is clearly marked, but we really look for news stories to incorporate input from independent sources \u2014 beyond what may be available in a news release.", "answer": 0}, {"article": "You're fighting depression and you're wondering, 'Is an era of your life over?'\nIn the past, many doctors assumed implants would wear out in about 10 or 15 years, and they urged young patients to put off surgery as long as possible to minimize the risk of needing a costly and difficult revision surgery\u2014or even two.\nStill, there are no long-term data on how any of the latest implants will fare in actual patients.\nLast year, one manufacturer, Smith & Nephew , won clearance from the Food and Drug Administration to market its latest technology as a \"30-year knee\" based on tests mimicking 30 years of wear.\nSeveral studies of hips and knees implanted in patients long ago have found that 85% to 90% are still functioning well after 20 years.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included comments from several independent sources. It was not clear, however, whether any of the expert sources had conflicts of interest with implant manufacturers. Information on financial conflicts would have aided in the interpretation of their comments. Though several of the experts made comments that were intended to curb the enthusiasm expressed by the patients, it would have been helpful to know whether any of the physicians receive payments from device manufacturers\u2014given the widespread conflicts-of-interest that have affected this field in recent years.\n\n \n", "answer": 0}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\nAlthough some objective measures of spasticity noted improvement trends, there were no changes found to be significant in post-treatment assessments.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A HealthDay story reported: \nBut this WebMD story included no independent perspective \u2013 a major shortcoming. ", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Cites a lead researcher from the trial and the National Heart, Lung, and Blood Institute. Missing the perspective of an independent expert without ties to the study. ", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\nThe FDA granted the approval of Rydapt to Novartis Pharmaceuticals Corporation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the research leading to the approval, although some readers might be able to guess that Novartis Pharmaceuticals, the manufacturer of Rydapt, and Invivoscribe Technologies, the makers of the LeukoStrat CDx FLT3 Mutation Assay, sponsored the trials since the approval was given to them.", "answer": 0}, {"article": "Food sources of vitamin D include milk, breakfast cereals and orange juice fortified with vitamin D, as well as some fatty fish, like salmon and mackerel.\n\u201cHowever,\u201d the researcher said, \u201cthere is a lack of clinical studies of the effect of vitamin D supplementation for preventing respiratory infections.\u201d\n\nFor the current study, Laaksi\u2019s team randomly assigned 164 male military recruits to take either 400 international units (IU) of vitamin D or inactive placebo pills every day for six months \u2014 from October to March, covering the months when people\u2019s vitamin D stores typically decline and when respiratory infections typically peak.\nThe findings, Laaksi said, offer \u201csome evidence\u201d of a benefit from vitamin D against respiratory infections.\nSome past research has indeed found that people with relatively lower vitamin D levels in their blood tend to have higher rates of respiratory infections than those with higher levels of the vitamin, said Dr. Ilkka Laaksi of the University of Tampere in Finland, the lead researcher on the new study.\nAlong with that evidence, recent lab research has shown that vitamin D may play an \u201cimportant role\u201d in the body\u2019s immune defenses against respiratory pathogens, Laaksi wrote in an email to Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nAlthough this story refers to the findings of other studies and the recommendations of health agencies and experts, there is no identified independent source to comment on the trial.\n In their journal article, the researchers reported no potential conflicts of interest. It would have been helpful to tell readers that the trial was funded by the Medical Research Fund of Finnish Defence Forces, in order to distinguish this trial from studies funded by supplement manufacturers or others with a vested interest in the results.", "answer": 0}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nShe noted that strawberries have also shown benefits in past studies looking at the effect of food on cognitive function.\n(MIND stands for Mediterranean-DASH Intervention for Neurodegenerative Delay.)\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\n\"People who eat this diet consistently over the years get the best protection,\" said lead author Martha Clare Morris.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appear to be no independent sources used in this story.\u00a0 The paper indicates that there is no conflict of interest for the authors, so no mention of conflict is acceptable. A comment by an expert not affiliated with the study would have provided context.", "answer": 0}, {"article": "But vitamin D can reinforce it and prevent illnesses like pneumonia, influenza and bronchitis.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\nThe study co-authors include Patrick Blatchford, PhD, Keith Breese, MA, Lida Zarrabi, MPH, Sunny Linnebur, PharmD, Jeffrey Wallace, MD, MPH and Robert Schwartz, MD.\n\"After studying these patients for a year, we found a 40 percent reduction in acute respiratory illness among those who took higher doses of vitamin D,\" said the study's lead author, Adit Ginde, MD, MPH, professor of emergency medicine at the University of Colorado School of Medicine.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not make any mention of funding sources. The published study lists government agencies, including the Veterans Administration, as sponsors.\u00a0\u00a0  ", "answer": 0}, {"article": "In the cognitive behavioral therapy, participants were asked to identify positive activities they used to engage in and then are asked to actively plan those activities again.\nIt's also not clear if this kind of program could be scaled up.\nStill, Buntrock seems pleased with the results, especially since the German insurance company BARMER GEK that sponsored the trial is now providing it to its customers.\n\"And of course, I'm surprised about what happens now; that a health insurance company offers the intervention to its members.\n\"I was surprised by the big response to our study,\" Buntrock wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does tell readers who funded the work, which is great. However, the only source quoted in the article is the lead author of the relevant study. An independent expert opinion would have been extremely valuable.", "answer": 0}, {"article": "For more information on biopsies, visit the U.S. National Library of Medicine.\n\"Doing image-guided biopsy allows more definitive diagnosis and shorter hospital stays,\" said Dr. Robert Quencer, chair of radiology at the University of Miami Miller School of Medicine, who was not involved on the study.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nMoreover, by 2008, 67 percent of these biopsies were being done through the skin with the help of CT scans, ultrasound and MRI, Kwan's group found.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert was quoted, although not to provide any data-driven evidence.\u00a0 And his quote, \"I doubt there is variation to this in any major medical center\" begs verification. ", "answer": 1}, {"article": "Airways became less likely to close off after exposure to an allergen.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nBlood tests showed that Gleevec did reduce mast cell activity in patients, Israel said.\nThe study was published May 18 in the New England Journal of Medicine.\nPeople whose severe asthma isn't controlled despite use of high-dose steroid medications are at risk of declining lung function and poor quality of life, the researchers said in background notes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that the study\u2019s senior researcher,\u00a0Dr. Elliot Israel, has worked as a consultant for Novartis, which makes Gleevec. It also didn\u2019t mention who funded the study. In this case, it was primarily the National Institutes of Health.", "answer": 0}, {"article": "Research has shown that our unhealthy eating habits and sedentary lifestyles are playing a major role in the development of lifestyle-related metabolic diseases such as diabetes, heart disease and obesity.\nThe research team was led by Hoon-Ki Sung of The Hospital for Sick Children in Ontario, Canada.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nThe recurring regimen saw the animals being fed for two days, followed by one day without anything to eat.\nTheir calorie intake was not adjusted otherwise.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The research was funded by a variety of grants which were listed in the sidebar of the EurekAlert! site, but not in the news release text. The authors declared in the journal article that they had no conflicts of interest.", "answer": 1}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\n\"It adds another brick in the wall that suggests there may be an opportunity to develop treatment for one of the core symptoms of autism.\n\"We need to be mindful of the fact that the majority of human studies of oxytocin have been conducted using adults, including this study, and only one paper has included individuals between the ages of 12 and 18.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nBut Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does use several independent sources apart from the study authors. The study authors themselves declared no conflicts of interest. \nWe welcomed the balanced addition of Clara Lanjonchere\u2019s cautionary note\u00a0in the last paragraph. It provides balance to the story, offsetting the enthusiasm expressed by other sources.\u00a0", "answer": 1}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\nFor another, the formulations used were less safe in their dosage, mix of hormones and delivery method (pills, which travel through the liver and can cause clots).\nJohnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested pharmaceutical bio-identical hormones that are made by drug companies and approved by the Food and Drug Administration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was clear imbalance in the story. The article only presents quotes from two doctors who were supportive of HRT. It also failed to identify sources for some of the claims in the article.", "answer": 0}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nAll used the product for three months, for a total of 23,000 doses.\nAt the meeting, Sharlip presented the pooled results of two pivotal studies of PSD502 involving 530 men with premature ejaculation.\nThe rest of the men used a placebo spray.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One researcher\u2019s financial links to the drug company were disclosed.\u00a0 One independent expert was interviewed. ", "answer": 1}, {"article": "Philadelphia, PA, June 2, 2016 - Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nConsequently, there is no consensus in international BCC guidelines on the first choice of noninvasive therapy for superficial BCC.\nElsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention funding sources.", "answer": 0}, {"article": "Dieters who go vegetarian not only lose weight more effectively than those on conventional low-calorie diets but also improve their metabolism by reducing muscle fat, a new study published in the Journal of the American College of Nutrition has found.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nBoth diets were restricted by 500 kilocalories per day compared to an isocaloric intake for each individual.\nSeventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not discuss the funding source for the research. However, the organization that the\u00a0researchers are representing is the Physicians Committee for Responsible Medicine, a group that is a proponent of vegetarian and vegan diets and of dietary management of diseases (where appropriate).", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly notes relevant conflicts of interest and is very well-sourced for a story of this length, quoting authors of both studies as well as two independent sources. If those independent sources had been asked about the studies, and not just the products, the story would have been stronger.", "answer": 1}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nDr. Roy Davidovitch, director of NYU Langone's Hip Center, said he performs around 400 hip replacements a year and approximately 40 percent of those patients will go home the same day.\nNYU Langone Medical Center said it became the first academic medical center in New York City to implement a same-day hip replacement program, in 2015.\nHe said his department performs the most hip replacements of any institution in the U.S., doing about 5,000 a year.\nHowever, not every surgeon is embracing the same-day trend.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story does include a surgeon who is skeptical of the benefits of \u201csame-day\u201d hip replacements. However, as noted above, the surgeon advocating the \u201csame-day\u201d procedure is featured far more prominently, likely creating an imbalance in reader perceptions. But the main reason for marking down the story on this criterion is that it fails to tell readers that NYU Langone has a marketing campaign tied to \u201csame-day\u201d hip surgery. The result is that the story supports the promotional efforts of the hospital and its surgeons without alerting readers to the commercial aspects of the matter.\nThe hospital tweeted an image of an earlier story on \u201csame-day\u201d hip replacement, indicating the marketing department understands the value of friendly coverage. HealthNewsReview.org also reviewed that Wall Street Journal story.", "answer": 0}, {"article": "\u201cWhy would we?\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\n\u201cIf you do something to a shoe, different people will react differently.\u201d\n\nThe next problem is that there may be little agreement among orthotics makers about what sort of insert to prescribe.\n\u201cBut choosing the right one requires a great deal of care.\u201d\n\nYet Scott D. Cummings, president of the American Academy of Orthotists and Prosthetists, says the trade is only now moving toward becoming a science.\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article did present the views of several independent sources. However, the article did not address or identify potential financial conflicts among the contributors beyond identifying their organizations or institutions. Both biomechanical research and footwear research rely heavily on industry funding, which may skew the views of researchers. So this is an important issue. And we can\u2019t give a satisfactory score for half a loaf.\n\n \n", "answer": 0}, {"article": "Soon after Zane relapsed, he and his father bumped into friends in a local doughnut shop who told them about a TV segment on CAR T-cell therapy.\nHer mother added, \u201cWe just need this to work and to stay working.\u201d\n\nNCI\u2019s Fry is careful not to make any promises about an extended remission.\nIt is also far from clear that such a personalized approach \u2014 possibly costing hundreds of thousands of dollars \u2014 is economically viable on a large scale or will produce the lasting remissions that everyone hopes to see.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\nBut the leukemia was still producing another common protein, called CD22, and that offered an opportunity.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a tricky one. There are multiple sources in the article who speak to the research itself, and most of them are clearly identified as being involved with the research in some way. There appears to be at least one expert source who is not affiliated with any of the clinical trials, but that is inferred, rather than explicitly stated. What makes this tricky is that the story discusses multiple trials, without clearly identifying most of them. That makes it difficult to provide a judgment call here. When it\u2019s a toss-up, we try to err on the side of the story, so we\u2019ll give this a Satisfactory.", "answer": 1}, {"article": "Excluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\nThe U.S. Physicians Health Study II included nearly 50,000 male doctors aged 50 and older and spanned more than 10 years.\n\u201cThis is indeed a landmark study,\u201d said Cory Abate-Shen, a professor of urological oncology at Columbia University Medical Center who was not involved in the trial.\nParticipants were randomly assigned to a multivitamin - Pfizer Inc\u2019s Centrum Silver - or a placebo.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from two experts not involved\u00a0with the research, but its explanation of the funding was not quite as thorough as the competing AP piece. Reuters says that the study was sponsored by NIH, which is true, but it didn\u2019t note that Pfizer supplied\u00a0its Centrum multivitamin free of charge. Since we\u2019re talking about 15,000 men taking pills for 10 years, that\u2019s more than pocket change\u2013and worth pointing out to readers.\nThis is a grey area. Explicitly pointing out the role Pfizer played in the study is important for readers to know.", "answer": 0}, {"article": "Lowering A1C levels helps reduce the risk of long-term complications from diabetes such as eye, kidney and heart disease.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\n* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\n(Reporting by Susan Kelly, editing by Dave Zimmerman)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nNot only does this story lack an independent source, it makes no mention of the ties between the researchers and manufacturers of insulin pumps and blood glucose sensors. Indeed, the disclosure summary included in the New England Journal of Medicine is 30 percent longer than the news report about the study. The story does note that the trial was sponsored by Medtronic, which manufactures the pump used by researchers.(Disclosures are summarized at the end of the article posted online at: http://content.nejm.org/cgi/content/full/NEJMoa1002853Disclosure statements provided by each auther are available at: http://content.nejm.org/cgi/content/full/NEJMoa1002853/DC3 ", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There do not appear to be any conflicts of interest. However, this story did not include independent sources.", "answer": 0}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nThe study\u2019s lead investigator, Rebecca Kristeleit, defended the performance of rucaparib, adding that one can\u2019t compare Clovis\u2019s drug to Tesaro\u2019s: \u201cIt\u2019s a completely different population, and a different use of the drugs,\u201d she said.\nA few weeks ago, the Food and Drug Administration granted Tesaro\u2019s drug fast-track approval status \u2014 and this new data will support its registration applications to both the FDA and the European Medicines Agency, Tesaro CEO Lonnie Moulder said.\nThe results were published this weekend in the New England Journal of Medicine.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes commentary from a researcher from the National Cancer Institute who has studied the currently available drug, Lynparza. That\u2019s good. However, the story does not adequately disclose the affiliations of an investigator focused on another drug (Dr. Kristeleit) whose consulting and advisory roles with Clovis and several of drug companies were not made clear.", "answer": 0}, {"article": "\"Our body knows best.\"\nResults of the study were published today (Dec. 17, 2018) in the journal Nature Communications.\nUW-Madison radiology professor Weibo Cai is also a senior author on the study.\nThis research was supported by grants from the National Institutes of Health (R01EB021336 and P30CA014520).\nThat ongoing maintenance can be a big barrier to use, says Luke Funk, a surgery professor in UW-Madison's Division of Minimally Invasive, Foregut and Bariatric Surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that funding was provided by grants from the National Institutes of Health. It\u2019s noteworthy that the journal article reporting the trial results states the authors declared no competing interests. However, the release discloses that the researchers patented the device. This is a glimpse at the varying and incomplete ways in which conflicts of interest are (or are not) reported in journals and in downstream news coverage.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Included in the story is a quote from vaccine expert Dr. Paul A. Offit, and we detected no potential conflicts of interest.", "answer": 1}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\n\u201cIt will be important to let patients know that fertility will have declined greatly in the years preceding the final ovulation.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story briefly quotes one source other than the study\u2019s lead author.\u00a0 ", "answer": 1}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nSeveral independent researchers said the study results were promising.\nYee's team tried to do this more precisely.\nThe immunotherapy allowed him to return to work three weeks after treatments began.\nBut Yee bet that the extra effort would pay off with better results and fewer side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were quoted.", "answer": 1}, {"article": "\"It's just a matter of time.\"\nThe National Association of Dental Plans couldn't give a definitive answer about coverage, but calls to some individual carriers and dental offices suggest it depends entirely on the type of plan you have.\nHe says part of what's making fluoride treatments popular for adults is a move to make dental care personal, with an individual treatment plan for each patient.\nAt this point, Featherstone says, two-thirds of dental schools in the U.S. teach some kind of disease management model based on a thorough risk assessment.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes a number of sources discussing this trend in dentistry, instead of just relying on one dentist.\nBut the piece would be more balanced had it included at least one source pointing out that some of the techniques advocated in the story could be overkill or wasteful for many people who are at just average risk for tooth decay. As the piece was written, all the sources are very rosy about more aggressive preventive dental care.\u00a0We also found via an internet search that source\u00a0John Featherstone\u00a0has accepted consultation fees from dental companies that make products for these purposes. However, since he wasn\u2019t specifically endorsing one of these products\u00a0in this story,\u00a0we\u2019ll\u00a0give this a pass.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter clearly read a lot about the problem and the potential treatments and does a fairly good job synthesizing this information. The story makes it clear that the two outside sources were not involved in this research. It is unclear whether these doctors are involved in any competing research or research into a similar product.", "answer": 1}, {"article": "HIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\nThe article recently appeared in the Journal of Controlled Release.\nThe implants were tested in an animal model and the team observed a significant reduction in T cell activation, meaning that the vaginal tract was demonstrating an immune quiescent state.\nThey later found the women possessed T cells that were naturally immune quiescent.\n\"We know that some drugs taken orally never make it to the vaginal tract, so this implant could provide a more reliable way to encourage T cells not to respond to infection and therefore more reliably and cheaply prevent transmission,\" said Emmanuel Ho, a professor in the School of Pharmacy at Waterloo.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention funding sources.\nThe published study does not include any disclosures of financial conflicts of interest by the authors.", "answer": 0}, {"article": "Studies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nThe other groups showed no significant change.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\nThe study was small, involving 50 men and women ages 50 to 72 who ranged from normal weight to overweight.\nThen they took tests involving memorizing words.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed one of the study researchers, a lead researcher in a related study and one independent expert. \n\u00a0", "answer": 1}, {"article": "J Natl Cancer Inst.\nThis study brought together the principal investigators from the groundbreaking 2014 study on 3D MAMMOGRAPHY\u2122 exams, also published in JAMA, this time led by Elizabeth Rafferty, MD, a co-author on the prior study.3 A total of 452,320 examinations (278,906 conventional mammograms compared to 173,414 Genius\u2122 3D MAMMOGRAPHY\u2122 exams), were analyzed.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nThere can be no assurance the systems will achieve the benefits described here, or that such benefits will be replicated in any particular manner with respect to an individual patient.\n\"Density creates challenges for conventional mammography by obscuring the images, which often results in additional visits and exams for women,\" said Edward Evantash, MD, board certified OB/GYN and Medical Director for Hologic.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release is distributed by the company that makes the 3D mammography so we can assume it played a role in funding the study. What\u2019s troubling is that the release gives no mention of potential conflicts of interest \u2014 or the absence of conflict \u2014 among the many investigators involved with the study. The published research notes that none of the researchers reported a potential conflict but that five of the researchers received research grant funding from Hologic. Also concerning is a note included with the disclosure section of the study: \u201cThe study contracts and data sharing agreements specified that Hologic had the right to review all publications prior to submission, but could not mandate any revision of the manuscript or prevent submission for publication.\u201d\nAt bare minimum the release should have noted that at least some of the researchers received grant funding from the manufacturer.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\n\"The simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\"\nThe researchers looked at data from 54,762 women in the Nurses' Health Study, which tracked women for over 30 years.\nThe sample only included women, so these results may not be generalizable to men.\nThis research was supported in part by the California Walnut Commission (CWC).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release discloses that the study was funded in part by the California Walnut Commission. However, it should also have mentioned that funding for the 30-year Nurses Health Study came from the National Institutes of Health and that one researcher involved in the study has received a grant from the International Nut and Dried Fruit Council to study nuts and cognitive function in aging.", "answer": 0}, {"article": "Unlike some other organs in the body, such as the liver or skin, the brain does not regenerate new connections, blood vessels or new tissue structures.\nThe study was supported by funds from the National Institutes of Health.\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\nCarmichael and Segura collaborated on the study.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding is listed as from the NIH. The authors stated they had no financial conflicts of interest.", "answer": 1}, {"article": "This compared with 1.9 percent using mitoxantrone.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\n\u201cThe development of cabazitaxel is one of many investigational compounds we hope to present to the cancer community in the months and years to come,\u201d Debasish Roychowdhury, Sanofi\u2019s oncology senior vice president, said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources were quoted to evaluate the claims made by the drug company. ", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The report cites three sources and their credentials, but mentions a potential conflict of interest for only the lead author, who received funding from Hershey and the CDC. It is impossible to judge the independence of the other sources. Nonethless, we'll give the story the benefit of the doubt. ", "answer": 1}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nParticipants were also followed up after 20 years, by which point 1,634 of the original participants had died as a direct result of cancer.\nThe study is by Peter Rothwell, MD, PhD, FRCP, of John Radcliffe Hospital in Oxford, England, and colleagues, and has been published online by the journal the Lancet.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two outside experts to good effect. One of them, Dr.\u00a0Peter Elwood, \u201can expert on aspirin from Cardiff University who was not involved in the study, says that doctors are often reluctant to recommend aspirin because \u201cthe risk of causing a bleed by what the doctor prescribes is going to be uppermost in a doctor\u2019s mind.\u201d A patient might interpret the risk differently, he says.\u201d", "answer": 1}, {"article": "While some people are helped by over-the-counter medications like ibuprofen, others need prescription medications that may cause side effects, such as dizziness.\nNothing helped.\nHowever, the price tag could be as much as $10,000 a year.\n\u201cIt hurt to move my head from side to side; my tongue felt heavy, my eyes hurt, my sense of smell was off.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had no independent sources. Including some would have likely strengthened the story.", "answer": 0}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nOchiai also occasionally serves as an instructor at the Orthopaedic Learning Center, a surgeon's training lab in Rosemont, Ill., where he said three sessions are offered each year in hip arthroscopy and all are booked solid.\nBut those experiencing hip pain or stiffness have had more-limited options.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n \nThe story includes interviews with two surgeons who perform a substantial number of hip arthroscopies. But the story should also include testimony from a trusted independent source who is not a proponent.", "answer": 0}, {"article": "Colorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nApproximately half of the people who started the study agreed to continue.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\n\u201cThe findings in this study don\u2019t necessarily make that decision any easier,\u201d said Dr. Andrew Chan of Massachusetts General Hospital and Harvard Medical School, who did not participate in the research.\nThe scientists then followed the people willing to continue the research for another 2 years, noting who developed new polyps, including advanced polyps with features that suggest they\u2019re more likely to become cancerous.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the study was funded by Pfizer, maker of Celebrex, and includes commentary from an independent expert who didn\u2019t participate in the study.", "answer": 1}, {"article": "During a salvage radical prostatectomy, the prostate gland and surrounding tissue are surgically removed to keep the cancer from spreading.\n\"However, this study shows that it is a viable treatment option.\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\nUsing the Surveillance, Epidemiology and End Results (SEER) program database, Pokala and his research team studied 364 patients who underwent a salvage radical prostatectomy surgery after unsuccessful radiation treatments.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There\u2019s no mention of who funded the study or if there were potential conflicts of interest in the release. The journal article stated there were no conflicts of interest.", "answer": 0}, {"article": "(Reuters Health) \u2013 - Adding spice \u2013 in the form of curcumin supplements \u2013 to the daily diets of people with risk factors for heart disease may lower inflammation, a new study suggests.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\nOne of the authors is CEO of Sabinsa Corporation and Sami Labs Ltd, manufacturers of curcumin supplements.\nSahebkar added that he is often asked about the possibility of using turmeric instead of pure curcumin supplements.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does acknowledge that one of the study authors is the CEO of two companies that manufacture curcumin supplements. However, it includes no independent sources. Given the obvious potential for industry influence, this story really needed an independent voice to help evaluate claims for readers.", "answer": 0}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nOf the 444 patients with lung cancer, 318 died during the three years of follow-up, the researchers wrote.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Barely satisfactory \u2013 only because the story quotes a lung cancer expert\u00a0who was not involved with the study.\u00a0\u00a0 But that expert did not provide any useful criticism of this minimally important study, including the fact that all the findings could have been related to other non-dietary factors.", "answer": 1}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One source works for the DOD, but it\u2019s not clear whether he\u2019s involved with the funding of biomarker research. The story, as written, colors it that way. Another source is the president of a company investigating the biomarkers. Dr. Hall is presumably an independent source not involved with the Banyan research or any competitive research, but that\u2019s an assumption and preferably should\u2019ve been stated explicitly. Dr. Hall evaluates the Banyan work and describes an open question with this research. This cautionary point is, however, immediately countered by an anonymous citation that \"Other scientists say that Banyan\u2019s work may help doctors distinguish between different types of brain injury.\"\u00a0\nWe give the story credit for using a seemingly independent source and identifying conflicts of interest, at least in large strokes. There was room for improvement, though.", "answer": 1}, {"article": "For ongoing (or chronic) pain \u2014 a sore lower back, say, or the kind of degenerative arthritis that typically develops with age \u2014 ibuprofen still outperforms acetaminophen.\nMoore has looked at all the evidence for what he calls \"infrequent tension headaches\" and found \"it is surprising how poor [the research] is and how little it tells us.\"\nIt turns out this is another fascinating problem area for pain researchers.\nMore specifically, every researcher I contacted for this piece said some variation of what Andrew Moore, a pain researcher at Oxford University, told me: Tylenol doesn't actually work that well for pain.\nI didn't think much about whether it was more or less effective than any other type of over-the-counter pain reliever, and I suspect the same is true for many folks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sourcing is a very strong component of the article. The story quotes three pain experts from three different institutions as sources. No conflicts of interest were apparent.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does an excellent job citing varied sources to provide the reader with multiple perspectives on this new breast augmentation technique.\u00a0 The story provides both positive and cautious testimonials from a range of cosmetic and reconstructive specialists, researchers and a patient who had the procedure.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Research was discussed at an American College of Cardiology meeting. No abstract was available on-line. A quote from an American Heart Association spokesman, reported to have no role in the study, was included as part of the story. However, it does report on the use of a proprietary software and machine, and the story gave no details regarding the author\u2019s relationship to the company. ", "answer": 0}, {"article": "It may be necessary, however, for surgeons to do 80 or more procedures to ensure that they do not leave cancerous tissue behind.\nIn about one in 250 surgeries, the robot failed to work properly.\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story does not use any comments from experts in the field without a direct connection to the study reported on.", "answer": 0}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nWe need to wait for these results, expected later this year, to see how effective this approach is compared to chemotherapy alone.\u201d\n\nProfessor Udai Banerji\u200b, author of the study and deputy director of the Drug Development Unit at The ICR and Royal Marsden, acknowledged in an interview with Newsweek the cohort of patients was small, \"however anything more than 20 patients usually gives one a rough idea [of the effectiveness of a treatment].\"\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was no information about conflicts of interest. The study was funded by drugmaker AstraZeneca with support from the UK-based Institute of Cancer Research (ICR) and The Royal Marsden. Some of the researchers reported ties with AstraZeneca.", "answer": 0}, {"article": "\"There was no line I could mistake.\"\nAlthough it's not the first ever at-home test, SpermCheck Fertility is the first one to use the lateral flow assay method, Lopez said.\nThe test is not intended to be a complete semen analysis or an overall indicator of a man's fertility, Lopez said.\nAlthough it's not a comprehensive evaluation and could give some consumers a false sense of security, the test does provide a starting point while drawing attention to male infertility as a legitimate health concern.\nThere are several characteristics of sperm alone \u2014 at least three that aren't addressed by SpermCheck \u2014 that affect male fertility.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story extensively quotes Dr. Robert Brannigan, a urologist at Northwestern University Feinberg School of Medicine. And Brannigan provides much needed context for the test. For example: \u201cThe male reproductive system should not be oversimplified, Brannigan said. There are several characteristics of sperm alone \u2014 at least three that aren\u2019t addressed by SpermCheck \u2014 that affect male fertility. In addition, hormones and the delivery of the sperm play a part.\u201d The story also quotes\u00a0Brad Imler, the president of the American Pregnancy Association, who provided good comments.", "answer": 1}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\n\"This is a field that has been full of skepticism and misconception, where patients have been viewed to have invented their disease.\n\"There is much to learn,\" Komaroff writes, in the journal.\nKomaroff also notes a recent increase in research funding by the National Institutes of Health, which has included a comprehensive in-house study aimed at unraveling the underlying causes of the condition.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the researchers are \u201cworking on developing a panel that could be used commercially,\u201d thus at least implying that they stand to financially or professionally benefit from positive research results.\nThe story includes comments from one of the reviewers of the study, but should have noted that the reviewer and the lead author of the study also collaborate on other research. This connection was clearly noted in the footnotes of the journal article.\nThe story would have been better if it had included comments from at least one expert not closely associated with the authors of this journal article, and more strongly pointed out the potential conflict of interest.", "answer": 0}, {"article": "Silicone breast implants were pulled off the market in 1992 amid concerns that leaks from the implants could lead to cancer or autoimmune disease.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nBut there have been more serious outcomes.\nJust shy of two decades later she noticed something unusual.\nHer doctor immediately recommended removing them, which she did.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two independent experts were quoted.\u00a0 (Sidney Wolfe\u2019s name was misspelled.) However, the article could have benefited from:", "answer": 1}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n\"Detection of these important types of precancer by stool DNA testing offers promise in our efforts to more effectively and affordably prevent colorectal cancer.\nThe studies are slated to be presented on Monday and Tuesday at the annual meeting of the American Gastroenterological Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the Mayo Clinic researcher quoted in the news release is quoted in the story.\u00a0 Given all of the competing approaches to colon cancer screening, someone independent of this work needed to comment to put this research into perspective. ", "answer": 0}, {"article": "To study what effect THC has on the aging brain, scientists gave low doses of THC to mice at three different life stages\u2014two months, 12 months and 18 months.\nMoving this research forward, however, will be problematic: \u201cTesting in humans is going to be difficult.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nIn humans it could be years before an effect is noticed.\u201d\n\n\u201cFinally, there is the issue surrounding safety.\nHuman lifespan is very extensive.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although the outside principal source of commentary is an Oxford University scientist with skin in the game of cannabis research, his words are\u00a0temperate and cautionary about any eventual therapeutic use of cannabinoids to duplicate the mouse finds in people.", "answer": 1}, {"article": "Studies have found that runners have significantly higher injury rates than walkers (one study found that young men who run or jog had a 25 percent higher risk of injuries than walkers), and that ultramarathoners are at an even greater risk.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nI wanted to see what the highest-quality evidence \u2014 trials and reviews are the gold standard \u2014 said about the relative risks and benefits of these two forms of exercise.\nThe key word there is \"moderately.\"\nYou need to consider the trade-offs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes independent sources, and there were no potential conflicts of interests that we could detect.", "answer": 1}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\n\"The findings of this study are the early steps toward identifying CTE during life.\nNew research released Tuesday may make that possible.\nBut one of the biggest obstacles in understanding CTE has been the inability to diagnose it in the living.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does incorporate input from one independent source \u2014 who raised valuable points about the limitations of this discovery and the amount of work that remains to be done. There do not appear to be any conflicts of interest.", "answer": 1}, {"article": "The findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\nThe significance of that is not clear.\nThere are caveats.\nFurther, long-term studies are needed to see whether that is the case, the researchers say.\nA BMI between 25 and 30 is considered overweight.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not quote any independent sources.", "answer": 0}, {"article": "In the study of 35,016 older women with no history of breast cancer, those who reported currently taking fish oil supplements on a regular basis had a 32% reduced risk for developing invasive ductal breast cancer, compared with women who did not take fish oil supplements.\nThe new research is part of the Vitamins and Lifestyle (VITAL) study, which included data from women 50 to 76 years old from Washington state.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Four different sources were quoted \u2013 a strength of the story. ", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThis compares to just 21 percent for PSA alone, the researchers told a meeting of the American Urological Association in San Francisco.\n\u201cThat\u2019s pretty good, actually,\u201d said Dr. David Crawford of the University of Colorado School of Medicine, who helped lead the study.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nThe test was approved for use in Europe in 2006 but is not yet approved in the United States.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a single conflicted source was quoted: one of the principal investigators of the study reported on. \u00a0Considering this study was presented at the annual meeting of the American Urological Association, it seems that there were many around who could have offered expert opinion and insight about this test.", "answer": 0}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used one source who appears to be independent, Katherine Hamilton, MD, of Penn State.\nHowever, it didn\u2019t disclose that another source, Stephen Silberstein, MD,\u00a0 has substantial conflicts of interest. He personally received more than $620,000 from companies that make those and other migraine drugs from 2013 to 2017, according to CMS\u2019s Open Payments database. Most of the payments were for consulting, but he also pocketed money for such things as travel, food and beverages, and speaking fees.\nThe story did mention that Silberstein was involved in testing one of the drugs \u2014 erenumab \u2014 and helped design and run the trial for another \u2014 fremanezumab. But that didn\u2019t fully inform readers.", "answer": 0}, {"article": "IRE uses strong electric fields that cause cells to die without exposing the tissue to radiation or heat.\nAt the Prostata-Center which he founded in 2010, Stehling has treated hundreds of patients at every grade and stage of prostate cancer, and helped to advance the use of image guided treatment technologies.\nDr. Stehling has treated the most prostate cancer patients in the world using this image guided treatment, while generating the best therapeutic results.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\nCHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not identify funding sources for the research. Frehling is the director of a for-profit treatment center, Prostata.", "answer": 0}, {"article": "Novartis also plans to underscore canakinumab\u2019s potential cancer fighting properties with the European Medicines Agency and the U.S. Food and Drug Administration.\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\n\u201cIf the company cuts the price of the product in its current orphan indications, then it instantly sacrifices sales which currently total about $400 million per year with the hope that future sales in a new CV setting will more than offset this,\u201d Anderson said in a note.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\nOne leading expert described the benefit as \u201cmodest\u201d.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story, which is more of a \u201cbusiness of medicine\u201d story, uses a drug industry analyst source to good effect, and included commentary from the study\u2019s accompanying editorial.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nNo?\nAnd they consider themselves lucky.\nGot milk?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has quotes from \u2018fans\u2019 of raw milk, a scientist with expertise in food safety, and material from the FDA.\u00a0", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert and one satisfied patient who happens to be a physician. The story should have quoted other clinicians/researchers who could have provided some additional perspective.", "answer": 0}, {"article": "While the study offers insights on managing the disease, there's not enough evidence yet on whether HGH treatments could extend the lives of those with cystic fibrosis.\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\nThat growth also resulted in larger internal organs, particularly the lungs, making breathing easier.\nThe study, published Monday in the journal Pediatrics, was produced by the UConn/Hartford Hospital Evidence-based Practice Center and was funded by the U.S. Department of Health and Human Services.\nLungs are clogged with a thick mucus, which can lead to lung infections.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"What makes this paper unique is that it looked at the effects of EPA and DHA on coronary heart disease specifically, which is an important nuance considering coronary heart disease accounts for half of all cardiovascular deaths in the U.S.,\" said Dr. Dominik Alexander, lead author and Principal Epidemiologist for EpidStat.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is a really close call. The story makes clear that the research was funded by the Global Organization for EPA and DHA Omega-3s (GOED) \u2014 which also issued this news release, through AAAS\u2019s EurekAlert! news service. The release also quotes two GOED employees, and clearly identifies them as such. However, the release doesn\u2019t include any language explaining what GOED is, what it does, or who its members are. And that\u2019s important, because GOED is not an independent research organization, it\u2019s an industry group that exists to promote consumer use of products that contain omega-3 fatty acids.", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\nNewswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention its funders or potential conflicts of interest. Just because a funder has no apparent conflicts of interest does not mean that that information need not be included. In this case, inclusion of the fact that the Wellcome Trust and the Guide Dogs for the Blind Association paid for the work would have strengthened the release\u2019s credibility. Instead, a reader is left to wonder whether perhaps a group representing citrus growers is behind the study (it wasn\u2019t).", "answer": 0}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\nI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\n\u201cWe want people to be aware that HSCT is an aggressive treatment that comes with significant risks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Funding sources are not identified, but the principal investigator for the international trial notes that \u201cwe have achieved this [the international clinical trial] without industry backing,\u201d which is helpful. \u00a0Most of the sources in the story are either doctors involved with the trial or patients participating in the trial.\u00a0 One potentially independent source, who heads clinical trials at the MS Society in the UK, reacts cautiously to the testimonials, reminding readers that HSCT \u201cneeds to be carried out at an accredited centre or as part of a clinical trial.\u201d\nAlthough It isn\u2019t clear that anyone quoted doesn\u2019t have a vested interest in this trial, including the head of clinical trials for the MS society, we\u2019ll give the story the benefit of the doubt since it does at least specify no involvement from industry. The story would have been better had it commented on involvement from other vested interests.", "answer": 1}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\nThey write that they are \"excited about the potential of TAK-875 and are eager to conduct larger trials to find out how well this drug works, how safe it is and what its place is in the treatment of diabetes.\"\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story says clearly that the study was funded by the company making the drug being studied: \u201cThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\u201d The story also includes two valuable comments from independent researchers. Dr. Loren Wissner Green says that, \u201cuntil more is known about short-term and long-term cardiovascular effects, we need to proceed with moderated enthusiasm for each new drug and drug mechanism.\u201d And Dr. Minisha Sood, says that \u201cfurther investigation is warranted, especially including [heart disease] patients.\u201d", "answer": 1}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nFunded by the Bowel Disease Research Foundation (BDRF) charity, the work has been published in the Lancet Oncology journal.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\nThe research team was led from Manchester, working hand in hand with centres in Leeds and Switzerland.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes funding is from the Bowel Disease Research Foundation (BDRF).", "answer": 1}, {"article": "If you need a reason to become a dog lover, how about their ability to help protect kids from allergies and obesity?\nThe study, funded by the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE), was published in the journal Microbiome, along with an editorial in Nature.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nHer team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release tells us that the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE) funded the study.", "answer": 1}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nDr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center, said that the study really doesn't provide enough information to make a definitive conclusion.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nThe National Osteoporosis Foundation has more on osteoporosis.\nWomen in the control arm had no change in risk.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes some good independent sources, including Dr. Philip Houck, assistant professor of internal medicine at Texas A&M Health Science Center College of Medicine, and Dr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center.\n", "answer": 1}, {"article": "According to the recently released 2015-2020 Dietary Guidelines for Americans, small shifts in food choices can make a big difference; including a shift from solid fats to oils, like the oil in fresh avocados.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\nA 12-member board representing domestic producers and importers of Hass Avocados directs HAB's promotion, research and information programs under supervision of the United States Department of Agriculture.\nFunding for HAB comes from Hass avocado producers and importers in the United States.\n\"This study supports the body of research showing the many benefits that fresh avocados have to offer when consumed in everyday healthy eating plans,\" says Emiliano Escobedo, Executive Director, HAB.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the research was \u201cconducted at the University of the Pacific and independently funded.\u201d The published study doesn\u2019t tell us who funded the study either.\u00a0 Under \u201cFinancial disclosures\u201d it states \u201cThe views expressed in this material are those of the authors and do not reflect the official policy or position of the U.S. Government, the Department of Defense, the Department of the Air Force or University of the Pacific.\u201d That statement has nothing to do with financing the study.", "answer": 0}, {"article": "Tau has been tied to neurofibrillary tangles in the brain; researchers find that an increase in tau in cerebrospinal fluid is associated with Alzheimer's also.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\nBut it's too early to use this as a diagnostic tool in clinical settings, says Brickman.\nResearchers report these findings in the journal Archives of General Psychiatry.\n\"The way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert\u2019s comments added needed perspective to the findings.", "answer": 1}, {"article": "When dentists administer lidocaine or another local anesthetic, they usually combine it with another drug called epinephrine, which acts to constrict the blood vessels.\nIn the clinical trials there were no serious side effects, Novalar said.\nIs a drug really needed for what seems like a trivial use?\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviewed only company executives and dentists who consult with the company. No independent medical sources were consulted.\u00a0 \nGiven the questionable premise of the product, this is a remarkable omission. ", "answer": 0}, {"article": "During menopause, levels of estrogen decline in vaginal tissues, which may cause a condition known as VVA, leading to symptoms such as pain during sexual intercourse.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\nThe safety of Intrarosa was established in four 12-week placebo-controlled trials and one 52-week open-label trial.\nWomen were randomly assigned to receive Intrarosa or a placebo vaginal insert.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t disclose the funders of the studies the drug approval was based on. In the one study we could find via an online search, it disclosed that EndoCeutics sponsored the research. The first author of the Menopause journal article is also the President and CEO of EndoCeutics, while the second author is an EndoCeutics consultant and receives grants for clinical studies.\nWe feel this is a major conflict of interest that should have been highlighted in the news release.", "answer": 0}, {"article": "January 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nThe researchers identified women over age 65 who underwent DTI reconstruction at the Cleveland Clinic between 2012 and 2015.\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for the study are not disclosed.", "answer": 0}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\nWhen they removed New York City data to make sure those other factors weren\u2019t driving the findings, the pattern didn\u2019t change.\n\u201cThere has been a lot of looking into whether trans fats are harmful,\u201d said Brandt.\n\u201cWe still found the same thing,\u201d Brandt said.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a weak point in the story\u2013no independent sources were quoted.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources gave helpful perspectives in the story.", "answer": 1}, {"article": ".\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nThe next logical question is whether those changes might be detected early enough to predict and prevent lung cancer.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\nWith small brushes on the bronchoscope, they can take some of those cells and, using genomic testing that has been available only in recent years, reach a conclusion.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The good news is that the study\u2019s publication in a peer reviewed journal of high reputation suggests that the data have been vetted and the information is valid. That said, however, news articles that rely on journal articles and statements by commercial interests are greatly\u00a0strengthened by comments from independent sources. This article clearly outlines the commercial interests of the primary investigator and developer of the genomic test. But readers might have learned more about the limitations of the study and the test if other experts had been interviewed.", "answer": 0}, {"article": "Vitamin D can be obtained in the diet, particularly from fortified foods, from supplements, and from sun exposure.\nThe analysis included over 5,700 colorectal cancer cases and 7,100 controls from the United States, Europe, and Asia.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\nThe study appears online in the Journal of the National Cancer Institute.\n\"Currently, health agencies do not recommend vitamin D for the prevention of colorectal cancer,\" said Marji L. McCullough, ScD, American Cancer Society epidemiologist and co-first author of the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Vitamin D supplement manufacturers appeared to play no role in the analysis, and the funders are from the American Cancer Society, the Harvard T.H. Chan School of Public Health, and the U.S. National Cancer Institute.", "answer": 1}, {"article": "WATCH: The naked mole rat might help us cure cancer\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nFor now, it's up to patients to talk to their doctors about their particular risk profiles and how to screen accordingly.\nYou can see this clearly in the chart below: The number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\nThe authors of the newest study don't advocate no screening.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites independent commentary from an accompanying editorial that provides useful context. Inclusion of a second independent voice might have drawn attention to some of the study\u2019s limitations as discussed above. The story doesn\u2019t discuss potential conflicts of interest among the study authors, but the only conflict disclosed with the manuscript was related to a company that makes thermometers. Overall, this seems Satisfactory to us.", "answer": 1}, {"article": "But researchers at Johns Hopkins suggest that a common diagnostic technique doesn't help doctors much for patients whose chronic lower back pain appears to be due to arthritis of the joints in the spine.\nPatients don't care much about the finer points of diagnostic accuracy.\nBut some pain experts defend the value of the diagnostic tests.\nDoctors may not change their approach anytime soon, however.\nThey just want relief.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The NPR\u00a0news org can\u2019t be given credit for eliciting an independent source \u2013 only for \"borrowing\" what Reuters reported.\u00a0 Why not get your own source? ", "answer": 0}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\n\"They're interactive, and there's little games\" to keep it dynamic.\nGreenwood says he'd like to see many more patients try diabetes prevention programs.\nOverall, he says he would recommend the Omada Health program to a friend.\nAfter all, pulling off these changes is difficult\n\n\"I'm still on the journey to get to more optimal, health\" says Lonny Northrup, who lives in Utah.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two people who have tried the program, the company CEO, and a doctor who helped run the Utah study. We think readers deserve to hear from independent experts in the field of weight loss or those involved in motivating patients to improve their diets and exercise routines. Their voices would add needed context for this ever-vexing area of health care.\nWe did want to commend the story for including a personal story about the program that wasn\u2019t fully positive, which helps balance the story out.", "answer": 0}, {"article": "Flibanserin is taken nightly at bedtime.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nUpdated reports on data from the North American \"Daisy\" and \"Violet\" studies were made by Krychman and other researchers at this week's annual meeting of the American College of Obstetricians and Gynecologists in San Francisco.\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Conflicts of interest are disclosed.\u00a0 The story noted that the study researcher\u00a0interviewed is a paid consultant for the drug manufacturer.\u00a0 An alternative point of view is provided by\u00a0two independent experts, a\u00a0psychologist and a sex-therapist.\u00a0 The independent sources comment on the role that personal relationships play in sexual desire and experience which was not addressed or acknowledged by the researchers.\u00a0 ", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes two independent sources and clearly identifies those sources who are affiliated with the industry-funded Sonata trial or the manufacturer of the technology used in Sonata.", "answer": 1}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nThe test delivered impressive results, identifying abnormal semen samples with approximately 98 percent accuracy according to the researchers, who published their findings Wednesday in the journal Science Translational Medicine.\nShafiee\u2019s team plans to continue refining the test and then file for approval from the Food and Drug Administration (FDA).\nAs things stand now, men have to provide samples \u201cin these specific rooms in hospitals under so much stress and embarrassment,\u201d the study\u2019s principal investigator, Hadi Shafiee, PhD, told CBS News.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources were included, and the story didn\u2019t disclose that the one source who was interviewed\u2013researcher Hadi Shafiee\u2013holds a patent on the technology.", "answer": 0}, {"article": "\"It takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults' working day.\nCases were confirmed through medical records and pathology reports, and cause of death was determined by death certificate and medical record, and secondarily by next of kin.\nThis study was supported by grants from the Prostate Cancer Foundation and the National Institutes of Health.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\nReducing intake of processed meats would cut the risk by 12 percent, they reported.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were clearly identified, and there are no clear conflicts of interest.", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe only comments from an expert who was not a member of the research team come from the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The story fails to tell readers that this institute provided funding for the study and issued a news release praising the results, thus the source doesn\u2019t seem to be as independent as readers deserve.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story quotes an editorial writer but did not appear to go beyond a news release for interpretation of the study results.\u00a0 ", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story talked to multiple sources and clearly identified those who played a role in studies that were cited in the story.", "answer": 1}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\nThe study excluded anyone who said they consumed more than five portions of fruit and vegetables per day, and all participants were told to stick to their normal diet throughout.\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release included the important fact that a commercial enterprise selling blueberry juice concentrate and blueberry capsules provided the samples and some of the funding for the study.\nThe published paper states the authors declared they had no conflicts of interest.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Story includes perspective from\neditorial writer.", "answer": 1}, {"article": "\"It's like 'Star Trek.'\nThose factors do not prevent Campbell from dreaming.\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"\n\nA microchip to help someone see may sound more like a \"Star Trek\" device than legitimate science, but it is real.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story draws on three sources, all of whom are self-interested:\nAt least one independent source should have been consulted. The self-interest of the three sources used should have been explained.", "answer": 0}, {"article": "The researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nAll patients were interviewed about diet, health habits and medical history.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nFor this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted.", "answer": 0}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nHill said the lower antibody levels, together with a lower response detected in the immune system\u2019s T-cells, suggested to him that a booster may well be needed.\n\u201cPeople typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish,\u201d Hill said.\nThe volunteers got one of three doses - low, medium, or high - and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story utilized quotes from the lead author and a representative of the sponsoring organization. \u00a0Both were clearly identified as such so the the reader could place their comments into perspective. The two individuals quoted provided a very balanced view of the study results. However, our standard is to include the perspective of at least one person not affiliated with the research, so the story rates unsatisfactory on this criterion.", "answer": 0}, {"article": "For more information on stents, visit the U.S. National Library of Medicine.\nThe study was released online Sept. 27 ahead of print publication in the Oct. 5 issue of the Journal of the American College of Cardiology.\n\"Similar to other comparative stent trials, the sirolimus-eluting stent seemed to come out ahead in safety and efficacy,\" said Fonarow, who is also a cardiology professor at the University of California, Los Angeles.\nMONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nHowever, they said a limitation of their study is the one-year follow-up period, and noted that a longer, ongoing study pitting zotarolimus-eluting stents against sirolimus-eluting stents will provide more safety information.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One source, Dr. Fonarow, was apparently not affiliated with the study. We appreciated his placing the results in context with prior research and on clinical decision-making.\u00a0Google tells us that he has a\u00a0financial relationship\u00a0with the company that makes zotarolimus-coated stents. But given the fact that his quotes\u2014and the study\u2014are not in favor of zotarolimus, perhaps the lack of this disclosure is excusable.\nOne key conflict of interest, study funding from a stent manufacturer, was identified. However, we fail the article on this criterion because it neglects to mention that the researchers disclosed a web of financial relationships with literally all the stent manufacturers. We count 9 financial relationships with Cordis, who makes the sirolimus-coated stent, which came out \u201con top\u201d in this article.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Unfortunately, the story depended on quotes only from the lead author of the study. Verification of the significance of study findings by an independent expert would have strengthened credibility of the story.", "answer": 0}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nSince these changes could not be detected based on a PSA blood test alone, this new test would be very helpful in determining early on which therapy to choose in a given patient.\"\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nHowever, Goluboff also noted that research from animal-based studies does not always pan out in humans and \"further, larger studies are of course required to confirm these findings.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Perhaps the only thing that salvaged the story was the story-ending caveat from an independent expert:\n\u2026research from animal-based studies does not always pan out in humans and \u201cfurther, larger studies are of course required to confirm these findings.\u201d", "answer": 1}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThe research is published in the New England Journal of Medicine and is being presented at the European Society of Cardiology Annual Congress in Munich.\nResearchers say current guidelines should be updated to incorporate the scans into routine care.\nThe study was funded by the Chief Scientist Office of the Scottish Government and the British Heart Foundation.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "National funding sources of the study are mentioned.\nWhat\u2019s not mentioned is that the lead author quoted in the release receives grant funding from Siemens, a major manufacturer of CTA scanners.", "answer": 0}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nWhat if we told you that a guy with no background in science or medicine - not even a college degree - has come up with what may be one of the most promising breakthroughs in cancer research in years?\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\nWell it's true, and if you think it sounds improbable, consider this: he did it with his wife's pie pans and hot dogs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The segment draws exclusively on the inventor and three credible but potentially self-interested supporters, one of whom is dead. \nThis is unsatisfactory: One or more independent cancer researchers should have been interviewed, including one who is currently doing other research with nanoparticles and one expert radiologist.\nThese sources could have provided necessary context for this history and outcomes of previous promised \"breakthroughs,\" the implications of novelty and the many things which remain unknown.\nThe segment should have reported whether the researchers interviewed have a financial or other interest in the procedure. ", "answer": 0}, {"article": "\"We adopted the treatment approach and started offering it to all our laryngeal cancer patients,\" Wolf says.\nAs part of a Specialized Program of Research Excellence, or SPORE, grant, the team was already maintaining long-term follow-up data on patients.\nThe non-responders can be referred immediately for surgery.\nAll three must be involved to assess the patient and refer to the appropriate therapy.\nThe non-responders who were immediately referred for surgery had better outcomes too.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly noted in the release and there do not appear to be relevant conflicts of interest.", "answer": 1}, {"article": "\u201cSometimes you don\u2019t get the same result.\nA study published in 2015 by the Center for Cancer Research found that fusion biopsy is 30 percent more accurate in diagnosing high-risk, aggressive cancers than a TRUS biopsy.\nAccording to the Center for Cancer Research study, MRI targeted biopsies detect 17 percent fewer low-risk tumors.\nAn MRI can also help determine how aggressive a tumor is, Yu said, and indicates if the tumor extends outside of the prostate and involves other areas \u2014 all information that helps urologists and radiation oncologists determine the best course of treatment.\nIn addition to enhancing detection of prostate cancer, magnetic resonance technology also enhances the biopsy process with a procedure called magnetic resonance/ultrasound fusion biopsy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name a funding source, but it\u2019s not based on one study. It focuses heavily on selected outcomes and patient anecdotes from a single treatment center, the VCU Massey Cancer Center.\nThere are no apparent undisclosed conflicts of interest or funding sources related to VCU. However, two authors of the NCI\u2019s Center for Cancer Research study (briefly referenced in the release) had reported holding a patent related to the MRI biopsy platform, and a third reported holding multiple patents in the field. That research was supported by the National Institutes of Health, the National Cancer Institute, the Center for Cancer Research, and Center for Interventional Oncology. The NIH, Philips Healthcare, and devicemaker Invivo Corp. have a cooperative research and development agreement.", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\n\u201cThis is definitely a game changer,\u201d Dr. Kapil Bharti, an investigator at the National Eye Institute in Bethesda, Maryland who is not involved with the research, says.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThe team will conduct human trials later this year.\nNeither of the implants is able to restore color to vision yet, and Bharti has questions about the durability of organic eye implants.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three sources are quoted in the story. One researcher from the Italian team, one researcher from the Californian team, and one researcher who is independent of both research groups.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We get three different physicians from New York University, Mayo Clinic and the MS Society. No conflicts are reported. In future stories, it is always better to state whether a patient who comments is someone whom the drug company provided to the reporter or whether he/she was independent of that. This story gives us a patient but does not explain whether she has ties to Novartis \u2013 makers of Gilenya.", "answer": 1}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\nStill, he was surprised by an audience poll at the end of the discussion: 70 percent now supported the idea that women deliver at 39 weeks, 21 percent remained unsure and only 9 percent were against the idea.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\nDekker said that the ACOG debate should have instead compared the medical model of care to midwife-led care.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the story includes several sources who criticize the proposition that labor should be induced earlier routinely. The story also quotes an opponent who charges that obstetricians have a philosophical bias in favor of medical intervention, which in a way flags a potential conflict of interest for readers.", "answer": 1}, {"article": "\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\n\u201cHowever, it should not replace other therapy such as quad strengthening exercises, and weight loss, which we know will provide benefit.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two American experts, neither of whom seem to be associated with this European study. We applaud the effort to get outside perspective, but wish the article made clear if these sources do or do not\u00a0have conflicts of interest with pharmaceutical companies that make any kind of arthritis pain medication.", "answer": 1}, {"article": "Cocaine use is widespread in the Western World.\nIt is also important to emphasize that, in this study patients were seeking treatment for their cocaine addiction in a hospital setting: the group studied, albeit small, was a \"real world\" sample.\nAs author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nAt the end of the first 29 days of the experiment, the experimental group was given the option of continuing the treatment, whereas those in the control group were given the possibility of receiving the same rTMS treatment as the experimental group for 63 days.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release fails to point out the funding sources for this work, or to address any possible information on potential conflicts of interest, even though that information is readily available in the research paper.\nThe published study states that funding was provided by several public and private sources in Italy and the National Institute on Alcohol Abuse (US), and that the study authors had no financial or potential conflicts of interest.", "answer": 0}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\n\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article only quotes the lead investigator, which can be biasing. The article did not quote an independent source of information. ", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an independent source who wasn\u2019t affiliated with the research. Christina Annunziata, a director with the Center for Cancer Research at the National Institutes of Health, said that while she found the study \u201cinteresting\u201d and \u201cthought-provoking,\u201d she cautioned that \u201cI don\u2019t think it\u2019s practice-changing quite yet.\u201d Annunziata co-authored an editorial accompanying the report which were both published in the American Cancer Society\u2019s Cancer journal.\nThe story would have been even stronger had it outlined the funding sources for this study, which included government and foundation grants. However, since we didn\u2019t find any significant conflicts in the list of funding sources, we didn\u2019t think this omission unbalanced the coverage.", "answer": 1}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\n\u201cIf the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families,\u201d Lambracht-Washington said in a statement.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nPrevious attempts to find an Alzheimer's vaccine either caused harmful side effects, such as brain inflammation, or used less effective approaches, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story has no independent sources. The authors asserted no conflicts in the published paper.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As already stated, no independent source was quoted about the evidence, about the benefits or harms. Even the news-release-lifted quote from the FDA official said only that the approval shows FDA\u2019s \u201ccommitment to innovative new devices that provide patients with other treatment options.\u201d\u00a0 That\u2019s more of a self-promotional statement about FDA than it is a helpful comment about the role of this particular device.\nThis is indeed unfortunate given the availabilty of the information about the pivotal study in toto from the FDA website. But the online story didn\u2019t even link to that information.", "answer": 0}, {"article": ".\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\n\u2022 Both transfemoral and transapical approaches to TAVR appear to be safe and effective for treatment of aortic stenosis in select patients age 90 years and older.\nThe study also showed that the 30-day stroke risk was 3.6% in TF-TAVR patients and 2.0% in TA-TAVR patients.\n\u2022 By 6 months post-surgery, most quality-of-life measures had stabilized at a level considerably better than baseline, meaning patients quality of life was better than it was prior to surgery.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not mention funding sources or conflicts of interest. This is particularly problematic for a release that leads with a statement that valve replacement surgery should be an option for older patients \u2014 given that the relevant journal article makes clear that six of the study authors have financial relationships with companies who have a vested interest in valve replacement surgeries.", "answer": 0}, {"article": ".\nThe study is funded by the National Institutes of Health and Georgia State's Center for Biotechnology and Drug Design and Molecular Basis of Diseases Program.\nHe co-led the study with Phang C. Tai, Regents' Professor of Biology at Georgia State, who is an expert on the functions of SecA in bacteria.\nTheir findings were published in the journal Bioorganic & Medicinal Chemistry in November.\nCollaborators for the paper published in Bioorganic & Medicinal Chemistry include Hsiuchin Yang, Hao Zhang, Krishna Damera, Ying-Hsin Hsieh, Arpana Sagwal Chaudhary, Jianmei Cui and Jinshan Jin of Georgia State.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes the study\u2019s funding sources are the National Institutes of Health and Georgia State\u2019s Center for Biotechnology and Drug Design and Molecular Basis of Diseases Program.\nNo conflicts of interest are disclosed in the release or published study results.", "answer": 1}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nThe American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\nWhen 57-year-old Dean Cowles suddenly suffered a heart attack, he was lucky that he worked at a company that made defibrillators,reports.\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\nSays Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A patient who underwent this treatment and had a good outcome as well as two physicians (a neurologist and a cardiologist) at a hospital which uses this treatment were interviewed for this story.\nIt would have been helpful to understand why only a limited number of hospitals include this treatment in their management of heart attack.", "answer": 1}, {"article": "Digital tomosynthesis (DBT), or 3D mammography, does slightly better, detecting approximately 25 percent more cancers, or roughly 5 cancers in 1,000 women screened.\nIn addition to Weinstein, additional authors include Mitchell D. Schnall, Elizabeth S. McDonald, Alice Chong, and Emily F. Conant.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\nBased on the results from Penn's study, the AB-MR may be a better option.\nThe School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not mention any source of funding for the study. Nor did it address whether there were any conflicts of interest among the researchers at the University of Pennsylvania.", "answer": 0}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nCorgenix provided the test kits.\nThis study was funded by a gift from the Abundance Foundation (Stephen Kahn).\n\"Laboratory results can sometimes take days to return.\nSurprisingly, the findings also revealed that the standard altona RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We\u2019re told the Abundance Foundation funded the test and the maker of the rapid-diagnostic test, Corgenix, provided the kits.", "answer": 1}, {"article": "Obesity is a major breast cancer risk factor in postmenopausal women, and scientists believe increased inflammation is an important underlying cause in this population.\n\"This represents an example of a personalized approach to breast cancer prevention.\"\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does identify the funding sources for this research as well as the suppliers of the drugs used in this study so possible conflicts of interest are adequately addressed.", "answer": 1}, {"article": "But in some people HPV leads to genital warts and cancers \u2013 notably, cervical cancer.\n\u201cSeveral therapeutic vaccines have shown great promise in phase 1 and then not panned out in phase 2,\u201d she noted in an e-mail.\nThis happens in anywhere from 10% to 25% of women infected with HPV, Kim said.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe researchers did not observe any side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did provide a quote from an independent researcher who was not involved with the current research (and does not appear to be affiliated with the vaccine manufacturer).", "answer": 1}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nOverall, the studies involved nearly a million participants.\n\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nIn the study, researchers analyzed information from 18 studies on coffee and diabetes and another 13 studies that included data on decaffeinated coffee and tea drinking and diabetes.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent experts in the field were quoted to provide context for the information presented.", "answer": 0}, {"article": "Decongestants such as Sudafed work by shrinking swollen blood vessels in the nose.\nWorth knowing: so far, insurers have continued to pay for similar prescription sprays, Eghrari-Sabet says.\nBut that does not mean they work for everyone, says James Sublett, a Louisville allergist and president of the allergy group.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\nHere's what some top allergists say you need to know about these non-prescription options.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were some obvious conflicts of interest with one of the expert sources quoted in this story.\nDr. James Sublett is not only a Louisville allergist and president of the American College of Allergy, Asthma & Immunology, but he is also a \u201cspeaker for numerous pharmaceutical and medical device companies,\u201d says his profile on the digital media company Everyday Health. A bit more digging finds that Sublett \u201chas received payment for lectures from GlaxoSmithKline, Merck, Sunovion, and Teva and has stock/stock options with AllergyZone LLC,\u201d according to disclosure statement for a 2013 study on cockroaches in The Journal of Allergy and Clinical Immunology.\nWe believe such conflicts of interests are troubling and should be disclosed, especially when the first product mentioned by the story includes a nasal steroid spray from GlaxoSmithKline \u2013 the same pharmaceutical company that engages Sublett as a speaker. That, together with the lead quote from the allergy group (where Sublett is president) claiming steroid nasal sprays are the \u201csingle most effective drug class,\u201d throws the story somewhat off balance. We\u2019re glad a second, seemingly independent expert was also consulted for her opinion.", "answer": 0}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nThe strain used in this clinical trial, Clostridium novyi-NT, had been weakened to prevent it from producing its toxin, which can be lethal in humans, Janku said.\nFifteen of the patients had sarcoma, two patients had melanoma, and seven had a variety of cancers, the researchers said.\nThe trial results were to be presented Sunday at the International Cancer Immunotherapy Conference, in New York City.\nWhen both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted two researchers who were involved in the trial, with no independent sources. It did not say that the trial was sponsored by a company called BioMed Valley Discoveries.", "answer": 0}, {"article": "In February, the World Health Organization offers a prediction \u2014 based on surveillance and laboratory and clinical studies \u2014 and then each country uses that prediction to approve vaccines in its jurisdiction.\nOne key caveat here is that the evidence, overall, is pretty poor quality.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\nIt's true that flu vaccines don't work spectacularly well, at least according to the best evidence we have (and most of the evidence on flu vaccines is of poor methodological quality).\nSo, yes, the flu vaccine can prevent illness, but it's hard to detect major effects on public health in the data.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The author of this story compiles ample evidence from reliable and respected independent sources concerning influenza.\u00a0\u00a0 It does not, however, offer any information concerning conflicts of interest, but with this type of story, we\u2019re hard pressed to see how there would be a conflict.", "answer": 1}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story quoted no independent experts. The only comments it used that were not from the lead researcher were from GlaxoSmithKline. \u201cBut GlaxoSmithKline Consumer Healthcare, which makes Nicorette, Nicoderm, Commit lozenges and other smoking cessation products, said that would be premature. The company noted that most of the adults in the study who used nicotine replacement products didn\u2019t use them for the recommended eight weeks. Had those people followed directions, they might have had more success.\u201d This idea appears to have been refuted in the study itself, which showed that the duration that people took the products did not seem to make a difference. A better criticism might have been that it is difficult to tell how these people truly complied with the product because they were not being actively monitored in a clinical trial but were only responding to survey questions.", "answer": 0}, {"article": "If you already have osteoporosis, check with your doctor before embarking on a weight lifting program because if you try to lift too much weight too soon, you could fracture a bone.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nBut remember: Not exercising also puts you at risk.\nWalking has not been shown to restore bone that is already lost to osteoporosis, but it can help preserve the bone density that a person has, said Dr. Carol Hartigan, a spine specialist at New England Baptist Hospital.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Quotes from two clinicians with an expertise in exercise and bone health were included in this piece.", "answer": 1}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes from two experts in the field, neither of whom appears to be associated with the two NEJM studies. However, one of the sources \u2014 Dr. Sidney Starkman \u2014 has been an unpaid investigator on another trial run by a device manufacturer discussed in the story, and has disclosed in his previous writing that his employer (University of California) holds a patent on a clot removal device. Although it sounds like he stands to benefit if this technology becomes more widely adopted, we\u2019re not really in a position to know the extent of his personal conflict of interest. We\u2019ll give the benefit of the doubt here, with the caveat that it\u2019s always useful to give readers a clear sense of the source\u2019s independence (or lack thereof).", "answer": 1}, {"article": "According to World Cancer Research Fund International, 84 percent of cervical cancers occur in less developed countries, with the highest rates in Africa, Latin American and the Caribbean.\nThey plan to continue modifying the test to improve the urine sensitivity to that of the cervical tissue samples.\nNewswise \u2014 Johns Hopkins Medicine specialists report they have developed a urine test for the likely emergence of cervical cancer that is highly accurate compared to other tests based on genetic markers derived directly from cervical tissue.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThe research was funded by National Cancer Institute grants (U01 CA084986, K01 CA164092 and U01 CA084986).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release offers no information about possible conflicts of interest (the article on which the release was based indicates the absence of such conflicts), it does provide information about funding. And it does disclose the start of a collaboration between the team and a company that intends to design and market a urine test product.", "answer": 1}, {"article": "\u201cPeople need to focus on the health benefits,\u201d she said.\n\u201cMost prior studies of weight loss only followed patients for a year, and a few out to two years,\u201d said the study\u2019s lead author, Dr. Erin Bohula, an assistant professor of medicine at Harvard Medical School and a cardiologist and investigator with the TIMI Study Group at Brigham and Women\u2019s Hospital in Boston.\nThat doesn\u2019t surprise Dr. Vijaya Surampudi, an endocrinologist and an assistant professor of medicine at the Center for Human Nutrition at the University of California, Los Angeles.\n\u201cIn hypertension, there are more than 100 medications and more than 10 therapeutic categories,\u201d he added.\nThe media attention that followed would scare patients off diet pills for years \u2014 a fear that continues today.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story didn\u2019t disclose that two physician sources, Erin Bohula and Louis Aronne, received payments in the tens of thousands of dollars in connection with weight drugs, according to ProPublica\u2019s Dollars for Docs database.\nA third physician quoted in the story, Vijaya Surampudi, has received smaller payments from Novartis that were not tied to a weight-loss drugs.\nThe story would have benefited from more independent sources.", "answer": 0}, {"article": "SUNDAY, Oct. 23, 2011 (HealthDay News) -- Older women who take nonsteroidal anti-inflammatory drugs -- such as aspirin or ibuprofen -- appear to have a lower risk of death from colorectal cancer than women who don't use these medications, a large new study suggests.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources cited from outside the study. The only comment came from a doctoral student at the University of Washington.", "answer": 0}, {"article": "Jerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category.\n[1] Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle with some showing an even earlier onset of action.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\nResearch in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007).\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no mention in the release of who funded the study. Also, there is no information about where the study was conducted, or which institutions were involved, although it identifies the study as \u201cmulticenter.\u201d There is a quote from an individual identified as a \u201cstudy investigator\u201d but no other information is offered, including any disclosures as to possible conflicts of interest.", "answer": 0}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nThe work was supported by Mead Johnson Nutrition.\nIn their new study, the team concentrated solely on the effects of prebiotics.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded by Mead Johnson Nutrition, the manufacturer of a prebiotic infant formula.", "answer": 1}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\nRichard Neal, professor of primary care oncology at the University of Leeds who was not involved in the research, welcomed the study.\nThe patients were selected at random from a national database.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used\u00a0information and quotes from those not associated with the study, and we detected no conflicts of interest.", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story sought out a variety of views and, even in quoting the lead researcher, emphasized how nobody \u201cwould say the results will completely change the way we do things.\u201d\nThe comments of the experts are balanced and provide the reader with some semblance of the difficulties that are inherent in this type of decision making.", "answer": 1}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As with the STAT News story, this one didn\u2019t note the financial disclosures of the study authors, including the senior author, Ruth Etzioni, who disclosed she owns equity in a company developing medical imaging technology that it says could be applied in prostate cancer patients. Dr. Etzioni stated that she does not consider the equity ownership to be a conflict of interest, but considering that an increase in PSA screening would boost demand for more precise and less invasive follow-up testing, it appears that her company would benefit.\nWhile the story does quote an independent source, it would have been helpful to note that he consults for the medical industry.\nThe study was funded by the National Cancer Institute. While that source does not raise any red flags, and the study stated that the funder had no role in the study, news stories are more informative when they note study funding.", "answer": 0}, {"article": "That protein is known as an epidermal growth factor receptor (EGFR) kinase.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source is cited besides the ACS statistics on lung cancer. Any story that allows a researcher to make bold claims such as that this research \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide\" demands an independent perspective.\u00a0 ", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\nBut experts say the findings provide hope for future treatments for people.\nJust because the system produced strong results in mice does not mean people will respond the same way.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Most of the sources are connected to the study, either from the research institutions involved or the funders. But we give the story points for taking the next step and talking to people in the pharmaceutical research world who would be among those actually taking a discovery like this and making it therapeutic. The story quotes someone from Semma and someone from VitaCyte, both of whom provide a good dose of realistic context. While ideally we would\u2019ve heard from someone with no stake at all in this line of research, we think there are enough voices with enough distance from the studies to earn the story a Satisfactory rating. And to the article\u2019s credit, the sources\u2019 affiliations are all clearly stated.", "answer": 1}, {"article": "Load up on berries.\nBut he says it's important to point out that the women in this study weren't prime candidates for heart attacks anyway.\nCassidy says the association between berry consumption and heart disease was strengthened when she and her collaborators controlled for other reasons that could have explained the finding.\nPeriodically over the past 18 years the nurses have reported details about their diets and lifestyles to researchers.\nAt the same time, researchers have monitored the nurses' health to see which diseases they go on to develop, or not.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Cardiologist Dr. Robert Eckel is the independent source in the study who talks about a major study limitation. His comments are extremely helpful and bring more perspective to the study.", "answer": 1}, {"article": "Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe study, however, has some limitations, Bernik noted.\nMammography does lead to ''overtreatment\" in some cases, Bernik acknowledged.\nThe study findings ''add to the body of evidence supporting the fact that mammography matters in improving detection and survival,\" said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Although there is no specific indication of whether or not there is a conflict of interest ,the article is considered satisfactory because it names the source of the study and provides one independent source, Dr. Stephanie Burnik.", "answer": 1}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\nThe program led to a significant and clinically important reduction of pain, she said.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\nThe regimen included the best known exercises for back pain and general exercises, she said.\nThe report was published online April 16 in JAMA Neurology.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An outside expert was quoted and we detected no conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Adolescence is the key period for bone development, and poor development at this stage is linked to reduced peak bone mass (the amount of bone mass at the end of the skeletal maturation, around age 30), increased fracture risk and osteoporosis later in life.\nThe research was funded by the EU via a Marie-Sklodowska-Curie fellowship awarded to principal investigator Dr Luis Gracia-Marco, also of the University of Exeter.\nThe research is part of a larger University of Exeter study called PRO-BONE.\nThe year-long study, of 116 boys aged 12-14, took a variety of measures including bone mineral content (BMC).\nThough swimming and cycling have proven health benefits, the scientists said their study \"raises a question\" about whether they are good for bone development due to the non-weight bearing training - and they say young swimmers and cyclists could benefit from more weight-bearing exercise in training regimes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that funding for the study came from a Marie Sklodowska-Curie fellowship, provided by the European Union. The researchers do not appear to have any conflicts of interest in connection with this study.", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story failed to point out that the Dr. Castro, who led the study discussed in this story, is a paid consultant for Asthmatx, which manufactures the thermoplasty device tested in the study and which provided funding\u00a0for the study. \u00a0", "answer": 0}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThe Bradford team had scored 100 cells per slide, but the Pathfinder\u2122 system is able to analyse up to 10,000 cells per slide, and uses Artificial Intelligence concepts in its proprietary software.\nIMSTAR's vice-president for medical applications, Dr Michel Soussaline, confirmed that the company will be working to automate the full test workflow further to take it to market.\nThe test was developed at the University of Bradford, UK.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While it is not clear who is funding this latest study, the company, IMSTAR, which has licensed the test, identifies the University of Bradford as a \u201cpartner\u201d on its website.\u00a0 Additionally, the PI quoted most extensively in the release appears to co-own a 2010 patent for a similar test.", "answer": 0}, {"article": "Aug. 30, 2010 -- Three puffs a day of cannabis, better known as marijuana, helps people with chronic nerve pain due to injury or surgery feel less pain and sleep better, a Canadian team has found.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In the original AP version (939 words long), the reporter quoted 5 expert sources.\u00a0 In the vastly cut-down Cincinnati version (369 words), only two sources appeared.\u00a0 \nIt does not appear that anyone independent of the study in question was interviewed. \u00a0\u00a0", "answer": 0}, {"article": "Leaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story discloses\u00a0that the featured patient, Yvonne Felix, is an eSight spokesperson. The story adds\u00a0some needed backstopping from Walter Wittich, a researcher at the University of Montreal. However, the story didn\u2019t disclose that his lab has accepted grants from eSight.", "answer": 0}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\nCertainly, Mr. Paduda, who used Latisse daily from November through February, is a happy customer.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\nBut the fact is that many men \u2014 and women \u2014 simply do not accept baldness easily.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We think this one is a wobbler. The story did quote two hair loss specialists. We wish it had gone a little broader in scope and talked with someone who is not currently prescribing Latisse and could speak to the safety and efficacy of an uNPRoven product like this.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Less than optimum: The sole source of this article appears to be a New England Journal of Medicine article. No additional sources were apparent. \nStrong point: The story stated, \u201cCAUTIONS: This study was funded by AstraZeneca the maker of candesartan and the company was also involved in the analysis of the data.\u201d ", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nThey can also administer simple paper-and-pencil tests.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\n[ID:nN13273900] These proposed rules included measurements of cerebral-spinal fluid.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not include comments from an independent source and it fails to tell readers that several of the study authors are or were employees of the company that developed key components of the test. It also does not mention that the study was funded by an institute that receives funding from pharmaceutical companies, including the company that makes the test.", "answer": 0}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\nBut taking out wisdom teeth when there aren't any symptoms is where the professionals get into it.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources include a dentist and two oral surgeons as well as numerous published reports and professional association position reports. The story also reminds us\u00a0that \u201coral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\u201d", "answer": 1}, {"article": "\"I think people should be able to do this as part of their personal hygiene - just like brushing your teeth and taking a shower.\"\nThe new study appears in Circulation, a journal of the American Heart Association.\nCollaborators on the study included first author Dr. Erin Howden, Research Fellow with UT Southwestern's Graduate School of Biomedical Sciences and the IEEM and now a faculty member at the Baker Heart and Diabetes Institute in Melbourne, Australia.\nTo start the study, researchers recruited 53 participants, ages 45 to 64.\nFunding came from the National Institutes of Health and the American Heart Association.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions the funding sources for the study (NIH and American Heart Association). There are no conflicts of interest listed in the news release or study.", "answer": 1}, {"article": "\u201cBut difficulty with navigation is increasingly recognised as one of the very earliest symptoms.\nThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nThis now appears to be the first part of the brain that succumbs to Alzheimer\u2019s.\nNot all will be destined to be affected by the disease, however.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that the forthcoming study has received funding from the Alzheimer\u2019s Society. However, the only source cited in the story is one of the researchers who will be conducting the study. Input from an independent expert about the viability of such a study would have been very welcome.", "answer": 0}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Comments from several clinicians were included in this piece to point out some of the potential confounders with the study results.\nIt was mildly amusing that one of the clinicians interviewed stated categorically that there are over\u00a0800 previous studies on robot-assisted prostate -v the majority of which demonstrate superiority. \u00a0This is an awfully large number of studies about a relatively new technology; further, one of the important points of this story is that there are both short term and longer term outcomes to be considered.", "answer": 1}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to two authors of the study reported on, a spokesperson from the American Diabetes Association commented on the impact of gastric bypass on type II diabetes.", "answer": 1}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nBut so far it has only been tried with patients who have not responded to other treatments, he said.\nXeljanz targets certain proteins involved in the body's inflammatory and immune responses that other so-called biologic drugs don't, the researchers said.\nSandborn said he has received research grants from the company and served as a consultant for Pfizer.\nThe study was funded by Pfizer, Inc., the maker of Xeljanz.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story handles this very well. The study\u2019s lead author is clearly identified, the story clearly states that Pfizer (which makes Xeljanz) funded the study, and that the lead author has consulted for Pfizer. In addition, two independent sources are included in the article. One of those sources was also the author of an editorial on the NEJM paper, which the story notes.", "answer": 1}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe study had some limitations, the authors acknowledged.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\n\"This is a promising avenue for future research,\" said Alcalay, an advisor for the Parkinson's Disease Foundation.\n\"If you need to be on statins for your heart, it is not going to increase your risk for Parkinson's,\" Alcalay said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two independent experts, providing good balance for the story.", "answer": 1}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nAmong the nurses studied, 199 developed MS over the 16-year study period.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nThe disease most often strikes adults after age 20, but it can develop in children.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent experts were interviewed for this story.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nAnd with rates of those diseases rising, experts say that more primary care physicians\u2014not neurology experts\u2014will have the task of identifying these patients early so they can take advantage of whatever early interventions might be available.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes and comments by one of the authors of the study. An independent expert would likely have identified many of the coverage gaps we discuss in this review. HealthNewsReview.org provides a list of independent experts who are willing to talk with journalists who need help fleshing out their stories.", "answer": 0}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There is no specific trial referenced, just a review of the author\u2019s past work relating to blood and saliva screening tests and his opinions that AD can be prevented through \u201cself treatment by consumption of non-steroidal anti-inflammatory drugs, adhering to a Mediterranean diet, and consuming antioxidants such as quercitin which is contained in coffee.\u201d\nThe release makes many claims and cites a lot of research, but as readers we have no idea who may stand to gain what. It\u2019s not clear who funded the studies, nor what stake Dr. Greer,\u00a0the president and CEO of Aurin Biotech, may have in any products that eventually result from this research.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only uses one source of information, and he is the lead author of the study. There were many other diabetes specialists at the American Diabetes Association meeting \u2013 where these data were presented \u2013 who could have helped put this in perspective for readers. ", "answer": 0}, {"article": "\"Eating tomatoes is a good thing, but we don't know if there is really anything unique about tomatoes apart from other fruits and vegetables that reduce stroke risk,\" explains Dr. Walter Willett, chair of the Department of Nutrition at Harvard School of Public Health in Boston, Massachusetts.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\n\"But it's not proof that if you eat tomatoes you're going to have less risk of stroke.\"\nIt seems the jury is still out, but researchers suggest we eat healthy as they continue to search for answers.\nSo are lycopene packed tomatoes really the magic fruit?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There was\u00a0excellent input from independent experts on stroke and nutrition. This was a strength of the story.", "answer": 1}, {"article": "Their findings are published in the Royal Society of Chemistry's journal, Chemical Science.\n\"This simplified design and more efficient synthesise will enable work to be carried out at a commercial level.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nNow, we have discovered that we can in fact use amino acids which are structurally different, and are commercially-available.\nThe work builds on the success of the team's pioneering research to tackle antimicrobial resistance over the past 18 months.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not discuss either funding or conflicts of interest. Readers would have to go to the journal article to learn:\nSince other researchers investigating teixobactin have submitted patent applications and commercialization of basic research has become a routine part of academic science, it would have been nice to see this news release directly address the potential financial interest the researchers may have in the development of their work.", "answer": 0}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nIn addition to showing that NR boosts NAD+ in humans without adverse effects, the trial confirmed that NAAD is a highly sensitive biomarker of NR supplementation in people.\nIn addition to Brenner, the research team included lead study author Samuel Trammell, Mark Schmidt, Benjamin Weidemann, Zhonggang Li, and E. Dale Abel at the UI Carver College of Medicine; Philip Redpath and Marie Migaud at Queens University Belfast; Frank Jaksch at ChromaDex in Irvine, Calif, and Ryan Dellinger, formerly at ChromaDex.\nThe trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses.\n\"Now that we have demonstrated safety in this small clinical trial, we are in a position to find out if the health benefits that we have seen in animals can be reproduced in people,\" says Brenner, who also is co-director of the Obesity Research and Education Initiative, professor of internal medicine, and a member of the Fraternal Order of Eagles Diabetes Research Center at the UI.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release lists the funders and states that the manufacturer, ChromaDex, supplied NR for use in the trial and that lead researcher, Charles Brenner, is a consultant for ChromaDex and co-counder and chief scientific advisor of ProHealthspan, which sells NR supplements under the trade name Tru NIAGEN.\nThe release does not state that Brenner has other conflicts including owning stock in ChromaDex, or that four of the other nine researchers have financial conflicts.", "answer": 1}, {"article": "Iron deficiency is the most common and widespread nutritional disorder in the world, affecting 2 billion people, according to the World Health Organization.\nThey said ensuring that pregnant women get this basic prenatal care could have a big effect on the educational futures of children who live in poor communities where iron deficiency is common.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\n\u201cThese results speak to a large swath of people residing in that part of the world.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does point out how the study was funded, but it does not make use of any experts other than one of the study\u2019s authors. This is too bad because certainly another researcher in the field could have provided some context for how widely applicable a program like this would be. There are always significant barriers to scaleup for public health interventions in poor countries, and something as simple in theory as vitamin supplementation may not be simple on the ground.\u00a0Another researcher or clinician with global health experience could have provided perspective.", "answer": 0}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThe interviews with participants are poignant, and reveal the struggle and isolation that can come with mental illness.\nMark Longsjo, the program director of adult services at McLean Southeast, an inpatient mental facility in Middleborough, Mass., says that the interviews in the study reflect his professional experiences.\nBrooks says, \"Many felt deep emotional connections with their pet that weren't available from friends and family.\"\nBrooks and her colleagues interviewed 54 people with serious long-term mental illnesses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly highlights one source\u2019s role in the research and incorporates input from a second source who was not associated with the research.", "answer": 1}, {"article": "Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.\n\u201cThis approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,\u201d said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA\u2019s Center for Drug Evaluation and Research.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nApproximately 75 percent of Americans with HCV have genotype 1; 20-25 percent have genotypes 2 or 3; and a small numbers of patients are infected with genotypes 4, 5 or 6.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release did not identify funding sources or state whether there were any conflicts of interest.This release describes the approval of a new drug by a regulatory agency, but we\u2019d still like to know who sponsored the study that\u2019s the basis for the approval. It\u2019s not enough to state who manufactures and markets the drug.", "answer": 0}, {"article": "The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about hip replacement.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\n\"While complication rates are low, there are some cases with serious consequences that include infection, joint dislocation, blood clots and even death.\"\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources. The story did not include the conflict of interest disclosures that were clearly posted at the top of the journal article online.", "answer": 0}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\nCosette Wheeler, PhD, at The University of New Mexico Comprehensive Cancer Center, was the lead author of the report.\nThe study showed that women in this age group were still protected from HPV infections.\nThis study focused on the benefit of vaccinating women 26 years and older.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The study was funded by GlaxoSmithKline, the vaccine manufacturer, but that\u2019s not mentioned in the news release.", "answer": 0}, {"article": ".\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nFunding for the study was provided in part by a grant from the National Institutes of Health/National Cancer Institute Cancer Center.\nThe study is being published online in Menopause, the journal of The North American Menopause Society (NAMS).\nIts multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the research was funded in part by the National Cancer Institute but it makes no mention of potential conflicts of interest on the part of the researchers involved. We\u2019ll give them the benefit of the doubt here since we don\u2019t have access to the full published study to verify who the funders are or assess whether there are financial conflicts of interest.\u00a0 We encourage news releases to always disclose whether or not there are conflicts.", "answer": 1}, {"article": "Mental disorders lack what most other health diagnoses rely on: biological markers.\nIt took a few years to find the right \u2018formula\u2019 of meds.\u201d While the doctors recommended some medication that helped, it was a matter of trial and error, since Orlando still doesn\u2019t have a concrete diagnosis today.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\n\u201cAs the development costs of a test are very high, there is a risk that the test will not be commercially viable.\u201d For severe mental illnesses like schizophrenia, it\u2019s also the case that even if a test made it through development and hit the market, it may not be successfully integrated into psychiatric practice.\nThe problem is that mental health diagnosis has essentially remained unchanged for 100 years, relying on symptoms and clinical interviews.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story interviews a patient, a professor who is an expert in mental disorders, and a researcher looking at one avenue for biomarker identification. It\u2019s also clear that the reporter read through a lot of studies to develop this piece.\nHowever, the story doesn\u2019t point out that source Dr. Sabine Bahn has apparent financial stakes in the success of this blood test.", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nWhile the story notes the conflicts of some sources, it appears that all the experts quoted were participants in a conference call arranged by Pfizer.", "answer": 0}, {"article": "Doctors can try to treat glioblastoma with surgery to remove the cancerous cells, and blast them with radiation and chemotherapy.\nThe condition recently made headlines as the disease that killed senator John McCain at the age of 81.\nCurrently, most people diagnosed with the condition die within two years.\nThese are its ability to cross the blood-brain barrier and to selectively infect and concentrate in the brain tumor stem cells left behind after surgery.\"\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include an independent source though we wish the source had been tapped more to explain the very limited human implications of the research.", "answer": 1}, {"article": "Common symptoms in the aftermath of concussion include confusion, headache, changes in vision or hearing, thinking or memory problems, fatigue, sleep changes and mood changes.\nThe research was funded through project grants from the National Institutes of Health and the Department of Defense.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nAlthough effective drug treatments for mTBI await discovery, rest and counseling are known to be helpful for patients, Mukherjee said.\nAdditional co-authors include researchers from UCSF, the University of Texas at Austin, the University of Pittsburgh Medical Center, Virginia Commonwealth University, the Icahn School of Medicine at Mount Sinai, and University Hospital Antwerp, Belgium.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding sources for this research project included the National Institutes of Health and the Department of Defense. In the original journal article, all authors stated they were free of competing financial interests.\nSince the news release disclosed the funding sources, we give it a Satisfactory rating here.", "answer": 1}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\nThe is looking at it, according to people in the field.\nI had to do all these things I never thought I\u2019d have to do at 41.\nFor hours on a recent morning at the , Dr. Andrew Lowy painstakingly performed the therapy on a patient.\nThe procedure took six hours.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Many different voices with different perspectives were heard in the story.", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nIn the future, the test could also be used to diagnose other neurodegenerative diseases.\"\nOur developments mean we could diagnose patients 10 years earlier than was previously possible.\"\nThe equipment used in the study was funded by a grant from Imperial Health Charity.\nThe research is funded by Wellcome Trust.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder is named and we are told that \u201cUCL Business, the commercialisation company of UCL, holds the patents for the technology.\u201d", "answer": 1}, {"article": "Tissue plasminogen activator, known as tPA, can dramatically reverse stroke symptoms in those whose strokes are caused by blood clots and blockages, which account for an estimated 85 percent of all strokes.\nThe main limitation is the limited access to MRI in emergency rooms worldwide.\"\nWhat more could we as doctors want?\"\nIf they don't, \"the major reason .\nThe condition is a leading cause of serious, long-term disability in the United States.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from independent experts.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes some good contextual comments from\u00a0Dr. James Aisenberg, a gastroenterologist and clinical professor of medicine at Mount Sinai Medical Center in New York. It also points out that there is a financial upside for the lead researcher in the study and the company that helped fund it: \u201cDr. Zalis and some of his co-investigators developed the software. The American Cancer Society, the National Institutes of Health and General Electric Co.\u2019s health-care unit\u2014which markets scanning devices and accessories\u2014supported the researchers. Dr. Zalis says the company had no influence on the study.\u201d", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert provided the only balance and the only caveat in the story.", "answer": 1}, {"article": "The F.D.A.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\nBut Mitchell H. Gold, the company\u2019s chief executive, told analysts in a conference call that the outcome was \"unambiguous\" and met the goals the company and the F.D.A.\nMark Monane, an analyst at Needham & Company, said sales of Provenge might reach $500 million to $1 billion a year.\nMr. Girgus, 65, who also owns Dendreon stock, said patients like himself were \"looking into the abyss.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes six sources:\nToo many sources are biased in favor of the company and its product, and they are given signficantly more space in the story than independent voices.\u00a0 \nThere is no source who is openly skeptical or even ambivalent about the findings. There is no one who suggests that conclusions made before findings are published may be premature. ", "answer": 0}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\nDr. Heng reports her experience using curcumin gel on such injuries using three examples of patients treated after burns and scalds, and provides a detailed explanation why topical curcumin may work on such injuries.\n\"When taken by mouth, curcumin is very poorly absorbed into the body, and may not work as well,\" notes Dr. Heng.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The journal article (but not the news release) states that Dr. Heng has shares in Omnicure Inc., a company that manufactures and markets topical curcumin gel. We also found that Dr. Heng is the founder and practicing research physician of this US-based company. Its main product line Psoria-Gold has been used as an anti-inflammatory gel in various spas, health stores and medical clinics in the US and Canada, according to its website. Did the company also help fund the research? That isn\u2019t made transparent in either the news release or the journal article.\nSince the news release does not disclose funding sources and conflicts of interest, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.\nThis test seems to provide such information,\u201d says Allan S. Jaffe, M.D., senior author of the study, cardiologist at Mayo Clinic and chair of the Division of Clinical Core Laboratory Services.\nMayo Medical Laboratories collaborated with some of the original researchers who established the role of ceramides in cardiovascular disease and Zora Biosciences Oy, a diagnostics discovery company based in Finland, to develop and refine the test.\nThe present study is also the first to test its clinical utility in a U.S. population.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that Mayo Clinic funded the trial and notes in the same paragraph that the ceramide test is available through Mayo Medical Laboratories, making the potential conflict of interest quite clear. It also notes that the study\u2019s senior author is a Mayo Clinic cardiologist and chair of the \u201cDivision of Clinical Core Laboratory Services\u201d and that Mayo Medical Laboratories collaborated with Finland-based Zora Biosciences to develop the test.", "answer": 1}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nThis research received no specific grant from any funding agency, commercial or not-for-profit sectors.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe association makes no representation or guarantee as to their accuracy or reliability.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release noted \u201cthis research received no specific grant from any funding agency, commercial, or not-for-profit sectors.\u201d No conflicts of interest are identified in the published study.", "answer": 1}, {"article": "\u201cFor moving your system to a later time, such as would be necessary when traveling East-to-West, light during the first few hours of the night is ideal,\u201d he said.\nMistiming light therapy can make jet lag worse, cautioned Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland, who was not part of the new study.\n\u201cJet lag itself is really a nuisance syndrome as it is self-resolving,\u201d said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nAs for frequent flyers trying this themselves, it is \u201cfar too early \u2013 neither the methodology is available outside research, nor any guidance about safety, nor tests of simulated jet lag in an appropriate \u2018realistic\u2019 protocol,\u201d Wirz-Justice told Reuters Health by email.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This article scores well on consulting an independent source by quoting a researcher who was not part of the study,\u00a0Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland.", "answer": 1}, {"article": "Many in the Alzheimer's research community are awaiting these drugs with bated breath, but \"none are ready for prime time,\" he said.\nThe new study was conducted and funded by the drug's manufacturer, F. Hoffmann-LaRoche Ltd., in Basel, Switzerland.\nThe new drug was given at either 60 or 200 milligrams (mg) doses.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nThe higher dose yielded greater reductions in amyloid levels, the study showed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Independent experts perspectives were helpful.\u00a0 Funding by the drug\u2019s manufacturer was disclosed.", "answer": 1}, {"article": "When Ali Andrew Li was born on Jan. 7, he was gently placed on his mother's chest, where doctors cleaned and examined him and covered him with a warm blanket.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nEven a little bit of kangaroo contact, he says, can be beneficial.\nBut doctors were surprised to see that babies whose mothers carried them close, skin to skin, not only survived but thrived.\nThe benefits are many, according to Dr. Lydia Kyung-Min Lee, an ob-gyn at UCLA.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story appears to have at least one independent medical source, and there are no apparent conflicts of interest.\nThat said, the story would have benefited from an expert discussing research on kangaroo care. As we noted in our review of NBC News\u2019s story on the follow-up study, there are some nuances worth pointing out to parents.", "answer": 1}, {"article": "\"It's clearly muddying the waters,\" he said.\nLearn more about screening mammograms by visiting the U.S. National Cancer Institute.\nThe American Cancer Society still recommends annual mammograms starting at age 40, as long as a woman is still in good health.\nMaybe Not and Here's Why, suggested that with better treatment and increased awareness of the importance of seeking care for breast abnormalities, screening mammography may be less important now than in the past.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 0}, {"article": "tears.\nSeveral top-flight orthopedic surgeons I contacted say that they remain convinced that surgery leads to a better long-term outcome for certain patients, particularly if they want to return to pivoting sports.\nThe \u201cbelief among most surgeons and patients is that surgery is a \u2018must,\u2019 at least if you aim to go back into an active lifestyle,\u201d the Swedish authors of the study e-mailed in response to questions.\ntreatment is \u201ccontroversial,\u201d The New England Journal study\u2019s authors, Richard Frobell, Ph.D., and Stefan Lohmander, M.D., Ph.D., of Lund University, wrote in their e-mail.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It cites the opinions of orthopedic surgeons, including one who seems clearly uninvolved in the NEJM study, and the author of the 2009 British Journal of Sports Medicine study.\u00a0It also tells us the affiliations of interviewees who were involved and not involved in the two studies. \nNote that the study publication discloses that the research was funded by a number of organizations in Sweden as well as Pfizer. As this wasn\u2019t a drug study, we\u2019re not sure what Pfizer\u2019s interest were and point it out as an FYI.", "answer": 1}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nMs. Stewart\u2019s physician, Dr. Andrew G. Kaufman, director of interventional pain management at Overlook Hospital in Summit, N.J., described a patient who tested a stimulator and experienced \u201cunbelievable\u201d pain relief, yet simply couldn\u2019t adjust to the sensation created by the device and decided not to keep it.\nDoctors say simple adjustments to the device may solve that problem.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides a good mix of sources, including one patient and three pain experts (one of whom relates the story of a dissatisfied patient). It also reports a potential conflict of interest among the authors of the study it cites, as well as with one of the expert sources.", "answer": 1}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nThe mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.\nHowever, Novartis said this price will not be charged to patients who do not respond within a month of treatment.\n(CNN) A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story squeaked by on this criterion, because it quoted\u00a0a news release\u00a0by the Patients for Affordable Drugs group that provides important counterbalance to the drug company\u2019s claims. The story would have been stronger if it had contained more input from an independent medical expert who could comment on the veracity of the evidence itself.\n[Editor\u2019s note: This criterion was updated on 1/11/18 to reflect the correct rating. It was previously rated \u201cNot Satisfactory.\u201d This change does not affect the overall rating.]", "answer": 1}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nThe study is called RAZOR (randomized open versus robotic cystectomy trial) and was funded by the National Cancer Institute.\nDr. Gupta added that the study provides evidence demonstrating that the robotic approach performs at least as well as the open approach.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Although the release reports that the study was supported by the National Cancer Institute, it fails to note the financial disclosures several researchers made about money they have received from companies relevant to this study.", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote two directors of major Alzheimer\u2019s research centers. The story could have quoted other clinicians or researchers who may have provided some additional perspective.", "answer": 1}, {"article": "A compressed and herniated disk, in which the rubbery cushion between vertebrae impinges on and irritates nearby nerves, is a major cause of low back pain that can radiate to the legs.\n\"Following this treatment, inflammation and pain go away.\n\"The results have been extraordinary.\nSix patients required a second pulsed radiofrequency session.\nPatients have been relieved of pain and resumed their normal activities within a day.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It\u2019s not obvious from the release who funded this work.", "answer": 0}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nThe study found none.\nWhen the study started, the women were having an average of nearly 10 hot flashes each day.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources referenced in this post. In addition, while the story notes that the study was federally funded, it should have pointed out that at least one of the study researchers receives research funding and is a consultant for Forest Laboratories, which makes Lexapro.", "answer": 0}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nhttp://www.nejm.org/\n\nThis study would not have been possible without the generous support of the Chain Reaction Foundation, the Key Foundation and the National Health and Medical Research Council.\nIn the vast majority of cases the cause of these problems has remained a mystery.\n\u201cThe ramifications are likely to be huge.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t name any of the study\u2019s many public or private foundation funders. ", "answer": 0}, {"article": "When Finnish researchers randomly assigned 230 babies at high risk of type 1 diabetes to receive either a regular infant formula, or one that was extensively hydrolyzed -- which means the proteins in the formula are already partially broken down and more readily available for digestion -- they found that the extensively hydrolyzed formula cut the rate of developing diabetes-linked antibodies in the blood by about half.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\n\"I think this is an important study because we need to understand what causes type 1 diabetes,\" said Harlan, who added the caveat: \"In this study, while there is an apparent signal, there are also some causes for withholding complete faith in the conclusion that the formula caused diabetes.\"\n\"The data in this study is not sufficiently strong to support recommending any changes for parents,\" said the author of an accompanying editorial, Dr. David Harlan, co-director of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester.\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several clinical experts who provide explanation of the results and put these into context with current formula recommendations.\u00a0 Study authors are cited as well as clinical experts who feel the research is noteworthy, but should not change recommendations for a hydrolyzed formula to prevent Type 1 diabetes.\u00a0\u00a0 Affliations of all sources are listed in the story postscript.", "answer": 1}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nSuch work is already happening at UCLA and other institutions that meld these approaches into novel ways to improve patient care.\n\"Patients seem to enjoy reviewing results of their imaging studies, more so than reading the results of their blood tests or other clinical evaluations.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not specify funding sources for the work, which included the National Institute of Biomedical Imaging and Bioengineering and the National Institutes of Health. Many of the authors are consultants for medical device and pharmaceutical companies, including Toshiba (cited as \u201crelated\u201d or relevant in the original research report). The release does not disclose this.", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release makes no mention of funding sources or conflicts of interest. The study itself states that it was funded by the NIH and notes that 13 of the authors, including the primary investigator, have ties to drug companies.", "answer": 0}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\nRetested with the blood pressure cuff, the group eating the American Heart Association-style diet continued to display normal, healthy blood flow.\n\u201cThose on the high-fat diets showed no harmful impacts\u201d after 45 days or so, she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several individuals who were not connected with the study reported provided comments and context for thinking about the diets discussed.", "answer": 1}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nStill, he said the new test could help patients if it was used with caution.\nIt was released online on Wednesday, a journal spokeswoman said, because \u201cit is a very active area of research with a lot of competition.\u201d\n\nResearchers long knew that the disease often runs in families.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nThat resulted in the discovery, by several groups of investigators in Iceland and the United States, of the gene variants, small alterations in gene sequences.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included comments from experts in the field who were not connected to the study reported on.", "answer": 1}, {"article": ".\nRegister now for the 2018 AAN Annual Meeting Press Room in Los Angeles, April 21-27, 2018\n\nThe study was supported by the National Institute on Aging.\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\n\"Making a lifestyle change such as changing your diet is often preferred over taking medications, so we wanted to see if diet could be an effective way to reduce the risk of depression.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the study was supported by the National Institute on Aging, which is good. However, conflicts of interest are not explicitly addressed. Given that only one of the researchers involved with the study was named, it is impossible for readers to determine if there are any conflicts of interest. For example, one can buy any number of DASH diet cookbooks online \u2014 are any study co-authors associated with those? Given the paucity of information in the release, it\u2019s impossible to tell. (As noted above, we obtained a copy of the study abstract and didn\u2019t see any obvious conflicts of interest \u2014 but the information isn\u2019t readily available in the release.)", "answer": 1}, {"article": "It is less common than Type 2 diabetes, which is associated with obesity.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nBut it didn't work for two of them.\nOne patient was as young as 14.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes two experts \u2013 one of whom was apparently not involved in the study. \u00a0\u00a0", "answer": 1}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nSuch screening is increasingly used in research.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is a strong point of the story. It includes three independent experts in addition to study authors and the author of an editorial about the research.", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nDr. Biesecker acknowledged that there was no guarantee of success.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nStill, Mr. Del Sontro is preparing for the worst.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of qualified experts weigh in regarding the\u00a0significance of this research.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\n(CNN) In the future, a new class of anti-inflammatory drugs could be used to treat depression, say University of Cambridge researchers.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The CNN story offers a quote from a source not associated with the research; and it offers links to websites and other sources where readers could find out more about funding and sponsorship of the study. This is a strong point of the story.", "answer": 1}, {"article": "Concussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\nThe technology is subject to a patent application filed through WORLDiscoveries\u00ae, the joint technology transfer office of Lawson and Western.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nIn fact, with fine tuning we can now look at sets of as few as 20-40 specific metabolites and maintain the diagnostic accuracy level of the test over 90 per cent.\"\nWestern delivers an academic experience second to none.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes the funder and acknowledges that the \u201cThe technology is subject to a patent application filed through WORLDiscoveries\u00ae, the joint technology transfer office of Lawson and Western.\u201d", "answer": 1}, {"article": "BOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\n\"And for many women, they cannot get through their daily activities, getting out of bed, taking a shower, and preparing food for themselves.\nIt's certainly reassuring news for Dr. Katherine Economy, a maternal fetal medicine specialist at the Brigham who cares for many pregnant women on antidepressants.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We didn\u2019t find one of the sources quoted in the story \u2014 Dr. Katherine Economy \u2014 on the list of study authors, nor in the acknowledgements, which suggests she wasn\u2019t involved in the study. But as the story points out, she works at the same institution as several of the authors and could therefore be less objective than some other independent observers. Her comments are certainly valuable and add important perspective to the piece. But to be consistent with our standard, we are obligated to rule this Not Satisfactory. We feel that it\u2019s always a good idea to reach an outside source for comment.", "answer": 0}, {"article": "He is concerned that patients will think to themselves, \"Even though I have this weird stomach pain that won't go away, I know it's not cancer.\nFirst, he notes, the Hopkins team will need to demonstrate that the test will be useful in patients without symptoms.\nIt combines two methods into one test.\nA low false-positive rate is critical for any test that could be used widely to screen people for cancer.\nBut these methods alone don't give reliable results.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The two independent sources cited provide important context for understanding the strengths, limitations, and clinical context of the screening test.", "answer": 1}, {"article": "Babies with SCID often come down with recurrent, severe respiratory infections that can be life threatening, according to the American Academy of Allergy, Asthma and Immunology.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nEven the common cold can be deadly.\nThey enrolled baby Evangelina in a clinical trial there.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only two people quoted are the clinical investigator and the parent of a child treated. \u00a0A comment or two from other experts in the field would have rounded out the reporting.", "answer": 0}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nMoreover, patients and their doctors need to consider the potential risks of taking aspirin, including stomach bleeding, Cao said.\nAmounts ranged from less than one aspirin a week to 15 or more, the researchers said.\nSome, though not all, previous studies have indicated that aspirin might slightly lower risk of certain other cancers, including breast cancer, prostate cancer and lung cancer, he added.\nThe results of the study were to be presented Sunday at an American Association for Cancer Research meeting in Philadelphia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes an independent source from the American Cancer Society. But it\u00a0makes no mention of possible conflicts of interest, even though they would not have been hard to find: The American Association for Cancer Research news release notes that Yin\u2019s team includes Andrew Chan of Harvard Medical School, \u201cwho has previously served as a consultant for Bayer Healthcare [which makes aspirin], Pfizer Inc., and Pozen Inc.\u201d", "answer": 0}, {"article": "The disease causes patches of thick, red, inflamed skin that have silvery scales.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\nWEDNESDAY, Oct. 26, 2011 (HealthDay News) -- An experimental psoriasis treatment performed significantly better than the commonly prescribed medication methotrexate in a new clinical trial.\nResults of the study are published in the Oct. 27 issue of the New England Journal of Medicine.\nOf the increased infections and cancers, Reich said, \"Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did state that Abbott Labs had funded the study and it did get an independent comment from the National Psoriasis Foundation.\nBut we judge this to be unsatisfactory because the story did not disclose what is clearly disclosed in the journal article \u2013 that the principal investigator:\nIt also didn\u2019t disclose what the journal article disclosed, that Abbott personnel helped write the manuscript and helped with the statistical analyses.\nThe Statement of Principles of the Association of Health Care Journalists includes these clauses:\n\u00a0", "answer": 0}, {"article": "\u201cIt's a question of having the knowledge and awareness of keeping your options open.\u201d\n\nThe test is a simple blood analysis that usually costs less than $100.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nAt her regular gynecology visit, Gold took the AMH test and received news she didn\u2019t wanted to hear but it helped her take the next right step for her.\nTurns out there\u2019s a simple blood test that could tell her.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The doctor interviewed in this story stands to gain from positive news coverage of this blood test, especially considering the clinic he works for is actively trying to get women to take the test, which will result in an increase in patient referrals. We think that\u2019s suspect enough that the journalists reporting the story should have sought out additional, independent opinions.", "answer": 0}, {"article": "Although prostate tumors generally respond well to radiation therapy (RT), the possibility of radiation exposure to healthy tissue in the genitourinary (GU) and gastrointestinal (GI) systems can be of concern.\nThis news release contains updated data from the study author(s).\n\u201cSingle-institution studies on the use of SBRT as the primary treatment for prostate cancer have illuminated the treatment as a cost-effective and faster alternative to IMRT,\u201d said Robert Meier, MD, lead author of the study and a radiation oncologist at Swedish Medical Center in Seattle.\nThe study is the first large, multi-institutional study of SBRT in prostate cancer with long-term follow-up.\nOverall survival (OS) was measured as a secondary outcome for the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not say how the study was funded or whether any of the investigators have conflicts of interest. In papers on the topic published in 2015, the researchers declared no conflicts of interest.", "answer": 0}, {"article": "It\u2019s quite unusual,\u201d she added.\nA couple of major drug companies have already expressed interest in his vaccine, he said.\nThe researchers tested this vaccine, known as p53MVA, in a 2013 clinical trial and found it to be safe in patients with advanced gastrointestinal cancers.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\nYoung, who tested positive for the p53 mutation, has been fighting breast cancer for eight years and has undergone \u201cone chemo after another,\u201d Yuan said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "There was no mention of where the funding for the vaccine research came from, but the researcher who\u00a0developed the vaccine was quoted\u00a0in the release saying they were seeking funding for a larger vaccine trial. There was also mention of several drug companies expressing interest in the vaccine, but it\u2019s unclear if any of those same companies have given any money for testing.", "answer": 0}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\n\u201cThis research has been tested on human tissue, which is promising, but not on humans themselves, so there is still some way to go.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story had an independent source \u2014 a \u201cstatement\u201d from the British Association of Dermatologists. However, the story didn\u2019t explain that the study was sponsored by Giuliani SpA, an Italian pharmaceutical company that makes dermatology products.\nAn independent source knowledgeable about research and drug development\u2013rather than a professional association\u2019s spokesperson statement\u2013would have helped here.", "answer": 0}, {"article": "Any kind of mini-stroke \u201cshould lead you to be evaluated,\u201d said Arnett, who was not involved in the study.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nOutcomes in this study were at least 50 percent lower than those reported in previous studies,\u201d Sacco and Rundek write.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites an independent expert source, as well as drawing on the third-party editorial published in NEJM. However, the story does not tell readers that the study was supported by pharmaceutical companies Sanofi and Bristol-Myers Squibb, which is an important oversight.", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nScott Shikora of Tufts Medical Center in Boston says that until recently he hadn't performed a second obesity operation on anybody but is already up to about a half-dozen patients.\nThe ability to control the tightness is presumably part of the reason that patients who opt for banding lose less weight, at least initially, than gastric bypass patients -- an average of 50 to 65 percent of their excess weight in the first three years.\nOf course, a second obesity surgery comes with increased risk.\nObesity surgeons, Fielding included, report a high success rate for the bypass.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several clinicians were quoted as part of this story indicating that they were seeing an increased number of individuals seeking to have a second weight loss procedure because they felt gastric bypass was not sufficient to enable them to maintain their weight loss. \u00a0Beyond this, the story included no expert commenting with concrete information about the risks and benefits associated with this approach to weight control.", "answer": 0}, {"article": "\"The work by [first author] Price et al.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\n\"This field has been extremely controversial.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Yes, the story turned to an independent expert at the end.\nAnd, yes, it noted the conflicts of interest for the senior study author.\nBut it seemed to go out of its way to include a quote from the CEO of the drug company developing reseveratrol-like molecules \u2013 quoting him from an email he sent the journal that published the work.\u00a0 And it never explained WHY the company halted clinical trials of resveratrol in 2010.\u00a0 Before letting the CEO make new claims (\u201cfirst definitive evidence\u201d) about a new approach, it might have been helpful to review for readers why another approach was abandoned.\nWe think that\u2019s only half a loaf, and give it an unsatisfactory score for that reason.", "answer": 0}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nAnd by and large, they did.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included quotes from three clinicians and one patient \u2013 of which at least three appeared at the media briefing.\u00a0 There was no disclosure of any financial conflicts of interest among the three clinicians.\u00a0 Maybe there was none, but given the setting \u2013 a company-hosted media briefing \u2013 this issue should have been discussed. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes one expert who is the lead author on the study.", "answer": 0}, {"article": "\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\nIn contrast, the control group only showed an average score of around 2.7 after treatment.\u201d\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\nAndrea Fagiolini, a professor who led the study and presented it at the European College of Neuropsychopharmacology conference in Vienna on Monday, said the treatment may prove useful during the Northern hemisphere\u2019s darker winter months.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use any independent source and does not address conflicts of interest, though we could not identify any.", "answer": 0}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nBut no cause-and-effect relationship has been established.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAll the children spent one night in a sleep laboratory to record their sleep and breathing patterns.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In the story, only a single expert is quoted, the author of the research article in the journal Pediatrics.", "answer": 0}, {"article": "Previous research has shown that Mozart's music can provide a significant short-term boost to spatial-temporal reasoning, which involves a person's ability to compare and transform mental images in space and time.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\nThe study was slated for presentation Monday at the American College of Gastroenterology's annual meeting in Washington, D.C. Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThis was up from a baseline detection rate of 21 percent before the study began.\nWhile this is a small study, the results highlight how thinking outside the box -- in this case using Mozart -- to improve adenoma detection rates can potentially prove valuable to physicians and patients.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources cited from outside the study. The only comment came from the lead researcher, Dr. Catherine Noelle O\u2019Shea from the University of Texas Health Science Center.", "answer": 0}, {"article": "FEFs measure how fast air can be exhaled from the lung and are an important measure of lung function because they can detect airway obstruction.\nThis study was funded by the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nAll participants received smoking cessation counseling throughout the study, and about 10 percent of the women quit smoking during the study.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding is very clearly attributed to the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\nConflicts of interest are not mentioned, and none were found.\n\u00a0", "answer": 1}, {"article": "Merck suffered a setback last year when its attempts to win marketing approval to sell Erbitux in lung cancer were rebuffed by regulators.\n\u201cThis study clearly opens the field ...\nSales last year were $1.7 billion.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Glioblastoma is the most common and aggressive malignant brain tumor in adults.\nAnd starting at two years after treatment, the two groups' survival rate began to diverge, the researchers reported.\nSome other researchers praised the results.\nThe treatment can cause a dangerous swelling in the brain that can lead to seizures and other complications, the researchers found.\nAfter three years, 21 percent of the poliovirus treated patients survived, compared with 4 percent of the other group, according to the researchers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did have an independent source, but did not mention that seven of the researchers on the study reported financial interests in the company that holds the license for the treatment.", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\n\"The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nImportantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.\"\n\"We are committed to providing patients with the highest quality, most effective options to address their urology needs,\" said Matthias Hofer, MD , urologist at Northwestern Memorial Hospital.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release is silent on issues related to conflict of interest. The studies cited in the release were funded by the device manufacturer. The Northwestern urologist quoted in the release has received small payments (amounting to $121.50) from the manufacturer for food and beverages. These could have been acknowledged in a footnote.", "answer": 0}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The statements made by\u00a0a company representative\u00a0are counterbalanced by comments from Dr. Virmani, an independent expert in coronary artery disease and a very outspoken individual.", "answer": 1}, {"article": "Relatively few women at high risk of breast cancer take tamoxifen, and some patient advocates question whether they should, saying many women are exposed to side effects for each case of cancer prevented.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nDr. Patricia A. Ganz of the University of California, Los Angeles, who presented the quality-of-life data here, said decisions should be made based on each woman's circumstances.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nThe new data are not likely to settle the debate about which drug is better.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites information from both the editorial that accompanied these studies as well as the researcher who presented the results at a professional meeting. It might have been helpful to note that neither the authors of the editorial nor the presenter appear to have any financial relationship with either drug manufacturer; this information was available in the published articles. ", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did not appear to make use of any independent sources of information regarding the clinical efficacy of this drug.", "answer": 0}, {"article": "For example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nHe said statin treatment in children was still controversial, and that no long-term safety data existed.\nMore than seven in 10 school kids had first-degree relatives with heart disease, and about one percent of those had \u201cbad\u201d cholesterol (LDL cholesterol) levels that might require drug treatment in addition to diet changes and exercise, according to the researchers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe journal Pediatrics stated that the study authors did not report any relevant financial interests. The story did include comments from an independent expert.", "answer": 1}, {"article": ".\nFunding & Disclosures: The study was funded by Eli Lilly and Company.\nLimitations: Patnaik explained that because this study included 225 patients with different types of cancer, confirmatory clinical trials in specific patient populations are necessary to precisely define the role of abemaciclib in cancer care.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nTo interview Amita Patnaik or Geoffrey I. Shapiro, contact Julia Gunther at julia.gunther@aacr.org or 215-446-6896.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release includes a \u201cFunding & Disclosures\u201d paragraph. It lists funding by Eli Lilly and Company. It also lists some of the payments and other connections between key researchers and the company. We like the format used for this EurekAlert version of the release, which also notes the funder in a box just to the right of the release\u2019s headline.", "answer": 1}, {"article": "\"Why throw away an important tool?\"\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\nWhat is clear is that studies don't supply an answer that fits all women.\nDr. Elizabeth Steiner, director of the breast health education program at\n\n, said each woman must decide for herself, with full knowledge of the pros and cons, whether to perform self-exams.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on an update of a report by the Cochrane Collaboration, a credible international group that analyzes bodies of scientific literature to determine overall findings. A range of clinicians put the report and practice of BSE in perspective.\u00a0 Physicians appropriately talk about the revised guidelines for this screening, and note that regular BSE is still an individual woman\u2019s choice.\u00a0 Women should be aware of the harms and lack of sensitivity of the exam.\u00a0 A patient is interviewed for the story, but her story of misdiagnosis seems to undercut the overall message of the piece: women must weigh the pros and potential downsides of regular BSE. ", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0The story included comments from a number of clinicians and adipose tissue researchers who had no connection with the highlighted devices.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\nThe new study looked at a highly sensitive type of troponin I test that may be more accurate in less time.\nDr. Michael Lanigan, an emergency room doctor at the SUNY Downstate Medical Center in Brooklyn, NYC, said the ultimate goal is a highly specific and sensitive test that can tell doctors right away if you are having a heart attack.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story mentioned that the study was funded by two pharma companies but it did not include any of the individual disclosures included in the journal article itself.\nAnd, in terms of sourcing, while the story did include quotes from two independent physicians, neither of them directly addressed the quality of the evidence.\nOne said \u201cwe can rule out heart attacks more quickly with the new test\u201d but it wasn\u2019t clear if she had used the test or if she was commenting on the data reported. So we don\u2019t know why she was used as a source.\nThe other spoke in only very general terms about the ultimate goal of such research and about the need for such a blood test \u2013 but nothing about the evidence itself.", "answer": 0}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nWilliams said her daughter went to sleep in a crib with cushiony bumpers, stuffed animals and an added blanket beneath the fitted sheet and never woke up.\nShe said the coroner determined the bedding caused the death.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tells readers that the Baby Box Co. is a \u201cfor-profit\u201d company. But they don\u2019t give us any details about the company\u2019s relationship with the pediatrician, Kathryn McCans, who is the only physician quoted in the story.\nDoes Dr. McCans receive any funding or payment from The Baby Box Company? We can\u2019t tell from the story. At the company\u2019s own website, she is listed as one of \u201cour experts\u201d on this page. \nShe may have donated her time, but that isn\u2019t made clear. At the very least, it should have been clarified that that McCans has a relationship with the company and is not totally independent.", "answer": 0}, {"article": "Pregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\nThe Baylor scientists were able to correct for those variables.\nThe research in question involved mice, not women.\nHow does this relate to our own species?\nDid they smile?)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There appear to be no overlooked conflicts of interest in this story. However, because there were no independent sources, this falls under Not Satisfactory.", "answer": 0}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nThat's in contrast to many past studies, where researchers have injected stem cells -- often from patients' bone marrow -- into the heart.\nIn the new study, the researchers used stem cells from the patients' own thigh muscle to create a patch they placed on the heart.\nInstead, Sawa explained, they seem to produce chemicals called cytokines that can promote new blood vessel growth in damaged areas of the heart.\nHowever, experts cautioned that while the results are encouraging, there's a lot of work left ahead before stem cells can be used to treat heart failure.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story uses an independent source to good effect, which we are always glad to see. However, the story misses a key point in terms of conflicts of interest. While this specific study was funded by Japanese government agencies, the journal article notes that the research team also receives funding from TERUMO Company. TERUMO Company makes a product called HeartSheet, which Nature described in 2015 as being \u201cmade of skeletal-muscle stem cells that are taken from a patient\u2019s thigh and grown in the lab. The sheet\u2026is then applied to the hearts of people who have severe cardiac failure.\u201d\nIn other words, the researchers receive funding from the company whose product they were testing \u2014 even though they don\u2019t explicitly explain in the paper that what they are doing is virtually identical (if not identical) to TERUMO\u2019s product.", "answer": 0}]